{"title": "PDF", "author": "PDF", "url": "biomedizin.unibas.ch/fileadmin/user_upload/biomedizin/about_us/media/scientific_reports/DKBW_Report_2000-2004.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "DKBW 2000\u20132004\nDepartement Klinisch-\nBiologische Wissenschaften\nUniversit\u00e4t Basel\nDepartment \nClinical-Biological Sciences\nUniversity of Basel\nwww.dkbw.chInhaltsverzeichnis\nVorwort Pr\u00e4sident Departementsrat  4\nVorwort Vorsitzender Departementsleitung  5\nDie Organe des DKBW  6\nKennzahlen des DKBW  7\nOrganisation des DKBW  8\nDie Geb\u00e4ude des DKBW  10\nEin neues \u00abZentrum f\u00fcr Biomedizin\u00bb  12\nNewly Appointed Professors 2002\u20132004  14\nNeue Professorinnen und Professoren 2002\u20132004\nDKBW Schwerpunkt Neurobiologie  16\nNeurobiology\nDKBW Schwerpunkt Zellplastizit\u00e4t und Gewebereparatur  36\nCell Plasticity and Tissue Repair\nDKBW Schwerpunkt Onkologie  78\nOncology\nDKBW Schwerpunkt Immunologie  92\nImmunology\nSpinn-Off Firmen  126\nDKBW Publications 2000\u20132004  128\nPersonen Index  1582/3\nImpressum\nKonzept: \nDKBW, Advolis Life Science Concepts GmbH, 4057 Basel\nKoordination: Advolis\nRedaktion: Advolis, DKBW\n\u00dcbersetzungen: Advolis, DKBW \nGestaltung: \nVischerVettiger, Kommunikation und Design AG, Basel\nFotos: \nRalf Steininger D-79713 Bad S\u00e4ckingen, \nVerena J\u00e4ggin DF DKBW, z.Vfg.\nDruck: Isenegger AG, 4313 M\u00f6hlin\nwww.dkbw.ch\n\u00a9 DKBW 2004Vorwort\nDas Departement f\u00fcr Klinisch-Biologische Wissenschaften hat 2000-2004 eine \nsehr positive Startphase hinter sich gebracht. Zahlreiche Ordinarien und \nExtraordinarien wurden berufen, international renommierte, wissenschaftliche \nPers\u00f6nlichkeiten konnten nach Basel gewonnen werden. \nDie vielen Gespr\u00e4che mit den \u00abNeuen\u00bb zeigen ein einheitliches Bild. Grund f\u00fcr \nden Wechsel nach Basel und Einzug ins DKBW ist das Grundkonzept \ndieses Departements: enge Zusammenarbeit zwischen Grundlagenexperten \nund Klinikern, kurze Wege zwischen \u00abbench\u00bb und bedside\u00bb, gemeinsame \nInteressen und Projekte.\nDas DKBW Fundament steht. Es braucht nun etwas Zeit und auch Geld, \num den Ruf zu festigen. Die Basler Universit\u00e4t und Medizinische F akult\u00e4t sind \ninternational gesehen klein. Das DKBW hat deren Vorteile erfasst. \nDie Bedingungen f\u00fcr eine erfolgreiche Zukunft sind jedoch gelegt, die \u00abhuman \nressources\u00bb sind gesichert. Die Fakult\u00e4t freut sich, die weitere positive \nEntwicklung des Departements zu verfolgen und unterst\u00fctzen.\nAndr\u00e9 P . Perruchoud\nDekan Medizinische Fakult\u00e4t,\nPr\u00e4sident des DKBW-RatsAls das DKBW von den drei Vertragspartnern Universit\u00e4t, Sanit\u00e4tsdepartement \nund Universit\u00e4tskinderspital beider Basel vor 4 Jahren gegr\u00fcndet wurde, \nwaren unter den vertraglichen festgesetzten Zielsetzungen: \u00ab...die intensive \nVernetzung und F\u00f6rderung der klinischen mit der vorklinisch-naturwissen -\nschaftlichen Forschung; ...die Schwerpunktbildung\u00bb , sowie \u00ab...den Standort \nBasel f\u00fcr Spitzenkr\u00e4fte der medizinischen Forschung und f\u00fcr Sponsoren \naufzuwerten\u00bb . Das Departement ist in den vier Jahren diesen Zielen erfreulich \nn\u00e4her gekommen, was in der vorliegenden Schrift dokumentiert sei. \nDie Forschung formierte sich neu in vier Schwerpunkten von zentraler wissen-\nschaftlicher und klinischer Bedeutung: Neurobiologie (S. 16), Zellplastizit\u00e4t \nund Gewebereparatur (Regenerative Medizin) (S. 36), Onkologie (Krebs-\nforschung) (S. 78) und Immunologie (S. 92).\nDas neue Konzept erlaubte eine erfolgreiche Serie neuer Berufungen von \nProfessorinnen und Professoren, die auf S. 14 kurz vorgestellt werden. \nDie Berufbarkeit von Spitzenkr\u00e4ften ist bekanntlich ein valabler Gradmesser \nder Qualit\u00e4t einer Universit\u00e4t!\nF\u00fcr die Entwicklung eines Departements ist auch die bauliche Erneuerung \nein wichtiger Schrittmacher. Das Kernst\u00fcck der baulichen Entwicklung bildete \nein von Novartis an die Universit\u00e4t geschenktes Geb\u00e4ude, wo neu das \n\u00abZentrum f\u00fcr Biomedizin\u00bb entstand (S. 12). Am 3. November 2004 soll es offi-\nziell eingeweiht werden. Ein \u00fcber 4 Jahre dauernder Planungs-, Finanzierungs- \nund Bauprozess findet somit einen erfreulichen Abschluss.\nDie Kurzberichte der \u00fcber 50 Forschungs-Gruppen, finden sich nach den vier \nSchwerpunkten gegliedert, sind englisch verfasst mit einer auch f\u00fcr den \nLaien lesbaren deutschen Zusammenfassung. Die Beitr\u00e4ge dokumentieren die \nzunehmende Bedeutung der DKBW-Forschung f\u00fcr das Life Science Konzept \nder Universit\u00e4t Basel wie f\u00fcr den Pharmaforschungsplatz Basel. \nDie in der Schrift aufgelisteten \u00fcber 1200 Publikation geben ein erfreuliches \nBild der wissenschaftlichen Kapazit\u00e4t des DKBW.   \nIch danke im Namen der Departementsleitung allen, die zum Erreichen der \nZiele beigetragen haben. Mein besonderer Dank an Rektor G\u00e4bler als \nersten Pr\u00e4sidenten des Departementsrates und an die weiteren Mitglieder des \nDepartementsrates. Unser Dank schliesslich allen, die zu diesem \nBericht beigetragen haben und sich auch in Zukunft f\u00fcr das DKBW in L ehre \nund Forschung einsetzen. \nChristoph Moroni  \nVorsitzender der Departementsleitung4/5\nDie Organe des Departements \nKlinisch-Biologische Wissenschaften\nDepartementsrat\nVertreter der Universit\u00e4t:\nProf. Dr. A. P . Perruchoud, \nDekan Medizinische Fakult\u00e4t, Pr\u00e4sidium \nProf. Dr. U. G\u00e4bler, Rektor der Universit\u00e4t, \nPr\u00e4sidium 2000\u20132003\nProf. em. Dr. Werner Arber\nDr. Kurt Altermatt, \nVerwaltungsdirektor\nProf. Dr. Walter E. Haefeli, \nUniversit\u00e4t Heidelberg\nVertreter des Sanit\u00e4tsdepartements:\nFrau lic. oec. Rita Ziegler, \nSpitaldirektorin USB\nHerr lic. iur A. Faller, \nLeiter Spitalplanung im Sanit\u00e4tsdepartement\nVertreter des Universit\u00e4ts-Kinderspitals \nBeider Basel:\nDr. Hanspeter Meister \nMitglied UKBB-Rat Prof. Dr. med. Christoph Moroni, Vorsitz\nProf. Dr. rer. nat. Gerhard Christofori\nProf. Dr. med. Georg A. Hollaender\nProf. Dr. med. Radek Skoda\nJean-Jacques Jobin, Gesch\u00e4ftsf\u00fchrer\nDepartementsleitungKennzahlen \ndes DKBW\nForschungsgruppen\n50\nDienstleistungsgruppen\n5\nVollamtliche Professuren\n26\nBeim DKBW besch\u00e4ftigte Personen \n527 (voll- und teilzeitlich)\nBudget\nDas Globalbudget betr\u00e4gt insgesamt \nCHF 31,174 Mio und gliedert sich auf in:\nPersonalkosten  CHF  21,149  Mio\nSachkosten   4,203\n  25,352\nErtr\u00e4ge   - 3,502\n  21,850\nOverheadkosten   9,324\nTotal  CHF  31,174  Mio\nInvestitionen\nCHF 7,8 Mio in den Jahren 2000\u20132003\nEingeworbene Drittmittel\nCHF 52 Mio\nZur Verf\u00fcgung stehende Gesamtfl\u00e4che\n11 315 m2\n6/7Organisation des Departements \nKlinisch-Biologische Wissenschaften\n\u00dcbersicht \u00fcber die Institute und Forschungsgruppen\nInstitut f\u00fcr Medizinische \nMikrobiologie\nProf. Christoph Moroni\nPetersplatz 10, 4003 Basel\nwww.unibas.ch/immDepartement Forschung des Universit\u00e4tsspitals Basel\nProf. Radek Skoda\nHebelstrasse 20, 4031 Basel\nwww.dfbs.chRoche Professur\nSNF Professur\nMattenstrasse 28, 4058 Basel\nImmunonephrology\nProf. J. A. Schifferli\nExperimental Critical Care \nMedicine\nProf. U. Eriksson\nNeurosurgery\nProf. O. Gratzl\nNeuro-Oncology\nProf. A. Merlo\nSignal Transduction\nProf. Th. J. Resink\nProf. P . Erne\nTissue Engineering\nDr. I. Martin\nProf. M. Heberer\nExperimental Hematology\nProf. R. Skoda\nProf. A. Wodnar-Filipowicz\nGynaecological Endocrino-\nlogy\nProf. Ch.  DeGeyter\nPerioperative Patient \nSafety\nDr. S.  Treves\nDr. T.  GirardInfectious Diseases\nProf. R. Landmann\nProf. M. Battegay\nMolecular Nephrology\nPD Dr. B. Biedermann\nProf. R. Krapf\nNeurobiology\nPD Dr. N. Schaeren-\nWiemers\nProf. A. J. Steck\nOncology Surgery\nProf. G. C. Spagnoli\nProf. M. Heberer\nVascular Biology\nProf. E. J. Battegay\nPneumology\nPD Dr. M. Roth\nProf. M. Tamm\nDermatology\nDr. M.  Bigliardi-Qi\nProf. Th.  Rufli\nHepatology\nProf. M.  H. HeimExperimental Immunology\nProf. G. De Libero\nTransplantation Immunol -\nogy and Nephrology\nProf. E.  Palmer\nProf. J.  Steiger\nImmunobiology\nDr. C. Hess\nClinical Neuroimmunology\nProf. D. Leppert\nProf. L. Kappos\nMedical Oncology\nProf. Ch. Rochlitz\nDr. M. Pless\nMetabolism\nProf. U. O. Keller\nPD Dr. B. M\u00fcller\nCardiothoracic Surgical \nResearch\nProf. H.-R. Zerkowski\nClinical Pharmacology\nProf. J. Drewe\nProf. St. Kr\u00e4henb\u00fchl\nGastroenterology\nProf. Ch. Beglinger\nPrenatal Medicine\nPD Dr. S. Hahn\nProf. W. HolzgreveDevelopmental and \nMolecular Immunology\nProf. A. Rolink\nDevelopmental \nImmunology\nProf. D. FinkeTransplantation Virology\nProf. H. H. Hirsch\nMolecular Diagnostics\nPD Dr. T. Klimkait\nExperimental Immunology\nProf. P . Erb\nPD Dr. U. G\u00fcnthert\nExperimental Oncology\nProf. Ch. Moroni\nAbteilung f\u00fcr Diagnostik\nProf. P . Erb \nProf. H. H. Hirsch \nPD Dr. T. KlimkaitInstitut f\u00fcr Anatomie\nProf. Rolf Zeller\nPestalozzistrasse 20, 4056 Basel\nwww.unibas.ch/anatomieInstitut f\u00fcr Biochemie \nund Genetik\nProf. Gerhard Christofori\nMattenstrasse 28, 4058 Basel\nwww.unibas.ch/dbmw/bio-\nchemie, www.unibas.ch/genetikInstitut f\u00fcr Physiologie\nProf. Bernhard Bettler\nKlingelbergstrasse 50/70, \n4056 Basel (Pharmazentrum)\nund Vesalgasse 1, 4051 Basel \n(Vesalianum): www.unibas.ch/\ndbmw/physiologie\nMolecular Neurobiology\nSynaptic Plasticity\nProf. B. Bettler\nMolecular Neurobiology\nSynapse Formation\nProf. HR. Brenner\nMolecular Neurobiology\nNeural-Immune Inter-\nactions\nProf. U. OttenTumor-Stroma Interactions\nDr. G. Orend\nMolecular Genetics\nProf. P . Sch\u00e4r\nTumor Biology\nProf. G. Christofori\nCancer- and Immuno-\nbiology\nProf. M. WymannFunctional Neuroanatomy\nProf. C. Nitsch\nDevelopmental Neurobiol -\nogy and Regeneration\nProf. J. Kapfhammer\nCytomorphology\nProf. L. Landmann\nDevelopmental Genetics\nProf. R. Zeller\nElectron Microscopy\nProf. U. Spornitz\nHistology\nProf. K. Beier\nAnatomisches Museum\nDr. h.c. H. KurzHuman Genetics\nProf. Hj. M\u00fcller\nGenetic Counselling and \nDiagnostics\nProf. Hj. M\u00fcller\nProf. P . MinyPediatric Immunology\nProf. G. A. Holl\u00e4nderDiabetology\nPD Dr. U. Zumsteg\nEndocrinology\nProf. A. N. EberleCardiobiology\nProf. M. Brink\nProf. P . Buser\nLegende\nSchwerpunkte:\nImmunologie\nNeurobiologie\nOnkologie\nZellplastizit\u00e4t und \nGewebereparaturDienstleistungenSpezialit\u00e4tenUKBB-Gruppen\nExterne DF-Gruppe\nExterne Physiologie-\nGruppe8/9\nIntegrative Biology\nProf. D. HaagInstitut f\u00fcr Anatomie\nPestalozzistrasse 20, 4056 Basel\nZentrum f\u00fcr Lehre und Forschung (ZLF)\nHebelstrasse 20, 4031 Basel \nPharmazentrum (7. Stock)\nKlingelbergstrasse 50/70, 4056 Basel \nZentrum f\u00fcr Biomedizin\nMattenstrasse 28, 4058 Basel\nVesalianum\nVesalgasse 1, 4051 Basel\nInstitut f\u00fcr Medizinische Mikrobiologie\nPetersplatz 10, 4003 Basel\nDie Geb\u00e4ude des Departements \nKlinisch-Biologische Wissenschaften\n1\n2\n43\n5\n16\n12\n3\n4\n5\n610/11Ein neues \u00abZentrum f\u00fcr Biomedizin\u00bb \nDas neue DKBW Geb\u00e4ude ist ein Geschenk der Novartis an die Univer-\nsit\u00e4t Basel, die es dem DKBW zugeteilt hat. Die Architekten Wirth & \nWirth, Gewinner des hierf\u00fcr ausgeschriebenen Architekturwettbe -\nwerbs planten und leiteten Umbau und Anpassung des Geb\u00e4udes.\nDas DKBW Geb\u00e4ude an der Mattenstrasse soll im November 2004 fei -\nerlich eingeweiht werden. Es beherbergt rund zehn Forschungsgruppen \naus drei Schwerpunkten.\nArchitektonischer Baubeschrieb\nGeb\u00e4udeh\u00fclle\nDas Geb\u00e4ude an der Mattenstrasse ist ein lang gezogener, f\u00fcnfgeschossiger Bau \nmit einem Attikageschoss (und Untergeschossen), Er pr\u00e4sentiert sich nach aus -\nsen als Skelettkonstruktion mit sichtbaren, gestrichenen Stirnen von Betonpfeil -\nern und -decken, dazu abgesetzt Wandausfachungen aus rotem Sichtbackstein. \nFenster und Lamellenstoren wurden saniert, haben aber die optische Erschei -\nnung nicht ver\u00e4ndert.\nNeu dagegen ist der \u00f6ffentliche Eingang an der Mattenstrasse. Er war notwendig \ngeworden, da Areal und Geb\u00e4ude aus dem Syngenta-Areal ausgegliedert wur -\nden. Ein Vordach bietet Wetter- und Sonnenschutz f\u00fcr den Eingangsbereich und \ngrossz\u00fcgige, neue Fenster erhellen die angegliederte Cafeteria. Die ehemaligen, \nr\u00fcckw\u00e4rtigen Zug\u00e4nge dienen neu zur Anlieferung.\nDas sanierte Dach ist mit einer Extensivbegr\u00fcnung und f\u00fcr die begehbaren Be -\nreiche mit Zementplatten gestaltet worden.\nAllgemeine Geb\u00e4udestruktur und Nutzung\nDas Innere des Geb\u00e4udes wird l\u00e4ngs von der Gangzone in einen breiteren, zum \nInnenhof orientierten Bereich und eine schm\u00e4lere, auf die Strasse gerichtete \nZone geteilt. An beiden Enden des Geb\u00e4udes befinden sich Treppenh\u00e4user und \nPersonenliftanlage.\nDer Besucher findet im Eingangsbereich den Empfang und die kleine, helle Caf -\neteria zur Selbstbedienung. In der r\u00fcckw\u00e4rtigen Zone des Erdgeschosses sind \nein grosser Seminarraum sowie kleinere Besprechungsr\u00e4ume und eine kleine \nBibliothek untergebracht.\nIn den oberen Etagen wurden die Labor- und B\u00fcror\u00e4umlichkeiten des DKBW \neingerichtet und gegen die Strasse weitere B\u00fcros und Nebenr\u00e4ume.\nIm 1.Untergeschoss sind die Tier- mit dazugeh\u00f6rigen Arbeits-, Lager- und \nReinigungsr\u00e4umen untergebracht und im 2.Untergeschoss befinden sich die \nEnergiezentrale sowie verschiedene Lagerr\u00e4ume f\u00fcr die Labors.\nChristian Schmid, Direktor Wirth & Wirth AG\nWir danken folgenden Firmen, die am Umbau beteiligt \nwaren, und die uns f\u00fcr die vorliegende Schrift grossz\u00fcgig \nunterst\u00fctzt haben:12/13Prof. Dr. Ed Palmer , born in 1952 in Oceanside, New York, USA, obtained a PhD in microbiol -\nogy and a MD, both obtained at the Rochester University in 1980. After a postdoctoral fellow -\nship at the Salk Institute in La Jolla, California he became assistant professor at the University \nof Colorado in Denver in 1984. He is specialist in transplantation immunology and his work \nfocuses on the domains of T-cells and T-cell receptors. In 2001, he joined the Department of \nTransplantation Immunology and Nephrology of the University Hospital Basel and became \n2003 full Professor of Transplantation Immunology at the DKBW.\nProf. Dr. Antonius Rolink , born 1953 in the Netherlands, \nstudied Molecular Sciences at Agricultural School in Wage -\nningen, Netherlands. He obtained his PhD at the Red Cross blood transfusion center of the \nUniversity of Amsterdam in 1982. He moved to Basel in 1983, where he joined the Basel \nInstitute for Immunology. He habilitated in 1997 at the University of Basel and was appointed \n2001 Roche Professor for Immunology, a professorship financed by Roche. His work focuses \non hematopoietic stem cells and the development of the immune system.\nProf. Dr. Primo Sch\u00e4r , born 1961 in Willisau-Stadt, Switzer -\nland, studied biology at the University of Bern and obtained \nhis PhD in 1991 at the Institut f\u00fcr Zellbiologie. From 1993 to 1997, he was a postdoctoral fellow \nat the Imperial Cancer Research Fund in London thereafter as researcher and teacher at the \nInstitut f\u00fcr Medizinische Radiobiologie of the University of Z\u00fcrich. Appointed Professor of \nMedical Genetics at the DKBW in 2003, his research focuses on the molecular mechanisms \ninvolved in DNA repair using genetic and biochemical approaches. \nProf. Dr. Radek Skoda , born 1956 in Bratislava, Slovakia, \nstudied medicine at the University of Z\u00fcrich. After research \nactivities at the Biozentrum in Basel, training in internal medicine at the Basler Kantonsspital \nand a fellowship at the National Cancer Institute in Bethesda, USA, he was from 1989 to \n1993 in the Department of Genetics of the Harvard Medical School in Boston, USA. Back in \nSwitzerland, he was a recipient of a SCORE-A fellowship by the Swiss National Science Foun -\ndation and specialized in internal medicine. He habilitated in 1998 at the University of Basel \nand became Assistant Professor at the Biozentrum. From 2000 on, he was at the Deutsche \nKrebsforschungszentrum in Heidelberg, Germany. In 2001 he has returned to Basel and was \nappointed Professor of Molecular Medicine and head of the Department of Research at the \nUniversity Hospital Basel. \nProf. Dr. Matthias Wymann , born 1960 in Solothurn, Switzerland, studied biochemistry at \nthe ETH Z\u00fcrich and obtained his PhD in 1988 at the Theodor Kocher Institut of the University \nof Bern. After research activities at the Department of Medical Microbiology of the University \nof Link\u00f6ping, Sweden, he came back to Switzerland in 1991 and habilitated in cell biology \nand biochemistry at the University of Fribourg (CH) in 1997. His projects are dealing with the \nrole of lipid kinases in the cellular processes underlying tumor inception and inflammation. \nHe was appointed Professor of Biochemistry in 2004.\nProf. Dr. Rolf Zeller , born in 1957 in Basel, Switzerland, \nstudied molecular biology at the Biozentrum, Basel. After his \nPhD in 1984, he was a postdoctoral fellow from 1985 to 1989 in the Department of Genetics \nat the Harvard Medical School in Boston, USA. He became group leader at the European \nMolecular Biology Laboratory in Heidelberg, then head of the Department of Developmen -\ntal Biology at the University of Utrecht (NL), and was appointed Professor of Anatomy and \nEmbryology at the DKBW in 2002. He is the head of the Institute of Anatomy. His research \nfocuses on the molecular and genetic analysis of cell to cell communication during growth \nand morphogenesis.Prof. Dr. Bernhard Bettler , born 1957 in Baden, Switzerland, studied microbiology at the \nUniversity of Z\u00fcrich where he obtained his PhD in 1986. Between 1989 and 1997 he worked \nin the biotechnology department at CIBA-Geigy in Basel, at the Salk Institute for Biological \nSciences in San Diego, California in Neurobiology, and at the CIBA-Geigy Pharma division in \nBasel. From 1998, he has been group leader in neurobiology research at Novartis in Basel. \nIn 2001, Prof. Bettler was been appointed Professor of Physiology and heads the Institute of \nPhysiology. His work focuses on the role of GABA receptors in the brain.\nProf. Dr. Marijke Brink , born in 1959 in Bussum, NL, studied \nbiology and biochemistry at the Rijksuniversiteit in Leiden. In \n1989, she obtained her PhD in Biochemisty at the Max Planck Institut in Martinsried/M\u00fcnchen \nand was a postdoctoral fellow at the University of Amsterdam (until 1992), in Ciba-Geigy \nBasel (until 1994) and at the Emory University in Atlanta, USA (until 1996). She habilitated at \nthe University Hospital in Geneva in 1997. She has been appointed Professor of Physiology \nin 2004. Her work focuses on the role of growth factors in cardiology and she is an expert in \nclinical research in the domains of cardio-vascular biology and endocrinology .\nProf. Dr. Gerhard M. Christofori , born in 1957 in \nPforzheim, Germany, studied biology at the University of Heidelberg where he obtained \nhis PhD in molecular biology in 1988. He worked at the Krebsforschungszentrum in Heidel -\nberg and at the Biozentrum in Basel as postdoctoral fellow. From 1989 to 1994, he stayed \nat the Hormone Research Institute in the Department of Biochemistry and Biophysics of the \nUniversity of California, San Francisco. In 1994, he became group leader at the Research \nInstitute for Molecular Pathology (IMP) in Vienna and habilitated in 2001. He was appointed \nProfessor for Biochemistry in 2001 and heads the Institute for Biochemistry and Genetics. \nHis work focuses on the identification and characterization of genes and factors involved in \ncarcinogenesis and metastasis.\nProf. Dr. Urs Eriksson , born in 1964 in studied chemistry at the ETH in Z\u00fcrich and medicine \nat the University of Z\u00fcrich. In addition to his clinical training at the University Hospitals of \nZ\u00fcrich and Basel, he was a research fellow from 2001\u20132003 at the Departments of Medical \nBiophysics and Immunology, Princess Margaret Hospital, at the University of Toronto, Canada. \nIn 2004 he obtained a professorship from the Swiss National Science Foundation and joined \nthe Department of Research at the University Hospital Basel. His work focuses on inflamma -\ntion of the cardiac muscle, on the frequent causes of heart failures of young persons and on \nclarifying the mechanisms leading to inflammatory heart disease.\nProf. Dr. Daniela Finke , born in 1964, studied medicine \nin Freiburg i.B. where she graduated 1994. After two clinical years, she moved to Lausanne \nwhere she trained in immunology at the Ludwig Institute, for Cancer Research, at the Swiss \nInstitute for Experimental Cancer Research, and at the Institute of Biochemistry of the Univer -\nsity of Lausanne. She works on developmental aspects of immunology, on the formation of \nlymphatic tissue that is important in the immune defense. Since 2003 she holds a professorship \nfrom the Swiss National Science Foundation and chose the DKBW as host insitution.\nProf. Dr. Hans H. Hirsch , born in 1958 in Flensburg, Ger -\nmany, studied medicine in Freiburg i. Br. and biochemistry \nat the University of Oregon State in Corvallis, USA. In 1986, he joined the Biotechnology \nDepartment of Ciba-Geigy in Basel. From 1989, he was at the Institute for Medical Microbiol -\nogy at the University of Basel where he habilitated in 1997. After clinical training in internal \nmedicine and infectiology in the University Clinics of Basel, he was appointed Professor of \nMedical Microbiology in 2004 with a joint appointment at the DKBW (Institute of Medical \nMicrobiology) and the Department of Infectious Diseases of the University Hospital. His work \nfocuses on viral infections of immuno-compromised patients. \nNewly Appointed Professors\n2002\u20132004\n14/15DKBW Schwerpunkt\nNeurobiologie\nDer DKBW-Schwerpunkt Neurowissenschaften wurde ins Leben gerufen, \nweil die Aufkl\u00e4rung der Erkrankungen des Nervensystems mit zu den gr\u00f6ssten \nHerausforderungen der biomedizinischen Forschung geh\u00f6rt. Der DKBW-\nSchwerpunkt erg\u00e4nzt die Neurobiologie-Schwerpunkte des Biozentrums und \ndes Friedrich-Miescher-Instituts und ist Teil des fakult\u00e4ts\u00fcbergreifenden \u00abBasel \nNeuroscience Programs\u00bb (BNP, http://www.biozentrum.unibas.ch/neuro). Das \nBNP vereint mehr als 400 Basler Neurowissenschaftler aus 40 verschiedenen \nLaboratorien der Universit\u00e4t und pharmazeutischen Industrie. Im Rahmen des \nBNP finden w\u00f6chentliche interdisziplin\u00e4re Veranstaltungen, wie beispiels -\nweise die \u00abThursday Seminars in Neurobiology\u00bb oder die \u00abBasel Neurobiology \nLectures\u00bb, statt. Diese bieten eine ideale Plattform f\u00fcr einen regen Austausch \nzwischen Grundlagenforschern und klinischen Forschern. Zus\u00e4tzlich koordi -\nniert Neurex (http://www.neurex.org/), ein tri-nationaler Zusammenschluss \ndes BNP mit den Neuro-Netzwerken der Universit\u00e4t Freiburg (NeurAG, http:\n//www.neurag.uni-freiburg.de) und der Universit\u00e4t Strassburg/Rouffach (IFR \n37, http://neurochem.u-strasbg.fr), regelm\u00e4ssig Workshops im Dreil\u00e4ndereck. \nNeurex verleiht zudem \u00fcberregionale Forschungsstipendien, von denen auch \nDKBW-Neurowissenschaftler profitieren. \nDer DKBW-Schwerpunkt hat sich zum Ziel gesetzt, die in der Region Basel \naussergew\u00f6hnlich starke Ballung von neurowissenschaftlicher Expertise zu \nnutzen, um Erkrankungen von grosser medizinischer und gesellschaftlicher \nRelevanz zu untersuchen. Aufgrund dieser Initiative sind die ersten gemeinsa -\nmen Forschungsprojekte von Biologen und Medizinern des DKBW beim Sch -\nweizerischen Nationalfonds eingereicht worden. Die vorliegenden Beitr\u00e4ge illus -\ntrieren die laufenden DKBW-Forschungsprojekte, welche sich insbesondere auf \ndie Erforschung neuroinflammatorischer, neurodegenerativer, psychiatrischer, \nneuro-onkologischer und neuromuskul\u00e4rer Erkrankungen konzentrieren.\nEine vordringliche Aufgabe ist, wissenschaftliche Erkenntnisse so rasch wie \nm\u00f6glich in den Dienst des Patienten \u00fcberzuf\u00fchren. Unser Schwerpunkt hat \ndeshalb \u2013 zusammen mit dem BNP \u2013 im September 2003 zum ersten Mal das \nBasel Neuroscience Symposium: \u00abFrom Bench-to-Bedside\u00bb durchgef\u00fchrt. Das \nTreffen hat 150 Basler Neurowissenschaftler aus den Forschungslabors von \nNovartis, Roche, dem Friedrich-Miescher Institut, der Universit\u00e4t sowie dem \nUniversit\u00e4tsspital zusammengef\u00fchrt. Der Erfolg des Symposiums hat uns darin \nbest\u00e4rkt, das Symposium j\u00e4hrlich durchzuf\u00fchren und damit den Basler Neurow -\nissenschaftlern ein Forum f\u00fcr neue medizinische Konzepte und Ideen zu bieten \n(http://www.bench-bed-basel.ch). \nProfessor B. Bettler\nInstitut f\u00fcr Physiologie\nUniversit\u00e4t Basel Professor A. J. Steck\nNeurologische Klinik\nUniversit\u00e4tsspital Basel \n16/17Functional \nNeuroanatomy\nProf. Dr. Cordula Nitsch\nInstitut f\u00fcr Anatomie\nGroup Members\nDr. I.-Piotr Maly\nDr. Florence Vollenweider\nDr. Kerstin Bendfeldt\nAnelis Kaiser Lic. phil. psychol.\nOlga Bollag (technician)\nGabriela Kalt (technician)\nEsther K\u00fcnzli (MD student)\nConstantine Bloch (MD student)Neuronal plasticity\nBrain lesions\nStroke\nLanguage learning\nBilingualismThe Role of Calcium-binding Proteins in \nStroke-related Neurodegeneration\nThe causes and consequences of neurodegeneration, this is the central topic of \nour research. How does the brain react to an insult and why are certain nerve \ncells and brain areas more resistant than others against identical noxious inter -\nventions? Are there endogenous mechanisms protecting against nerve cell loss \nwhich could be exploited therapeutically? Mediators of local cerebral inflamma -\ntion could influence stroke-related neurodegeneration (1). Presently, we focus \non the role of cytosolic calcium-binding proteins, parvalbumin and calbindin-\nD28K in particular, which help to control intracellular calcium concentrations \nand which are differentially distributed in defined nerve cell populations. \nCalcium is one of the most important intracellular second messengers and a key \nelement in neuronal excitation and neurodegeneration. Chronically elevated in -\ntracellular calcium levels have serious consequences: induction of apoptotic sig -\nnalling cascades, stimulation of catabolic enzymes and a collapse of mitochondri -\nal membrane potential, all leading towards nerve cell death. Thus, overload with \ncalcium can have a deleterious effect on neurons. Calcium levels are therefore \ntightly controlled via calcium pumps, calcium storing organelles as mitochondria \ne.g., and calcium-binding proteins. Deficiency in the calcium-binding protein \nparvalbumin in certain inhibitory neurons is correlated with spontaneous epilep -\ntiform seizures (2), while neurons expressing parvalbumin (3) or other cytosolic \ncalcium binding proteins survive an excitotoxic or ischemic episode.\nThe pathophysiological processes resulting in stroke-related (ischemic) nerve \ncell death involve the excessive release of the excitatory neurotransmitter gluta -\nmate. This causes an overstimulation of target neurons with depolarisation and \nincreased calcium influx and ultimately neurodegeneration. Therefore, wouldn\u2019t \nit be advantageous if all neurons in the brain expressed cytosolic calcium bind -\ning proteins? Transgenic mice expressing parvalbumin in all neurons (via the \nTHY1-promoter, in cooperation with Beat Schwaller, Inst. of Histology, Univ. \nFribourg) could provide some answers. In an in vivo model of transient global \nischemia we observed that, in sharp contrast to the widely held assumption, par -Kalzium-Puffer sind neuroprotektiv \u2013 aber \nnicht ausschliesslich\nKalzium (Ca) ist ein bedeutender zellul\u00e4rer Signalstoff, \nder die Erregungseigenschaften und die \u00dcberlebens -\nf\u00e4higkeit von Nervenzellen massgeblich beeinflusst. \nSeine intrazellul\u00e4re Konzentration wird durch mehrere \nMechanismen kontrolliert: Ca-Pumpen, Ca-Speicher \u2013 in \nNervenzellen sind dies insbesondere die Mitochondrien \n\u2013 und Ca-bindende Proteine, die als Puffer wirken k\u00f6n -\nnen. Chronisch gesteigerte Ca Konzentrationen, wie sie \nbei verschiedenen neurodegenerativen Erkrankungen, \ninsbesondere beim Schlaganfall auftreten, f\u00fchren meist \nzum Nervenzelltod. Nervenzellen, die konstitutiv zyto -\nsolische Ca-bindende Proteine besitzen, wie z.B. Parval -\nbumin oder Calbindin-D28K, scheinen gegen diese Art \ndes Nervenzelltods gesch\u00fctzt zu sein. \nWir haben bei transgenen M\u00e4usen untersucht, ob die An- \noder Abwesenheit dieser Kalziumpuffer in Modellen f\u00fcr \nSchlaganfall tatschlich neuroprotektive Wirkungen hat. \nM\u00e4use, die in allen Nervenzellen Parvalbumin enthalten, \nsind jedoch viel anf\u00e4lliger auf transiente Unterbrechung \nder Durchblutung und zeigen gr\u00f6ssere Ausf\u00e4lle nach \nApplikation von Neurotoxinen. Ist hingegen die Expres -\nsion von Parvalbumin und/oder Calbindin-D28K ausge -\nschaltet, so wird eine Unterbrechung der Durchblutung \nl\u00e4nger toleriert und die Ausf\u00e4lle sind geringer. Mangel an \nCalbindin-D28K und Parvalbumin ist also neuroprotektiv, \nw\u00e4hrend die Expression von Parvalbumin in Neuronen, \ndie dieses Protein normalerweise nicht enthalten, zu \ngesteigerter Anf\u00e4lligkeit f\u00fchrt. Die einfache Beziehung, \nmehr Ca-Puffer gleich mehr Neuroprotektion, stimmt \nalso nicht. Dar\u00fcber hinaus zeigt diese Untersuchung, \ndass sich bei transgenen Tieren Kompensationsprozes -\nse entwickeln k\u00f6nnen. Dies ist wohl insbesondere bei \nInteraktionen mit Schl\u00fcsselsubstanzen der Fall, die durch \nverschiedene parallele Mechanismen konstant gehalten \nwerden \u2013 wie hier dem Kalzium. So ist das Volumen an \nMitochondrien in den Neuronen, die ektopisch Parvalbu -\nmin exprimieren, um 50% reduziert. Die Kompensation \nist demnach \u00fcberschiessend und kann so die Anf\u00e4lligkeit \nder Nervenzellen steigern.\nSelected Publications\n\u2013 Vollenweider F , Herrmann M, Otten U, Nitsch C (2003) \nInterleukin-6 receptor expression and cellular localiza -\ntion after transient global ischemia in gerbil hippocam -\npus. Neurosci. Lett. 341: 49-52\n\u2013 Scotti AL, Bollag O, Kalt G, Nitsch C (1997) Loss of \nperikaryal parvalbumin immunoreactivity from surviv -\ning GABAergic neurons in the CA1 field of epileptic \ngerbils. Hippocampus 7: 524-535\n\u2013 Nitsch C et al. (1989) GABAergic hippocampal neurons \nresistant to ischemia-induced neuronal death contain \nthe Ca2 +-binding protein parvalbumin. Neurosci. Lett. \n105: 263-268\n\u2013 Maetzler W, Nitsch C, Bendfeldt K, Racay P, Vollen -\nweider F, Schwaller B. (2004) Ectopic parvalbumin \nexpression in mouse forebrain neurons increases sus -\nceptibility to excitotoxic injury provoked by ibotenic \nacid injection into the striatum. Exp. Neurol. 186: \n78-88\n\u2013 Franceschini R, Zappatore D, Nitsch C (2003) Lexicon \nin the brain: What neurobiology has to say about lan -\nguages. In: \u201cThe Multilingual Lexicon\u201d Kluver, Amster-\ndam, pp.153-166\nvalbumin-overexpressing mice are highly vulnerable against ischemia. Also, \nintracerebral injections of excitotoxic glutamate agonists result in significantly \nlarger lesions in the parvalbumin-overexpressing mice than in controls. From \nthis it can be concluded that presence of cytosolic calcium-buffering capacity \nper se is not neuroprotective and further, that an increase in cytosolic cal -\ncium buffering impairs other mechanism of calcium sequestration. In fact, in \nneurons ectopically expressing parvalbumin, the mitochondrial volume is de -\ncreased to 50 % of control and the mitochondrial marker enzyme COXI is re -\nduced (4). Mice devoid of parvalbumin and/or calbindin-D28K (PV-KO and \nPVxCB-KO) were, on the other hand, more resistant against transient global \nischemia as their wild-type counterparts (Fig. 1), in part possibly because \ntheir mitochondrial pool is enlarged. In addition, improved survival was seen \nalso intraoperatively, where they tolerated vagal stimulation. This observation \ninitiated an ongoing study on the role of parvalbumin and calbindin-D28K in \nthe control of respiratory reflexes (Fig. 2).\nOur present studies show that ectopic presence of calcium-binding proteins \nis deleterious, while absence of these calcium-binding proteins is protective. \nThis demonstrates first that global alterations in the expression of key pro -\nteins as provided by the transgenic technologies are a superior tool to test hy -\npotheses, and second that interference with the expression of key molecules \nof neuronal homeostasis can induce compensation mechanisms which might \neven result in an opposite effect. \nFig. 1:  Neurodegenera -\ntion after global transient \nischemia. (A) The hip -\npocampus of a PVxCB-KO \nmouse is well preserved. \n(B) Severe damage in \nthe hippocampus of a \nwild type mouse. (C) The \nstriatum of a PVxCB-KO \nmouse is well preserved. \n(D) Marked nerve cell loss \nin the striatum of a wild \ntype mouse.\nFig. 2:  GABAergic neu -\nrons in the respiratory \ncentre of the nc. tractus \nsolitarius are labelled in \nblue and contrasted with \ncalcium-binding proteins, \nlabelled in brown. (A) \nDistinct calbindin-D28K \ncontaining neurons do not \ncolocalize with GADm -\nRNA. (B) A subgroup of \nGABAergic neurons colo -\ncalizes with parvalbumin. \n1a\n 1c\n1b\n 1d\nFig. 3:  Regional cerebral activation during \nprocessing of the third language, learned \nduring early adulthood (data analysis by \nBrain Voyager, random effect, p (uncorr.) < \n0.05). (A) Strong activation of Broca\u2019s area \nin explicit learners  (n=9). (B) No activation \nin Broca\u2019s area in implicit learners  (n=11).Transdisciplinary project\nProf. Dr. phil. Rita Franceschini, Institut f\u00fcr Romanistik, Universit\u00e4t Saarland, D \nProf. Dr. phil. Georges L\u00fcdi, Romanisches Seminar, Universit\u00e4t Basel\nProf. Dr. med. Ernst Wilhelm Rad\u00fc, Departement Radiologie, Universit\u00e4tsspital Basel\nThe Multilingual Brain\nMore than half of mankind is multilingual or lives in a multilingual environment. Languages \nare learnt at different ages and in different settings and up to different levels of compe -\ntence. Nevertheless, there is a prevalent prejudice: monolingualism is considered the \nnorm, monolingual upbringing necessary for high proficiency in the \u201cnative tongue\u201d, and \nit is believed that there are innate constraints in learning second and third languages. In \nthe multilingual brain project, researchers from linguistics and from neurosciences join to \naddress different features of multilingualism with the common goal to gain new insights \ninto the use and processing of multiple languages in the individual, in his/her brain and \nin society. The investigations are carried out in students proficient in at least 3 languages. \nTheir language biographies are recorded and analyzed with respect to age and form of \nlanguage acquisition, attitudes towards language learning, use etc. The proficiency is \ncontrolled in language competence tests. Using functional Magnetic Resonance Imaging \n(fMRI) the regional cerebral activation during processing of the three single languages is \nstudied. Results suggest that presence of two languages in the early childhood results in \ndifferences in language processing in the first language indicating that the age of second \nlanguage learning influences the construction of multilingual repertoires in the brain. Also, \nlanguage learning (rule-based and structured i.e. explicit; or focused on meaning and \ncommunication i.e. implicit) influences the representation of languages in the brain (Fig. \n3). Questions currently pursued are the presence/absence of a critical time window for \nnative-like learning of languages and the influence of early second language acquisition \non third language learning. Further we address the issue of the construction of boundaries \nbetween languages. What are the conditions under which the brain deals with a related \nlanguage as an independent entity or as a variety? (E.g.: Is Swiss German a language or \na dialect in this respect?)18/19\nDevelopmental \nNeurobiology \nand \nRegeneration \nProf. Dr. Josef Kapfhammer\nInstitut f\u00fcr Anatomie\nGroup Members\nDr. Vesna Radojevic\nMarkus Saxer (technician)\nBrenda Bonnici (PhD student)\nAlexandra Zelenskaya (PhD student)Axonal regeneration\nOrganotypic slice cultures\nDendritic development\nProtein kinase C\nNeural repair\nNeuronal plasticityThe Regulation of Axonal and Dendritic \nGrowth\nAxonal projections build the neuronal connections within the CNS. They can be \ndestroyed by traumatic lesions (e.g. spinal or head injury), but also by vascular \ninsults and neurodegenerative diseases. During embryonic development the \nconnections between neurons are generated by the directed growth of axons \ntowards their target regions, followed by synapse formation with the appropri -\nate target neurons. This axonal growth program cannot be easily recalled in the \nadult CNS. After lesions, severed axons cannot regrow and the disconnected \nneurons remain permanently dysfunctional. In the moment several experimental \nstrategies are being explored by many laboratories worldwide with the goal to \neventually be able to offer therapeutic options to patients suffering from axonal \ndamage. In our laboratory we are focusing on the entorhino-hippocampal pro -\njection. This axonal projection can be studied in a tissue culture setup, so-called \norganotypic slice cultures. The entorhino-hippocampal projection develops in \nthese cultures and mechanical lesions of the axons can be made. This tissue \nculture approach, therefore, allows the study of axonal regeneration avoiding \nor reducing the need for in vivo experiments. We have studied the potential for \naxonal regeneration in entorhino-hippocampal slice cultures during maturation, \ni.e. when the axons loose growth potential present during embryonic develop -\nment. We could show that there is a sharp decline in the regeneration of this \nprojection between day 4 and day 6 of postnatal development. We have then \ntested whether the regeneration of the lesioned fibers could be stimulated by \npharmacological intervention (Fig. 1). These experiments demonstrated that \nsome growth factors, for example neurotrophin 4 ( =NT4) and glial cell line \u2013 de -\nrived neurotrophic factor (GDNF), could promote axonal regeneration. Simi -\nlarly, interference with the protein kinase C signaling pathway with the drug GF \n109203X or of G-protein signaling with pertussis toxin (PTX) promoted axonal \nregeneration. In ongoing experiments we now explore the ability of transplanted \nimmature neural cells (\u201cstem cells\u201d) to rebuild this specific axonal projection after \nlesion or degeneration of the original axons.Die Regulation des Wachstums von Axonen \nund Dendriten\nAxonale Projektionen bilden gerichtete neuronale Ver -\nbindungen im Zentralnervensystem, die entscheidende \nBedeutung f\u00fcr die Funktion des Nervensystems haben. \nTraumatische Verletzungen, Durchblutungsst\u00f6rungen \noder neurodegenerative Krankheiten k\u00f6nnen diese \nVerbindungen zerst\u00f6ren. Durch L\u00e4sionen unterbro -\nchene Axone wachsen nicht nach und die Funktion der \nbetroffenen Systeme ist verloren. In unserem Labor un -\ntersuchen wir die axonale Verbindung zwischen zwei \nHirngebieten, dem entorhinalem Cortex und dem Hip -\npokampus. Diese Verbindung kann in Zellkultur in so -\ngenannten organotypischen Schnittkulturen untersucht \nwerden. Wir zeigten, dass Schnittkulturen von M\u00e4usen \ndie F\u00e4higkeit zur Reparatur dieser Verbindung 4-6 Tage \nnach der Geburt abrupt verlieren. Durch pharmakolo -\ngische Behandlung mit neurotrophen Faktoren sowie \nInhibitoren der Signalmolek\u00fcle Protein Kinase C (PKC) \nund Pertussistoxin konnte die Regeneration verbessert \nwerden. In weiteren Versuchen pr\u00fcfen wir die F\u00e4higkeit \nimplantierter neuronaler Stammzellen, spezifisch die ge -\nsch\u00e4digte axonale Projektion zu ersetzen. \nEin zweites Arbeitsgebiet unserer Gruppe ist die Ent -\nwicklung des Dendritenbaums einer Nervenzelle. Die \nForm des Dendritenbaums ist ein typisches Merkmal \njeder Nervenzelle und von grosser Bedeutung f\u00fcr ihre \nFunktion. Das Signalmolek\u00fcl PKC ist hier ein wichtiger \nRegulator der Dendritenbildung. Stimulierung von PKC \nhemmt die Ausbildung der Dendriten von Purkinjezellen \n(den gr\u00f6ssten Zellen des Kleinhirns), w\u00e4hrend eine Hem -\nmung von PKC die Ausbildung des Dendritenbaums \nf\u00f6rdert. Mit Hilfe von verschiedenen Mausmodellen, \ndenen jeweils ein bestimmter Subtyp des PKC-Molek\u00fcls \nfehlt, konnten wir die Rolle f\u00fcr zwei PKC-Subtypen in \nder Ausbildung der Dendriten von Purkinjezellen cha -\nrakterisieren. In weiteren Experimenten untersuchen wir \ndie Rolle von neuronaler Aktivit\u00e4t und der Aktivierung \nvon Neurotransmitterrezeptoren f\u00fcr die Ausbildung des \nDendritenbaums von Purkinjezellen. \nSelected Publications\n\u2013 Metzger, F ., and Kapfhammer, J.P . (2000) Protein \nkinase C activity modulates dendritic differentiation \nof rat Purkinje cells in cerebellar slice cultures. Eur. J. \nNeurosci., 12, 1993-2005.\n\u2013 Prang, P ., Del Turco, D., Kapfhammer, J.P . (2001) \nRegeneration of entorhinal fibers in mouse slice \ncultures is age dependent and can be stimulated \nby NT-4, GDNF and modulators of G-proteins and \nprotein kinase C. Exp. Neurol., 169, 135-147.\n\u2013 Schrenk, K., Kapfhammer, J.P ., Metzger, F . (2002) \nAltered dendritic development of cerebellar Purkinje \ncells in slice cultures from protein kinase Cgamma-\ndeficient mice. Neuroscience, 110, 675-689.\n\u2013 Radojevic, V ., Kapfhammer, J.P . (2004) Repair of \nthe entorhino-hippocampal projection in vitro. Exp. \nNeurol. 188, 11-19. \n\u2013 Adcock, K. H., Metzger, F ., Kapfhammer, J.P . (2004) \nPurkinje cell dendritic tree development in the \nabsence of excitatory neurotransmission and of \nbrain-derived neurotrophic factor in organotypic \nslice cultures. Neuroscience, 127, 137-145. \nIn a second area of research we study the development of dendritic trees. \nThe outgrowth of dendritic trees is an important step in the differentiation of \nneurons. Most types of neurons can actually be identified by the morphology \nand the shape of their dendritic tree. Because the dendritic tree harbors most \nof the synaptic input of a neuron its growth and shape will determine the \nsynaptic connectivity of the cell. We have shown that the activity of Protein \nKinase C (PKC) is an important regulator of the dendritic growth of Purkinje \ncells, a major neuron of the cerebellum with a large dendritic tree. Stimulation \nof PKC activity inhibits Purkinje cell dendritic growth and branching. In con -\ntrast, inhibition of PKC activity thus stimulates Purkinje cell dendritic growth \nand branching (Fig. 2). PKC is a signaling molecule, which was shown before \nto determine synaptic function of Purkinje cells, raising the possibility that \nsimilar signalling mechanisms are involved in the regulation of synaptic plas -\nticity and dendritic growth. By using different mouse strains deficient for spe -\ncific isoforms of the Protein kinase C proteins we could attribute the function \non dendritic development to the alpha- and gamma-Isoforms of the protein. \nIn ongoing experiments we explore the role of activity and neurotransmitter \nreceptors for the development of Purkinje cell dendritic trees.\nFig. 1:  Schematic representation (lower row) and experimental data (upper row) for \nthe regeneration of the entorhino-hippocampal projection in culture. W ithout lesion \n(left images) entorhinal axons (red in schematic drawings) grow into the hippocampus \nand terminate in the outer molecular layer (OML) of the dentate gyrus (DG). \nAfter a lesion (middle images) the axons stop at the lesion site (arrow). After pharma -\ncological stimulation the axons re-grow, cross the lesion site (arrow) and rebuild the \ntypical projection to the OML (right images).Fig. 2:  Cerebellar Purkinje cells develop a typical dendritic tree in organotyic slice \ncultures (middle, Control). After activation of Protein Kinase C (PKC) the dendritic \ntree shrinks and loses side-branches (left, PKC-Activation). \nIn contrast, stimulation of PKC inhibition leads to increased growth and branching of \nthe Purkinje cell dendrites (right, PKC-Inhibition)\n Normal projection   After Lesion  After Lesion \n  and treatment20/21Synaptic \nPlasticity\nProf. Dr. Bernhard Bettler\nInstitut f\u00fcr Physiologie\nGroup Members\nDr. Martin Gassmann\nDr. Samuel Barbieri\nDr. Emilio Casanova\nDr. Claire-Marie Vacher\nDr. Rejan Vigot\nCorinne Haller (technician)\nBarbara Biermann (PhD student)\nNicole Guetg (PhD student)Mental Health\nBrain tumors\nGABA\nNotch\nNeurotransmitter\nKnock-outGABAB Receptor Subtypes as Drug Targets \nfor the Treatment of Anxiety and Depression\n\u03b3-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain \nand as such plays a key role in controlling neuronal activity. GABA mediates \nits action via two receptor systems, the GABAA and GABAB receptors. Unlike \nGABAA receptors that are ion channels, GABAB receptors are G-protein coupled \nreceptors (GPCRs) and signal through second messenger systems. Dysfunction \nof GABA-mediated synaptic transmission in the brain is a cause or a consequence \nof various neurological and psychiatric disorders. For example, a hypoactivity of \nthe GABA system was proposed to underlie epilepsy, spasticity, anxiety, stress, \nsleep disorders, depression, addiction and pain. In contrast, a hyperactivity of \nthe GABA system was associated with schizophrenia. The pharmaceutical indus -\ntry successfully exploited the GABA system and introduced a variety of drugs, \nsuch as e.g. the benzodiazepines and barbiturates, to the clinic. Most of these \ndrugs target the GABAA system, while progress in developing GABAB drugs was \nslow. Baclofen (Lioresal\u00ae), the only GABAB drug on the market, is used as a mus -\ncle-relaxant to treat spasticity. Baclofen showed therapeutic potential in mental \nhealth indications. However, its main therapeutic effect, muscle relaxation, is a \nsevere side-effect when it comes to psychiatric indications. All attempts to de -\nvelop GABAB drugs without muscle-relaxant activity failed, which prohibited a \nmore widespread use of GABAB drugs in man. \nTo reduce side-effects, a goal in pharmaceutical research is to target drugs se -\nlectively to structurally distinct receptor subtypes. The shortage of clinically suc -\ncessful GABAB drugs was attributed to this lack of subtype-selectivity. In 1997, \nour laboratory succeeded in cloning the first GABAB receptors. Revealing a new \nprinciple for GPCRs, we showed that GABAB receptors are not monomeric \nproteins but instead consist of two distinct subunits. Dimerization between \nGABAB(1a), GABAB(1b) and GABAB(2) subunits generates two pharmacologically \nindistinguishable receptor subtypes in the brain, GABAB(1a,2)  and GABAB(1b,2) . \nThese subtypes represent the only means for directing the search for novel \nGABAB drugs towards molecularly distinct receptor populations. We have \nstarted to address the individual functions of GABAB(1a,2)  and GABAB(1b,2)  recep -\ntors by generating knock-out mice that selectively express one, but not the other \nsubtype. Preliminary experiments indicate that these mice exhibit a subset of \nthe phenotypes, i.e. epilepsy, impaired memory, hyperactivity, hyperalgesia and \nanxiety that we observed in mice expressing no GABAB receptors at all. Most \nimportantly, we found that the muscle-relaxant effect of baclofen is mediated by \nonly one of the two GABAB subtypes. This now allows designing GABAB drugs \nthat dissociate the unwanted side-effects from the therapeutic effects. This will \nexpand the scope of medical applications to hopefully include anxiety and de -\npression. This project is carried out in collaboration with Novartis. Die Rolle verschiedener GABAB Rezeptoren \nbei Angst und Depression\nGamma Amino-Butters\u00e4ure ( \u03b3-aminobutyric acid, GABA) \nist der wichtigste hemmende Neurotransmitter (Boten-\nstoff) im Gehirn. Er vermittelt seine Aktivit\u00e4t auf die \nNervenzellen \u00fcber GABAA und GABAB Rezeptoren. \nSt\u00f6rungen des GABA Systems k\u00f6nnen sowohl Ursache \nals auch Folge von neurologischen und psychiatrischen \nErkrankungen, wie beispielsweise Epilepsie, Spastizit\u00e4t, \nAngstzust\u00e4nde, Schlaflosigkeit, Depression, Sucht, \nSchmerz und Schizophrenie sein. Einige bekannte Pro-\ndukte der Pharmaindustrie zur Behandlung dieser \nErkrankungen, wie etwa die Barbiturate und Benzodia -\nzepine, greifen an den GABAA Rezeptoren an. Baclofen \nist zurzeit das einzige Medikament welches \u00fcber GABAB \nRezeptoren wirkt. Baclofen wird vor allem bei der The -\nrapie von Muskel-Spasmen verwendet. Baclofen kann \nleider nicht zur Behandlung von psychiatrischen Erkran -\nkungen eingesetzt werden, da Muskelrelaxation f\u00fcr diese \nIndikationen eine unerw\u00fcnschte Nebenwirkung darstellt. \nBisher ist es leider nicht gelungen, GABAB-Medikamente \nohne muskelrelaxierende Wirkungen zu entwickeln. Wir \nhaben 1997/98 die ersten GABAB Rezeptoren kloniert \nund konnten zeigen, dass das Gehirn zwei verschiedene \nRezeptoren exprimiert. In Zusammenarbeit mit Novartis \nhaben wir Knock-out M\u00e4use hergestellt, welche die zwei \nGABAB Rezeptoren in Abwesenheit des jeweils anderen \nRezeptors exprimieren. In einer der beiden Maus-Linien \nbeh\u00e4lt Baclofen seine therapeutischen psychiatrischen \nWirkungen, praktisch ohne dass dabei Muskelrelaxation \neintritt. Damit bietet sich nun ein molekular Ansatz f\u00fcr \ndie Entwicklung von spezifischeren GABAB-Pharmaka, \nwelche auch bei psychiatrischen Erkrankungen einge -\nsetzt werden k\u00f6nnen.\nSelected Publications\n\u2013 Kaupmann, K., Huggel, H., Heid, J., Flor, P . J., Bischoff, \nS., Mickel, S. J., McMaster, G., Angst, C., Bittiger, H., \nFroestl, W . and Bettler, B. (1997) Expression cloning of \nGABAB receptors uncovers similarity to metabotropic \nglutamate receptors. Nature 386, 239-246. \n\u2013 Kaupmann, K., Malitschek, B, Schuler, V ., Heid, J., \nFroestl, W ., Beck, P ., Mosbacher, J., Bischoff, S., Kulik, \nA., Shigemoto, R., Karschin, A. and Bettler, B. (1998) \nGABAB receptor subtypes assemble into functional \nheteromeric complexes. Nature 396, 683-687. \n\u2013 Schuler, V ., L\u00fcscher C., Blanchet, C, Klix, N., Sansig, G., \nKlebs, K., Schmutz, M,. Heid, J., Gentry, C., Urban, L., \nFox, A., Spooren, W ., Jaton, A.-L., Vigouret, J.-M., Pozza, \nM., Kelly, P .H., Mosbacher, J., Fr\u00f6stl, W., K\u00e4slin, E., \nKorn, R., Bischoff, S., Kaupmann, K., Van der Putten, H. \nand Bettler, B. (2001) Epilepsy, hyperalgesia, impaired \nmemory and loss of pre- and postsynaptic GABAB re-\nsponses in mice lacking GABAB(1). Neuron 31, 47-58.\n\u2013 Kaupmann, K., Cryan, J.F ., Wellendorph, P ., Mom-\nbereau, C., Sansig, G., Klebs, K., Schmutz, M., Froestl, \nW ., Van der Putten, H., Mosbacher, J., Br\u00e4uner-Osbor-\nne, H., Waldmeier, P . and Bettler, B. (2003) Specific \n\u03b3-hydroxybutyrate-binding sites but loss of pharma-\ncological effects of \u03b3-hydroxybutyrate (GHB) in \nGABAB(1)-deficient mice. Eur. J. Neurosci. 18, 2722-\n2730.\n\u2013 Bettler, B., Kaupmann, K., Mosbacher, J and Gass-\nmann M. (2004) Structure and function of GABAB \nreceptors. Physiol. Rev. 84, 835-867.Tumor Suppressors and \nOncogenes Operative in \nHuman Brain Tumors\nThe research of the Molecular Neuro-Oncology Laboratory \nis focusing on the genetics of malignant brain tumors of glial \norigin (gliomas). We conducted several studies about the \nmutational frequencies in gliomas at the INK4A/ARF locus \nand of the PTEN gene. These are two critical tumor suppres -\nsor loci that are frequently altered during gliomagenesis. In \naddition, we have identified focal adhesion kinase (FAK) \nto be overexpressed in invasive malignant gliomas and \nshowed that dominant negative FAK impairs invasion and \nsurvival of glioblastoma cells. Moreover, we performed a \nsomatic mapping study on the 10q arm which points to the \n10q25-26 region and identified GPR26 as a candidate gene, \na novel member of the amine-like receptor subgroup of G \nprotein-coupled receptors, for which no cognate ligand has \nbeen identified so far. This gene is inactivated by epigenetic \nsilencing in 50% of GBMs. Furthermore, we performed a \nsomatic mapping study of the 1p arm in different types of \ngliomas and found that, in oligodendrogliomas, the deletion \nbreakpoint targets the Notch2 gene. The Notch2 protein is \nnot detectable in oligodendrogliomas by immunohistochem -\nistry. In contrast, Notch2 is highly expressed in astrocytoma \ncell lines and primary malignant astrocytomas. Moreover, \nthe genetic status of the Notch2 alleles appears to allow the \nprediction of patient survival.\nNotch2  as a Drug Target for the Treatment \nof Malignant Brain Tumors\nMalignant astrocytomas are among the most aggressive brain tumors in \nman. Screening for genetic alterations in astrocytomas revealed frequent \namplifications at the Notch2  locus. Notch2  has been linked to cancer before, \nbut never in the etiology of brain tumors. We currently carry out transgenic \nexperiments to clarify whether expression of Notch2  in mature astrocytes, \nwhich normally do not express this protein, causes malignant astrocytomas. \nOur experiments will reveal whether blocking Notch2  function represents a \nvalid treatment for this most devastating human disease. \nProf. Dr. Adrian Merlo \nNeurochirurgische Klinik \nUniversit\u00e4tsspital Basel\nFig. 1:   Co-localization of GABAB(1a) and GABAB(1b) (1a+1b) with \nGABAB(2) (2) mRNA in rat brain. This highlights that both a GABAB(1) \nand GABAB(2) subunit is necessary to form a functional receptor.Fig. 2:   Differential localization of GABAB(1a) and GABAB(1b) mRNA \nin the rat cerebellum, indicating that these two subunits fulfill distinct \nphysiological roles.\n22/23Neuro-\nOncology\nProf. Dr. Adrian Merlo\nNeurochirurgische Klinik\nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Jean-Louis Boulay \nDr. Roland Imber\nDr. Mihai Ionescu\nFran\u00e7oise David (technician)\nBeatrice Dolder (technician)\nDr. Elisabeth Taylor (technician)\nBalasubramanian Sivasankaran (PhD student)\nViviane Egler (PhD student)\nMike Failly (PhD student)Brain Tumors\nGlioblastoma\nSomatic deletion mapping \nGPR26\nNotch2\nPKI inhibitorsHuman Brain Tumors: From Genetic \nAlterations to Therapeutic Interventions\nOn the role of the INK4A/ARF and PTEN locus in human gliomas\nOur research laboratory is focusing on the molecular genetics of malignant brain \ntumors of glial origin (gliomas). During clonal expansion, stochastic selection of \ngrowth and survival promoting mutations leads to the outgrowth of ever more \nmalignant clonal tumor cell populations. The consequence of these progressive \ngenetic changes is gain or loss of function, also classified as alterations in onco -\ngenes and/or tumor suppressor genes. Our focus is to identify critical genes and \npathways involved in brain tumorigenesis. \nWe conducted a genetic study about the frequency of homozygous deletions \nat the INK4A/ARF locus on chromosome 9p21. We compared real-time PCR \nwith microsatellite mapping and fluorescence-in situ-hybridisation (FISH). Ho -\nmozygous deletions were discovered in nearly half of all glioblastomas. Thus, \nthe INK4A/ARF locus is an important mutational target during gliomagenesis \n(Fig. 1). Interestingly, this deletion was found to be associated with poor survival \nin elderly glioblastoma patients. We also analyzed the mutational frequency of \nPTEN in gliomas and studied the role of PTEN in invasion, using the two highly \ninfiltrative glioma cell lines U87MG (which lacks functional PTEN) and LN229 \n(wild-type PTEN). Constitutive expression of wild-type PTEN reduced phospho -\nrylation on Ser-473 of PKB/Akt in U87MG cells (Fig. 2). Moreover, we showed \nthat overexpression of PTEN is sufficient to reduce the invasive potential of \nglioma cells, independently of the phosphatase activity. In addition, we have \nidentified focal adhesion kinase (FAK) to be overexpressed in invasive malignant \ngliomas and showed that dominant negative FAK impairs invasion and survival \nof glioblastoma cells.\nIdentification of GPR26  and Notch2  by somatic deletion mapping\nA second tumor suppressor region involved in a number of human cancers has \nbeen identified on 10q25.3-26. Therefore, we performed a somatic mapping \nstudy on the 10q arm which points to the 10q25-26 region, an area that harbors \nthe DMBT1 candidate tumor suppressor gene, which we could not ascertain as \na glioma suppressor gene. Instead, we identified GPR26 as a candidate gene, a \nnovel member of the amine-like receptor subgroup of G protein-coupled recep -\ntors, for which no cognate ligand has been identified so far. This gene is inacti -\nvated by epigenetic silencing in 50% of GBMs (Glioblastomas). Genetik und Biologie von Hirntumoren\nIm Gehirn k\u00f6nnen sich Nervenzellen und St\u00fctz- oder \nGliazellen nach der Geburt normalerweise nicht mehr \nteilen, mit Ausnahme von neuralen Vorl\u00e4uferzellen, die \nin Verdacht stehen, auch zu Tumoren f\u00fchren zu k\u00f6nnen. \nTumorzellen unterscheiden sich aber durch eine Reihe \nvon erworbenen genetischen Ver\u00e4nderungen von die -\nsen Vorl\u00e4uferzellen. Unsere Gruppe befasst sich mit der \nIdentifikation von Genen und deren Signaltransduktions -\nregelkreise, welche bei der Bildung von Gehirntumoren \neine entscheidende Rolle spielen. Auf dem Chromosom \n9p21 befindet sich ein f\u00fcr die Krebsentstehung wichtiger \nGenlokus, der zwei Genprodukte \u2013 INK4 und ARF \u2013 co -\ndiert. Wir fanden in Glioblastomen eine Mutationsrate \nvon etwa 50%. Weiter untersuchten wir die Rolle von \nPTEN (Phosphatase and Tensin Homolog). PTEN ist ein \nProtein, das Phosphatgruppen von anderen Proteinen \nabspaltet und damit deren Aktivit\u00e4t reguliert. PTEN ist \nh\u00e4ufig in invasiven Glioblastomen durch erworbene \nMutationen ausgeschaltet. Dies f\u00fchrt dann z.B. zur Ue -\nberaktivierung der Proteinkinase B (Akt). Neben PTEN \nspielt auch FAK (focal adhesion kinase) eine wichtige \nRolle in der Tumorzellmigration, welches in Glioblasto -\nmen \u00fcberexprimiert wird. Im Rahmen einer strukurellen \nAnalyse von weiteren h\u00e4ufigen Bruchstellen im Genom \nvon Hirntumoren haben wir GPR26 identifiziert, ein G \nProtein gekoppelter Rezeptor, dessen Ligand noch nicht \nidentifiziert ist. Daneben stiessen wir auf Notch2 auf \nChromosom 1p11, welches in Oligodendrogliomen ab-, \nin Glioblastomen aber angeschaltet ist. Die Analyse \ndieser Gendefekte hilft neue Regelkreise zu charak -\nterisieren, welche wiederum Ans\u00e4tze f\u00fcr innovative \ntherapeutische Interventionen liefern k\u00f6nnen.\nSelected Publications\n\u2013 Merlo A., Bettler B. (2004) Glioblastoma on the move. \nScience STKE. 229: p 18-19\n\u2013 Jones G., Machado J., Tolnay M., Merlo A. (2001) \nPTEN-independent induction of caspase-mediated \ncell death and reduced invasion by the focal adhe -\nsion targeting domain (FAT) in human astrocytic brain \ntumors which highly express FAK. Cancer Res. 61, \n5688-5691.\n\u2013 Maier D., Jones G., Li X., Sch\u00f6nthal A., Gratzl O., \nVan Meir E.G., Merlo A. (1999) The PTEN lipid phos -\nphatase domain is not required to inhibit invasion of \nglioma cells. Cancer Res. 59: 5479-5482. \n\u2013 Maier D., Zhang Z., Taylor E., Hamou M.F ., Gratzl \nO., van Meir E., Scott R.J., Merlo A. (1998) Somatic \ndeletion mapping on chromosome 10 and sequence \nanalysis of PTEN/MMAC1  point to the 10q25-26 \nregion as the primary target in low-grade and high-\ngrade gliomas. Oncogene 16, 3331-3335. \n\u2013 Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson \nE., Burger P .C., Baylin S.B., Sidransky D. (1995) 5' \nCpG island methylation is associated with transcrip -\ntional silencing of the tumour suppressor CDKN2/\np16 in human cancers. Nature Med., 1: 686-693, \n1995. \nClinical studies showed that anaplastic oligodendrogliomas clearly respond \nto conventional chemotherapy, while malignant astrocytomas are chemore -\nsistant. A deletion on chromosome 1p was found to correlate with this char -\nacteristic. We performed a somatic mapping study of the 1p arm and found \nthat, in oligodendrogliomas, the deletion breakpoint targets the Notch2  \ngene. The Notch2  protein is not detectable in oligodendrogliomas by immu -\nnohistochemistry. In contrast, Notch2  is highly expressed in astrocytoma cell \nlines and primary malignant astrocytomas. Moreover, the genetic status of \nthe Notch2  alleles appears to allow the prediction of patient survival.\nA combinatorial strategy against glioblastoma cells\nWith regard to novel therapeutics, we have set up an in vitro assay system \nto test single and combinatorial strategies for genetically well characterised \nglioblastoma cell lines. We test a new generation of protein kinase inhibitors \n(PKI) against EGFR, KDR, PDGFR and mTOR as well as a histone deacetylase \ninhibitor and new highly potent cytotoxic drugs (Novartis). The question is, \nwhether biologically active drugs alone or in combination can induce cell \ndeath in glioblastoma cells, or whether an additional cytotoxic stimulus is \nrequired.\nFig. 1:  50% of glioblastomas display homozygous deletions at the INK4A/ARF \nlocus on chromosome 9p21 as assessed by real time PCR. Exon 1a is plotted against \nexon1b. Hemizygous deletions cluster around -1, homozygous deletions around -2. \nThe genetic structure of the INK4A/ARF locus is shown on the right. Two entirely \ndifferent reading frames are transcribed from this complex locus, which are translated \ninto the p16INK4A and p14ARF (in mice p19ARF) proteins.Fig. 2:  Expression of wild-type PTEN protein in PTEN-\ndeficient U87 glioblastoma cells dephosphorylates PKB/\nAkt (Ser-473), whereas expression of the PTENC124S \nprotein does not.\n24/25Synapse \nFormation\nProf. Dr. Hans Rudolf Brenner\nInstitut f\u00fcr Physiologie \nGroup members\nDr. Alex Blindenbacher \nDr. Pascal Escher \nDr. Eric Lacazette \nDr. Agnieszka Sadowska \nMich\u00e8le Courtet (technician)\nSoizic Carnejac (PhD student)Neurobiology\nDevelopment\nNeuromuscular Junction\nMuscle\nAgrinSignaling Mechanisms Regulating \nthe Formation of the Neuromuscular\nJunction\nCongenital myasthenic syndromes are diseases of the neuromuscular junction \n(NMJ), the synapse that motor neurons form on skeletal muscle fibers. They \ncause severe muscle weakness, and some are ultimately lethal. In recent years, \nan increasing number of these diseases have been linked to various mutations \nof genes encoding components of the neuromuscular junction. Nevertheless, \nthe molecular events regulating the formation of synapses are only poorly un -\nderstood. \nThe billions of synapses formed during development of the nervous system \nfunction, in principle, in a similar way as the NMJ. Consensus is that their forma -\ntion share common mechanisms. Detailed investigation of NMJ formation at the \nmolecular level will thus contribute to understanding not only the etiology of \ncongenital myasthenic syndromes, but will also yield insights into how synapses \nin the brain are formed. This will be important to understand CNS disorders \nwhich are thought to be related to malfunctioning of central synapses. The NMJ \nis particularly well suited for studies of synapse formation because of its easy \nexperimental accessibility compared to synapses in the brain. \nAim of our research project is to understand the signals exchanged between \nmotor neurons and skeletal muscle fibers and leading to the formation of the \nneuromuscular junction. Specifically, we investigate the molecular mechanisms \nby which motor neurons are made to contact muscle fibers, how through this \ncontact they induce the muscle fiber to form a subsynaptic apparatus and how \nthe fiber reciprocates to induce the differentiation of the motor nerve terminal \n(see Figures). \nTwo molecules required for NMJ formation are Agrin, a heparansulfate prote -\noglycan secreted from nerve terminals, and its receptor MuSK expressed by \nthe muscle. We found that Agrin/MuSK are sufficient for the induction of a \npostsynaptic muscle membrane, including the localized expression of the musk \ngene by a subset of nuclei located in the synaptic region of the muscle fiber. This \ninvolves a novel signaling loop that can maintain MuSK levels at the synapse, a \ncondition for the maintenance of neuromuscular function throughout life (for Bildung und Erhaltung der neuromusku-\nl\u00e4ren Synapsen\nNeuromuskul\u00e4re Synapsen (motorische Endplatten) sind \ndie Strukturen, an denen Nerven-Impulse auf die Ske -\nlettmuskeln \u00fcbertragen und damit Muskelbewegungen \nder Steuerung durch das Gehirn unterstellt werden. Bei \nneuromuskul\u00e4ren Erkrankungen ist die Impuls-Ueber -\ntragung gest\u00f6rt. Solche Defekte verursachen schwere \nMuskelschw\u00e4chen, die t\u00f6dlich sein k\u00f6nnen. Obschon die \ngenetischen Defekte bei einer Vielzahl dieser Erkrankun -\ngen identifiziert wurden, ist \u00fcber die molekularen Mecha -\nnismen der Synapsenbildung noch wenig bekannt. Ihre \nUntersuchung ist daher f\u00fcr das Verst\u00e4ndnis von Ueber -\ntragungsst\u00f6rungen und die Entwicklung neuer Thera -\npieans\u00e4tze von zentraler Bedeutung. Wegen vermuteter \nGemeinsamkeiten zwischen den neuromuskul\u00e4ren und \nzentralen Synapsen im Gehirn k\u00f6nnen sie aber auch f\u00fcr \ndas Verst\u00e4ndnis von St\u00f6rungen des Zentralnervensys -\ntems relevant sein. Wir untersuchen den Austausch der \nSignale zwischen Motoneuronen und Skelettmuskelfa -\nsern, die zur Bildung von neuromuskul\u00e4ren Synapsen \nf\u00fchren, insbesondere die molekularen Mechanismen, \nwelche die Neuronen dazu bringen, mit Muskelfasern \nin Kontakt zu kommen und wie durch diesen Kontakt \ndie Muskelfasern einen subsynaptischen Apparat und \ndie Motoaxone Nervenendigungen ausbilden. Zwei \nf\u00fcr die Endplattenbildung unerl\u00e4ssliche Signalmolek\u00fcle \nsind das von Nervenzellen gebildete Agrin und dessen \nRezeptor MuSK in den Muskelzellen. Wir zeigten, dass \nAgrin/MuSK ausreichen, um im Muskel die Expression \ndes musk Gens sowie weiterer Gene zu induzieren, die \nf\u00fcr die Bildung der Endplatte notwendig sind. Ueber \neinen Signalr\u00fcckkoppelungs-Mechanismus wird dabei \ndie ausreichende Expression von MuSK und Acetycho -\nlin-Rezeptoren und damit die Funktionst\u00fcchtigkeit der \nEndplatte auf Lebzeiten gesichert. Die Kontaktaufnahme \nzwischen Motoneuron und Muskelfaser selber erfordert \naber noch weitere Signale, die v.a. von inaktiven Muskeln \ngebildet werden. Um diese zu identifizieren, vergleichen \nwir das Proteinmuster (Proteom) von aktiven mit demje -\nnigen von gel\u00e4hmten Muskelfasern.\nSelected Publications\n\u2013 Jones, G., Meier, T ., Lichtsteiner, M., Witzemann, V ., Sak-\nmann, B. and Brenner, H.R. (1997) Induction by agrin \nof ectopic and functional postsynaptic-like membrane \nin innervated muscle. Proc.Natl.Acad.Sci. USA 94, \n2654-2659.\n\u2013 Meier, T., Masciulli, F ., Moore, C., Schoumacher, F . , \nEppenberger, U., Denzer, A.J., Jones, G. and Brenner, \nH.R. (1998) Agrin can mediate AChR gene expression \nin muscle by aggregation of muscle-derived neuregu -\nlins. J. Cell Biol. 141, 715-726.\n\u2013 Moore, C., Leu, M., M\u00fcller, U. and Brenner, H.R. (2001) \nInduction of multiple signalling loops by agrin during \nneuromuscular synapse formation. Proc.Natl.Acad.Sci. \nUSA 98, 14655-14660. \n\u2013 Naguib, M.B., Flood, P ., McArdle, J.J. and Brenner, \nH.R. (2002) Advances in the neurobiology of the \nneuromuscular junction-implications for the anesthe -\nsiologist. Anesthesiology 96, 202-231.\n\u2013 Lacazette, E., Le Calvez, S., Gajendran, N. and Bren -\nner, H.R. (2003) A novel pathway for MuSK to induce \nkey genes in neuromuscular synapse formation. J. Cell \nBiol. 161, 727-736.\ndetails, see Fig. 2). The same path can also regulate synaptic acetylcholine re -\nceptors (AChR) whose malfunctioning causes different forms of myasthenic \nsyndromes. In fact, this pathway appears more important for the expression \nof synaptic AChR than a classical path generally thought to regulate AChRs \n(via neuregulin/ErbB). Our models are currently tested in mouse mutants \nthat we are generating by gene targeting. Motor neurons made to secrete \nAgrin and muscle fibers overexpressing MuSK are not sufficient for synapse \nformation, however. Rather, the formation of a neuromuscular contact re -\nquires additional muscle factors that are expressed when muscles become \nelectrically inactive, e.g. by denervation. To identify such factors we compare \nthe proteomes of normally innervated and of denervated muscle fibers. \nFig. 1:  Top. Schematic of \nneuromuscular junction. \nSynaptic (dark coloured) \nand extrasynaptic nuclei \n(light coloured) express \ndifferent sets of genes \nunder neural control. \nSubsynaptic apparatus \nincluding membrane folds \nis induced by recombinant \nAgrin.\nBottom: Longitudinal \nsection through skeletal \nmuscle fiber after \ndetection of acetylcholine \nreceptor e-subunit mRNA \n(arrow: accumulation of \nsilver grains). Fig. 2:  Model for synapse-specific gene expression under control by \nthe nerve terminal. \n26/27Molecular \nNeurobiology\nNeural-Immune \nInteractions\nProf. Dr. Uwe Otten\nInstitut f\u00fcr Physiologie\nGroup Members\nPD Dr. Dieter Kunz \nDr. Pia M\u00e4rz \nMartine Schwager (technician)\nB\u00e9atrice Dimitriades-Schmutz (technician)\nDaniela Thommen (PhD student)\nChristelle Aug\u00e9 (PhD student)Interleukin-6\nNeuroprotection\nNeurodegeneration\nSignaling\nTransgenic animalsThe Role of Interleukin-6 (IL-6) in \nNeuroprotection and Neurodegeneration\nInterleukin-6 (IL-6) and related cytokines play a key role in inflammation and im -\nmune responses. In addition, IL-6 exerts specific effects in the central nervous \nsystem (CNS). Transcripts for IL-6 and its receptor have been detected in various \nbrain regions.\nIL-6 can have completely opposite activities on neurons promoting either neu -\nronal survival or contributing to neurotoxicity. Many of these effects can be \nexplained by the unique feature of the IL-6 receptor complex.\nIL-6 actions are mediated by cellular receptors, which upon dimerization and \ninteraction with the signal transducing component gp130 induce signal trans -\nduction through the JAK/STAT pathway. IL-6 also binds to a soluble form of the \nIL-6 receptor (s-IL-6 R) which can transfer IL-6 responsiveness to cells which are \ndevoid of membrane-bound receptor. This new signaling principle called \u201ctrans-\nsignaling\u201d is characteristic for neurons and glial cells.\nAt present, we know little about IL-6-regulated genes/gene products and the \nmechanisms contributing to the physiological or pathophysiological functions of \nIL-6- type cytokines in the CNS.\nOur research is directed towards elucidation of the mechanisms involved in IL-\n6-mediated events.\na) neuroprotection\nb) neurodegeneration in chronic inflammatory disorders including Alzheim -\ner\u2019s disease (AD)\nad a)  Using genechip technology induction of gene expression in neuronal \ntargets by IL-6/s IL-6 R was monitored. Promising IL-6-induced candidate \ngenes have been identified. Strategies are being developed to define the \ncellular origin and function of these gene products. Elucidation of the \nmolecular mechanisms involved in neuronal differentiation and plasticity \nshould help to develop new therapeutic concepts (see Fig.).\nad b)  Alzheimer\u2019s disease (AD) is a chronic and progressive neurodegenerative \ndisorder affecting the elderly population. A hallmark of this disorder is \nthe accumulation of amyloid- \u03b2 protein in the brains of diseased patients \nresulting in an inflammatory response leading to neuronal dysfunction \nand death. IL-6 has been implicated in the cascade of events leading to \nAlzheimer\u2019s dementia. In order to unravel the role of IL-6 in AD patho -\ngenesis it is necessary to generate a transgenic animal model of AD which \noverexpresses h-amyloid- \u03b2 precursor protein (APP) + human presenilin-2 \nwith deficiency in IL-6. These animals should help to answer the following \nkey questions:\n1) does IL-6 deficiency alter the formation of amyloid plaques in the CNS?\n2) is the time-course of plaque formation altered by lack of IL-6?\n3) is glial activation, notably microglial activation, significantly affected by \nIL-6?\n4) does IL-6 deficiency affect death or survival of neuronal subpopulations \nin brain?Funktionelle Bedeutung neuer Interleukin-6 \n(IL-6)\u2013induzierter Gene/Genprodukte f\u00fcr \nNeuroprotektion und Neurodegeneration\nIL-6 artige Zytokine mediieren sowohl neuroprotektive \nals auch neurotoxische Effekte im Zentralnervensystem \n(ZNS). Obwohl die intrazellul\u00e4ren IL-6 Signaltransduk -\ntionswege detailliert untersucht sind, ist bisher un -\nverstanden, welche Zielgene die neuron-spezifischen \nWirkungen von Zytokinen wie IL-6 vermitteln.\nMittels moderner \u201cgene chip array\u201d Technologie haben \nwir verschiedene \u201ccandidate genes\u201d wie pancreatitis-\nassociated protein-1 (PAP1) und Ataxin 10 identifiziert, \ndie mit neurodegenerativen Erkrankungen wie M. Alz -\nheimer und Spinozerebell\u00e4rer Ataxie Typ 10 assoziiert \nsein k\u00f6nnten.\nZiel unseres Forschungsvorhabens ist es, mit Hilfe neu -\nester molekularer und zellbiologischer Methoden wie \nz.B. der small interfering RNA (siRNA)-Technologie \nund definierten Zellkultursystemen f\u00fcr ZNS Neurone \nund Gliazellen sowie IL-6 transgenen Tiermodellen f\u00fcr \nneurodegenerative Erkrankungen die spezifische funk -\ntionelle Bedeutung IL-6-induzierter Gene/Genprodukte \nf\u00fcr Neurone des ZNS aufzukl\u00e4ren.\nErforschung der molekularen Mechanismen, die den \nneuroprotektiven und neurotoxischen Wirkungen \nvon IL-6 induzierten Genen im ZNS zugrunde liegen, \nk\u00f6nnte die Basis f\u00fcr neue therapeutische Ans\u00e4tze bei \nneurodegenerativen Erkrankungen sein.\nSelected Publications\n\u2013 M\u00e4rz, P ., Chen, J., Gadient, R.A., Patterson, P ., Stoy -\nan, T., Otten, U., Rose-John, S. (1998) Sympathetic \nneurons can produce and respond to interleukin-6. \nProc. Natl. Acad. Sci (USA) 95: 3551-3556. \n\u2013 Hock, C.,Heese, K., M\u00fcller-Spahn, F ., Huber, P ., \nRiesen, W., Nitsch, R.M. and Otten, U. (2000) \nIncreased CSF levels of nerve growth factor in \npatients with Alzheimer\u2018s disease. Neurology 54: \n2009-2011.\n\u2013 Otten, U., M\u00e4rz, P ., Heese, K., Hock, C., Kunz, D. and \nRose-John, S. (2001). Signals regulating neurotrophin \nexpression in glial cells. Prog. Brain Res. 132: 545-\n554.\n\u2013 M\u00e4rz, P ., Oezbek, S., Fischer, M., Voltz, N., Otten, \nU. and Rose-John, S. (2002). Differential response \nof neuronal cells to a fusion protein of ciliary neuro -\ntrophic factor/soluble CNTF-receptor and leukemia \ninhibitory factor. Eur. J. Biochem. 269: 3023-3031.\n\u2013 M\u00e4rz, P ., Probst, A., Lang, S., Schwager, M., Rose-\nJohn, S., Otten U. and \u00d6zbek, S. (2004) Ataxin-10, \nthe SCA 10 neurodegenerative disorder protein, is \nessential for survival of cerebellar neurons. J. Biol. \nChem. 279: 35542-35550.\nOur research is performed in collaboration with the groups of:\nProff. Dr. R. Nitsch/Dr. C. Hock, Division of Psychiatric Research, \n University of Z\u00fcrich\nProf. Dr. F . M\u00fcller-Spahn, Psychiatrische Universit\u00e4tsklinik, Universit\u00e4t Basel\nProf. Dr. S. Rose-John, Dept. of Biochemistry, University of Kiel\nProf. Dr. M. Jucker, Institut f\u00fcr Pathologie, Universit\u00e4t Basel\nProf. Dr. C. Nitsch, Anatomisches Institut, Universit\u00e4t Basel\nProf. Dr. I. Campbell, Mol. Biol. School of Molecular and Microbial Biosciences, \n University of Sidney\nPD Dr. H. Langen, Roche Center for Medical Genomics, Basel\nDr. M. Staufenbiel, Novartis Neuroscience, Basel\nInvestigation of IL-6-mediated mechanisms of neuroprotection:\nAnalysis of IL-6-induced genes\nInterleukin-6 (IL-6) binds to its specific receptor leading to dimerisation of gp130 \nmolecules and intracellularly to activation of different tyrosine kinases (JAK- \nand MAP-kinases), resulting in phosphorylation of transcription factors (TF) of the \nSTAT-family. In the CNS, IL-6 elicits both neuroprotective and neurotoxic effects. \nIt is not clear, which target genes are involved in the neuron-specific actions of IL-6.\n28/29Neurosurgery\nProf. Dr. Otmar Gratzl\nNeurochirurgische Klinik\nUniversit\u00e4tsspital Basel\nGroup members:\nDr. Marie-Fran\u00e7oise Ritz \nPetra Schmidt (technician)\nYann Curin (PhD student)Cerebral Ischemia\nNeuroprotection\n17-estradiol\nRed Wine Polyphenols\nBrain Injury\nHypothermiaThe Neuroprotective Effects of 17-Estradiol \nand Red Wine Polyphenols against Stroke \nInduced Damage in a Model of Transient \nIschemia in Rats.\nFocal decrease of cerebral blood flow during stroke produces rapid brain cell \ndeath induced by a complex neurotoxic cascade of events. In developed coun -\ntries, stroke is one of the leading causes of death and neurological impairment \nand its number is growing rapidly, due to ageing of the population. In subjects \nwith established cardiovascular disease, consideration is now given to a range of \nsecondary preventive steps with proven success. These include the administra -\ntion of antihypertensive drugs, anticoagulants (aspirin), diuretics and a series of \nlifestyle adaptations. An important challenge, however, will be to find ways to \nreduce the damaging effects of stroke once it has occurred in order to minimize \npain and disability of patients. Despite the completion of a number of clinical \ntrials investigating neuroprotective agents with various mechanisms of action, as \nyet no truly effective agent has been identified, probably because the neuropro -\ntective agents studied so far target only a single specific pathway of the complex \nischemic cascade. \nDuring ischemia, the cascade of biochemical events is initiated by the reduc -\ntion of blood flow and leads to an increase in extracellular excitatory amino acid \nconcentration (excitotoxicity), to the formation of free radicals and nitric oxide, \nto the activation of proteases, and finally to mitochondrial dysfunction and ap -\noptosis.\nRecent evidence suggests that estrogens and polyphenols are important neuro -\nprotective players in the cerebrovascular pathophysiologic context, therefore, \ntherapeutical approaches using these agents in the acute stage of stroke are of \ngreat interest. \nUsing intracerebral microdialysis monitoring, we showed that 17-estradiol injec -\ntion at the onset of the middle cerebral artery occlusion in male rats (the clinically \nrelevant model for human stroke) is able to significantly reduce the efflux of the \nexcitotoxic amino acids glutamate and aspartate (Figure 1). This effect allows \ncellular survival and a tremendous reduction of the cerebral infarct (Figure 2). \n17-estradiol also possesses antioxidative, anti-apoptotic and anti-inflamma -\ntory properties that may contribute to its brain-protective role in the context \nof ischemia. Both prolonged and short-term administration of polyphenols ex -\ntracted from red wine to rats with cerebral ischemia protects brain cells mainly \nby vasodilatatory effects. We showed that chronic treatment induced a general \nenlargement of the arteries in rats, therefore reducing the risk of an occlusion of \nthe small cerebral vessels (Figure 3). A beneficial effect on the efflux of amino \nacids is also observed after acute treatment with polyphenols.Oestrogene und Rotweinextrakte \nals neuroprotective Substanzen\nIn entwickelten L\u00e4ndern geh\u00f6rt der Schlaganfall zu \nden h\u00e4ufigsten Todesursachen und zu den h\u00e4ufigsten \nUrsachen f\u00fcr Behinderungen neurologischer Art. Bei \nPatienten mit bekannten kardiovaskul\u00e4ren Krankheiten \nsind nun effiziente, sekund\u00e4re Pr\u00e4ventivmassnahmen \nbekannt. Diese umfassen die medikament\u00f6se Behand -\nlung von Bluthochdruck, die Einnahme von Koagulati -\nonshemmern (Aspirin) und Diuretika, sowie eine Reihe \nvon Massnahmen der Lebenshygiene. Dennoch lassen \nsich durch diese Massnahmen lange nicht alle Schlag -\nanf\u00e4lle verhindern. Es ist eine grosse Herausforderung, \nnun Behandlungsformen zu finden, mit denen sich die \nFolgen des Schlaganfalls, die Schmerzen und die Behin -\nderungen abwenden oder zumindest begrenzen lassen. \nDer Schlaganfall ist ein lokalisierter Unterbruch der Ge -\nhirndurchblutung (Ischemie) der zum raschen Zelltod und \nso zum Verlust von Nervenzellen f\u00fchrt. Der Zelltod wird \ndurch eine Kaskade von Reaktionen hervorgerufen. Es ist \nbisher nicht gelungen Medikamente zu finden, welche \ndie Nerven vor der Zerst\u00f6rung sch\u00fctzen k\u00f6nnen. Zu \nden durch Ischemie induzierten Reaktionen geh\u00f6ren \ndie Aussch\u00fcttung der sog. exitatorischen Aminos\u00e4uren \nund die Bildung von freien Radikalen und von Stickoxid. \nOestrogene und Polyphenole aus Rotwein sind potentiell \nneuroprotektive Substanzen. Wir haben festgestellt, dass \nsich die Isch\u00e4mie-bedingte Aussch\u00fcttung der exitatori -\nschen Aminos\u00e4uren, sowohl durch Oestrogen als auch \ndurch Rotwein-Polyphenole vermindern l\u00e4sst (Fig. 1). \nMit Hilfe von Ratten, die einem k\u00fcnstlichen Schlaganfall \nunterworfen werden, erforschen wir die Effekte dieser \nSubstanzen im Detail. Rotwein-Polyphenole sch\u00fctzen \nzudem vor Schlaganf\u00e4llen durch eine allgemeine Gef\u00e4s -\nserweiterung (Fig. 3). Wir haben auch eine transcraniale \nMikrodialysesonde entwickelt, mit der sich die verschie -\ndenen Parameter der Ver\u00e4nderungen nach einem Schlag -\nanfall oder nach einem Gehirntrauma verfolgen lassen. \nDamit konnten wir zeigen, dass sich die Ver\u00e4nderungen \nin diesen zwei F\u00e4llen deutlich unterscheiden.\nSelected Publications\n\u2013 Langemann H, Feuerstein T, Gratzl O, Mendelowitsch \nA. (2001) Microdialytic Monitoring of Uric and Ascor -\nbic Acids in the Brains of Patients after Severe Brain \nInjury and during Neurovascular Surgery. J. Neurol. \nNeurosurg. Psychiatry 71: 169-174.\n\u2013 Langemann H, Alessandri B, Mendelowitsch A, \nFeuerstein T, Landolt H, Gratzl O. (2001) Extracellular \nlevels of Glucose and Lactate measured by quantita -\ntive Microdialysis in the Human Brain. Neurol. Res. 23: \n531-536.\n\u2013 Feuerstein TH, Langemann H, Gratzl O, Mendelow -\nitsch A. (2000) A four lumen screwing device for \nmultiparametric brain monitoring. Acta. Neurochir. \n(Wien)142, 909-12.\n\u2013 Mendelowitsch, A., Ritz, M.F ., Ros, J., Langemann, H. \nand Gratzl, O. (2001) 17beta-Estradiol reduces corti -\ncal lesion size in the glutamate excitotoxicity model by \nenhancing extracellular lactate: a new neuroprotective \npathway. Brain Res. 901, 230-6.\n\u2013 Ritz, M.F ., Schmidt, P . and Mendelowitsch, A. (2002) \n17beta-estradiol effect on the extracellular concen -\ntration of amino acids in the glutamate excitotoxicity \nmodel in the rat. Neurochem. Res. 27, 1677-83.Clinics\nIn patients with severe brain injury, the final outcome de -\npends on both the extent of the original damage and on \nthe later appearance of secondary lesions. Microdialysis is \nthe only minimally invasive method currently available for \ncontinuous monitoring of metabolites in the brain extracel -\nlular fluid. Results of such a monitoring should cast light on \nthe origin of the lesions and enable effective therapy. We \nhave therefore developed a transcranial screw with four \nlumina, which enables multiparametric monitoring of the \ntraumatized brain (Fig. 4). \nIn a current project we are investigating the neuroprotec -\ntive effect of moderate hypothermia on cerebral metabolism \nand its relation with the outcome of severe head injured \npatients.\nEffects of 17-estradiol and polyphenols on brain energy metabolism, on their \nrole in free radical scavenging and on changes in specific protein expression \nare also investigated in our laboratory. The molecular mechanisms involved \nare investigated with the help of transgenic mice (estrogen receptors knock-\nout mice).\nA drug for the treatment or prevention of stroke-induced damage will only \nbe beneficial if the therapeutic time-window for its application is sufficient \nto enable treatment of patients coming to the critical care unit. Estradiol may \nalso exert its neuroprotective effect on cerebral metabolism after the onset \nof ischemia and during reperfusion. The therapeutic time window and the \noptimal doses of 17-estradiol and polyphenol for post-ischemia intervention \nare being determined in order to be able to significantly improve the recovery \nof patients in the future.\nPD Dr. Aminadav \nMendelowitsch \nDepartement Forschung \nUniversit\u00e4tsspital Basel\nFig. 4:  a. Instrumenta -\ntion used for the 4-way \nscrew, together with \nthe screw. b: The four \nlumen screw with ICP \ncatheterm microdialysis \nand paratrend sensors.Fig. 2:  The unstained \nbrain region depicts the \nischemic infarct, where \nall cells are damaged. \nAcute treatment with \n17-estradiol reduces \nthis area by 50%.\nFig. 1:  One single \ninjection of 17 -estradiol \nin rats (depicted by the \narrow) during the \nocclusion of the middle \ncerebral artery (gray bar) \nreduces the efflux of \nglutamate in the extracel -\nlular fluid. *: p 0.05 \ncompared with operated \nbut untreated controls. \nSham animals are con -\ntrols in which the middle \ncerebral artery was not \noccluded. Fig. 3:  Measurements \nof the internal diam -\neters of the rat arteries \n(solidified by the injec -\ntion of methyl-meth -\nacrylate) indicated that \nchronic polyphenol \nconsumption for one \nweek induces sustained \nvasodilation, hence \ndiminishing the risk to \nhave an occlusion.\nFig. 3Fig. 230/31Neurobiology\nPD Dr. Nicole Schaeren-Wiemers \nDepartement Forschung \nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Michael Erb\nDr. U. Graumann\nBeat Erne (technician)\nFrances Kern (technician)\nChantal Urdieux (technician)\nThomas Zeiss (PhD student)\nBettina Fl\u00fcck (PhD student)\nAndres Buser (PhD student)Myelin\nMultiple Sclerosis\nPeripheral Neuropathy\nMembrane Domains\nAutoimmune Disease\nNeuroprotectionMolecular Mechanisms of Myelin \nMaintenance in Health and Disease\nThe myelin sheath is a multilamellar plasma membrane structure that enwraps \naxons in the central (CNS) and the peripheral nervous system (PNS) of ver -\ntebrates. The insulating properties of this specialized membrane enable fast \npropagation of electrical signals. Two specialized cell types \u2013 the oligodendro -\ncytes in the CNS, and the Schwann cells in the PNS generate their spiral sheaths \nin a structurally similar but biochemically distinct way (Fig. 1). The focus of our \nresearch is the characterization of the molecular mechanisms of myelin forma -\ntion and maintenance, and their regenerating capacity in major demyelinating \ndiseases such as Multiple sclerosis (MS) and peripheral neuropathies. \nWe study the molecular and cellular mechanisms regulating the coordinated \nexpression and translocation of myelin constituents to the different compart -\nments during development and in the adult. The detergent-insoluble glycolipid-\nenriched microdomains, called rafts, are thought to serve as a platform for the \npolarized delivery of specialized plasma membrane structures in epithelial and \nalso in myelinating cells. The \u201cmyelin and lymphocyte protein\u201d (MAL) is a major \nplayer in polarized sorting mechanisms in epithelial cells. We have identified \nand characterized MAL in myelinating cells, and shown that MAL is exclusively \nlocalized in rafts of myelin membranes. Genetic ablation of mal in mice resulted \nin cytoplasmic inclusions within the compact myelin, in paranodal loops that \nwere everted away from the axon and in disorganized transverse bands at the \naxon-glial junction in the adult CNS (Fig. 2). These structural changes were ac -\ncompanied by a marked reduction of the paranodal proteins Caspr, Neurofas -\ncin 155 (NF155) and juxtaparanodal of potassium channel Kv1.2, while nodal \nclusters of sodium channels were unaltered. Developmental analysis revealed \nthat initial node formation appeared normal in mal -/- Mice, but got altered at \na stage, paralleling the onset of MAL expression in the controls. Biochemical \nanalysis showed that MAG, MBP and NF155 protein levels were reduced in my -\nelin and in myelin-derived rafts. These results demonstrate a critical role for MAL \nin the maintenance of the CNS axo-glial junction and the nodal environment, \nmost likely by controlling the trafficking/sorting of NF155 and other membrane \ncomponents in oligodendrocytes. \nParallel to these studies, we characterized the functional role of the two splic -\ning variants of the myelin-associated glycoprotein (MAG), L- and S-MAG. For a \nbetter differentiation of the two isoforms, we generated a genomic construct in \nwhich the coding sequence for the green fluorescent protein (GFP) was intro -\nduced. Thereby, we could demonstrate the S-MAG expression was regulated \nby cAMP . A transgenic mouse line, which expresses the S-MAG isoform fused \nto GFP, allows us now to characterize the cellular and spatial regulation of both \nisoforms separately (Fig. 3). Myelin \u2013 der Schutz der Nervenfasern \nDie Myelinscheide ist eine spezielle Membran, welche \nNervenfasern im Gehirn und in der Peripherie umh\u00fcllt. \nIhre isolierende Eigenschaft erm\u00f6glicht eine schnelle \nLeitgeschwindigkeit der elektrischen Nervensignale. \nGesch\u00e4digte Myelinscheiden kommen in der Multiplen \nSklerose (MS) und in vielen peripheren Neuropathien \nvor. Die Bildung der Myelinscheide bedingt koordi -\nnierte Expression und korrekte Eingliederung von \nMyelin-Bestandteilen. Wir konnten nachweisen, dass \ndas MAL-Protein im Nervensystem ausschliesslich in \nMyelinmembranen zu finden ist. Dort scheint dieses \nin speziellen zellul\u00e4ren Transportmechanismen von \nbestimmten Membrandom\u00e4nen eine zentrale Rolle \nzu spielen. Mit transgenen M\u00e4usen, welche kein MAL \nbilden k\u00f6nnen, zeigten wir, dass MAL die korrekte Ein -\ngliederung bestimmter Myelinbestandteilen kontrolliert \nund dadurch eine wichtige Rolle f\u00fcr die Erhaltung der \nNervenfaser-Myelin Interaktion hat. \nDie MS Erkrankung f\u00fchrt zu einem chronischen Zerfall \ndes Myelins im Zentralnervensystem. Mit Gen-Chips \nuntersuchten wir die molekularen Mechanismen in MS \nHirngeweben, welche auch nach langer Krankheits -\ndauer nicht gesch\u00e4digt waren. Wir zeigten, dass dort \nviele Gene angeschaltet wurden, die Hinweise dar\u00fcber \ngeben, dass einerseits krankheitsverursachende Abl\u00e4ufe \nstattfinden, andererseits auch viele nervensch\u00fctzende \nMechanismen angeschaltet wurden. Detailliertere \nErkenntnisse \u00fcber diese Vorg\u00e4nge werden Ans\u00e4tze \nf\u00fcr neue Therapieformen bringen, um den Verlust der \nNervenfunktionen einzuschr\u00e4nken.\nMAG ist ein weiteres Protein der Myelinscheide. Eine \nder h\u00e4ufigsten Myelinerkrankungen der Peripherie ist \neine Autoimmunreaktion des K\u00f6rpers gegen MAG. \nImmunglobuline des Typs IgM lagern sich dabei an \ndie Myelinscheide. Wir konnten zeigen, dass sich IgM \nMolek\u00fcle, ausschliesslich bei dieser Erkrankung, auch in \nkleinen Nervenfasern in Biopsien der Haut nachweisen \nlassen. Dieser neuartige Nachweis ist relativ einfach, \nbedeutet f\u00fcr den Patienten nur einen kleinen Eingriff \nund erlaubt eine fr\u00fche Diagnose und die Beobachtung \ndes Behandlungserfolges.\nSelected Publications\n\u2013 U. Graumann, R. Reynolds, A.J. Steck, N. Schae -\nren-Wiemers. (2003). Molecular changes in normal \nappearing white matter in Multiple Sclerosis are \ncharacteristic of neuroprotective mechanisms against \nhypoxic insult. Brain Patho.13:554-573, . \n\u2013 M. Erb, A.J. Steck, K. A. Nave, N. Schaeren-Wiemers. \n(2003). Differential expression of L- and S-MAG upon \ncAMP stimulated differentiation in oligodendroglial \ncells. J Neurosci Res. 71: 326-337. \n\u2013 M. Sollberger, B. Erne, S. Sansano, A.J. Steck, N. \nSchaeren-Wiemers. (2002). Characterization of hu -\nman nerve basal lamina for their binding properties of \nanti-MAG antibodies. J Neurocytol. Jan;31(1):5-14. \n\u2013 B. Erne, S. Sansano, M. Frank, N. Schaeren-Wiemers. \n(2002). Rafts in adult peripheral nerve myelin contain \nmajor structural myelin proteins and MAL and CD59 \nas specific markers. J Neurochem. 82: 550-562.\n\u2013 Empl, M., Renaud, S., Erne, B., Fuhr, P ., Straube, P ., \nSchaeren-Wiemers, N., and Steck, A.J. (2001). TNF-\nalpha expression in painful and non-painful neuropa -\nthies. Neurology, 56, 1371-1377.Clinics\nPrimary demyelinating peripheral neuropathies can be \ninherited or the result of an autoimmune reaction to myelin \ncomponents. Although the causes of these diseases are \nknown and the pathophysiology well documented, the \nmolecular mechanisms of the myelin disturbance is still \npoorly understood. One of the most common autoimmune \nmediated demyelinating neuropathies is the anti-MAG M-\nIgM polyneuropathy. We showed that the monoclonal IgM \nantibodies bind to specific myelin epitopes and that they can \npenetrate into the myelin sheath. Further, we have localized \nIgM antibodies on the basal membrane of peripheral nerve \nfibers. In a recent study, we investigated the presence of IgM \ndeposits in dermal myelinated nerve fibers. Skin biopsies \nfrom 14 patients with anti-MAG neuropathy, 8 patients with \nCIDP (chronic immune demyelinating polyneuropathy), and \n2 patients with IgM paraproteinemic neuropathy were com -\npared. MAG positive fibers with IgM deposits were found \nin all anti-MAG neuropathy patients. IgM deposits were \nlocated throughout the length of the fibers as well as at the \nparanodal loops and on the basal membrane. CIDP and IgM \nparaproteinemic neuropathies did not show any myelinated \nfiber with IgM deposit. In summary, we demonstrated that \nin anti-MAG neuropathy, specific IgM deposits are also \nfound in cutaneous myelinated sensory fibres. Therefore, \nskin biopsy provides a useful, minimally traumatic method \nfor early diagnosis and, possibly, to monitor the follow-up \nin patients with an anti-MAG neuropathy.Fig. 2:  Paranodal loops (arrows) that are \neverted away from the axon in MAL-de -\nficient miceFig. 3:  GFP-Autofluorescence of \nS-MAG-GFP fusion protein specifically \nlocalized in Schmidt-Lantermann in -\ncisures and periaxonal membranes\nProf. Dr. \nAndreas J. Steck \nDepartement Neurologie \nUniversit\u00e4tsspital BaselFig. 1:  Schematic draw -\ning of (a) CNS and (b) PNS \nmyelination. The neurons \nwith their axons are shown \nin green. The oligodendro -\ncytes (yellow) generate \nthe myelin sheaths in the \nCNS and the Schwann cells \n(red) in the PNS.\nMultiple sclerosis (MS) is a chronic demyelinating disease of the CNS. The \nmolecular mechanisms of lesion formation is still unknown. We performed \na microarray study in which we compared the expression pattern of normal \napperaring subcortical white matter from MS and control patients. The genes \nthat were upregulated in MS patients indicate the occurrence of oxidative \nstress, but also of many neuroprotective mechanisms. Our data introduce \nnovel concepts of the molecular pathogenesis of MS with ischemic precondi -\ntioning as a major mechanism for neuroprotection. A deeper understanding \nof the underlying mechanisms is required for the development of new and \nmore specific treatments to protect residing cells and thus minimize progres -\nsive oligodendrocyte and axonal loss.\n(a)\n(b)32/33Clinical Neuro-\nimmunology\nProf. Dr. \nDavid Leppert\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup members\nPD Dr. Raija LP Lindberg\nDr. Jens Kuhle\nFrancine Hoffmann (technician)Multiple sclerosis\nExpression profiling\nMetabolomics\nAntibodies\nMatrix metalloproteinasesMolecular Analysis of Multiple Sclerosis\nGene expression profiling in Multiple Sclerosis and related animal mod -\nel (DTH) with microarrays\nThe aim of this work is to define comprehensively altered physiologic pathways \nat various stages of development of multiple sclerosis (e.g. during the develop -\nment of lesions, during relapses and remissions) in various tissue compartments. \nWe approach this by studying the gene expression pattern in brain tissue, cer -\nebrospinal fluid (CSF), and peripheral blood mononuclear cells (PBMC) from MS \npatients, and in brain tissue in the delayed-type hypersensitivity (DTH) model of \nMS. The goals are the following: 1) to define an array of genes that are related \nto susceptibility and the course of disease with the perspective for the use as \ndiagnostic markers, and 2) to define MS differentially regulated genes, but not \nknown to participate in its pathogenesis. We are also investigating the effects \nof current treatments of MS, e.g. IFN- \u03b2 and Natalizumab, on gene expression \nprofiles in blood to define markers for treatment efficacy in order to identify \nresponders and non-responders.\nIn brain tissue from MS, inflammatory changes are not confined to plaques but \nappear as a continuum of cellular and humoral immune response between acute \nlesions and surrounding normal appearing white matter (NAWM). The two tis -\nsue compartments distinguish by a stronger up-regulation of genes related to \ncellular immune response in normal appearing white matter, while genes related \nto synthesis of immunoglobulins and regulation of B-cells were more prevalent \nin acute lesions. These results challenge the concept of MS as a focal disease. \nThey are in line with recent MRI findings of generalized brain atrophy and extra-\nlesional changes in the normal appearing white matter indicating of neuronal loss \nand diffuse water accumulation. A group of genes has been found to be differ -\nentially expressed in PBMC of untreated MS patients in remission as compared \nto age and gender matched healthy volunteers.\nSince the availability of early stage and longitudinal samples of MS tissue is \nscarce, we used an experimentally-induced, delayed-type-hypersensitivity \n(DTH) model of MS for gene expression profiling studies. We have examined \nthe development of lesions at Day 0, 5, 12, and 31 after peripheral sensitization \nwith BCG by gene expression profiling with microarrays, and compared it with \nthat of tissue in the vicinity of the lesion, and in the opposite hemisphere. We \nfound 48 genes upregulated, and 25 genes downregulated at a certain time \npoint and tissue compartment. The most prominent feature is the increased \nexpression of TNF-related receptors and FAS ligand, suggesting the importance \nof the TNF-pathway in the development of DTH lesions. \nThe pathogenetic role of matrix metalloproteinases and their regulators \nin multiple sclerosis (MS)\nMatrix metalloproteinases (MMPs) are a family of proteolytic enzymes that act as \neffectors of parenchymal invasion by immune cells and tissue destruction during \ninflammation. Based on our previous work it is now accepted that the beneficial \neffect of IFN- \u03b2 on the course of MS results from its downmodulatory effect on \nMMPs in T-cells. The study of the expression pattern of MMPs in cerebrospi -\nnal fluid and blood cells during different phases of MS will allow determining \nthe disease relevant targets for future therapy with MMP-inhibitors. We have \nrecently shown that some MMPs are constantly up-regulated in cerebrospinal \nfluid and in brain tissue of MS patients, irrespective of clinical disease activity. \nFurthermore, MMP-upregulation is present not only in MS plaques, but also in \nbrain tissue that appears to be unaffected by conventional microscopic criteria. \nThese findings also challenge the concept of MS as a focal disease and imply that \nconstant suppression of MMP-activity may be required to ameliorate the course \nof disease. In collaboration with Drs. E. Waubant and D. Goodkin (UCSF), we \nhave found that serum levels of MMP-9 are increased in secondary progressive \nMS. Moreover, MMP-9 and its physiologic inhibitor TIMP-1 are related to the Molekulare Analyse der Multiplen Sklerose\nDie Multiple Sklerose ist nebst der bakteriellen Meningi -\ntis einer unserer Forschungsschwerpunkte. Unser Ziel ist \nes, in Zusammenarbeit mit Forschern in Bern und Z\u00fcrich, \nneue Ans\u00e4tze f\u00fcr die Diagnostik und die Therapie dieser \nKrankheiten zu finden.\nWir m\u00f6chten die ver\u00e4nderten physiologischen Abl\u00e4ufe \nw\u00e4hrend den verschiedenen Phasen der Multiplen Skle -\nrose (MS) kennenlernen. Um dies zu erforschen unter -\nsuchen wir, welche Gene in verschiedenen Geweben \nvon MS Patienten und MS Tiermodellen angeschaltet \nsind. Wir konzentrieren uns dabei auf zwei Gruppen von \nGenen. 1. Gene die wir mit der Pathogenese von MS \nin Zusammenhang bringen k\u00f6nnen und die daher f\u00fcr \ndie Diagnostik von Bedeutung sein k\u00f6nnten 2. Gene \ndie bei MS auffallend reguliert sind, von welchen aber \nein Zusammenhang mit dem Krankheitsverlauf bislang \nnicht bekannt ist. Unter diesen k\u00f6nnten einige Ziele f\u00fcr \nneuartige Therapieans\u00e4tze liefern. \nMatrix-Metalloproteinasen (MMPs) sind Enzyme, die \nProteine spalten. Diese spielen eine Rolle bei der Gewe -\nbezerst\u00f6rung w\u00e4hrend Entz\u00fcndungsreaktionen. Einige \ndieser MMPs sind im Gehirn von MS Patienten dauernd \nhochreguliert, unabh\u00e4ngig vom klinischen Zustand des \nPatienten und dies im ganzen Gehirn, d.h. auch in Regio -\nnen, welche frei von MS bedingten Plaques sind. Dieser \nBefund weist darauf hin, dass MS nicht eine Krankheit \nist, deren \u00c4usserung sich auf gewisse Regionen des \nGehirns konzentriert. Eine konstante Unterdr\u00fcckung \nder MMP Aktivit\u00e4t k\u00f6nnte sich positiv auf den Verlauf \nder Krankheit auswirken. \nIn einem weiteren Ansatz pr\u00fcfen wir das metabolisch-bio-\nchemische Muster von z.B. MS Geweben im Vergleich \nzu gesunden Geweben. Dieser Ansatz, Metabolomics \ngenannt, gibt Auskunft \u00fcber den aktuellen Zustand des \nGewebes. Mit diesen Informationen lassen sich Krank -\nheitsverlauf und die Wirkung von Therapien verfolgen.\nSelected Publications\n\u2013 Leppert D, Lindberg RLP, Kappos L, Leib SL. (2001) \nMatrix metalloproteinases: multifunctional effectors \nof inflammation in bacterial meningitis and multiple \nsclerosis. Brain Res Rev 36, 249-257.\n\u2013 Waubant E, Goodkin D, Bostrom A, Bacchetti P, \nHietpas J, Lindberg R, Leppert D. (2003) IFN beta \nlowers MMP-9/TIMP-1 ratio which predicts of new \ngadolinium enhancing lesions in secondary progres -\nsive multiple sclerosis. Neurology 60, 52-57.\n\u2013 Gilli F , Bertolotto A, Sala A, Hoffmann F ,Capobianco M, \nMalucchi S, Glass T, Kappos L, Lindberg RLP, Leppert \nD. (2004) Neutralizing antibodies against IFN-beta in \nmultiple sclerosis: antagonization of IFN-mediated \nsuppression of MMPs. Brain 127, 259-268.\n\u2013 Lindberg RLP, De Groot CJA, Certa U, Ravid R, \nHoffmann F, Kappos L, Leppert D. (2004) Multiple \nsclerosis as a generalized CNS disease \u2013 comparative \nmicroarray analysis of normal appearing white matter \n(NAWM) and lesions in secondary progressive MS.J \nNeuroimmunol 152 154-167\n\u2013 Leppert D, Martin R. (2004) A Plea for \u201cOmics\u201d Re -\nsearch in Complex Diseases such as Multiple Sclero -\nsis \u2013 A Change of Mind is needed. J Neurol Sci 222, \n3-5\noccurrence of new gadolinium-enhancing lesions in secondary progressive \nMS. MxA is a type-I-IFN-induced protein. Although MxA seems not to be \ndirectly involved in the pathogenesis of MS, its concentration in serum, and \nthe transcriptional expression in PBMC can be used as a functional marker of \nIFN-activity. Hence, measurement of MxA allows to monitor functionally the \neffects of neutralizing antibodies (NAB) against IFN- \u03b2, a method we believe \nbeing clinically more relevant than the measurement of neutralising antibod -\nies per se, which is notoriously difficult and poorly standardizable. \nAs IFN treatment decreases MMP-9 and increases TIMP-1, we hypothesize \nthat the decreased effect of IFN due to neutralizing antibodies does not only \nmanifest by decreased serum concentrations of MxA, but also by a lack of, \nor reduced downregulation of MMP-9 and upregulation of TIMP-1. This has \nbeen confirmed as well as the increase of MMP-9 transcripts after the occur -\nrence of NABs quantitatively correlated with the NAB titer (collaboration with \nProf A. Bertolotto, Orbassano, Italy).\nMetabolite pattern analysis and metabolite identification in CSF and \nserum of MS patients\nMetabolomics is used to determine cellular and systemic biochemical profiles \nby comprehensive spectroscopic detection and identification of endogenous \nmetabolites in biological samples, mainly body fluids, but also in tissue. The \naim of such procedure is to extract latent biochemical information that is of \ndiagnostic and prognostic value, and which reflects \u2018actual\u2019 biological events \n(real-world end points, biomarkers), as opposed to the potential for such \nevents with measurements of DNA, and mRNA. We have started to use me -\ntabolomics technique (1H-NMR) to analyze human CSF samples with differ -\nent clinical diagnosis, e.g. from MS, inflammatory CNS diseases of non-MS \ntype, tumours, intracranial bleeding, and compared the metabolite profiles \nto that of control CSF-samples. Preliminary results indicate that the metabo -\nlite profile allows defining a specific pattern that distinguishes each disease \ngroup. This work aims at analyzing cohorts of MS patients homogeneous for \nextrinsic (type of therapy) and intrinsic (age, gender, disease state, clinically \nisolated syndrome (CIS), rrMS, spMS), actual disease activity (relapse, clini -\ncally stable) by 1H-NMR spectroscopy. Differential spectral patterns will be \nsearched for specific metabolites differentially expressed, that may be deter -\nminants of disease processes in the respective groups.\nMyelin oligodendrocyte glycoprotein (MOG) and Myelin basic pro -\ntein (MBP) antibodies as prognostic markers for patients with Clini -\ncally Isolated Syndrome (CIS)\nMost of MS patients initially present with a clinically isolated syndrome \n(CIS), which is caused by inflammatory, demyelinating lesions in the optic \nnerve, brain stem or spinal cord. Up to 80% of CIS cases progress to clini -\ncally definite MS (CDMS) by time. Prognostic indicators for the transition \nto clinically definite MS are still imprecise. Antibodies against myelin basic \nprotein (MBP) and myelin oligodendrocyte glycoprotein (MOG) have been \nfound in serum and active lesions of MS patients. We have set up Western \nblot analysis for MBP and MOG antibodies in serum and CSF (in collaboration \nwith Dr. Markus Reindl, Innsbruck) and could show a high reproducibility \nof the method in the two labs. Our goal is to evaluate the importance of an -\ntiMBP and -MOG antibodies as a prognostic marker for disease activity and \nprogression in well-defined patient cohorts. We are now offering MBP/MOG \nantibody test for Swiss physicians for clinical use as a lab test in CIS.Prof. Dr. \nLudwig Kappos\nAbteilung Neurologie\nUniversit\u00e4tsspital Basel\n34/35DKBW Schwerpunkt\nZellplastizit\u00e4t und Gewebereparatur\nDer Forschung an embryonalen und adulten Stammzellen wird zurzeit grosse \nBeachtung geschenkt. Dies vor allem wegen ihrer Eigenschaft sich in verschie-\ndene, von einander unabh\u00e4ngige Zelltypen entwickeln zu k\u00f6nnen. Diese Viel-\nf\u00e4ltigkeit l\u00e4sst hoffen, dass therapeutische Anwendungen von Stammzellen \nneue M\u00f6glichkeiten in der Behandlung von kranken Geweben und Organen \ner\u00f6ffnen werden. \nEine beachtliche Anzahl Forschungsgruppen des DKBW hat sich in den letzten \nJahren mit der Erforschung von Grundlagen sowie klinisch relevanten Aspekten \nder Stammzellenbiologie und -therapie besch\u00e4ftigt. Mehrere Gruppen un -\ntersuchen dabei h\u00e4matopoietische Stammzellen aus Menschen oder M\u00e4usen \nim Hinblick auf ihr Differenzierungspotential und ihre N\u00fctzlichkeit in ver -\nschiedenen therapeutischen Anwendungen wie z.B. neue Ans\u00e4tze der Therapie \nvon Autoimmunkrankheiten.\nAusserdem wurde in Basel eine Nabelschnurbank mit Stammzellen von Neu -\ngeborenen angelegt. Andere Forscher widmen sich der in vitro Z\u00fcchtung von \nGewebe f\u00fcr Knorpel- und Knochenersatz.\nTrotz rascher Fortschritte werden Themen wie die gezielte Differenzierung \nvon Zelltypen, die in vitro Z\u00fcchtung von Gewebe und die therapeutische An -\nwendung von Stammzellen weiter intensiv untersucht und auch eingehend \ndiskutiert.\nInsbesondere ist es entscheidend herauszufinden, wie der Signalaustausch \nzwischen den Zellen funktioniert, welcher die Stammzellen dazu veranlasst, sich \nzu spezifischen Geweben zu differenzieren, wie dies w\u00e4hrend der Embryogen -\nese und bei einer Geweberegeneration geschieht.\nDer DKBW Forschungsschwerpunkt \u00abZellplastizit\u00e4t und Gewebereparatur\u00bb stellt \nsich die Aufgabe die Gundlagenforschung und die Klinik zusammenzubringen \num gemeinsam die L\u00fccke zwischen Labor und Krankenbett zu schliessen.\nEin kleiner aber wichtiger Schritt auf dem Weg zu diesem Netzwerk des Wis -\nsens ist der \u00abStammzellen-Club\u00bb, der als Forum dazu dient, \u00fcber Forschung zu \ndiskutieren und die Zusammenarbeit voranzutreiben. In K\u00fcrze wird dieser neue \nSchwerpunkt seine Aktivit\u00e4ten noch erweitern.\nProfessor R. Zeller\nInstitut f\u00fcr Anatomie\nProfessor A. Gratwohl\nAbteilung H\u00e4matologie\nUniversit\u00e4tsspital Basel36/37Cardiobiology\nProf. Dr. Marijke Brink\nInstitut f\u00fcr Physiologie\nDepartement Forschung \nUniversit\u00e4tsspital Basel \nGroup Members\nPD Dr. Christian Zaugg \nDr. Dagmar Keller \nDr. Thomas Dieterle \nDr. Silvia Butz\nDr. Isabelle Plaisance\nDr. Vivian Suarez Domenech \nDietlinde John (technician)\nChristian Morandi (technician)\nSerguei Driamov (PhD student)\nClaire Murigande (PhD student)Cytokines\nGrowth Factors\nApoptosis\nCardiomyopathies\nCardiomyocytes\nMyofibrillogenesisDie Wirkung von Wachstumsfaktoren auf \nden Herzmuskel\nMit progressivem Gewichtstraining l\u00e4sst sich die Ske -\nlett-Muskelmasse vergr\u00f6ssern. Auch der Herzmuskel \nreagiert auf gr\u00f6ssere Belastung mit einer kompensato -\nrischen Hypertrophie, d.h. die Herzmuskelzellen (die \nMyofibrillen) gewinnen an Gr\u00f6sse und Masse. IGF-I \n(insulin-like growth factor), ein Wachstumsfaktor, ist \nin beiden Muskeltypen bei der Entstehung der Hy -\npertrophie beteiligt. Im Herz f\u00fchren Stressfaktoren wie \nIsch\u00e4mie (unzureichende Durchblutung) und Bluthoch -\ndruck zur Aussch\u00fcttung weiterer Faktoren, welche \u00fcber \nkurze Zeit die Funktion des Herzes gew\u00e4hrleisten. Lang \nandauernde Einwirkung dieser Faktoren f\u00fchren jedoch \nzur Verminderung der Herzfunktion und schliesslich zum \nHerzversagen. Von Herzversagen spricht man dann, \nwenn das Herz die anderen Organe nur unzureichend \nmit Blut versorgen kann. Unser Ziel ist, die Mechanismen \nzu Verstehen, welche von einer Hypertrophie des Herzes \nschliesslich zum Herzversagen f\u00fchren um Therapiean -\ns\u00e4tze zu finden, wie man diese Entwicklung verhindern \nkann. Wir verwenden hierzu:\n1. Myozyten Zellkulturen: Damit untersuchen wir die \nWirkung von Wachstumsfaktoren auf die Differenzie -\nrung der Zellen, auf den Umsatz von Muskelproteinen \nund den programmierten Zelltod.\n2. Tiermodelle und isolierte Organkulturen f\u00fcr Isch\u00e4mie \nund Herzversagen um physiologische Parameter zu mes -\nsen und neue sch\u00fctzende Substanzen zu finden.\n3. Menschliche Molekulargenetik: Wir suchen nach \nunbekannten Mutationen welche Ionenkan\u00e4le oder \nMuskelproteine betreffen und etablieren die Relation \nzwischen der Genetik und den klinischen Befunden \nvon Herzkrankheiten und Herz-Rhythmusst\u00f6rungen. \nDa Herzversagen zu den wichtigsten Krankheiten \nund Todesursachen geh\u00f6rt, verfolgen wir in der Klinik \nmultizentrische Studien mit dem Ziel, Resistenz und \nBehandlung von Herzinfarkt und Rhythmusst\u00f6rungen \nzu verbessern. \nSelected Publications\n\u2013 Brink M, Chrast J, Price SR, Mitch WE, Delafontaine \nP . (1999) Angiotensin II stimulates gene expression \nof cardiac insulin-like growth factor I and its receptor \nthrough effects on blood pressure and food intake. \nHypertension. 34:1053-1059.\n\u2013 Keller DI, Coirault C, Rau T, Cheav T, Weyand M, \nAmann K, Lecarpentier Y, Richard P, Eschenhagen T, \nCarrier L. (2004) Human homozygous R403W mutant \ncardiac myosin presents disproportionate enhance -\nment of mechanical and enzymatic properties. J Mol \nCell Cardiol. 36:355-362.\n\u2013 Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch \nWE, Delafontaine P . (2001) Angiotensin II induces \nskeletal muscle wasting through enhanced protein \ndegradation and down-regulates autocrine insulin-\nlike growth factor I. Endocrinology. 142:1489-1496.\n\u2013 Zhu P, Zaugg CE, Hornstein PS, Allegrini PR, Buser \nPT. (1999) Bradykinin-dependent cardioprotective \neffects of losartan against ischemia and reperfusion \nin rat hearts. J Cardiovasc Pharmacol. 33:785-790.\n\u2013 Brink M, Anwar A, Delafontaine P . (2002) Neurohor -\nmonal factors in the development of catabolic/ana -\nbolic imbalance and cachexia. Int J Cardiol. 2002;85:\n111-121.Prevention and Therapy of \nHeart Failure\nAs a consequence of improved survival of acute coronary \ndisease, valvular and congenital heart disease and chang -\ning demographics, heart failure is the main epidemic of the \nnext decades. Diabetes mellitus is the strongest single risk \nfactor for the development of coronary artherosclerosis. Our \nclinical research aims at optimizing prevention and treat -\nment of coronary artery disease, which accounts for 65 to \n70 % of heart failure etiology. The TIME-DIA trial detects \nasymptomatic coronary artery disease in diabetics and tests \nif early treatment prevents ischemic events and heart failure. \nBASKET evaluates if drug eluting stents decrease the rate of \nischemic events and repeat revascularization in a real world \npopulation with coronary artery disease. The TIME-CHF \nrandomized multicenter trial checks if biomarker guided \nheart failure therapy in elderly patients improves quality \nof life and reduce hospitalization rates for decompensated \nheart failure. In patients with end stage heart failure, can IGF \ntherapy and modulation of the RAAS have a favorable effect \non hemodynamics and the sympathoadrenergic receptor \nexpression on myocytes? An ongoing study will give insight \ninto the role of neurohumoral modulation in end stage heart \nfailure. Patients with severe asynchrony of the left ventricle \nmay show dramatic symptom improvement with resynchro -\nnization therapy whereas biventricular, multi-site pacing de -\nvices are used to improve individual response. Moreover, \nheart failure with preserved left ventricular function has re -\ncently been identified as a major cause for hospitalization of \nelderly patients with pulmonary edema. To characterize this, \nechocardiographic, Doppler, Tissue Doppler and strain rate \nimaging are used as well as to study hemodynamic mecha -\nnisms and prevention of the high altitude pulmonary edema \nat an altitude of 4\u2019500 m. In the Swiss Cardio-Gene Program \nbetween Universities of Basel and Lausanne, genetic analy -\nsis of the extremely heterogeneous phenotypes of familial \nhypotrophic cardiomyopathy will help to identify patients \nwith an increased risk for sudden death. A genetic consult -\ning will be institutionalized.\nEffect of Cytokines and Growth Factors on \nCardiomyocyte Architecture and Function\nMuch as skeletal muscle grows with progressive weight training, the myocar -\ndium responds to increased mechanical load by compensatory hypertrophy, i.e. \nincreasing size and mass of its myocytes. Autocrine insulin-like growth factor \n(IGF)-I production contributes to hypertrophy in both muscle types, as it is re -\nquired for protein synthesis and myofibril formation. In the heart, stress stimuli \nsuch as ischemia or hypertension cause the release of various other factors that \non the short term preserve its function, but when acting for extended periods \nmay lead to diminished cardiac output. Ultimately, when myocardial perform -\nance becomes insufficient to adequately supply blood to other organs, the dis -\nease is referred to as heart failure (HF).\nWe aim at understanding the mechanisms that cause the progressive change \nfrom cardiac hypertrophy to end-stage HF, and hope to contribute to new strate -\ngies to prevent or treat this disease. We use the following approaches: \n(1) Myocyte cell culture models to analyze molecular mechanisms of cardomyo -\ncyte generation from stem cells and of cardiac remodelling, in particular \nmechanisms whereby cytokines, growth factors, and ion channels modulate \ncontractile-protein turn-over, sarcomere-assembly, and apoptosis.\n(2) Animal models of ischemia and heart failure to measure physiological param -\neters and identify new cardioprotective substances in and ex vivo.\n(3) Human molecular genetics to analyze mutations in contractile and ion chan -\nnel proteins and genotype/phenotype relationships of cardiomyopathies \nand arrhythmic syndromes.\nCommon features observed in cardiomyocytes of patients with HF of various \netiology are myofibril disarray and apoptosis. Examples of factors that can ad -\nversely change cytoarchitecture are angiotensin II (ang II), endothelin-1, and \ncytokines such as tumor necrosis factor (TNF)- \u03b1. Using cardiomyocyte cultures, \nwe analyzed how these factors change the protective activity of IGF-I. IGF\u2019s role \nin cardioprotection may be multiple, in that (1) it promotes protein synthesis and \nprevents protein degradation, each involving distinct mechanisms but together \nenhancing myofibril formation, (2) it protects against apoptosis, and (3) it pre -\nvents the shift of contractile proteins toward their fetal isoform, usually occuring \nin cardiac hypertrophy. TNF- \u03b1 decreased IGFBP-4 mRNA, an inhibitor of IGF-I \nactivity, whereas ang II had no effect, indicating that TNF- \u03b1 potentiates IGF-I ac -\ntivity in the cardiomyocyte. In contrast, TNF- \u03b1 blunted immediate IGF-induced \nAkt phosphorylation, decreased the anti-apoptotic protein Bcl-2 and increased \nbax, consistent with a pro-apoptotic function (Fig. 1). Thus, TNF- \u03b1 appears to be \na double-edged sword for the cardiomyocyte. Rodent models of heart failure \nwill be used to analyze the role of IGF-I, TNF- \u03b1 and the activation state of down -\nstream-mediators such as Akt and NF \u03baB, in cardiac remodeling. In addition, an \nisolated organ Langendorff set-up allows assessment of electro-physiological \nparameters. Our studies will be extended to analysis of novel potentially protec -\ntive factors, such as NF \u03baB inhibitors or urocortin II.\nFig. 1:  (a) TNF-\u03b1 decreases IGFBP-4 mRNA in cardiomyocytes isolated from adult rat \nheart, suggesting the induction of a protective mechanism. (b) TNF- \u03b1 increases the \npro-apoptotic protein bax and decreases the anti-apoptotic bcl-2 in cardiomyocytes.Fig. 2:  Immunohistochemical detection of IGF-I \nin a cardiac specimen from a heart failure patient \n(brownish staining; cell nuclei are blue). IGF-I is \nproduced in response to increased work load, \nand may enhance myofibrillogenesis or prevent \napoptosis.Clinical relevance of our work in cell culture- and animal-models is assessed \nusing samples from HF patients. In their plasma, significantly lower IGF-I levels \nwere detected than in healthy controls. Stratification for the use of angiotensin \nconverting enzyme (ACE) inhibitors by patients, combined with data from our \nexperimental rat studies has established that low systemic IGF-I is related to \nincreased ang II levels. In contrast, preliminary data shows high levels of IGF-\nI mRNA in cardiac specimens of HF patients, with IGF-I protein detectable \nin cardiomyocytes (Fig. 2). The proposed beneficial role of IGF-I to prevent \napoptosis and enhance myofibrillogenesis, has led to clinical trials aimed at \nincreasing IGF-I levels, e.g. achieved by growth hormone treatment. The ef -\nfects of direct IGF-I treatment is analyzed in further clinical investigations.\nProf. Dr. Peter Buser\nAbteilung Kardiologie\nUniversit\u00e4tsspital Basel\n38/39Cardiothoracic \nSurgical \nResearch\nProf. Dr. Hans-Reinhard Zerkowski\nUniversit\u00e4tsklinik f\u00fcr Herz-und Thoraxchirurgie\nUniversit\u00e4tsspital Basel\nGroup Members\nProf. Dr. Ivan Lefkovits \nDr. Martin Grapow \nDr. Peter Matt \nDr. Thomas Grussenmeyer \nDr. Else M\u00fcller-Schweinitzer \nDr. David Reineke \nBenedikt Wiggli (MD student)\nEmmanuel Traunecker (technician)Proteome\nEndothelial function\nApoptosis\nChronic heart failure\nVentricular assist devices\nValve surgeryKliniknahe Grundlagenforschung \u2013 fast \ntrack zum Fortschritt in der Chirurgie\nDer Langzeiterfolg von koronarchirurgischen Bypass -\noperationen  ist in grossem Masse von der Qualit\u00e4t der \nVenen und Arterien abh\u00e4ngig, die als Byp\u00e4sse verwen -\ndet werden. Wir untersuchen Bypass-Gef\u00e4sse auf ihre \nfunktionellen Unterschiede innerhalb verschiedener \nGef\u00e4ssgruppen, Einfl\u00fcsse von Aufbewahrungsl\u00f6sungen \nund unterschiedliche Operationstechniken auf Gef\u00e4ss -\nfunktion, Integrit\u00e4t der Gef\u00e4ssinnenschicht (Endothel) \nund Ver\u00e4nderungen der Serumproteine. Schritt f\u00fcr \nSchritt wurden H\u00e4modynamik, extra- und intrazellul\u00e4re \nSignaltransduktion und Genexpression in unterschiedli -\nchen Erkrankungen des Herzens untersucht. All dieses \nspiegelt sich wieder in Ver\u00e4nderungen der Proteinzu -\nsammensetzung in Gewebe und Blut. Proteomics , die \nAnalyse des Proteoms, untersucht die gesamte Prote -\ninzusammensetzung einer Zelle oder eines Organismus \nzu einem bestimmten Zeitpunkt. Erste Resultate unserer \nGruppe in einem bislang wenig erforschten Gebiet sind \nabrufbar unter: http://pubs.acs.org/subscribe/journals/\njprobs/3/specialissue/. Obwohl die Herztransplantation \n(HTx) der Goldstandard in der Behandlung der dilatativen \nKardiomyopathie (DCM) ist, versterben viele Patienten \nauf ein Spendeherz wartend auf der Transplantations -\nliste mangels Spendeorgane. Die Implantation mecha -\nnischer Unterst\u00fctzungspumpen, sog. Ventricular Assist \nDevices  (VAD), welche zur sofortigen Entlastung der \nHerzkammer(n) f\u00fchrt, wurde als \u00dcberbr\u00fcckungsmass -\nnahme bis zur HTx eingef\u00fchrt. In den letzten Jahren \nwurde zunehmend dar\u00fcber berichtet, das VAD die kon -\ntraktile Funktion des entlasteten Herzens normalisieren \nkann und damit eine ev. Herzerholung m\u00f6glich macht. \nDer Begriff Bridge to Recovery wurde gepr\u00e4gt. Unser \nInteresse gilt dem Aufsp\u00fcren von Pr\u00e4diktoren in Blut \noder Gewebe, die in Zukunft Aussage dar\u00fcber erlauben \nk\u00f6nnten, welcher Patient sich von Anfang an f\u00fcr eine \nsolche Therapie eignet.\nSelected Publications\n\u2013 Ponicke K., Vogelsang M., Heinroth M., Becker K., \nZolk O., Bohm M., Zerkowski HR., Brodde OE. (1998) \nEndothelin receptors in the failing and nonfailing hu -\nman heart. Circulation 3; 97:744-51.\n\u2013 Bartling B., Milting H., Schumann H., Darmer D., \nArusoglu L., Koerner MM., El-Banayosy A., Koerfer \nR., Holtz J., Zerkowski HR. (1999) Myocardial gene \nexpression of regulators of myocyte apoptosis and \nmyocyte calcium homeostasis during hemodynamic \nunloading by ventricular assist devices in patients \nwith end-stage heart failure.Circulation 100:II216-23.\n\u2013 Morawietz H., Szibor M., Goettsch W., Bartling B., \nBarton M., Shaw S., Koerfer R., Zerkowski H.R., Holtz \nJ. (2000) Deloading of the left ventricle by ventricular \nassist device normalizes increased expression of en -\ndothelin ET(A) receptors but not endothelin-convert -\ning enzyme-1 in patients with end-stage heart failure. \nCirculation 102:III188-93.\n\u2013 Grapow M.T., Kern T., Reineke D.C., Brett W., Bernet \nF ., Rueter F ., Muller-Schweinitzer E., Zerkowski H.R. \n(2003) Improved endothelial function after a modified \nharvesting technique of the internal thoracic artery. Eur \nJ Cardiothorac Surg. 23:956-60.\n\u2013 Zerkowski H.R., Grussenmeyer T., Matt P ., Grapow \nM., Engelhardt S., Lefkovits I. Proteomics Strategies \nin Cardiovascular Research. J Prot Res. 3(2):200-208Division of Cardio-Thoracic Surgery, \nDeptartment of Surgery\nCoronary Artery Bypass Surgery\nBypass surgery accounts for 59% of the operations performed in the Cardiothoracic \nSurgery Division, a significant figure. Almost 92% of these patients receive arterial \nrevascularisation using internal thoracic and radial arteries. Around 20% of our bypass \noperations are performed on the beating heart without using the heart-lung-machine.\nTiming of Valve Replacement and Repair\nSurgery of the heart valves is routinely performed in our institution (using all techniques); \nthe primary goal is preservation of the valve (reconstruction). If a valve replacement \nis required, prostheses of synthetic or biological materials are implemented. Special \nemphasis is laid on the optimal time for surgery. This can be defined as the latest date \nin the natural course of chronic heart valve disease at which all changes of myocardial \nadaptation are completely reversible. Clinical, echocardiographic and hemodynamic \nparameters do not offer a precise way to determine the stage of the disease so far. \nChanges of genome and proteome may provide us with data being helpful to find the \noptimal time frame for surgery.\nArtificial Heart for Recovery\nPublic interest has focused for a long time on heart transplantation and the use of the \u201carti -\nficial hearts\u201d (mechanical circulatory support systems), both procedures being performed \nin our institution as well. The growing shortage of donor organs resulted in a frequent \nuse of those devices for bridge to transplantation. Few patients surprisingly recovered on \nthe device and underwent explantation \u2013 the term bridge to recovery was introduced. \nOur Institution is involved with basic research to find predictors of outcome.\nBasic Science in Cardiac-Surgery \u2013 Keeping \nthe Distance Short to Clinical Treatment\nLong-term outcome of coronary artery bypass surgery is in important part \ndependent on the excellence of grafts which are used for revascularisation. \nTherefore, we investigated functional differences in between grafts, i.e. arterial \n(radial vs. internal thoracic artery) and venous grafts, but also evaluated different \npreparation techniques and the impact of storage solutions on vascular function. \nUsing organ bath experiments, we demonstrated that a worldwide accepted \nharvesting technique of the internal thoracic artery resulting in blocking the per -\nfusion through the vessel for less than one hour has unfavourable influence on \nendothelial function. On the other hand, a slight modification of the preparation \nby keeping the artery under perfusion improves the early function. Furthermore \nwe used biochemical and visualization methods (i.e. scanning electron micros -\ncopy) to support our findings. Functional, biochemical and structural investiga -\ntions demonstrated that maintained perfusion of this vessel during grafting of \nthe other coronary target vessels induces considerably less endothelial damage \nthan the conventional method indicating the importance of changing historical \nsurgical techniques for optimal arterial graft function.\nStep by step hemodynamics, signal-transduction and gene expression in cardiac \ndisease were performed as well as an analysis of changes in the proteome. Pro -\nteomic analysis investigates the entire protein composition of a cell or organism \nat a given state. The core technology of proteomic research is 2-dimensional gel \nelectrophoresis. Proteins are separated on differences in their charge and mass \nof polypeptides 2-D gels are analysed using specialized software. The identifica -\ntion of protein spots is then performed by matching to a known master pattern \nor by mass spectrometry. First results of our group mark the rare publications \nof human protein analysis in cardiac disease. http://pubs.acs.org/subscribe/\njournals/jprobs/3/special _issue/\nDilative cardiomyopathy (DCM) is one important indication for heart transplan -\ntation (HTx). Although HTx is the gold-standard in treatment of DCM, many \npatients die awaiting HTx, due to shortage of donor-hearts. The implantation \nof ventricular assist devices (VAD) in DCM patients, leading to an immediate \nunloading of the dilated ventricle, was established as a bridge to transplantation. \nHowever, recent reports indicated that VADs might normalize the contractile \nfunction of the unloaded heart, leading to the idea of bridging to recovery. \nOur interest is to detect alterations on the humoral and cellular level, investi -\ngating the apoptosis related network, signal transduction pathways in human \ncardiac tissue, and various stress markers. Tissue samples of the left ventricular \nmyocardium were obtained during implantation of the VAD and consecutively \nat cardiac transplantation. \nFirst results demonstrated an increased transcription of anti-apoptotic sFas \n(FasEx06Del) and Bcl-xl indicating a myocardial phenotype shift towards less \nsusceptibility for myocyte apoptosis as a consequence of reduced mechanical \nstress due to decreased ventricular wall tension during VAD support.\nFig. 1:  Silver stained proteomic pattern \nof left ventricular tissue of the wild-type \ncounterpart of the b1-ardenergic receptor \ntransgenic strain. The proteomic pattern \nis based on wide range IEF separation (3-9 \npI range) and size separation in 10\u201320% \nacrylamide gradient gels in SDS milieu.Fig. 2:  Scanning electron micrographs \nof the endothelium of a perfused (a) and \na clipped internal thoracic artery (b). \nRepresentative tracings showing spontane -\nous rhythmic activity of rings from radial \narteries (RA) in comparison with rings \nfrom internal mammary (IMA) without \nany rhythmic activity (c). Cumulative con -\ncentration-response curves on rings from \nunstored human IMA and RA for KCl (top, \nn=8), NA (middle, n =10) and ET-1 (bottom, \nn=14). IMA and RA were taken from the \nsame patients. Responses are expressed in \ng. Vertical bars represent mean SEM (d).\nd40/41Clinical \nPharmacology \nand Toxicology \nProf. Dr. Stephan Kr\u00e4henb\u00fchl \nInstitut f\u00fcr Klinische Pharmazie \nUniversit\u00e4tsspital Basel\nGroup members\nDr. Markus Wenk\nDr. Michael T\u00f6r\u00f6k\nDr. Paul Roberts\nLiliane Todesco (chemist)\nPriska Kaufmann (Ph D student)\nAndrea Knapp (PhD student)\nSaskia L\u00fcde (PhD student)\nBettina Link (PhD student)\nKatri Waldhauser (PhD student)Carnitine\nMitochondrial energy metabolism\nHepatotoxicity\nRhabdomyolysis\nMitochondrial cytopathiesToxikologie und Energiestoffwechsel \nDie Forschung unserer Gruppe konzentriert sich auf 2 \nGebiete, n\u00e4mlich Energiemetabolismus (insbesondere \nMitochondrien und Carnitinmetabolismus) sowie toxi -\nkologische Fragestellungen in Bezug auf Medikamente \n(insbesondere Toxizit\u00e4t auf die Leber und die Skelett -\nmuskulatur).\nWir haben ein Tiermodell f\u00fcr die Carnitindefizienz \nentwickelt, indem wir Ratten mit dem Carnitinanalog \nTrimethylhydraziniumpropionat (THP) behandeln. \nDiese Ratten entwickeln innerhalb von 2 bis 3 Wochen \neinen schweren Carnitinmangel. In diesem Modell \nuntersuchten wir die Entwicklung der charakteristi -\nschen Fettleber, Kardiomypathie und Myopathie der \nSkelettmuskulatur.\nZudem sind wir an der Analytik von Carnitin und Acyl -\ncarnitinen interessiert. Diese Methoden brauchen wir \nf\u00fcr in vivo Untersuchungen des Carnitinmetabolismus \nvor allem bei Sportlern.\nIm Bereich Toxikologie haben wir den Mechanismus der \nHepatotoxizit\u00e4t von Amiodarone beschrieben. Danach \nuntersuchten wir das hepatotoxische Potential der \nStrukturanaloga Benzbromaron und Benzaron. Diese \nSubstanzen entkoppeln die Mitochondrien, hemmen \ndie \u03b2-Oxidation und die Atmungskette und \u00f6ffnen eine \nPore in den mitochondrialen Membranen. Durch diese \nMechanismen k\u00f6nnen sie Nekrose und/oder Apoptose \nhervorrufen.\n\u00c4hnliche Eigenschaften haben die lipophilen Statine auf \nMitochondrien aus der Skelettmuskulatur und k\u00f6nnen \nso zu Rhabdomyolyse f\u00fchren. Gegenw\u00e4rtig interessiert \nuns die Frage, ob mitochondriale St\u00f6rungen ein Risi -\nkofaktor f\u00fcr die Rhabdomyolyse unter Statinen sind. \nDie Beantwortung dieser Frage k\u00f6nnte zur Herstellung \nvon in vitro Systemen f\u00fchren, welche ein fr\u00fchzeitiges \nScreening von Substanzen auf mitochondriale Toxizit\u00e4t \nerlauben.\nSelected Publications\n\u2013 Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz \nM, Stieger B, Kr\u00e4henb\u00fchl S. (2001) Development \nand characterization of an animal model of carnitine \ndeficiency. Eur J Biochem, 268:1876-1887.\n\u2013 Spaniol M, Bracher R, Ha HR, Follath F , Kr\u00e4henb\u00fchl S. \n(2001) Toxicity of amiodarone and amiodarone ana -\nlogues on isolated rat liver mitochondria. J Hepatol, \n35:628-36.\n\u2013 Spaniol M, Kaufmann P, Beier K, W\u00fcthrich J, T\u00f6r\u00f6k \nM, Scharnagl H, M\u00e4rz W, Kr\u00e4henb\u00fchl S. (2003) \nMechanisms of liver steatosis in rats with systemic \ncarnitine deficiency due to treatment with trimethyl -\nhydraziniumpropionate. J Lipid Res, 44:144-153.\n\u2013 Zaugg CE, Spaniol M, Kaufmann P, Bellahcene M, \nBarbosa V, Tolnay M, Buser PT, Kr\u00e4henb\u00fchl S. (2003) \nMyocardial function and energy metabolism in carni -\ntine-deficient rats. Cell Mol Life Sci, 60:335-40.\n\u2013 Vernez L, Wenk M, Kr\u00e4henb\u00fchl S. (2004) Determi -\nnation of carnitine and acylcarnitines in plasma by \nhigh-performance liquid chromatography-electro -\nspray ionization ion trap tandem mass spectrometry. \nRapid Commun Mass Spectrom, 18:1233-1238.Clinics\nOur research is quite often closely related to clinical observations. In the case of carnitine \nmetabolism and mitochondrial dysfunctions, there is a link to mostly pediatric diseases, \ni.e. organic acidurias and mitochondrial cytopathies. We can diagnose and classify \norganic acidurias in the urine or the plasma of suspected patients using own analytical \nmethods. We are currently introducing these methods into the routine analytical spec -\ntrum of the Department of Clinical Chemistry at the University Hospital. In addition, \nwe develop routine assays using our expertise in measuring the activities of enzymes \ninvolved in \u03b2-oxidation and in the activity of the respiratory chain, which should facilitate \nthe diagnosis of mitochodrial disorders.\nIn collaboration with neurologists and neuropathologists, a special attention is given \nto investigate patients with rhabdomyolysis, as this disease is often associated with \nmitochondrial disorders and/or toxicities of chemicals or drugs.\nOur research in toxicology is obviously connected to our own clinical activities, but also \nto many facets of internal medicine and pathology. Quite often, we notice poisonings by \nchemicals or drugs and we can then investigate possible mechanisms in the laboratory. \nExamples thereof are given by the toxicity of amiodarone, benzbromarone or benzarone \nand the elucidation of the mechanism underlying the hepato- and myotoxicity of the \nemetic toxin produced by Bacillus cereus (N Engl J Med 1997;336:1142- 1148).\nBasel offers optimal conditions for the whole spectrum of our activities as we have \nmany highly qualified partners for scientific exchange in the clinic and in research in the \nUniversity Hospital, at the University and in the local industry .\nToxicology and Energy Metabolism\nThe carnitine system is important for tissues using fatty acids as energy source, \nsince carnitine is needed for the import of fatty acids into mitochondria. In or -\nder to be able to study the pathological consequences of carnitine deficiency, \nwe developed and characterized an animal model with biochemically-induced \ncarnitine deficiency. Rats treated with trimethyl-hydrazonium-propionate (THP), \na substance similar to carnitine and its biosynthetic precursor butyrobetaine, \ndevelop symptomatic carnitine deficiency within 2 to 3 weeks. THP interferes \nwith renal carnitine reabsorption and inhibits carnitine biosynthesis. Such rats \ndevelop microvesicular fatty liver (Fig. 1). We could show that the principle \nmechanism leading to microvesicular steatosis is decreased \u03b2-oxidation of \nfatty acids due to carnitine deficiency, leading to an accumulation of cytosolic \npalmitoyl-CoA with an increase in the formation of VLDL. Furthermore, we could \nshow that cardiac carnitine depletion is associated with functional but no mor -\nphological alterations of the heart. Our model is therefore suitable to study the \ndevelopment of cardiomyopathy associated with carnitine deficiency. Recent, \nso far unpublished, studies reveal also changes in the metabolism and structure \nof skeletal muscle.\nAnother focus in the carnitine field are clinical studies. We have shown that long-\nterm ingestion of high amounts of carnitine is not able to elevate the carnitine \ncontent in skeletal muscle in healthy volunteers. Nevertheless, oral carnitine ad -\nministration has been shown to be associated with a decrease in muscle sourness \nafter eccentric exercise. We are therefore currently performing a controlled clini -\ncal study in healthy volunteers investigating whether carnitine administration is \nindeed able to prevent muscle sourness and which are the mechanisms involved. \nFurthermore, we are interested to study carnitine homeostasis and the effect of \ncarnitine administration in vegetarians. Vegetarians develop carnitine deficiency \nover time and may therefore be able to profit from carnitine administration.\nIn order to perform clinical studies, suitable analytical methods are needed. We \nhave recently developed an LC-MS/MS method for the determination of buty -\nrobetaine, carnitine and acylcarnitines in urine and plasma (Fig. 2). The method \nhas been used to characterize the carnitine profile in patients undergoing \nchronic hemodialysis with and without carnitine administration. Such patients \nhave an increased amount of acylcarnitines in plasma (e.g. acetyl- and propio -\nnylcarnitine) and the elimination of acylcarnitines can be increased by treatment \nwith carnitine.\nFig. 1:  Microvesicular steatosis in rats treated with THP . Treatment with THP over 3 \nweeks induces microvesicular steatosis in rat hepatocytes. Oil red stain (fat is stained \nred). (A) casein, (B) casein/THP, (C) vegetarian, (D) vegetarian/THP .Fig. 2:  Determination of urine acylcarnitines in a patient with medium chain acyl-CoA \ndehydrogenase deficiency (MCAD) using LC-MS/MS. In comparison to a control \nsample, the patient has significant peaks of hexanoyl- and octanoylcarnitine (arrow). \n1=carnitine, 2 =acetylcarnitine, 3 =propionylcarnitine, 4 =isovalerylcarnitine, 5 =hex-\nanoylcarnitine, 6 =octanoylcarnitine.\nConsidering our toxicological projects; we have recently provided a mecha -\nnism of the hepatic toxicity of amiodarone, a frequently used antiarrhythmic \ndrug. Amiodarone uncouples oxidative phosphorylation and inhibits the \nmitochondrial respiratory chain and \u03b2-oxidation, possibly leading to apop -\ntosis and/or necrosis of hepatocytes. Unpublished data show that this is also \nthe case for benzbromarone and benzarone. Benzarone is structurally very \nclose to amiodarone and capable of opening the mitochondrial membrane \npermeability transition pore (MPTP), leading to the disruption of the outer \nmitochondrial membrane and inducing apoptosis.\nA last field of interest is rhabdomyolysis associated with statins. We have \nbeen able to show that statins are mitochondrial toxins, leading to inhibition \nof fatty acid oxidation and to opening of the MPTP . Current experiments \ninvestigate the question whether underlying mitochondrial diseases could \nbe a risk factor for rhabdomyolysis associated with statins. Such experiments \ncould also be usable to create test systems for early screening of chemical \ncompounds for mitochondrial toxicity.42/43Clinical \nPharmacology \nand Toxicology\nProf. Dr. J\u00fcrgen Drewe\nInstitut f\u00fcr Klinische Pharmazie \nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Heike Gutmann\nDr. Petr Hruz (MD PhD student)\nUrsula Behrens (technician)\nMarco Netsch (PhD student)\nManisha Poddar (PhD student)\nPhilipp Schlatter (PhD student)\nChristian Zimmermann (PhD student)Drug-drug interaction \nTransport porteins \nDrug safety \nResistanceMedikamenten-Transporter und Arzneimit -\ntelinteraktionen\nMedikamente werden h\u00e4ufig oral verabreicht, der Wir -\nkungsort der Medikamentenwirkstoffe ist aber in der \nRegel nicht im Magen-Darm Trakt. Sie m\u00fcssen vielmehr \nerst an den Wirkungsort gelangen und dazu verschie -\ndene biologische Membranen (Darm, Bluthirn-Schranke \nusw.) passieren. Hauptgegenstand unserer Arbeit sind \ndie Mechanismen dieser Membrantransporte und deren \nSt\u00f6rungen, die dann in Wirkungsverlust oder Toxizit\u00e4t \n(erh\u00f6hte Blutspiegel, Interaktionen) m\u00fcnden k\u00f6nnen. \nH\u00e4ufig sind spezielle Transportproteine f\u00fcr die Permea -\ntion durch Membranen verantwortlich. Von der Vielzahl \nder bisher bekannten Transporter interessieren uns vor \nallem die f\u00fcr die Multidrug-Resistenz verantwortlichen \nABC-Transporter, sowie spezielle organische Anionen -\ntransporter. \nEinigen Vertreter der ABC-Transportern kommt eine \nbesondere klinische Bedeutung zu, so verursacht z.B. \nein Defekt des ABC-Transporters CFTR die Erbkrank -\nheit Mukoviszidose, w\u00e4hrend z.B. P-Glykoprotein \n(P-gp) und Multidrug-Resistenz assozierte Proteine \n(MRPs) eine wichtige Rolle beim Auftreten von sog. \nMultidrug-Resistenzen z.B. gegen Zytostatika in der \nTumortherapie spielt. \nSchwerpunkt unserer Arbeitsgruppe ist es, Interakti -\nonen, die auf Transportern beruhen, auf molekularer \nEbene zu erkl\u00e4ren, bzw. vorauszusagen. Dazu haben \nwir in unserer Forschungsgruppe verschiedene in-\nvitro Modelle etabliert, an denen Transportprozesse \nuntersucht werden k\u00f6nnen. Mit solchen Modellen \nlassen sich potentielle Risiken neuer Wirkstoffe, die \nMechanismen aufgetretener unerw\u00fcnschter Arzneimit -\ntelnebenwirkungen untersuchen, potentiell gef\u00e4hrliche \nArzneimittelkombination vorherzusagen und somit das \nRisiko f\u00fcr k\u00fcnftige Patienten verringern.\nSelected Publications\n\u2013 Bogman K., Peyer A.K., T\u00f6r\u00f6k M., K\u00fcsters E. and \nDrewe J. (2001) HMG-CoA reductase inhibitors and \nP-glycoprotein modulation. Br J Pharmacol, 132:1183-\n1192.\n\u2013 Gutmann H., Fricker G., Drewe J., Toeroek M. and \nMiller D.S. (1999) Interactions of HIV protease inhibi -\ntors with ATP-dependent drug export proteins. Mol \nPharmacol, 56:383-389.\n\u2013 Pfrunder A., Gutmann H., Beglinger C. and Drewe J. \n(2003) Gene expression of CYP3A4, ABC-transport -\ners (MDR1 and MRP1-MRP5) and hPXR in three \ndifferent human colon carcinoma cell lines. J Pharm \nPharmacol, 55:59-66.\n\u2013 Pfrunder A., Schiesser M., Gerber S., Haschke M., \nBitzer J. and Drewe J. (2003) Interaction of St John\u2019s \nwort with low-dose oral contraceptive therapy: a \nrandomized controlled trial. Br J Clin Pharmacol, 56:\n683-690.\n\u2013 Sieber C.C., Beglinger C., Bart S., Tschoepl M., Currie \nG., Larsen F . and Drewe J. (2004) Lanreotide effect \non splanchnic blood flow in healthy subjects: effect of \nthe rate of infusion. Clin Pharmacol Ther, 75:70-79.cooperation with the Division of Gastroenterology (Prof. C. Beglinger) we \ninvestigate in a large clinical study mucosal biopsies from IBD patients and \nwe try to develop in vitro models to mimic drug-induced treatment resistance \nin IBD.\nBlood-brain barrier (BBB)\nBBB is another physiological barrier, which controls brain uptake in order to \nprotect the brain from potentially toxic xenobiotics, such as drugs. The BBB \nis built by the endothelial layer of brain capillary endothelial cells (BCEC). To \nstudy these transport processes across the BBB, we have established an in \nvitro model of the BBB based on primary cell cultures of porcine BCEC. Using \nthe porcine BCEC model, we have investigated a series of different drugs to \npredict cerebral uptake and could validate the predicted uptake with litera -\nture animal data on brain penetration (Fig. 1). Currently, we are developing \nan in vitro model based on human cells. \nKidney\nTransport processes are importance physiological functions of the kidneys. \nTubular function is studied by us in a killifish in situ model of proximal tubules \n(in collaboration with Dr. David S. Miller, NIEHS (North Carolina) and Prof. G. \nFricker, University of Heidelberg, Germany). A cell culture model based on \nprimary cell cultures of proximal tubular cells is currently in validation (Fig. 2). \nGenetic Polymorphisms\nA large part of the pharmacokinetic variability of drugs may be caused by \ngenetic differences between different individuals. There are several single \nnucleotide polymorphisms (SNPs) described for many of these transport pro -\nteins. We are investigating the functional importance of these SNPs and their \nrelevance for the development or modulation of certain diseases (risk factor, \ntreatment resistance, and prognosis). \nDrug Transporters and Drug-Drug \nInteractions\nDrugs are often given orally. However, their site of action is usually not in the \ngastrointestinal tract (gut). They have to travel through the body to their site of \naction and have to pass different physiological barriers (such as gut wall, blood-\nbrain barrier). Our main research interests are to study the mechanisms of the \ninvolved transport processes and their disturbances. The latter could lead to loss \nof drug effect or toxicity (increased blood levels, drug-drug interactions). These \ntransport processes are mainly mediated by specific transport proteins. The \nmost important group of these proteins are the superfamily of ABC-transporters \n(such as multidrug resistance proteins) and organic anion transporters. \nFor some of these transporters it was shown that they are involved in the \ndevelopment of clinically relevant diseases: for example, a defect of the ABC-\ntransporter CFTR causes cystic fibrosis, and P-glycoprotein and some multidrug \nresistance associated protein transporters (MRPs) are involved in the develop -\nment of resistance to various drugs (such as anticancer medication). \nEffects on transport protein function or their gene expression may lead to clini -\ncally significant drug-drug interaction. One major research focus is the devel -\nopment of in vitro screening models to investigate the molecular mechanisms \nof clinically observed drug-drug interactions. These models may by helpful to \nanticipate potentially dangerous drug combinations, which may lead to drug-\ndrug interaction and adverse effects by affecting transport protein function. This \nwould reduce the risk of pharmacotherapy for future patients\nGut\nThe epithelium of the gut is the most important barrier for enteral absorption of \ndrugs. In the gut mucosa there are various transport proteins expressed, which \nmay secrete absorbed drug immediately back into the gut lumen. This may lead \nto substantially decreased oral bioavailability of these drugs. We have devel -\noped several in vitro screening models to assess the mechanisms of enteral drug \nabsorption their interaction with different drugs. Currently, we are investigating \nthe functional regulation of these transporters and how it can be modulated by \ndifferent drugs or endogenous factors. \nThe main project in this area is the investigation of the importance of ABC-trans -\nporters in the development of inflammatory bowel diseases (ulcerative colitis, \nCrohn\u2019s disease). Disturbancies in transporter function may be an important \nmechanisms or cofactor for the frequently observed treatment resistance (20-\n30% of the patients). We know that several drugs used in the treatment of IBD \nare transported by some of these transport proteins. Impaired function may lead \nto decreased cellular availability of those drugs and a loss of their function. In \nFig. 1:  Dose-dependent \ninhibition of P-glycopro -\ntein mediated export \nof absorbed radiolabelled \nsaquinavir from BCECs by \nincreasing concentrations \nof the P-glycoprotein in -\nhibitor ritonavir. Inhibition \nresults in an increased \ncellular uptake and accu -\nmulation of saquinavir.Fig. 2:  Study of \nkidney transport of \nfluorescence labelled \nHIV protease inhibitor \nsaquinavir in isolated \nproximal tubules of \nthe killifish (Fundulus \nheteroclitis) (A): \nwithout inhibitor (B), \nwith inhibitor of trans -\nport (C)\nA\nB C44/45Structural Cell \nBiology\nProf. Dr. Lukas Landmann\nInstitut f\u00fcr Anatomie\nGroup Members\nDr. Piotr Maly\nDr. Permsin Marbet\nMireille Toranelli (technician)\nJean Paul Boeglin (technician)\nEva Bryson (technician)Cholestasis\nEndocytosis\nMembrane Traffic\nTight Junctions\n3D-MicroscopyMechanismen der Cholestase\nDie Sekretion von Galle ist eine Hauptfunktion der Leber. \nSie beruht auf dem gerichteten Transport gallepflich -\ntiger Substanzen vom Blut- ins Gallenkompartiment \nund wird von polar exprimierten Transportproteinen \nin der Zellmembran der Leberzellen vermittelt. Tight \nJunctions zwischen den Leberzellen stellen die einzige \nBarriere zwischen Galle und Blut dar; sie verhindern \ndie Regurgitation von sezernierter Galle aus dem Ca -\nnaliculus. Cholestase manifestiert sich in reduziertem \nGallenfluss und erh\u00f6hten Serumwerten gallepflichtiger \nSubstanzen. Sie kann auf dem Niveau der Leberzelle \nmit beeintr\u00e4chtigter Expression von Transportsystemen \nund/oder ihrer ver\u00e4nderten subzellul\u00e4ren Verteilung als \nauch mit Defekten der Tight Junctions assoziiert sein. \nAlle Arten von Cholestase resultieren innert Tagen zu \neiner verminderten Expression der Transportsysteme. \nBei einem Verschluss des Gallengangs akkumulieren \naber schon nach 6 h canalicul\u00e4re Exportsysteme in \nsubapikalen Vesikeln. Diese Ver\u00e4nderung kann durch \n2 Mechanismen erkl\u00e4rt werden: 1) Neu synthetisierte \napikale Membranproteine, die in Leberzellen indirekt \n\u00fcber die transcytotische Route zu ihrer Destination \ntransportiert werden, verlieren ihre F\u00e4higkeit, in \ndie apikale Zellmembran inkorporiert zu werden. 2) \nTransportsysteme in der apikalen Membran werden \nendocytotisch internalisiert und in subapikalen Vesikeln \nakkumuliert. Dass der erste Mechanismus involviert ist, \nkonnte gezeigt werden; eine Beteiligung des Zweiten ist \nplausibel. Die durch Cholestase verursachte Zunahme \nder Tight Junction Permeabilit\u00e4t ver\u00e4ndert weder die \nVerteilung von junctionalen Proteinen noch die Menge \nvon mRNA und Proteinen. Deshalb sollen die inhomo -\ngen exprimierten Membranproteine Claudin 1 und 3 \ndetaillierter charakterisiert werden.\nSelected Publications\n\u2013 Stieger, B.; Meier, P ., and Landmann, L. (1994) Effect \nof obstructive cholestasis on membrane traffic and \ndomain-specific expression of plasma membrane \nproteins in rat liver parenchymal cells. Hepatology \n20, 201-212.\n\u2013 Rahner, C.; Stieger, B., and Landmann, L. (1996) \nStructure-function correlation of tight junctional im -\npairment after intrahepatic and extrahepatic cholesta -\nsis in rat liver. Gastroenterology 110, 1564-1578.\n\u2013 Rahner C.; Stieger, B., and Landmann, L. (2000) \nApical endocytosis in rat liver cells in situ involves \nclathrin, passes the subapical compartment and leads \ninto lysosomes. Gastroenterology 119, 1692-1707.\n\u2013 Landmann, L. and Stieger, B. (2001) Tight junctions in \nliver disease. In: Tight Junctions, 2nd Ed. (Cereijido, \nM. and Anderson, J.M., Eds).:CRC Press, Baton Rota, \nFA, 575-597.\n\u2013 Landmann, L. (2002) Deconvolution improves colo -\ncalization analysis of multiple fluorochromes in 3D \nconfocal data sets more than filtering techniques. J \nMicr (Oxford) 208, 134-147.and spacing of the constituent particles is not affected. Preliminary results \nindicate that subcellular distribution of integral and peripheral junctional pro -\nteins is not altered by cholestasis. In addition, mRNA and protein expression \nlevels are not changed. Therefore, the inhomogenously expressed mem -\nbrane proteins (claudin1 and 3) will be characterized to greater detail and the \nrole of macromolecular interactions involved in the maintenance of junctional \nintegrity will be explored.\nMechanisms of Cholestasis\nBile secretion is a major function of the liver and depends on vectorial transport \nof cholephilic compounds from blood to bile. The high concentration in bile of \nsome constituents ( > 1000-fold for bile acids) is mediated by polar expression \nof specific transport systems (Fig. 1) the export proteins of which belong to the \nABC gene family of active transporters. Regurgitation of secreted bile from the \ncanaliculus to the blood space is prevented by hepatocellular tight junctions \nwhich are the only barrier between the two compartments. Cholestasis inter -\nferes with bile formation or bile flow resulting in decreased hepatic secretion of \nwater and/or organic anions, e.g. bilirubin and bile acids. Clinically, cholestasis \nis defined by increased serum levels of cholephilic compounds and specific en -\nzymes. Therefore, possible alterations resulting in cholestasis include impaired \nexpression and/or subcellular distribution of transport systems as well as dam -\nage of the sealing tight junctional belt. \nMost of the transport systems are known to be downregulated by all types of \ncholestasis within days. However, as soon as 6 h after experimentally induced \ncholestasis, accumulation of canalicular export systems in subcanalicular (sub -\napical) vesicles becomes apparent (Fig. 2). This short term alteration may be \ncaused by two mechanisms: (i) Defective insertion of newly synthesized apical \nmembrane proteins, which are sorted indirectly by the transcytotic route to \ntheir final destination. This defect is induced by carrier vesicles having lost their \ncompetence for fusion with the apical membrane. As a matter of fact, cholesta -\nsis severely affects functional transcytosis in hepatocytes as demonstrated by \nbiliary secretion of various markers for transcytosis including polymeric IgA. (ii) \nInternalization of transport systems by apical endocytosis and reinsertion into \nthe apical plasma membrane may be a regulatory mechanism controlling the \nnumber of functional transport proteins. Using high resolution confocal micros -\ncopy in combination with various markers we demonstrated an apical endocytic \npathway in hepatocytes. It is conceivable that the apical recycling pathway is also \naffected by cholestasis. Current work characterizes endocytic routes in greater \ndetail in order to localize and define the mechanisms by which cholestasis affects \nmembrane traffic in liver cells. \nTight junctions are known to be affected functionally and structurally. Cholesta -\nsis induced alterations include increased permeability for peroxidase and other \nmarker molecules as well as disorganization of the junctional network resulting \nin a decreased number of strands. Strand quality, however, as reflected by size \nFig. 1:  Fig. 1: Polar expression of basolateral uptake (red) and canalicular export \n(green) systems in rat hepatocytes. BA = bile acids, OA = organic anions, TJ = tight \njunctions.Fig. 2:  Accumulation of pericanal -\nicular (subapical) vesicles that display \nimmunoreactivity for canalicular \nmembrane proteins including export \npumps after bile duct ligation in the \nrat. Human hepatocytes show a similar \nresponse in various forms of \ncholestasis.\nFig. 3:  TxR-labeled dextran (red) infused retrogradely through the common bile duct \nshows colocalization (white) with endolyn76 (green) and rab11 (blue, left panel) or \npIgA (blue, right panel). All three marker proteins travel through a subapical compart -\nment. Bar = 0.5 mm.\nFig. 4:  3D characterization of the \nearly endosomal compartment in rat \nhepatocyte couplets. After uptake of \nTxR-conjugated dextran (red) for 5 min \ncells were fixed and immunostained \nfor the recycling basolateral receptor \nfor asialoglycoprotein (blue) and \nthe early endosomal antigen 1 (green). \nOverlap of all three markers defines \nunambiguously functional early endo -\nsomes \n46/47Neuroimmuno-\ndermatology\nDr. Mei Bigliardi-Qi\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup members\nPD Dr Paul Bigliardi\nGoran Vucelic (technician)\nKatrin Pfaltz (MD student) \nHao Cai (trainee)Opiate\nPeripheral nerve\nCell differentiation and growth\nItch\nWound healing\nAging Die Opiat-Rezeptoren der Haut\nDas Gebiet der Neuro-Immuno-Dermatologie umfasst \ndas Studium der Funktionen verschiedener neuronaler \nBotenstoffe und deren Interaktion mit verschiedenen \nWachstumsfaktoren, Hormonen, und Signalmolek\u00fclen \nin der Haut. Unser Labor untersucht die Rolle von Opi -\nat-Rezeptoren in der Haut und deren Wechselwirkung \nmit dem Nerven- und Immunsystem. Das Opiat Rezep -\ntorsystem der Haut ist wichtig f\u00fcr die Differenzierung \nder Hautzellen und f\u00fcr das Wachstum der Haut, hat \naber auch eine Rolle im Schmerzempfinden und beim \nJuckreiz. Dieses Opiat-Rezeptor System stellt somit ein \nenormes Potential an Therapieans\u00e4tzen f\u00fcr Krankheiten \nmit starkem Juckreiz, wie Neurodermitis oder Psoriasis \ndar, aber auch bei der Wundheilung, bei Alterungspro -\nzessen der Haut und bei Hautkrebs.\nWir konnten erstmals die Gegenwart von funktionellen \nOpiatrezeptoren in Hautzellen (Keratinozyten) und in \nNervenendigungen der Haut nachweisen. Dass auch \nNervenendigungen der Haut Opiatrezeptoren und \nderen Liganden exprimieren, kann zur Erkl\u00e4rung bei -\ntragen, weshalb Stress h\u00e4ufig Hauterkrankungen wie \nNeurodermitis oder Psoriasis verst\u00e4rkt.\nVerschiedene Experimente zeigten uns, dass die Opi -\natrezeptoren nicht nur beim Juckreiz, sondern auch \nbei der Wundheilung und im Schmerzempfinden eine \nRolle spielen. Das Opiat-Rezeptor System der Haut ist \nvor allem bei chronischem Juckreiz von Bedeutung, bei \nakutem Juckreiz spielen Botenstoffe wie zum Beispiel \nHistamin eine Rolle. Auch ist bei chronischen, nicht-\nheilenden Wunden die Opiat-Rezeptoren Dichte in der \nHaut ver\u00e4ndert. Diese v\u00f6llig neuen Erkenntnisse, welche \nan Hautbiopsien von Menschen gewonnen wurden, \nwerden nun mit Experimenten an transgenen M\u00e4usen \nbest\u00e4tigt. Diese M\u00e4use k\u00f6nnen keine Opiat-Rezeptoren \nin der Haut ausbilden. Die bisher erzielten Resultate be -\nst\u00e4tigen die Erkenntnisse, dass die Opiat-Rezeptoren in \nder Haut eine wichtige Rolle beim chronischen Juckreiz \nund auch in der Wundheilung spielen. \nSelected Publications\n\u2013 Bigliardi-Qi M, Lazar Sumanovski, B\u00fcchner S, Rufli \nT and Bigliardi PL,: Expression of \u03bc-opiate receptor \nand \u03b2-endorphin in peripheral nerve endings in skin. \nDermatology in press\n\u2013 Bigliardi PL, Sumanovski LT, B\u00fcchner S, Rufli T and \nBigliardi-Qi M (2003) Different expression of \u03bc-opiate \nreceptor in chronic and acute wounds and the effect of \n\u03b2-endorphin on TGF- \u03b2 type II receptor and cytokeratin \n16 expression. J Invest Dermatol. 120 (1): 145-152.\n\u2013 Bigliardi PL, B\u00fcchner S, Rufli T and Bigliardi-Qi M \n(2002) Specific stimulation of migration of human \ncultured foreskin keratinocytes in vitro by \u03bc-opiate \nreceptor agonists. Journal of Receptor and Signal \ntransduction 22(1-4): 191-199.\n\u2013 Bigliardi-Qi M, Bigliardi PL, B\u00fcchner S and Rufli T \n(2000) b-Endorphin stimulates expression of dif -\nferentiating factor cytokeratin 16 and downregulate \n\u03bc-opiate receptor expression. J Invest Dermatol ,114: \n527-532.\n\u2013 Bigliardi PL, Bigliardi-Qi M, B\u00fcchner S and Rufli T \n(1998): Expression of \u03bc-opiate receptor in human \nepidermis and keratinocytes. J Invest Dermatol, 111: \n297-301.New Therapeutic Approach \nto Pruritus and Wound \nHealing\nOur research discovery that opiate system is actively in -\nvolved in cell differentiation and growth in skin and regulate \npain and itch has great therapeutic potentials in topical pain \nand itch relief, wound healing, aging and cancer. \nThere is increasing evidence that the reinnervation of the \nskin is important for the wound healing and that keratino -\ncytes directly influence innervation. Patients with diabetes \nmellitus (Fig. 3) or leprosy have peripheral neuropathy and \nalso a severely impaired wound healing. Not much is known \nabout the impact of damaged peripheral nerve endings on \nwound healing. Therefore our research is focused on the \nbasic mechanisms and influences of nerve endings and \nneuropeptides such as opioids in acute, chronic wound \nand neuropathic diabetic wounds.\nItching is one of the major symptoms in pruritic skin diseases \nsuch as atopic dermatitis, prurigo nodularis, and psoriasis. \nAntihistamines can treat acute itching but are not effective \nagainst chronic itching. Opioid receptor antagonists are \nused to treat different forms of chronic pruritus and in -\nvolved in the activation of chronic itching as seen in atopic \ndermatitis (Fig. 4) or cholestatic pruritus. Therefore, it is \ncrucial to distinguish between chronic and acute forms of \nitching to understand the complexity of the different itching \nmechanisms. Novel effective topical drugs with minimum \nside effect for treatment of pruritus with different origins \nPathophysiology of Opioid Receptor in Skin \nNeuro-immuno-dermatology is a novel research field studying the influence \nand effects of various neuropeptides, cytokines and growth factors from nerv -\nous and immune systems on skin physiology and pathology. All of these factors \nare involved in wound healing, itching and various skin diseases. Our research \ngroup is interested in neuroimmunology of opiate system in skin. Opiate recep -\ntor system is involved in cell differentiation and growth in skin and regulates pain \nand itch. This has great therapeutic potential in itching, topical pain relief, wound \nhealing, aging and cancer. \nClinically applied methylnaltrexone (quaternary derivative of naltrexone that \ndoes not cross the blood-brain barrier) has been used to treat opioid induced \nitching and bowel motility. This suggests that the effects of opioids on itching are \nnot only on the CNS system but also on the peripheral nerve system. Our group \nwas the first to publish on \u03bc-opiate receptor expression and its function in skin \nphysiology and pathology. Our studies have shown that human epidermal ke -\nratinocytes express \u03bc-opiate receptor on both mRNA and protein level. We have \nnot only shown a functional active \u03bc-opiate receptor in human keratinocytes but \nalso \u03bc-opiate receptor on peripheral epidermal, non-myelinated C-fibers. This \nsuggests a direct interaction of \u03bc-opiate receptors on keratinocytes and nerve \nendings and is a possible explanation for the flare-up of different skin diseases \nsuch as atopic dermatitis and psoriasis by stress. We are especially interested in \nthe involvement of the \u03bc-opiate receptor system on keratinocytes and peripheral \nepidermal nerve endings in itch (e.g. hepatogenic) and pruritic skin diseases like \natopic dermatitis, prurigo nodularis, and psoriasis. \nWe also investigated the opiate receptor system in wound healing and study \nif epidermal \u03bc-opiate receptor expression is changed at the wound margins in \nacute and chronic wounds. Using classical and confocal microscopy, we were \nable to compare the expression level of \u03bc-opiate receptors and the influence of \n\u03b2-endorphin on TGF- \u03b2 type II receptor in organ culture. Our results show indeed \na significantly decreased expression of \u03bc-opiate receptors on keratinocytes close \nto the wound margin of chronic wounds compared to acute wounds. Addition -\nally \u03b2-endorphin upregulates the expression of TGF- \u03b2 type II receptor in human \nskin organ cultures. These results suggest a crucial role of opioid peptides not \nonly in pain control but also in wound healing. Opioid peptides have already \nbeen used in animal models in treatment of wounds, they induce fibroblast \nproliferation, growth of capillaries, accelerate the maturation of granulation tis -\nsue and the epithelialization of the defect. Furthermore, opioid peptides may \nfine-tune pain and the inflammatory response while healing takes place. This \nnew knowledge could be potentially used to design new locally applied drugs to \nimprove the healing of painful chronic wounds.\nThe common, troublesome skin problems of old age such as cancer and xero -\nsis with pruritus senilis remain a major cause of morbidity and yet are poorly \nexplained. Opiatergic neurons undergo significant functional changes by pro -\nducing opiate peptides. Altered peptides may trigger the loss of reproductive \ncapacity. The midlife shift in opiate peptide production is a component of natural \ndevelopmental processes that begin in the neonate and continue through old \nage. Our observations of opiates involvement in cell migration, differentiation \nFig. 1:  Interaction of \u03b2-Endorphin, \u03bc-opioid receptor \npositive keratinocytes and nerve ending in human \nepidermis. Red: PGP 9.5 positive nerve endings;\nGreen: \u03bc-opioid receptor positive keratinocytes; blue: \n\u03b2-endorphine positive keratinocytes. and growth in skin proved their important role in cancer and aging as well. \nCurrently, we are investigating opioid receptor knockout mice model. The re -\nsults obtained so far confirmed our hypothesis and revealed new fascinating \nopioid receptor functions involved in itching and wound healing. \nRecently, we have received Roche Prize 2003 Dermatology and granted US \npatent on wound healing. \nFig. 2:  (a) \u03bc-opioid receptor expression in human normal skin epidermis (b) \u03bc-opioid \nreceptor expression in atopic dermatitis epidermis.\nProf. Dr. Theo Rufli\nDermatologische \nUniversit\u00e4tsklinik\nUniversit\u00e4tsspital Basel\nFig. 3:  Wound \nfrom diabetes mellitus \npatients\nFig. 4:  Lesion \nfrom atopic dermatitis \npatients\n48/49Developmental \nGenetics\nProf. Dr. Rolf Zeller\nInstitut f\u00fcr Anatomie\nGroup Members\nDr. Aim\u00e9e Zuniga \nDr. Antonella Galli \nNadege Lagarde (technician)\nCristina Torres de los Reyes (technician)\nCornelia Lehmann (technician)\nJean-Denis B\u00e9nazet (PhD student)\nOdyss\u00e9 Michos (PhD student)\nLia Panman (PhD student)Development\nMouse\nMolecular genetics\nOrganogenesis\nSignalling\nStem cellsDie embryonale Entwicklung braucht \nSignale f\u00fcr die Koordination von Wachstum \nund Musterbildung\nW\u00e4hrend der embryonalen Entwicklung \u00fcbernehmen ge -\nwisse Zellen wichtige Rollen in der balancierten Organisa -\ntion von Wachstum, Differenzierung und Musterbildung. \nStimulierende und hemmende Signale werden durch \ndiese Zellen ausgesandt. Damit erhalten andere Zellen \nInstruktionen f\u00fcr ihre Bestimmungen (Determination). \nDetermination f\u00fcr eine Zelle bedeutet die \u00dcbernahme \neiner \u00abVerpflichtung\u00bb eine gewisse Rolle zu \u00fcbernehmen \nund sich entsprechend zu differenzieren. \nWie wichtig der Signalaustausch zwischen den Zellen \nw\u00e4hrend der embryonalen Entwicklung ist, zeigen die \nschwerwiegenden Missbildungen zu denen es bei \nfehlerhafter Regulation im Embryo kommt. Werden \nandererseits nach der Geburt embryonale Signalketten \neingeschaltet, so f\u00fchrt dies zu schweren Erkrankungen \nu.a. zu Krebs. \nUnsere Gruppe untersucht den Signalaustausch zwi -\nschen verschiedenen embryonalen Geweben. Eines \nunserer Hauptziele ist es, die molekularen Hintergr\u00fcnde \nzu verstehen, welche bei der Entstehung und Aufrecht -\nerhaltung von Signal-R\u00fcckkoppelungs-Mechanismen \nim Spiel sind. Bei einem dieser R\u00fcckkoppelungs-Me -\nchanismen sind das genaue zeitliche und \u00f6rtliche Ex -\npressionsmuster von BMP (bone morphogenic protein) \nund von seinen Antagonisten \u00abGremlin\u00bb unerl\u00e4sslich f\u00fcr \ndie korrekte Ausbildung von Organen und Gliedmassen. \nBei der Untersuchung, wie diese komplexe Koordination \nzustande kommt, entdeckten wir eine ganze Regulations -\nbatterie, eine sogenannte GCR (global control region). \nVerschiedene Gene, welche alle auf Maus-Chromosom \n2 nebeneinander lokalisiert sind, bilden diese GCR. Sie \nteilen sich ihre Steuerungselemente, was die koordi -\nnierte Expression sichert. Mit der Analyse dieses und \nvon weiteren GCRs versprechen wir uns Aufschluss \n\u00fcber die Feinheiten des Zell-Zell Signalaustausches in \nsolchen Organisationszentren zu erhalten.\nSelected Publications\n\u2013 Panman L. and Zeller R. (2003) Patterning the Limb \nBefore and After SHH Signalling. J. Anatomy (Review) \n202, 3-12. \n\u2013 Zuniga A, Michos O., Spitz F ., Haramis A.P .G., Pan -\nman L., Vintersten K., Klasen C., Mansfield W., Kuc \nS., Duboule D., Dono R. and Zeller R. (2004) Mouse \nlimb deformity  mutations disrupt a global control re -\ngion within the large regulatory landscape required \nfor Gremlin  expression. Genes Dev. 18, 1553-1564.\n\u2013 teWelscher P ., Zuniga, A, Kuijper S., Drenth T ., Goede -\nmans H, Meijlink F . and Zeller R. (2002) Progression \nof Vertebrate Limb Development through SHH-Medi -\nated Counteraction of GLI3. Science 298, 827-830.\n\u2013 teWelscher P, Fernandez-Teran M, Ros M. and Zeller \nR. (2002) Mutual genetic antagonism involving GLI3 \nand dHAND prepatterns the vertebrate limb bud \nmesenchyme prior to SHH signalling. Genes Dev. \n16, 421-426.\n\u2013 Zuniga A., Haramis A.G., McMahon A.P . and Zeller R. \n(1999) Signal relay by BMP antagonism controls the \nSHH/FGF-4 feedback loop in vertebrate limb buds. \nNature 401, 598-602.The expression of such potent morphoregulatory signals is tightly controlled \nas changes in their temporal and spatial expression patterns disrupt organo -\ngenesis and cause malformations. Therefore, we have begun to analyse the \nmolecular mechanisms underlying regulation of their tissue-specific expres -\nsion. In the course of these studies, we have identified the large regulatory \nlandscape that controls expression of the BMP antagonist Gremlin  in the limb \nbud mesenchyme. This novel type of regulatory landscape encodes a so-\ncalled global control region (GCR) that regulates tissue-specific expression \nof functionally and structurally unrelated genes located next to one another \non mouse chromosome 2. In silico  and transgenic analysis indicates that the \nGCR consists of several highly conserved cis-regulatory elements scattered \nover a large distance. These elements function cooperatively to regulate \nactivation of genes whose promoters are located at least 150\u2013200kb up- \nand down-stream. Evidence indicates that such regulatory landscapes are \npossibly more common than so far assumed and serve to co-regulate tissue-\nspecific expression of apparently unrelated neighbouring genes. The analysis \nof tissue-specific activation, modulation and fine-tuning of genes functioning \nin signalling cascades is one aspect crucial to understanding how morpho -\ngenesis of different organs is controlled by repeated use of the same type of \nsignals and antagonists. By combining mouse molecular genetics with in vitro  \nmanipulation of embryonic organ rudiments and genome-wide expression \nprofiling, we hope to gain insights into the temporal and spatial regulation of \nthe cell-cell signalling interactions that control establishment and activity of \norganising centres during vertebrate organogenesis.\nSignals Coordinating Growth and Patterning \nin Vertebrate Embryos\nDuring embryonic development, cells with so-called organiser properties con -\ntrol the balance of growth, patterning and differentiation. Organisers emit both \npositive and negative (antagonistic) signals to instruct undetermined cells with \nrespect to their fate and eventual differentiation. In the advent of the complete \nsequencing of several genomes, many of the candidate genes involved in these \ndeterminative processes are now known and research is rapidly shifting towards \nfunctional analysis of whole cascades, cross-talk and interactions in their entirety \n(systems biology). Therefore, a major challenge is now to unravel the regulatory \nnetworks and feedback loops, which control these determinative embryonic \nprocesses over time. The importance of tight regulation of embryonic cell-cell \nsignalling is best illustrated by the fact that any deregulation of organiser signal -\nling results in severe congenital malformations. Furthermore, inappropriate (re-) \nactivation of embryonic signalling cascades during post-natal life causes disease, \nas many embryonic regulator genes are e.g. proto-oncogenes or tumour sup -\npressor genes. \nOur group uses mouse molecular genetics and embryology to study vertebrate \norganogenesis and in particular the epithelial-mesenchymal signalling interac -\ntions coordinating embryonic growth with patterning. Sonic Hedgehog  (SHH) \nis a long-range signal that controls proliferation and patterning of many organs. \nIn particular in the developing limb, SHH signalling is maintained by a signalling \nfeedback loop between ectoderm (expressing FGFs, fibroblast growth factors) \nand the mesenchyme (expressing SHH; called SHH/FGF feedback loop). One of \nour main goals is to understand the molecular mechanisms controlling establish -\nment of such feedback loops and how they regulate embryonic development. \nWe have recently shown that signal antagonists such as Gremlin , which inhibits \nBMP (bone morphogenic protein) signalling, are crucial to both establish and \npropagate epithelial-mesenchymal signalling feedback loops during organogen -\nesis. We are currently exploring the use of such antagonists and small molecules \neither mimicking their function or constitutively activating signal transduction \ncascades to analyse the cell-cell signal interactions during mammalian limb and \nkidney organogenesis. \nFig. 2:  Schematic representation of the genetic \ncascades and key regulator genes we analyse to gain \ninsight into the molecular mechanisms controlling \nestablishment and epithelial-mesenchymal signaling \nby the SHH expressing limb bud organizer.\nFig. 1:  Transcript distribution of \nthe BMP antagonist Gremlin  (dark \nblue) in a mouse embryo during \nearly organogenesis (embryonic \nday 10.5, detected by whole mount \nRNA in situ  hybridization). Note the \nhigh levels of Gremlin  expression \nin specific regions of the limb buds, \nsomites, brain, otic vesicle etc.50/51Endocrinology\nProf. Dr. Alex N. Eberle\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Sylvie Froidevaux \nDr. Kerstin Wunderlich \nDr. Martine Calame-Christe \nDr. Gabriele Mild \nDr. Kurt M\u00fcller \nVerena J\u00e4ggin (technician)\nHeidi Tanner (technician)\nOlivier Wenger (PhD student)\nMatthias Hoch (PhD student)\nJean-Philippe Bapst (PhD student)\nSteven Knecht (PhD student)Peptides\nTumor targeting \nMelanoma metastases \nHuman adipocytes\nObesityPeptide und Rezeptoren f\u00fcr Tumor-\nTargeting und Regulation von metabo -\nlischen Prozessen\nDas Labor Endokrinologie befasst sich schwerpunktm\u00e4s -\nsig mit Peptiden und deren Rezeptoren, insbesondere \nMSH, MCH, Agouti, Leptin, Ghrelin, GLP-1 und PYY . \nEines der Hauptthemen ist das so genannten rezeptor -\nvermittelte Targeting von Melanommetastasen mit Hilfe \nvon radioaktiv markierten Peptidderivaten des \ue02b-MSH, \nderen Funktion es ist, durch Bindung an den MC1-Re -\nzeptor die Radionuklide spezifisch in die Melanomzellen \neinzuschleusen. Auf diese Weise kann entweder mit \nSzintigraphie der Tumor sichtbar gemacht werden (diag -\nnostisches Targeting) oder mit therapeutisch wirksamen \nRadioisotopen behandelt werden (therapeutisches Tar -\ngeting). Anhand eines Maus-Melanommodells konnten \nneue Derivate hergestellt werden (z.B. NAPamid; Figur \n1), die ein spezifisches Targeting von kleinsten Metasta -\nsen in Lunge und Leber erm\u00f6glichen (Figur 2) und den \nTumor mit PET sichtbar machen (Figur 3). Gegenw\u00e4rtig \narbeiten wir insbesondere daran, die unerw\u00fcnschte \nunspezifische Akkumulation von Radiopeptiden in den \nNieren zu vermindern, um eine bessere Tumor-Selekti -\nvit\u00e4t zu erhalten.\nWeitere Projekte des Labors betreffen (1) vergleichende \nUntersuchungen von Regulationsmechanismen am Fett -\ngewebe von Patienten mit schwerer Adipositas (siehe \nenglischer Text); (2) zusammen mit Prof. J. Flammer das \nStudium von Ver\u00e4nderungen von Signalmechanismen \nund metabolischen Zust\u00e4nden (u.a. von Mitochon -\ndrien) bei Glaukompatienten; (3) den Transport von \nPeptiden durch Monolayer-Zellschichten als Modell \nf\u00fcr das D\u00fcnndarmepithel und deren Modulation durch \nBegleitsubstanzen, und (4) den Einfluss von schwachen \nWechselwirkungen auf biologische Regulationsprozes -\nse, z.B. das Wachstum von Tumorzellen. \nSelected Publications\n\u2013 Froidevaux S, Calame-Christe M, Schuhmacher J, \nTanner H, Saffrich R, Henze M, Eberle AN. (2004) \nA gallium-labeled DOTA- \u03b1-melanocyte-stimulat -\ning hormone analog for PET imaging of melanoma \nmetastases. J. Nucl. Med. 45, 116-23. \n\u2013 Froidevaux S, Eberle AN, Christe M, Sumanovski L, \nHeppeler A, Schmitt JS, Eisenwiener K, Beglinger C, \nM\u00e4cke HR. (2002) Neuroendocrine tumor targeting: \nstudy of novel gallium-labeled somatostatin radiopep -\ntides in a rat pancreatic tumor model. Int. J. Cancer \n98, 930-7.\n\u2013 Schlumberger SE, J\u00e4ggin V, Tanner H, Eberle AN. \n(2002) Endogenous receptor for melanin-concen -\ntrating hormone in human neuroblastoma Kelly cells. \nBiochem. Biophys. Res. Commun. 298, 54-9.\n\u2013 Eberle AN, Bodi J, Orosz G, S\u00fcli-Vargha H, J\u00e4ggin V, \nZumsteg U. (2001) Antagonist and agonist activities \nof the mouse agouti protein fragment (91-131) at the \nmelanocortin-1 receptor. J. Recept. Signal Transduct. \n21, 25-45. \n\u2013 Eberle AN, Froidevaux S. (2003) Radiolabeled \u03b1-\nmelanocyte-stimulating hormone analogs for recep -\ntor-mediated targeting of melanoma: from tritium to \nindium. J. Mol. Recognit. 16, 248-54.Another part of the project is directed to the development of a nanoparticle \ndelivery system for targeting metastatic melanoma cells. The aim is to even -\ntually offer nanoparticles as \u201cmagic bullets\u201d for a potentially more effective \ncurative treatment for larger melanoma lesions, owing to higher intensities of \nionizing radiation or of toxins delivered to the metastases by these particles. \nIn the frame of this project, the nanoparticles will primarily be evaluated with \nthe experimental B16 melanoma tumor model, in order to determine the \nselectivity of targeting and the distribution, penetration and accumulation of \nnanoparticles in melanoma metastases.\nPeptide Targeting of Melanoma Tumor \nMetastases\nMelanoma is one of the most rapidly increasing malignancies in the white popu -\nlation and has a poor prognosis after formation of metastases because it is rela -\ntively resistant to conventional chemotherapy or external beam irradiation. New \nimmunological methods long awaited for, e.g. melanoma vaccination, have not \nyet reached a state of general applicability. Our approach is therefore to develop \nnovel tools for internal radiotherapy of tumor metastases using radiolabelled \npeptides or peptide-coated nanoparticle carriers for delivery of high doses \nof chemotherapeutics specifically (in-)to metastases. Most melanoma cells \n(over-)express the melanocortin-1 receptor (MC1R) which binds and internal -\nizes \u03b1-melanocyte-stimulating hormone ( \u03b1-MSH); hence MC1R is considered \nas potential target for internal radiotherapy or targeted chemotherapy. Over \nseveral years of research, we have analyzed the in vitro and in vivo expression, \nregulation and internalization of MC1R in mouse and human melanoma cells and \nrecently, we have developed and tested a first series of promising new MSH \nradiopeptides, including DOTA-MSHOCT, which localize almost exclusively to \nexperimental melanoma metastases after in vivo application (except for the kid -\nneys). Figure 1 shows the structure of a very recent MSH radiopeptide, DOTA-\nNAPamide, and the experimental steps for its in vivo application. We could dem -\nonstrate that DOTA-NAPamide exhibits an almost 7-fold higher MC1R binding \npotency as compared to DOTA-MSHOCT, and in B16F1 melanoma-bearing mice, \nboth [111In]DOTA-NAPamide and [67Ga]DOTA-NAPamide radiopeptides exhib -\nited higher tumor and lower kidney uptake, leading to tumor-to-kidney ratios \nthat were 4.6 times (111In) and 7.5 times (67Ga) greater than that obtained with \n[111In]DOTA-MSHOCT. In addition, the 4-h kidney uptake of [67Ga]DOTA-NAPa -\nmide could be reduced by 64% by co-injection of 15 mg L-lysine, without affect -\ning tumor uptake. Skin primary melanoma as well as lung and liver melanoma \nmetastases could be easily visualized on tissue section autoradiographs after \nsystemic injection of [67Ga]DOTA-NAPamide or [111In]DOTA-MSHOCT (Fig. 2). \nThe melanoma selectivity of DOTA-NAPamide was further confirmed with \npositron emission tomography (PET) imaging studies using the positron emitter \n[68Ga]DOTA-NAPamide (Fig. 3). \nCurrently we are developing and clinically assessing smaller MSH radiopeptides \nwith even better tumor-to-kidney ratios, with the purpose of offering a tool for \na more specific localization of disseminated melanoma microdeposits (by PET, \nSPECT) and, more importantly, for targeting cytotoxic radiometals ( \u03b2-emitters, \n\u03b1-emitters) into these microdeposits (for internal radiotherapy). If successful, \nmelanoma patients may soon benefit from a new way of palliative if not curative \ntreatment. Fig. 3:  PET imaging of melanoma-bearing \nmice with [68Ga]DOTA-NAPamide. Coro -\nnal (A) and transaxial (B) images of mice \n0.5 h and 1 h after injection. Only melano -\nma, kidneys, bladder and to a lesser extent \nheart are detectable (in collaboration with \nDr. J. Schuhmacher, Dr. R. Saffrich and Dr. \nM. Henze from the Department of Diag -\nnostic and Therapeutic Radiology, German \nCancer Research Center, Heidelberg, \nGermany).\nFig. 1:  Chemical structure and steps of labelling and application of the highly \nselective MC1R agonist DOTA-NAPamide for targeting melanoma metastases.Fig. 2:  Autoradiographs of tissue sections from melanoma-bearing mice. \n[111In]DOTA-MSHOCT was injected to mice inoculated with B16-F1 cells and tissues \nwere collected 4 h postinjection. A\u2013D, Autoradiographs (left panel) and scanner im -\nages (right panel) of a primary melanoma with surrounding skin tissue (A), lung with \nmelanotic melanoma metastases (B), lung with amelanotic melanoma metastases (C), \nliver with melanotic melanoma metastases (D). Arrows indicate the melanoma lesions.\n52/53\nThe Bariatric Patient as Model for the Study \nof Factors Influencing Obesity\nIn a collaborative project between Dr. Ralph Peterli (surgeon) and PD Dr. Thomas Peters \n(endocrinologist/internist) of the St.Claraspital Basel and our laboratory, we are study -\ning genetic causes and endocrine factors that contribute to the condition of obesity in a \nlarge group of bariatric patients undergoing gastric banding or gastric by-pass operations \n(compared to healthy controls). In a first subproject, we analyzed melanocortin-4 recep -\ntors (MC4R) for mutations known to be associated with up to 6% of monogenetic causes \nof obesity. Correlations between defects of MC4R and complications of laparoscopic \ngastric banding operation have recently been reported. However, we could not confirm \nthese observations in a group of 37 patients analyzed for MC4R mutations. At present, \nomental and subcutaneous adipose tissue of these patients is used for a comparative \nstudy of the functional role of melanocortins and their receptors, as well as related \nregulators, with respect to activation of mitochondria and lipolysis. It appears that in \nobese patients MC1R expression is elevated as compared to controls.Experimental \nHematology\nProf. Dr. \nRadek Skoda\nDepartement Forschung \nUniversit\u00e4tsspital Basel\nGroup members\nDr. Christian Kalberer \nDr. Robert Kralovics\nDr. J\u00f6rn Coers \nDr. Ralph Tiedt \nDr. Andreas Buser \nDr. Alexandre Theocharides \nEmilie Bouliong (technician)\nVerena Dalle Carbonare (technician)\nSilvia Sendelov (technician)\nHui Hao-Shen (technician)\nSoon-Siong Teo (technician)\nKun Liu (PhD student)\nKarolina Nowak (PhD student)\nPegah Nowbakht (PhD student)\nTibor Schomber (PhD student)\nUwe Siegler (PhD student)\nStephanie Bridenbaugh (MD student)\nAndreas Rohner (MD student)Hematopoietic stem cells \nLeukemia \nMyeloproliferative disorders \nSevere aplastic anemia \nStem cell transplantation \nImmunotherapyFurther studies aim at understanding the mechanisms, which regulate the \nbone marrow function during hematopoietic and immune recovery after \nhematopoietic stem cell transplantation (HSCT). We demonstrated that en -\ngraftment of stem cells after HSCT is preceded by a profound overexpression \nof flt3 ligand (FL), suggesting that this hematopoietic cytokine is important \nfor restoring the normal bone marrow function. This is further supported by \nfindings that patients with bone marrow failure due to severe aplastic anemia \n(SAA) have constitutively elevated FL serum levels. T cells were identified as \na reservoire of FL stored in the Golgi apparatus during steady-state hemat -\nopoiesis and rapidly released in response to activation associated with stem \ncell deficiency (Fig. 3). We are studying the influence of FL on the stem cell \nengraftment and the development of dendritic cells and natural killer (NK) \ncells after HSCT. Further, we are investigating the molecular mechanisms, \nwhich regulate the expression of FL during hematopoiesis in humans. These \ninclude studies on the role of FL receptor signaling and the effect of drugs \ntargetting the mutated flt-3 receptor in human acute myeloid leukemias. \nThe potential of NK cells for immunotherapy against leukemia\nOur studies address the molecular interactions between NK cells and malig -\nnant cells in human leukemia. We analyse the role of activating NK receptors \nand ligands in recognition and killing of leukemic targets (Scheme 1). These \nstudies include NK cells from patients with leukemia and the genetically mod -\nified NK cells generated in vitro  following lentiviral vector-mediated transfer \nof genes encoding natural cytotoxicity receptors. To assess the cytotoxic \nproperties of NK cells in vivo , we have established a human leukemia trans -\nplantation model of nonobese diabetic/severe combined immunodeficient \n(NOD/SCID) mice. The goal of this project is to develop NK cells as an im -\nmunotherapy tool to enhance the anti-tumor response and prevent disease \nrelapse after HSCT.\nControl of Blood Cell Development and \nPathogenesis of Hematopoietic Stem Cell \nDisorders\nBlood cells have a limited life span and must be continuously replaced through -\nout life. This regenerative process is called hematopoiesis and is characterized \nby rapid cell division, commitment and differentiation of progenitor cells. Hemat -\nopoietic stem cells (HSC) are essential for maintaining hematopoiesis, as all func -\ntional subtypes of blood cells are derived from these multipotent cells. A large \nnumber of blood diseases, including leukemia, myeloproliferative disorders and \nsevere aplastic anemia, are now recognized as stem cell disorders and for many \nof these life-threatening conditions transplantation of normal HSC has become \na first line therapy that often can cure a patient. Our research aims at advancing \nour understanding in three areas of normal and aberrant hematopoiesis: \nThe pathogenesis of myeloproliferative disorders\nMyeloproliferative disorders (MPD) are a group of diseases characterized by \naberrant proliferation of one or more myeloid lineages. They represent clonal \nstem cell disorders of unknown etiology with an inherent tendency towards \nleukemic transformation. MPD can be subdivided into three disease entities: \npolycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofi -\nbrosis (IMF). We combine genetic and genomic approaches for the search of \nthe molecular alterations that cause MPD. We identified the first mutations in \nthe thrombopoietin (TPO) gene as the cause for an inherited form of thrombo -\ncythemia. More recently, we identified 3 additional genomic intervals that harbor \nthe genes mutated in other familial forms of MPD. We are pursuing a candidate \ngene approach to search for the mutations. In addition, we examine sporadic \nforms of MPD. Using genome-wide microsatellite screening, loss of heterozy -\ngosity (LOH) on chromosomes 9p was identified as the most frequent chromo -\nsomal aberration in PV, present in approximately 30% of patients. We defined a \nminimal common LOH region and we are now searching for the alterations that \nprovide a selective clonal advantage to cells bearing 9pLOH. These studies are \ncomplemented by expression profiling using microarrays, which defined a set of \ngenes up- or downregulated in MPD (Fig. 1). The observed changes are part of \nthe transcriptional fingerprint of MPD that will allow us to examine correlations \nwith the clinical course of the disease and derive new hypotheses about the \npathogenetic mechanisms involved.\nThe control of hematopoiesis and stem cell behavior\nUsing a knock-in mouse model, our earlier work showed that the decision of \nhematopoietic progenitors to commit to megakaryopoiesis or granulopoiesis is \nnot influenced by lineage dominant cytokines such as thrombopoietin (TPO) or \ngranulocyte colony-stimulating factor. To assess the importance of individual sig -\nnaling pathways on hematopoiesis we are studying the effects of TPO-receptor \nmutants in transgenic mice. Mutated TPO-receptors did not affect differentia -\ntion of megakaryocytic progenitors, but rather change platelet numbers, further \nsupporting the conclusions from our knock-in studies. To create lineage specific \nknockouts in the megakaryocytic lineage, we generated transgenic mice that \nexpress the cre-recombinase under the control of the regulatory elements from \nthe platelet factor 4 (PF4) gene. These mice allow the excision of genomic re -\ngions that are flanked by loxP sites (Fig. 2). To allow studies on human HSC and \nprogenitors, we devised a lentiviral siRNA vector and showed that stable and \nefficient silencing can be obtained in transduced human CD34 + cells. We are \nusing these tools to extend our studies on how hematopoietic progenitors make \ncell fate decisions by analyzing components of the TGF-beta and Wnt signaling \npathways. Fig. 2:  Megakaryo -\ncyte-specific expres -\nsion of Cre-recombi -\nnase in a transgenic \nPF4-Cre mouse. The \npresence of functional \nCre recombinase pro -\ntein in bone marrow \nmegakaryocytes was \nvisualized by blue \nstaining. Note that \nnon-megakaryocytic \ncells do not express \nCre and therefore do \nnot stain blue.Prof. Dr. \nAleksandra \nWodnar-Filipowicz\nFig. 3:  Expression of flt3 ligand by human T cells. Confo -\ncal microscopy of purified human peripheral blood T cells, \nresting and activated with interleukins IL-2 and IL-7. Cells \nwere stained with antibodies against flt3 ligand (green \nsignals) and the Golgi marker, giantin (red signals).\nScheme 1:  NK cell \u2013 target recognition. KIR, killer inhibi -\ntory receptor; NCR, natural cytotoxicity receptor; MHC I, \nmajor histocompatiblity complex class I; ULBP and MIC, \nligands for NKG2D receptor. NK cells recognize their tar -\ngets using 2 types of receptors: Inhibitory receptors, such \nas KIRs, interact with class I molecules. This recognition \nprotects healthy cells from attack by the NK cell. Activa -\ntory receptors, such as NKG2D, interact with several \nligands, called ULBP and MIC molecules. These ligands \nhave been shown to be upregulated in virus-infected cells \nand in tumors of epitherlial origin.\nFig. 1:  Gene expression profiling of myeloproliferative \ndisorders. Microarray analysis of granulocyte RNA of \nhealthy controls and patients with myeloproliferative \ndisorders (MPD) revealed 280 differentially expressed \ngenes. Red color in MPD represents up-regulated genes, \nblue color down-regulated genes. To assess gene expres -\nsion similarity among the samples, cluster analysis was \nperformed which clearly separated the healthy individuals \nfrom patients. Green line represents the assigned relation \nbetween the samples.  \nhealthy\ncontrols\nMPD\nResting T cells Activated T cells54/55Selected Publications\n\u2013 Chklovskaia, E., Nowbakht, P ., Nissen, C., Gratwohl, \nA., Bargetzi, M., Wodnar-Filipowicz A. (2004) Recon -\nstitution of dendritic and natural killer-cell subsets \nafter allogeneic stem cell transplantation: effects of \nendogenous flt3 ligand. Blood, 103:3860-3868.\n\u2013 Schomber, T., Kalberer, C., Wodnar-Filipowicz, A., \nSkoda, R.C. (2004) Gene silencing by lentivirus-medi -\nated delivery of siRNA in human CD34\ue02b cells. Blood, \n103:4511-4513.\n\u2013 Kalberer, C.P ., Siegler, U., and Wodnar-Filipowicz, A. \n(2003) Human NK cell development in NOD/SCID \nmice engrafted with cord blood CD34\ue02b cells. Blood \n102: 127-135.\n\u2013 Kralovics, R., Buser, A.S., Teo, S.S., Coers, J., Tichelli, \nA. van der Maas, A.P .C., Skoda, R.C. (2003) Compari -\nson of molecular markers in a cohort of patients with \nmyeloproliferative disease. Blood 102: 1869-1871.\n\u2013 Ziegler, S., B\u00fcrki, K., Skoda, R.C. (2002) A 2 kb c-mpl \npromoter fragment is sufficient to direct expression \nto the megakaryocytic lineage and sites of embryonic \nhematopoiesis in transgenic mice, Blood 100: 1072-\n1074.\n\u2013 Chklovskaia, A., Nissen, C., Landmann, L., Rahner, \nC., Pfister, O. and Wodnar-Filipowicz, A. (2001) Cell \nsurface trafficking and release of flt3 ligand from \nT lymphocytes is induced by common cytokine \nreceptor gamma chain signaling and inhibited by \ncyclosporin A. Blood 97: 1027-1034.\n\u2013 Luther-Wyrsch, A., Costello, E., Thali, M., Buetti, E., \nNissen, C., Surbek, D., Holzgreve, W., Gratwohl, A., \nTichelli, A. and Wodnar-Filipowicz, A. (2001) Stable \ntransduction with lentiviral vectors and amplification \nof immature hematopoietic progenitors from cord \nblood of preterm human fetuses. Human Gene \nTherapy 12: 377-389.\n\u2013 Stoffel, R., Ziegler, S., Ghilardi, N., Ledermann, B., \nde Sauvage, F .J., and Skoda, R.C. (1999) Permissive \nrole of mpl and G-CSF-receptors in hematopoietic cell \nfate decisions in vivo. Proc. Natl. Acad. Sci. USA 96: \n698-702.\n\u2013 Chklovskaia, E., Jansen, W., Nissen, C., Lyman, S.D., \nRahner, C., Landmann, L. and Wodnar-Filipowicz, A. \n(1999) Mechanism of flt3 ligand expression in bone \nmarrow failure: translocation from intracellular stores \nto the surface of T lymphocytes following chemother -\napy-induced suppression of hematopoiesis. Blood 93: \n2595-2604.\n\u2013 Wiestner, A., Schlemper, R.J. van der Maas, A.P .C., \nand Skoda, R.C. (1998) An activating splice donor \nmutation in the thrombopoietin gene causes heredi -\ntary thrombocythemia. Nature Genetics 18: 49-52.Leukemias and severe \naplastic anemia (SAA) are \nrare disorders and at first \nsight appear to have lit -\ntle in common. Massive \nproliferation of malignant \ncells, leukemic blasts and \ntumor formation in all \nhematopoietic organs are \nthe hallmark of the typical \nacute leukemias; absence \nof all normal elements of \ncirculating blood, so-called \nsevere pancytopenia, and \nan empty bone marrow, characterize SAA. Both disorders are due to an aberrant produc -\ntion of blood cells by a sick hematopoietic stem cell. In leukemia it is too much, in SAA it is \ntoo little. The defect can be intrinsic to the leukemic stem cells as it occurs in patients with \nchronic myeloid leukemia (CML) after chromosome 9/22 translocation, which leads to a \nconstitutive activation of the tyrosine kinase BCR/ABL, and it can be extrinsic via an autoim -\nmune blockade of stem cells in SAA. Hence, two different therapeutic approaches for the \ntwo disease categories: complete replacement of an abnormal hematopoietic system by a \nhematopoietic stem cell transplantation (HSCT) or an approach, which is targeted directly \nto the primary defect. Diagnostic and Therapeutic Hematology at the University Hospital in \nBasel has pioneered HSCT and targeted therapies for leukemias and SAA for thirty years. \nOver 80 HSCT are now performed annually by the Basel Stem Cell Transplant team for ma -\nlignant and non-malignant disorders of the hematopoietic system. Bone marrow, peripheral \nblood and cord blood are used as stem cell sources from the patients themselves (autologous \nHSCT) or from HLA-identical siblings, haploidentical family members or unrelated volunteer \ndonors (allogeneic HSCT). They are used directly or after intensive in vivo manipulation \nand selection ex vivo in the laboratory. As an alternative to replacement therapy, targeted \ntherapy is used in patients with leukemias. An increasing number of targeted drugs bring \nabout the arrest of leukemic proliferation, such as retinoic acid receptor blockade by all trans \nretinoic acid in acute promyelocytic leukemia, BCR/ABL blockade by imatinib mesylate in \nCML or flt-3 receptor blockade by PKC412 in patients with acute myeloid leukemias carrying \nflt-3 mutations in the leukemic cells. In SAA, the targeted therapy is in the form of selective \ninhibition of the presumed T-cell mediated stem cell blockade by anti-thymocyte globulin \n(ATG) and cyclosporine. Applying current knowledge and all available tools, risk adapted \ntailored therapy for individual patients is becoming a reality in leukemias and SAA.\nCML was the first disease in which a recurrent chromosomal abnormality was found. Today, \nthe diagnosis of CML is made when in a patient with typical blood changes the Philadelphia \nchromosome or its molecular fusion gene BCR/ABL can be demonstrated. CML was origi -\nnally considered part of a syndrome called \u201cmyeloproliferative disorders\u201d (MPD). Based \non BCR/ABL, today CML is regarded as a separate entity. For the remaining three MPD \nsubtypes, polycythemia vera (PV) essential thrombocytemia (ET) or chronic idiopathic my -\nelofibrosis (IMF), no specific genetic defect known. The diagnosis of these entities is based \nupon morphologic findings from blood and bone marrow with laboratory and clinical obser -\nvations. However, overlaps between PV, ET and IMF exist. Importantly, there is currently no \ncurative treatment available and these disorders pose therapeutic dilemmas for practicing \nhematologists. As a regional reference center, Diagnostic and Therapeutic Hematology at the \nUniversity Hospital in Basel treats more than 100 patients with MPD. Correlation between \ndiagnosis, prognostic criteria, clinical history and the molecular genetic markers is analyzed \nin close collaboration with the research laboratory. The goal of these studies is to improve \nthe management of patients with MPD and to provide a basis for the search of the primary \ncause of MPD. These efforts also aim at identifying new drug targets, which ultimately could \nlead to the development of specific new drugs for the treatment of MPD.\nProf. Dr. Alois Gratwohl\nAbteilung H\u00e4matologie\nUniversit\u00e4tsspital Basel\nProf. Dr. Andr\u00e9 Tichelli\nAbteilung H\u00e4matologie\nUniversit\u00e4tsspital BaselKrankheiten der H\u00e4mopoiese\nBlutzellen haben eine beschr\u00e4nkte Lebensdauer und m\u00fcssen kontinuierlich ersetzt \nwerden. Dieser Ersatz, genannte H\u00e4mopoiese, wird durch Proliferation, und Differen -\nzierung von Stammzellen gew\u00e4hrleistet. Eine Vielzahl von Blutkrankheiten wird durch \neine Pathologie der Stammzelle verursacht. Unter diesen Stammzellkrankheiten sind die \nakuten Leuk\u00e4mien, die Myeloproliferativen Krankheiten und die schwere aplastische \nAn\u00e4mie. Unsere Forschung untersucht die abnorme H\u00e4mopoiese in 3 Gebieten:\nDie Pathognenese der myeloproliferativen Krankheiten\nWir haben die erste Mutation im Thrombopoietingen als Ursache einer vererbten Throm -\nbozyt\u00e4mieform identifiziert. Durch Kombination von genetischen und genomischen Me -\nthoden ist es uns gelungen weitere genetische Aberrationen aufzudecken, welche bei \nfamili\u00e4ren myeloproliferativen Krankheiten vorkommen. Der Verlust der Heterozygosie \nauf dem langen Arm des Chromosoms 9 (9pLOH) ist die h\u00e4ufigste chromosomale Anoma -\nlie in Polycythemia vera Patienten und betrifft 30% dieser Patienten. Die Microarray (Gen-\nChip)-Analysen dienen dazu diese genetischen Regionen besser zu charakterisieren. \nAnhand der molekularen Studien und der Korrelation zum klinischen Verlauf kommen \nwir zu neuen Hypothesen \u00fcber die Mechanismen dieser Krankheiten.\nDie Kontrolle der H\u00e4mopoiese\nWir studieren die Wege der Signal\u00fcbermittlung in Transgenen M\u00e4usen, denen ein be -\nstimmtes Gen ausgeschaltet wurde. Damit wollen wir aufkl\u00e4ren, in welchem Moment, \nwelche Signale ben\u00f6tigt werden damit sich die spezifischen Zelllinien ausdifferenzieren. \nDie hierbei erworbenen Kenntnisse \u00fcberpr\u00fcfen wir mit menschlichen Zelllinien und der \nTechnik der RNA-Interferenz. Zudem Untersuchen wir die Mechanismen welche die \nImmunrekonstitution nach Stammzelltransplantation beeinflussen. Wir konnten zeigen, \ndass eine Zunahme der h\u00e4mopoietischen Wachstumsfaktors, flt3 Ligand, dem Angehen \ndes Transplantates vorausgeht. Die T-Zellen dienen hierbei als Reservoir f\u00fcr den flt3 \nLiganden. Zurzeit untersuchen wir dessen Wirkung auf das Angehen der Stammzellen \nim Knochenmark, sowie beim Ausreifen von dendritischen Zellen und Natural Killer \n(NK)\u2013Zellen nach einer Stammzelltransplantation.\nDas Potential der NK-Zellen in der Immuntherapie gegen Leuk\u00e4mien\nUnser Studien dienen dem besseren Verst\u00e4ndnis der molekularen Interaktionen zwischen \nNK-Zellen und malignen Zellen. Unser Ziel ist eine Entwicklung der Immunotherapie \nmit NK-Zellen, als Zusatz zum antitumoralen Effekt der Stammzelltranplantation. Wir \narbeiten mit einem Mausmodel einer humanen Leuk\u00e4mie, sowie mit genetisch-ver\u00e4n -\nderten NK-Zellen.\nKlinik\nDie Diagnostische und Therapeutische H\u00e4matologie des Kantonsspitals Basel war ein \nPionier in der Stammzelltransplantationen f\u00fcr schwere Aplastische An\u00e4mien und Leuk -\n\u00e4mien. Mit diese Erfahrung werden aktuell \u00fcber 80 Stammzelltransplantationen pro Jahr \nin Basel durchgef\u00fchrt. Es handelt sich dabei sowohl um autologe (vom Patienten selbst \nstammende Stammzellen) wie um allogene (von HLA-identischen Geschwistern oder von \nFremdspendern stammende Stammzellen) Transplantationen. Diese werden direkt oder \nnach in vitro Manipulation im h\u00e4matologischen Labor verabreicht. Zunehmend werden \nauch gezielte Therapien wie all-trans-Retins\u00e4ure in der akuten Promyelozytenleuk\u00e4mie, \nGlivec und PKC412 in der chronisch myeloischen Leuk\u00e4mie und ATG in der schweren \naplastischen An\u00e4mie verwendet. Es entstehen somit f\u00fcr jeden Patienten massgeschnei -\nderte Therapien. Die Diagnostische und Therapeutische H\u00e4matologie behandelt als \nregionales Referenzzentrum mehr als 100 Patienten mit einem myeloproliferativen \nSyndrom pro Jahr. Die Korrelation von Diagnose, prognostischen Kriterien, klinischem \nVerlauf und genetischen Markern werden in Zusammenarbeit mit dem Forschungslabor \nuntersucht. Diese Arbeiten erlauben eine optimierte Behandlung der Patienten und die \nWeiterentwicklung neuer Therapiemodalit\u00e4ten.Fig. 4:  Bone marrow cel -\nlularity: (a) normal (b) \naplastic (c) leukemicFig. 5:  Patient and donor 10 years after \nsuccessful hematopoietic stem cell trans -\nplantation.\nClinics56/57Gastro-\nenterology\nProf. Dr. Christoph Beglinger\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup Members\nPD Dr. Lukas Degen \nDr. Franziska Piccoli\nSilvia Ketterer (technician)\nGerdien Gamboni (technician)\nLuisa Baselgia (technician) \nClaudia Bl\u00e4si (research nurse)\nSibylle Oesch (PhD student) \nSandro Schroller (MD student)\nMichel Casanova (MD student)Appetite regulation\nPerception\nGastrointestinal signals\nObesity\nFunctional disordersDie Regulierung des Appetits\nIm Labor befassen wir uns mit zwei Aspekten der Ap -\npetit-Regulierung. \n1. Die Signale aus dem Gastrointestinaltrakt, welche die \nNahrungsaufnahme beeinflussen: Das Interesse dieses \nForschungsgebiet wird vor allem durch die Suche nach \nTherapieformen gegen die Fettleibigkeit motiviert. We -\nnig ist bekannt wie biochemisch Hunger und S\u00e4ttigung \nkontrolliert werden. Sicher ist aber, dass Signale vor der \nAbsorption der Nahrung eine entscheidende Rolle spie -\nlen. Verschiedene Peptidhormone werden im Moment \nder Nahrungsaufnahme ausgesch\u00fcttet und kontrollieren \ndie Kurzzeit-Nahrungsaufnahme. Wir untersuchen wie \nes zur Aussch\u00fcttung dieser Peptidhormone kommt \nund sind insbesondere an potentiellen Interaktionen \nzwischen diesen S\u00e4ttigungssignalen und an m\u00f6glichen \nTherapieans\u00e4tzen bei Fettleibigkeit interessiert.\n2. Die Wahrnehmung aus dem Verdauungstrakt: Die \nPhysiologie der Gef\u00fchlsempfindungen wird seit einiger \nZeit intensiv studiert. Eine dieser Affekte, der bei Tier \nund Mensch vorkommt, ist der Angstreflex. In unan -\ngenehmen Situationen ist dieser Reflex intensiviert, \nw\u00e4hrend er bei Freude abnimmt. Die Modulation die -\nses Reflexes wird durch alle klassischen Sinneswahrneh -\nmungen beeinflusst. Bislang fehlt jedoch die Aufkl\u00e4rung, \nwelchen Einfluss hierbei Signale aus dem Verdauungs -\ntrakt haben. Mit Hilfe eines Barostaten untersuchen \nwir nun diesen Einfluss. Wir k\u00f6nnen mit diesem Ger\u00e4t \nSpannungsver\u00e4nderungen in den Verdauungsorganen \nmessen ,ob diese vom Probanden wahrgenommen wer -\nden oder nicht. In einer Doktorarbeit wurde aufgezeigt, \ndass Verspannungen in der Magenkuppel den durch \nSchall ausgel\u00f6sten Angstreflex steigert. Solche Befunde \npassen gut zu unseren klinischen Beobachtungen. Ab -\nl\u00e4ufe im Gastrointestinaltrakt k\u00f6nnen schwerwiegende \nemotionale Konsequenzen haben. Unbewusst erlebte \nSignale aus dem Verdauungstrakt scheinen zur negati -\nven Verarbeitung von Gef\u00fchlen beizutragen. Diese Er -\nkenntnisse m\u00fcssen bei der Behandlung von Patienten \nmit Verdauungsst\u00f6rungen ber\u00fccksichtigt werden.\nSelected Publications\n\u2013 Beglinger C, Degen L, Matzinger D, D\u2018Amato M, \nDrewe J. (2001) Loxiglumide, a CCK-A receptor \nantagonist, stimulates calorie intake and hunger \nfeelings in humans. Am J Physiol Regul Integr Comp \nPhysiol;280(4):R1149-1154.\n\u2013 Degen L, Matzinger D, Drewe J, Beglinger C. (2001) The \neffect of cholecystokinin in controlling appetite and \nfood intake in humans. Peptides;22(8):1265-1269.\n\u2013 Feinle-Bisset C, Meier B, Fried M, Beglinger C. (2003) \nRole of cognitive factors in symptom induction follow -\ning high and low fat meals in patients with functional \ndyspepsia. Gut;52(10):1414-1418.\n\u2013 Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Hu -\nber AR, Kreyenbuehl M, et al. (2004) Glucagon-like \npeptide 1 induces natriuresis in healthy subjects and \nin insulin resistant obese men. J Clin Endocrinol Me -\ntab;89:3055-3061.\n\u2013 Gutzwiller JP, Degen L, Matzinger D, Prestin S, \nBeglinger C. (2004) Interaction between GLP-1 and \nCCK33 in inhibiting food intake and appetite in men. \nAm J Physiol Regul Integr Comp Physiol;287(3):\nR562-567.\nRegulation of Appetite\nThe gastroenterology laboratory in the Department of Research of the Univer -\nsity Hospital Basel focuses on two specific projects in the field of appetite regula -\ntion in health and disease:\nI. Gastrointestinal signals in the regulation of food intake\nThe investigation of human eating behavior, especially the regulation of appe -\ntite and satiety, has become a very active field of research with potential for the \ndevelopment of a specific therapy for obesity. Limited information is available \nabout the biochemical processes that control hunger and satiety. However, there \nis evidence that pre-absorptive factors are important cofactors in this regulation. \nNutrient intake is associated with the secretion of a number of gastrointestinal \nhormones, including peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and \ncholecystokinin (CCK). These peptides have been shown to affect the short-\nterm control of food intake in healthy subjects, but also in specific patient groups. \nThe three peptides have been proposed to act as hormonal satiety signals. Our \ngroup is interested to characterize the specific gastrointestinal pathways, which \nare initiated after food intake with a focus on the peptides GLP-1 and PYY . We \nare especially interested to investigate potential interactions between individual \nsatiety signals.\nII. Pathways of gastrointestinal perception\nThe last two decades experienced an increase of emotion research, much of \nwhich was focusing on the physiology of affective processing. This became \npossible by advanced models generalizing affective mechanisms into a broader \nbiological context, shared by animal species and humans. One of such mecha -\nnisms refers to the polysynaptic startle reflex, which is modulated by amygdala-\nbrainstem associations. The startle reflex is facilitated in unpleasant context, \nsuch as threat, and diminished during pleasure. This phenomenon, called \u2018affec -\ntive startle modification\u2019, has been shown to reflect the affective dimensions of \nclassical sensory inputs (visual, auditory, olfactory, somato-sensory) \u2013 but effects \nof visceral afferents are not established. This is surprising, as visceral afferent \nsensations have already been linked to subjective emotional experience one \ncentury ago.\nWe recently assessed the consequences of gastrointestinal stimulation on startle \nresponsiveness by the means of Barostat procedures. The Barostat system has \nbeen developed and applied in numerous studies to describe changes of visceral \nperception induced by mechanical distension. The Barostat maintains a constant \npressure within an air-filled flaccid bag positioned in the lumen of the organ to \nbe studied. When this organ contracts, the Barostat aspirates air to maintain a \nconstant intrabag pressure. \nIn a doctoral thesis we could demonstrate that antral Barostat distension may \nenhance auditory startle responsiveness. This was true regardless whether dis -\ntensions were consciously perceived (supraliminal) or whether distensions were \ntoo weak to be consciously perceived (subliminal). We also found evidence that \nthe effect of antral distensions are not mediated by somato-sensory afferents. As \nduodenal stimulation did not have effects on auditory startle responsiveness, it \nmay be concluded that antral/gastric afferents, specifically activate fight\u2013flight \noperating amygdala\u2013brainstem networks, could increase auditory startle re -\nsponsiveness. \nThese results fit well to clinical observations that gastrointestinal processes may \nhave profound emotional consequences. They furthermore suggest a concept \nthat subliminal gastrointestinal stimuli potentially induce aversive-like emotional \nprocessing. A concept of \u201cvisceral subliminal afferent signals shaping emotions\u201d  \nmay prove helpful to explain affective disturbances and the preference of reas -\nsuring, help-seeking behaviour in certain clinical populations, such as patients \nwith functional gastrointestinal disorders.Clinics\nObesity is a growing epidemic that results in an increasing morbidity and mortality. It is \ncausally associated with a number of medical conditions, including diabetes mellitus, \ncoronary heart disease, and a number of cancers. Recent discoveries have expanded \nour knowledge on the regulation of food intake and appetite, and significant advances \nhave been made in our understanding of the peripheral signals that regulate appetite \nand energy homeostasis. Several peptides synthesized and secreted within the gastroin -\ntestinal tract are known to regulate eating behavior. Our research interest focuses on \na better understanding of these mechanisms in order to understand the development \nof obesity.58/59\nThe figure depicts a happy subject intubated with a barostat bag. The barostat con -\nsists of a double-lumen polyvinyl tube connected to an ultrathin polyethylene bag \n(1100 ml capacity, 20 cm maximum diameter) which is placed in the gastrointestinal \ntract (stomach, small intestine). The barostat measures either the volume or the pres -\nsure at a constant pre-selected level by an electronic feedback mechanism. A dial in \nthe electronic system allows selection of the desired volume level or pressure level \nto be maintained within the bag. The barostat can be used to induce gastric or small \nintestinal distension.\nThe bag of the barostat is introduced through the mouth into the stomach or small \nintestine. After placement of the barostat assembly, the participant is placed in a 30 \u00b0 \nrecumbent position and asked to relax comfortably.\nThe computer unit besides the bed controls the barostat and records the parameters \nof interest.\nGynaecological \nEndocrinology\nProf. Dr. Christian De Geyter\nAbteilung f\u00fcr Gyn\u00e4kologische Endokrinologie \nund Reproduktionsmedizin\nUniversit\u00e4ts-Frauenklinik Basel\nGroup members\nDr. Hong Zhang\nHsuping Gao (PhD student)Ovary\nFollicle\nApoptosis\nGranulosa\nOocyte\nInfertilityDas Zusammenwirken der Eizelle und dem \nHormonmilieu im Eierstock f\u00fcr die Fertilit\u00e4t\nDer Eierstock besteht im Wesentlichen aus drei Kom -\nponenten: den Eizellen, der Granulosa und der Theka. \nW\u00e4hrend die Theka f\u00fcr die Bereitstellung des Grundsub -\nstrates f\u00fcr die Produktion der weiblichen Geschlechts -\nhormone verantwortlich ist, ist das enge Zusammenwir -\nken der Granulosa und der Eizelle f\u00fcr die Follikelreifung \nentscheidend. Die Granulosa produziert die weiblichen \nGeschlechtshormone, und umgibt die Eizelle, die von der \nad\u00e4quaten Funktion dieser Zellen abh\u00e4ngig ist. Die Gra -\nnulosazellen stehen in enger Verbindung mit der Eizelle \nund versorgen diese mit Sauerstoff und \u201cBausteinen\u201d. \nUmgekehrt beeinflusst die Eizelle auch die sie umgeben -\nde Granulosazellschicht. Die Signale der Eizelle werden \ndort verst\u00e4rkt und an die umgebende Theka weiterge -\nreicht. Klinisch-experimentelle Untersuchungen haben \ngezeigt, dass eine Unterdr\u00fcckung der Eierstockfunktion, \nz.B. mit einem oralen Ovulationshemmer, auch die Hor -\nmonproduktion in der Nebennierenrinde unterdr\u00fcckt. \nM\u00f6glicherweise verursacht der Verlust der Signalwirkung \nvon der Eizelle zur Granulosa die Ver\u00e4nderungen der \nMenopause, welche auftritt, wenn der Vorrat an Eizel -\nlen aufgebraucht ist. Somit kann eine Aufschl\u00fcsselung \nder Signalwirkung der Eizelle auch Erkl\u00e4rungen f\u00fcr die \nVer\u00e4nderungen im Alter der Frau bieten.\nUnser Ziel ist die Erforschung der Signalwirkung im Ovar, \ninsbesondere zwischen Eizelle und ihrer engeren Umge -\nbung. Hierf\u00fcr verwenden wir die modernsten Methoden \nder Molekularbiologie und der Bioinformatik. Es ist uns \ngelungen, verschiedene neuartige Gene, die f\u00fcr die \nWechselwirkung zwischen der Hormonwirkung und dem \nprogrammierten Zelltod (sogenannte \u201cApoptose\u201d) ver -\nantwortlich sind, zu identifizieren. Dar\u00fcber hinaus f\u00fchr -\nten wir im Labor experimentelle Untersuchungen durch, \nin denen wir die Signalwirkung zwischen menschlichen \nEizellen, die im Rahmen der in-vitro Fertilisation (IVF) ge -\nwonnen wurden, und den Granulosazellen untersuchten. \nZu diesem Zweck identifizierten und charakterisierten wir \neinen immortalisierten Granulosazellstamm, welcher im \nLabor auch interzellul\u00e4re Verbindungen zur Eizelle \naufnehmen kann. Mit der Genchipanalyse versuchen \nwir derzeit neue Signale, ausgehend von der Eizelle, zu \nidentifizieren und deren Funktion zu evaluieren.\nSelected Publications\n\u2013 De Geyter, Ch., De Geyter, M., Huber, P .R., Nieschlag, \nE., Holzgreve, W. (2002) Progesterone levels during \nthe follicular phase of the menstrual cycle originate \nfrom the crosstalk between the ovaries and the adrenal \ncortex. Human Reproduction 17: 933-939.\n\u2013 Vollmer, M., Wenzel., F ., De Geyter, Ch., Zhang, H., \nHolzgreve, W., Miny P . (2000) Assessing the chromo -\nsome copy number in metaphase II oocytes by sequen -\ntial fluorescence in situ hybridization (FISH). Journal \nof Assisted Fertilization and Genetics 17: 596-602.\n\u2013 Zhang, H., Holzgreve, W., De Geyter, Ch. (2000) \nEvolutionarily conserved Bok proteins in the Bcl-2 \nfamily. FEBS Letter 480: 311-313.\n\u2013 Zhang, H., Holzgreve, W., De Geyter, Ch. (2001) \nBcl2-L-10, a novel anti-apoptotic member of the Bcl-\n2 family, blocks apoptosis in the mitochondria death \npathway but not in the death receptor pathway. Hu -\nman Molecular Genetics 10: 2329-2339.Reproductive Medicine\nInfertility is a widespread problem in modern society affecting 10 to 15 % of all couples. \nIt frequently causes an emotional crisis in the patients involved often lasting many years \nand compelling the individuals involved to seek medical care over prolonged periods \nof time. Nowadays, various methods of assisted reproductive technology are available, \nsuch as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). However, \nall these techniques heavily rely on the concomitant stimulation of ovarian function with \ngonadotropins. The response of the ovaries to these treatments decreases with age and \nthose patients, who do not react properly to the activity of the hormonal preparations \nadministered, are not likely to achieve pregnancy. In addition, those individuals, who \nreact well to these treatments, bear some risk to suffer from complications, such as the \novarian hyperstimulation syndrome (OHSS) or multiple pregnancies. Therefore, these \ntreatments must be monitored using some of the biological signals originating in the de -\nveloping follicles. The quality of the maturing follicle is assessed with serial measurements \nof the estradiol concentration in the serum and with ultrasound. However, final maturity \nof the follicle is substantiated by visualizing the perifollicular vascularization with Power \nDoppler Ultrasound and with the incremental rise of the progesterone concentration in \nthe serum. The timely coordination of follicular maturity and the oocyte\u00b4s meiosis can only \nbe achieved, if it is assumed that some of these signals are coordinated by the oocyte. The \neffect of these events is not only limited to the ovary, but results in changes throughout \nthe woman\u00b4s body, as demonstrated by the modification of the adrenal steroidogenesis \nduring the periovulatory phase. Therefore, knowledge of the interaction between the \noocyte and the surrounding tissues may help to develop new treatment modalities aiming \nat improving the sensitivity of the body to the signalling from the oocyte. Furthermore, \nbetter understanding of these phenomena will also contribute to cure some of the \nchanges occurring during the menopausal transition and thereafter .\nInterplay Between the Hormonal Regulation \nof Follicular Development and Oocyte-\ncentered Signaling in Ovarian Physiology\nThe principal components of the ovarian follicle are the egg (e.g. oocyte), the \ngranulosa and the surrounding theca. Whereas the oocyte depends on the nutri -\ntive action of the granulosa, the latter relies on the theca for the provision of an -\ndrogenic substrate in order to ensure the production of estrogens. Most women \nare endowed with several millions of follicles at birth, but only a few hundred of \nthem will develop up to ovulation. The fate of most follicles depends on the equi -\nlibrium between the proliferation and apoptosis of granulosa, culminating either \nin the development of the dominant follicle or in its degeneration (e.g. atresia). \nThe factors involved in the selection process of the dominant follicles are largely \nunknown. The development of the ovarian follicle during the menstrual cycle \nis predominantly regulated by hormones, most particularly those secreted by \nthe pituitary. However, the role of these hormones can only partially explain the \nchanges observed during the menstrual cycle and those during the woman\u2019s life \ncycle. If the number of follicles drops below a critical level, the ovaries will stop \nthe production of follicles and the transition into the postmenopausal status will \nensue despite the strengthened stimulatory action of various hormones secreted \nby the pituitary. The factors involved in these processes are still largely unknown. \nIt is increasingly thought that signaling originating in the oocytes plays a crucial \nrole. Several factors originating from the oocyte and influencing the surrounding \ngranulosa during various phases of follicular development have already been \nidentified, but many aspects of the interplay between the oocyte-centered sign -\naling and the hormonal factors involved must still be determined.\nThe goal of our research is to identify new factors and pathways acting in ovar -\nian physiology and in reproductive organs. We are particularly interested in the \nhormonal regulation of tissue modeling in ovarian follicular development and in \nclosely related organ systems, such as the breast. In order to study the interac -\ntion between granulosa and oocytes, a large set of human granulosa cell lines \nwas established and characterized, either using cells from granulosa cell tumors \nor by transfection of hTERT into granulosa cells recovered from infertile women \ntreated with assisted reproduction. In addition, a human ovary-gene expres -\nsion profile was established by identifying the expression, the abundance and \nthe corresponding annotation from ESTs of NCBI GenBank derived from non-\nFig. 1:  Immortalized granulosa cells \n(COV434) in the absence of an oocyte, \nas demonstrated by confocal light \nmicroscopy.normalized human ovarian cDNA libraries, such as the Stanford microarray \ndatabase, the HUGE database of the Kazusa DNA Research Institute and \nPubMed. These profiles provided data of transcripts for genes of both known \nand unknown function that were ovary-specific or ovary-enriched and lead to \nthe identification of several novel genes involved in follicular maturation, such \nas Kiaa1573, inhbp, o/t ring, ADAMTS-16 and others. Further elaboration of \nanother gene, human Bcl-2-related ovarian killer gene (hBok), demonstrated \nthat it blocked apoptosis induced by IL-3 withdrawal and Bax expression and \nthat it was expressed in ovarian granulosa, in testicular tissue as well as in vari -\nous estrogen-dependent breast cancer cell lines. The hormonal regulation of \nhBok expression was studied in detail using several immortalized cell lines, \nsuch as those of granulosa, breast cancer and heart muscle.\nIn order to further construct an in vitro model for studying the interaction be -\ntween the oocytes and its surrounding granulosa, immature human oocytes \nwere matured in vitro both with and without immortalized granulosa cells. \nThe effect of the granulosa on the maturation of the oocyte was studied \nwith high frequency videography. The signals originating in the co-cultured \noocyte and acting on the surrounding granulosa was studied with cDNA ar -\nray technology. The results of these experiments will provide further clues for \nthe co-regulation of follicular development by the oocyte.\nUnraveling oocyte-centered signaling may not only be crucial for our under -\nstanding of the mechanisms in the selection of the dominant follicle, but also \nfor the study of ovarian ageing and menopause altogether. The hormonal \nchanges observed during menopause seem to be caused by a progressive \nloss of function of all reproductive tissues, which may very well originate in \nthe aged oocytes. As the transition from reproductive life into menopause is \nassociated with an upsurge of several diseases, such as breast cancer, car -\ndiovascular events and osteoporosis, the results of this research may have \nclinical implications far beyond reproductive medicine.\nFig. 2:  Immortalized granulosa cells \n(COV434) in the presence of a human \noocyte, as demonstrated by confocal \nlight microscopy. Within hours \nintercellular connections are formed \nbetween the granulosa cells. \nThe molecular nature of the signalling \noriginating in these immature oocytes is \ncurrently under investigation.\n60/61Hepatology\nProf. Dr. Markus Heim\nDepartement f\u00fcr Innere Medizin\nUniversit\u00e4tsspital Basel\nGroup Members\nDr. F . Duong\nElke Bieck (technician)\nSimone Stutvoet (PhD student)\nVerena Christen (PhD student)\nSabina Hernandez (PhD student)\nMichael Dill (MD student)\nXueya Wang (diploma student)Jak-STAT signaling\nHepatitis C virus\nInterferon\nLiver regenerationSignalaustausch in der Leber w\u00e4hrend \nRegeneration und Krankheit \nDie Leber hat eine enorme Kapazit\u00e4t zur Regenerati -\non. Infektionen mit dem Hepatitis C Virus Infektionen \ngeh\u00f6ren zu den weltweit wichtigsten chronischen Le -\nbererkrankungen, welche zu Zirrhose und Leberkrebs \nentarten k\u00f6nnen. Mit der aktuellen Behandlung (u.a. \nmit Interferonen) k\u00f6nnen rund 45-60% der chronisch \nerkrankten Patienten geheilt werden. \nUnsere Gruppe befasst sich daher mit zwei spezifischen \nProjekten: Einerseits geht es darum die molekularen \nGrundlagen der Regenerationskapazit\u00e4t der Leber \nbesser zu verstehen, um neue Therapieans\u00e4tze f\u00fcr \nLebererkrankungen oder nach partieller Leberentfer -\nnung (Hepatektomie) zu finden. Andererseits m\u00f6chten \nwir verstehen warum das Hepatitis C Virus in so vielen \nF\u00e4llen der Interferonbehandlung ausweichen kann, um \nWege zu finden wie man dies verhindern kann.\nMit Hilfe von transgenen M\u00e4usen konnten wir zeigen, \ndass der Wachstumsfaktor Interleukin 6 (Il-6) f\u00fcr das \n\u00dcberleben, jedoch nicht das Wachstum der Leberzellen \nnach einer Hepatektomie wichtig ist. F\u00fcr Regenerati -\nonsprozesse, d.h. Zellteilung scheinen Elemente der \nsogenannte STAT Signalkette (Stat: signal transducer \nand activator of transcription) die entscheidende Rolle \nzu spielen. Welche Element dies sind \u00fcberpr\u00fcfen wir \nzurzeit mit einer Reihe von transgenen M\u00e4usen.\nDie Resistenz des Hepatitis C Virus gegen\u00fcber Interfero -\nnen scheint \u00e4hnliche Signalmechansimen zu betreffen. \nK\u00f6rpereigene, sowie medikament\u00f6se Interferone schal -\nten selber Zielgene \u00fcber die sogenannte Jak-STAT Sig -\nnalkette an. Dieser Signalmechanismus ist eine entschei -\ndende und effiziente fr\u00fche Reaktion von Virus-infizierten \nZellen. Wir stellten fest, dass diese Signalkette sowohl in \nder Leber von transgenen M\u00e4usen, welche das Hepatitis \nC Virus tragen, als auch in Leberbiopsien von chronisch \nHepatitis C erkrankten Patienten unterbrochen ist. Wir \nsind dabei den Mechanismus dieser Unterbrechung auf \nmolekularer Ebene aufzukl\u00e4ren. \nSelected Publications\n\u2013 Blindenbacher, A., Duong F .H., L. Hunziker, Stutvoet \nS.T., Wang X., Terracciano L., Moradpour D., Blum \nH.E., Alonzi T., Tripodi M., La Monica N., and Heim \nM.H. (2003a) Expression of hepatitis c virus proteins \ninhibits interferon alpha signaling in the liver of trans -\ngenic mice. Gastroenterology 124: 1465-75.\n\u2013 Blindenbacher, A., Wang X., Langer I., Savino R., \nTerracciano L., and Heim M.H. (2003b) Interleukin 6 \nis important for survival after partial hepatectomy in \nmice. Hepatology 38: 674-82.\n\u2013 Duong, F .H., Filipowicz M., Tripodi M., La Monica \nN., and Heim M.H. (2004) Hepatitis C virus inhibits \ninterferon signaling through up-regulation of protein \nphosphatase 2A. Gastroenterology 126: 263-277.\n\u2013 Heim, M.H., Moradpour D., and Blum H.E. (1999) \nExpression of hepatitis C virus proteins inhibits signal \ntransduction through the Jak-STAT pathway. J Virol \n73: 8469-75.Clinics\nHepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. An \nimportant and striking feature of hepatitis C is its tendency towards chronicity. In over \n70% of infected individuals, HCV establishes a persistent infection over decades that \nmay lead to cirrhosis and hepatocellular carcinoma. Chronic hepatitis C is treated with \na combination therapy with pegylated (long-acting) interferon alpha injected subcuta -\nneously and ribavirin taken as capsules. The treatment duration is 6 to 12 months, and \nthe overall success rate is 45-60%. The reasons for treatment failures in up to half of the \npatients are currently not understood.\nIntracellular Signaling in Liver Disease and \nRepair\nThe hepatology laboratory in the Department of Research of the University Hos -\npital Basel focuses on two specific projects in the field of intracellular signaling in \nliver diseases and during hepatic repair processes after liver damage.\nI. Intracellular signaling through the Jak-STAT pathway in liver cell pro -\nliferation, apoptosis and differentiation\nThe liver has an enormous capacity to regenerate after damage. A better under -\nstanding of the molecular mechanisms that control the repair processes can lead \nto better prevention and better therapies of liver diseases in the future. Over the \nlast years, our group has investigated the role of interleukin-6 and Stat3 signaling \nin the liver during regeneration after partial hepatectomy. Using IL-6 deficient \nmice, we found that IL-6 signaling is important for survival after partial hepatec -\ntomy, but not essential for the proliferation of liver cells during liver regeneration \n(Blindenbacher et al. 2003b). We now focus our efforts on the generation of 3 \ntransgenic mouse lines that express fusion proteins between a mutated estrogen \nreceptor ligand binding domain and signal transducer and activator of transcrip -\ntion (Stat) 1, Stat3 and Stat5, respectively, in hepatocytes. These fusion proteins \ncan be activated by 4-hydroxy tamoxifen, a synthetic steroid, independently \nfrom endogenous ligands (gain-of-function models). We plan to study the ef -\nfects of Stat activation in various physiological and pathophysiological models of \nliver development, liver damage, and liver repair. \nII. Hepatitis C virus interference with interferon induced intracellular \nsignaling through the Jak-STAT pathway\nHepatitis C virus (HCV) has a striking capacity to establish a chronic infection. \nIn order to do so, HCV must escape the host immune response. Type I interfer -\nons (IFN) are crucial and potent components of the early host response against \nvirus infection. The most important signal transduction pathway for IFNs is the \nJak-STAT pathway (Figure 1). IFNa and IFNb activate STAT1, STAT2 and often \nSTAT3. Signal transducers and activators of transcription (STAT) proteins are \nactivated by members of the Jak kinase family through the phosphorylation \nof a single tyrosine residue. Activated STATs form dimers, translocate into the \nFig. 1:  Interferon signal transduction through the Jak-STAT pathway.nucleus and bind specific DNA elements in the promoters of target genes. \nThis activation cycle ends by tyrosine dephosphorylation in the nucleus, fol -\nlowed by the decay of dimers and the nuclear export of STATs. IFN induced \ngene transcription can be inhibited by protein inhibitor of activated STAT1 \n(PIAS1). The binding of PIAS1 to STAT1 is regulated by methylation of STAT1 \non arginine 31 by protein arginine methyl-transferase PRMT. Arginine meth -\nylation inhibits binding of PIAS1 to STAT1, whereas demethylation of STAT1 \nenhances its association with PIAS1.\nSeveral years ago we found that the expression of HCV proteins in human \nosteosarcoma cell lines inhibits IFN induced signaling through the Jak-STAT \npathway (Heim et al. 1999). These findings could be confirmed in trans -\ngenic mice that express the entire open reading frame of the hepatitis C \nvirus genome in the liver under the control of the hepatocyte specific alpha1-\nantitrypsin promoter (Blindenbacher et al. 2003a). Recently, we observed \nthat IFN signaling is also inhibited in liver biopsy samples of patients with \nchronic hepatitis C (Duong et al. 2004). Furthermore we identified Stat1 as \nthe cellular target of HCV interference with IFN signaling. In the presence of \nHCV proteins, Stat1 molecules are hypomethylated on arginine 31. This hy -\npomethylation leads to an increased association with the inhibitor PIAS1. As \na consequence, STAT1 can not induce interferon target genes. By inhibiting \nIFN signaling, HCV can protect itself from endogenous and exogenous IFN. \n62/63Metabolism\nProf. Dr. \nUlrich O. Keller\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nDr. Henryk Zulewski\n(principle investigator stem cell project)\nGroup Members\nDr. Philippe Linscheid\nDalma Seboek (PhD student)\nMichael Eberhard (PhD student)Obesity\nDiabetes mellitus\nAdipocytes\nIsle-derived stem cells\nHormokinesHormokine und das Fettgewebe bei Entz\u00fcndun -\ngen : Fettleibigkeit ist eines der wichtigsten Gesund -\nheitsprobleme weltweit; die Vermehrung des Fettge -\nwebes bewirkt eine Insulin-Resistenz und zieht damit \neine Reihe von Komplikationen nach sich, darunter Typ 2 \nDiabetes. \u00dcbergewichtige weisen zudem einen Zustand \neiner leichtgradigen, chronischen Entz\u00fcndung auf, die \nf\u00fcr die Insulinresistenz mitverantwortlich ist. Schwer -\nkranke mit Insulinresistenz und Sepsis profitieren von \neiner \u00dcberwindung der Insulinresistenz durch eine In -\nsulintherapie mit einer ca. 50% Abnahme der Mortalit\u00e4t \nHormokine sind die im Zusammenhang mit Entz\u00fcndun -\ngen ausgesch\u00fctteten Hormone, wobei uns besonders \ndie Kalzitonin-Peptide interessieren. Wir zeigten, dass \ndas neben anderen Geweben, auch menschliches Fett -\ngewebe Hormokine herstellt, und dass die Gene, die \nz.B. f\u00fcr Prokalzitonin kodieren im Falle von Sepsis und \nbei Entz\u00fcndungen eingeschaltet werden. Es muss also \nin der Regulation dieser Gene Elemente haben, welche \nauf die Signale von mikrobiellen Eindringlingen reagie -\nren. Zum Studium dieser Mechanismen verwenden wir \ninnovative Techniken mit menschlichen Zellkulturen und \neine Kombination aus experimenteller und klinischer \nForschung. Insbesondere erforschen wir, ob diese den \nStoffwechsel w\u00e4hrend Entz\u00fcndungsreaktionen beein -\nflussen. Unsere Resultate weisen darauf hin, dass CT \nPeptide in den Zellen des Fettgewebes eine Rolle bei \nder Entstehung der Insulin-Resistenz spielen.\nStammzellen als Quelle von Insulin produzieren -\nden Zellen: Unter der Leitung von H. Zulewski wird \nnach einer neuen auf Stammzellen basierten Therapie \nf\u00fcr Diabetes mellitus gesucht. Die ersten Resultate \nzeigen, dass in der Bauchspeicheldr\u00fcse des Men -\nschen, in der normalerweise Insulin produziert wird \nauch Stammzellen existieren und unter besonderen \nBedingung ebenfalls in Insulin produzierende Zellen \nverwandelt werden k\u00f6nnen. Diese Stammzellen haben \naber auch die F\u00e4higkeit sich in Leber- und Fettzellen zu \nverwandeln, was ein Hinweis auf deren besonderes \nEntwicklungspotenzial ist. \u00c4hnliche Stammzellen wer -\nden auch im Knochenmark vermutet und gegenw\u00e4rtig \nin unserem Labor untersucht. \nSelected Publications\n\u2013 Linscheid P ., Seboek D., Nylen E.S., Langer I., Schlat -\nter M., Becker K.L., Keller U., M\u00fcller B. (2003) In vitro \nand in vivo calcitonin I gene expression in parenchy -\nmal cells: a novel product of human adipose tissue. \nEndocrinology 144 (12): 5578-5584.\n\u2013 Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay \nMM, Huber PR, Tamm M, Muller B. (2004) Effect of \nprocalcitonin-guided treatment on antibiotic use and \noutcome in lower respiratory tract infections: cluster-\nrandomised, single-blinded intervention trial. Lancet \n363: 600-607.\n\u2013 Linscheid P ., Keller U., Blau N., Schaer D.J., M\u00fcller \nB. (2003) Diminished production of nitric oxide syn -\nthase cofactor tetrahydrobiopterin by rosiglitazone \nin adipocytes.Biochem Pharmacol 65 (4): 593-598\n\u2013 Linscheid P ., Seboek D., Schaer D.J., Zulewski H., Kel -\nler U., M\u00fcller B. (2004) Expression and secretion of \nprocalcitonin and calcitonin gene-related peptide by \nadherent monocytes and by macrophage-activated \nadipocytes. Crit Care Med. 32(8):1801-1802.\nNew Ways toApproach the Problem of \nDiabetes and Inflammation-studies Involving \nHormokines, Adipocytes and Islet-derived \nStem Cells.\nObesity is one of the most expanding health problems world-wide. It is charac -\nterized by the excess accumulation of body fat. Consecutively, obesity-related \ninsulin resistance leads to an array of inflammatory complications, diabetes mel -\nlitus type 2 with a relative insulin deficit and impaired insulin action on glucose \nand lipid metabolism, metabolic syndrome, more severe infections including a \nhigher mortality in sepsis. Conversely, aggressive insulin infusion therapy to \ncounter the insulin resistance and improve glycemic control reduced mortality \nby 50% in septic patients. Procalcitonin, a precursor of the hormone calcitonin, \nis circulating in large amounts in many infection-related diseases, e.g. bacterial \nsepsis. Though procalcitonin measurements are now routinely used in clinical \npractice, the induction mechanisms and the source this enigmatic family of pep -\ntides are still obscure.\nOur research aims to unravel the common underlying molecular mechanisms us -\ning three innovative approaches using human cell culture models and combining \nclinical and experimental research:\na) Human adipose tissue as source of hormokines and inflammatory \npeptides\nBased on our published data on ubiquitous procalcitonin production in sepsis, \nwe postulated the presence of microbial infection-specific response-elements \n(MISRE) in the CALC I gene promoter, which, upon an inflammatory stimulus, \noverride the tissue-selective neuroendocrine expression pattern. The term \n\u201chormokines\u201d depicts this inflammation-related, widespread expression of \nhormones. Accordingly, we reported a sepsis- and inflammation-mediated CT-\nmRNA transcription and procalcitonin secretion in human adipose tissue and in \nmesenchymal stem cell- (MSC) derived adipocytes. In analogy to the non-neu -\nroendocrine expression of CT peptides, we hypothesized that other hormones \n(e.g. SRIF) might be \u201cectopically\u201d expressed upon inflammatory stimulation, \ncharacteristic for so-called \u201chormokines\u201d. Accordingly, we also identified that \nSRIF is secreted by human adipose tissue, both, ex vivo upon LPS and IL-1 \u03b2 \nstimulation.\nFig. 1:  Adipocytes are not only an inert storage depot of fat but also a secretory- \nendocrine glandb) Human adipose tissue as site action of inflammatory peptides\nThe role of adipose tissue is by far not limited to inert triglyceride storage \n(Fig 1). We want to elucidate whether adipose-tissue-derived cytokines, \nCT-peptides, and SRIF plays a role in the metabolic regulation during inflam -\nmatory diseases, e.g. by modulating insulin secretion in conditions of insulin \nresistance and relative insulin deficiency (e.g. obesity or sepsis). To assess \ninsulin resistance we measure glucose uptake and lipolysis in our human \nadipocyte model. Nitric oxide (NO), the main synthesis product of iNOS is a \nsuspected mediator of insulin resistance. We found the respective mRNAs of \nCT receptor, CT receptor like receptor (CRLR)-, RAMP 1- and 2-mRNA to be \nexpressed in preadipocyte- and MSC-derived adipocytes (Fig 2). Hence, we \nexpect CT-peptides to exert defined effects on adipocytes (e.g. induction of \ninsulin resistance, modulation of iNOS activity)\nc) Ex vivo generation of human insulin producing cells \nBoth, diabetes mellitus Typ 1 and 2 are characterized by an absolute and rela -\ntive Insulin deficit, respectively. After discovery of potential stem cells in the \nislets of Lanherhans by members of our group we were able to isolate and \nreversibly immortalise these stem cells that express not only several stem cell \nmarker but also the transcriptionfactor islet-1 that is critical for development \nof endocrine pancreatic cells (Fig 3). In addition, in a proof of principle study \nwe show in a SCID mouse transplantation model that human islet derived \nstem cell are able to adopt a hepatic phenotype in vivo. \nPD Dr. \nBeat M\u00fcllerFig. 2:  Adipocytes \nwere subjected to in -\nflammatory treatments \n(\u201cmix\u201d of cytokines, \ni.e. IFNg, TNF \u03b1, IL-1\u03b2, \nand LPS) for 6 hours. \nThereafter, CT mRNA \nwas analysed by \nRT-PCR. TNF mRNA \nand IL-6 mRNA were \nanalyzed as controls. \nAfter stimulation pro -\ncalcitonin mRNA was \nexpressed and the \npeptide was secreted \nin supernatants as \nmeasured by a sensi -\ntive chemilumometric \nassay with a detection \nlimit of 5 pg/mL.\nFig. 3:  Expression of \nstem cell markers and \nisl-1 in human islets \nof Langerhans and \ndifferent islet derived \nstem cells. NIP =nestin \npositive islet derived \nprogenitor cells, islet \nderived stem cell lines \nBC11-T, BC11-BT, \nBC11-BT dsRed.\n64/65\n(Barbara B. Kahn and Jeffrey S. Flier, J Clin Inves: 106:473, 2000)Pneumology\nPD Dr. \nMichael Roth\nDepartement Forschung \nund Klinik f\u00fcr Pneumologie\nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Michel Bihl \nDr. Jochen R\u00fcdiger\nDr. Mesut Cornelson Gencay\nDr. Martin Brutsche\nDr. Lukas Hunziker\nDr. Pieter Borger\nSt\u00e9phanie Goulet (PhD student)\nJingqing Yang (PhD student)Asthma\nCOPD\nFibrosis\nTranscription factor interaction\nCCAAT/enhancer binding protein\nGlucocorticoid receptorDie Regulation der Zelldifferenzierung du -\nrch Transkriptionsfaktoren und ihre Bedeu -\ntung f\u00fcr Asthma, COPD und Lungefibrose\nAsthma und chronisch obstruktive Lungenerkrankung \n(COPD) sind die h\u00e4ufigsten entz\u00fcndlichen Lungener -\nkrankungen mit weltweit stetig ansteigender Inzidenz. \nBisher wurde die Entz\u00fcndungsreaktion als Hauptursa -\nche dieser Erkrankungen angesehen. Man nahm an, \ndass infolge die Balance zwischen Gewebeaufbau und \n\u2013abbau in der Lunge gest\u00f6rt sei und es je nach Verschie -\nbung dieser Balance zu einer Gewebezunahme bzw. \n\u2013abnahme k\u00e4me. Die Grundlage dieser Hypothesen \nbezog sich meistens auf Tiermodele. Neue Ergebnisse \nan menschlichem Gewebe und Zellkulturen weisen in \neine andere Richtung. In unserem Labor arbeiten wir \nausschliesslich mit Zellkulturen die aus Gewebeproben \nder menschlichen Lunge angez\u00fcchtet werden. An die -\nsen Zellen untersuchen wir, ob es Unterschiede in der \nZelldifferenzierung gibt, die zu einem bestimmten Krank -\nheitsbild passen. Wir untersuchen hierbei die Zellreak -\ntion so breit wie m\u00f6glich und bestimmen die Rolle von \nsogenannten Transkriptionsfaktoren und ihrer Interaktion \ninbezug auf: (i) die Zellteilung und ihre Regulatoren, (ii) \nden Auf- und Abbau des Bindegewebes (extrazellul\u00e4re \nMatrix), (iii) Zellzuckermolek\u00fcle (Glykosamionoglykane), \nund (iv) die Aussch\u00fcttung von Wachstumsfaktoren und \nderen Inhibitoren.In enger Zusammenarbeit mit der \nUniversit\u00e4t Sydney (Australien) haben wir ein erh\u00f6htes \nWachstum bronchialer Muskelzellen von Asthmatikern \nzeigen k\u00f6nnen (1). Diese Pathologie konnte auf die feh -\nlerhafte Produktion eines Transkriptionsfaktors (C/EBP-\n\u03b1) zur\u00fcckgef\u00fchrt werden und erkl\u00e4rt warum Asthma gut \nbehandelt, aber nicht geheilt werden kann (2-5). Auch \nbei Patienten mit COPD liegen grundlegende St\u00f6rungen \ndes Zellverhaltens vor. Mit Hilfe dieser menschlichen \nZellkulturen wird die Krankheitsentstehung von Asth -\nma COPD und Lungenfibrosen besser verstanden und \nk\u00f6nnen neue Medikamente und Behandlungsarten im \nFr\u00fchstadium getestest werden. Von grosser Wichtig -\nkeit ist uns die enge Zusammenarbeit von Klinikern und \nGrundlagenwissenschaftlern die wir in unserem Team \nt\u00e4glich praktizieren.\nSelected Publications\n\u2013 Ruediger J.J., Roth M., Bihl M.P ., Cornelius B.C. \nJohnson M., Ziesche, R., and Block L.H.(2002) Glu -\ncocorticoids act through a C/EBP- \u03b1-glucocorticoid \nreceptor complex. FASEB-J, 16: 177-184.\n\u2013 Roth, M., Johnson, P .R.A., R\u00fcdiger, J.J., King G., Ge \nQ., Burgess J.K., Anderson G., Tamm, M., and Black, \nJ.L (2002) Interaction between glucocorticoids and \n\u03b22-agonists on bronchial airway smooth muscle cells \nthrough synchronised cellular signalling. The Lancet, \n360: 1293-1299. \n\u2013 Roth M, Johnson PR, Borger P, Bihl MP, Rudiger \nJJ, King GG, Ge Q, Hostettler K, Burgess JK, Black \nJL, Tamm M. (2004) Dysfunctional interaction of \nC/EBPalpha and the glucocorticoid receptor in asth -\nmatic bronchial smooth-muscle cells. N Engl J Med, \n351:560-574.\n\u2013 Gencay-Cornelsen M. M., Tamm, M., Glanville, A., \nPerruchoud, A.P ., and Roth, M. (2003) Chlamydia \npneumoniae activates epithelial cell proliferation via \nNFKB and the glucocorticoid receptor. Infection and \nImmunity, 71:5814-22.\nCell Differentiation and Transcription Factors \nin Asthma, COPD and Lung Fibrosis\nInflammatory lung diseases including asthma, chronic obstructive pulmonary \ndisease (COPD), lung fibrosis, and emphysema have been considered to result \nfrom either a defect in the immune response to allergens, or infections, or are \nbased on a disturbed balance between protein synthesis and protein degrada -\ntion. Most of these hypotheses were established in animal models but it was \nrecently concluded that none of the models could be proven in humans. In our \nlaboratory we exclusively work with human cells that are established routinely \nfrom patient lung tissue specimen and that are not transformed.\nOur research on inflammatory lung diseases is focused on the role of transcrip -\ntion factors as the major regulators for cell proliferation and differentiation and \nhow these transcription factors are modulated by the cells\u2019 direct environment.\nSince 5 years we have a close co-operations with The Woolcock Institute of \nMedical Research, University of Sydney, Australia, that is specialised in lung \ndiseases. Based on this co-operation we could demonstrate that asthmatic bron -\nchial smooth muscle cells from asthmatic patients proliferate much faster than \nthose from controls. This could explain the increased mass of muscle bundles in \nasthmatic airways and its hyperresponsiveness to environmental triggers such as \ninhaled grass pollen, cat hair, or house dust mite. We could further demonstrate \nthat the clinically observed beneficial effect of combined glucocorticoids togeth -\ner with long acting \u03b22-agonists is based on the synchronised activation of tran -\nscription factors: the glucocorticoid receptor and the CCAAT/enhancer binding \nprotein-\u03b1 (C/EBP-\u03b1). Only when both transcription factors are activated at the \nsame time they form a complex that than induces the transcription/activation of \nthe negative cell cycle regulator p21(Waf1/Cip1) which in consequence inhibits cell \nproliferation (figure 1) (1-2). \nThis system does not work in asthmatic bronchial smooth muscle cells. The rea -\nson why the proliferation of asthmatic bronchial smooth muscle cells cannot be \ninhibited by glucocorticoids is due to a lack of C/EBP- \u03b1. (3). The lack of C/EBP-\n\u03b1 does not affect the anti-inflammatory action of glucocorticoids, a finding that \nfits well with the drugs\u2019 clinically documented action. Our findings imply that \nthe pathology of asthma is based on an alteration of cell differentiation. We also \ncould show that an asthma associated micro-organism, Chlamydia pneumoniae , \nuses the same signalling pathway to modify the cells response (4).\nIn a recently submitted manuscript we demonstrate that the lack of C/EBP- \u03b1 in \nasthmatic cells is due to an impaired translation of the mRNA of C/EBP- \u03b1 and \nnot to a gene defect. Furthermore, this study shows for the first time a molecular \ndifference between asthma and COPD/emphysema. Both diseases were con -\nsidered to represent two extreme phenotypes of the same pathology. Our study \nclearly demonstrated that both diseases are linked to a de-regulation of the \nC/EBP protein family, however, while asthma is linked with a lack of C/EBP- \u03b1 \nprotein, COPD/emphysema is associated with an up-regulation of C/EBP- \u03b4. \nIn ongoing studies we investigate the feedback mechanism of: (a) the conse -\nquences of the lack/overexpression of C/EBP-proteins on cell differentiation, \n(b) the modification of the transcription factors by the extracellular matrix and \nvice versa, (c) the effect of micro-organisms linked to asthma (Respiratory Syn -\ncytial Virus, Rhino virus, Chlamydia pneumoniae ) on the transcription factors, \nand (d) new drugs on the above described transcription factors.Our cell culture models using primary human fibroblasts, vascular smooth \nmuscle cells, bronchial smooth muscle cells and epithelial cells of the lung \noffer the unique opportunity to study pathogenic mechanisms of asthma, \nCOPD and fibrosis. Our findings allow to investigate risk factors for the \ndevelopment these diseases. Furthermore, new therapeutic approaches and \ndrugs can be tested at an early stage on human tissue. These methods might \nallow to define individual optimal treatment in the near future. The success of \nour research group is decisively based on the good collaboration of clinicians \nwith the molecular biologists. A close international network allows address -\ning specific questions in an efficient way. \nProf. Dr. \nMichael Tamm, \n66/67Prenatal \nMedicine\nPD Dr. Sinuhe Hahn\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup members\nProf. Dr. Wolfgang Holzgreve\nDr. Satheesh KR Chinnapapagari\nDr. Susanne Mergenthaler\nDr. Corinne Rusterholz\nDr. Andreina Schoeberlein\nDr. Xiao Yan Zhong\nNicole Chiodetti (technician)\nLisbeth Dudler (technician)\nVivian Kiefer (technician)\nTatiana Babochina (PhD student)\nAnurag K Gupta (PhD student)\nYing Li MSc (PhD student)\nSashka Hristoskova (PhD student)\nBernhard Zimmerman (PhD student)\nSonja Seelman (MD student)Non-invasive prenatal diagnosis\nErythroblast-differentiation\nCell free fetal DNA\nSize separation\nPlacentally-derived microparticlesRisikofreie Pr\u00e4nataldiagnose \nDie aktuell vielversprechendsten Ans\u00e4tze zu Etablierung \neiner sicheren und effizienten, riskiofreien, nicht-invasi -\nven Pr\u00e4nataldiagnostik basieren auf der Untersuchung \nseltener fetaler kernhaltiger Zellen aus m\u00fctterlichem Blut \neinerseits, sowie der Analyse zellfreier fetaler DNA aus \nm\u00fctterlichem Plasma oder Serum andererseits.\nDie Analyse der zellfreien fetalen DNA w\u00e4hrend der \nSchwangerschaft gilt mittlerweile als sehr robuste und \nverl\u00e4\u00dfliche Analysemethode, und eine Vielzahl gro\u00dfer \nStudien belegen Sensitivit\u00e4ts-Werte von nahezu 99% \nmit 100% Spezifit\u00e4t. \nAuf dieser Basis wird diese Methode bereits in Kliniken, \nwie auch in unserem Zentrum in Basel, zur Untersuchung \ndes fetalen Rhesus D-Status in Schwangerschaften mit \neinem Risiko f\u00fcr Rhesus-Inkompatibilit\u00e4t, sowie zur Be -\nstimmung des fetalen Geschlechts in Schwangerschaf -\nten mit einem Risiko f\u00fcr X-chromosomal-gekoppelte \nErkrankungen durchgef\u00fchrt.\nDiese Aspekte stehen zudem im Mittelpunkt des neu \netablierten EU-Netzwerkes \u201cSAFE\u201d, innerhalb dessen \nunser Zentrum als \u00fcbergreifender wissenschaftlicher \nKoordinator und Projektleiter t\u00e4tig ist. \nSelected Publications\n\u2013 Troeger C, Zhong X.Y, Burgemeister R, Minderer S, \nTercanli S, Holzgreve W and Hahn S (1999) Approxi -\nmately half the erythroblast in maternal blood are of \nfetal origin. Human Mol Reprod 5:1162-1165. \n\u2013 Zhong XY, Holzgreve W, and Hahn S (2002) The \nlevels of circulatory fetal DNA in maternal plasma \nare elevated prior to the onset of preeclampsia. Hyp \nPregnancy 2002: 21: 77-83.\n\u2013 Hristoskova S, Holzgreve W, Hahn S (2003) Fetal \nnucleated erythrocytes in maternal circulation do \nnot display a classic membrane-associated apoptotic \ncharacteristic (phosphatidylserine exposure) despite \nbeing positive by terminal dUTP nuclear end labeling. \nClin Chem. 49:1934-1937.\n\u2013 Li Y, Zimmerman B, Rusterholz C, Kang A, Holzgreve \nW , Hahn S (2004) Size Separation of Circulatory DNA \nin Maternal Plasma Permits Ready Detection of Fetal \nDNA Polymorphisms. Clin Chem 50:1002-1011.\n\u2013 Gupta A, Holzgreve W, Huppertz B, Malek A, Sch -\nneider H, Hahn S (2004) Detection of fetal DNA and \nRNA in placentally derived syncytiotrophoblast micro-\nparticles generated in-vitro. Clin Chem (in press).Clinical Applications\nThe analysis of cell free fetal DNA in maternal plasma has been found to be very robust \nand reliable, and a number of large studies have indicated that sensitivities of close to \n99% with 100% specificity can be attained. Consequently this method is already be -\ning used clinically, including our centre in Basel, for the examination of the fetal RhD \nstatus in pregnancies with a rhesus constellation and sex in those at risk for an X-linked \ngenetic disorder.\nThese aspects are being addressed in a newly established EU Network of Excellence \n\u201cSAFE\u201d, where our centre is acting as overall Scientific Coordinator and Work-package \nLeader.\nDevelopment of Risk Free Methods for Fetal \nAssessment\nPrenatal diagnosis addresses mainly the detection of fetal chromosomal aberra -\ntions and single gene disorders, which affect almost 3% of all fetuses. Current \nmethods to retrieve fetal material rely on invasive practices (amniocentesis, \nCVS), associated with a risk of fetal loss. In the developed world, many profes -\nsional women consider pregnancy only at a relatively advanced maternal age, \nwhich is associated with a naturally elevated risk for an aneuploid fetus. Often, \nthese couples chose to have only one child and are therefore reluctant to expose \nthe fetus to the invasive prenatal diagnostic procedure. Therefore concerted \nefforts world-wide are undertaken to develop safe efficacious non-invasive \nalternatives. \nThe most promising strategies are the enrichment of rare fetal nucleated red \nblood cells from the blood of pregnant women, and the isolation of cell free fetal \nDNA from maternal plasma or serum. \nAfter enrichment fetal erythroblasts can be examined by FISH to detect aneu -\nploidies or by single cell PCR following micro-manipulation for single gene \ndisorders. A large scale multi-centre clinical study conducted by the National \nInstitutes of Health (NIH), with our laboratory as the only non-US participant, ex -\namined the efficacy of this approach but found it currently not sufficiently robust \nto reliably permit large scale analyses. Further studies will now be performed in \na newly established EU Network of Excellence, SAFE.\nSpin-off examinations from these studies concerning erythroblast differentiation \nand their enucleation showed that this event uses apoptotic processes without \ninvoking actual cell death, in that the nuclear DNA is cleaved, cell organelles like \nmitochondria are lost, but there is no loss of membrane integrity .\nThe caveat in analysing fetal DNA from maternal plasma or serum is the maternal \norigin of the majority of total cell free DNA in the maternal circulation. Thus it \nwas initially suggested that this technique may only be suitable to reliably exam -\nine paternally inherited fetal loci absent in the maternal genome, such as fetal sex \nand rhesus D status in Rhd pregnancies.\nInvestigating biochemical properties of the circulatory DNA, we recently found \nthat fetal DNA species were generally smaller than comparable maternal ones, \nand that this observation can be used to selectively enrich fetal DNA, permitting \nthe ready detection of fetal genetic loci not otherwise discernible. First applica -\ntions of this size-separation approach to detect fetal Mendelian disorders, par -\nticularly the hemoglobinopathies are very promising.\nFurthermore we found that circulatory fetal nucleic acids are associated with pla -\ncentally-derived microparticles. These particles, released in increased amounts \nby the syncytiotrophoblast monolayer in pathological conditions such as preec -\nlampsia, have been implicated in the inflammatory cascade and endothelial dam -\nage associated with this disorder.Fig. 1:  Fragmented \nDNA in erythroblast \nnuclei detected by \nTUNEL assay\nFig. 2:  Size fractionation permits detection of fetal genetic loci which are otherwise \nmasked by maternal DNA sequences. Mother: maternal STR pattern (133 & 141 bp), \nFetus: fetal STR pattern (133, 137, 141 bp), indicative of trisomy 21, Total plasma: \nOnly maternal STR loci are detected. <300bp: Analysis of size-fractionated plasma \nDNA permits detection of fetal STR loci.\nFig. 3:  Syncytiotro -\nphoblast micro-parti -\ncles generated in-vitro.\n68/69Prenatal \nMedicine\nProf. Dr. Dr. h.c. mult. Wolfgang Holzgreve\nUniversit\u00e4ts-Frauenklinik BaselHematopoiesis \nIn utero thearpy \nStem celll treatment \nFetal immunocompetenceStammzelltransplantation f\u00fcr in-utero \nTherapie\nViele genetisch bedingten Erkrankungen beeintr\u00e4ch -\ntigen die fetale Entwicklung erheblich, und k\u00f6nnen \npostnatal nicht mehr behandelt werden. Um schwere \npr\u00e4natale Sch\u00e4den zu vermeiden, verfolgen wir daher \ndie Entwicklung eines Stammzell-basierten Ansatzes \nzur in-utero Therapie. Der Vorteil dieser Methode ist \ndie unvollst\u00e4ndige fetale Immunkompetenz, wodurch \ndie Abstossung von Donor-Zellen verhindert wird. \nErste klinische Anwendungen dieser in-utero Therapie \nf\u00fcr fetale Erkrankungen mit schwerer Immundefizienz \nberichteten positive Ergebnisse, wohingegen Erbkrank -\nheiten ohne Immundefizienz nicht erfolgreich behandelt \nwerden konnten. \nZur Entwicklung neuer Strategien testeten wir xenogene \nund allogene Transplantation in NOD/SCID Maus-F\u00f6 -\nten und Schafen, wobei xenogene Transplantation nur \nin 2.2%, jedoch allogene Transplantation in 80% der \nEmpf\u00e4nger erfolgreich war. Anteile von Donor-Zellen \nbetrugen bis 50% im Blut, 5% im Knochenmark und 88% \nin der Milz. In Blut und Milz dominierten die Donor-\nZellen als B- und T-Zellpopulationen, w\u00e4hrend sie im \nKnochenmark v.a. myeloide Linien und Granulozyten \nbildeten. \nWeiterhin verglichen wir das Engraftment-Ausmass \nzwischen autologer und allogener Stammzell-Transplan -\ntation in einem immunkompetenten Empf\u00e4nger, um die \nRolle immunologischer Abstossung unter Ber\u00fccksichti -\ngung von MHC-Barrieren zu untersuchen.\nZuk\u00fcnftige Studien werden sich auf M\u00f6glichkeiten zur \nProloferationsf\u00f6rderung der Donor-Zellen konzentrie -\nren, sowie die Verwendung mesenchymaler Stammzel -\nlen f\u00fcr die in-utero Transplantation pr\u00fcfen.\nDar\u00fcberhinaus erarbeitet unsere Gruppe innerhalb eines \nEU-Projekts (ENFET) klinische Protokolle und ethische \nGrundlagen f\u00fcr die in-utero Transplantation.\nSelected Publications\n\u2013 Surbek D.V ., Holzgreve W., Nicolaides K.H. (2001) \nHematopoietic stem cell transplantation and gene \ntherapy in the fetus: Ready for clinical use? Hum \nReprod Update; 7: 85-91\n\u2013 Surbek D.V ., Schatt S., Holzgreve W . (2001) Stem Cell \nTransplantation and gene therapy in-utero. Infusion \nTherapy and Transfusion Medicine; 28: 150-158\n\u2013 Surbek D.V ., Young A., Danzer E., Schoeberlein \nA., Holzgreve W. (2002) Ultrasound-guided stem \ncell sampling from the early ovine fetus for prenatal \nex-vivo gene therapy. Am J Obstet Gynecol; 187: \n960-963\n\u2013 Young A., Holzgreve W., Dudler L., Surbek D. \n(2003) Engraftment of human cord blood-derived \nstem cells in ovine fetuses after ultrasound-guided \nin-utero transplantation. Am J Obstet Gynecol; 189: \n698-701\n\u2013 Schoeberlein A., Holzgreve W., Dudler L., Hahn \nS., Surbek D.V . (2004) In utero transplantation of \nautologous and allogeneic fetal liver stem cells in \novine fetuses. Am J Obstet Gynecol; (in press)\nStem Cell Transplantation for in Utero \nTherapy\nMost genetic diseases with prenatal origin can not be treated any more postna -\ntally and the advantages of the proposed in-utero stem cell application approach \ninclude the lack of immune competence in the fetus, avoiding rejection of donor \nstem cells, and the potential to prevent severe prenatal morbidity .\nPrenatal stem cell transplantation is now at the edge of moving from preclini -\ncal research into clinical application. The first clinical experiences have already \nshown that inborn diseases, which lead to a severe immunodeficiency, can be \ntreated successfully in-utero by transplantation of haploidentical adult or fetal \nliver stem cells. No therapeutic success has been achieved so far in genetic \ndisorders which do not severely affect the immune system. Therefore, we are \ntrying to develop new strategies to improve the success.\nBy making use of two distinct animal models (immunodeficient fetal mice and \nsheep) we test strategies such as graft modification, prenatal conditioning of the \nfetus, postnatal transplantation after prenatal induction of immune tolerance, \nand fetal gene therapy using autologous fetal stem cells (ex-vivo fetal gene \ntherapy). \nInitially we used the immunodeficient NOD/SCID mouse model for in-utero \ntransplantations. Human-to-mouse transplants yielded engraftment rates of only \n2.2% (1 of 45 pups) with a very low level of chimerism, detectable only by nested \nPCR at 4 weeks of age in the spleen. In contrary, allogeneic in-utero transplants \nyielded 80% chimeric recipients with high-level engraftment.\nOverall, engraftment levels increased in the given timeframe, reaching 50%, 5% \nand 88% in peripheral blood, bone marrow and spleen, respectively. In all cases, \nrecipients with donor cells in the peripheral blood also showed engraftment in \nthe bone marrow and the spleen. Donor cells in the peripheral blood and the \nspleen 4 and 16 weeks after transplantation consisted mostly of B- and T-cells, \nas represented by the specific markers B220 and CD3 respectively. In the bone \nmarrow, however, the cell markers Mac 1 and Gr 1, specific for myeloid lineages \nand granulocytes were more prominent, both increasing with time after trans -\nplantation. The relative number of c-kit positive donor cells in the bone marrow \nslightly increased between 4 and 16 weeks after transplantation. \nIn fetal sheep we transplanted human cord blood stem cells across xenogeneic \nbarriers and achieved low-level engraftment. In recent experiments, we aimed \nto compare engraftment of autologous and non-matched allogeneic stem cells \nin an immunocompetent recipient to assess the role of immunologic rejection \namong MHC (major histocompatibility) barriers. Time-mated white alpine ewes \nFig. 1:  Peritoneal injection of stem cells into the mouse fetus at \ngestation day 13.5 under narcosis.were used. As donor SC, either allogeneic male fetal liver cells at 49 days\u2019 \ngestation, or autologous fetal liver cells were collected using an ultrasound-\nguided technique which we previously described. Stem cells were labeled \nand cryopreserved until transplantation. Fetuses were sacrificed and donor \ncell engraftment was analyzed by FACS and real-time PCR targeting the SRY \ngene (in allogeneic grafted animals). We found that donor cells engrafted \npreferentially in the spleen (1.14 \u00b11.62%), followed by bone marrow (0.56 \n\u00b10.54%), thymus (0.40 \u00b10.69%), liver (0.23 \u00b10.25%) and peripheral blood \n(0.11 \u00b10.12%) by FACS. Real-time PCR data showed similar distribution. Fu -\nture strategies will now focus on providing growth advantage to donor cells \nrather than immunosuppressive manipulation of the recipient. A further in -\nterest of our group is the use multipotent mesenchymal stem cells stem cells \nobtained from bone marrow or fetal liver as donor cells for in-utero transplan -\ntation. First experimental series show multitissue-engraftment in fetal sheep \nrecipients including neural tissue in the fetal brain. These engrafted cells are \nnow being analysed regarding functional transdifferentiation.\nWithin the framework of an EU-funded European collaboration (ENFET \nproject) which includes centers in the U.K., France, Italy, and Israel, our \ngroup is developing standards for clinical protocols and ethical frameworks. \nEthical implications, in particular regarding fetal gene therapy and the use of \npluripotent stem cells, are being addressed.\nFig. 3:  Ultrasound scan dur -\ning intra-uterine puncture and \ninjection of stem cells into the \nperitoneal cavity of the sheep \nfetus at the end of the first \ntrimester.\n70/71\nPD Dr. Daniel Surbek\nUniversit\u00e4ts-Frauenklinik Basel\nFig. 2:  Longitudinal view of \nan ultrasound scan at the\nend of the first trimester of \ngestation (day 50) in a sheep \nmodel.Signal\nTransduction\nProf. Dr. Th\u00e9r\u00e8se Resink\nDepartement Forschung \nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Maria Philippova \nDr. Danila Ivanov \nRoy Allenspach (technician)\nVanya Morf (PhD student)\nManjunath Joshi (PhD student)Occlusive Vascular Disease \nTissue Remodelling \nAngiogenesis \nCell Phenotype \nCell Adhesion Molecules \nT-cadherin Zelladh\u00e4sionsmolek\u00fcle und Blutgef\u00e4sse\nDie Angiogenese \u2013 die Bildung von neuen Blutgef\u00e4s -\nsen \u2013 und der Gef\u00e4ssverschluss sind zwei grundlegend \nverschiedene Vorg\u00e4nge. Die Angiogenese wird durch \nAktivierung der Endothelialzellen eingeleitet, w\u00e4hrend \nbeim Gef\u00e4ssverschluss eine interne Expansion von \nglatten Muskelzellen beteiligt ist. Bei beiden Vorg\u00e4n -\ngen spielen sich jedoch gemeinsame Mechanismen ab. \nDiese erlauben den beteiligten Zellen (Endothelialzellen \noder glatte Muskelzellen) eine \u00f6rtliche Reorganisation, \nBewegungen, Wachstum und ihr \u00dcberleben. Wir unter -\nsuchen die Rolle von Zelladh\u00e4sionsmolek\u00fclen bei Ver -\n\u00e4nderungen in Blutgef\u00e4ssen. Zellah\u00e4sionsmolek\u00fcle sind \nf\u00fcr die den Kontakt zwischen den Zellen und zwischen \nZellen und deren Umgebung (Matrix) verantwortlich. \nInsbesondere interessieren wir uns f\u00fcr T-Cadherin. \nT-Cadherin ist in Zellen von allen Blutgef\u00e4ssen zu \nfinden, scheint aber eine besondere Rolle im Falle von \nArteriosklerose, Restenose (Gef\u00e4ssverschluss nach chir -\nurgischer Gef\u00e4sserweiterung) und Tumor-Angiogenese \nzu spielen. Wir konnten zeigen, dass T-Cadherin sich \nhomogen um ruhende Zellen verteilt aber bevorzugt an \nder Front von wandernden Zellen zu finden ist . Bringt \nman Endothelialzellen auf eine Kulturplatte, welche \nT-Cadherin enth\u00e4lt, so kommt es zu morphologischen \nVer\u00e4nderungen, welche f\u00fcr die Angiogenese typisch \nsind. Wir vermuten, dass T-Cadherin f\u00fcr phenotypische \nVer\u00e4nderungen der Zellen verantwortlich ist und eine \nDe-adh\u00e4sion (ein Losl\u00f6sen) f\u00f6rdert. \nIn der Abteilung Kardiologie des Kantonsspital Luzern \nbefassen wir uns mit vier klinischen Forschungspro -\ngrammen: 1. Stumme Isch\u00e4mie 2. Eine nicht-invasive \nCharakterisierung des Risikos maligner ventrikul\u00e4rer \nArrhthmien. 3. Angina pectoris bei Patienten ohne \nkoronare Herzkrankheit und 4. Die Evaluation einer \nlokalen Strahlentherapie bei Patienten mit vasospasti -\nscher Herzkrankheit. \nSelected Publications\n\u2013 Ivanov, D., Philippova, M., Tkachuk, V ., Erne, P ., and \nResink, T. (2004). Cell adhesion molecule T-cadherin \nregulates vascular cell adhesion, phenotype and motil -\nity. Exp Cell Res 293, 207-218.\n\u2013 Philippova, M., Ivanov, D., Tkachuk, V ., Erne, P ., and \nResink, T.J. (2003). Polarisation of T-cadherin to the \nleading edge of migrating vascular cells in vitro: a \nfunction in vascular cell motility? Histochem Cell Biol \n120, 353-360.\n\u2013 Ivanov, D., Philippova, M., Antropova, J., Gubaeva, F ., \nIljinskaya, O., Tararak, E., Bochkov, V ., Erne, P ., Resink, \nT., and Tkachuk, V . (2001). Expression of cell adhe -\nsion molecule T-cadherin in the human vasculature. \nHistochem Cell Biol 115, 231-242.\n\u2013 Kudrjashova, E., Bashtrikov, P ., Bochkov, V ., Parfyono -\nva, Y ., Tkachuk, V ., Antropova, J., Iljinskaya, O., Tararak, \nE., Erne, P ., Ivanov, D., Philippova, M., and Resink, T .J. \n(2002). Expression of adhesion molecule T-cadherin \nis increased during neointima formation in experimen -\ntal restenosis. Histochem Cell Biol 118, 281-290.\n\u2013 Philippova, M.P ., Bochkov, V .N., Stambolsky, D.V ., \nTkachuk, V .A., and Resink, T.J. (1998). T-cadherin \nand signal-transducing molecules co-localize in ca -\nveolin-rich membrane domains of vascular smooth \nmuscle cells. FEBS Lett 429, 207-210.Clinical Partner\nWe focus on four clinical research programs. Silent Ischemia: \nOur department coordinates two long-lasting prospective, \nmulticenter studies to evaluate the course and prognosis \nof patients with silent ischemia. In the first study, a preven -\ntive treatment is compared to no treatment in patients that \nhad no overt coronary heart disease before. In the second \nstudy, maximal anti-ischemic treatment is compared to \nPTCA (percutaneous transluminal coronary angioplasty) in \npatients with silent ischemia after a myocardial infarction. \nMalign Ventricular Arrhythmias: We evaluate the accuracy \nof 3 non-invasive analyses in the case of arrhythmias retro -\nspectively with data collected since 1991, and, prospectively \ndetermine the criteria to predict the risk of cardiac arrest or \nthe need of therapy based on the collected data. Angina \nPectoris without coronary heart disease: Coronary heart \ndisease can be excluded in ca. 10% of the patients inves -\ntigated invasively for angina pectoris. In these cases, the \nsymptoms have their origins in a vasospastic heart disease, \nin pulmonary hypertension or in small vessel diseases. Data \nfor 600 patients with right heart catheterization and after \nintracoronary infusion of acetylcholine has been collected. \nWe are documenting the course of these patients for 1-6 \nyears. Vasospastic Heart Disease: We repeatedly noticed \na marked reduction of the symptoms of vasospastic heart \ndisease after a local radiotherapy. In addition, the extensive \nvasoconstriction was diminished after intracoronary infusion \nof acetylcholine. This led us to conduct a prospective inves -\ntigation with patients who have severe vasospastic disease \nand who are resistant to available therapies. We irradiate a \nvasospastic segment of the coronary artery and monitor the \ncourse of the symptoms.adhesion molecules should function in an anti-adhesive capacity is perhaps \nparadoxical, but not to be ignored. Cellular de-adhesion is as important as \nadhesion in modulating the attachment, detachment, attraction, repulsion \nand navigation processes that enable cells to appropriately migrate, grow, \n(de)-differentiate and survive in the process of tissue development and re -\nmodelling and as well as for cell transmigration. \nOur specific current goals are to: (a) demonstrate that T-cad can regulate mi -\ngration, survival and angiogenic/invasive properties of human vascular cells \nby modulating adhesiveness to the matrix and/or influencing cell navigation \nnegative guidance, (b) elucidate mediatory cellular and signalling mecha -\nnisms, and (c) determine the functional domain(s) of T-cad, and generate \nmodifications which abrogate or sustain de-adhesion /negative guidance/\nrepulsive responses. \nCell Adhesion Molecules in Vascular\nRemodelling and Neovascularization\nOur basic research interests lie in the field of vascular remodelling and encom -\npass the control of both smooth muscle cell (SMC) function in the context of \nrestenosis/atherosclerosis and endothelial cell (EC) function in the context of \nangiogenesis. Our objectives are two-fold: (A) basic understanding of the func -\ntion and molecular mechanisms of action of molecules participating in regulation \nof smooth muscle cell and endothelial adhesion, migration and proliferation, \nwith focus on cell adhesion molecules; (B) Extrapolation of knowledge gained \nfrom basic research toward therapeutic targeting (pharmaco- or gene- based) of \nSMC and EC functions relevant to restenosis, atherosclerosis and angiogenesis.\nVascular occlusion is morphologically characterized by extensive intimal expan -\nsion that develops through activation of SMC\u2019s, whereas angiogenesis, the \nformation of new blood vessels, is initiated through activation of EC\u2019s. Although \nocclusion and angiogenesis are distinct processes, analogies exist with respect \nto cell migration, growth, (de)differentiation and survival responses. These \nresponses require positional reorganization and movement of the participating \ncells (SMC and EC) and are dependent upon modulations in the cell-cell and \ncell-matrix adhesive interactions that supply cues for attachment, detachment, \nattraction, repulsion and navigation. Various cell adhesion molecules including \nintegrins, members of the immunoglobulin superfamily, selectins and cadherins \nmediate these interactions, and impaired expression or function of such mol -\necules have been implicated in a number of occlusive cardiovascular disorders \nsuch as atherosclerosis, (re)stenosis, as well as their common clinical complica -\ntions (thrombosis, myocardial ischaemia and infarction), and deregulated ang -\niogenesis.\nT-cadherin (T-cad) is an atypical GPI-anchored (GPI glycosylphosphatidylinosi -\ntol) member of the cadherin family of homophilic cell adhesion molecules. \nAlthough widely expressed in the cardiovascular system, and with elevated \nexpression in vascular cells in atherosclerosis, restenosis and tumour angiogen -\nesis, the physiological functions of T-cad in vascular tissue are unknown. Given \nits GPI-anchorage, T-cad has been proposed to act as a signalling/recognition \nreceptor rather than as a true adhesion molecule. We have shown that unlike the \nclassical cadherins, T-cad is globally distributed and not located at intercellular \njunctions of resting vascular cells and it undergoes redistribution to the lead -\ning edge of migrating cells (Fig. 1A). Mimicry of homophilic ligation by seeding \ncells onto immobilized substrata of recombinant T-cad results in poor spreading, \ninhibited adhesion and changes in the morphology and cytoskeletal distribution \nof adherent cells characteristic of a more motile phenotype (Fig. 1B). Moreover, \nT-cad overexpression in vascular cells increases the rate of proliferation. \nWe hypothesize that T-cad modulates vascular cell phenotype and behaviour by \nfacilitating de-adhesion. The notion that a member of the cadherin family of cell Prof. Dr. Paul Erne\nDepartement \nKardiologie\nKantonsspital Luzern\nFig. 1 A:  T-cadherin in vascular \nEC and SMC is globally distributed \nin resting cultures but undergoes \nredistribution to the leading edge \nof migrating cells (arrows indicate \ndirection of migration). Fig. 1 B:  In EC, homophilic li -\ngation (i.e. by seeding on T-cad \ncoated substratum) induces \nalterations in morphology and \ncytoskeletal distribution that \nare characteristic of the more \nmotile, angiogenic phenotype.\nEC SMCMigrating cells Resting cellsEC morphology Actin stainingT-cadherin \nsubstratum BSA substratum72/73Tissue \nEngineering\nDr. Ivan Martin\nInstitut f\u00fcr Chirurgische \nForschung und Spital-\nmanagement, ICFS\nUniversit\u00e4tsspital Basel\nLeiter Forschungsgruppe \nTissue Engineering\nGroup members\nDr. Andrea Barbero\nDr. Sylvie Miot \nDr. Arnaud Scherberich\nDr. David Wendt\nFrancine Wolf (technician) \nAlessandra Braccini (PhD student)\nSilvia Francioli (PhD student)\nSourabh Ghosh (PhD student)\nAnna Marsano (PhD student)\nSimon Str\u00f6bel (PhD student)\nDaniel Vonwil (diploma master student)\nUlas Gogus (diploma student)Cell differentiation\nGrowth factors\nBiomaterials\n3D cultures\nBioreactors Gewebeengineering von Knorpel \nund Knochen mit menschlichen Zellen\nWir entwickeln Gewebe f\u00fcr die Wiederherstellung von \nKnochen- und Knorpel- defekten. Ziel ist die Behand -\nlung von verletzten Gelenken, Menisken, Knochen \nsowie von komplexen, gr\u00f6sseren osteochondralen \nL\u00e4sionen. Gewebeproben werden dem Patienten ent -\nnommen, und die isolierten Zellen im Labor vermehrt. \nAuf speziell entwickelten Tr\u00e4germaterialien lassen sich \ndie vermehrten Zellen in Bioreaktoren kultivieren. Hier -\nbei l\u00e4sst sich die Reifung in Richtung des gew\u00fcnschten \nGewebetyps beeinflussen. Derart kultivierte Gewebe \nk\u00f6nnen den Patienten wieder eingesetzt werden.\nUnsere Forschung befasst sich daher (1) mit der Un -\ntersuchung der Biologie der mesenchymalen Zellen, \n(2) mit dem Einfluss von Wachstumsfaktoren auf die \nVermehrung, Ausreifung und Differenzierung dieser \nZellen, (3) mit der Interaktion der Zellen mit 3-dimensi -\nonalen Ger\u00fcsten definierter Architektur und (4) mit dem \nEinfluss physikalischer Stimuli in den Bioreaktoren. \nWir konnten die Entstehung von 3-dimensionalen \nGeweben im von uns entwickelten, gepr\u00fcften Bio -\nreaktor nachweisen und fanden Ausgangsgewebe, \ndie gute Kapazit\u00e4ten besitzen, sich in verschiedene \ngew\u00fcnschte Zelltypen und Gewebe zu differenzieren. \nIm Kaninchenmodell konnten wir mit unserem System \ndie Struktur und Funktion von experimentell erzeugten \nosteochondralen L\u00e4sionen in Gelenken ersetzen. \nF\u00fcr eine Vielzahl von Knochen- und Knorpeldefekten \nverspricht diese Methode eine qualitative Verbesserung \nder Reparatur. Oft sind nach Verletzungen, Abn\u00fctzun -\ngen oder im Falle von erblich bedingten Defekten die \nchirurgischen Eingriffe mit autologen Knochen- oder \nKnorpeltransplantationen aufwendig, nicht immmer \nzufriedenstellend und beinhalten das Risiko von se -\nkund\u00e4ren Beschwerden. Unser Ziel ist es, mit unserer \nMethode eine bahnbrechende Alternative zu bestehen -\nden Behandlungsmethoden zu offerieren.\nSelected Publications\n\u2013 D\u00e9marteau O, Wendt D, Braccini A, Jakob M, Sch\u00e4fer \nD, Heberer M, Martin I. (2003) Dynamic compression \nof cartilage constructs engineered from expanded \nhuman articular chondrocytes. Biochem Biophys \nRes Comm 310:580-588 \n\u2013 Wendt D, Marsano A, Jakob M, Heberer M, Martin \nI. (2003) Oscillating perfusion of cell suspensions \nthrough three-dimensional scaffolds enhances cell \nseeding efficiency and uniformity. Biotech Bioeng \n84:205-214 \n\u2013 Barbero A, Ploegert S, Heberer M, Martin I. (2003) \nPlasticity of clonal populations of de-differentiated \nadult human articular chondrocytes. Arthritis Rheum \n48:1315-1325 \n\u2013 Sch\u00e4fer D, Martin I, Jundt G, Seidel J, Heberer M, \nGrodzinsky AJ, Bergin I, Vunjak-Novakovic G, Freed \nLE. (2002) Tissue engineered composites for the re -\npair of large osteochondral defects. Arthritis Rheum \n46:2524-2534 \n\u2013 Frank O, Heim M, Jakob M, Barbero A, Sch\u00e4fer D, \nBendik I, Dick W, Heberer M, Martin I. (2002) Real-\ntime quantitative RT -PCR analysis of human bone mar -\nrow stromal cells during osteogenic differentiation in \nvitro. J Cell Biochem 85:737-746 Clinics\nIn the three clinical scenarios, engineered tissues are envi -\nsioned to be produced within the Hospital, using specialized \nbioreactor systems. By automating and standardizing tissue \nmanufacture, these bioreactors could assure the production \nof functional grafts with reproducible quality at acceptable \ncost.\n1. Trauma and disease of joints frequently involve structural \ndamage to the articular cartilage surface and the underlying \nsubchondral bone. These pathologies result in severe pain \nand disability for millions of people world-wide and represent \na major challenge for the orthopaedic community. Albeit a \nseries of therapeutic approaches has been developed to \ntreat osteochondral defects, none of them has proved yet \nto ensure long-lasting regeneration. The vision of our group \nconsists in the implantation of cell-based, functional osteo -\nchondral composite tissues. These would replace autologous \nosteochondral units harvested from a minorly loaded area of \nthe same joint (mosaicplasty technique). \n2. Congenital malformations of the ear and of the nasal sep -\ntum are currently surgically corrected by grafting autologous \ncartilage (e.g., from the ribs), with extensive \u2018handcraft\u2019 work \nto match the required size and shape. Engineered cartilage \nwould provide an attractive alternative to autologous tissue, \nwith the additional advantage of precise shaping.\n3. The current standard in a variety of bone repair procedures \n(e.g., fusion in spinal surgery or bone reconstruction follow -\ning tumor excision) is based on autologous bone (e.g., from \nthe iliac crest), which requires operation at an additional site \nand frequently leads to donor site morbidity. The goal of our \ngroup is to replace autologous bone with engineered cell-\nbased osteoinductive grafts.  \nTissue Engineering of Cartilage and Bone \nusing Human Cells\nThe goal of the research group is to generate grafts for the treatment of damaged \nor lost articular and meniscus cartilage, bone, as well as for more complex, large \nosteochondral lesions. Our approach involves fundamental investigations on (i) \nthe biology of differentiated and progenitor human mesenchymal cells, (ii) the \neffect of growth factors on cell proliferation, commitment and differentiation, \n(iii) the interaction between cells and 3D scaffolds of defined compositions and \narchitectures, and (iv) the controlled application of physical stimuli using tissue \nculture bioreactors. The engineered constructs are not only being considered as \npotential grafts, but also as controlled 3D model systems of cell differentiation \nand tissue development. Research is strongly financially supported in the con -\ntext of european consortia (a total of 4 projects within EU Frameworks V and VI) \nand has led to filing of a number of patent applications.\nRecent achievements of the group:\n1. We have demonstrated that a limited fraction of clones of human articular \nchondrocytes, expanded in the presence of specific growth factors, exhibit \nmultilineage differentiation capacity. Studies are ongoing to identify markers \nto selectively isolate chondrocyte subpopulations with an increased capacity \nof differentiation. \n2. We have developed and validated a bioreactor for the efficient, reproducible \nand uniform seeding of mesenchymal cells into three-dimensional scaffolds, \nbased on direct perfusion of cell suspensions through the scaffold pores. The \nsystem has been further developed to integrate perfusion seeding and per -\nfusion culture of cells into porous scaffolds within a single bioreactor module \nwhile monitoring oxygen consumption. Seeding and culturing cells in a 3D \ncarrier under controlled perfusion is expected to improve the quality of the \nresulting cartilaginous and bone-like tissues by enhancing cell survival and \nextracellular matrix synthesis. \n3. Using a bioreactor allowing highly controlled mechanical loading of cell-\nscaffold constructs, we have demonstrated that dynamic compression of \nengineered cartilaginous tissues enhances the deposition of cartilage-specific \nmolecules, if cells are embedded within sufficient amounts of extracellular \nmatrix prior to loading. The bioreactor system is currently being evaluated as \na \u2018functional quality control system\u2019 to determine at which stage engineered \ncartilage is sufficiently developed to tolerate physiological loading regimes.\nFig. 1:  Bioreactor system \nfor seeding and 3D culture \nof cells into porous scaf -\nfolds under controlled per -\nfusion. Controlled regimes \nof fluid flow are necessary \nto uniformly distribute \ncells in the scaffold and to \nmaintain their viability and \nfunction even in the inner -\nmost pores (Wendt et al., \n2003). 4. We have evaluated the suitability of several human cell sources (periosteal \ncells, bone marrow stromal cells, synovial membrane cells, fat pad cells, \nmeniscus cells, as well as ear, nasal, rib and articular chondrocytes) to \nengineer bone and cartilage tissues. Under our experimental conditions, \nbone marrow stromal cells and articular chondrocytes have been identified \nas the cell types allowing the most reliable generation of respectively bone \nand cartilage tissues.\n5. We have validated that composites consisting of a layer of engineered \ncartilage combined with an osteoconductive material can structurally and \nfunctionally restore large experimental osteochondral defects in rabbit \njoints. The approach is now being extended to a larger size animal model, \ni.e., goats.\nFig. 2:  Bioreactor \nsystem for the applica -\ntion of controlled re -\ngimes of compressive \ndeformation to native \nor engineered tissues. \nAssessing the re -\nsponse of engineered \ncartilage to dynamic \nloading may help to \ndetermine if it is suf -\nficiently functional for \ngrafting in a loaded \njoint (D\u00e9marteau et al., \n2003)\nProf. Dr. \nMichael Heberer  \nLeiter Institut f\u00fcr Chirurgi-\nsche Forschung und \nSpitalmanagement, ICFS\nUniversit\u00e4tsspital Basel\n74/75\nGroup Members\nJian Farhadi, MD \n(Plastic and Recons-\ntructive Surgery)\nMarcel Jakob, MD \n(Orthopaedic and \nTrauma Surgery)\nClaude Jaquiery, MD \n(Plastic and Recons-\ntructive Surgery)\nDirk Sch\u00e4fer, MD \n(Orthopaedic Surgery)\nStefan Sch\u00e4ren, MD \n(Orthopaedic Surgery)Vascular \nBiology\nProf. Dr. Edouard J. Battegay\nMedizinische Universit\u00e4tspoliklinik\nDepartement Forschung \nUniversit\u00e4tsspital Basel\nGroup members:\nDr. Rok Humar\nDr. Nicole Butz\nKaija Paris (technician)\nFabrice Kiefer (PhD student)\nShiva Neysari (PhD student)\nWeimin Li (PhD student)\nVeronica Munk (PhD student)\nMarco Petrimpol (PhD student)Angiogenesis\nRAAS System\nHypoxia/Ischemia\nmTOR-Signaling\nLeft Ventricular Hypertrophy (LVH)\nHypertensionBlutgef\u00e4ssbildung bei Bluthochdruck\nAngiogenese ist die Bildung von neuen Blutgef\u00e4ssen. \nWir sind insbesondere interessiert, die Kaskade von Si -\ngnalen zu verstehen, die bei einer Unterversorgung von \nSauerstoff (Isch\u00e4mie) in einem Organ zur Angiogenese \nf\u00fchrt. Eine gezielte F\u00f6rderung der Blutgef\u00e4ssneubildung \nw\u00fcrde es erm\u00f6glichen, die Folgen eines Herzinfarkts \noder eines Schlaganfalls zu vermindern. Die Angio -\ngenese wird von verschiedenen Stimuli reguliert. Das \nRenin-Angiotensin Aldosteron System (RAAS) \u2013 das Re -\ngulationssystem von Blutdruck, Plasmavolumen und Os -\nmolarit\u00e4t \u2013 spielt hier eine entscheidende Rolle. Hemmt \nman das Enzym ACE (angiotensin converting enzyme), \nso f\u00fchrt dies \u00fcber einen h\u00f6heren Bradykinin (BK) und \neinen niedrigeren Angiotensin II Spiegel zur Blutdruck -\nsenkung und zur Schonung des Herzes. Wir konnten \nzeigen, dass in der Klinik verwendete Blutdruck-Senker \n(ACE Hemmer) auch die Angiogenese f\u00f6rdern. Diese \nF\u00f6rderung beruht auf h\u00f6heren BK Mengen, Hypoxie \n(Sauerstoffmangel) und Stickstoff-Monoxid (NO) \n\u2013 Synthese. Bradykinin und Angiotensin II sind, mit \ngegens\u00e4tzlicher Wirkung, die Hauptakteure in diesem \nRegulations-System. Wir untersuchen daher die Rolle \nvon verschiedenen Bradykinin-Rezeptoren und Effektor -\nmolek\u00fclen in der Kette der Reaktionen, welche zur An -\ngiogenese f\u00fchren. Parallel hierzu untersuchen wir eine \ndurch Hypoxie induzierte Reaktionskette welche \u00fcber \nden Transkriptionsfaktor HIF-1 \u03b1 zur Aussch\u00fcttung von \nVEGF (vascular endothelial growth factor) f\u00fchrt \u2013 einem \nStimulator der Angiogenese. \u00dcber diesen Weg erh\u00f6ht \nsich die Teilungsbereitschaft von Blutgef\u00e4sszellen wel -\nche nun schneller auf Wachstumsfaktoren reagieren.\nAndererseits lassen sich f\u00fcr die Blutdrucksenkung nebst \nder Hemmung von ACE auch Angiotensin II Rezeptor \nAntagonisten einsetzen. In der Klinik untersuchen wir \ndie F\u00e4higkeit beider Molek\u00fcltypen auch eine links \nventrikul\u00e4re Hypertrophie signifikant zu verringern. \nPatienten bei denen trotz Bluthochdruck-Behandlun -\ngen eine Reduktion der Hypertrophie ausbleibt, haben \nein erh\u00f6htes Risiko f\u00fcr ein kardiovaskul\u00e4res Ereignis. \nBei diesen Studien, an denen mehrere Zentren betei -\nligt sind, kommen wir zum Schluss, dass verschiedene \nMedikamente, obschon sie alle den Blutdruck senken, \nverschieden auf die Organe wirken. Es ist m\u00f6glich, \ndass hierbei der Einfluss dieser Medikamente auf die \nAngiogenese eine Rolle spielt.\nSelected Publications\n\u2013 Humar, R., Kiefer, F . and Battegay, E.J. (2004) \nFormation of new blood vessels in the heart can \nbe studied in cell cultures. 3R-Info Bulletin 25, \nwww.forschung3r.ch/de/publications/bu25.html \n\u2013 Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Bat -\ntegay EJ. (2003) Hypertension and angiogenesis. Curr \nPharm Des. 9(21): 1733-44. \n\u2013 Kiefer F . N., Misteli H., Kalak N., Tschudin K., Fingerle \nJ., van der Kooij M., Stumm M., Sumanovski L. T., \nSieber C. C., and Battegay E. J. (2002) Inhibition of \nNO biosynthesis, but not increased blood pressure, \nreduces angiogenesis in rat models of secondary \narterial hypertension. Blood Pressure 11: 116-124.\n\u2013 Humar, R., Kiefer, F .N., Berns, H., Resink, T .J. and Bat -\ntegay, E.J. (2002) Hypoxia enhances vascular cell prolif -\neration and angiogenesis in vitro via rapamycin (mTOR) \ndependent signaling. FASEB J. 16 (8): 771-780.Clinics\nTreatment of hypertension and other cardiovascular risk factors is crucial for preventing \ncoronary heart disease, heart failure, dementia, and stroke. The main focus of our studies \nis to improve treatment of patients at cardiovascular risk.\nIn series of studies we have assessed and plan to further assess the role of different \nantihypertensive drugs in reducing left ventricular hypertrophy (LVH) and other hy -\npertensive target organ damages. A lack of decrease in left ventricular mass following \nantihypertensive treatment is associated with a higher risk for cardiovascular events. \nIn particular, we have been assessing drugs targeting angiotensin converting enzyme \n(ACE) and angiotensin II receptors. Angiotensin II, formed from angiotensin I in a reac -\ntion catalyzed by ACE, is a potent vasoconstrictor, the primary vasoactive hormone of \nthe renin-angiotensin system and an important component in the pathophysiology of \nhypertension. Various prospective, randomized clinical trials are underway to prove \nwhether ACE inhibitors or angiotensin II type 1 receptor antagonists are particularly \ncapable of improving the prognosis of patients with LVH. We have found that differ -\nent drugs act distinctly on end organs, even if reduction of blood pressure is identical. \nThese might be due to additional protective effects of antihypertensive drugs such as \nangiogenesis (see our research part). Furthermore, we have initiated studies on the ef -\nfects of antihypertensive drugs and investigative procedures on target organ damage \nin patients with hypertension.(mammalian target of rapamycin) to be driven by hypoxia. This rapamycin \ndependent pathway enhances the mitogenic response of vascular wall cells \nand angiogenesis to PDGF- and other growth factors. In line with this we \ncould show, that hypoxia- and growth factor-triggered mTOR signaling en -\nhances HIF-1 \u03b1 nuclear accumulation. Further analysis of signaling pathways \nshowed, that MAPK (ERK)-signaling is required for GF-induced proliferation \nand HIF-1 \u03b1 nuclear accumulation specifically under conditions of normoxia. \nThese results suggest that active HIF-1 \u03b1 is regulated at different levels that \ndepend on oxygen saturation, growth factor-triggered mTOR and MAPK-\nsignaling (Fig. 2).\nThus, altered signaling plays a role in mediating the angiogenic response dur -\ning ischemia in heart disease and peripheral vascular disease. Novel thera -\npeutic targets in intracellular signaling downstream of ACE inhibition and/or \nBK may be discovered that will improve microvascularization of ischemic left \nventricle in hypertension.\nFig. 2:  Hypoxia response is regulated at different levels Hypoxia increases mT OR \nactivity in dependence of growth factor stimulation via PI3K. This increase in mTOR \nactivity increases angiogenesis via (1.) induction of vascular cell proliferation and (2.) \nthe induction of HIF-1 \u03b1, that induces angiogenic genes such as VEGF . Under condi -\ntions of normoxia, PDGF- and bFGF- induced signaling shifts to the MAPK pathway . \nHIF-1\u03b1 Prolylhydroxylase (HIF-1 \u03b1 PH) is inhibited under hypoxia and independently \ncontributes to HIF-1 \u03b1 stabilization.\n(A) (B) \nMechanisms of Angiogenesis during \nHypertension and Left Ventricular \nHypertrophy\nAngiogenesis, the formation of microvascular networks from existing ones, is a \nhighly regulated process that arises in response to hypoxia and other stimuli and \nrelieves tissue ischemia in patients with ischemic heart and peripheral vascular \ndisease. The renin-angiotensin-aldosteron-system (RAAS) plays an essential role \nin the maintenance of vascular homeostasis. Inhibition of Angiotensin Convert -\ning Enzyme (ACE) with its resulting increase in bradykinin (BK) and decrease in \nangiotensin II levels is a powerful treatment against hypertension. Several lines \nof evidence suggest a role of angiotensin II and BK in angiogenesis. Indeed, we \ndemonstrate that under hypoxia specific ACE inhibitors (e.g. Quinapril), that are \nused in the treatment of hypertension, induce an angiogenic response in an in \nvitro assay of angiogenesis of the heart muscle (Fig. 1). This angiogenic effect is \ndue to increased BK levels, dependent on a hypoxic environment and nitric ox -\nide (NO) biosynthesis. We have shown previously, that reduced NO biosynthe -\nsis, a main attribute of arterial hypertension, contributes to impaired formation \nof new vessels, i.e., angiogenesis, and thus to microvascular rarefaction. Specifi -\ncally, NO plays a crucial role both in mediating angiogenesis in portal \u2013 and arte -\nrial hypertension. We currently investigate how BK induces angiogenesis at the \nmolecular and cellular level. Specifically we will determine presence and role of \nBK receptor subtypes (BK type1, type2 receptors), key signaling relay enzymes \n(PI3K, Akt, mTOR, MAPK) and effector molecules of BK-induced angiogenesis \n(iNOS, eNOS/HSP90, VEGF, bFGF, PDGF-BB). \nIn connection with these projects we examine specific hypoxia- and growth \nfactor-induced signaling pathways that regulate vascular cell proliferation and \nthe induction of hypoxia-inducible factor 1 \u03b1 (HIF-1\u03b1). This transcription factor \ninduces hypoxia-adaptive genes such as Vascular Endothelial Growth Factor \n(VEGF), a potent angiogenic molecule. We have characterised a specific, evo -\nlutionally highly preserved signaling pathway via the molecule PI3K and mTOR \nFig. 1:  (A) Angiogenesis assay in vitro. A piece (ca. 1 mm3) of the left ventricular \nmyocardium of a mouse heart is embedded in a fibrin-gel, overlayed with growth \nmedium and angiogenic stimulant (basic Fibroblast Growth Factor, 10ng/ml). After \n10 days, double in-gel-staining with FITC-coupled seed lectin from G. simplicifolia \n(green) and Cy3-coupled antibody against -smooth muscle actin (red) reveal en -\ndothelial sprouts with single attached smooth muscle- or pericyte-like cells. P ericyte \nattachment forming endothelial tubes have been observed in vivo and contribute to \nvessel remodeling, maturation and stabilization.\n(B) Detail of two crossing endothelial sprouts. Deconvolved confocal image, maxi -\nmum intensity projection of in-gel-staining with FITC-coupled lectin G. simplicifolia \n(green fluorescent). Arrow points to filopodia arising from the endothelial cells. Di -\nmensions of stack 100 m (x/y) and 10.5 m (z).76/77DKBW Schwerpunkt\nOnkologie\nDefiniertes Ziel dieses Schwerpunktes ist es, die Forschung auf dem Gebiet der \nOnkologie im Raum Basel zu f\u00f6rdern und weiter auszubauen. Insbesondere soll \ndie molekular-onkologische und die klinisch-onkologische Forschung der Uni -\nversit\u00e4t Basel und der im Raum Basel ans\u00e4ssigen Spit\u00e4ler, Forschungsinstitute \nund Pharmafirmen vernetzt werden, um die L\u00fccken zwischen Grundlagenfor -\nschung, angewandter Forschung und klinischer Forschung zu schliessen und \ninnovative, gemeinsame Projekte zu erm\u00f6glichen. Offensichtlich lebt der Schw -\nerpunkt vom Enthusiasmus und der Eigeninitiative der beteiligten Forscher. \nLangfristig soll die konzertierte Aktion in diesem Forschungsbereich zur Bildung \neines regionalen Krebszentrums f\u00fchren. \nDer Schwerpunkt wird derzeit vom Leiter des Institutes f\u00fcr Biochemie und \nGenetik, Prof. Gerhard Christofori, und vom Leiter der Klinischen Onkologie \ndes Universit\u00e4tsspitals Basel, Prof. Richard Herrmann, koordiniert. In Zeiten \nbeschr\u00e4nkter finanzieller Mittel, hat der Schwerpunkt Onkologie sich bisher \nhaupts\u00e4chlich darauf konzentriert, die Kommunikation zwischen den Forscher -\ngruppen zu erh\u00f6hen und Plattformen f\u00fcr den wissenschaftlichen Austausch \nanzubieten. Insbesondere werden eint\u00e4gige Symposien veranstaltet, bei denen \nsich die Forscher mit ihren Projekten vorstellen und gemeinsame Interessen \ndiskutiert werden k\u00f6nnen. Desweiteren f\u00fchrt der Schwerpunkt \u2013 auch mit der \ndankenswerten Hilfe einer Reihe von externen Sponsoren \u2013 die \u201cDKBW Schw -\nerpunkt Seminare Onkologie\u201d durch, in denen herausragende Krebsforscher \naus aller Welt ihre Forschungsergebnisse pr\u00e4sentieren. Bisher haben sich aus \ndiesen Aktivit\u00e4ten einige hoffnungsvolle Kollaborationen zwischen den beteil -\nigten Arbeitsgruppen entwickelt, die vor allem \u00fcber Instituts- und Firmengren -\nzen hinweg neuartige Forschungsprojekte und Therapieans\u00e4tze bearbeiten. \nDer Schwerpunkt Onkologie ist in den letzten Jahren nicht zuletzt auch durch \nNeuberufungen in diesem Forschungsgebiet und durch den Neubau des Zen -\ntrums f\u00fcr Biomedizin an der Mattenstrasse gef\u00f6rdert worden. Eine wichtige \nAufgabe der Zukunft wird es nun sein, den Schwerpunkt gezielt durch defini -\nerte Forschungsprogramme weiter zu st\u00e4rken, sei es durch den Austausch von \nForschern zwischen Labor und Klinik, durch die Bereitstellung von Laborraum \nund durch zus\u00e4tzliche Finanzierungshilfen. \nProfessor \nG. Christofori\nInstitut f\u00fcr Biochemie\nund GenetikProfessor \nR. Herrmann\nKlinische Onkologie\nUniversit\u00e4tsspital BaselSymposien\n2002  1st SPO Symposium  13.06.02  Schauenburg\n  2nd SPO Symposium  03.12.02  Castelen\n2003  3rd SPO Symposium  07.05.03  Castelen\n  4th SPO Symposium  10.12.03  Castelen\nSchwerpunkt-Seminare\n2003  19. Juni Wolfhard Semmler, Heidelberg\n  25. September  Gernot Walter, San Diego\n  16. Oktober  Mariano Barbacid, Madrid\n  20. November  Kari Alitalo, Helsinki\n  04. Dezember  Bernd Groner, Frankfurt\n2004  07. Januar  Walter Birchmeier, Berlin\n  22. Januar  Margot Z\u00f6ller, Heidelberg\n  11. Februar  Anton Berns, Amsterdam\n  18. M\u00e4rz  Alan Hall, London\n  31. M\u00e4rz  Curzio R\u00fcegg, Lausanne\n  21. April  Cathrin Brisken, Lausanne78/79\nCastelenGenome Stability\nDNA Damage\nCytosine Deamination\nDNA Repair\nBase Excision Repair\nDouble-Strand Break RepairMaintenance of Genome Stability through \nDNA Surveillance and Repair.\nReactive agents of endogenous and environmental origin pose a constant threat \nto the integrity of our genomic material, the DNA. DNA damage, if it goes unre -\npaired, destabilizes genomes and, thus, increases the risk of cancer. We explore \nbiological processes that enforce genome stability at the level of DNA damage \nresponse and repair. The objective of our work is to provide a clear understand -\ning of both, the molecular mechanisms involved in the repair of DNA base \ndamage and broken DNA backbones, and the biological consequences of their \ndysfunction.\nDNA base excision repair (BER)\nA substantial fraction of p53 mutations found in colon tumors are C \ue0d4T transitions \nin CpG dinucleotides that have likely arisen through spontaneous deamination \nof 5-metyhylcytosine (5-mC). 5-mC deamination produces G \u2022T mispairs that \nmust be repaired to G \u2022C, if C\ue0d4T mutation is to be avoided. Similarly, deamination \nof cytosine generates G \u2022U mispairs that also produce C \ue0d4T transitions, unless \nrepaired. The restoration of G \u2022C pairs is accomplished by the BER pathway. The \nthymine DNA-glycosylase (TDG) was postulated to initiate this BER process by \nhydrolyzing the N-glycosidic bonds of mispaired T or Us in DNA (F ig. 1).\nTowards clarifying the biological role of TDG, we launched a concentrated \nprogram of biochemical and genetic investigation. Systematic analyses of the \nsubstrate spectra of purified yeast, insect and human TDGs revealed that, rather \nthan being specialized for the repair of cytosine deamination products, this \nfamily of DNA glycosylases fights a much wider spectrum of DNA base dam -\nage. Further biochemical work disclosed a role of SUMO (small ubiquitine-re -\nlated modifier)-modification in coordinating the BER process. We observed that \nSUMOylation of human TDG modulates its interaction with AP-sites and, thus, \nprovides a mechanism for the coordinated dissociation of the enzyme from the \nmutagenic repair intermediate. We made use of fission yeast as a genetic pilot \nmodel to address the biological role of TDG. Widespread phenotypic analyses \nSelected Publications \n\u2013 Sch\u00e4r, P ., Herrmann, G., Daly, G. & Lindahl, T. (1997). \nA newly identified DNA ligase of Saccharomyces cer -\nevisiae involved in RAD52-independent repair of DNA \ndouble-strand breaks. Genes Dev. 11, 1912-1924.\n\u2013 Herrmann, G., Lindahl, T. & Sch\u00e4r, P . (1998). Saccha -\nromyces cerevisiae LIF1: a function involved in DNA \ndouble-strand break repair related to mammalian \nXRCC4. EMBO J. 17, 4188-4198.\n\u2013 Valencia, M.*, Bentele, M.*, Vaze, M.B., Herrmann, G., \nKraus, E., Lee, S.E., Sch\u00e4r, P .* & Haber, J*. (2001). NEJ1 \ncontrols non-homologous end joining in Saccharo -\nmyces cerevisiae. Nature 414, 666-669. (*co-first and \ncorresponding authorships).\n\u2013 Hardeland, U., Steinacher, R., Jiricny, J. & Sch\u00e4r, P . \n(2002). Modification of the Human Thymine-DNA \nGlycosylase by Ubiquitin-Like Proteins Facilitates \nEnzymatic Turnover. EMBO J. 21, 1456-1464\n\u2013 Hasan, S., El-Andaloussi, N., Hardeland, U., Hassa, P .O. \nB\u00fcrki, C., Imhof, R., Sch\u00e4r, P . & Hottiger, M.O. (2002) \nAcetylation Regulates the DNA End-Trimming Activity \nof DNA polymerase b. Mol. Cell 10, 1213-1222Die Stabilit\u00e4t des Erbguts \u2013 \u00dcberwachen \nund Reparieren der DNA\nUnsere Erbsubstanz, die DNA, ist konstant sch\u00e4digenden \nFaktoren ausgesetzt. In jeder Zelle werden spontan ver -\nschiedene Arten von DNA Sch\u00e4den generiert. Werden \ndiese nicht durch die zelleigenen Systeme repariert, \nkann es zur genetischen Mutation und damit zu einem \nerh\u00f6hten Krebsrisiko kommen. Wir untersuchen die \nmolekularen Mechanismen der DNA-Reparatur mit \ndem Ziel die biologischen Konsequenzen fehlerhafter \nReparaturmechanismen zu verstehen.\nDie h\u00e4ufigsten DNA Sch\u00e4den betreffen die Purin- und \nPyrimidin Basen. Fehlerhafte Basen werden durch die Ba -\nsen-Exzisionsreparatur (BER) ersetzt. Hierbei schneidet \nzuerst eine DNA Glykosylase die besch\u00e4digte Base aus, \nwodurch eine basenlose Stelle entsteht (abasic site, AP), \nwelche schliesslich \u00fcber mehrere enzymatische Schrit -\nte durch ein intaktes Nucleotid ersetzt wird (Fig. 1). Die \nThymin-DNA-Glykosylase (TDG) prozessiert spezifisch \ndesaminierte Cytosin-Basen in der DNA und verhindert \nsomit C \ue0d4T Transitionsmutationen. C \ue0d4T Mutationen \nsind unter anderem massgeblich an der Inaktivierung \ndes p53 Tumorsuppressorproteins beteiligt. Mittels \nmolekulargenetischer Studien untersuchen wir, inwiefern \nTDG \u2013 vermittelte Exzisionsreparatur zur Genomstabilit\u00e4t \nbeitr\u00e4gt und die Bildung von Tumoren unterdr\u00fcckt. Die \nEntdeckung, dass die Funktion der TDG \u00fcber SUMO \u2013 \nModifikation moduliert und koordiniert wird bescherte \nuns neue Erkenntnisse \u00fcber den Prozess der BER. Das \nStudium von Koordinationsmechanismen der DNA Repa -\nratur ist von grosser Bedeutung, weil eine unkoordinierte \nAnh\u00e4ufung mutagener Reparaturzwischenprodukte er -\nheblich zur Instabilit\u00e4t unsrer Genome beitr\u00e4gt.\nDoppelstrangbr\u00fcche der DNA sind weitere, sehr ernst-\nhafte Sch\u00e4den. Diese entstehen meist w\u00e4hrend der nor-\nmalen DNA-Replikation oder bei Zelldifferenzierungs-\nvorg\u00e4ngen. Die Reparatur von Doppelstrangbr\u00fcchen \nkann entweder \u00fcber homologe Rekombination (HR) \noder \u00fcber nicht-homologe End-zu-End Verbindung \n(NHEJ) repariert werden (Fig. 2). Wir untersuchen mit \nverschiedenen Modellen die NHEJ und interessieren uns \ninsbesondere f\u00fcr die Komponenten der Regulation und \nKoordination dieser Reparaturvorg\u00e4nge.Molecular \nGenetics\nProf. Dr. Primo Sch\u00e4r\nInstitut f\u00fcr Biochemie und Genetik\nGroup members\nDr. Christophe Kunz\nDr. Yusuke Saito\nDr. Roland Steinacher\nBarbara Grubeski (technician)\nDaniel Cortazar (PhD student)\nFrauke Focke (PhD student)\nSanja Kais (PhD student)\nMarcel Locher (Diploma student)\nof disruption mutants established that TDG and the functionally related uracil \nDNA glycosylase share the task of eliminating uracil from DNA and contrib -\nute significantly to the cellular response to 5-fluorouracil induced DNA dam -\nage. These studies also showed that BER of DNA base damage accounts for \na substantial fraction of gross genomic instability. Work on mouse knockout \nmodels led to the finding that TDG is essential for embryonic development, \nan unexpected turn that warrants intense investigation.\nCoordination of DNA double strand-break repair DSBR\nDNA double-strand breaks (DSBs) represent the most severe form of DNA \ndamage. Most frequently, they occur as a consequence of the DNA transac -\ntions involved in cell proliferation and differentiation. Eukaryotic cells utilize \ntwo distinct modes of DSBR \u2013 homologous recombination (HR) and non-ho -\nmologous-end-joining (NHEJ), both of which are critical for genome stability \nand suppression of tumor development (Fig. 2).\nWe have been studying NHEJ in a yeast model with a particular interest \nin exploring regulatory components of DSBR. This led to the discovery of \nNej1p and Nej2p that interact physically with Lif1p, an orthologue of human \nXRCC4. Lif1p also interacts with Dnl4p to constitute the DNA ligase complex \nrequired for NHEJ. Nej1p turned out to be an essential component of the \nNHEJ system, acting as key regulator of cell-type specific NHEJ activity in \nyeast. Nej2p is highly conserved from yeast to human and appears to have a \nnegative regulatory role in NHEJ.\nFig. 1:  The BER pathway \nfixes DNA base damage. \nFirst, a DNA glycosylase \nbinds and releases the \ndamaged base. \nThe resulting AP-site is \nthen excised and replaced \nwith the original nucle -\notide by the concerted \nactions of AP-endonucle -\nase, DNA polymerase and \nDNA ligase activities.Fig. 2:  Eukaryotic cells repair broken chromosomes by either of two pathways. HR is \nnon-mutagenic and uses a homologous, undamaged partner molecule as a template \nfor repair synthesis. The NHEJ pathway joins broken DNA ends in the absence of a \nhomologous partner. This process may involve some DNA end-trimming and is there -\nfore mutagenic. Defects in both pathways have been associated with cancer prone \nhuman disease.\n80/81Angiogenesis\nInvasion\nLymphangiogenesis\nMetastasis\nMigration\nTumorigenesis Tumor Angiogenesis, Lymphangiogenesis \nand Metastasis\nThe major objective of our research is the identification and characterization of \nmolecular events involved in late stage tumorigenesis. In particular, we focus \non the contribution of tumor angiogenesis and lymphangiogenesis to tumor \nprogression and on the molecular mechanisms underlying the transition from \nbenign neoplasia to malignant cancers and the metastatic dissemination of tumor \ncells. In addition to tumor cell lines in vitro, we employ transgenic mouse models \nof tumorigenesis to determine causal connections between the expression of a \nparticular gene and tumor progression in vivo. \nThe development of malignant tumors is in part characterized by a tumor cell\u2019s \ncapability to overcome cell-cell adhesion and to invade surrounding tissue. E-\ncadherin is the main adhesion molecule of epithelia, and it has been implicated \nin carcinogenesis, because it is frequently lost in human epithelial cancers. Us -\ning transgenic complementation experiments in a transgenic mouse model of \npancreatic cell carcinogenesis (Rip1Tag2), we have shown that the loss of E-\ncadherin-mediated cell-cell adhesion is causally involved in the transition from \nwell-differentiated adenoma to invasive carcinoma. Currently, we are investigat -\ning the signal transduction pathways that are activated by the loss of E-cadherin \nfunction and that induce tumor cell migration and invasion.\nDuring the development of many human cancers, expression of another cell-cell \nadhesion molecule, NCAM (Neural Cell Adhesion Molecule), is downregulated \nand, recently, we have demonstrated that in Rip1Tag2 transgenic mice the loss \nof NCAM function results in the formation of lymph node metastasis. NCAM \nis able to modulate integrin-mediated cell-matrix adhesion by binding and ac -\ntivating fibroblast growth factor receptors. The data suggest that abrogation of \nNCAM function results in the loss of signals that are required for the activation \nand maintenance of cell-matrix adhesion, thereby modulating the metastatic dis -\nsemination of tumor cells. Notably, the loss of NCAM function also correlates \nwith upregulated expression of the vascular endothelial growth factor C (VEGF-\nC), which is a lymphangiogenic factor, and with a dramatic increase in lymphatic \nvessel density. Interfering with VEGF-C function by adenoviral expression of a \nsoluble form of VEGF receptor 3, the cognate receptor for VEGF-C, resulted in \nthe repression of lymphangiogenesis and in a reduction of lymph node metas -\ntasis. Conversely, transgenic expression of VEGF-C during Rip1Tag2 tumorigen -\nesis induced lymphangiogenesis and the formation of lymph node metastasis, \ndemonstrating that upregulated expression of VEGF-C is causally involved in \nlymph node metastasis.\nPrevious work in our laboratory has indicated that, besides VEGF, members of \nthe fibroblast growth factor (FGF) family are involved in the onset and mainte -\nnance of tumor angiogenesis. Recently, an antagonist of FGF function has been \nidentified in Drosophila development, named Sprouty. Subsequently, we have \nisolated cDNAs encoding four different mouse Sprouty proteins and investigat -\nFig. 1  In Rip1Tag2 transgenic mice, loss of E-cadherin-mediated cell-cell adhesion \nis causally involved in the transition from adenoma to carcinoma. In contrast, loss of \nNCAM cell adhesion is a rate-limiting event in the actual metastatic dissemination of \ntumor cells.Selected Publications \n\u2013 Cavallaro, U., Niedermeyer, J., Fuxa, M., and Christo -\nfori, G. (2001) N-CAM modulates integrin-mediated \ncell adhesion by activating FGF receptor signalling. \nNature Cell Biol. 3, 650-657.\n\u2013 Gannon, G., Mandriota, S., Pepper, M., and Christo -\nfori, G. (2002) Overexpression of human VEGF-A165 \nresults in accelerated tumor angiogenesis but not me -\ntastasis during transgenic cell carcinogenesis. Cancer \nResearch 62, 603-608.\n\u2013 Christofori, G. (2003) Changing neighbors, changing \nbehavior: cell adhesion molecule-mediated signalling \nduring tumor progression. EMBO J. 22, 2318-2323.\n\u2013 Orend, G., Huang, W., Olayioye, M.A., Hynes, \nN.E., and Chiquet-Ehrismann, R. (2003) Tenascin-C \nblocks cell-cycle progression of anchorage-depend -\nent fibroblasts on fibronectin through inhibition of \nsyndecan-4. Oncogene 22, 3917-3926.Signaling by Tenascin-C \nin Tumorigenesis\nThe high expression levels of the adhesion-modulatory ex -\ntracellular matrix molecule tenascin-C in stroma of breast \ncancer and glioma inversely correlates with patient survival. \nPotential mechanisms for a tumorigenesis supporting effect \nof tenascin-C involve stimulation of tumor cell proliferation, \npromoting angiogenesis and suppression of the immune \nsystem. A major focus of the laboratory is the identification \nof tenascin-C-specific signal transduction pathways and \ntheir link to enhanced tumor cell proliferation. We identi -\nfied syndecan-4, tropomyosin-1, and MAP kinase and Wnt \nsignaling pathways as targets of tenascin-C and will address \nthe effect of tenascin-C on these molecules and pathways \nin more detail. The in vivo function of tenascin-C is cur -\nrently being investigated by its overexpression in transgenic \nmouse models of carcinogenesis.Dr. Gertraud Orend\nInstitut f\u00fcr Biochemie \nund Genetik\nGroup members\nDr. Wentua Huang \nErika Fluri (technician)\nKatrin Lange \n(PhD student)Fig. 2  Expression of the lymphangiogenic factor VEGF-C during cell tumorigenesis \nin Rip1Tag2 transgenic mice results in upregulated lymphangiogenesis in developing \ntumors. In these mice, circulating clusters of tumor cells are detected within lymphatic \nvessels (left panel), subsequently leading to the formation of lymph node metastasis \n(right panel). ed their role in the regulation of angiogenesis. We have found that Sproutys \ninhibit FGF- and VEGF-induced endothelial cell proliferation and differentia -\ntion by repressing the activation of mitogen-activated protein kinase (MAPK) \npathway. Sproutys are anchored to membranes by palmitoylation and them -\nselves are also a target of the MAPK signaling cascade, for example by regu -\nlation of their subcellular localization and by phosphorylation. Currently, we \nare investigating the mechanism by which Sproutys intersect tyrosine kinase Gef\u00e4ssbildung, Zell-Zell- und Zell-Matrix-\nInteraktion bei Krebs und Metastasen\nDie Entwicklung eines b\u00f6sartigen Karzinoms h\u00e4ngt weit -\ngehend von der zellul\u00e4ren Umgebung des Geschwulstes \nab. Bei der Entwicklung eines metastasierenden Tumors \nist sowohl die Bildung neuer Blut- und Lymphgef\u00e4sse, als \nauch der Verlust der Adh\u00e4sion zwischen den Zellen und \nder Adh\u00e4sion der Zellen zu ihrer Umgebung (Matrix) \nbeteiligt. Diese Prozesse sichern die Versorgung des Tu -\nmors mit Nahrung und Sauerstoff, erm\u00f6glichen dessen \nWachstum und erlauben das Losl\u00f6sen von Krebszellen \nund ihre Invasion in das Nachbargewebe. Durch die \nneuen Gef\u00e4sse k\u00f6nnen diese Krebszellen nun auch \nentferntere Gewebe erreichen und Metastasen bilden. \nMit Hilfe von Zellkulturen und transgenen Maus-Mo -\ndellen untersuchen wir die molekularen Mechanismen \nder Angiogenese und Lymphangiogenese (Blut- und \nLymphgef\u00e4ssbildung) w\u00e4hren der Tumorentwicklung \nund w\u00e4hrend der Bildung von Metastasen. \nIn zahlreichen menschlichen Tumorkrankheiten zeigt \nsich der Verlust der Funktion von zwei \u00abAnkermole -\nk\u00fclen\u00bb, E-cadherin und NCAM. Untersuchungen mit \nM\u00e4usen welche spontane Pankreaskrebs ausbilden, \nzeigen, dass der Verlust von E-cadherin Krebszellen \nvom Tumor l\u00f6st. Der Verlust von NCAM l\u00f6st zus\u00e4tzlich, \ndurch eine indirekte Wirkung auf andere Molek\u00fcle, die \nZellen von der Matrix ab (Abbildung 1). Somit ist der \nVerlust von NCAM einer der limitierenden Faktoren f\u00fcr \ndie Bildung von Metastasen. Weiter induziert der Verlust \nvon NCAM die Bildung von Wachstumsfaktoren welche \ndie Lymphangiogenese f\u00f6rdern.\nUnsere Partnergruppe befasst sich mit der Funktion \neines Molek\u00fcls der Matrix, Tenascin-C. Tenascin-C \nbeeinflusst sowohl die Haftung von Krebszellen an ihre \nUmgebung als auch die Geschwindigkeit des Tumor -\nwachstums. Tenascin-C spielt vor allem in Gehirn- und \nBrusttumoren, sowohl bei der Zellteilung als auch bei \nder Angiogenese und in der Unterdr\u00fcckung des Immun-\nsystems eine entscheidende Rolle. Je h\u00f6her die Tenas -\ncin-C Expression, desto geringer die Lebenserwartung \nder Patienten.\nWhereas glioblastoma cells spread \non fibronectin with actin stress fib -\ners formed, they remain round in \nthe presence of tenascin-C. Cell \nspreading is restored upon activation \nof syndecan-4 and tropomyosin-1, \nrespectively.\nTumor Biology\nProf. Dr. Gerhard Christofori\nInstitut f\u00fcr Biochemie und Genetik\nGroup Members\nDr. Fritz Brawand \nDr. Miguel Cabrita \nDr. Ugo Cavallaro \nDr. Fran\u00e7ois Lehembre \nDr. Malte Lewerenz \nHelena Antoniadis (technician)\nBeat Hostettler (technician)\nRoland Jost (technician)\nKarin Strittmatter (technician)\nUrsula Schmieder (technician)\nLucie Kopfstein (MD-PhD student)\nIvana Crnic (PhD student)\nStefan Grotegut (PhD student)\nFabienne J\u00e4ggi (PhD student)\nAngelika Kren (PhD student)\nBirgit Schaffhauser (PhD student)\nMahmut Yilmaz (PhD student)\nSandra Widjaja (MD student)\nChristoph Caviezel (MD student)\nChristoph Wunderlin (Diploma student)\nIntravascular Tumor Cell Lymph Node Metastasis\n82/83Familial cancer\nHereditary colorectal cancer\nGenomic instability\nCancer prevention\nPresymptomatic genetic testingPrevention of Colorectal Cancer through \nGenetics\nSince 1979 the activities of the research group Human Genetics have focused on \nthe identification and characterization of predispositions leading to cancer with \nthe goal of providing the most reliable genetic counseling and most effective \nmedical care to affected patients and their relatives. Originally, several types of \nfamilial tumors, e.g. breast cancer and melanomas were included in these stud -\nies. During the recent years special attention has been given to genetic traits \nassociated with a high risk of developing colorectal cancer (CRC) and other \nassociated malignancies. Hereditary colorectal cancers are among the most suit -\nable in vivo models for the study of the role of the underlying predispositions on \nthe initiation and progression of carcinogenesis (adenoma-carcinoma sequence; \nwell characterized histopathological changes related to a temporal order of sev -\neral genetic events) as well as of the influence of proven and putative modifiers \non this process. Germ line mutations of the APC-gene are found in the majority \nof patients with familial adenomatous polyposis coli (FAP). Their cancers exhibit \nchromosomal instability (CIN) characterized by bizarrely abnormal karyotypes \nwhereas cancers caused by germ line loss of function mutations of DNA mis -\nmatch repair (MMR)- genes are characterized by the phenomenon of microsat -\nellite instability (MSI or MIN). Germ line mutations with the base-excision repair \ngene MYH lead to the formation of multiple adenomas and cancer. Different \ntypes of genomic instability disorders have, therefore, the common feature of \nbeing able to increase the rate of progression along the path to CRC. The insta -\nbility status of cancer cells offers new options for prediction of the outcome of \ntherapy and the delineation of innovative therapeutic and preventive measures.\nOur current main research projects concentrate on:\n\u2013 Improvement of the individual risk assessment in familial adenomatous poly -\nposis and in hereditary nonpolyposis colorectal cancer (HNPCC) as well as in \nhamartomatous polyposis syndromes by determining the genetic events oc -\ncurring in the tumour cells.\n\u2013 Identification of novel genetic pathways and genes predisposing to hereditary \ncolon cancer\nSelected Publications \n\u2013 M\u00fcller, Hj., Scott, R.J., Weber, W. Hereditary Cancer. \n(1996)\n\u2013 M\u00fcller, Hj., Heinimann, K. (2003) Hereditary color -\nectal cancer: From bedside to bench and back. \nAdvances in Colon Cancer 7, 11-14.\n\u2013 Sieber, OM., Lamlum, H., Crabtree, MD., Rowan, AJ., \nBarclay, E., Lipton, L., Hodgson, S., Thomas, HJW., \nNeale, K., Phillips, RKS., Farrington, SM., Dunlop, \nMG., M\u00fcller, Hj., Bisgaard, ML., Bulow, S., Fidalgo, P ., \nAlbuquerque, C., Scarano, MI., Bodmer, W., Tomlin -\nson, IP ., Heinimann, K. (2002) Whole-gene APC dele -\ntions cause classical familial adenomatous polyposis, \nbut not attenuated polyposis or \u201cmultiple\u201d colorectal \nadenomas. Proc Natl Acad Sci USA 99, 2954-2958.\n\u2013 Sieber, OM., Heinimann, K., Tomlinson, IP . (2003) \nGenomic instability \u2013 the engine of tumorigenesis? \nNat Rev Cancer 3, 701-708\n\u2013 Plasilova, M., Russell, AM., Wanner, A., Wolf, A., \nDobbie, Z., M\u00fcller, Hj., Heinimann, K. (2004) Ex -\nclusion fo an extracolonic disease modifier locus \non chromosome 1p33-36 in a large Swiss familial \nadenomatous polyposis kindred. European Journal \nof Human Genetics 12, 365-371.Clinics\nFive to ten percent of all colorectal cancers (CRCs) can be attributed to an ascertainable \ncancer predisposition, which can be subdivided into those that are related to a preexist -\ning polyposis, either adenomatous or hamartomatous in nature and those that are not. \nSuch inherited susceptibilities should be suspected if a patient is young and/or presents \nwith synchronous or metachronous tumours or polyps with characteristic histological \nfeatures. A strong family history of CRC and associated neoplasms also suggests a pre -\ndisposition. However, a predisposition can also occur because of a de novo mutation \naffecting only one family member or can be inherited in an autosomal-recessive fashion \nsuch as MYH-mutations.\nMutated genes predisposing to CRCs exhibit considerable variation in penetrance and \nexpressivity. This can create serious difficulties when an individual mutation carrier \nseeks medical help. It is often not possible to predict the occurrence of cancer in the \ncolon and other organs at risk and to suggest the best kind of preventive measures and \ntherapy, including heroic measures such as colectomy. Modifying factors, genetic and \nenvironmental in nature, that might influence the clinical consequences of a particular \nmonogenic predisposition have yet to been defined.\nMorbidity and mortality from hereditary CRCs can be considerably reduced by regu -\nlar screening of the organs at risk and early treatment, mainly removal of developing \ntumours. Genomic instability could be a promissing target for new chemopreventive \nactions.\nMany familial CRCs cannot be attributed to the already known predisposing genes. This \ncauses frustration and uncertainty among patients, their relatives, and the responsible \nphysicians. Further research is needed to clarify the genetic mechanisms responsible \nfor a majority of familial CRCs.Forschungsgruppen Humangenetik\n5% \u2013 10% aller Tumorkrankheiten entstehen auf dem \nBoden einer durchschlagskr\u00e4ftigen Veranlagung. Die \nForschungsgruppe Humangenetik versucht seit 1979, \nsolche zu erfassen und zu charakterisieren. Heute ist \nihr erkl\u00e4rtes Ziel, Risikopersonen f\u00fcr gastrointestinale \nTumoren, speziell solche f\u00fcr Kolorektalkarzinome \n(KRK), zuverl\u00e4ssig identifizieren und dann im Hinblick \nauf Pr\u00e4ventionsm\u00f6glichkeiten individuell beraten zu \nk\u00f6nnen, stehen dabei doch heroische Massnahmen, \nwie die Entfernung des gesamten gef\u00e4hrdeten Organs, \nalso die totale Kolektomie zu Diskussion. Vorerst wird \nbei Patienten aus Familien, in denen KRK und assoziiert \nauftretende Neubildungen geh\u00e4uft auftreten, respektive \ndiese sich in ungew\u00f6hnlich fr\u00fchem Alter und eventuell \nsogar mehrfach manifestieren, nach Keimbahnmu -\ntationen in bereits bekannten Krebsgenen gesucht. \nLassen sich solche nicht entdecken, geht es darum, \nnoch unbekannte Gene zu finden, deren Mutationen \nentsprechende Krebsveranlagungen darstellen k\u00f6nnen. \nGrosse Familien, in denen ein bekanntes \u201cKrebsgen\u201d \nweitervererbt wird, dienen dazu, die modifikatorischen \ngenetischen und anderen Einfl\u00fcsse zu erfassen, die das \nAusbrechen eines Tumors im Gastrointestinaltrakt beein -\nflussen. Heredit\u00e4re Tumorkrankheiten erweisen sich als \nvon der Natur gegebene Modelle, um die Mechanismen \nder Karzinogenese beim Menschen zu studieren. Aus \nden dabei gewonnenen Erkenntnissen lassen sich in -\nnovative M\u00f6glichkeiten der Vorbeugung, speziell der \nChemopr\u00e4vention ableiten.Human \nGenetics\nProf. Dr. Hansjakob M\u00fcller\nAbteilung Medizinische Genetik \nUKBB / Departement Forschung\nUniversit\u00e4tsspital Basel\nGroup members\nProf. Walter Weber (external collaborator)\nDr. Ursula Albert \nDr. Nicole B\u00fcrki (external collaborator)\nDr. Karl Heinimann \nDr. Martina Plasilova \nMarianne H\u00e4usler (family study professional)\nMich\u00e8le Attenhofer (technician)\nSibylle Bertschin Woodtli (technician)\nCarole Egenter (technician)\nThomas Woodtli (technician)\nJudith Luz (PhD-student)\nJian Zhang (PhD-student)\nThe \u201ctreasure chest\u201d which provides the basis for these research activities \nis our cancer family registry which currently contains more than 300 well \ndocumented kindreds with hereditary colorectal cancer syndromes originat -\ning from all parts of Switzerland. Tumor samples were/are collected from af -\nfected family members with identified and yet unknown gene mutations.84/85AU-rich element\nmRNA decay\nCytokines\nAU-binding protein\nEmbryonal stem cellsmRNA Turnover and Oncogenesis\nSynthesis, turnover and consequently the steady-state levels of mRNA are fre -\nquently perturbed in cancer cells. The malignant phenotype of a cell is due to \na large part to over-expression of a set of genes collectively called oncogenes. \nWhile over-expression of these genes results mainly from increased transcrip -\ntion, the rate of mRNA turnover is another important parameter in setting the \nexpression level of many genes related to growth control.\nOur interest in mRNA turnover derived from the original observation that ex -\nperimental mast cell tumors induced by the viral ras oncogene carried a defect in \ndegrading the mRNA encoding interleukin-3 (IL-3), thus accumulating increased \nlevels of IL-3 transcripts and protein leading to the establishment of autocrine \ngrowth and oncogenesis. The observation that the stable IL-3 mRNA could \nbe destabilized by cyclosporinA, an inhibitor of the phosphatase calcineurin, \nprovided an early indication that mRNA turnover is regulated by kinases and \nphosphatases through intra-cellular signalling networks. The intrinsic rapid \ndecay of IL-3 mRNA is due to the presence in the 3\u2019UTR of a so-called AU-rich \nelement (ARE), a stretch of about 50 nucleotides containing several AUUUA \npentamers. In TNFa, another cytokine of importance in the defense against \ntumors and microorganisms, we discovered a second element that we have \ntermed the CDE (Constitutive Decay Element) as it promotes TNFa mRNA decay \nindependently of the ARE. The ARE is present in the 3\u2019UTRs of many growth \nfactors, oncogenes, cell-cycle genes and other regulators of growth. When cells \nare physiologically activated by exogenous signals or become transformed into \ncancer cells, signaling pathways antagonize the rapid mRNA decay driven by the \nARE resulting in mRNA stability and over-expression of the respective proteins. \nWe have identified three signaling pathways, which upon activation stabilize \nmRNA: the c-jun N-terminal kinase pathway, the p38 MAP kinase pathway \nand the PI3-kinase/PKB pathway. Key to understanding how mRNA turnover \nis regulated is identification of the proteins binding the ARE and their expected \nrole as phosphorylation targets of signaling pathways. Using a functional genetic \nscreen, we have recently identified and cloned a gene called BRF1 that promotes \nthe degradation of ARE-containing mRNA. \nOur current work focuses on BRF1. Unpublished data show that phosphoryla -\ntion at a specific serine residue of BRF1 inhibits BRF1 decay promoting activity \nand stabilizes mRNA. Phosphorylation occurs in response to insulin stimulation \nand is catalyzed by protein kinase B. Our current model (Fig. 1) postulates that \nthe viral ras oncogene stabilizes ARE-mRNA via the PI3-kinase/PKB pathway, \nwhich leads (among other effects) to phosphorylation of BRF1 at a specific \nserine, thus inhibiting the basal decay promoting function of this protein. Our \nrecent work suggests that the regulation of ARE-mRNA decay by BRF1 is not \nonly important in cell activation and oncogenesis, but also in the differentiation \nof embryonal stem cells. In these, induction of differentiation led to rapid down-\nregulation of BRF1, and down-regulation of BRF1 by siRNA was conversely able \nto trigger morphological changes typical for ES-cell differentiation (unpublished \nobservation). This indicates that the decision between cycling and differentia -\ntion of embryonal stem cells may be co-regulated by BRF1 and suggests that this \nmodel may provide a clue to studying \u201cdifferentiation therapy\u201d of cancer cells. \nWe have also established a screening system for regulators of ARE-dependent \nmRNA turnover.Selected Publications \n\u2013 Nair, A. P . K., Hahn, S., Banholzer, R., Hirsch, H. H., \nand Moroni, C. (1994). Cyclosporin A inhibits growth \nof autocrine tumour cell lines by destabilizing inter -\nleukin-3 mRNA. Nature 369, 239-42.\n\u2013 Stoecklin, G., Lu, M., Rattenbacher, B., and Moroni, C. \n(2003). A constitutive decay element (CDE) promotes \nTNFAlpha mRNA degradation via an ARE-independent \npathway. Mol. Cell Biol. 23, 10:3506-15.\n\u2013 Ming, X.-F ., Looser, R., Stoecklin, G., and Moroni, C. \n(1999). Differential regulation of AUUUA-mediated \nmRNA turnover by the p38 MAPK and PI3-K path -\nways. EMBO J. 17, 6039-48.\n\u2013 Ming, X. F ., Stoecklin, G., Lu, M., Looser, R., and \nMoroni, C. (2001). Parallel and independent regulation \nof interleukin-3 mRNA turnover by phosphatidylinosi -\ntol 3-kinase and p38 mitogen-activated protein kinase. \nMol. Cell Biol. 21, 5778-89.\n\u2013 Stoecklin, G., Colombi, M., Raineri, I., Leuenberger, \nS., Mallaun, M., Schmidlin, M., Gross, B., Lu, M., \nKitamura, T., and Moroni, C. (2002). Functional clon -\ning of BRF1, a regulator of ARE-dependent mRNA \nturnover. EMBO J. 21, 4709-18.\n\u2013 Schmidlin, M., Lu, M., Leuenberger S.A., Stoecklin, \nG., Mallaun, M., Gross, B., Gherzi, R., Hess, D., \nHemmings, B.A., and Moroni, C. (2004) The ARE-de -\npendent mRNA destabilizing activity of BRF1 is regu -\nlated by protein kinase B. EMBO J, 2004, in pressFig. 2:  Protein Kinase B (PKB) controls a membrane-activated, pleiotropic signalling \npathway that affects \u2013 via several key proteins \u2013 multiple processes including cell \ncycle, growth, translation, metabolism and apoptosis. The novel finding that BRF1 is a \ntarget of PKB and that BRF1 phosphorylation leads to stability of ARE-containing tran -\nscripts links mRNA turnover to the pleiotropic PKB response. As the PKB pathway is \nfrequently mutated in cancer cells, tumor cells are likely to have alterations in mRNA \nturnover rates.RNA Stabilit\u00e4t und Krebs\nEine massiv erh\u00f6hte Menge einzelner kritischer Proteine \nliegt dem Ph\u00e4nomen Krebs zugrunde. Da Molek\u00fcle so -\nwohl synthetisiert wie auch dynamisch wieder abgebaut \nwerden, kann eine \u00dcberproduktion eines Proteins zwei \nGr\u00fcnde haben: erh\u00f6hte Syntheserate oder verminderte \nAbbaurate. Unser Interesse in der Abbaurate von Gen-\nkopien (mRNA) und damit von Proteinen kam von unse -\nrer Beobachtung, dass sich in Tumorzellen der Maus ein \nDefekt im Abbau von Interleukin-3 mRNA fand. Dieser \nAbbaudefekt konnte durch das Medikament Cyclo-\nsporinA korrigiert werden. Der Abbau selbst ist durch ein \nkurzes genetisches Element gesteuert, das sogenannte \nARE (AU-rich element). Unsere Arbeiten zeigten, dass der \nARE-gesteuerte Abbau von mRNA durch zwei gegenl\u00e4ufi -\nge Enzymsysteme gesteuert wird: durch Phosphokinasen \n(Enzyme, die Phosphatgruppen an Proteine binden), sie \nf\u00fchren zur Stabilisierung und damit Ueberproduktion von \nmRNA, und von Phosphatasen, die Proteine die Phosphat -\ngruppen abspalten. Das Verst\u00e4ndnis dieser Mechanismen \nerfordert Wissen \u00fcber die Proteine, die das ARE binden. \nWir klonierten ein entsprechendes Gen (BRF1), und \nkonnten zeigen, dass durch seine Phosphorylierung an \neiner bestimmten Aminos\u00e4ure die mRNA Abbauaktivit\u00e4t \nvon BRF1 beeinflusst wird. Wenn eine Zelle von aussen \ndurch ein Signal, zum Beispiel ein Hormon, beeinflusst \nwird, kann sich der Phosphorylierungszustand von BRF1 \nver\u00e4ndern, und damit \u00e4nderte sich die Abbaurate von \nARE-haltigen mRNA Molek\u00fclen. Dies ist ein neuartiger \nModus der Zellregulation und k\u00f6nnte in Krebszellen \ndazu f\u00fchren, dass unerw\u00fcnschte Produkte akkumulieren. \nJ\u00fcngste Daten zeigten, dass embryonale Stammzellen, \nwenn sie zur Differenzierung angeregt werden, die \nMenge an BRF1 drastisch reduzieren. Wir vermuten, dass \ndamit spezifische ARE-mRNA gezielt angereichert wird, \nund dass BRF1 in der Entscheidung von Stammzellen, sich \nzu differenzieren oder nicht, eine Rolle spielt. Experimental\nOncology\nProf. Dr. Christoph Moroni\nInstitut f\u00fcr Medizinische Mikrobiologie \nGroup members\nDr. Don Benjamin \nDr. Tobias Herzig \nDr. Ines Raineri\nMarco Colombi (technician)\nBrigitte Gross (technician)\nMin Ji-Lu, (technician)\nSabrina Leuenberger (PhD student)\nBernd Rattenbacher (PhD student)\nMartin Schmidlin (PhD student)\nDaniel Wegm\u00fcller (PhD student)\nKarin Kieser (diploma student)\nClelia Sasselli (diploma student)\nFig. 1:  ARE-containing mRNA is targeted by BRF1 to exosomal nucleases. \nCell surface receptor activation, via ras, leads to PKB activation and phosphorylation \nof BRF1, which inactivates this protein, presumably by binding to the 14-3-3 protein, \nresulting in increased mRNA levels.\n86/87Tumor immunology\nImmunotherapy\nTumor antigens\nVaccination\nCytotoxic T lymphocytesCancer Immunotherapy Between Laboratory \nand Bedside\nThe working hypothesis of our group is that, upon vaccination, the immune \nsystem might be able to react against antigens expressed in cancer cells. In \nparticular, the generation of specific cytotoxic T lymphocytes (CTL) might sig -\nnificantly impact the clinical course of discrete tumors. A few years ago only, \nthis hypothesis appeared to be highly speculative. However, in the past decade \nmany tumor associated antigens (TAA) were identified and a series of clinical \ntrials based were performed, with encouraging results.\nWe focused on (i) the clinical relevance of human TAA expression; on (ii) pre -\nclinical investigation of adjuvants and antigen formulations suitable for the im -\nmunization of cancer patients and on (iii) clinical active specifi c immunotherapy.\nCharacterization of the clinical relevance of human TAA expression\nWe generated monoclonal antibodies recognizing cancer/testis TAA (C/T TAA) \nalso in paraffin embedded clinical specimens. They were successfully used to ad -\ndress C/T TAA expression in large series of patients (for a review: Juretic et al., \n2003) (fig. 1). By using tumor microarrays, in collaboration with the Institute of Pa -\nthology of the University of Basel, we showed that in tumors of as high epidemio -\nlogical relevance as bladder and lung cancers, C/T TAA expression is associated \nwith a more severe prognosis as compared to negative cases (Kocher et al., 2002; \nBolli et al., 2002). These data suggest that, in patients bearing these tumors, spe -\ncific immunization procedures could be applied early during the clinical course of \nthe disease, in stages not (yet) characterized by high neoplastic cell burdens.\nPreclinical investigations on adjuvants and antigen formulations suit -\nable for cancer patients immunization.\nSynthetic class I restricted epitopes can be degraded by soluble peptidases in \nthe plasma. Less explored is the role of cell associated peptidases. We used \ngp100 280-288 TAA epitope as a model to investigate degradation by cell asso -\nciated enzymes. First, we showed that, in the presence of U937 monocytoid cell \nline but in the absence of sera, gp100 280-288 peptide is rapidly digested, with \na <5 minutes half-life by cell associated amino- and carboxy-peptidases (Albo \net al., 2003). We extended our research to enzymes associated to fibroblasts, a \nmajor cellular component of the dermis where immunogenic peptides are usu -\nally injected. In the absence of serum, gp100 280-288 peptide was found to be \ndigested by fibroblast associated peptidases to a half life of about four minutes \n(Albo et al., 2004). These data indicate that synthetic class I restricted epitopes \nare characterized by extremely short lasting bio-availability, likely to severely \njeopardize their immunogenic capacity.\nWe also explored the possibility to use adjuvants to complement our vaccinia \nvirus based immunization procedures (fig. 2). Notably, adjuvants licensed for \nhuman use only include alum salts and virosomes (Gluck and Metcalfe, 2003). \nWhile the former do not to support CTL induction, we showed that the latter \nprovide effective adjuvancy to the generation of CTL specific for HLA class I \nrestricted epitopes \u201cin vitro\u201d (Schumacher et al., 2004). Selected Publications \n\u2013 Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, \nPadovan E, Adamina M, Schumacher R, Harder F, \nHeberer M, Spagnoli GC. (2002) Rapid induction of \ncytotoxic T -lymphocytes against melanoma associated \nantigens by a recombinant vaccinia virus vector ex -\npressing immunodominant epitopes and costimulatory \nmolecules \u201cin vivo\u201d. Hum Gene Ther, 13: 569-575.\n\u2013 Bolli M, Kocher T, Adamina M, Guller U, Dalquen P . \nHaas P . Mirlacher M, Gambazzi F, Harder F, Heberer \nM, Sauter G, Spagnoli GC. (2002) Tissue microarray \nevaluation of MAGE tumor associated antigens ex -\npression: potential indications for specific immuno -\ntherapy and prognostic relevance in squamous cell \nlung carcinoma. Ann Surg, 236:785-793.\n\u2013 Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic \nB. (2003) Cancer/testis tumour associated antigens: \nimmunohistochemical detection with monoclonal \nantibodies. The Lancet Oncology, 4:104-109. \n\u2013 Zajac P, Oertli D, Marti W, Adamina M, Bolli M, \nGueller U, Noppen C, Padovan E, Schultz-Thater E, \nHeberer M, Spagnoli G (2003) Phase I/II clinical trial \nof a non replicative vaccinia virus expressing multiple \nHLA-A0201 restricted tumor associated epitopes \nand costimulatory molecules in metastatic melanoma \npatients. Hum Gene Ther, 14:1497-1510.Immuntherapie gegen Krebs: \nZwischen Labor und Klinik\nUnsere Arbeitshypothese besagt, dass das Immunsystem \ndes Menschen nach einer entsprechenden Impfung ge -\ngen gewisse Marker (Antigene) von Krebszellen reagie -\nren kann. Viele tumor-assoziierte Antigene (TAA) wurden \nidentifiziert, eine Reihe von klinischen Impfstudien mit \nermutigenden Resultaten durchgef\u00fchrt. Unsere Arbeit \ngliedert sich in drei Teile:\n1. Klinische Relevanz der menschlichen TAA\nMit Hilfe eines eigens hergestellten Erkennungsproteins \n(monoklonaler Antik\u00f6rper) konnten wir verschiedene \nKrebsarten auf TAA untersuchen. Tumoren der Harn -\nblase und Lunge, die diese TAA exprimierten, waren \nmit einer deutlich schlechteren Prognose assoziiert. \nDies suggeriert eine Impftherapie im fr\u00fchen Verlauf \nder Erkrankung.\n2. Antigenformulierungen/Hilfsmittel (sog. Adjuvantien)\nHauptproblem von synthetischen TAA ist deren geringe \nBioverf\u00fcgbarkeit aufgrund rascher Degradierung. Als \nkompetentes Adjuvans haben wir rekonstruierte H\u00fcllen \ndes Grippevirus (Influenza-Virosomen) untersucht. \n3. Aktive spezifische Immuntherapie bei Patienten mit \nmalignem Melanom\nMit einem gentechnisch hergestellten, inaktivierten \nVacciniavirus, das 3 TAA und kostimulatorische Molek\u00fcle \nexprimiert, und synthetischen TAA zur Auffrischung \n(Boost) haben wir eine Impftherapie bei Patienten mit \nmetastasierendem Melanom durchgef\u00fchrt. Eine erkenn -\nbare Immunantwort ohne relevante Toxizit\u00e4t wurde in der \nMehrheit vor\u00fcbergehend erreicht. In unserer aktuellen \nStudie wird der Impfstoff nicht mehr in die Haut, sondern \nin die Lymphknoten verabreicht.\nAufgrund fehlender Phase III Studien kann \u00fcber die \nallgemeine Ansprechrate von Melanompatienten auf \nImpftherapien noch keine Aussage gemacht werden. \nNeue Impfprotokolle mit verst\u00e4rkter Wirksamkeit geben \nAnlass zur Hoffnung.Oncology \nSurgery\nProf. Dr. \nGiulio C. Spagnoli\nInstitut f\u00fcr Chirurgische \nForschung und Spital-\nmanagement (ICFS)\nUniversit\u00e4tsspital Basel\nStv. Leiter ICFS und Leiter\nForschungsgruppe \nOnkologie\nGroup members\nProf. Dr. Daniel Oertli\nPD Dr. Walter W. Marti\nDr. Michel Adamina\nDr. Martin Bolli \nDr. Rachel Rosenthal\nDr. Walter Weber\nDr. Paul Zajac\nElke Schultz-Thater (technician)\nReto Schumacher (PhD student)\nCelia Groeper (PhD student)\nChantal Feder (PhD student)\nAnca Reschner (PhD student)\nSourabh Ghosh (PhD student)\nFig. 2:  Vaccination protocol; The immunization protocol consists of 2 cycles of 5 \nweeks separated by 3 weeks for a total duration of about 3 months. Each cycle is com -\nposed of 3 weeks of treatment, each separated by 1 resting week. F or the immune \nmonitoring during each cycle, blood samples ( \u2022) are obtained before,12 days after \nthe virus injection and 12 days after the last peptide boost (thus on days 1, 15, 43, 57, \n71 and 99). GM-CSF ( \u00ae) is injected sub-cutaneously on each day of the vaccination \nweeks (5mg/kg.b.w./day). Non-replicative recombinant virus (vvmelB7), is delivered \nintra-nodally and represents the first antigenic formulation of each cycle at doses of \n107 pfu on day 3 and 108 pfu on day 59. Soluble peptides boosts containing 100mg \nof GP280-288 , MART-1/Melan-A27-35 and Tyrosinase1-9 are also provided intra-nodally on \ndays 17 and 31 (cycle 1) and days 73 and 87 (cycle2). Peptides are also administered \n(in absence of GM-CSF) after each cycle (day 43 and 99) for DTH evaluation.\nFig. 1:  A NSCLC section was stained with \nMAGE tumor associated antigen (TAA) \nspecific monoclonal antibody 57B (red). \nStaining is only evident on tumor cells.\nActive Specific Immunotherapy in \nMetastatic Melanoma Patients\nWe performed a phase I/II clinical trial based on the administration of a replication inac -\ntivated recombinant vaccinia virus encoding gp100 280-288, Melan-A/MART-1 27-35 \nand tyrosinase 1-9 HLA-A0201 restricted immunodominant TAA epitopes together with \nCD80 and CD86 (rVV-mel-B7) and boosts by synthetic peptides in stage III/IV metastatic \nmelanoma patients (Oertli et al., 2002; Zajac et al., 2003, figure 2). Immunogens were \ninjected intradermally in the context of a systemic GM-CSF treatment and monitoring was \nperformed by tetramer staining and CTL precursors (CTLp) frequency analysis on \u201cin vitro\u201d \nrestimulated CD8 + cells. Of 20 patients entering the protocol, 2 had to withdraw due to \nrapidly progressing disease. Immune responses were evaluated in 18 patients (stage III, \nn=5; stage IV, n =13) and increases in specific CTLp frequencies were observed in 15. \nIn 16 patients, responsiveness against all antigens could be analyzed : 7 (43%) including \nall stage III cases showed evidence of induction of CTL specific for the three epitopes, \n2 (12%) and 4 (25%) respectively, showed reactivity against two or one TAA. In 3 stage, \nIV patients no specific CTL reactivity was induced. Increases in CTLp frequency were \nmostly detected after rVV-mel-B7 injections. However, in a large majority of patients final \nCTLp levels were comparable to initial ones. Tetramer characterization of Melan-A/Mart-1 \n27-35 specific CTL also suggested a preferential expansion following recombinant virus \nadministration. Vector specific humoral responses, frequently undetectable in stage IV \npatients did not prevent TAA specific CTL induction. Beside a single transient grade 3 \nleukopenia, no major clinical toxicity was reported. This study suggests that rVV-mel B7 \nis a highly effective inducer of specific CTL.Reactivity, however is not sustained and it is \nusually undetectable at the end of the immunization cycles. A lower responsiveness in \nstage IV as compared to stage III patients is also emerging. Indeed, among the former \npatients, over 50% did not respond to any of the three antigens or only responded to \none of them (poor responders), whereas all stage III patients responded to all antigens. A \nfurther analogous trial based on intranodal immunization is currently under way . \nOutlook\nClinical application of active specific immunotherapy is still in its infancy. In particular, \nregarding metastatic melanoma, due to the lack of specifically designed phase III clinical \ntrials, its potential clinical impact cannot presently be evaluated on solid bases. However, \nimprovements in the immunogenicity of CTL inducing vaccines and in immunization pro -\ntocols, rise high hopes in the scientific community. An early application of immunotherapy, \npossibly prior to the development of high metastatic tumor burdens would be most ad -\nvantageous. On the other hand, encouraging data in melanoma suggest that other tumor \ntypes of high epidemiological relevance, where TAA were also characterized, including \nlung and breast cancers, might represent targets of specific immunotherapy trials.88/89\nProf. Dr. \nMichael Heberer  \nLeiter Institut f\u00fcr Chirurgi-\nsche Forschung und \nSpitalmanagement, ICFS\nUniversit\u00e4tsspital Basel\nImmunoliposomes\nEGFR\nTargeted Therapies\nDendritic Cells\nTumor VaccinationMolecular Approaches to the Treatment of \nCancer\nOur group has a long-standing interest in molecular approaches to the diagnosis \nand treatment of cancer. In previous studies, we have defined genetic factors \nhelping to predict chemotherapy benefit in colorectal and other cancers, and we \nhave performed numerous clinical trials of gene therapy and other experimental \ntreatments in cancer patients. Recently, we have focussed our interest on two \nnew approaches to cancer treatment, i.e. immunoliposomal targeting and vac -\ncination strategies, which will be described in more detail below .\nImmunoliposomal targeting \nImmunoliposomes combine the pharmacokinetic and drug delivery advantages \nof long circulating, sterically stabilized liposomes with targeting receptor-specific \nproperties of monoclonal anti-EGFR antibodies. Already, we have described the \ndevelopment of immunoliposomes (ILs) that bind EGFR or mutant EGFRvIII and \ninternalize in target tumor cells, enabling intracellular delivery of potent antican -\ncer agents in vitro and in in vivo tumor xenograft models. \nAnti-EGFR ILs are constructed modularly with Fab\u2019 fragments of cetuximab \n(IMC-C225) or EMD 72000, covalently linked to liposomes containing various \ndrugs, such as anthracyclines (doxorubicin or epirubicin), or the vinca alkaloid \nvinorelbine. \nIn vitro studies using various EGFR or EGFRvIII-overexpressing cell lines indi -\ncated that anti-EGFR ILs produced highly efficient binding and internalization, \nresulting in selective intracellular delivery of various drugs including doxorubicin \n(dox) and others. In each case, ILs were markedly more cytotoxic than the cor -\nresponding liposomal drug in target cells (Fig. 1). In vivo, ILs loaded with dox \n(anti-EGFR ILs-dox) showed extended circulation time after i.v. administration, \nwith an 18 h terminal half-life in rats and 90% drug retention at 48h. Therapy \nstudies with anti-EGFR ILs-dox given i.v. showed potent anticancer activity in \nEGFR-overexpressing MDA-MB-468 breast cancer and U87 glioma xenograft \nmodels. In each study, anti-EGFR ILs-dox produced significantly superior effi -\ncacy to all other treatments, including free dox and liposomal dox.\nIn summary, anti-EGFR ILs provide efficient and targeted drug delivery of an -\nticancer compounds and may be applicable to a variety of EGFR- or EGFRvIII-\noverexpressing tumors. Clinical studies using immunoliposoml targeting are \ncurrently prepared.Selected Publications \n\u2013 Schuler, M. et al. and Rochlitz, C.F . (2001) Ad -\nenovirus-Mediated Wild-Type p53 Gene Transfer in \nPatients Receiving Chemotherapy for Advanced \nNon\u2013Small-Cell Lung Cancer . J. Clin. Oncol., 19, 1750.\n\u2013 Mamot, C., Mild, G., Reuter, J., Laffer, U., Metzger, U., \nTerracciano, L., Boulay, J.-L., Herrmann, R., Rochlitz, \nC. (2003) Infrequent mutation of the tumor suppres -\nsor gene Smad4 in early stage colorectal cancer. Brit. \nJ. Cancer, 88, 420-423.\n\u2013 Rochlitz, C., Figlin, R., Squiban, P ., Salzberg, M., Pless, \nM., Herrmann, R., Tartour, E., Zhao, Y ., Bizouarne, N., \nBaudin, M. Acres, B. (2003) Phase I immunotherapy \nwith a modified vaccinia virus (MVA) expressing \nhuman MUC1 as antigen-specific immunotherapy \nin patients with MUC1-positive advanced cancer. J. \nGene Medicine, 5, 690-699.\n\u2013 Jantscheff, P . et al. and Rochlitz, C. (2003) Expres -\nsion of CEACAM6 in Resectable Colorectal Cancer: \nA Factor of Independent Prognostic Significance. J. \nClin. Oncol., 21, 3638-3646.\n\u2013 Mamot, C., Drummond, D.C., Greiser, U., Hong, \nK., Kirpotin, D.B., Marks, J.D. & Park, J.W. (2003) \nEGFR-targeted immunoliposomes mediate specific \nand efficient drug delivery to EGFR- and EGFRvIII-\noverexpressing tumor cells. Cancer Res., 63, 3154.Hybrid cell cancer vaccine for renal cell cancer \nMinimal requirements for a tumor vaccine are that it contains tumor-specific \nantigens which enables the immune system to mount a protective immune \nresponse, that these antigens are present in the tumor to be treated, and \nthat the immune system is fully activated upon antigen recognition. These \nconditions are not easy to meet: in our study a simple strategy is used by \nelectrofusing the tumor cells with antigen presenting dendritic cells (DC). \nWith this method, an artificial \u201chybrid-cell\u201d is created, expressing all relevant \ntumor antigens and all necessary costimulatory molecules (Fig. 2). While the \ntumor cells need to be autologous, the DC can either be derived from the pa -\ntient or from an unrelated donor (allogeneic DC). We employ this method in \na clinical trial with patients with metastatic renal cell cancer (RCC). As of now, \n20 patients, all with progressing renal cell cancer have been treated and are \nevaluable. We found no severe side effects of the vaccine. Nine patients had \na tumor progression, in 10 patients the tumor stabilized (for 4-17 months) and \nin 2 patients there was tumor regression (Fig. 3). A specific immune monitor -\ning was set up for patients with RCC and HLA-A2: it focuses on CTL detection \nagainst the tumor associated antigens MUC1, HER2 and G250, concurrently \nattempted by surface staining and limiting dilution analysis of specific precur -\nsor frequency. Specific reagents for phenotypic studies are constructed by \nloading soluble HLA-A2.1 based fusion molecules with the peptides under \ninvestigation. In one of three patients studied so far we could detect a signifi -\ncant induction of CTLs against HER2, this patient had a disease stabilization \nof 12 months. \nDr. Miklos Pless Molekulare Krebstherapien\nUnsere Gruppe befasst sich mit neuen Methoden der \nTherapie und Diagnostik f\u00fcr Krebs. Bislang haben wir \nunter anderem molekulare Marker identifiziert, mit de -\nnen sich die Effizienz einer Chemotherapie absch\u00e4tzen \nl\u00e4sst und verschiedene Formen der Gentherapie klinisch \ngetestet. Im Fokus stehen zurzeit die immunoliposomale \nKrebstherapie und Vakzinationsstrategien. Immunolipo -\nsome sind Liposome, denen Teile von Antik\u00f6rpern auf -\ngesetzt werden. Damit wird erreicht, dass die Liposome \nspezifische Zellen erreichen, welche die entsprechenden \nOberfl\u00e4chenantigene tragen. Krebszellen tragen h\u00e4ufig \ntypische Proteine (Antigene), die sie von anderen Zel -\nlen unterscheiden. Ein Beispiel hierf\u00fcr sind Krebszellen, \nwelche EGFR (epidermal growth factor receptor) \u2013 ei -\nnen Wachstumsfaktor-Rezeptor \u2013 an ihrer Oberfl\u00e4che \ntragen. Werden nun Liposome mit Antik\u00f6rperteilen, die \nEGFR spezifisch erkennen, ausger\u00fcstet, so lagern diese \nsich an die Krebszellen an. Bei der Verschmelzung der \nLiposome mit der Membran der Krebszellen wird der \nInhalt der Liposome, sehr wirksame Chemotherapeuti -\nka, in die Zelle gesch\u00fcttet. Diese Strategie erm\u00f6glicht \neine sehr gerichtete Behandlung mit geringeren Risiken \nund Nebenwirkungen. Wir werden die Immunliposom-\nTherapie demn\u00e4chst in klinischen Studien testen. Die \nEffizienz von Anti-Karzinom-Vakzinen h\u00e4ngt davon ab, \nob die Tumorzellen die Antigene, mit denen immunisiert \nwird, tats\u00e4chlich exprimieren und ob eine Immunreaktion \nerfolgt. Um dies sicherzustellen, haben wir Tumorzellen \nmit dendritischen Zellen fusioniert, welche nun dem Pa -\ntienten injiziert werden. Dendritische Zellen sind Zellen \ndes Immunsystems, welche Antigene pr\u00e4sentieren und \ndadurch die zellul\u00e4re Immunantwort stimulieren. Eine \nDendrit-Tumor Fusionszelle wird nun die tumor-spezifi -\nschen Antigene selbst enthalten und die Immunantwort \neinleiten. Klinische Tests an Patienten mit Nierenkrebs-\nMetastasen zeigen uns, dass diese Methode Erfolg \nversprechend ist. \nMedical \nOncology\nProf. Dr. \nChristoph Rochlitz \nDepartement Forschung \nund Abteilung f\u00fcr Onkologie\nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Christoph Mamot \nDr. Willy K\u00fcng \nBrigitte Vogel (technician)\nJ\u00fcrgen Reuter (technician)\nReto Ritschad (technician)\nMathias Irouschek (technician)\nFig. 1:  In vivo uptake of non-targeted liposomes (a) \nand immunoliposomes (b) in an U87vIII xenograft \nmodel. Fig. 2:  Fluorescence-\nmicroscopy of hybrid \ncells using a \nmembrane dye: green \nfor dendritic cells (a), \nred for U266 cells \n(myeloma cell line) (b), \nyellow denotes fused \ncells (c), direct-Phase \nMicroscopy shows \ntwo nuclei in hybrid \ncells(d).\nFig. 3:  Regression of \nlung metastases in a \npatient with renal cell \ncancer after hybrid cell \nvaccine.\nA B\nC D90/91DKBW Schwerpunkt\nImmunologie\nMit der Evolution vom Einzeller zu einem mehrzelligen Lebewesen hat sich auch \ndie lebenswichtige F\u00e4higkeit entwickelt, den K\u00f6rper vor sch\u00e4digenden Infek -\ntionserregern und maligne transformierten Zellen zu sch\u00fctzen. Diese essentielle \nFunktion wird durch das angeborene und erworbene Immunsystem sicher \ngestellt. Die zellul\u00e4re und molekulare Komplexit\u00e4t des Immunsystems birgt aber \nauch die Gefahr, dass Fehler in der Reifung von Effektorzellen beziehungsweise \nin der Funktion von an der Abwehr beteiligten Molek\u00fclen zu Immunpatholo -\ngischen Zust\u00e4nden wie Immundefizienzen und Autoimmunerkrankungen \nf\u00fchren k\u00f6nnen.\nVier Forschungsgruppen des Departementes f\u00fcr Klinisch-Biologische Wissen -\nschaften besch\u00e4ftigen sich mit zellul\u00e4ren und molekularen Aspekten der Orga -\nnogenese prim\u00e4rer und sekund\u00e4rer lymphatischer Organe. Diese spezifischen \nanatomischen Orte stellen die geeignete Mikroumgebung zur Ausreifung und \nSelektion von Lymphozyten bereit. Hierbei ist von Interesse, unter welchen \nBedingungen diese Effektorzellen des erworbenen Immunsystems f\u00fcr ihre \nunterschiedlichen Funktionen selektioniert werden. Bei angeborenem, er -\nworbenem und therapeutisch induziertem Immunmangel sind virale Infekte von \nspezieller Gefahr. Drei DKBW-Forschungsgruppen untersuchen deshalb M\u00f6gli -\nchkeiten, virale Infekte (HIV, EBV, und Poliomavirus) fr\u00fch im Ablauf einer Infek -\ntion zu diagnostizieren, zu quantifizieren und mittels immunologischer Effektor -\nmechanismen zu beseitigen. Die Infektabwehr des Immunsystems bedient sich \nebenfalls entwicklungsgeschichtlich gut konservierter Mechanismen, welche \ngesamthaft als nat\u00fcrliche Immunit\u00e4t umschrieben werden. Hierzu z\u00e4hlt auch \ndie M\u00f6glichkeit, gegen bakterielle Zellwandbestandteile \u00fcber die Vermittlung \nvon Membran-st\u00e4ndigen und l\u00f6slichen Effektormolek\u00fclen effizient reagieren zu \nk\u00f6nnen. Zwei Forschungsgruppen innerhalb des Schwerpunktes Immunologie \nbesch\u00e4ftigen sich mit diesem Aspekt des Immunsystems. Zus\u00e4tzlich richtet sich \ndas Immunsystem auch gegen transformierte Zellen im Kontext maligner Er -\nkrankungen, doch sind die spezifischen Mechanismen dieser Form der Abwehr \nnoch unvollst\u00e4ndig bekannt und die Kenntnis zu ihrer therapeutischen Nutzung \nnoch nicht ausreichend untersucht. Ein Teil der immunologischen Forschung \nam DKBW geht deshalb der Frage nach, wie sich Hauttumoren der Erkennung \ndurch das Immunsystem entziehen k\u00f6nnen und wie das Immunsystems durch \nImpfung zu einer gezielten Abwehr von Tumorzellen stimuliert werden kann. \nSchliesslich f\u00fchrt eine Immunantwort gegen k\u00f6rpereigene oder transplantierte \nZellen zu einem Funktionsverlust und gelegentlich zu deren vollst\u00e4ndiger De -\nstruktion, eine Pathologie, wie sie bei der Graft-versus-Host-Disease, bei der \nTransplantatabstossung und bei Autoimmunit\u00e4t beobachtet werden kann. F\u00fcnf \nForschungsgruppen innerhalb des Schwerpunktes Immunologie besch\u00e4ftigen \nsich mit den molekularen und zellul\u00e4ren Grundlagen f\u00fcr diese ungewollte Im -\nmunreaktion.\nProfessor A. Rolink\nRoche Professur \nf\u00fcr ImmunologieDie Forschung im Bereich \u00abImmunologie\u00bb am Departement f\u00fcr Klinisch-Bi -\nologische Wissenschaften bietet eine bedeutsame Plattform f\u00fcr die Interaktion \nzwischen klinischer und Labor-orientierter Forschung und erm\u00f6glicht Interak -\ntionen mit den anderen Schwerpunkten des Departements. Bereits heute sind \nwesentliche Kooperationen zwischen den einzelnen Forschungsgruppen etabli -\nert und erm\u00f6glichen so den wissenschaftlichen Austausch und die Realisation \ngemeinsamer Projekte. Schliesslich bietet der Schwerpunkt Immunologie auch \ndie einmalige Chance, Aktivit\u00e4ten in Lehre und Forschung der medizinischen \nund naturwissenschaftlichen Fakult\u00e4ten konstruktiv zu integrieren.\nProfessor \nG. A. Holl\u00e4nder\nUniversit\u00e4tskinderspital \nBeider Basel\nDepartement Forschung\nUniversit\u00e4tsspital Basel92/93Developmental \nand Molecular \nImmunology\nProf. Dr. Antonius Rolink\nRoche Professur f\u00fcr Immunologie\nGroup members\nProf. Dr. Jan Andersson \nDr. Rod Ceredig\nDr. Gina Balciunaite \nDr. Steffen Massa \nCorinne D\u00e9molli\u00e8re (technician)\nGiuseppina Capoferri (technician)\nHannie Rolink (technician) \nErnst Wagner (technician)\nAng\u00e8le B\u00e9nard (PhD student)\nAnnalisa Camporeale (PhD student)\nLukas Fl\u00fcck (PhD student)\nEvita Harfst (PhD student)\nMelanie Rauch (PhD student)\nLee Kim Swee (PhD student)\nMaja Brenner (MD student)\nSarah M\u00e4rki (diploma student)\nPatrick Fl\u00fcckiger (diploma student)Hematopoietic stem cells\nEarly hematopoietic progenitor cells\nPax-5\nStromal cells\nGrowth factorsMolecular Mechanisms Guiding the \nDevelopment of Cells of the Immune System\nPractically all mature blood cells have a limited lifespan. Hence, to maintain their \nperipheral pools, they have to be generated throughout life. A rare cell found in \nthe bone marrow, called hematopoietic stem cell (HSC), is responsible for the \nlifelong production of the blood cells. \nMuch progress has been made in the phenotypic characterization of this rare \nHSC and of early hematopoietic precursor cells. However, at both the molecular \nand the cellular level, the mechanisms that guide the differentiation of these into \nthe various blood cells are still poorly understood. We aim at a better under -\nstanding of the mechanisms underlying these differentiation processes.\nEarly hematopoietic progenitor cells with multi-lineage developmental \npotential in vitro  and in vivo\nWe have shown earlier that pre-B cells derived from Pax-5 deficient mice possess \nthe potential to differentiate into practically all cells of the blood. Recently, we \nhave identified a similar cell type in bone marrow of normal mice. The summary \nof the multi-lineage development potential of this cell type in vitro and in vivo is \nshown in Fig. 1. Thus, B220+, c-kit+, CD19- cells isolated from bone marrow of \nnormal mice differentiate into macrophages when cultured on OP9 stromal cells \nand M-CSF . The culture of these same cells on OP9 stromal cells in the presence \nof IL-7 results in the formation of pre-B cells. These ones can be maintained and \nexpanded long-term in vitro. Most interestingly, transplantation of these cells \ninto immunodeficient mice results in the establishment of a small but significant \nand functional B cell compartment. \nIn marked contrast, B220+, c-kit+, CD19- bone marrow cells cultured on OP9 \nstromal cells expressing the Notch ligand delta-1 like in the presence of IL-7 \ndifferentiate into pre-T cells. These pre-T cells as well, can be maintained and \nexpanded long-term in culture and, upon transplantation into immunodeficient \nmice, can reconstitute the thymus and the peripheral T cell compartment. Cur -\nrently, we use this as well as the Pax-5-/- pre-BI cell differentiation system for \nthe identification of genes guiding the development of the various cells of the Die molekulare Entwicklung der Zellen \ndes Immunsystems\nBlutzellen haben eine beschr\u00e4nkte Lebensdauer und \nm\u00fcssen daher konstant durch die sogenannte H\u00e4 -\nmatopoese erneuert werden. Diese Erneuerung wird \ndurch Stammzellen im Knochenmark gew\u00e4hrleistet. In \nunserem Labor untersuchen wir die molekularen Me -\nchanismen, die die Differenzierung in die verschiedenen \nZelltypen, insbesondere die Zellen des Immunsystems \nsteuern. Dies letztlich mit dem Ziel, therapeutische \nAnwendungen zu finden.\nVorstufen von B Zellen (pr\u00e4-B Zellen) aus M\u00e4usen, die \nPax-5 nicht exprimieren, k\u00f6nnen sich praktisch zu allen \nBlutzelltypen differenzieren. Von einem \u00e4hnlichen \nZelltyp in genetisch unver\u00e4nderten M\u00e4usen entstehen \nMakrophagen, pr\u00e4-B Zellen oder pr\u00e4-T Zellen. Diese \npr\u00e4-B und pr\u00e4-T Zellen k\u00f6nnen in Kultur gehalten und \nvermehrt werden und dienen zur Identifikation von \nGenen, die die weiteren Differenzierungsvorg\u00e4nge \nder Zellen des Immunsystems steuern.\nIm Knochenmark von adulten M\u00e4usen entstehen t\u00e4g -\nlich 10\u201312 Millionen pr\u00e4-B Zellen. Nur 10\u201320 % davon \nwandern in die Milz. In der Milz kann man drei Entwick -\nlungsstufen von unreifen B Zellen unterscheiden (T1, \nT2, und T3), die alle drei ihren Entwicklungsvorgang \nnoch abbrechen k\u00f6nnen. Eine grosse Mehrheit dieser \nZellen werden sich in der Milz jedoch zu reifen B Zellen \ndifferenzieren. Somit sind alle unausgereiften B Zellen \nin der Milz (T1-3) potentielle Vorstufen von follikul\u00e4ren \nB Zellen. Unklar hingegen bleibt, welches die Vorstufen \nder B Zellen der marginalen Zone sind. Wir untersuchen \neine Reihe von Genen, die in den verschiedenen B Zell-\nSubpopulationen unterschiedlich exprimiert werden, \num deren Rolle bei den Differenzierungsprozessen \nzu verstehen.\nSelected Publications\n\u2013 Rolink, A. G., Nutt, S. L., Melchers, F . and Busslinger, \nM. (1999) Long-term in vivo reconstitution of T-cell \ndevelopment by Pax5- deficient B-cell progenitors. \nNature 401, 603-606.\n\u2013 Nutt, S. L., Heavey, B., Rolink, A. G. and Busslinger, \nM. (1999) Commitment to the B-lymphoid lineage \ndepends on the transcription factor Pax5. Nature 401, \n556-562.\n\u2013 Schaniel, C., Bruno, L., Melchers, F . and Rolink, A. G. \n(2002) Multiple hematopoietic cell lineages develop \nin vivo from transplanted Pax5-deficient pre-B I-cell \nclones. Blood 99, 472-478.\n\u2013 Rolink, A. G., Tschopp, J., Schneider, P . and Melchers, \nF . (2002) BAFF is a survival and maturation factor for \nmouse B cells. Eur J Immunol 32, 2004-2010.\n\u2013 Rolink, A. G., Andersson, J. and Melchers, F . (2004) \nMolecular mechanisms guiding late stages of B-cell \ndevelopment. Immunol Rev 197, 41-50.\nFig. 1 : In vitro and in vivo differentiation potential of an early hematopoietic \nprogenitor cell found in mouse bone marrow\nAbout 0.1% of mouse bone marrow cells are B220+, c-kit+, CD19-. Under various \nculture conditions these cells can differentiate into pre-B cells, pre-T cells and \nmacrophages. Pre-B cells and pre-T cells can be maintained in culture and can be \nused to reconstitute the B- and T-cell compartments in immunodeficient mice.immune system. We are looking for a human cell type with a similar develop -\nmental potential. Such a cell might, in future, be used in therapy for patients \nwith defects in the immune system. \nLate stages of B cell development (Fig. 2)\nIn the bone marrow of young adult mice, 1-2 x 107 immature B cells are \ngenerated per day. For so far largely unknown reasons, only 10\u201320% of \nthese migrate to the spleen. In there, the immature B cell compartment can \nbe subdivided into three populations called: Transitional B cell 1 (T1), 2 (T2) \nand 3 (T3). All three immature B cell populations are still sensitive for nega -\ntive selection since they go into apoptosis upon cross-linking of their antigen \nreceptor. Nevertheless, the very vast majority of immature B cells that reach \nthe spleen will differentiate into mature B cells. The TNF family member BAFF \nplays a crucial role in this differentiation process. \nThe mature B cell compartment in the spleen comprises follicular and mar -\nginal zone B cells. The immature splenic B cells (T1-3) are precursors that \ngive rise to follicular B cells, while the precursor for marginal zone B cells has \nnot yet been identified. \nWe have found several genes that are differentially expressed in these \nsplenic B cell sub-populations and we are testing their roles in this differen -\ntiation process, using transgenic and \u201cknock-out\u201d approaches. Moreover, a \ndetailed analysis of the role of BAFF in late stages of B cell development is \nin process. \nFig. 2:  Late stages of B cell development\nOf the immature B cells produced in the bone marrow only a minor fraction migrates \nto the spleen. In the spleen the immature B cells go through three developmental \nstages before they enter the mature B cell compartment. The TNF family member \nBAFF plays a crucial role in this immature-mature B cell transition. T he immature \nsplenic B cells are the precursors of the mature follicular B cells. T he precursors of the \nmarginal zone B cells have not yet been identified. \n94/95Developmental \nImmunology\nProf. Dr. Daniela Finke\nInstitut f\u00fcr Immunologie\nGroup members\nCaroline Bornmann (technician)\nDominik Meier (PhD student)\nSandrine Schmutz (PhD student)\nStephane Chappaz (PhD student)\nAlan Valaperti (diploma student)Lymphoid organs\nAutoimmunity\nFetal development\nChemokines\nLymphotoxinThe Development of Secondary Lymphoid \nOrgans\nLymphoid organs harbor hematopoietic cells in a framework of mesenchymal \ncells. Adaptive immune responses are generated in secondary lymphoid organs \nsuch as lymph nodes (LN), spleen and intestinal Peyer\u2019s patches (PP). Secondary \nlymphoid organs are not only important for anti-viral and anti-bacterial defense \nreactions but also for anti-tumor immune responses. Individuals who fail to de -\nvelop organized lymphoid organs have a severe immunodeficiency.\n1) Role of fetal hematopoietic cells in Peyer\u2019s patch and lymph node develop -\nment. PP organogenesis starts around embryonic day 15.5 with the clustering of \nLT\u03b2R+VCAM-1+ mesenchymal cells in the proximal small intestine that extends \nuntil birth to the distal gut (Fig. 1a and b). One of the earliest hematopoietic cells \ncolonizing the developing gut and fetal spleen expresses IL-7R \u03b1 and CD4 but \nlacks CD3 expression (Fig. 1d). RAG-2-/- \u03b3c-/-mice, which generate CD4+CD3- \ncells without a functional IL-7R, fail to develop inguinal LN and PP (Fig. 1c). We \nhave shown that the cellular interaction of mesenchymal and hematopoietic \nCD4+CD3- cells is critical for PP formation during ontogeny (Fig. 2). The chem -\nokine CXCL13 (BLC), which is expressed in the follicles of secondary lymphoid \norgans, interacts with CXCR5 receptors expressed by CD4+CD3- cells. This in -\nduces both LT \u03b11\u03b22 expression and \u03b14\u03b21 integrin activation on CD4+CD3- cells \nfollowed by high affinity attachment to VCAM-1+ mesenchymal cells. Adhesion \nto mesenchymal cells via \u03b14\u03b21/VCAM-1 is critical for efficient transmission of \nthe lymphotoxin (LT) \u03b2R signal via LT \u03b11\u03b22, a key step in tissue differentiation and \nlymphoid organ formation.\n \n2) Crosstalk between epithelial and hematopoietic cells. The follicle-associated \nepithelium (FAE) that overlies PP expresses distinct features, when compared \nto the adjacent villus epithelium. Besides the presence of antigen-sampling \nM cells, the FAE constitutively expresses the chemokine CCL20. CCL20 is \nresponsible for the recruitment of dendritic cells to the subepithelial region Die Entwicklung sekund\u00e4rer lymphatischer \nOrgane\nDas Vorhandensein von Lymphknoten, Milz und \nPeyer\u2019schen Platten im Darm (sogenannten sekund\u00e4 -\nren lymphoiden Organen) ist wichtig f\u00fcr die Ausbildung \neiner normalen Immunantwort und Abwehr von Viren, \nBakterien oder Tumorzellen. Die Faktoren, die die \nEntwicklung von lymphatischem Gewebe w\u00e4hrend der \nembryonalen Organogenese regulieren, sind wenig be -\nkannt. Es wird vermutet, dass molekulare Mechanismen \neine Rolle spielen, die auch w\u00e4hrend einer chronischen \nEntz\u00fcndung (z.B. Darmentz\u00fcndung) wirksam sind. Wir \nhaben gezeigt, dass hematopoietische CD4+CD3- Zellen \nlymphoides Gewebe induzieren k\u00f6nnen. Diese Zellen \nkommunizieren mit anderen Zelltypen, z.B. Epithelzellen \nund Mesenchymalzellen und binden an den Lymphoto -\nxin \u03b2 Rezeptor (LT) \u03b2R, einem Schl\u00fcsselmolek\u00fcl bei der \nReifung und Differenzierung von lymphatischem Ge -\nwebe. Das Chemokin CXCL13 (BLC) induziert LT \u03b11\u03b22, \nden Liganden f\u00fcr (LT) \u03b2R und aktiviert a4 \u03b21 Integrin. Die \nAdhesion von hematopoietischen CD4+CD3- Zellen auf \nMesenchymalzellen via \u03b14\u03b21/VCAM-1 ist entscheidend \nf\u00fcr die effiziente Signal\u00fcbertragung von Lymphotoxin \n(LT)\u03b2R. Es ist uns gelungen, Chemokine zu identifizie -\nren, die durch LT \u03b2R induziert und ausschliesslich von \nEpithelzellen in Peyer\u2019schen Platten gebildet werden. \nDas erkl\u00e4rt, wie hematopoietische Zellen, die ein LT \u03b2R-\nSignal auf Epithelzellen induzieren, gewebsspezifische \nDifferenzierung und Chemotaxis erzeugen k\u00f6nnen. \nDar\u00fcber hinaus konnten wir zeigen, dass \u00e4hnlich wie \nin einer chronischen Immunantwort, aktivierte B Lym -\nphozyten die Entwicklung von follikul\u00e4ren dendritischen \nZellen und lymphoiden Follikeln im Darm unterst\u00fctzen. \nDamit haben wir ein Modell entwickelt, mit dem wir die \nEntstehung von lymphatischem Gewebe w\u00e4hrend einer \nchronischen Entz\u00fcndung untersuchen k\u00f6nnen.\nSelected Publications\n\u2013 Rumbo, M., F . Sierro, N. Debard, J.P . Kraehenbuhl, \nD. Finke (2004) Lymphotoxin b receptor signaling in -\nduces the chemokine CCL20 in intestinal epithelium. \nGastroenterology, 127, 213-223\n\u2013 Finke. D., S. Luther, H. Acha-Orbea (2003) The role of \nneutralizing antibodies for mouse mammary tumor vi -\nrus transmission and mammary cancer development. \nPNAS, 100, 199-204.\n\u2013 Finke, D., H. Acha-Orbea, A. Mattis, M. Lipp, J.P . \nKraehenbuhl (2002) CD4+CD3- cells induce Peyer\u2019s \npatch development: role of _4_1-integrin-activation \nby CXCR5. Immunity, 17, 363-373.\n\u2013 Finke, D. and J.P . Kraehenbuhl (2001) Formation of \nPeyer's Patches. Curr. Opin. Gen. Develop. Biol., 11, \n561-567\n\u2013 Wehrli, N., Legler, D.F ., D. Finke, K.-M. Toellner, \nP . Loetscher, M. Baggiolini, J.C.M. MacLennan, H. \nAcha-Orbea (2001) Changing responsiveness to \nchemokines allows medullary plasmablasts to leave \nlymph nodes. Eur. J. Immunol. 31, 609-616.\nFig. 1 : Peyer\u2019s patch and Lymph node development. (a) Peyer\u2019s patches in mouse \nsmall intestine (b) Whole mount immunohistochemistry with anti-VCAM-1 MAb \nshows PP anlage (c) In contrast to wild type animals (top), RAG-2-/- \u03b3c-/- mice (bot -\ntom) lack inguinal lymph nodes (d) CD4+CD3- cells in lymph node.of PP . The mechanisms that induce FAE differentiation and CCL20 expres -\nsion are poorly understood. We tested whether LT \u03b2R signaling mediates \nFAE differentiation and CCL20 expression. LT \u03b2R and LTa1 \u03b22 as well as \nCCL20 expression were monitored during embryonic development by in \nsitu hybridization. CCL20 is expressed in the FAE before birth at the time \nthe first hematopoietic CD4+CD3-LT\u03b2+ cells are found in the gut. Gene ex -\npression studies following agonistic anti-LT \u03b2R antibody treatment in vivo  \nand in vitro  by laser micro-dissection and quantitative RT-PCR revealed \nthat LT\u03b2R signaling can induce CCL20 expression in intestinal epithe -\nlial cells, suggesting that this pathway triggers constitutive production of \nCCL20 in the FAE.\n3) Role of activated B cells in lymphoid tissue neoformation. There is strong \nevidence that the mechanism for lymphoid organogenesis in embryos and \nectopic lymphoid tissue formation during chronic inflammation is similar. \nWe tested the role of activated lymphocytes in neoformation of lymphoid \ntissue. Wild type B cells were adoptively transferred into neonatal LT \u03b1-/- \nmice, which are unable to form PP or LN. Subsequent activation of B cells \nin recipient mice by MAb treatment caused the neoformation of lymphoid \nfollicles in the small intestine of LT \u03b1-/- mice. In addition, the develop -\nment of mesenteric LN anlage was observed. The Ab-cocktail alone or \nnon-activated B cells failed to induce lymphoid tissue. Our data suggest \nthat the infiltration of activated B cells into inflamed tissues as observed in \nautoimmune diseases and chronic inflammations can initiate a cascade of \ninteractions resulting in lymphoid follicle and tissue formation.\nFig. 2 : Peyer\u2019s patch development during ontogeny. \nIntegrin activation by chemokines, adhesion and LT \u03b2R engagement are crucial steps.\n96/97Experimental \nCritical Care \nMedicine\nProf. Urs Eriksson\nDepartement Forschung\nDepartement f\u00fcr Innere Medizin\nUniversit\u00e4tsspital Basel\nPD Dr. Patrick. Hunziker (guest scientist)\nGroup members\nDr. Julia Burian \nDr. Przemyslaw Blyszczuk\nDr. Peter Burger\nDr. Marc Wolf\nHeidi Bodmer (Technician)\nNora Mauermann (PhD student)\nRen\u00e9 Marty (PhD student)Sepsis\nMyocarditis\nCardiomyopathy\nAtherosclerosis\nInflammation\nAutoimmunityTargeting Inflammatory Heart Disease\nViral infections triggering autoimmunity have been implicated in the pathogen -\nesis of certain dilated cardiomyopathy, the commonest cause of heart failure in \nyoung patients. We have shown that dendritic cells loaded with heart specific \nself-peptides induce T-cell mediated myocarditis in na\u00efve, non-transgenic mice \n(Fig. 1). After resolution of acute myocarditis, mice develop heart failure. This \nmodel of autoimmune myocarditis (EAM) reflects a unifying theory as to how \ntissue damage and activation of Toll-like receptors (TLRs) during infections can \ninduce autoimmunity, autoimmune relapses, and cardiomyopathy (Fig. 2) and \noffers a nice approach to study inflammatory mechanisms and the pathophysi -\nological response of the failing ventricle to volume or pressure overload. It will \nbe of help in the development of novel treatment strategies and will be of help \nin refining current therapeutic options for inflammatory heart disease and heart \nfailure.\nIn particular, induction of autoimmune myocarditis requires priming of auto -\nreactive T-cells that migrate to the heart and interact with resident tissue cells \nexpressing self-antigen. Expression of activation markers on tissue resident den -\ndritic cells expressing MHC class II always precedes inflammation in the course \nof autoimmune myocarditis. As antigen-presenting cells, they are involved \nin the generation or aggravation of autoimmune responses upon activation. \nFurthermore, these cells might be critical for the attraction and recruitment of \nT-cells, as well as other inflammatory cells. Various chemokines and cytokines \nare capable of fine-tuning the functional role of heart resident dendritic cells. \nTNF-\u03b1 for example, has been recognized as a key cytokine mediating activation \nof tissue resident dendritic cells. It also promotes apoptosis of cardiomyocytes, \nand directly impairs cardiac contractility. Our research focuses on the role of \nspecific mediators and cytokines that activate tissue resident dendritic cells. We \ntake advantage of knockout mice lacking specific cytokines, chemokines and/or \ntheir receptors. We hope that this approach will allow us to develop novel treat -\nment strategies based on in vivo  blocking of specific proinflammatory mediators. \nPossible target cytokines include IL-1 \u03b2, TNF-\u03b1, and IL-6 (Fig. 2). Inflammatory \nmechanisms are also critically involved in the pathogenesis of atherosclerosis \nand coronary heart disease the most prevalent heart disease worldwide. We \nare also interested in inflammatory aspects of atherosclerosis (the \u201cvulnerable \nplaque\u201d) and our research focuses on the exploration of nanoscience tools for \ndiagnostic and therapeutic purposes in this area.\nOur working hypotheses are guided by clinical observations. In turn, we are \ninterested in a straight transfer of our experimental findings to clinical practice. \nTherefore, our group established close local, national and international collabo -\nrations with both clinicians and basic researchers. \nOur current and future projects focus on the autoimmune myocarditis model \nwhile studying the mechanisms involved in induction and healing of inflammato -\nry heart disease, as well as in mediation of tolerance. Focusing on the vulnerable \nplaque leading to acute coronary syndromes, Patrick Hunziker\u2019s projects involve Entz\u00fcndung und Herzkrankheit\nZusammen mit der genetischen Pr\u00e4disposition sind \nautoimmune Prozesse daf\u00fcr verantwortlich, dass In -\nfektionen mit kardiotropen Viren gelegentlich in der \nEntstehung der dilativen Kardiomyopathie m\u00fcnden, \nder h\u00e4ufigsten Form der Herzschw\u00e4che bei Kindern und \nJugendlichen. Um diese Autoimmunprozesse, d.h. die \ngegen das eigene Herz gerichteten Entz\u00fcndungsvor -\ng\u00e4nge zu verstehen, verwenden wir ein Mausmodell. \nIn diesem Modell wird durch Immunisation mit k\u00f6rper -\neigenem Herzmuskelmyosin in empfindlichen M\u00e4usen \neine schwere Herzmuskelentz\u00fcndung ausgel\u00f6st, die \nschliesslich zur Herzinsuffizienz fortschreitet. Durch \nVerwendung von genetisch ver\u00e4nderten Tieren, de -\nnen spezifische Entz\u00fcndungsmediatoren (Botenstoffe) \nfehlen, kann eruiert werden, welche Mediatoren f\u00fcr die \nKrankheitsentstehung notwendig sind. Auf diese Weise \nkann die Basis zur Entwicklung neuartiger Therapies -\ntrategien gelegt werden. Ein weiterer Schwerpunkt ist \ndas Verst\u00e4ndnis der entz\u00fcndlichen Prozesse die der Ent -\nstehung der Koronaren Herzkrankheit zugrunde liegen. \nIn diesem Zusammenhang nutzt PD Dr. Hunziker die \nFortschritte der Nanotechnologie zur Entwicklung neuer \nund revolution\u00e4rer diagnostischer und therapeutischer \nVerfahren.\nDie Forschung des Labors f\u00fcr experimentelle Intensiv -\nmedizin ist innerhalb des DKBW mit dem Schwerpunkt \nImmunologie vernetzt. Zudem bestehen Kollaboratio -\nnen mit den Abteilungen f\u00fcr Kardiologie, H\u00e4matologie, \nIntensivmedizin, und der Allgemeinen Inneren Medizin \ndes Universit\u00e4tsspitals Basel. National und international \nbestehen \u201cjoint-ventures\u201d mit dem Institut f\u00fcr Molekula -\nre Biotechnologie der \u00d6sterreichischen Akademie der \nWissenschaften in Wien (Prof. J. Penninger), sowie mit \nder ETH Z\u00fcrich.\nSelected Publications\n\u2013 Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY , \nWatts TH, Sonderegger I, Bachmaier K, Kopf M, Pen -\nninger JM (2003) Dendritic cell-induced heart failure \nrequires essential cooperation between adaptive and \ninnate immunity. Nat Med; 9:1484-1489\n\u2013 Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozi -\neradzki I, Sasaki T, Irie-Sasaki J, Gidrewicz D, Rybin \nVO, Wada T, Steinberg SF, Backx PH,Penninger JM \n(2003) Phosphoinositide 3-Kinase g-deficient mice \nare protected from isoprotenerol-induced heart \nfailure. Circulation; 108:2147-2152\n\u2013 Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri \nA, Hunziker L, Suzuki S, Bachmaier K, Bingisser RM, \nPenninger JM, Kopf M (2003) Activation of dendritic \ncells through the IL-1 receptor 1 is essential for the \ninduction of autoimmune myocarditis. J Exp Med; \n197(3):323-331\n\u2013 Eriksson U, Kurrer MO, Schmitz N, Fontana A, Marsch \nSC, Eugster HP, Kopf M (2003) IL-6 deficient mice \nresist development of autoimmune myocarditis as -\nsociated with impaired upgulation of Complement \nC3. Circulation; 107:320-325To Recognize and Understand \nHeart Failure\nThe laboratory of Experimental Critical Care Medicine fo -\ncuses on the pathogenesis of inflammatory mechanisms in \nheart failure and atherosclerosis. At the bench, we are devel -\noping novel treatment strategies and diagnostic approaches. \nOur partners at the Division of Medicine A (Head Prof. A.P . \nPerruchoud), Department of Internal Medicine are directly \ntransferring our research progress \u201cbedside\u201d to the patients \nof the University Hospital. Prof. Christian M\u00fcller and his \nteam at the Division of Medicine A are taking advantage of \nthe so-called B-type natriuretic peptide (BNP) as a specific \nmarker for volume overload of the heart. Prof. M\u00fcller re -\ncently showed that BNP measurement clearly discriminates \nbetween heart failure and other causes of acute dyspnea. \nAt the moment several studies addressing the relevance of \nneuroendocrine and inflammatory mediators as diagnostic \nand prognostic markers in patients with proven or suspected \nheart diseases are under way. \nimaging of the vulnerable plaque by atomic force imaging, bedside diagnosis \nof coronary syndromes by novel microfluidics-based immunoassays, and \ntherapeutic targeting of the vulnerable plaque by nanocontainer targeting \n(Fig. 3).\nFig. 1:  Inflammatory infiltrates include macrophages and dendritic cells expressing \nMHC class II molecules (a), and lymphocytes. CD4 + T lymphocytes (b) are critical for \ndisease development.Prof. Dr. \nChristian M\u00fcller\nMedizinische Klinik A\nUniversit\u00e4tsspital Basel\nFig. 2:  Dendritic cells \nscavenging apoptotic and \nnecrotic heart tissue after \nvirus infection, express \nself antigen, and prime \nautoreactive T cells if \nactivated through Toll-\nlike receptors (TLR). TLR \nactivation results in pro -\nduction of proinflamma -\ntory cytokines. Activated \ncomplement contributes \nto the development of \nmyocarditis. Fig. 3:  Targeting of activated plaque macro-\nphages by functionalized polymer nanocontainers\n98/99\na bExperimental\nImmunology\nProf. Dr. Gennaro De Libero\nDepartment Forschung, Universit\u00e4tsspital Basel\nGroup Members\nDr. Lucia Mori De Libero \nDr. Sabrina Mariotti \nDr. Emmanuel Rossy \nLena Angman (technician)\nSebastiano Sansano (technician)\nAnthony Collmann (PhD student)\nHans-J\u00fcrgen Gober (PhD student)\nMagdalena Kistowska (PhD student)\nMarco Cavallari (PhD student)T Lymphocyte\nAntigen Presentation\nTuberculosis\nVaccine\nInfection\nAutoimmunityRecognition of Non-peptidic Antigens \nby T Lymphocytes\nAntigen recognition by T cells is a central event in the initiation of acquired im -\nmune responses. The capacity of T cells to recognize a large variety of antigens, \nincluding peptides, glycolipids, and phosphorylated metabolites has been re -\ncently appreciated.\nWe are studying the recognition of non-peptidic ligands by T cells with special \nattention on the following two topics. \n1) Recognition of glycolipid antigens and role of this recognition \nin autoimmunity and infection.  \nIn Multiple Sclerosis patients we have described T cells specific for self gly -\ncosphingolipids presented by CD1 molecules. Crystal structure analyses of \nCD1-glycolipid complexes have shown that the lipid tails are embedded in \nhydrophobic pockets within CD1 molecules, whereas the hydrophilic parts are \nexposed on CD1 surface. We have investigated how the hydrophilic moieties of \nglycolipids are correctly positioned for T cell receptor (TCR) recognition. CD1a \nsite directed mutagenesis and binding assays of fluorescent glycolipids to syn -\nthetic CD1a molecules have revealed amino acids which hold and orient the hy -\ndrophilic part of bound glycolipids. This interaction stabilizes the highly flexible \nsugar moiety of glycolipids, thus contributing to the formation of immunogenic \nCD1-lipid complexes. \nThe immunogenicity of glycolipids is also affected by the acyl chain structure, \nwhich indirectly influences the position of hydrophilic parts as demonstrated \nby studying binding of anti-glycolipid monoclonal antibodies to soluble CD1-\nglycolipid complexes and investigating the response of glycolipid-specific T cell \nclones to synthetic glycolipids differing only in the length of one acyl chain.\nThis is important in light of the different types of acyl chains added during syn -\nthesis of glycosphingolipids in different tissues in physiological conditions or \nduring the inflammatory response.\nIn another series of studies we have found that in patients with active tubercu -\nlosis a large number of T cells recognize a novel mycobacterial lipid (Ac2SGL). \nAc2SGL is presented by CD1b and stimulates T lymphocytes with the T helper \n1 functional phenotype. The Ac2SGL-specific T cells recognize macrophages \ninfected with Mycobacterium tuberculosis and show bactericidal capacities. \nAc2SGL is currently being tested as a novel anti-tuberculosis vaccine in guinea \npigs.Die T Lymphozyten erkennen ein reiches \nRepertoire an Antigenen\nDas Erkennen von Antigenen durch T Lymphozyten \nist ein \u00e4usserst wichtiger Schritt in der Entwicklung der \nImmunantwort. T Lymphozyten erkennen verschiedene \nKlassen von Antigenen: Peptide, Glykolipide und phos -\nphorylierte Metabolite. Wir untersuchen die Mechanis -\nmen und die physiologische Bedeutung der Erkennung \nder letzteren zwei Antigenklassen.\nAus dem Blut von Patienten, die an Multipler Sklerose \nleiden, lassen sich T Zellen isolieren, welche k\u00f6rperei -\ngene Glykolipide erkennen. Glykolipide geh\u00f6ren zu \nden h\u00e4ufigsten Bestandteilen der Myelinscheide im \nGehirn. Die Zerst\u00f6rung dieser Myelinscheide f\u00fchrt \nzum Zerfall der Nerven bei der Multiplen Sklerose. T \nZellen mit k\u00f6rpereigenen Glykolipidspezifizit\u00e4t sind \nim Blut von Patienten mit Multipler Sklerose h\u00e4ufiger \nals im Blut von gesunden Probanden. Da zudem diese \nT Zellen entz\u00fcndungsf\u00f6dernde Zytokine aussch\u00fctten, \nliegt die Vermutung nahe, dass sie an der Autoimmun-\nReaktion beteiligt sind, welche zu den verheerenden \nL\u00e4sionen im Gehirn f\u00fchrten. Diese Hypothese wollen \nwir \u00fcberpr\u00fcfen.\nWir untersuchen andererseits, die Immunantwort von \nT Zellen gegen Lipide aus Mycobacterium tuberculosis, \ndem Bakterium, das f\u00fcr die Tuberkulose verantwortlich \nist. Im Blut von Patienten, welche an Tuberkulose \nerkrankt sind aber auch im Blut von gesunden Proban -\nden mit vorausgegangener Infektion, sind die Titer von \nlipid-spezifischen T Zellen sehr hoch. Dies zeigt, dass \ndieser Typ von Immunantwort sehr h\u00e4ufig ist. Wir haben \nein hoch immunogenes Glykolipid von Mycobakterien \nisoliert und dessen Struktur bestimmt. Gegenw\u00e4rtig \npr\u00fcfen wir dieses Glykolipid als m\u00f6glichen Bestandteil \nSelected Publications\n\u2013 De Libero G. 2004. The Robin Hood of antigen pres -\nentation. Science. 303, 485-487.\n\u2013 Gilleron M., Stenger S., Mazorra Z., Wittke F ., Mariotti \nS., Bohmer G., Prandi J., Mori L., Puzo G., De Libero \nG. 2004. Diacylated sulfoglycolipids are novel myco -\nbacterial antigens stimulating CD1-restricted T cells \nduring infection with Mycobacterium tuberculosis. J. \nExp. Med. 199, 649-659.\n\u2013 Gober H.-J., Kistowska M., Angman L., Jen\u00f6 P ., Mori \nL., De Libero G. 2003. Human TCR gamma/delta cells \nrecognize endogenous mevalonate metabolites in tu -\nmor cells. J. Exp. Med. 197, 163-168.\n\u2013 Shamshiev A., Gober H.-J., Donda A., Mazorra Z., \nMori L. and De Libero G. 2002. Presentation of the \nsame glycolipid by different CD1 molecules. J. Exp. \nMed. 195, 1013-1021.\n\u2013 Shamshiev A., Donda A., Prigozy T.I., Mori L., Chi-\ngorno V ., Benedict C.A., Kappos, L., Sonnino S., \nKronenberg M., and De Libero G. 2000. The alpha -\nbeta T cell response to self-glycolipids shows a novel \nmechanism of CD1b loading and a requirement for \ncomplex oligosaccharides. Immunity 13, no. 2:255-\n64.Tuberculosis, the Infection Causing \nthe Largest Number of Deaths\nTuberculosis, a major cause of death in developing countries, is caused by Mycobacte -\nrium tuberculosis, an obligately aerobic intracellular bacterium. \nM. tuberculosis survives and grows in resting alveolar macrophages. Thus, the ability \nof a person to mount a rapid and effective immune response determines whether the \noutcome of exposure will be symptomatic disease or not. \nInitial interaction between M. tuberculosis-infected macrophages and T cells elicits a \nhelper (CD4) and a cytotoxic (CD8) T cell response. The main contribution of the CD4 T \ncells is the release of IFN gamma, which activates macrophages. CD8 T cells kill and dis -\nrupt infected phagocytes that have not succeeded in stopping bacterial growth together \nwith intracellular pathogens. Both aspects are of main importance in the contribution to \nimmunity. An effective vaccine must stimulate the right type of immune response if it is \nto provide long lasting immunity to Tuberculosis. \nIdentification of T cells specific for mycobacterial lipids has opened new perspectives to \ngeneration of novel vaccines for two major reasons. First, because lipids are presented \nto T cells by non-polymorphic CD1 antigen-presenting molecules. This allows the entire \nhuman population to react to immunogenic lipids. Second, because unlike proteins, \nlipids cannot be modified under selective pressure in bacteria. Therefore, the lipid \nspecific immune responses reduce the risk to select bacterial mutants not expressing \nthat particular lipid. \nOur experimental observation that T cells specific for mycobacterial lipids release large \namounts of IFN gamma and also kill infected phagocytes, is a strong indication to further \ninvestigate lipids as subunit components of a anti-tuberculosis vaccine.\nFig. 1 : Structure of the CD1a-sulfatide \ncomplex. Only the alpha 1 and alpha 2 \nhelices of CD1a are shown (blue ribbons). \nThe CD1a aminoacids interacting with the \nhydrophilic part of sulfatide are shown \nin blue, yellow and red. Sulfatide is shown \nin white with colored sulfur (yellow) and \noxygen atoms (red).Fig. 2 : The same \nCD1a-sulfatide com -\nplex as in Fig.1 tilted \n45\u00b0 on the horizontal \nplane. Colors as in \nFig. 1.2) Recognition of phosphorylated mevalonate metabolites \nby human TCR gamma/delta T cells\nWe have shown that a major population of human T cells expressing the TCR \ngamma/delta recognizes as antigens small phosphorylated non-peptidic \nmetabolites generated in the mevalonate pathway. Recognition of these an -\ntigens is dependent on presentation on the cell surface by dedicated ubiqui -\ntous and non-polymorphic antigen-presenting molecules. \nTumor cells, such as Burkitt\u2019s lymphoma cells, accumulate large amounts of \nthe stimulatory mevalonate metabolites and thus are potent stimulators of \nTCR gamma/delta T cells.\nThis feature has been exploited to target tumor cells from different human \ntissues for TCR gamma/delta T cell recognition. When tumor cells are incu -\nbated with aminobisphosphonate drugs, they accumulate the stimulatory \nmevalonate metabolites and acquire the capacity to be recognized and killed \nby TCR gamma/delta cells. \nThese studies indicate that tumor delivery of these drugs may represent a \nnovel approach to immunotherapy of tumors. 100/101Experimental\nImmunology\nProf. Dr. \nPeter Erb\nInstitut f\u00fcr Medizinische \nMikrobiologie\nGroup Members\nDr. Ji Jinming \nAndrea Glaser (technician ATA)\nMarion Wernli (technician ATA) \nJacqueline Samaridis (technician)\nKarsten Stauffer (technician)\nErwin Kump (PhD student)\nAinhoa Mielgo (PhD student)Skin Cancer \nUV Damage \nApoptosis \nImmune Escape \nRNA InterferenceThe Role of an Apoptosis-Inducing Regulator\nin Nonmelanoma Skin Tumors (Prof. Dr. P . Erb)\nLong-term UV-light exposure of human skin epidermis is associated with an in -\ncreased risk for the development of skin cancers. UV radiation not only induces \nDNA damage in epidermal cells, it also interferes with skin homeostasis, which \nis maintained by a unique distribution pattern of apoptosis-inducing and \u2013pre -\nventing molecules. If the DNA damage is not repaired or the damaged cells are \nnot eliminated by apoptosis, this can lead to cell transformation, uncontrolled \nproliferation and eventually to tumor formation (Fig. 1). \nApoptosis is induced by Fas-ligand (FasL) or TRAIL upon interaction with their \ncorresponding receptors, Fas or TRAIL-receptors (TRAIL-R). FLIP or certain \nmembers of the bcl-2 family can prevent apoptosis. We are investigating the \nrole of several cell death-inducing and -preventing molecules in the formation \nof nonmelanoma skin tumors, basal cell carcinoma (BCC) and squamous cell \ncarcinoma (SCC), but also in the escape of these tumors from the recognition \nby the immune system. \nIn normal, UV-protected skin epidermis, FasL but not Fas is expressed (Fig. 2a). \nFasL functions as a sensor, i.e. it not only prevents the influx of inflammatory \ncells, but also controls cell transformation. Exposure of the skin to UV-light up -\nregulates Fas and downregulates FasL. In chronic sun-exposed skin FasL cannot \nbe detected anymore at all, neither at the protein nor mRNA level (Fig. 2b). Thus, \nthe sensor function of FasL is lost, transformed cells cannot be efficiently elimi -\nnated and the risk of tumor formation is increased. Indeed, in actinic keratosis, \na precancerous stage, which can develop into SCC, FasL is not expressed. In \naddition, TRAIL-R are downregulated and apoptosis induction via the alternative \nTRAIL \u2013 TRAIL-R pathway is prevented as well.\nHowever, as soon as BCC or SCC have formed a complete turn-around becomes \nmanifest, FasL, but not Fas is now strongly expressed in the tumor cells (Fig. 2c). \nThus, FasL behaves like a double-edged sword. On the one hand, it protects the \nskin from tumor formation, on the other hand, once a tumor has formed it pre -\nsumably protects the tumor from the attack of the immune system. While ample \nevidence for such an immune escape mechanism is available in vitro, this has not \nas yet been proven in vivo. Therefore, we devised experiments to directly down -\nregulate FasL expression in tumor tissue. Two approaches were chosen, FasL \ngene silencing via specific phosphorothiated antisense oligonucleotides (ASO) \nor by RNA interference using synthetic short interfering RNA duplexes (siRNA). \nWith both, FasL-specific ASOs as well as siRNAs we successfully downregulated \nFasL expression not only in cell lines but also in normal skin epidermis and in \nBCC tissue. Thus, it is not only possible to transfect tumor tissue with ASOs or \nsiRNAs, but also to silence the gene of interest. These experiments now provide \nthe basis to test the immune escape hypothesis in vivo.Weichen Hauttumorzellen dem Immun-\nsystem aus? \u2013 Kann man dies verhindern?\nZuviel Sonne ist ein Hauptgrund f\u00fcr die Bildung von \nHauttumoren wie Melanom, Plattenepithelkarzinom \nund Basaliom. Die UV-Strahlen im Sonnenlicht k\u00f6nnen \nDNA in der Zelle mutieren. Solche Zellen m\u00fcssen durch \nprogrammierten Zelltod (Apoptose) eliminiert werden, \nsonst besteht das Risiko, dass sie sich zu Tumoren entwi -\nckeln. Ein Hauptmechanismus der Apotpose geschieht \nvia Interaktion zweier Molek\u00fcle, des Fas-Liganden (FasL) \nmit seinem Rezeptor Fas. In normaler, lichtgesch\u00fctzter \nHaut wird FasL exprimiert. Dieser verhindert, dass \nEntz\u00fcndungszellen in die Epidermis eindringen und \neliminiert transformierte Zellen. UV-Licht bewirkt nun, \ndass FasL nicht mehr exprimiert wird, dadurch geht die \n\u00abSchutzfunktion\u00bb gegen transformierte Zellen verloren \nund das Risiko der Tumorbildung ist stark erh\u00f6ht. Sobald \nsich aber ein Basaliom oder Plattenepithelkarzinom ge -\nbildet hat, wird FasL wieder exprimiert. Seine Funktion \nist jetzt aber eine andere, er sch\u00fctzt vermutlich den \nTumor vor dem Angriff des Immunsystems (\u00abImmune \nEscape\u00bb). Um dies zu beweisen haben wir eine Strategie \nentwickelt, um die Bildung von FasL im Tumorgewebe \nzu verhindern. Mittels spezifischen Antisense-oligonu -\nkleotiden oder sog. \u00abshort interfering RNA\u00bb (siRNA) \nMolek\u00fclen blockieren wir in den Zellen die mRNA, \nwelche das FasL Protein herstellt. Es ist uns gelungen, \nnicht nur diese Molek\u00fcle in das Tumorgewebe zu brin -\ngen, sondern auch die Expression des FasL im Tumor \nzu unterdr\u00fccken. Damit sind die Voraussetzungen ge -\nschaffen, die \u00abImmune Escape\u00bb Hypothese zu pr\u00fcfen. \nBewahrheitet sich diese Hypothese, so ergeben sich mit \nsiRNA Molek\u00fclen neue m\u00f6gliche Therapieformen f\u00fcr \ndiese Hauttumoren.\nSelected Publications\n\u2013 Buechner, S. A., Wernli, M., Harr, T., Hahn, S., Itin, \nP ., and Erb, P . (1997). Regression of basal cell carci -\nnoma by intralesional interferon-alpha treatment is \nmediated by CD95 (Apo-1/Fas)-CD95 ligand-induced \nsuicide, J Clin Invest 100, 2691-2696.\n\u2013 Bachmann, F ., Buechner, S. A., Wernli, M., Strebel, \nS., and Erb, P . (2001). Ultraviolet light downregulates \nCD95 ligand and trail receptor expression facilitating \nactinic keratosis and squamous cell carcinoma forma -\ntion, J Invest Dermatol 117, 59-66.\n\u2013 Buechner, S. A., Wernli, M., Bachmann, F ., Harr, T., \nand Erb, P . (2002). Intralesional interferon in basal cell \ncarcinoma, Recent Results in Cancer Research 160, \n246-250.\n\u2013 Ji, J. M., Wernli, M., Buechner, S., and Erb, P . (2003). \nFas ligand downregulation with antisense oligonucle -\notides in cells and in cultured tissues of normal skin \nepidermis and basal cell carcinoma, J Invest Dermatol \n120, 1094-1099.\n\u2013 Ji, J. M., Wernli, M., Klimkait, T., and Erb, P . (2003). \nEnhanced gene silencing by the application of mul -\ntiple specific small interfering RNAs, FEBS Lett 552, \n247-252.Clinics\nSkin cancers are by far the most frequent human malig -\nnancy . In the USA, every third cancer diagnosed is a skin \ncancer. These tumors include malignant melanomas and \nnonmelanoma skin cancers that are neoplasms of epithelial \norigin such as the basal cell carcinoma (BCC) and the squa -\nmous cell carcinoma (SCC). BCC is the most common cancer \nin humans. It is estimated that more than 1 million new cases \noccur per year in the United States. In central Europe, the \nincidence of BCC is around 30/10\u2019000 per year and the \nincidence of SCC is around 15/10\u2019000. An epidemiologi -\ncal survey in Switzerland has shown that the incidence of \nBCC has risen between 1976 and 1998. Exposure of the \nskin to UV radiation along with decreaseing ozon levels \nare thought to be responsible for the increase of the cases. \nNonmelanoma skin cancers occur predominantly in patients \nwith pale skin, red-blond hair and blue eyes. Moreover, 80% \nof the tumors are located on sun-exposed skin, i.e. the face \nand neck for BCCs and the back of the hand and the face \nfor SCCs. Most of the nonmelanoma skin cancers are due \nto mutations in the PTCH and p53 genes. Nodular BCC is \nthe dominant clinical variant of BCC. This tumor has an \ninfiltrating and destructive growth but in contrast to SCC \nusually does not metastasize. \nFig. 2  FasL expression in skin epidermis and SCC. \n(a) Sun-protected \nskin, FasL is ex -\npressed (red cells)(b) Sun-exposed \nskin, FasL is not \ndetectable(c) strong FasL \nexpression in SCC(d) Histological \nsection of BCC\nSCC  BCC Prof. Dr. \nStanislaw B\u00fcchner\nDermatologische \nUniversit\u00e4tsklinik\nUniversit\u00e4tsspital Basel\nFig. 1  Sun-light (UV)  \nexposure of the skin \ncan induce basal cell or \nsquamous cell \ncarcinoma formation.\n102/103\nPD Dr. \nUrsula G\u00fcnthertCD44 variant isoforms\nApoptosis\nAutoimmune diseases\nColorectal cancer\nHaematological tumorsProtection against Apoptosis is Mediated by \nCD44 Variant Isoforms (PD Dr. U. G\u00fcnthert)\nThe transmembrane glycoprotein CD44 and its many isoforms are adhesion \nmolecules, which are functionally involved in haematopoiesis, immune pathol -\nogy, embryonic development and neoplastic transformation. Although only \nencoded by one gene, CD44 isoforms represent a large family of molecules that \ndiffer in the primary structure. These differences are produced by alternative \nsplicing of at least ten unique exons, encoding extracellular regions out of a total \nof twenty exons (see scheme). We have generated genetically modified mice in \nwhich exons of the variant region are deleted without affecting the expression \nof the remaining exons. These exon-specific k.o. mice allowed for the functional \nanalysis of these regions in haematologic malignancies, in colon carcinogenesis \nand in autoimmune diseases.The role of CD44 as a survival factor, especially in \nautoimmune diseases and in colon carcinogenesis is a central project. Our goal \nis to find out which apoptotic pathways are involved, how they are regulated and \nhow the CD44 variant isoforms functionally block apoptosis in these diseases. \n1. Function of CD44v in autoimmunity\nA. In experimental autoimmune encephalomyelitis (EAE), a model for Multiple \nSclerosis (MS).  CD44v isoforms are required for the onset and maintenance \nof EAE \u2013 mice with deficiencies of these isoforms display reduced incidence \nand severity of EAE. With active and passive immunisation protocols we are \nevaluating whether CD44v deletions cause increased apoptosis of leukocytes \nin the central nervous system (CNS), altered cytokine profiles, and reduced \nmigration to the target organ (CNS) resulting in fewer infiltrates. Expression \nstudies are also performed in human MS brains, which showed CD44v pres -\nence in inflamed lesions. \nB. In experimental colitis, a model for human inflammatory bowel disease (IBD). \nIn mice, CD44v deletion results in reduced incidence and severity of colitis, \nincreased apoptotic capacity in the inflammatory lesions and reduced ability \nto develop CD4 transfer-induced colitis. Furthermore, in the chronically dis -\neased IL-10 k.o. mice, the deficiency for CD44v reduced substantially inflam -\nmatory lesions in the lamina propria. Comparative studies are performed with \ncells from patients with Crohn\u2019s disease.\nC. In collagen II induced arthritis (CIA), a model for human rheumatoid arthritis \n(RA).  CD44v deletion in mice results in reduced incidence and severity of ar -\nthritis (CIA and genetic model), increased production of CD4/CD44v cells in \nthe spleen of arthritogenic mice (genetic model), increased apoptotic capac -\nity in the inflammatory lesions of the joints (both models) and serum transfer \nfrom arthritogenic mice (KRNxNOD) results in reduced RA in CD44v k.o. \nrecipient mice.CD44 Isoformen sch\u00fctzen vor Programmi -\nertem Zelltod\nDas transmembran\u00e4re Gykoprotein CD44 existiert \nin vielen Formen. Diese verschiedenen Formen sind \nAdh\u00e4sionsmolek\u00fcle, welche bei der H\u00e4mopoiese \n(der Erneuerung der Blutzellen), bei Immunkrank -\nheiten, w\u00e4hrend der embryonalen Entwicklung und \nbei der Krebsentstehung eine wichtige Rolle spielen. \nEin einziges Gen ist f\u00fcr die verschiedenen Formen \nverantwortlich. Die Unterschiede entstehen durch so-\ngenanntes alternatives Splicing, eine unterschiedliche \nZusammensetzung von Genst\u00fccken, welche dann \nauch zu unterschiedlichen Proteinen f\u00fchrt (siehe die \nschematische Darstellung). Um die Funktionen dieser \nverschiedenen CD44 Formen zu studieren, haben wir \ngenetische Konstrukte generiert, welche, wenn sie ei -\nner Maus eingesetzt werden, die Herstellung gewisser \nspezifischer Zusammensetzungen von CD44 Einheiten \n(gewisse Isoformen) nicht mehr erlauben. Damit un -\ntersuchen wir nun die Rolle von CD44 Isoformen als \nzellul\u00e4re \u00dcberlebensfaktoren, insbesondere in Autoim -\nmunkrankheiten und bei Darmkrebs. Es gibt transgene \nM\u00e4use, welche gewisse Krankheiten (verschiedene \nKrebsarten, Autoimmun- od. Verdauungskrankheiten) \nschneller ausbilden und so als Modellsysteme dienen, in \ndenen wir spezifisch die Rolle unserer Konstrukte testen. \nUnsere Resultate zeigen, dass in Mausmodellen ohne \ngewisse CD44 Isoformen ,sich eine autoimmune Form \nder Enzephalomyelitis, gewisse Darmkrankheiten und \nArthritis weniger, weniger oft oder weniger gravierend \nentwickeln. Wenn man umgekehrt in Zelllinien gewisse \nCD44 Isoformen einbringt so zeigt sich, dass diese vor \ndem programmierten Zelltod sch\u00fctzen. Das Absterben \nfehlerhafter Zellen ist jedoch f\u00fcr die Gesundheit und das \n\u00dcberleben des ganzen Organismus Lebenswichtig. Zu -\nsammengefasst k\u00f6nnen wir mit den erlangten Erkennt -\nnissen neue Immuntherapieformen gegen spezifische \nCD44 Isoformen schon im Mausmodell testen und f\u00fcr \nmenschliche Anwendungen ins Auge fassen.\nSelected Publications\n\u2013 G\u00fcnthert, U., Hofmann, M., Rudy, W., Reber, S., Z\u00f6l-\nler, M., Hau\u00dfmann, I., Matzku, S., Wenzel, A., Ponta, \nH., Herrlich, P . (1991) A new variant of glycoprotein \nCD44 confers metastatic potential to rat carcinoma \ncells. Cell 65, 13-24.\n\u2013 Stauder, R., Eisterer, A., Thaler, J., G\u00fcnthert, U. (1995) \nCD44 variant isoforms in non-Hodgkin\u2019s lymphoma: A \nnew independent prognostic factor. Blood 85, 2885-\n2899.\n\u2013 Wittig B., Johannson, B., Z\u00f6ller M., Schw\u00e4rzler C., \nG\u00fcnthert U. (2000) Abrogation of experimental colitis \ncorrelates with increased apoptosis in mice deficient \nfor CD44v7. J. Exp. Med., 191, 2053-2063.\n\u2013 Eisterer W., Bechter O., Hilbe W., van Driel M., \nLokhorst H.M., Thaler J., Bloem A.C., G\u00fcnthert U., \nStauder R. (2001) CD44 isoforms are differentially \nregulated in plasma cell dyscrasias and CD44v9 rep -\nresents a new independent prognostic parameter in \nmultiple myeloma. Leuk. Res. 25, 1051-1057.\n\u2013 van Driel, M., G\u00fcnthert, U., van Kessel, A.C., Joling, P ., \nStauder, R., Lokhorst, H.M., Bloem, A.C. (2002) CD44 \nvariant isoforms are involved in plasma cell adhesion to \nbone marrow stromal cells. Leukemia 16, 135-143.Clinics\nWe have a long-standing collaboration on haematological tumours with haematologist \nProf. Dr. Reinhard Stauder , University Hospital Innsbruck, Austria. \nThe specific upregulation of CD44 variant isoforms in Non-Hodgkin lymphoma (NHL) \ncells and Multiple myeloma (MM) cells is an independent indication for an adverse \nprognosis of the patient. Protection of the tumour cells against Fas mediated cell death \nis another cause for tumour progression and hence poor prognosis. The upregulation \nof CD44v isoforms in haematological tumours and the resistance to undergo cell death \nappear to be directly and functionally linked. Understanding the mechanisms how CD44v \nisoforms interfere with Fas mediated cell death may lead to the development of new \nstrategies for diagnosis and treatment of NHL and MM patients. The insensitivity to cell \ndeath induction is a major enigma in haematological diseases resulting in accumulation \nof malignant cells in the specific sites. Moreover, defects in the apoptosis pathways \nmay lead to resistance towards chemotherapy and irradiation, pointing out the need \nfor specific diagnostic approaches (to distinguish susceptible patients groups) as well \nas apoptosis-based therapies. Despite numerous efforts to elucidate the mechanisms \nof resistance to apoptosis in tumourigenesis, no conclusive results were obtained so \nfar. Crohn\u2019s disease, a human inflammatory bowel disease, is characterised by strong \nexpression of CD44v in the lamina propria of inflamed lesions. Therapeutic strategies \nfor apoptosis induction of the CD44v expressing cells is evaluated in collaboration with \ngastroenterologist PD. Dr. Bianca Wittig , University Hospital Benjamin Franklin, Charit\u00e9 \nBerlin, Germany. Fig. 1  Colocalization of CD95 and CD44v on the surface of Jurkat cells.2. Function of CD44v in tumour progression:\nInitiation of neoplastic alterations in colorectal tumors \u2013 the role of CD44 \nvariant isoforms in interaction with adenomatous polyposis coli (APC) in the \nwnt signaling pathway.  Mice carrying an APC mutation called Min (multiple \nintestinal neoplasia), and that are, in addition, deficient for CD44v isoforms, \ndevelop considerably fewer polyps and survive much longer than APC/Min \nmice, which carry the CD44 wildtype gene. The concomitant truncation of \nthe APC protein and the overexpression of CD44v isoforms are seemingly \nlinked in the earliest stages of colon carcinogenesis. We are interested to find \nout how these molecules interact and which mechanisms lead to resistance \nof the tumour cells against programmed cell death. \n3. Function of CD44v in apoptosis blockade:\nCD44 variant isoforms interfere with Fas mediated cell death. CD44v trans -\nfected Jurkat cells are strongly protected against Fas-mediated apoptosis. \nFurthermore, CD44v9 transfected XG-1 plasmacytoma cells are protected \nagainst Fas-mediated apoptosis. CD44v co-localises with Fas on the surface \nof Jurkat cells and implicates a functional correlation.\nAnti-CD44v therapeutic approaches could be an intriguing novel potential \nfor the treatment of autoimmune diseases and tumourigenesis by specifically \ninducing cell death in these CD44v positive regions.\nOrganization and \nnomenclature of \nCD44v isoforms\n104/105Immuno-\nbiology\nDr. Christoph Hess\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup members\nDr. Olivier Gasser\nDr. Anna MissiouKidney transplantation\nEpstein-Barr virus (EBV)\nPost-transplant lymphoproliferative disorder \n(PTLD)\nCD8 T cells\nQuality and quantity of the immune responseImpact of Post Kidney-allograft Immuno-\nsuppression on the Host Immune Response \nto Epstein-Barr Virus\nAbstract\nThe newly formed Immunobiology lab aims at investigating the impact of iatro -\ngenic immuno-suppression (IS), as established in kidney allotransplantation, on \nthe Epstein-Barr virus (EBV)-specific CD8 T cell response. The transplant setting \noffers a unique window into in vivo-strategies utilized by the immune system to \nefficiently control lytic EBV infection, and prevent malignant transformation of \nlatently infected B cells. Furthermore, an improved knowledge of EBV-specific \nimmunity may allow identification of individuals at risk for developing EBV-as -\nsociated pathology.\nBackground\nRenal transplantation is the therapy of choice for end-stage renal disease. In \nSwitzerland around 200 kidney transplants are performed yearly, 60\u201370/year \nin Basel. Cyclosporine, tacrolimus or sirolimus combined with mycophenolate \nmofetil (or azathioprine) and prednisone, are the mainstays of IS. Induction \ntherapies include T cell antibodies and, more recently, interleukin-2 receptor \nblockers. Complications include infection, rejection, and malignancy. Chronic \nallograft failure remains the main problem limiting long-term success.\nViral pathogens are an important cause of morbidity following transplantation. \nViruses playing prominent roles in the post-transplant setting include (i) herpes \nviruses (EBV, cytomegalovirus, herpes simplex virus, varizella zoster virus, hu -\nman herpes viruses 6-8), (ii) hepatitis viruses (hepatitis C virus, hepatitis B virus), \n(iii) the papillomavirus (JC virus), (iv) the polyomavirus (BK virus) as well as \n(v) influenza/parainfluenza viruses.\nEBV infection or reactivation is thought to play a major role in the genesis of post-\ntransplant lymphoproliferative disorder (PTLD), one of the most life-threatening \ncomplications of IS in allograft recipients. Most PTLD tumor cells present an acti -\nvated B-cell phenotype and an unrestricted pattern of latent EBV gene products. \nThe overall incidence of this malignancy in renal transplant recipients is 1\u20132%, \nbut varies with the nature and severity of the immunosuppressive regimen.\nHLA class I restricted CD8 T cells are an essential component of the protective \nimmune response against a variety of viral infections, including EBV. The out -\ncome of EBV-infection is containment rather than eradication. An effective host \nresponse to infection depends on production of (i) functional CD8 T cells and (ii) \ntheir attraction to sites of viral replication.Virusinfekte nach Nierentransplantationen\nDie Nierentransplantation ist das Nierenersatz-Wahlver -\nfahren bei chronischem Nierenversagen. \nUm Transplantatabstossungen zu verhindern, ist eine \nunspezifische medikament\u00f6se Schw\u00e4chung des Im -\nmunsystems n\u00f6tig. Durch diese Schw\u00e4chung kann es \ndazu kommen, dass bestimmte Viren die bei normalem \nImmunsystem problemlos in Schach gehalten werden, \nsich unkontrolliert vermehren und dadurch krankma -\nchend werden.\nIm k\u00fcrzlich gegr\u00fcndeten Immunobiologie Labor versu -\nchen wir die immunologische Grundlage von Problemen \nmit dem Epstein-Barr Virus (EBV) nach Nierentransplan -\ntation zu beleuchten. Ziel unserer Forschung ist es, Me -\nchanismen der immunologischen Kontrolle von viralen \nInfekten besser verstehen zu lernen. Schlussendlich \nhoffen wir dadurch Patienten bei welchen EBV ausser \nKontrolle zu geraten droht fr\u00fchzeitig nach Transplanta -\ntion indentifizieren zu k\u00f6nnen.\nSelected Publications\n\u2013 Hess C., S. Sadallah, A. Hefti, R. Landmann, J.A. \nSchifferli (1999) Ectosomes Released by Human \nNeutrophils are Specialized Functional Units. J. Im -\nmunol. 163:4564-73.\n\u2013 Hess C., S. Sadallah, J.A. Schifferli (2000) Induction \nof neutrophil responsiveness to myeloperoxidase an -\ntibodies by their exposure to supernatant of degranu -\nlated autologous neutrophils. Blood 15; 2822-7.\n\u2013 Hess C., Th. Klimkait, L. Schlapbach, V . Del-Zenero, \nS. Sadallah, G. Ballestra, V . Werder, C. Schaefer, M. \nBattegay, J.A. Schifferli (2002) HIV-1 is associated \nwith erythrocytes in vivo. Lancet 359: 2230-34.\n\u2013 Hess C., M. Altfeld, S.Y . Thomas, M.M. Addo, E.S. \nRosenberg, T.M. Allen, R. Draenert, R.L. Eldridge, \nJ.v. Lunzen, H.J. Stellbrink, B.D. Walker, A.D. Luster \n(2004) HIV-1-specific CD8 T-cells with an effector-\nphenotype and control of viral replication. Lancet \n363:863-6.\nIS, as initiated with kidney allotransplantation, alters the balance between the \nhost immune response and EBV. Breadth, magnitude, immune-phenotype, \nand ex-vivo function of EBV-specific CD8 T cells will be monitored through \nlongitudinal ELISpot analyses, flow-cytometry based phenotypic characteri -\nzation, cytotoxicity assays and proliferation assays.\nAttraction of leukocytes to tissues is essential for inflammation and the host \nresponse to infection. This process is controlled by chemokines, which are \nchemotactic cytokines . Regulation and function of chemokines/chemokine \nreceptors involved in controlling trafficking of EBV-specific CD8 T cells in kid -\nney allograft recipients will be studied prior and sequentially under IS. To this \naim, quantitative PCR, flow-cytometry based chemokine/chemokine recep -\ntor analyses, chemotaxis assays, calcium-flux assays, internalization-studies \nand western-blot analyses will be used.\nTogether these data will monitor quantitative  as well as qualitative  changes \nof the EBV-specific CD8 T cell response following transplantation, and may \nallow insight into both basic and clinical aspects of the EBV-specific immune \nresponse.\nFig. 1:  Immuno-suppression, as initiated at the time of kidney transplantation, \nindicates a shift in the balance between EBV and the EBV-specific immuneresponse.\n106/107Immuno-\nnephrology\nProf. J\u00fcrg A. Schifferli\nDepartement Forschung Universit\u00e4tsspital Basel\nGroup members\nDr. Marten Trendelenburg\nDr. Olivier Gasser\nDr. Jameel Inal\nDr. Salima Sadallah\nBrigitte Schneider (Technician)\nKwok Min Hui (PhD Student)\nCeylan Eken (PhD Student)\nSigrun Lange (PhD Student)Ectosome\nNeutrophil\nInflammation\nComplement\nCRITCharacteristics and Functions of Ectosomes \nreleased by Human Polymorphonuclear \nNeutrophils\nUpon activation, human polymorphonuclear neutrophils (PMN) release micro -\nvesicles, called ectosomes, directly from the cell surface. This release occurs \nin vitro as well as in vivo at sites of inflammation but also in blood when the \nactivation of PMN is generalized as in sepsis. Ectocytosis is known to include \nthe loss of cellular phospholipid-asymmetry, a process triggered by intra-cel -\nlular calcium influx. As a consequence, ectosomes bear phosphatidylserine on \ntheir outer membrane leaflet. Ectosomes express at their surface a series of \nproteins as well, including receptors and active enzymes, such as elastase and \nmyeloperoxidase. Some of the proteins present on ectosomes are acquired from \nplasma. For instance ectosomes bind C1q, the first component of the comple -\nment cascade. The binding of C1q is followed by activation of the classical \npathway of complement, leading to the opsonisation of PMN-ectosomes with \nC3- and C4-fragments. Complement-opsonisation of PMN-ectosomes is of \nprime importance for their fate in the circulation, since it drives their immune-ad -\nherence to erythrocytes (Fig. 1), similarly to immune complexes. The biological \nsignificance of this observation is unknown, however it might be suggested that \nthis binding contributes to the clearance of ectosomes by fixed macrophages \nand may prevent unwanted interactions with endothelial cells. Indeed, we could \nshow in vitro that ectosomes bind specifically to endothelial cells. Interestingly, \nmonocytic/macrophages (MM) bind and phagocytose ectosomes rapidly. How -\never, these reactions do not activate MM to become more aggressive. To the \ncontrary, this phagocytosis modifies the programme of MM so that they release \nanti-inflammatory cytokines such as TGFb1. This property of ectosomes is not \nwithout some resemblance to properties of cells undergoing apoptosis, which \ndie and are phagocytosed \u201cin silence\u201d. Whether the expression of phosphatidyl -\nserine is the main mediator of such effects is under investigation.\nIn sum, and as a general biological observations, cells \u2013 here PMN \u2013 communi -\ncate with other cells not only via soluble mediators or cell/cell contact, but also \nby the release of ectosomes which are capable of transmitting signals.Ectosome als interzellul\u00e4re Signal\u00fcber -\ntr\u00e4ger / Complement C2 Receptor Inhibitor \nTrispanning (CRIT)\nDie gr\u00f6sste Gruppe der weissen Blutk\u00f6rperchen sind \ndie Granulozyten, auch polymorphonukle\u00e4re Zellen \ngenannt. Die neutrophilen polymorphonukle\u00e4ren \nZellen (PMN) scheiden Mikrovesikel aus, wenn sie \naktiviert werden. Sie tun dies an entz\u00fcndeten Stellen \nim K\u00f6rper aber auch im Blut selbst im Falle von Infek -\ntionen. Das Ausscheiden der Mikrovesikel (auch PMN \nEctosomen genannt) geschieht durch Ectozytose. Die -\nse Mikrovesikel tragen an ihrer Oberfl\u00e4che zahlreiche \nProteine, wovon einige aus dem Plasma stammen. Von \nbesonderem Interesse ist, dass sie das Protein C1q \nbinden. C1q ist der erste Bestandteil im sogenannten \nKomplementsystem, einem wichtigen Bestandteil \ndes Immunsystems. Sobald C1q gebunden ist, wird \ndas Komplementsystem in klassischer weise aktiviert, \nwodurch die PMN Ectosome opsoniert werden. Unter \nOpsonisation versteht man eine Protein-Ummantelung \nwelche die Phagozytose erleichtert. Dies f\u00fchrt nun dazu, \ndass die PMN Ectosome an Erythrozyten binden (Fig. 1) \nund durch Makrophagen verschlungen werden. Die bio -\nlogische Bedeutung dieser Beobachtung ist unbekannt, \nwir vermuten jedoch, dass dadurch eine sch\u00e4dliche \nInteraktion der PMN Ectosome mit Endothelialzellen \nverhindert werden soll. Erstaunlicherweise werden \ndurch diese Phagozytose die Makrophagen \u2013 \u00e4hnlich \nwie bei der Phagozytose apoptotischer Zellen \u2013 nicht \naggressiver, sondern scheiden entz\u00fcndungshemmende \nZytokine wie TGFb1 aus.\nWir widmen unsere Forschung auch einem menschli -\nchen Protein, CRIT (Fig. 2). Ein Schistosom Parasit der \nBlutbahnen hat auch ein CRIT Protein und ist gegen\u00fcber \ndem Immunsystem \u00e4usserst resistent. Wir vermuten, \ndass das Parasit dieses Protein vom Wirt \u00fcbernommen \nhat um der Abwehr auszuweichen. CRIT verhindert eine \n\u00dcberreaktion des Komplementsystems und wir hoffen \nmit CRIT Therapieformen f\u00fcr gewisse Autoimmunreak -\ntionen zu entwickeln. \nSelected Publications\n\u2013 Hess, C., Sadallah S., Hefti A., Landmann R., and \nSchifferli J.A. (1999) Ectosomes released by human \nneutrophils are specialized functional units. J Immu -\nnol. 163:4564-73.\n\u2013 Gasser, O., Hess C., Miot S., Deon C., Sanchez J.-C., \nSchifferli J. A. (2003) Characterisation and properties \nof ectosomes released by human polymorphonuclear \nneutrophils. Exp Cell Res. May 1;285(2):243-57.\n\u2013 Gasser, O., Schifferli J. A. (2004) Activated polymor -\nphonuclear neutrophils disseminate anti-inflamma -\ntory microparticles by ectocytosis. Blood, in press\n\u2013 Inal, J., Schneider, B., Armanini, M., and Schifferli, \nJ.A. (2003) A peptide derived from the parasite recep -\ntor, Complement C2 Receptor Inhibitor Trispanning, \nCRIT, suppresses immune complex-mediated inflam -\nmation in mice. J. Immunol 170, 4310.\n\u2013 Inal, J. and Schifferli, J.A. (2002) Complement C2 \nreceptor inhibitor trispanning (CRIT) and the _-\nchain of C4 share a binding site for complement C2. \nJ. Immunol. 168, 5213.Clinics\nThe human Schistosome parasite lives in human blood ves -\nsels and has very efficient defence mechanisms against the \nattack of the human immune system, in particular against \nthe enzymes of the complement cascade. One of the para -\nsite proteins involved in this defence is CRIT (Complement \nReceptor Inhibitory Trispanning, Fig. 2), which is capable of \nblocking complement. We now found that humans have a \nprotein highly similar to parasite CRIT, suggesting that the \nSchistosome may have acquired CRIT from humans, thereby \ngaining an evolutionary advantage. In humans, CRIT con -\ntrols excessive activation of complement, suggesting that \nCRIT-based therapies could one day control diseases where \ncomplement attacks the body in an unregulated manner. \nFig. 1:  Fluorescence microscopy of the binding of labeled ectosomes (arrows) to \npurified erythrocytes in the presence of complement\nFig. 2108/109Infectious \nDiseases\nProf. Dr. Regine Landmann\nDepartement Forschung \nUniversit\u00e4tsspital Basel\nGroup members\nDr. Sascha Kristian \nDr. Anne Stalder \nDr. Andrea Steinhuber\nFabricia Ferracin (technician)\nZarko Rajacic (technician) \nHakim Echchchannaoui (PhD student)Staphylococcus Aureus\nInfection\nNosocomial Disease \nToll-like Receptor 2\nVirulence FactorMolecular Mechanisms of Host Defense and \nVirulence Factor Regulation in S. pneumoniae  \nand S. aureus Infection.\nHost defense via Toll-like receptor 2 against S. pneumoniae  and S. aureus\nToll-like receptors and CD14 are host pattern recognition receptors, which medi -\nate innate immune responses to pathogen-derived molecules. TLR2 and CD14 \nspecifically respond to teichoic acids and other cell wall and membrane compo -\nnents from gram-positive bacteria. Teichoic acids are positively charged polysac -\ncharides intercalated in the cell wall; they contribute to virulence by determining \nthe surface charge and thus the resistance against host-derived cationic peptides. \nIn isolated form, the wall components elicit an inflammatory response in host cells \nvia TLR2/CD14. The responses include cytokines, chemokine, nitric oxide in \nphagocytes, maturation in dendritic cells and defensin release in epithelial cells. \nThe function of these cell wall components in the interaction with host TLR2/\nCD14 is however unknown, if they are exposed as part of live pathogens such as \nStreptococcus (S.) pneumoniae , which is the major agent responsible for adult \nmeningitis and in Staphylococcus (S.) aureus , which causes device-related infec -\ntions, pneumonia and sepsis. Therefore we are investigating the impact of TLR2 \nand CD14 on infection in mice with either of these bacteria and of their isogenic \nmutants expressing altered TLR2/CD14 ligands. S. pneumoniae  meningitis is a \nsevere disease with a 30 % mortality. The pathogenesis is due to bacteria-induced \ninflammation, which leads to vascular and neuronal damage. TLR2 and CD14 \nmodulate the disease course, since TLR2-/- and CD14-/- mice are more severely \nsick and die earlier than wild type mice. Yet their mechanism of action differs; \nTLR2-/- mice have early enhanced bacterial load (Fig. 1 and 2), delayed phagocy -\ntosis and bacterial killing of granulocytes and CD14-/- mice have early accelerated \nleukocyte immigration; both mouse strains have consequently enhanced inflam -\nmation, measured as leukocyte-derived TNF in infiltrating cells, which is the \ncause of death. Our future studies aim at unravelling the mechanism how TLR2/\nCD14 affect bacterial killing and leukocyte migration.Staphylococci are the cause \nof device-related infections. A mouse tissue cage infection model, in which low \ninocula of S. aureus  or S. epidermidis  cause a persistent local infection, exactly \nreproduces orthopedic implant infection. Persistence is explained by the absence \nof vessels and opsonins and the presence of functionally weak leukocytes un -\ndergoing apoptosis. Virulence is dependent on the staphylococcal susceptibility \nto extracellular bactericidal activity in an immunocompetent host. Therefore this \nmodel serves to test S. aureus  mutants, which are altered in susceptibility to any Staphylokokkeninfekte an Fremd-\nk\u00f6rpern \u2013 wie passen sich der Wirt und das \nBakterium an?\nStaphylokokkeninfekte sind die h\u00e4ufigste Komplikati -\non von Prothesen- und Katheter-Implantationen. Der \nWirt verf\u00fcgt \u00fcber nat\u00fcrliche Abwehrmechanismen, \ndie \u2013 nach Stimulation durch Zellwandbestandteile \ndes Staphylokokken \u2013 zur Bakterienabt\u00f6tung und Ent -\nz\u00fcndung f\u00fchren k\u00f6nnen, im Fremdk\u00f6rperinfekt aber \noft nicht gen\u00fcgen. Wir zeigten die Rolle des \u201cToll-like \nRezeptors-2\u201d f\u00fcr die Abwehr gegen Staphylokokken \nund untersuchen weitere molekulare Mechanismen \nder nat\u00fcrlichen Immunantwort in einem Mausfremd -\nk\u00f6rperinfektmodell.\nStaphylokokken verf\u00fcgen ihrerseits \u00fcber Oberfl\u00e4chen -\nstrukturen (Adhesine) und Toxine, die die F\u00e4higkeit eine \nInfektion zu verursachen d.h. die Virulenz beeinflussen. \nDas obige Mausinfektmodell eignet sich hervorragend \nzur Untersuchung der Virulenzfaktoren. Wir zeigten, \ndass Gene, welche Virulenzaktoren kodieren in vivo \nund in vitro unterschiedlich exprimiert und reguliert \nsind. Weitere Analysen der molekularen Anpassung \nvon Staphylokokken im Fremdk\u00f6rperinfekt sind von \nBedeutung f\u00fcr die Erkennung der Faktoren, welche \ntherapeutische Ziele in S. aureus darstellen k\u00f6nnten.\nSelected Publications\n\u2013 Echchannaoui H., K. Frei, C. Schnell, S. Leib, W. \nZimmerli, R. Landmann (2002). Toll-like receptor 2-\ndeficient mice are highly susceptible to Streptococ -\ncus pneumoniae  meningitis due to reduced bacterial \nclearing and enhanced inflammation.J Infect Diseases \n186:798-806.\n\u2013 Wolz C., C. Goerke, R. Landmann, W. Zimmerli, U. \nFl\u00fcckiger (2002). Transcription of clumping factor A \nin attached and unattached Staphylococcus aureus  \nin Vitro and during device related infection. Infect. \nImmun, 70: 2758-2762.\n\u2013 Hirsch HH., W . Knowles, M. Dickenmann, J. Passweg, \nT. Klimkait, MJ.Mihatsch, J. Steiger (2002). Prospec -\ntive study of polyomavirus type BK replication and \nnephropathy in renal-transplant recipients. N Engl J \nMed, 347: 488-496.\n\u2013 Kristian S., X. Lauth, V . Nizet, F . Goetz, B. Neumeister, \nA. Peschel, R. Landmann (2003) Alanylation of tei -\nchoic acids protects Staphylococcus aureus  against \nToll-like receptor 2-dependent host defense in a \nmouse tissue cage infection model. J Infect Diseases, \n188: 414-423.\n\u2013 Dory D., M Letiembre, H. Echchanaouui, F . Ferracin, \nJ. Pieters, Y . Adachi, S. Akashi, R. Landmann (2003). \nGeneration and functional characterization of a clonal \nmurine periportal Kupffer cell line from H2Kb \u2013tsA-58 \ntransgene mice. J Leukoc. Biol. 74: 49-59.Clinics\nResearch concentrates on Staphylococcus aureus  infections, \ninfections in the transplant patients and HIV-infection. All \nareas are related to research within the DKBW . Staphylococ -\ncus aureus  infections are among the most serious bacterial \ninfections. We examine the epidemiological relevance of \nsevere S. aureus  infections and colonization as well as \npredictors of severe S. aureus  infection. Infections in the \ntransplant patient are a focus of our team. We are particularly \ninterested in fungal infections and in BK virus nephropathy \nwhich represents in renal-transplant recipients a secondary \ninfection. Clinical research of HIV infection has concentrated \non the natural disease course and the immune recovery of \nCD4-T-lymphocytes after start of highly potent antiretrovi -\nral therapy. Immune recovery is strongly dependent on the \ndegree of viral load reduction, individual factors such as \nage and pre-therapy baseline values such as immune status. \nOther clinical studies are directly related to clinical work \nsuch as a newly proposed algorithm for the management \nof tuberculosis in refugees.\nof the bactericidal mechanisms. The host response is mediated by phagocytes \nexclusively and comprises defensins, reactive oxygen species, cytokines, \nchemokines, leukocyte infiltration and apoptosis. S. aureus  expressing mutant \nteichoic acids, which lack positively charged alanine, are virulence-attenuated \nin cage infection in wild type mice, because they are more susceptible to host \ncationic antimicrobial peptides. Virulence is restored in the same infection in \nTLR2-/- mice, most likely because defensin production is TLR2-dependent. In \nfuture, the impact of other mutations in peptidoglycan and lipoproteins on \nS. aureus  virulence in intact and TLR-deficient mice is studied.\nRegulation and expression of virulence factors in S. aureus  \nThe tissue cage infection also serves to study gene expression of staphyloco -\nccal virulence factors. S. aureus  expresses multiple surface adhesins, which \nparticipate in colonization and invasion. Among them clumping factor A, a \nfibrinogen binding protein is important for adherence to extracellular matrix \ncoated surfaces. It is modulated by host factors, since its gene expression is \nhigher in vitro than in vivo, it is upregulated late in infection and is higher in \nadherent than in planktonic bacteria in tissue cages. In future the regulation \nand function of virulence factor genes and products, which affect biofilm, is \nfollowed in vivo (Fig.3). \nFig. 1:  Visualization of luci -\nferase-tagged S. pneumoniae  \nwith a CCD camera in live \nanaesthetized mice 6 to 24 h \nafter subarachnoidal \ninfection.Bacterial load is \nhigher in TLR2-/- (upper row) \nthan in wild type mice (lower \nrow).Fig. 2:  Scanning electron \nmicrograph of S. aureus  grown \nunder aerobic (left) and unaer -\nobic (right) conditions. Under \nunaerobic conditions the pro -\ncution of slime (polysaccharide \nadhesin) is strongly enhancedFig. 3:  Green fluorescent protein-tagged \nS. pneumoniae  (green in left picture) in ven -\ntricles of mice with pneumococcal meningitis, \nsurrounded by GFAP-stained astrocytes \n(red in left picture) and are associated with \nleukocytes stained with an antigranulocyte \nantibody (red in right picture). Insert: Larger \nmagnification of leukocyte-associated \nS. pneumoniae\nProf. Dr. \nManuel Battegay\nPD Dr. \nUrsula Fl\u00fcckiger\nInfektiologische Klinik \nUniversit\u00e4tsspital Basel\nPD Dr. Stefano Bassetti \nDr. Luigia Elzi \nDr. Gilbert Kaufmann \nDr. Gerd Laifer \nDr. Pedram Sendi \nDr. Maja Weisser\nProf. Dr. Hans Hirsch\n110/111Molecular \nResearch \nfor Diagnostics\nPD Dr. Thomas Klimkait \nInstitut f\u00fcr Medizinische Mikrobiologie\nGroup Members\nDr. Vincent Brondani\nDr. Fran\u00e7ois Hamy\nClaudia J\u00f6rg (Technician)\nSt\u00e9phane Hubert (Technician)\nS\u00e9verine Louvel (PhD Student)\nDaniela Kenzelmann (Diploma Student)Quantitative PCR\nPhenotyping\nTreatment resistance\nReporter systems\nHIV\nOncologyPhenotyping for Molecular Diagnosis \nof Therapy Resistance\nIn 2003 the research group Klimkait (\u201cMolecular Research for Diagnostics \n(MRD)\u201d) focused its anti-HIV activities on aspects of the co-existance of clini -\ncally relevant virus variants. The basis for this focus was the clinical observation \nthat even during highly effective therapy several viruses can co-evolve in the \nsame patients. This phenomenon can occur quite rapidly (within months) and \nposes a significant complication in the diagnosis of therapy-escaping viruses \nthat carry resistances to specific drugs. In addition viral recombination has now \nbeen demonstrated for retroviruses, another effective route for viral treatment-\nescape. The research group MRD has developed a phenotyping system, which \nfunctions quite analogous to the well-established antibiogram for microbes. This \nnew diagnostic tool has been designed to detect and characterize HIV-resistance \nin clinical samples; it is in Switzerland currently the only system of its kind and is \nreimbursed by the Swiss health care system. \nIn the year 2003 MRD has invested in a second, concept-expanding develop -\nment, which originated in the concept of phenotyping resistance to antiviral \ndrugs. The adaptation will lead to an application in drug resistant cancers by tar -\ngeting the molecular cause of chronic myeloid leukemia, the Philadelphia-chro -\nmosome-linked BCR-ABL. A reliable reporter system is being established for the \nassessment of Gleevec resistance as well as a patient\u2019s genetic predisposition \nlinked to treatment failure with this novel drug.\nAside from research towards diagnostics systems with direct utility, MRD invest -\ned research into treatment applications of oligonucleotides, to be used either \nas DNA- or small interfering RNA molecules. Using cell culture models in the \ncontext of cell functions (CXCR4 and the androgen receptor) these approaches \nmight have a direct bearing for cancer strategies (metastasis and prostate cancer, \nrespectively).\nIn June 2003 the group received, upon assistance by the University\u2019s technology \ntransfer office (WTT), a patent on an HIV inhibitor, which follows the unique \nconcept of simultaneously blocking viral gene activation and secondary events \non the target cell, triggered by HIV . Ph\u00e4notypisierung als \u201cMolekulares \nDiagnostikum\u201d von Therapieresistenzen\n \nIm Jahr 2003 konzentrierte die Forschungsgruppe \nKlimkait (MRD) ihre ani-HIV Aktivit\u00e4ten auf Aspekte \nder Ko-Existenz verschiedener klinisch relevanter HIV-\nVarianten im Patienten. Diese Fokussierung entstand \naus der Beobachtung, dass selbst unter Therapie im \nPatienten zeitgleich mehrere HIV-Mutanten evolvieren \nk\u00f6nnen. Dies kann innert weniger Monate geschehen, \nund solche resistente Viren stellen inzwischen ein sehr \nernstes Problem f\u00fcr das klinische Management einer \nHIV-Infektion dar. Die Entdeckung, dass Retroviren ihr \nErbgut rekombinieren k\u00f6nnen, erkl\u00e4rt ausserdem ein \nbeschleunigtes Therapieversagen. Das in der Gruppe \nMRD entwickelte Ph\u00e4notypisierungssystem \u201cPheno -\nTecT\u201d weist \u00c4hnlichkeiten zum \u201cAntibiogramm\u201d auf, \nwelches in der Mikrobiologie l\u00e4ngst breite Anwendung \ngefunden hat, und wurde so konzipiert, dass es f\u00fcr die \nRoutineanwendung an Plasmaproben sowie f\u00fcr Medi -\nkamentenprofilierungen in der Entwicklung ideal ist; in \nder Schweiz ist es zurzeit das einzige solche System, das \n\u00fcber die Analysenliste abgerechnet werden kann.\nEin zweites Projekt der Gruppe MRD erweitert das an \nHIV validierte Konzept in ein neues Anwendungsgebiet: \ndie Krebstherapie. Gegen chronisch myeloische Leuk -\n\u00e4mie wird heute Glivec erfolgreich eingesetzt, welches \ngezielt das mit dem Philadelphia-Chromosom assoziierte \nBcr-Abl Gen blockiert. Ein zuverl\u00e4ssiges Ph\u00e4notypisie -\nrungssystem ist in der Gruppe MRD in Entwicklung. Es \nsoll Glivec-Resistenz und eine ung\u00fcnstige genetische \nPr\u00e4disposition in betroffenen Patienten detektieren, \nohne dass ganze Chromosomenabschnitte sequenziert \nwerden m\u00fcssen. \nWeitere Forschungsprojekte befassen sich mit der Funk -\ntion der zellul\u00e4ren Co-Rezeptoren von HIV , Oligonukleo -\ntidanwendungen und neuen Diagnostik-Strategien in Vi -\nrologie und Onkologie. Im Jahr 2003 erhielt die Gruppe \nunter Mithilfe der WTT der Universit\u00e4t Basel ein Patent \nauf ein neues Konzept der HIV-Hemmung, bei welchem \n\u201cEntry\u201d und Genaktivierung blockiert werden. \nSelected Publications\n\u2013 Su\u00f1\u00e9, C.; L. Brennan; D.R. Stover; and T. Klimkait \n(2003) Effect of polymorphisms on the replicative \ncapacity of protease inhibitor-resistant HIV-1 vari -\nants under drug pressure. Clin.Microbiol.Inf. 10:\n119-126\n\u2013 Hamy, F .; V . Brondani; R. Spoerri; S. Rigo; C. Stamm; \nand T. Klimkait. (2003) Blocking Androgen Receptor \nActivity in LNCaP cells by Antisense Oligonucle -\notides. Prostate Cancer and Prostatic Diseases 6 (1), \n27-33\n\u2013 Hess, C.; T. Klimkait; L. Schlapbach; V . Del Zenero; \nS. Sadallah; E. Horakova; G. Balestra; V . Werder; C. \nSchaefer; M. Battegay; and JA. Schifferli (2002) As -\nsociation of a pool of HIV-1 with erythrocytes in vivo: \na cohort study. Lancet 359, 2230-2234\n\u2013 Hirsch, HH.; M. Mohaupt; and T. Klimkait (2001) \nProspective Monitoring of BK Virus Load in a Patient \nwith BK Virus Allograft Nephropathy under Sirolimus. \nJournal of Infectious Diseases 184, 1494-1495\nPartners for our research on molecular aspects of viral human pathogens are \nProf. Dr. H. Hirsch on topics related to transplantation virology, Prof. M. Bat -\ntegay in the context of clinical HIV-research, particularly therapy resistance, \nand Prof. M. Heim on hepatitis-associated virology. Additional research \nprojects are ongoing with Prof. J. Schifferli (University Hospital) and Prof. J. \nPieters (Biocenter). In the center of these collaborations are ex vivo evalua -\ntions and RNA and DNA quantification of central pathogens relevant in the \nrespective clinical context.\nFig. 1:  deCIPHR system for the phenotypic assessment of therapy resistance. \nThe idea behind this approach was to establish a test-system analogous to \nthe well-established \u201cantibiogram\u201d, which is widely used in microbiology and apply \nit to novel therapeutic areas such as in the fields of virology and oncology.Fig. 2:  Establishment of a phenotypic assessment scheme for testing susceptibility \nor resistance in CML to treatment with Gleevec. The underlying principle is to link \nthe therapeutic target function (Bcr-Abl hybrid kinase) to a reporter read-out (white \n\ue0dd yellow; yellow \ue0dd brown). This way a genetic predisposition for therapeutic \nfailure can be detected with high precision and sensitivity.\n112/113\nOn page 127 we introduce our spin-off company InPheno.Molecular \nNephrology \nPD Dr. Barbara Biedermann\nDepartement Forschung \nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Marco Kummer \nDr. Christine Stegmann \nDenise Wittwer (technician)Vascular Endothelium\nCytotoxic T Lymphocytes\nArteriosclerosis\nGraft vs Host Disease.Anti-endothelial Cytotoxic T-lymphocytes \nin Human Disease\nVascular integrity is required for tissue homeostasis. Cytotoxic T lymphocytes \nare important effector cells of antigen-specific immune responses. We have \nshown that vascular endothelial cells can activate CD8 T lymphocytes to differ -\nentiate into endothelial-selective cytotoxic T lymphocytes. In addition, vascular \nendothelial cells regulate T-lymphocyte differentiation in a complex way. The \nbalance of activating and suppressing signals is playing a decisive role in the \nevolution of immune-mediated vascular disease. \nAfter allogeneic stem cell or solid organ transplantation, vascular endothelial \ncells are the first cell type which is met by circulating, blood-borne alloreactive \nT-lymphocytes. Under these circumstances, endothelial cells are gate-keep -\ners but also activators and potential targets of antigen-specific T lymphocytes. \nEndothelialitis, the subendothelial accumulation of cytotoxic T lymphocytes \nis the histopathological hallmark lesion of vascular rejection after solid organ \ntransplantation. We have shown that endothelialitis also occurs after allogeneic \nstem cell transplantation. Endothelial injury by cytotoxic T lymphocytes leads to \nmicrovessel loss in this classical, antigen-mediated human disease: graft versus \nhost disease.\nArteriosclerosis is an inflammatory lipid storage disease of large arteries. The \ninflammatory infiltrate consists of antigen presenting cells (macrophages and \ndendritic cells) and T lymphocytes, predominantly CD8 T lymphocytes. Mo -\nlecular mediators of the innate immune system (e.g. Toll receptors, chemokines, \nadhesion molecules) are critically involved in the initiation and progression of ar -\nteriosclerosis. The role of an antigen-specific, acquired immune response in this \ncontext is still ill defined. In apolipoprotein E knock-out mice, an animal model \nof arteriosclerosis, anti-vascular cytotoxic T-lymphocytes accelerate the forma -\ntion of atherosclerotic lesions. We hypothesize that sustained, chronic vascular \ninjury by activated cytotoxic T lymphocytes causes symptomatic arteriosclerosis \nin man. We characterize the type of endothelial injury caused by cytotoxic T lym -\nphocytes in cell culture experiments and in an animal model of arteriosclerosis. \nWe have developed a human arterial tissue array to systematically examine the \narterial wall in different stages of arteriosclerosis. The tissue array is an important \nand valid tool to confirm the relevance of in vitro observations and results ob -\ntained from animal experiments for the pathogenesis of arteriosclerosis in man. Zytotoxische T Lymphozyten bei Blut-\ngef\u00e4sserkrankungen\nDie einwandfreie Funktion von Blutgef\u00e4ssen ist eine \nVoraussetzung f\u00fcr die Gewebe-Hom\u00f6ostase. Bestimmte \nweisse Blutk\u00f6rperchen (CD8-positive T Lymphozyten) \nk\u00f6nnen sich in Gegenwart von als fremd erkannten En -\ndothelzellen (Innenschichtzellen der Blutgef\u00e4sswand) \nzu endothel-spezifischen, zytotoxischen T Lymphozy -\nten entwickeln. Letztere spielen bei Immunreaktionen \ngegen Blutgef\u00e4sse eine wichtige Rolle. \nNach Organ- oder Stammzell-Transplantationen sind die \nEndothelzellen die ersten fremden K\u00f6rperzellen, welche \nmit zirkulierenden T Lymphozyten in Kontakt treten. Die \nAnsammlung von zytotoxischen T Lymphozyten unmit -\ntelbar unter dem Endothel (Endothelialitis) ist bei der his -\ntopathologischen Untersuchung das typische Anzeichen \nf\u00fcr ein gef\u00e4ssbedingtes Abstossen eines Organs nach \neiner Transplantation. Wir konnten aufzeigen, dass eine \nEndothelialitis auch nach Knochenmarks-Transplantatio -\nnen entstehen kann. In diesem Fall ist sie ein Anzeichen \nf\u00fcr die Graft versus Host (\u00abTransplantat gegen Wirt\u00bb) Re -\naktion. Im Labor untersuchen wir mit Tiermodellen und \nin Gewebekulturen die molekularen Mechanismen, die \nzur Aktivierung der T -Lymphozyten durch Endothelzellen \nf\u00fchren. Diese Mechanismen sind nicht nur bei Gef\u00e4ss -\nentz\u00fcndungen nach Transplantationen wichtig, sondern \nspielen vermutlich auch eine wesentliche Rolle bei der \nEntstehung der Arteriosklerose. \nDie Arteriosklerose (Arterienverkalkung) entsteht durch \neine chronische Entz\u00fcndung der Arterienwand, bei der es \nzur Verengung dieser Blutgef\u00e4sse, der Arterien, kommt. \nDurch die schlechte Durchblutung kann diese Krankheit \nsich als Hirnschlag und Herzinfarkt \u00e4ussern. Die Arteri -\nosklerose ist sehr verbreitet, nahezu die H\u00e4lfte unserer \nPatienten sind davon betroffen. Ist eine Organfunktion \ndurch die Arteriosklerose beeintr\u00e4chtigt, hilft meistens \nnur noch die Gef\u00e4ssoperation. Da die Arteriosklerose je -\ndoch eine Erkrankung aller Arterien im K\u00f6rper ist, sollte \nsich die Behandlung eigentlich nicht ausschliesslich auf \ndie am meisten betroffene Stelle beschr\u00e4nken. Unsere \nklinische Forschung befasst sich mit der Entwicklung von \nneuen, nicht-invasiven Diagnose- und Behandlungsm\u00f6g -\nlichkeiten der Arteriosklerose. \nSelected Publications\n\u2013 B. C. Biedermann, J. S. Pober (1998) Human endothe -\nlial cells induce and regulate cytolytic T cell differentia -\ntion. J Immunol; 161:4679-4687.\n\u2013 B. C. Biedermann, J. S. Pober (1999) Human vascular \nendothelial cells favor clonal expansion of unusual al -\nloreactive cytolytic T lymphocytes. J Immunol; 162: \n7022-7030.\n\u2013 B.C. Biedermann (2001)Vascular Endothelium check-\npoint to control inflammation and immunity. News \nPhysiol Sci; 16:84-88\n\u2013 B.C. Biedermann, S. Sahner, M. Gregor, D.A. Tsaki -\nris, C. Jeanneret, J.S. Pober, A. Gratwohl (2002) En -\ndothelial injury mediated by cytotoxic T lymphocytes \nand loss of microvessels in chronic graft versus host \ndisease. Lancet; 359:2078-83. \n\u2013 B.C. Biedermann, D.A. Tsakiris, M. Gregor, J.S. Pober, \nA. Gratwohl (2003) Combining altered levels of ef -\nfector transcripts in circulating T cells with a marker \nof endothelial injury is specific for active graft-vs-host \ndisease. Bone Marrow Transpl; 32:1077-1084.Molecular Medicine \nof Arteriosclerosis \nArteriosclerosis is a very common disease in civilized coun -\ntries. About half of the patients treated at our Department \n(Medizinische Universit\u00e4tsklinik, Kantonsspital Bruderholz) \nsuffer from arteriosclerosis. Arteriosclerosis can be asymp -\ntomatic or symptomatic. In asymptomatic arteriosclerosis, \nthe arterial lesion does not compromise the aterial flow in an \norgan. In symptomatic arteriosclerosis, the arterial perfusion \nof organs is critically impaired. Depending on the organ \ninvolved by symptomatic arteriosclerosis, a myocardial \ninfarction, a stroke or other cardiovascular events occur. At \npresent, the most efficient interventions to treat symptomat -\nic arteriosclerosis are percutaneous transluminal angioplasty \nor bypass surgery. However, since arteriosclerosis is a pan -\narterial disease, the therapy should not exclusively focus \non culprit lesions but rather be systemic. Since life-time \nincidence of symptomatic arteriosclerosis is 40-50%, treat -\nment should induce sustained remission of the disease after \na limited period of time. The focus of our clinical research \nis to develop non-invasive, molecular concepts to diagnose \nand to identify novel drug targets to treat arteriosclerosis. \nNovel diagnostic and therapeutic approaches are tested and \nvalidated in clinical trials. Fig. 1 : Activated cytotoxic \nT lymphocytes (red cells with \nyellow granules) attack vascular \nendothelial cells (blue). Prof. Dr. Reto Krapf\nKantonsspital \nBruderholz\nFig. 2 : Arteriosclerosis is an inflam -\nmatory lipid storage disorder of large \narteries.\nFig. 3 : Cellular and molecular events \ninvolved in chronic vascular inflam -\nmation, e.g. in transplant-associated \nvasculopathy or arteriosclerosis. \n114/115Pediatric Im-\nmunology and \nDiabetology\nProf. Dr. \nGeorg A. Holl\u00e4nder\nUniversit\u00e4tskinderspital Beider Basel\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup members\nDr. Marcel Keller \nDr. Werner Krenger\nDr. Luca Piali \nDr. Thomas Barthlott \nDr. Jason Gill \nDr. Elena Litvinova\nDr. Simona Rossi\nDr. Noriko Shikama-Dorn \nDr. Saulius Zuklys \nDr. Emanuela Burchielli (MD PhD student)\nDr. Mathias Hauri (MD PhD student)\nDr. Lukas Jeker (MD PhD student)\nThomas Boulay (technician)\nElli Christen (technician)\nKatrin Hafen (technician)\nAnnick Peter (technician)\nYves Mathieu (PhD student)\nKyung-jae Na (PhD student)Thymus\nDevelopment\nGene Profiling Microenvironment\nAutoimmunity\nAire\nGraft-Versus Host Disease deficient for Aire, we have created a murine model of APECED that lends \nitself to the analysis of the molecular mechanisms by which AIRE controls the \ninduction of T cell tolerance by thymic epithelial cells. \nType I diabetes mellitus constitutes one of the endocrine pathologies ob -\nserved in the presence of AIRE-deficiency. This disorder is caused by the au -\ntoimmune destruction of insulin-secreting \u03b2-cells in the islets of Langerhans. \nAlthough this pathology is mediated by T cells reactive to Self, the mechanism \nby which these cytotoxic effector cells gain access to the islets has remained \nunknown. We have now elucidated that several chemokines expressed by \n\u03b2-cells are responsible for the attraction of harmful T cells to the islets (Figure \n5). Importantly, mice deficient for the corresponding chemokine-receptor de -\nveloped diabetes either much later or not at all. This mechanism is presently \ntested for its potential for pharmacological intervention. \nThe thymic function is maintained throughout life and new T cells are con -\ntinuously generated. This capacity is particularly important for the swift \nrepletion with na\u00efve T cells. The kinetics by which donor-derived precursors \nrepopulate the recipient decide on the efficiency by which a functional im -\nmune system is re-established after hematopoietic stem cell transplantation. \nWe could now demonstrate that pre-transplant conditioning and graft-ver -\nsus-host disease (GVHD) negatively affect thymic epithelial cell function and \nthus impair intrathymic maturation and selection of T-cells. While the precise \nmolecular mechanisms responsible for this loss of thymic function are pres -\nently investigated, we could already reveal that fibroblast growth factor-7 \nserves a highly specific mediator of thymic epithelial cell proliferation and \nrepair when given in vivo to mice conditioned by radiation and/or challenged \nby GVHD. \nMolecular and Cellular Mechanisms of \nThymus Development and Function\nWith the development of higher organisms, the necessity evolved to establish \na cellular system able to distinguish between vital Self and injurious Non-Self. \nFrom the perspective of the immune system, this essential task is achieved by a \nmyriad of receptors and cells that belong either to the innate or to the adaptive \nimmune system. However, the most elaborate, dynamic and effective defence \nstrategies are carried out by the adaptive immune response. T lymphocytes \norchestrate this immune response and thus represent a key component of the \nadaptive immune system. \nThe thymus provides the ideal microenvironment for the survival, expansion, \nand differentiation of precursor cells to fully functional T cells. This intrathymic \nmaturation constitutes a process dependent on several non-lymphoid cell types \nand their membrane-bound and secreted molecules. Epithelial cells constitute \nthe most important component of the thymic stroma and can be differentiated \ninto functionally and phenotypically distinct subpopulations (Figure 1). Thymic \nepithelial cells are centrally involved in the active instruction of immature T cells \nto ignore Self antigens but to respond to Non-Self antigens. \nResearch in the laboratory of Pediatric Immunology is focused on the develop -\nment and function of thymic epithelial cells. Although the principles of thymic \norganogenesis are well preserved throughout vertebrate evolution, the mo -\nlecular mechanisms controlling this complex event are just beginning to be \nunravelled. The murine thymus emerges at day 10.5 post conceptionem (p.c.) \nas an epithelial anlage budding from the ventral endodermal lining of the third \npharyngeal pouch. In the course of the next 12 hours, a thymic primordium is \nformed that is separate from the endodermal lining of the foregut and thus posi -\ntioned in the mesenchyme of the third branchial arch. Immigration of lymphoid \nprecursor cells occurs by day 12. p.c. and is paralleled by a rapid proliferation \nand differentiation among thymic epithelial cells (Figure 2).\nWe have started to dissect the genetic programs that control the commitment to \na thymic epithelial cell fate, and that direct the functional maturation of thymic \nepithelial cells. For this purpose, we have physically isolated cells committed to \na thymic epithelial cell fate from embryos as early as day 10.5 p.c. The mRNA \nexpression profile of these cells was subsequently analysed for the presence \nof both new and known gene products that are preferentially expressed in en -\ndodermal cells with a thymic cell fate. Intriguingly, some of the identified gene \nproducts are directly related to the signalling pathways of Wnt, sonic hedgehog \nand the TGF- \u03b2 family of molecules, which have been known to provide devel -\nopmental cues critical for organ formation in organisms ranging from Drosophila \nto vertebrates. Mice deficient for a singular molecule in these pathways have \nnow been generated to assess their specific role in thymic organogenesis. In this \ncontext, we have also identified a novel family of nuclear proteins, which have \nbeen termed \u201cShoca\u201d based on their structure and function as SH2-domain \ncontaining adaptor molecules (Figure 3 and Figure 4). The in vitro  biological \nfunction of Shoca has been linked to Wnt signalling and its in vivo  role for thymic \norganogenesis is presently investigated in Shoca-deficient mice. \nAlthough thymic epithelial cells instruct developing T cells to be tolerant to \nSelf-Antigens, the molecular mechanisms operational in this process are only \nincompletely understood. However, rare autoimmune disorders have been \nobserved that could reveal the precise molecular basis to thymic tolerance since \nthese disorders are caused by a single gene defect. The Autoimmune Polyendo -\ncrinopathy Candidiasis Ectodermal Dystrophy Syndrome (APECED) constitutes \nsuch a disorder. APECED is caused by a loss of function of the transcription fac -\ntor Autoimmune Regulator (AIRE) in thymic epithelial cells. By generating mice Fig. 1:  \nSubpopulations of adult thymic epithelial \ncells are characterized by differential gene \nexpression. Cells are stained for cytokera -\ntin 8 (blue), a marker for cortical epithelial \ncells, for cytokeratin 5 (green) detecting \nmedullary epithelial cells, and for the cell \nsurface antigen MTS24, which serves as a \nstem cell marker (red).PD Dr. \nUrs Zumsteg\nFig. 2:  \nThymic anlage of an embryo at day 12 of \ngestation (green: MTS24; red: cytokeratin \n5; blue: cytokeratin 8) Fig. 3:  \nComputer \nmodel of the \nSH2 structure \nof Shoca. \nFig. 4:  \nShoca \nexpression \n(red) in the \nnucleus of \nthymic \nepithelial cells \n(green). \nFig. 5:  \nIslets of Langer -\nhans infiltrated \nwith cytotoxic \nT cells in the \ncourse of the \nimmunopatho-\nlogy leading to \nType I diabetes. \n116/117Selected Publications\n\u2013 W. van Ewijk*, G. Holl\u00e4nder*, C. Terhorst, B. Wang \n(2000) Crosstalk regulates the organization of thymic \nmicroenvironments. Development, 127:1583-1591. \n(* contributed equally) \n\u2013 S. Zuklys, G. Balciunaite, A. Agarwal, E. Palmer, P . \nNaquet, G. Holl\u00e4nder (2000) Differential thymic tran -\nscription of aire, the gene defective in the monogenic \nautosomal recessive autoimmune disease APECED. \nJournal of Immunology, 165:1976-1983.\n\u2013 Rossi, B. R. Blazar, C. L. Farrell, D. M. Danilenko, D. L. \nLacey, K. I. Weinberg, W. Krenger, and G. Holl\u00e4nder \n(2002) Keratinocyte Growth Factor Preserves Normal \nThymopoiesis And Thymic Microenvironment During \nExperimental Graft-Versus-Host-Disease. Blood, 100:\n682-91.\n\u2013 J. Gill, M. Marlin, G. Holl\u00e4nder, R. Boyd (2002) A \nsingle precursor population is sufficient to reconsti -\ntute the complex epithelial microenvironment of the \nthymus. Nature Immunology, 3: 635-642.\n\u2013 G. Balciunaite, E. Balciunaite, S. Zuklys, Y . D. Mathieu, \nJ. Gill, R. Boyd, D. J. Sussman, G. Holl\u00e4nder (2002) \nWnt glycoproteins regulate the expression of Foxn1, \nthe gene defective in nude mice. Nature Immunology, \n3: 1102-1108.\n\u2013 S. Frigerio, T. Tobias Junt, Bao Lu, Craig Gerard, U. \nZumsteg, G. Holl\u00e4nder*, L. Piali* (2002) In Insulitis, \nBeta Cells Are Responsible for CXCR3-Mediated T \nCell Infiltration. Nature Medicine 8:1414-1420. (* \ncontributed equally)Clinics\nType 1 diabetes mellitus (T1DM) is one of the most common chronic diseases in childhood \nwith a prevalence of about 1.7 per 1000 people aged \ue02b 20 years. Worldwide prospective \nstudies on the incidence have shown an increase in the past few decades and also in Swit -\nzerland a yearly average increase of 5.1% has been shown between 1991 and 1999. In the \npreschool age group a more than 4 fold increase has been recorded but the explanation \nfor this shift towards younger age at diagnosis remains unclear. The trigger of autoimmune \npancreatic beta-cell destruction in genetically prone children seems to be multifactorial and \nintervention strategies have not been successful so far. When a child gets T1DM, insulin de -\npendency and the need for appropriate nutrition is the same as in diabetic adults. However, \ndue to different stages of growth and development, there are major physiological, medical, \npsychological, social and emotional differences demanding a special approach and separate \nguidelines. Childhood diabetes has the potential to be profoundly destructive, both for \nthe affected individual as for his family relationships. Despite of modern intensified insulin \nreplacement therapy, the disease continues to be the leading cause of end stage renal dis -\nease, blindness and amputation, and still a major cause of cardiovascular complications and \npremature death. Prevention of T1DM must be a primary goal and research in the field of \nthe immunopathogenesis as well as advances in the molecular and biological understanding \nof pancreatic beta-cell destruction are a prerequisite for clinical prevention trials.Die Entwicklung des Immunsystems und Autoimmunit\u00e4t\nEin einwandfreies Funktionieren des Immunsystems erm\u00f6glicht die gezielte Abwehr \ngegen\u00fcber einer fast uneingeschr\u00e4nkten Vielzahl sch\u00e4dlicher Einfl\u00fcsse. Das aus unter -\nschiedlichen Zellen und Effektormolek\u00fclen zusammengesetzte Immunsystem besitzt \nhierzu die einmalige F\u00e4higkeit, zwischen k\u00f6rpereigenen, harmlosen \ue02bSelbst\u201cAntigenen \neinerseits und potentiell sch\u00e4digenden, so genannten \u00abFremd-\u00bb Antigenen andererseits \ngenau unterscheiden zu k\u00f6nnen. Diese essentielle Funktion wird vor allem durch T Lym -\nphozyten erm\u00f6glicht, die ihre Reifung und Selektion in direktem funktionellem Kontakt \nmit Epithelzellen und anderen Stromazellen des Thymus erfahren haben. Gegenw\u00e4rtig \nist aber noch wenig bekannt, wie Thymus Epithelzellen sich aus den entsprechenden \nVorl\u00e4uferzellen entwickeln k\u00f6nnen und in welcher Weise sie ihre f\u00fcr die Reifung des \nImmunsystems bedeutungsvollen Funktionen wahrnehmen.\nDie Forschung im Labor der p\u00e4diatrischen Immunologie untersucht das genetische \nProgramm, das f\u00fcr die Entwicklung und Funktion von Thymus Epithelzellen verant -\nwortlich zeichnet. Hierzu wurde das Genexpressionsmuster von Thymus Epithelzellen \nuntersucht, welche zu unterschiedlichen Stadien ihrer Entwicklung isoliert wurden. \nDabei konnten wir aufzeigen, dass die Thymus Entwicklung durch ein umfassendes \nNetzwerk von unterschiedlichen Molek\u00fclen gesteuert wird, zu denen unter anderem \nauch die Wnt Glykoproteine, die Sonic Hedgehog Proteine und Mitglieder der grossen \nFamilie der TGF-\ue02b Molek\u00fcle geh\u00f6ren. Diese Wachstums- und Differenzierungsmolek\u00fcle \nsind bekannter Weise auch bei der Entwicklung anderer Organe mitbeteiligt. Zus\u00e4tzlich \nzu diesen bereits bekannten Genprodukten haben wir auch in Thymus Epithelzellen \nTranskripte von bis anhin noch nicht identifizierten Genen isolieren k\u00f6nnen. Hierzu \ngeh\u00f6rt die von uns als \u00abShoca\u00bb (SH2 domain containing adaptors) bezeichnete Mole -\nk\u00fclfamilie, welche die Signaltransduktion \u00fcber den Wnt-vermittelten Aktivierungsweg \nmoduliert. \nDer Thymus kann durch unterschiedliche, sch\u00e4digende Einfl\u00fcsse in seiner Funktion \nwesentlich gest\u00f6rt werden. So k\u00f6nnen Thymus Epithelien durch die im Rahmen der \nTherapie von malignen und nicht malignen h\u00e4matologischen Erkrankungen verwen -\ndete Chemo- und Bestrahlungstherapie teilweise oder gar g\u00e4nzlich zerst\u00f6rt werden. \nDie genaue Kenntnis der regul\u00e4ren Entwicklung der Thymus Epithelien ist deshalb \nf\u00f6rderlich, neue therapeutische Strategien zu entwickeln, wie die Thymusfunktion in \nsolchen klinischen Situationen erhalten beziehungsweise umfassend wieder hergestellt \nwerden kann. \nIn welcher Weise Epithelzellen unreife T Zellen w\u00e4hrend ihrer Entwicklung im Thymus \nselektionieren k\u00f6nnen, ist noch \u00fcberwiegend unbekannt. Im Speziellen ist auf molekula -\nrer Ebene noch unaufgekl\u00e4rt, wie ein Repertoire an immunologischen Effektorzellen im \nThymus ausgew\u00e4hlt werden kann, das gegen\u00fcber Selbst-Antigenen tolerant ist, doch \ngegen Fremd-Antigene eine gezielte Abwehrantwort zulassen kann. Eine wesentliche \nAusnahme hierzu ist die neuere Erkenntnis, dass der Mangel des Transkriptionsfaktors \nAIRE (autoimmune regulator) zu einem komplexen Autoimmunsyndrom Anlass gibt. \nDieser Faktor kann unter physiologischen Bedingungen in einer kleinen Subpopulation \nvon Thymus Epithelzellen nachgewiesen werden und sein Fehlen ist f\u00fcr die Entste -\nhung einer komplexen Autoimmunerkrankung verantwortlich. Diese als autoimmune \nPolyendokrinopathie mit ektodermaler Dysplasie (APECED) bezeichnet Pathologie ist \ndurch eine immunologische Zerst\u00f6rung unterschiedlicher Organe und den damit ver -\nbundenen Funktionsverlust gekennzeichnet. Wir haben nun ein Mausmodel f\u00fcr diese \nErkrankung geschaffen, welches uns erlaubt, gezielt der Frage nachzugehen, wie ein \nDefekt eines singul\u00e4ren Transkriptionsfaktors zu einem solch vielf\u00e4ltigen, autoimmu -\nnologischen Pathologie wie dem APECED Syndrom Anlass geben kann. \nSchliesslich konnte in unserem Labor auch in den letzten Jahren aufgekl\u00e4rt werden, wie \nautoreaktive T Zellen bei der autoimmunen Form des Diabetes mellitus die Zellen der \nLangerhansinseln auffinden und zerst\u00f6ren k\u00f6nnen. Diese Erkenntnis wird gegenw\u00e4rtig \ndazu verwendet, in Zusammenarbeit mit einer Biotechnologie Firma, neue Ans\u00e4tze zur \nTherapie des Diabetes mellitus auszutesten. \n118/119Transplantation \nImmunology \nand \nNephrology\nProf. Dr. Ed Palmer \nDepartement Forschung \nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Mark Daniels\nDr. Diana Gil\nDr. Adam Schrum\nDr. Emma Teixeiro\nDr. Guy Werlen\nBarbara Hausmann (technician)\nDominique Roubaty (technician)\nGideon H\u00f6nger (technician)\nDenise Bielmann (technician)\nDoris Lutz (technician)\nDieter Naeher (PhD student)T cell\nSignaling\nThymocyte selection\nTransplantation\nToleranceT cell Biology and Transplantation Rejection\nWhile transplantation has been successfully used to treat many types of organ \nfailure, it is limited in the long term by the immune system\u2019s intolerance of the \ngraft. Graft rejection is initiated by T lymphocytes and reflects the immune \nsystems\u2019 pre-occupation with eliminating cells, which are \u201cnon-self\u201d. Profes -\nsors Palmer and Steiger have combined their scientific and clinical expertise \nto approach this difficult clinical problem. Their collaborative effort is based on \nthe idea that controlling graft rejection depends on understanding how T cells \nrecognize \u201cnon-self\u201d. \nThe T cell receptor: a decision maker for the T lymphocyte \nT cells develop in the thymus, where thymocytes differentiate if their TCRs can \nrecognize fragments of foreign proteins. This process is called positive selection \nand generates functional T cells, which are critical for defending the organism \nfrom infectious attack. A fraction of thymocytes has TCRs, which recognize \nnormal body constituents (self proteins). These thymocytes are self-reactive \nand must be eliminated to maintain T cell tolerance. The removal of self-reactive \nthymocytes is known as negative selection and is a critical step in avoiding auto-\nimmunity. The molecular bases of positive and negative selection are not under -\nstood. The question is how the TCR can deliver 2 different signals: one, which \ncan lead to thymocyte differentiation and another, which can lead to thymocyte \ndeath. We have identified a motif in the TCR \u03b1 chain called the \u03b1-CPM, which \nhas been conserved for 500 million years. Thymocytes expressing mutant TCRs, \nwhich lack this motif fail to undergo positive selection, although they are com -\npetent to undergo negative selection. The existence of such a mutant implies \nthat the TCR has distinct structural features, which control positive and negative \nselection signals. We are using a combination of genetic, biochemical and cell \nbiological approaches to dissect these two kinds of signals, which are used to \nestablish a functional T cell repertoire. \nIn the presence of foreign antigen, peripheral T cells divide, develop effector \nfunctions and eventually undergo activation induced cell death (AICD). A muta -\ntion in the transmembrane domain of the TCR \u03b2 chain generates a TCR, which \nfails to transmit signals leading to AICD. The mutant receptor does not engage \nthe signaling adaptor, Carma-1 and subsequently is defective in activating the \nNF-\u03baB signaling pathway. Our current focus is to better define how the TCR \nindependently signals T cell proliferation and AICD and how the ratio between \ndivision and death controls T cell homeostasis.\nWe have also developed a model of graft rejection by transplanting MHC-dis -\nparate skin onto mice, whose T cells express an allo-reactive TCR. This model T-Lymphozyten und Abstossungsreaktionen\nDas Ziel des Labors f\u00fcr Transplantationsimmunologie \nund Nephrologie ist, die Abstossungsreaktion der \ntransplantierten Organe zu erforschen und letztlich \nzu verhindern.\nDa die eigenen T-Lymphozyten des Empf\u00e4ngers der \nHauptgrund f\u00fcr die Abstossung sind, erforschen wir \nderen Aufgabe und Wirkung, sowie deren m\u00f6gliche \nBehandlung und Ver\u00e4nderung, um diese Zellen dem \nTransplantat gegen\u00fcber tolerant zu machen.\nSeit vielen Jahren forschen wir auf dem Gebiet der \nT-Lymphozyten und haben schon viel \u00fcber ihre Wir -\nkungsweise herausgefunden. T-Lymphozyten sind \nnormalerweise gegen\u00fcber den eigenen K\u00f6rperorganen \ntolerant, dennoch stossen sie ein gesundes transplan -\ntiertes Organ vehement ab. Warum das transplantierte \nOrgan als fremd erachtet wird, und wie man die Abstos -\nsungsreaktion verhindern kann, darauf fokussieren wir \nunsere Forschungsarbeit.\nDaneben entwickeln wir verschiedene klinische Tests, \num den fr\u00fchen Beginn einer Abstossung nachzuweisen, \nsowie zur Festlegung, welche Spender f\u00fcr einen m\u00f6gli -\nchen Empf\u00e4nger am besten geeignet sind.\nDurch die enge Zusammenarbeit zwischen unserer \nForschungsgruppe und der Nieren-Transplantations -\nabteilung des Universit\u00e4tsspitals Basel haben wir die \nGelegenheit, mit unserer Forschung die Qualit\u00e4t der \nBehandlung der Patienten positiv zu beeinflussen.\nSelected Publications\n\u2013 Teixeiro, E., Daniels, M.A., Hausman, B. Schrum, \nA.G, Naeher, D., Luescher, I., Thome, M., Bragado, \nR. and Palmer, E. T cell division and death are segre -\ngated by mutation of TCR \u03b2 chain constant domains, \nImmunity, in press (2004).\n\u2013 Werlen, G., Hausmann, B.T., Naeher, D. and Palmer, \nE. Life and death decisions in the thymus: Timing is \neverthing. Science 199: 1859-63 (2003).\n\u2013 Sayegh, M.H., Wu, Z., Langmuir, P .B., Sandner, S., \nKishimoto, K., Palmer, E., Mitchell, R.N. and L.A. \nTurka. Allograft rejection in a new allospecific CD4 + \nTCR transgenic mouse. Am J Transplant. 4:381-9 \n(2003)\n\u2013 Hirsch HH, Knowles W, Dickenmann M, Passweg J, \nKlimkait T, Mihatsch MJ, Steiger J: Prospective study \nof polyomavirus type BK replication and nephropathy \nin renal-transplant recipients. N.Engl.J.Med. 347:488-\n496, 2002\n\u2013 Werlen, G., Hausmann, B. and Palmer, E. A motif \nwithin the T cell receptor controls positive selection \nby modulating the ERK pathway, Nature, 406: 422-\n426 (2000).Clinics\nThe Department of Transplantation Immunology and Ne -\nphrology co-ordinates one of the major centers for kidney \ntransplantation in Switzerland and has been active in this \narea for over 40 years. The transplantation team carries out \napproximately 70 renal transplants per year and has pub -\nlished widely in the areas of renal physiology, infections of \ntransplant patients and clinical management of immunosup -\npression. The Department oversees the Clinical Transplanta -\ntion Laboratory, which is responsible for the immunological \ntesting of donated organs, living donors and recipients on \nthe waiting list. This clinical laboratory determines tissue and \nantibody compatibilities between donors and recipients and \nis one of the leading solid organ transplantation laboratories \nin Switzerland. As part of a novel concept, the Clinical and \nResearch laboratories share the same laboratory space and \nwork in concert, developing new diagnostic tests for the \ndetection cross-matching antibodies. In 2004, the Clinical \nLaboratory offered a course in flow cytometric methods, \nwhich was attended by laboratory staff from solid organ \ntransplantation centers all over Switzerland. One of the \nlong-term goals is to establish techniques to monitor the \nimmunological status of graft recipients, post-transplanta -\ntion. The goal of post-transplantation monitoring is to extend \nthe life-span of transplanted organs and the quality of life \nfor the recipient.allows one to follow the graft-rejecting T cells, through the activation and \neffector phases. These experiments will allow us to determine the lifespan of \nallo-reactive T cells under conditions of immunosuppression and to develop \nstrategies for inducing peripheral tolerance to the grafted skin. Finally, we are \ntrying to generate diagnostic tools to monitor the frequency of allo-reactive \n(graft-rejecting) T cells in transplant recipients. These types of reagents could \nbe clinically useful in predicting the onset of a rejection reaction.\nFig. 1:  T cell receptors containing the aCPM and CD3 \u03b4 are able to co-operate with \nthe CD8 co-receptor to generate a signal subsequent to pMHC ligand binding. Mu -\ntant T cell receptors that lack the \u03b1CPM or CD3 \u03b4 fail to generate specific signals with \nlow affinity pMHC ligands.Prof. Dr. J\u00fcrg Steiger\nAbteilung Nephrologie\nUniversit\u00e4tsspital Basel\nFig. 2:  Thymocytes from transgenic mice ex -\npressing a TCR lacking the \u03b1CPM are stained \nwith anti-CD4 and CD8 antibodies. These mice \nare blocked in undergoing positive selection and \nfail to generate mature (single positive) T cells.\nFig. 3:  Left panel: Cross-linking the TCR (yel -\nlow) on wild type T cells recruits and co-localizes \nthe adaptor, Carma-1 (red). Right panel: T cells \nexpressing a mutant T cell receptor can cross-link \nthe TCR (green) but fail to recruit Carma-1 (red). \nThis leads to a defect in AICD.\nFig. 4:  Fluorescent beads coated with different \nHLA antigens have been incubated with patient \nsera to detect anti-HLA antibodies. The left panel \nshows the analysis of beads incubated with a \nnegative serum, while the right panel shows the \nsame beads incubated with serum that contains \nmultiple anti-HLA antibodies.\n120/121Transplantation \nVirology\nProf. Dr. Hans H. Hirsch\nInstitut f\u00fcr Medizinische Mikrobiologie\nund Infektiologische Klinik\nUniversit\u00e4tsspital Basel\nGroup Members\nDr. Rainer Gosert\nDr. Adrian Egli (MD-PhD student)\nAriane Kaiser (research technician)\nBeatrice Hess (research technician)\nVroni Del Zenero (research technician)\nSimone Binggeli (PhD student)Polyomavirus\nCytomegalovirus\nAdenovirus\nViral load\nCellular immunity\nAdoptive T-cell transferControl of Viral Infections in Transplant \nPatients\nViral infections in transplant patients are associated with increased morbidity \nand mortality. A key reason for a pronounced vulnerability to viral infections re -\nsides in the impaired immune functions of transplant patients. In hematopoietic \nstem cell transplantation (SCT), immune effector cells are depleted following \ntherapy and conditioning, but immune dysfunction may persist long after the \nengraftment, particularly in patients with \u201cgraft-versus-host\u201d disease requiring \nthe administration of immunosuppressive drugs. In solid organ transplantation \n(SOT), immune functions are deliberately suppressed by drugs to protect the \ntransplant from \u201chost-versus-graft\u201d injury (rejection). Thus, a window of oppor -\ntunity is opened leading unchecked viral replication and more severe disease \nafter transplantation. Antivirals, if available at all, may reduce viral replication \nand disease, but are not sufficient to eradicate viral infections. This is particularly \ntrue for herpes-, polyoma- and adenoviruses, which may reactivate from latent \ninfections. Thus, specific antiviral immune functions are required for termination \nand control of viral infection.\nPolyomavirus hominis type 1 , also called BK virus (BKV) infects up to 90% of the \ngeneral population. Significant clinical manifestations are rare and limited to in -\ndividuals with impaired immune functions. Since 1995, polyomavirus-associated \nnephropathy (PVAN) has been recognized as an emerging disease affecting \n1-10% of renal transplant recipients with variable graft loss in 10-80% of cases. \nIntervention is difficult due to the lack of specific antivirals and relies mostly on \nimproving immune control by decreasing the immunosuppressive load. Cur -\nrently, three complementing areas of research are pursued:\nClinical studies\nQuantification of BKV DNA load in plasma and urine has been introduced into the \nclinical routine in 2002-2003 after demonstrating its role in screening and moni -\ntoring of renal transplant patients at risk for PVAN (Hirsch et al. 2002). Screening \nfor BKV replication identifies patients with earlier stages of limited focal involve -\nment which may respond better to reduced immunosuppression. Studies from \npatients with PVAN undergoing allograft nephrectomy show that the BKV load \nin plasma instantaneously disappears (Fig. 1) indicating that the plasma BKV load \nis entirely derived from the renal transplant and hence an important surrogate Virusinfektionen bei Transplantations-\npatienten\nVirusinfektionen bei Transplantationspatienten sind \nmit erh\u00f6hter Morbidit\u00e4t und Mortalit\u00e4t assoziiert, was \nauf gest\u00f6rte Immuneffektorfunktionen zur\u00fcckgef\u00fchrt \nwird. Polyomavirus BK (BK Virus) wird seit 1995 f\u00fcr den \nvorzeitigen Verlust von ca. 5% der Nierentransplantaten \nverantwortlich gemacht. Da keine wirksamen Virostatika \nverf\u00fcgbar sind, besteht derzeit die einzige Intervention \nin der Reduktion der immmunsuppressiven Therapie mit \ndem Risiko der nachfolgenden Abstossung. In klinischen \nUntersuchungen konnten wir die quantitative Bestim -\nmung der BK Viruslast im Plasma als einen wichtigen \nSurrogatmarker f\u00fcr Diagnose und Verlauf etablieren. \nUnsere virologischen Untersuchungen zeigen, dass \nbei Patienten mit Polyomavirus-Nephropathie zum \nTeil massive genetische Ver\u00e4nderungen in der nicht-\nkodierenden Kontroll-Region (NCCR) vorhanden sind, \ndie sich von den NCCR der Archetypen unterscheiden, \ndie bei nicht-immunsupprimierten Patienten im Urin \nnachweisbar sind. Mit einem bi-direktionalen Repor -\nter-Konstrukt, das fr\u00fche und sp\u00e4te Genexpression als \nRot- bzw. Gr\u00fcn-Fluoreszierendes Protein sichtbar macht, \nkonnten wir signifikante funktionelle Unterschiede der \nNCCR-Rearrangements nachweisen, die aber weiterhin \ndurch das virale Regulatorprotein Large-T-Antigen mo -\nduliert werden. In immunologischen Studien bereiten \nwir die Quantifizierung von BK Virus-spezifischen \nCD4- und CD8-T-Zellen vor, die die BK Viruslast im \nPlasma bez\u00fcglich Risiko und Verlauf bei Transplanta -\ntionspatienten erg\u00e4nzen sollen. Cytomegalieviruslast \nund die spezifische T-Zell-Aktivit\u00e4t dienen als Kontrolle. \nEine Idenifizierung der relevanten Epitope sollte auch die \nM\u00f6glichkeit der Entwicklung eines BK Virus Impfstoffs \nund des adoptiven T-Zelltransfers erm\u00f6glichen.\nSelected Publications\n\u2013 Hirsch, H.H. Knowles W., Dickenmann M., Passweg \nJ., Klimkait T., Mihatsch M.J., Steiger J. (2002) Pro -\nspective study of polyomavirus type BK replication \nand nephropathy in renal-transplant recipients. N \nEngl J Med 347: 488-96.\n\u2013 Hirsch, H.H. (2003) BK virus replication and disease \nin solid organ transplant recipients: an update. Curr \nOpin Org Transplant 8: 262-268.\n\u2013 Hirsch, H.H. and Steiger, J. (2003) Polyomavirus BK. \nLancet Infect Dis 3: 611-623.\n\u2013 Drachenberg CB, Papadimitriou JC, Wali R, Nogueira \nJ, Mendley S, Hirsch HH, Cangro CB, Klassen DK, \nWeir MR, Bartlett ST, Ramos E. (2004) Improved \noutcome of polyoma virus allograft nephropathy \nwith early biopsy. Transplant Proc 36: 758-9.\n\u2013 Drachenberg C.D., Papadimitriou J.C., Hirsch H.H., \nWali R., Crowder C., Nogueira J., Cangro C.B., \nMendley S., Mian A., Ramos E. (2004). Histological \npatterns of polyomavirus nephropathy: Correlation \nwith graft outcome and viral load. Am J Transplant 4: \n2201-2211.marker of allograft involvement. Moreover, significantly higher BKV plasma \nviral load was observed in cases with persisting PVAN, as compared to cases \nwith negative histology (P <0.001). Since the risk of false negative biopsies \ndue to sampling errors increases with early focal PVAN, a new definition has \nbeen put forward: \u201cPresumptive\u201d PVAN is defined by high plasma BKV load \n(>10\u2019000 copies/mL), but still negative or undetermined biopsy, and an inter -\nvention should be considered similar to histologically confirmed \u201cdefinitive\u201d \nPVAN. This approach requires validation in future clinical studies\nVirological studies\nThe BKV genome is small with 5.3 kb of double-stranded DNA and can be \ndivided in three regions of i) the noncoding control region (NCCR) contain -\ning the origin of replication and promoter/enhancer functions driving ii) the \nearly gene (large and small Tumor antigen) and iii) the late gene expression \n(agnoprotein, capsid proteins VP1-3). Sequencing of the NCCRs isolated \nfrom the urine of renal transplant patients with PVAN demonstrated arche -\ntype (WW) NCCR architecture. In contrast, we found deletions, insertions, \nand rearrangements in NCCRs isolated from plasma of patients with PVAN. \nTo investigate the functional consequences of these rearrangements, we \nconstructed a bi-directional reporter with red and green fluorescent proteins \nindicating early and late expression and found that archetype and NCCRs \ncontaining insertions were associated with transcription mainly from the late \nregion, whereas the NCCR with an extensive deletion of part of the Q-Block \nand most of the R-Block demonstrated a switch from late to early gene tran -\nscription. Importantly, expression of the large T-antigen induced a virologi -\ncally expected shift towards increased late gene expression, irrespectively \nof the NCCR. The impact of immunosuppressive drugs on BKV expression is \ncurrently investigated.\nImmunological studies\nViral load measurements for BK virus, cytomegalovirus, Epstein-Barr-virus \nand adenovirus correlate only to alimited extent with the risk for disease. The \nquantification and functional testing of virus-specific cellular immune effec -\ntors may provide complementing clinically relevant information in transplant \npatients. As demonstrated in Fig. 2, virus-specific interferon- \u03b3-producing \nCD4 and CD8 T-cells can be detected in whole blood of patients by FACS \nanalysis. Clearly, adoptive transfer of functional virus-specific immune effec -\ntors and corresponding monitoring at GLP-GMP level is within reach in the \ncoming years.\nFig. 1:  Progressive renal transplant dysfunction (serum creatinine concentration) \nand increasing BK viral load (PVAN, Polyomavirus-associated nephropathy; AR, acute \nrejection; CsA, cyclosporine; TAC, tacrolimus; AZA,azathioprine, MMF, mycopheno -\nlate mofetil; PRE, prednisone)Fig. 2:  \nCMV-specific inter -\nferon-\u03b3 (IFN-\u03b3) \nproducing \nCD4-cells in whole \nblood.\n122/123Perioperative \nPatient Safety\nDr. Susan Treves\nDepartement An\u00e4sthesie\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nGroup members\nProf. Dr. Albert Urwyler\nProf. Dr. Francesco Zorzato \nDr. Ayuk Agbor Anderson\nDr. Soledad Levano \nEsther Schmid (technician)\nMartine Singer (techncian)\nAntonio Teixera (technician)\nEvgueni Voronkov (technician)\nSylvie Ducreux (PhD student)Malignant hyperthermia\nCentral core disease\nCalcium homeostasis\nMutations\nProteomicsAnaesthetics and Disease: \nRyanodine Receptor 1 Mutations and their \nImpact on Calcium Homeostasis.\nChanges in the intracellular free calcium concentration underlie a variety of \nbiological phenomenon, such as neuronal excitability, muscle contraction, gene \nexpression and metabolism. Under resting conditions, eukaryotic cells maintain \nthe cytoplasmic calcium concentration ([Ca2+]) at very low levels (about 100 \nnM), but upon stimulation its concentration raises dramatically (more than \n10000-fold) in just a few milliseconds; these changes are sensed by specialized \nproteins, resulting in a cellular response. Because of the importance of Ca2+ in \ncell physiology, eukaryotic cells have developed specialized organelles (or su -\nbregions of organelles) to finely control the cellular [Ca2+] and many proteins \n(from channels on the plasma membrane which allow Ca2+ ions to flux into the \ncytoplasm from the extracellular milieu, to intracellular calcium storing proteins, \nintracellular calcium channels and Ca2+ pumps or CaATPases), are devoted to \ncalcium homeostasis. The most specialized organelle involved in Ca2+ regulation \nis the skeletal muscle sarcoplasmic reticulum; this organelle has a finely struc -\ntured architecture. In fact the protein(s) sensing the action potential generated \nby the nerve impulse on one subspecialized membrane (the transverse tubular \nmembrane), can physically interact with the calcium release channel (also known \nas the ryanodine receptor, RYR1) present on another specialized membrane, the \nterminal cisternae. \nThe importance of the fine regulation of [Ca2+] is illustrated by two neuromus -\ncular diseases, which in the majority of cases, are linked to mutations in the \nryanodine receptor calcium channel: malignant hyperthermia (MH) and central \ncore disease (CCD): \n(i) Malignant hyperthermia (MH) is an autosomal dominant pharmacogenetic \ndisease due to abnormal regulation of calcium homeostasis. In more than \n50% of the cases MHS individuals carry mutations in the RYR1 gene; these \nrender this calcium channel more sensitive to agonists, so that more calcium \nis released from the sarcoplasmic reticulum and available to bind to the con -\ntractile elements and lead to muscle contraction.\n(ii) CCD is a rare autosomal dominant congenital myopathy. Individuals affected \nby this disease have hypotonic muscles and generalized muscle weakness; \nin children one of the classical findings is a delay in achieving motor mile -\nstones. The clinical diagnosis relies on the histological examination of a mus -\ncle biopsy which is characterized by the presence of large centrally located \ncores which run the length of the muscle fiber. These cores do not stain with \noxidative and phosphorylase histochemical stains and contain amorphous \nlooking material. Maligne Hyperthermie\nDie Maligne Hyperthermie (MH) ist eine seltene aber \ngef\u00fcrchtete An\u00e4sthesiekomplikation. Bestimmte Nar -\nkosemittel f\u00fchren bei MH empfindlichen Personen zu \neinem dramatischen Anstieg des Stoffwechsels der \nSkelettmuskulatur, welcher unbehandelt rasch t\u00f6dlich \nverlaufen kann. Symptome treten ausschliesslich bei \nKontakt mit ausl\u00f6senden An\u00e4sthetika auf, im Alltag \nsind die betroffenen Personen beschwerdefrei. Die \nVeranlagung zur MH wird dominant vererbt. \nUnser Labor ist das nationale MH Referenzzentrum \nf\u00fcr die Schweiz und Liechtenstein, sowie f\u00fcr den \ns\u00fcddeutschen Raum und das Elsass. Personen, welche \neine MH Episode erlebt haben oder Angeh\u00f6rige MH \npositiver Personen werden auf MH getestet. Die Stan -\ndardmethode zur Diagnose einer MH Emfpindlichkeit \nist der in-vitro Kontrakturtest. Hierzu muss ein St\u00fcck \nMuskulatur aus dem Bein operativ entnommen und \nunmittelbar danach im Labor untersucht werden. Im \nRyanodinrezeptor des Skelettmuskels sind verschiede -\nne genetische Ver\u00e4nderungen bekannt, welche f\u00fcr MH \nverantwortlich sind. In bestimmten Familien erlauben \nuns diese Mutationen eine nicht-invasive MH Diagnos -\ntik. Bisher sind nur in 50% der MH Familien Mutationen \nbekannt, sodass sich unsere Forschung darauf konzen -\ntriert, die Hintergr\u00fcnde der MH besser zu verstehen \nund zus\u00e4tzliche Ursachen zu identifizieren. Das Ziel \nist es, eine nicht-invasive Testm\u00f6glichkeit f\u00fcr die MH \nzu entwickeln, um diese Veranlagung im Vorfeld einer \nAn\u00e4sthesie zu erkennen und somit die perioperative \nPatientensicherheit zu erh\u00f6hen.\nSelected Publications\n\u2013 F . Zorzato, N. Yamaguchi, L. Xu, G. Meissner, C. R. \nM\u00fcller, P . Pouliquin, F . Muntoni, C. Sewry, T. Girard \nand S. Treves (2003). Clinical and functional effects \nof a deletion in a COOH-terminal lumenal loop of the \nskeletal muscle ryanodine receptor. Human Mol. Ge -\nnetics 12:379-388\n\u2013 Anderson, S. Treves, D. Biral, R. Betto, D. Sandon\u00e0, \nM. Ronjat and F Zorzato (2003). The novel skeletal \nmuscle sarcoplasmic reticulum JP-45 protein: mo -\nlecular cloning, tissue distribution, developmental \nexpression and interaction with a.1 subunit of the \nvoltage gated calcium channel. J. Biol.Chem. 278:\n39987-39992\n\u2013 T. Girard, S. Treves, E. Voronkov, M Siegemund and \nA. Urwyler (2004). Molecular genetic testing for \nMalignant Hyperthermia susceptibility. Aesthesiol -\nogy 100:1076-1080\n\u2013 S. Treves, C. Franzini-Armstrong, L. Moccagatta, C. \nArnoult, C. Grasso, A. Schrum, S. Ducreux, M.X. Zhu, \nK. Mikoshiba, T. Girard, S. Smida-Rezgui, M. Ronjat \nand F . Zorzato (2004). Junctate is a key element in \ncalcium entry induced by activation of InsP3 recep -\ntors and/or calcium store depletion J. Cell Biol. 166:\n537-548 \n\u2013 S. Ducreux, F . Zorzato, C. R. M\u00fcller, C. Sewry, F, \nMuntoni, R. Quinlivan, G. Restagno, T. Girard and S. \nTreves (2004). Effect of ryanodine receptor mutations \non IL-6 release and intracellular calcium homeostasis \nin human myotubes from malignant hyperthermia \nsusceptible individuals and patients affected by \ncentral core disease. J. Biol.Chem. (in press)Clinics\nThe first reports of \u201cMalignant Hyperthermia (MH)\u201d or an -\naesthesia-related deaths associated with hyperthermia date \nto the beginning of the 20th century. MH is an autosomal \ndominant pharmacogenetic disorder, which develops in ge -\nnetically predisposed individuals after exposure to trigger \nagents (halogenated inhalative anesthetics and depolarizing \nmuscle relaxants). Such individuals are free of any symp -\ntoms in daily life but contact with the trigger agent can cause \na dramatic life-threatening increase in metabolism. Clinical \nsymptoms present as elevated muscular activity and hyper -\nmetabolism. Supportive measures and specific therapy with \ndantrolene are essential in case of a MH episode. With these \ntherapeutic actions MH mortality has decreased dramatically \nfrom 70% to less than 10%. \nAs MH is a subclinical myopathy, specific testing must be \nused to diagnose MH susceptibility (MHS). Presympto -\nmatic testing is important, because safe alternatives exist \nfor anesthesia in MHS patients. The gold standard for MH \ndiagnosis is an in vitro  muscle contracture test: after an open \nmuscle biopsy, a muscle bundle is challenged in vitro  with \ncaffeine and halothane. Contractile thresholds to both drugs \nare determined in several muscle strips. \nMH research has focused on the establishment of nonin -\nvasive or less invasive testing. The European MH Group \n(EMHG) published guidelines for genetic MHS tests. The \nSwiss MH investigation unit of our laboratory is an active \nmember of the EMHG. We perform MH diagnosis for all \nof Switzerland and Liechtenstein as well as southern parts \nof Germany and parts of France. Since 1986 the in vitro \ncontracture test  is performed in our laboratory and in recent \nyears we introduced molecular genetic methods for MH \ndiagnosis in selected MH families.\nTo date more than 60 missense mutations have been identified in the RYR1 \ngene and are associated with CCD and/or the MHS phenotype. \nThe aim of the research carried in our laboratory is:\n(I) Determining the functional impact of RYR1 mutations linked to MH and \nCCD. Since ryanodine receptors are intracellular calcium channels, the \nfunctional effect of most mutations linked to these neuromuscular disor -\nders lead to a dysregulation of intracellular calcium homeostasis. \n(II) Studying if there is a genotype-phenotype correlation between RYR1 \nmutations and specific alterations of intracellular calcium homeostasis.\n(III) Only approximately 50% of MHS individuals have mutations in the RYR1; \nwe are also using a proteomic approach to identify novel proteins which \nare involved in calcium homeostasis and which, upon mutation, may \ncause neuromuscular diseases.\nFig. 1:  Structural and biochemical subspecilaization of membrane compartments \ninvolved in skeletal muscle calcium homeostasis.Dr. Thierry Girard \nDepartement An\u00e4s -\nthesie\nDepartement Forschung\nUniversit\u00e4tsspital Basel\nFig. 2:  Calcium release stimulated by KCl in human myotubes Single cell intracellular \nCa2+ measurements of fura-2 loaded human myotubes. (A) Phase contrast; (B) resting \n[Ca2+]i before the application of 100 mM KCl; (C) 10, (D) 30 and (E) 40 seconds after \nthe application of 100 mM KCl. \n124/125Founded in October 2000, Aponetics \nfocuses on the discovery and develop -\nment of novel anti-cancer therapeutics \nthat modulate apoptosis, the body\u2019s phys -\niological ability to destroy diseased or \ndamaged cells. In cancer cells the apop -\ntotic program is disrupted allowing tumors \nto grow in an uncontrolled fashion. There -\nfore, the concept of apoptosis represents \na rational approach for the discovery of \ndrugs able to induce or restore the natural \napoptotic program in cancer cells.\nThe company\u2019s objective is to bring novel \nand safer anti-cancer drugs to patients.To \nsupport its drug discovery and develop -\nment activities, Aponetics has built up \ncapabilities in high throughput screen -\ning, medicinal chemistry and preclini -\ncal research. Aponetics has also gener -\nated a solid patent portfolio to protect its \nscreening technology as well as the newly \nidentified chemical entities and their ther -\napeutic use in oncology.\nBusiness Strategy\nAponetics\u2019 business strategy is to con -\ncentrate its research efforts in the discov -ery and development of novel anti-cancer \nsmall molecules with a better therapeu -\ntic window than conventional chemother -\napeutic agents, i.e. more specific and with \nless side effects. \nAponetics has discovered new drug can -\ndidates, representing different chemical \nclasses, that have proven to significantly \ninhibit tumor growth in mice xenografted \nwith human tumors. \nAponetics will advance these projects \nthrough preclinical and clinical studies up \nto Phase II, before out-licensing them. \nAponetics Facts\nAponetics started operations in June 2001 \nand has 12 employees. As of August 2004 \nthe company has raised CHF 10 million.\nProduct Pipeline\nJump start for innovative people\nFormation and coaching of companies in Biotechnology, Medicine, Chemistry, Nanotechnology\nEVA supports through\nProject challenging (Innovation level, Competition and Market, Patent situation)\nBusiness plan challenging (Plausibility, Design, Financial information)\nContacts to investors\nCompany formation and coachingCompanies with EVA participation:\nAponetics AG, Witterswil\nBiomit AG, Basel\nBogar AG, Z\u00fcrich\nChemspeed AG, Augst\nCovalys AG, WitterswilHerbonis AG, Augst\nInPheno AG, Basel\nMedgate AG, Basel\nSynphabase AG, Muttenz\nTheraSTrat AG, Allschwil\nCEO\nDr. Jost Harr\nChairman\nDr. Peter Sch\u00fctz\nErfindungsVerwertung AG (EVA)\nBirsigstrasse 10\nCH-4054 Basel\nPhone  +41 (0)61 283 84 85\nFax  +41 (0)61 293 84 86InPheno  is a spin-off from the University of Basel, Switzerland. It was founded \nby specialists in the fields of Microbiology & molecular Oncology and by scien -\ntists with experience in the development of modern therapeutics in pharmaceu -\ntical industry. \nThe mission for InPheno  is: \u201cTo provide novel test platforms for a direct pheno -\ntypic evaluation (for diagnostics or drug-discovery) of resistances to therapeutic \nintervention as a consequence of genetic instability in human diseases\u201d\nA first successful development of InPheno  is the \u201cdiagno-technological\u201d plat -\nform PhenoTecT . This complex, yet robust tool is used for the diagnostics of \nHIV-resistance as the only phenotypic test accredited and reimbursed by fed -\neral authorities. The next development of PhenoTecT  will adapt the platform to \nthe field of Oncology.\nThe success of PhenoTecT  combined with a flexible policy for collaborations \nallowed establishing a series of robust partnerships with the Pharma/Biotech \nIndustry.\nInPheno  also develops a novel proprietary molecule inhibitor of HIV replication \n(TF53) foreseen to enter clinical evaluation in 2006.\nEarly 2005 will see the opening of InPheno \u2018s operations in the USA.CEO\nDr. Thomas Klimkait\nCSO\nDr. Fran\u00e7ois Hamy\nInPheno AG\nSocinstrasse 55a\nCH-4051 Basel\nPhone  +41 (0)61 284 81 50\ninfo@inpheno.com\nwww.inpheno.com Contact\nDr. Alessandro Strebel\nHead of Business Development\nTel: +41 (0)61 726 86 01\nAponetics Ltd., Benkenstrasse 254, CH-4108 Witterswil, \nwww.aponetics.com\nDKBW Publications\n2000\u20132004\nOnly papers with peer review are listed\nAdamina, M., Bolli, M., Albo, F ., Cavazza, A., Zajac, P ., \nPadovan, E., Schumacher, R., Reschner, A., Feder, \nC., Marti, W. R., Oertli, D., Heberer, M., and Spag -\nnoli, G. C. (2004). Encapsulation into sterically sta -\nbilised liposomes enhances the immunogenicity of \nmelanoma-associated Melan-A/MART-1 epitopes, \nBr J Cancer 90, 263-9.\nAdcock, K. H., Metzger, F ., and Kapfhammer, J. P . \n(2004). Purkinje cell dendritic tree development in \nthe absence of excitatory neurotransmission and \nof brain-derived neurotrophic factor in organotypic \nslice cultures, Neuroscience 127, 137-45.\nAellig, M., and Battegay, E. (2004). [Combination \ntherapy versus monotherapy: which strategy is \nbetter?], Schweiz Rundsch Med Prax 93, 865-9.\nAffolter, N., Krahenbuhl, S., and Schlienger, R. G. \n(2003). Appropriateness of serum level determi -\nnations of antiepileptic drugs, Swiss Med Wkly \n133, 591-7.\nAkdis, C. A., Kussebi, F ., Pulendran, B., Akdis, M., \nLauener, R. P ., Schmidt-Weber, C. B., Klunker, S., \nIsitmangil, G., Hansjee, N., Wynn, T. A., Dillon, S., \nErb, P ., Baschang, G., Blaser, K., and Alkan, S. S. \n(2003). Inhibition of T helper 2-type responses, IgE \nproduction and eosinophilia by synthetic lipopep -\ntides, Eur J Immunol 33, 2717-26.\nAlbertsen, B. K., Schroder, H., Ingerslev, J., Jakob -\nsen, P ., Avramis, V . I., Muller, H. J., Carlsen, N. \nT., and Schmiegelow, K. (2001a). Comparison of \nintramuscular therapy with Erwinia asparaginase \nand asparaginase Medac: pharmacokinetics, \npharmacodynamics, formation of antibodies and \ninfluence on the coagulation system, Br J Haema -\ntol 115, 983-90.\nAlbertsen, B. K., Schroder, H., Jakobsen, P ., Avramis, \nV . I., Muller, H. J., Schmiegelow, K., and Carlsen, N. \nT. (2002). Antibody formation during intravenous \nand intramuscular therapy with Erwinia asparagi -\nnase, Med Pediatr Oncol 38, 310-6.\nAlbertsen, B. K., Schroder, H., Jakobsen, P ., Muller, \nH. J., Carlsen, N. T., and Schmiegelow, K. (2001b). \nMonitoring of Erwinia asparaginase therapy in \nchildhood ALL in the Nordic countries, Br J Clin \nPharmacol 52, 433-7.\nAlbo, F ., Cavazza, A., Giardina, B., Lippa, S., Marini, \nM., Roda, L. G., and Spagnoli, G. (2003). Degrada -\ntion of the immunogenic peptide gp100(280-288) \nby the monocyte-like U937 cell line, Peptides 24, \n371-8.\nAlbo, F ., Cavazza, A., Giardina, B., Marini, M., \nRoda, L. G., Schumacher, R., and Spagnoli, G. C. \n(2004). Degradation of the tumor antigen epitope \ngp100(280-288) by fibroblast-associated enzymes \nabolishes specific immunorecognition, Biochim \nBiophys Acta 1671, 59-69.Alessandri, B., Basciani, R., Langemann, H., Lyrer, \nP ., Pluess, D., Landolt, H., and Gratz, O. (2000). \nChronic effects of an aminosteroid on microdia -\nlytically measured parameters after experimental \nmiddle cerebral artery occlusion in the rat, J Clin \nNeurosci 7, 47-51.\nAltman, G. H., Horan, R. L., Lu, H. H., Moreau, J., Mar -\ntin, I., Richmond, J. C., and Kaplan, D. L. (2002a). \nSilk matrix for tissue engineered anterior cruciate \nligaments, Biomaterials 23, 4131-41.\nAltman, G. H., Horan, R. L., Martin, I., Farhadi, J., \nStark, P . R., Volloch, V ., Richmond, J. C., Vunjak-\nNovakovic, G., and Kaplan, D. L. (2002b). Cell \ndifferentiation by mechanical stress, Faseb J 16, \n270-2. Epub 2001 Dec 28.\nAltman, G. H., Lu, H. H., Horan, R. L., Calabro, T., \nRyder, D., Kaplan, D. L., Stark, P ., Martin, I., Rich -\nmond, J. C., and Vunjak-Novakovic, G. (2002c). \nAdvanced bioreactor with controlled application \nof multi-dimensional strain for tissue engineering, \nJ Biomech Eng 124, 742-9.\nAmmann, P ., Kiencke, S., Schaer, B., Cron, T. A., \nSticherling, C., Huldi, C., Linka, A., Buser, P ., \nPfisterer, M., and Osswald, S. (2004). Cardiac \nresynchronization in severe heart failure and left \nbundle branch block: a single center experience, \nSwiss Med Wkly 134, 277-82.\nAnderson, A. A., Treves, S., Biral, D., Betto, R., San -\ndona, D., Ronjat, M., and Zorzato, F . (2003). The \nnovel skeletal muscle sarcoplasmic reticulum JP-45 \nprotein. Molecular cloning, tissue distribution, de -\nvelopmental expression, and interaction with alpha \n1.1 subunit of the voltage-gated calcium channel, J \nBiol Chem 278, 39987-92. Epub 2003 Jul 17.\nAntonescu, C. R., Busam, K. J., Iversen, K., Kolb, D., \nCoplan, K., Spagnoli, G. C., Ladanyi, M., Old, L. J., \nand Jungbluth, A. A. (2002). MAGE antigen expres -\nsion in monophasic and biphasic synovial sarcoma, \nHum Pathol 33, 225-9.\nAnwar, A., Gaspoz, J. M., Pampallona, S., Zahid, A. A., \nSigaud, P ., Pichard, C., Brink, M., and Delafontaine, \nP . (2002a). Effect of congestive heart failure on the \ninsulin-like growth factor-1 system, Am J Cardiol \n90, 1402-5.\nAnwar, A., Zahid, A. A., Scheidegger, K. J., Brink, \nM., and Delafontaine, P . (2002b). Tumor necrosis \nfactor-alpha regulates insulin-like growth factor-1 \nand insulin-like growth factor binding protein-3 \nexpression in vascular smooth muscle, Circulation \n105, 1220-5.\nArber, C., Passweg, J. R., Fluckiger, U., Pless, M., Gre -\ngor, M., Tichelli, A., Schifferli, J. A., and Gratwohl, \nA. (2000). C-reactive protein and fever in neutro -\npenic patients, Scand J Infect Dis 32, 515-20.Arcaro, A., Gregoire, C., Boucheron, N., Stotz, S., \nPalmer, E., Malissen, B., and Luescher, I. F . (2000). \nEssential role of CD8 palmitoylation in CD8 core -\nceptor function, J Immunol 165, 2068-76.\nArefieva, T. I., Provatorov, S. I., Samko, A. N., Kras -\nnikova, T. L., Resink, T. J., Erne, P ., Tkachuk, V . \nA., and Chazov, E. I. (2001). Monocyte integrin \nexpression and monocyte-platelet complex for -\nmation in humans with coronary restenosis, Clin \nExp Pharmacol Physiol 28, 804-8.\nArranto, C. A., Mueller, C., Hunziker, P . R., Marsch, S. \nC., and Eriksson, U. (2003). Adverse cardiac events \nin ICU patients with presumptive antidepressant \noverdose, Swiss Med Wkly 133, 479-83.\nAsmar, R. G., London, G. M., O\u2019Rourke, M. E., Mal -\nlion, J. M., Romero, R., Rahn, K. H., Trimarco, B., \nFitzgerald, D., Hedner, T., Duprez, D., De Leeuw, \nP . W., Sever, P ., Battegay, E., Hitzenberger, G., de \nLuca, N., Polonia, P ., Benetos, A., Chastang, C., \nOllivier, J. P ., and Safar, M. E. (2001). Amelioration \nof arterial properties with a perindopril-indapamide \nvery-low-dose combination, J Hypertens Suppl 19, \nS15-20.\nAsosingh, K., Gunthert, U., Bakkus, M. H., De \nRaeve, H., Goes, E., Van Riet, I., Van Camp, B., \nand Vanderkerken, K. (2000). In vivo induction of \ninsulin-like growth factor-I receptor and CD44v6 \nconfers homing and adhesion to murine multiple \nmyeloma cells, Cancer Res 60, 3096-104.\nAsosingh, K., Gunthert, U., De Raeve, H., Van Riet, \nI., Van Camp, B., and Vanderkerken, K. (2001). A \nunique pathway in the homing of murine multiple \nmyeloma cells: CD44v10 mediates binding to bone \nmarrow endothelium, Cancer Res 61, 2862-5.\nAubry, F ., Satie, A. P ., Rioux-Leclercq, N., Rajpert-De \nMeyts, E., Spagnoli, G. C., Chomez, P ., De Backer, \nO., Jegou, B., and Samson, M. (2001). MAGE-A4, a \ngerm cell specific marker, is expressed differentially \nin testicular tumors, Cancer 92, 2778-85.\nAuer, M., Pfister, L. A., Leppert, D., Tauber, M. G., and \nLeib, S. L. (2000). Effects of clinically used antioxi -\ndants in experimental pneumococcal meningitis, J \nInfect Dis 182, 347-50. Epub 2000 Jul 6.\nAuf der Maur, C., Chatterjee, T., and Erne, P . (2004). \nPercutaneous transcatheter closure of coronary-\npulmonary artery fistula using polytetrafluoroeth -\nylene-covered graft stents, J Invasive Cardiol 16, \n386-8.\nAufderhaar, U., Holzgreve, W., Danzer, E., Tichelli, A., \nTroeger, C., and Surbek, D. V . (2003). The impact \nof intrapartum factors on umbilical cord blood stem \ncell banking, J Perinat Med 31, 317-22.\nAzzola, A., Havryk, A., Chhajed, P ., Hostettler, K., \nBlack, J., Johnson, P ., Roth, M., Glanville, A., and \nTamm, M. (2004). Everolimus and mycophenolate \nmofetil are potent inhibitors of fibroblast prolifera -\ntion after lung transplantation, Transplantation 77, \n275-80.\nBachli, H., Avoledo, P ., Gratzl, O., and Tolnay, M. \n(2003). Therapeutic strategies and management \nof desmoplastic infantile ganglioglioma: two case \nreports and literature overview, Childs Nerv Syst \n19, 359-66. Epub 2003 May 29.\nBachli, H., Minet, J. C., and Gratzl, O. (2004). Cerebral \ntoxocariasis: a possible cause of epileptic seizure in \nchildren, Childs Nerv Syst 12, 12.\nBachmann, A., Dickenmann, M., Gurke, L., Giannini, \nO., Langer, I., Gasser, T. C., Steiger, J., and Sulser, \nT. (2004). Retroperitoneoscopic living donor \nnephrectomy: a retrospective comparison to the \nopen approach, Transplantation 78, 168-71.Bachmann, F ., Buechner, S. A., Wernli, M., Strebel, S., \nand Erb, P . (2001). Ultraviolet light downregulates \nCD95 ligand and TRAIL receptor expression facili -\ntating actinic keratosis and squamous cell carcinoma \nformation, J Invest Dermatol 117, 59-66.\nBaechli, H., Nordmann, A., Bucher, H. C., and Gratzl, \nO. (2004). Demographics and prevalent risk factors \nof chronic subdural haematoma: results of a large \nsingle-center cohort study, Neurosurg Rev 18, 18.\nBalciunaite, G., Keller, M. P ., Balciunaite, E., Piali, L., \nZuklys, S., Mathieu, Y . D., Gill, J., Boyd, R., Suss -\nman, D. J., and Hollander, G. A. (2002). Wnt glyco -\nproteins regulate the expression of FoxN1, the gene \ndefective in nude mice, Nat Immunol 3, 1102-8.\nBalmelli, N., Domine, F ., Pfisterer, M., Krahenbuhl, \nS., and Marsch, S. (2002). Fatal drug interaction \nbetween cholestyramine and phenprocoumon, Eur \nJ Intern Med 13, 210-211.\nBarbero, A., Grogan, S., Schafer, D., Heberer, M., \nMainil-Varlet, P ., and Martin, I. (2004). Age related \nchanges in human articular chondrocyte yield, \nproliferation and post-expansion chondrogenic \ncapacity, Osteoarthritis Cartilage 12, 476-84.\nBarbero, A., Ploegert, S., Heberer, M., and Martin, \nI. (2003). Plasticity of clonal populations of dedif -\nferentiated adult human articular chondrocytes, \nArthritis Rheum 48, 1315-25.\nBarkhof, F ., van Waesberghe, J. H., Filippi, M., Yousry, \nT., Miller, D. H., Hahn, D., Thompson, A. J., Kap -\npos, L., Brex, P ., Pozzilli, C., and Polman, C. H. \n(2001). T(1) hypointense lesions in secondary \nprogressive multiple sclerosis: effect of interferon \nbeta-1b treatment, Brain 124, 1396-402.\nBassetti, S., and Battegay, M. (2004). Staphylococcus \naureus infections in injection drug users: risk factors \nand prevention strategies, Infection 32, 163-9.\nBassetti, S., Battegay, M., and Sudre, P . (2000a). \nAccess to antiretroviral therapy, Jama 283, 883-4; \nauthor reply 884.\nBassetti, S., Dunagan, D. P ., D\u2019Agostino, R. B., Jr., \nand Sherertz, R. J. (2001a). Nasal carriage of \nStaphylococcus aureus among patients receiving \nallergen-injection immunotherapy: associated fac -\ntors and quantitative nasal cultures, Infect Control \nHosp Epidemiol 22, 741-5.\nBassetti, S., Hoffmann, M., Bucher, H. C., Fluckiger, \nU., and Battegay, M. (2002). Infections requiring \nhospitalization of injection drug users who partici -\npated in an injection opiate maintenance program, \nClin Infect Dis 34, 711-3. Epub 2002 Jan 22.\nBassetti, S., Hu, J., D\u2019Agostino, R. B., Jr., and Sherertz, \nR. J. (2000b). In vitro zones of inhibition of coated \nvascular catheters predict efficacy in preventing \ncatheter infection with Staphylococcus aureus in \nvivo, Eur J Clin Microbiol Infect Dis 19, 612-7.\nBassetti, S., Hu, J., D\u2019Agostino, R. B., Jr., and Sher -\nertz, R. J. (2001b). Prolonged antimicrobial activ -\nity of a catheter containing chlorhexidine-silver \nsulfadiazine extends protection against catheter \ninfections in vivo, Antimicrob Agents Chemother \n45, 1535-8.\nBassetti, S., Wolfisberg, L., Jaussi, B., Frei, R., Kuntze, \nM. F ., Battegay, M., and Widmer, A. F . (2004). Car -\nriage of Staphylococcus aureus among injection \ndrug users: lower prevalence in an injection heroin \nmaintenance program than in an oral methadone \nprogram, Infect Control Hosp Epidemiol 25, \n133-7.Batchu, R. B., Moreno, A. M., Szmania, S., Gupta, S. \nK., Zhan, F ., Rosen, N., Kozlowski, M., Spencer, T., \nSpagnoli, G. C., Shaughnessy, J., Barlogie, B., Tri -\ncot, G., and van Rhee, F . (2003). High-level expres -\nsion of cancer/testis antigen NY-ESO-1 and human \ngranulocyte-macrophage colony-stimulating factor \nin dendritic cells with a bicistronic retroviral vector, \nHum Gene Ther 14, 1333-45.\nBattegay, E. (2003). [Modern therapy of hyperten -\nsion], Schweiz Rundsch Med Prax 92, 2153-7.\nBattegay, M. (2001). Critical issues of HIV treatment in \nthe era of highly active antiretroviral therapy, Expert \nOpin Investig Drugs 10, 175-83.\nBattegay, M., Berger, C., Rochlitz, C., Hurwitz, N., \nHirsch, H. H., De Geyter, C., Haque, T., and Nadal, \nD. (2004a). Epstein-Barr virus load correlating with \nclinical manifestation and treatment response in a \npatient with angioimmunoblastic T-cell lymphoma, \nAntivir Ther 9, 453-9.\nBattegay, M., Bucher, H. C., and Vernazza, P . (2004b). \nSexual risk behavior in HIV-infected injection drug \nusers, Clin Infect Dis 38, 1175-7. Epub 2004 Apr \n5.\nBattegay, M., and Fluckiger, U. (2003). [Therapy \nof severe fungal infections], Internist (Berl) 44, \n1549-56.\nBattegay, M., Holdener, M., Naef, M., and Wernli, M. \n(2000). Human immunodeficiency and hepatitis C \nvirus coinfection influenced by interferon-gamma, \nImmunol Lett 71, 141-2.\nBattegay, M., and Manns, M. P . (2004). [Travel in a \nsmaller world], Internist (Berl) 45, 639-40.\nBattegay, M., Seiler, P ., Hunziker, L., Wolf, K., and \nZinkernagel, R. M. (2001a). Neutralizing antiviral \nantibodies reduce hematogenic viral spread but not \nantiviral cytotoxic T cell induction and subsequent \nimmunopathology, J Infect Dis 183, 1425-7.\nBattegay, M., Vernazza, P . L., Bernasconi, E., Flepp, \nM., Sendi, P ., Erb, P ., Malinverni, R., Jaccard, C., \nMorgenthaler, S., Bedoucha, V ., and Hirschel, \nB. (2001b). Combined therapy with saquinavir, \nritonavir and stavudine in moderately to severely \nimmunosuppressed HIV-infected protease inhibi -\ntor-naive patients, HIV Med 2, 35-42.\nBaumann, T. P ., Hurwitz, N., Karamitopolou-Diamantis, \nE., Probst, A., Herrmann, R., and Steck, A. J. (2000). \nDiagnosis and treatment of intravascular lympho -\nmatosis, Arch Neurol 57, 374-7.\nBaykut, D., Bernet, F ., Wehrle, J., Weichelt, K., \nSchwartz, P ., and Zerkowski, H. R. (2001a). New \nsurface biopolymers for oxygenators: an in vitro \nhemocompatibility test of poly(2-methoxyethyl -\nacrylate), Eur J Med Res 6, 297-305.\nBaykut, D., Guller, U., Gebhard, M. M., Kadipasaoglu, \nK., Zerkowski, H. R., and Frazier, O. H. (2001b). \n[Intravascular detection of myocardial ischemia \nby spectrometry in the near infrared spectrum in \nexperimental animals], Arch Mal Coeur Vaiss 94, \n995-1000.\nBaykut, D., Weichelt, K., Wehrle, J., Zerkowski, H. \nR., and Bernet, F . (2003). The value of heparin \nconcentration monitoring in off-pump coronary \nbypass surgery, Eur J Med Res 8, 161-4.\nBaykut, D., and Zerkowski, H. R. (2004). [Biocom -\npatibility of the extracorporeal circulation. The \npresent and the future], Schweiz Rundsch Med \nPrax 93, 366-8.\nBecker, K. L., Nylen, E. S., Snider, R. H., Muller, B., \nand White, J. C. (2003). Immunoneutralization of \nprocalcitonin as therapy of sepsis, J Endotoxin Res \n9, 367-74.Becker, K. L., Nylen, E. S., White, J. C., Muller, B., and \nSnider, R. H., Jr. (2004). Clinical review 167: Procal -\ncitonin and the calcitonin gene family of peptides in \ninflammation, infection, and sepsis: a journey from \ncalcitonin back to its precursors, J Clin Endocrinol \nMetab 89, 1512-25.\nBecker, K. L., White, J.C., Nylen, E.S., Wagner, K.E., \nMuller, B., Preas, H.L., Suffradini, A.F ., Snider, R.H. \n(2001). Toxicity of Procalcitonin: Beneficial Effects \nof its Immunoneutralization., J An\u00e4stes Intensivbeh \n2001 2: 64-6.\nBeglinger, C. (2002). Overview. Cholecystokinin and \neating, Curr Opin Investig Drugs 3, 587-8.\nBeglinger, C. (2004). Comments from the Editors, \nDigestion 69, 1.\nBeglinger, C., Degen, L., Matzinger, D., D\u2019Amato, M., \nand Drewe, J. (2001). Loxiglumide, a CCK-A recep -\ntor antagonist, stimulates calorie intake and hunger \nfeelings in humans, Am J Physiol Regul Integr Comp \nPhysiol 280, R1149-54.\nBeglinger, C., Rosch, T., Renner, E. L., Schofl, R., Bau -\nerfeind, P ., Schwizer, W., Wirth, H. P ., and Fried, \nM. (2004). [Highlights in gastroenterology 2003], \nSchweiz Rundsch Med Prax 93, 655-65.\nBenacquista, B. L., Sharma, M. R., Samso, M., Zor -\nzato, F ., Treves, S., and Wagenknecht, T. (2000). \nAmino acid residues 4425-4621 localized on the \nthree-dimensional structure of the skeletal muscle \nryanodine receptor, Biophys J 78, 1349-58.\nBender, R., Hoffmann, M. C., Frotscher, M., and \nNitsch, C. (2000). Species-specific expression of \nparvalbumin in the entorhinal cortex of the Mon -\ngolian gerbil: dependence on local activity but not \nextrinsic afferents, Neuroscience 99, 423-31.\nBenjamin, D., Colombi, M., and Moroni, C. (2004). A \nGFP-based assay for rapid screening of compounds \naffecting ARE-dependent mRNA turnover, Nucleic \nAcids Res 32, e89. Print 2004 Jun.\nBenz, C. C., Thor, A. D., Eppenberger-Castori, S., \nEppenberger, U., and Moore, D., 3rd (2003). Un -\nderstanding the age dependency of breast cancer \nbiomarkers, Adv Gerontol 11, 117-20.\nBerneis, K., Battegay, M., Bassetti, S., Nuesch, R., Leis -\nibach, A., Bilz, S., and Keller, U. (2000). Nutritional \nsupplements combined with dietary counselling \ndiminish whole body protein catabolism in HIV-\ninfected patients, Eur J Clin Invest 30, 87-94.\nBerneis, K., Buitrago-Tellez, C., Muller, B., Keller, \nU., and Tsakiris, D. A. (2003). Antiphospholipid \nsyndrome and endocrine damage: why bilateral \nadrenal thrombosis?, Eur J Haematol 71, 299-302.\nBerneis, K., and Keller, U. (2000). Bioelectrical imped -\nance analysis during acute changes of extracellular \nosmolality in man, Clin Nutr 19, 361-6.\nBerneis, K., Staub, J. J., Gessler, A., Meier, C., Girard, \nJ., and Muller, B. (2002). Combined stimulation of \nadrenocorticotropin and compound-S by single \ndose metyrapone test as an outpatient procedure \nto assess hypothalamic-pituitary-adrenal function, \nJ Clin Endocrinol Metab 87, 5470-5.\nBernheim, A., and Buser, P . (2004). [In Process Cita -\ntion], Schweiz Rundsch Med Prax 93, 527-30.\nBerns, H., Humar, R., Hengerer, B., Kiefer, F . N., and \nBattegay, E. J. (2000). RACK1 is up-regulated in \nangiogenesis and human carcinomas, Faseb J 14, \n2549-58.\nBertolotto, A., Gilli, F ., Sala, A., Capobianco, M., \nMalucchi, S., Milano, E., Melis, F ., Marnetto, F ., \nLindberg, R. L., Bottero, R., Di Sapio, A., and \nGiordana, M. T. (2003). Persistent neutralizing an -\ntibodies abolish the interferon beta bioavailability \nin MS patients, Neurology 60, 634-9.128/129Betticher, D. C., Hsu Schmitz, S. F ., Totsch, M., \nHansen, E., Joss, C., von Briel, C., Schmid, R. A., \nPless, M., Habicht, J., Roth, A. D., Spiliopoulos, A., \nStahel, R., Weder, W., Stupp, R., Egli, F ., Furrer, M., \nHonegger, H., Wernli, M., Cerny, T., and Ris, H. \nB. (2003). Mediastinal lymph node clearance after \ndocetaxel-cisplatin neoadjuvant chemotherapy is \nprognostic of survival in patients with stage IIIA pN2 \nnon-small-cell lung cancer: a multicenter phase II \ntrial, J Clin Oncol 21, 1752-9.\nBettler, B., Kaupmann, K., Mosbacher, J., and Gas -\nsmann, M. (2004). Molecular structure and physi -\nological functions of GABA(B) receptors, Physiol \nRev 84, 835-67.\nBhatnagar, A., Gulland, S., Bascand, M., Palmer, E., \nGardner, T. G., Kearse, K. P ., and Backstrom, B. T. \n(2003). Mutational analysis of conserved amino \nacids in the T cell receptor alpha-chain transmem -\nbrane region: a critical role of leucine 112 and phe -\nnylalanine 127 for assembly and surface expression, \nMol Immunol 39, 953-63.\nBianchi, M., Rey-Roldan, E., Bettler, B., Ristig, D., \nMalitschek, B., Libertun, C., and Lux-Lantos, V . \n(2001). Ontogenic expression of anterior pituitary \nGABA(B) receptor subunits, Neuropharmacology \n40, 185-92.\nBiedermann, B., Bringmann, A., Franze, K., Faude, \nF ., Wiedemann, P ., and Reichenbach, A. (2004). \nGABA(A) receptors in Muller glial cells of the hu -\nman retina, Glia 46, 302-10.\nBiedermann, B., Landmann, C., Kann, R., Passweg, J., \nSoler, M., Lohri, A., Rochlitz, C., Herrmann, R., and \nPless, M. (2000). Combined chemoradiotherapy \nwith daily low-dose cisplatin in locally advanced \ninoperable non-small cell lung cancer, Radiother \nOncol 56, 169-73.\nBiedermann, B. C. (2001). Vascular endothelium: \ncheckpoint for inflammation and immunity, News \nPhysiol Sci 16, 84-8.\nBiedermann, B. C., Sahner, S., Gregor, M., Tsakiris, \nD. A., Jeanneret, C., Pober, J. S., and Gratwohl, A. \n(2002). Endothelial injury mediated by cytotoxic T \nlymphocytes and loss of microvessels in chronic \ngraft versus host disease, Lancet 359, 2078-83.\nBiedermann, B. C., Tsakiris, D. A., Gregor, M., Pober, \nJ. S., and Gratwohl, A. (2003). Combining altered \nlevels of effector transcripts in circulating T cells \nwith a marker of endothelial injury is specific for \nactive graft-versus-host disease, Bone Marrow \nTransplant 32, 1077-84.\nBigliardi, P . L., Buchner, S., Rufli, T., and Bigliardi-Qi, \nM. (2002). Specific stimulation of migration of hu -\nman keratinocytes by mu-opiate receptor agonists, \nJ Recept Signal Transduct Res 22, 191-9.\nBigliardi, P . L., Sumanovski, L. T., Buchner, S., Rufli, T., \nand Bigliardi-Qi, M. (2003). Different expression of \nmu-opiate receptor in chronic and acute wounds \nand the effect of beta-endorphin on transforming \ngrowth factor beta type II receptor and cytokeratin \n16 expression, J Invest Dermatol 120, 145-52.\nBigliardi-Qi, M., Bigliardi, P . L., Eberle, A. N., Buchner, \nS., and Rufli, T. (2000). beta-endorphin stimulates \ncytokeratin 16 expression and downregulates mu-\nopiate receptor expression in human epidermis, J \nInvest Dermatol 114, 527-32.\nBigliardi-Qi, M., Sumanovski, L.T., Buchner, S., Rufli, \nT., Bigliardi, P .L., (2004). Mu-opiate receptor and \nbeta-endorphin expression in nerve endings and \nkeratinocytes in humanin skin., Dermatology.\nBihl, M. P ., Heinimann, K., Rudiger, J. J., Eickelberg, \nO., Perruchoud, A. P ., Tamm, M., and Roth, M. \n(2002). Identification of a novel IL-6 isoform bind -\ning to the endogenous IL-6 receptor, Am J Respir \nCell Mol Biol 27, 48-56.Bilz, S., Wagner, S., Schmitz, M., Bedynek, A., Keller, \nU., and Demant, T. (2004). Effects of atorvastatin \nversus fenofibrate on apoB-100 and apoA-I kinetics \nin mixed hyperlipidemia, J Lipid Res 45, 174-85. \nEpub 2003 Oct 1.\nBischoff, F . Z., Hahn, S., Johnson, K. L., Simpson, J. L., \nBianchi, D. W., Lewis, D. E., Weber, W. D., Klinger, \nK., Elias, S., Jackson, L. G., Evans, M. I., Holzgreve, \nW., and de la Cruz, F . (2003). Intact fetal cells in \nmaternal plasma: are they really there?, Lancet \n361, 139-40.\nBisset, L. R., Cone, R. W., Fischer, M., Battegay, M., \nVernazza, P . L., Dubs, R. W., Weber, R., Grob, P . J., \nand Opravil, M. (2001). Long-term evaluation of \nT-cell subset changes after effective combination \nantiretroviral therapy during asymptomatic HIV-in -\nfection, J Acquir Immune Defic Syndr 27, 266-71.\nBlack, J. L., Roth, M., Lee, J., Carlin, S., and Johnson, \nP . R. (2001). Mechanisms of airway remodeling. \nAirway smooth muscle, Am J Respir Crit Care Med \n164, S63-6.\nBlanchard, C., Durual, S., Estienne, M., Bouzakri, K., \nHeim, M. H., Blin, N., and Cuber, J. C. (2004). IL-4 \nand IL-13 up-regulate intestinal trefoil factor expres -\nsion: requirement for STAT6 and de novo protein \nsynthesis, J Immunol 172, 3775-83.\nBlindenbacher, A., Duong, F . H., Hunziker, L., Stutvoet, \nS. T., Wang, X., Terracciano, L., Moradpour, D., \nBlum, H. E., Alonzi, T., Tripodi, M., La Monica, N., \nand Heim, M. H. (2003a). Expression of hepatitis \nc virus proteins inhibits interferon alpha signaling \nin the liver of transgenic mice, Gastroenterology \n124, 1465-75.\nBlindenbacher, A., Wang, X., Langer, I., Savino, R., Ter -\nracciano, L., and Heim, M. H. (2003b). Interleukin 6 \nis important for survival after partial hepatectomy in \nmice, Hepatology 38, 674-82.\nBlock, L. H., and Roth, M. (1996). [Cell proliferation \nfactors and vascular damage], Cardiologia 41, \n13-7.\nBogman, K., Erne-Brand, F ., Alsenz, J., and Drewe, \nJ. (2003). The role of surfactants in the reversal of \nactive transport mediated by multidrug resistance \nproteins, J Pharm Sci 92, 1250-61.\nBogman, K., Peyer, A. K., Torok, M., Kusters, E., and \nDrewe, J. (2001). HMG-CoA reductase inhibitors \nand P-glycoprotein modulation, Br J Pharmacol \n132, 1183-92.\nBogman, K., Zysset, Y ., Degen, L., Hopfgartner, G., \nGutmann, H., Alsenz, J., Drewe, J. (2004). P-glyco -\nprotein and surfactants: effect on intestinal talinolol \nabsorption., Clin Pharmacol Ther 2004 (in press).\nBolli, M., Kocher, T., Adamina, M., Guller, U., Dalquen, \nP ., Haas, P ., Mirlacher, M., Gambazzi, F ., Harder, F ., \nHeberer, M., Sauter, G., and Spagnoli, G. C. (2002). \nTissue microarray evaluation of Melanoma antigen \nE (MAGE) tumor-associated antigen expression: \npotential indications for specific immunotherapy \nand prognostic relevance in squamous cell lung car -\ncinoma, Ann Surg 236, 785-93; discussion 793.\nBolliger, C. T., Guckel, C., Engel, H., Stohr, S., Wyser, \nC. P ., Schoetzau, A., Habicht, J., Soler, M., Tamm, \nM., and Perruchoud, A. P . (2002). Prediction of \nfunctional reserves after lung resection: compari -\nson between quantitative computed tomography, \nscintigraphy, and anatomy, Respiration 69, 482-9.\nBolton, A. E., Peng, B., Hubert, M., Krebs-Brown, \nA., Capdeville, R., Keller, U., and Seiberling, M. \n(2004). Effect of rifampicin on the pharmacokinet -\nics of imatinib mesylate (Gleevec, STI571) in healthy \nsubjects, Cancer Chemother Pharmacol 53, 102-6. \nEpub 2003 Nov 7.Boni, J., Bisset, L. R., Burckhardt, J. J., Joller-Jemelka, \nH. I., Burgisser, P ., Perrin, L., Gorgievski, M., Erb, P ., \nFierz, W., Piffaretti, J. C., and Schupbach, J. (2004). \nPrevalence of human T-cell leukemia virus types I \nand II in Switzerland, J Med Virol 72, 328-37.\nBorger, P ., Black, J. L., and Roth, M. (2002). Asthma \nand the CCAAT-enhancer binding proteins: a holis -\ntic view on airway inflammation and remodeling, J \nAllergy Clin Immunol 110, 841-6.\nBoulay, J. L., Mild, G., Lowy, A., Reuter, J., Lagrange, \nM., Terracciano, L., Laffer, U., Herrmann, R., and \nRochlitz, C. (2002). SMAD4 is a predictive marker \nfor 5-fluorouracil-based chemotherapy in patients \nwith colorectal cancer, Br J Cancer 87, 630-4.\nBoulay, J. L., Mild, G., Lowy, A., Reuter, J., Lagrange, \nM., Terracciano, L., Laffer, U., Herrmann, R., and \nRochlitz, C. (2003). SMAD7 is a prognostic marker \nin patients with colorectal cancer, Int J Cancer 104, \n446-9.\nBoulay, J. L., Mild, G., Reuter, J., Lagrange, M., \nTerracciano, L., Lowy, A., Laffer, U., Orth, B., \nMetzger, U., Stamm, B., Martinoli, S., Herrmann, \nR., and Rochlitz, C. (2001). Combined copy status \nof 18q21 genes in colorectal cancer shows frequent \nretention of SMAD7, Genes Chromosomes Cancer \n31, 240-7.\nBoulay, J. L., Perruchoud, A. P ., Reuter, J., Bolliger, C., \nHerrmann, R., and Rochlitz, C. (2000). P21 gene \nexpression as an indicator for the activity of adeno -\nvirus-p53 gene therapy in non-small cell lung cancer \npatients, Cancer Gene Ther 7, 1215-9.\nBoureau, F ., Kappos, L., Schoenen, J., Esperanca, P ., \nand Ashford, E. (2000). A clinical comparison of \nsumatriptan nasal spray and dihydroergotamine \nnasal spray in the acute treatment of migraine, Int J \nClin Pract 54, 281-6.\nBoussard, C., Klimkait, T., Mahmood, N., Pritchard, \nM., and Gilbert, I. H. (2004). Design, synthesis and \nevaluation of potential inhibitors of HIV gp120-CD4 \ninteractions, Bioorg Med Chem Lett 14, 2673-6.\nBowery, N. G., Bettler, B., Froestl, W., Gallagher, J. \nP ., Marshall, F ., Raiteri, M., Bonner, T. I., and Enna, \nS. J. (2002). International Union of Pharmacology. \nXXXIII. Mammalian gamma-aminobutyric acid(B) \nreceptors: structure and function, Pharmacol Rev \n54, 247-64.\nBravo, A. E., Egger, S. S., Crespo, S., Probst, W. L., \nand Krahenbuhl, S. (2004). Lithium intoxication as \na result of an interaction with rofecoxib, Ann Phar -\nmacother 38, 1189-93. Epub 2004 Jun 8.\nBreitenbach, U., Tuckermann, J. P ., Gebhardt, C., \nRichter, K. H., Furstenberger, G., Christofori, G., \nand Angel, P . (2001). Keratinocyte-specific onset \nof serine protease BSSP expression in experimental \ncarcinogenesis, J Invest Dermatol 117, 634-40.\nBrem, R., Certa, U., Neeb, M., Nair, A. P ., and Mo -\nroni, C. (2001). Global analysis of differential gene \nexpression after transformation with the v-H-ras \noncogene in a murine tumor model, Oncogene \n20, 2854-8.\nBrennan, L. E., Sune, C., and Klimkait, T. (2002). A \nneutravidin-based assay for reverse transcriptase \nsuitable for high throughput screening of retroviral \nactivity, J Biochem Mol Biol 35, 262-6.\nBrett, W., Mandinova, A., Remppis, A., Sauder, U., \nRuter, F ., Heizmann, C. W., Aebi, U., and Zerkowski, \nH. R. (2001). Translocation of S100A1(1) calcium \nbinding protein during heart surgery, Biochem \nBiophys Res Commun 284, 698-703.Brettenthaler, N., De Geyter, C., Huber, P . R., and \nKeller, U. (2004). Effect of the insulin sensitizer \npioglitazone on insulin resistance, hyperandro -\ngenism, and ovulatory dysfunction in women with \npolycystic ovary syndrome, J Clin Endocrinol Metab \n89, 3835-40.\nBrex, P . A., Molyneux, P . D., Smiddy, P ., Barkhof, F ., \nFilippi, M., Yousry, T. A., Hahn, D., Rolland, Y ., Sa -\nlonen, O., Pozzilli, C., Polman, C. H., Thompson, \nA. J., Kappos, L., and Miller, D. H. (2001). The \neffect of IFNbeta-1b on the evolution of enhancing \nlesions in secondary progressive MS, Neurology \n57, 2185-90.\nBrezesinski, G., Muller, H. J., Toca-Herrera, J. L., and \nKrustev, R. (2001). X-ray diffraction and foam film \ninvestigations of PC head group interaction in \nwater/ethanol mixtures, Chem Phys Lipids 110, \n183-94.\nBriata, P ., Ilengo, C., Corte, G., Moroni, C., Rosen -\nfeld, M. G., Chen, C. Y ., and Gherzi, R. (2003). \nThe Wnt/beta-catenin--\ue02bPitx2 pathway controls \nthe turnover of Pitx2 and other unstable mRNAs, \nMol Cell 12, 1201-11.\nBrink, M., Anwar, A., and Delafontaine, P . (2002). \nNeurohormonal factors in the development of \ncatabolic/anabolic imbalance and cachexia, Int J \nCardiol 85, 111-21, discussion 121-4.\nBrink, M., Du, J., Peng, T., Mottironi, B., and Delafon -\ntaine, P . (2001a). Thrombin regulates insulin-like \ngrowth factor-1 receptor transcription in vascular \nsmooth muscle: characterization of the signaling \npathway, Circ Res 88, 1044-52.\nBrink, M., Price, S. R., Chrast, J., Bailey, J. L., Anwar, \nA., Mitch, W. E., and Delafontaine, P . (2001b). An -\ngiotensin II induces skeletal muscle wasting through \nenhanced protein degradation and down-regulates \nautocrine insulin-like growth factor I, Endocrinology \n142, 1489-96.\nBrodmann, S., Passweg, J. R., Gratwohl, A., Tichelli, \nA., and Skoda, R. C. (2000). Myeloproliferative \ndisorders: complications, survival and causes of \ndeath, Ann Hematol 79, 312-8.\nBrody, S., Keller, U., Degen, L., Cox, D. J., and Sch -\nachinger, H. (2004). Selective processing of food \nwords during insulin-induced hypoglycemia in \nhealthy humans, Psychopharmacology (Berl) 173, \n217-20. Epub 2004 Jan 15.\nBrondani, V ., Klimkait, T., Egly, J. M., and Hamy, \nF . (2002). Promoter of FGF8 reveals a unique \nregulation by unliganded RARalpha, J Mol Biol \n319, 715-28.\nBrooks, H., and Krahenbuhl, S. (2001). Identification \nand tissue distribution of two differentially spliced \nvariants of the rat carnitine transporter OCTN2, \nFEBS Lett 508, 175-80.\nBruder, E., Ersch, J., Hebisch, G., Ehrbar, T., Klim -\nkait, T., and Stallmach, T. (2000). Fetal varicella \nsyndrome: disruption of neural development and \npersistent inflammation of non-neural tissues, Vir -\nchows Arch 437, 440-4.\nBrune, T., Beier, K., Exeler, R., Harms, E., and Louwen, \nF . (2003). Neonatal Lymphocytes Dominate against \nLymphocytes of Their Own Mother but Not against \nAllogenic Maternal or Adult Lymphocytes in Bidi -\nrectional Mixed Lymphocyte Cultures, Fetal Diagn \nTher 18, 154-9.\nBruno, L., Schaniel, C., and Rolink, A. (2002). Plastic -\nity of Pax-5(-/-) pre-B I cells, Cells Tissues Organs \n171, 38-43.\nBrutsche, M. H., Joos, L., Carlen Brutsche, I. E., Biss -\ninger, R., Tamm, M., Custovic, A., and Woodcock, \nA. (2002). Array-based diagnostic gene-expression \nscore for atopy and asthma, J Allergy Clin Immunol \n109, 271-3.Bucher, H. C., Bichsel, M., Taffe, P ., Furrer, H., Tel -\nenti, A., Hirschel, B., Weber, R., Bernasconi, E., \nVernazza, P ., Minder, C., and Battegay, M. (2002). \nRitonavir plus saquinavir versus single protease \ninhibitor therapy in protease inhibitor-naive HIV-\ninfected patients: the Swiss HIV Cohort Study, HIV \nMed 3, 247-53.\nBucher, H. C., Kofler, A., Nuesch, R., Young, J., Bat -\ntegay, M., and Opravil, M. (2003). Meta-analysis \nof randomized controlled trials of simplified versus \ncontinued protease inhibitor-based antiretrovi -\nral therapy in HIV-1-infected patients, Aids 17, \n2451-9.\nBuechner, S., Wernli, M., Bachmann, F ., Harr, T., and \nErb, P . (2002). Intralesional interferon in basal cell \ncarcinoma: how does it work?, Recent Results \nCancer Res 160, 246-50.\nBuess, M., Terracciano, L., Reuter, J., Ballabeni, P ., \nBoulay, J. L., Laffer, U., Metzger, U., Herrmann, \nR., and Rochlitz, C. (2004). Amplification of SKI \nis a prognostic marker in early colorectal cancer, \nNeoplasia 6, 207-12.\nBurgess, J. K., Johnson, P . R., Ge, Q., Au, W. W., \nPoniris, M. H., McParland, B. E., King, G., Roth, \nM., and Black, J. L. (2003). Expression of con -\nnective tissue growth factor in asthmatic airway \nsmooth muscle cells, Am J Respir Crit Care Med \n167, 71-7.\nBusam, K. J., Iversen, K., Berwick, M., Spagnoli, G. \nC., Old, L. J., and Jungbluth, A. A. (2000). Im -\nmunoreactivity with the anti-MAGE antibody 57B \nin malignant melanoma: frequency of expression \nand correlation with prognostic parameters, Mod \nPathol 13, 459-65.\nBusslinger, M., Nutt, S. L., and Rolink, A. G. (2000). \nLineage commitment in lymphopoiesis, Curr Opin \nImmunol 12, 151-8.\nButz, S., Driamov, S., Remondino, A., Bellahcene, \nM., Beier, K., Ziegler, A., Buser, P . T., and Zaugg, \nC. E. (2004). Losartan but not enalaprilat acutely \nreduces reperfusion ventricular tachyarrhythmias in \nhypertrophied rat hearts after low-flow ischaemia, J \nPharm Pharmacol 56, 521-8.\nCabrita, M. A., and Christofori, G. (2003). Sprouty \nproteins: antagonists of endothelial cell signaling \nand more, Thromb Haemost 90, 586-90.\nCaduff, J., Sansano, S., Bonnet, A., Suter, U., and \nSchaeren-Wiemers, N. (2001). Characterization \nof GFP-MAL expression and incorporation in rafts, \nMicrosc Res Tech 52, 645-55.\nCamillo, F ., Marmorini, P ., Romagnoli, S., Cela, M., Du -\nchamp, G., and Palmer, E. (2000). Clinical studies \non daily low dose oxytocin in mares at term, Equine \nVet J 32, 307-10.\nCapone, M., Lees, R. K., Finke, D., Ernst, B., \nMeerwijk, J. P ., and MacDonald, H. R. (2003). \nSelective absence of CD8\ue02b TCRalpha beta\ue02b intes -\ntinal epithelial cells in transgenic mice expressing \nbeta2-microglobulin-associated ligands exclusively \non thymic cortical epithelium, Eur J Immunol 33, \n1471-7.\nCapone, M., Troesch, M., Eberl, G., Hausmann, B., \nPalmer, E., and MacDonald, H. R. (2001). A critical \nrole for the T cell receptor alpha-chain connecting \npeptide domain in positive selection of CD1-inde -\npendent NKT cells, Eur J Immunol 31, 1867-75.\nCarlin, S., Resink, T.J., Tamm, M., Roth, M. (2004). \nUrokinase signal transduction and its role in cell \nmigration., FASEB-J 2004 (in press).\nCarlin, S. M., Roth, M., and Black, J. L. (2003). Uroki -\nnase potentiates PDGF-induced chemotaxis of hu -\nman airway smooth muscle cells, Am J Physiol Lung \nCell Mol Physiol 284, L1020-6. Epub 2003 Feb 7.Carrier, L., Knoll, R., Vignier, N., Keller, D. I., Bausero, \nP ., Prudhon, B., Isnard, R., Ambroisine, M. L., Fisz -\nman, M., Ross, J., Jr., Schwartz, K., and Chien, \nK. R. (2004). Asymmetric septal hypertrophy in \nheterozygous cMyBP-C null mice, Cardiovasc Res \n63, 293-304.\nCasella, R., Moch, H., Rochlitz, C., Meier, V ., Seifert, \nB., Mihatsch, M. J., and Gasser, T. C. (2001). \nMetastatic primitive neuroectodermal tumor of \nthe kidney in adults, Eur Urol 39, 613-7.\nCathomas, G., Erne, P ., Schwenkglenks, M., and \nSzucs, T. D. (2002). The economic efficiency of \namlodipine in the treatment of coronary athero -\nsclerosis--an analysis based on the PREVENT study, \nCardiovasc Drugs Ther 16, 61-6.\nCavagna, D., Zorzato, F ., Babini, E., Prestipino, G., \nand Treves, S. (2000). Methyl p-hydroxybenzoate \n(E-218) a preservative for drugs and food is an \nactivator of the ryanodine receptor Ca(2\ue02b) release \nchannel, Br J Pharmacol 131, 335-41.\nCavallaro, U., and Christofori, G. (2000). Molecular \nmechanisms of tumor angiogenesis and tumor \nprogression, J Neurooncol 50, 63-70.\nCavallaro, U., and Christofori, G. (2001). Cell adhesion \nin tumor invasion and metastasis: loss of the glue is \nnot enough, Biochim Biophys Acta 1552, 39-45.\nCavallaro, U., and Christofori, G. (2004a). Cell adhe -\nsion and signalling by cadherins and Ig-CAMs in \ncancer, Nat Rev Cancer 4, 118-32.\nCavallaro, U., and Christofori, G. (2004b). Multitasking \nin tumor progression: signaling functions of cell ad -\nhesion molecules, Ann N Y Acad Sci 1014, 58-66.\nCavallaro, U., Niedermeyer, J., Fuxa, M., and Christo -\nfori, G. (2001). N-CAM modulates tumour-cell \nadhesion to matrix by inducing FGF-receptor \nsignalling, Nat Cell Biol 3, 650-7.\nCavallaro, U., Schaffhauser, B., and Christofori, G. \n(2002). Cadherins and the tumour progression: is \nit all in a switch?, Cancer Lett 176, 123-8.\nCavazza, A., Adamina, M., Ausiello, C. M., Gia -\nrdina, B., Marini, M., Palazzo, R., Roda, L. G., and \nSpagnoli, G. C. (2004). Hydrolysis of the tumor-\nassociated antigen epitope gp100(280-288) by \nmembrane-associated and soluble enzymes ex -\npressed by immature and mature dendritic cells, \nClin Immunol 111, 252-61.\nCaversaccio, M., Frenz, M., Schar, P ., and Hausler, R. \n(2001). Endonasal and transcanalicular Er:YAG laser \ndacryocystorhinostomy, Rhinology 39, 28-32.\nCazzola, M., and Skoda, R. C. (2000). Translational \npathophysiology: a novel molecular mechanism of \nhuman disease, Blood 95, 3280-8.\nCejka, P ., Stojic, L., Mojas, N., Russell, A. M., Heini -\nmann, K., Cannavo, E., di Pietro, M., Marra, G., \nand Jiricny, J. (2003). Methylation-induced G(2)/M \narrest requires a full complement of the mismatch \nrepair protein hMLH1, Embo J 22, 2245-54.\nCeredig, R., Bosco, N., Maye, P . N., Andersson, J., and \nRolink, A. (2003). In interleukin-7-transgenic mice, \nincreasing B lymphopoiesis increases follicular but \nnot marginal zone B cell numbers, Eur J Immunol \n33, 2567-76.\nCeredig, R., Rolink, A. G., Melchers, F ., and Anders -\nson, J. (2000). The B cell receptor, but not the pre-B \ncell receptor, mediates arrest of B cell differentia -\ntion, Eur J Immunol 30, 759-67.\nCerletti, A., Drewe, J., Fricker, G., Eberle, A. N., and \nHuwyler, J. (2000). Endocytosis and transcytosis \nof an immunoliposome-based brain drug delivery \nsystem, J Drug Target 8, 435-46.130/131Certa, U., Seiler, M., Padovan, E., and Spagnoli, G. \nC. (2001). High density oligonucleotide array \nanalysis of interferon- alpha2a sensitivity and \ntranscriptional response in melanoma cells, Br J \nCancer 85, 107-14.\nCerta, U., Seiler, M., Padovan, E., and Spagnoli, G. C. \n(2002). Interferon-a sensitivity in melanoma cells: \ndetection of potential response marker genes, \nRecent Results Cancer Res 160, 85-91.\nChambost, H., Van Baren, N., Brasseur, F ., Godelaine, \nD., Xerri, L., Landi, S. J., Theate, I., Plumas, J., \nSpagnoli, G. C., Michel, G., Coulie, P . G., and \nOlive, D. (2000). Expression of gene MAGE-A4 in \nReed-Sternberg cells, Blood 95, 3530-3.\nChatterjee, T., and Erne, P . (2003). Anomalous right \ncoronary artery originating from the mid left main \ncoronary artery, Heart 89, 132.\nChatterjee, T., Juelke, P . D., Thum, P ., and Erne, P . \n(2003). Successful brachytherapy of coronary \nvasospasm, Heart 89, e25.\nChen, C. Y ., Gherzi, R., Ong, S. E., Chan, E. L., \nRaijmakers, R., Pruijn, G. J., Stoecklin, G., Moroni, \nC., Mann, M., and Karin, M. (2001). AU binding \nproteins recruit the exosome to degrade ARE-con -\ntaining mRNAs, Cell 107, 451-64.\nChen, D., Lucey, M. J., Phoenix, F ., Lopez-Garcia, J., \nHart, S. M., Losson, R., Buluwela, L., Coombes, R. \nC., Chambon, P ., Schar, P ., and Ali, S. (2003). T:\nG mismatch-specific thymine-DNA glycosylase \npotentiates transcription of estrogen-regulated \ngenes through direct interaction with estrogen \nreceptor alpha, J Biol Chem 278, 38586-92. Epub \n2003 Jul 21.\nChhajed, P . N., and Tamm, M. (2003). Radiofrequency \nheat ablation for lung tumors: potential applications, \nMed Sci Monit 9, ED5-7.\nChitale, D. A., Jungbluth, A. A., Marshall, D. S., Leitao, \nM. M., Hedvat, C. V ., Kolb, D., Spagnoli, G. C., \nIversen, K., and Soslow, R. A. (2004). Expression \nof cancer-testis antigens in endometrial carcinomas \nusing a tissue microarray, Mod Pathol 23, 23.\nChklovskaia, E., Nissen, C., Landmann, L., Rahner, C., \nPfister, O., and Wodnar-Filipowicz, A. (2001). Cell-\nsurface trafficking and release of flt3 ligand from \nT lymphocytes is induced by common cytokine \nreceptor gamma-chain signaling and inhibited by \ncyclosporin A, Blood 97, 1027-34.\nChklovskaia, E., Nowbakht, P ., Nissen, C., Gratwohl, \nA., Bargetzi, M., and Wodnar-Filipowicz, A. (2004). \nReconstitution of dendritic and natural killer-cell \nsubsets after allogeneic stem cell transplantation: \neffects of endogenous flt3 ligand, Blood 103, 3860-\n8. Epub 2004 Feb 5.\nChrist, O., Gunthert, U., Haas, R., and Zoller, M. \n(2001). Importance of CD44v7 isoforms for hom -\ning and seeding of hematopoietic progenitor cells, \nJ Leukoc Biol 69, 343-52.\nChrist, O., Gunthert, U., Schmidt, D. S., and Zoller, M. \n(2002). Allogeneic reconstitution after nonmyeloab -\nlative conditioning: mitigation of graft-versus-host \nand host-versus-graft reactivity by anti-CD44v6, J \nLeukoc Biol 71, 33-46.\nChrist-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gen -\ncay, M. M., Huber, P . R., Tamm, M., and Muller, B. \n(2004a). Effect of procalcitonin-guided treatment \non antibiotic use and outcome in lower respiratory \ntract infections: cluster-randomised, single-blinded \nintervention trial, Lancet 363, 600-7.\nChrist-Crain, M., Meier, C., Guglielmetti, M., Huber, \nP . R., Riesen, W., Staub, J. J., and Muller, B. (2003). \nElevated C-reactive protein and homocysteine val -\nues: cardiovascular risk factors in hypothyroidism? \nA cross-sectional and a double-blind, placebo-con -\ntrolled trial, Atherosclerosis 166, 379-86.Christ-Crain, M., Meier, C., Huber, P ., Zimmerli, L., \nTrummler, M., and Muller, B. (2004b). Comparison \nof different methods for the measurement of serum \ntestosterone in the aging male, Swiss Med Wkly \n134, 193-7.\nChrist-Crain, M., Meier, C., Roth, C. B., Huber, P ., \nStaub, J. J., and Muller, B. (2002). Basal TSH \nlevels compared with TRH-stimulated TSH levels \nto diagnose different degrees of TSH suppression: \ndiagnostic and therapeutic impact of assay perform -\nance, Eur J Clin Invest 32, 931-7.\nChrist-Crain, M., Meier, C., Huber, P .R., Keller, U., \nStaub, J.J., Muller, B. (2004a). Effect of L-Thyrox -\nine Replacement Therapy on Skeletal and Cardiac \nFunction in Subclinical Hypothyroidism., The En -\ndocrinoligist 2004 14: 161-6.\nChrist-Crain, M., Meier, C., Puder, J.J., Staub, J.J., Hu -\nber, P .R., Keller, U., Muller, B. (2004b). Changes of \nLiver Function Test correlate with the Improvement \nof Lipid Profile after Restoration of Euthyroidism in \nPatients with Subclinical Hypothyroidism., EXCLI \nJournal 2004 3: 1-9.\nChrist-Crain, M., Meier, C., Zulewski, H., Huber, P .R., \nKeller, U., Staub, J.J., Muller, B. (2003). Effect of \nRestoration of Euthyroidism on Peripheral Blood \nCells in Women with Subclinical Hypothyroidism., \nHormones 2003 2: 209-14.\nChrist-Crain, M., Mueller, B., Gasser, T. C., Kraenzlin, \nM., Trummler, M., Huber, P ., and Meier, C. (2004c). \nIs there a clinical relevance of partial androgen defi -\nciency of the aging male?, J Urol 172, 624-7.\nChristofori, G. (2003a). Changing neighbours, chang -\ning behaviour: cell adhesion molecule-mediated \nsignalling during tumour progression, Embo J 22, \n2318-23.\nChristofori, G. (2003b). Split personalities: the agonis -\ntic antagonist Sprouty, Nat Cell Biol 5, 377-9.\nCipolat, C., Bader, U., Rufli, T., and Burg, G. (2003). \nTeledermatology in Switzerland, Curr Probl Der -\nmatol 32, 257-60.\nClanet, M., Kappos, L., Hartung, H. P ., and Hohlfeld, \nR. (2004). Interferon beta-1a in relapsing multiple \nsclerosis: four-year extension of the European \nIFNbeta-1a Dose-Comparison Study, Mult Scler \n10, 139-44.\nClanet, M., Radue, E. W., Kappos, L., Hartung, H. \nP ., Hohlfeld, R., Sandberg-Wollheim, M., Kooij -\nmans-Coutinho, M. F ., Tsao, E. C., and Sandrock, \nA. W. (2002). A randomized, double-blind, dose-\ncomparison study of weekly interferon beta-1a in \nrelapsing MS, Neurology 59, 1507-17.\nClarke, S., Bellmann, A., Meuli, R. A., Assal, G., and \nSteck, A. J. (2000). Auditory agnosia and auditory \nspatial deficits following left hemispheric lesions: \nevidence for distinct processing pathways, Neu -\nropsychologia 38, 797-807.\nClement-Jones, M., Schiller, S., Rao, E., Blaschke, R. \nJ., Zuniga, A., Zeller, R., Robson, S. C., Binder, G., \nGlass, I., Strachan, T., Lindsay, S., and Rappold, G. \nA. (2000). The short stature homeobox gene SHOX \nis involved in skeletal abnormalities in Turner syn -\ndrome, Hum Mol Genet 9, 695-702.\nCoers, J., Ranft, C., and Skoda, R. C. (2004). A trun -\ncated isoform of c-mpl with an essential C-terminal \npeptide targets the full-length receptor for degrada -\ntion, J Biol Chem 21, 21.Comi, G., Kappos, L., Clanet, M., Ebers, G., Fassas, A., \nFazekas, F ., Filippi, M., Hartung, H. P ., Hertenstein, \nB., Karussis, D., Martino, G., Tyndall, A., and van \nder Meche, F . G. (2000). Guidelines for autolo -\ngous blood and marrow stem cell transplantation \nin multiple sclerosis: a consensus report written \non behalf of the European Group for Blood and \nMarrow Transplantation and the European Char -\ncot Foundation. BMT-MS Study Group, J Neurol \n247, 376-82.\nCompagni, A., and Christofori, G. (2000). Recent \nadvances in research on multistage tumorigenesis, \nBr J Cancer 83, 1-5.\nCompagni, A., Wilgenbus, P ., Impagnatiello, M. A., \nCotten, M., and Christofori, G. (2000). Fibroblast \ngrowth factors are required for efficient tumor \nangiogenesis, Cancer Res 60, 7163-9.\nConfavreux, C., Suissa, S., Saddier, P ., Bourdes, V ., \nand Vukusic, S. (2001). Vaccinations and the risk \nof relapse in multiple sclerosis. Vaccines in Multiple \nSclerosis Study Group, N Engl J Med 344, 319-26.\nConstantinescu, C. S., Freitag, P ., and Kappos, L. \n(2000). Increase in serum levels of uric acid, an \nendogenous antioxidant, under treatment with \nglatiramer acetate for multiple sclerosis, Mult Scler \n6, 378-81.\nConstantinescu, C. S., Grygar, C., Kappos, L., and \nLeppert, D. (2001). Interleukin 15 stimulates pro -\nduction of matrix metalloproteinase-9 and tissue in -\nhibitor of metalloproteinase-1 by human peripheral \nblood mononuclear cells, Cytokine 13, 244-7.\nCrabtree, M., Sieber, O. M., Lipton, L., Hodgson, S. V ., \nLamlum, H., Thomas, H. J., Neale, K., Phillips, R. K., \nHeinimann, K., and Tomlinson, I. P . (2003). Refining \nthe relation between \u2018first hits\u2019 and \u2018second hits\u2019 at \nthe APC locus: the \u2018loose fit\u2019 model and evidence \nfor differences in somatic mutation spectra among \npatients, Oncogene 22, 4257-65.\nCrnic, I., and Christofori, G. (2004). Novel technolo -\ngies and recent advances in metastasis research, Int \nJ Dev Biol 48, 573-581.\nCron, T. A., Zellweger, M. J., Buser, P . T., Pfisterer, M. \nE., and Osswald, S. (2002). Late potential analysis: \nis a mathematically-derived X,Y,Z lead system com -\nparable to a true orthogonal X,Y,Z lead system?, \nAnn Noninvasive Electrocardiol 7, 302-6.\nCryan, J. F ., Kelly, P . H., Chaperon, F ., Gentsch, C., \nMombereau, C., Lingenhoehl, K., Froestl, W., \nBettler, B., Kaupmann, K., and Spooren, W. P . \n(2004). Behavioural Characterization of the Novel \nGamma-Aminobuytric Acid (B) (Gabab) Receptor \nPositive Modulator Gs39783 (N, N\ue02b- Dicyclopentyl-\n2-Methylsulfanyl-5-Nitro-Pyrimidine-4,6-Diamine): \nAnxiolytic-Like Activity without Side-Effects Associ -\nated with Baclofen or Benzodiazepines, J Pharmacol \nExp Ther 27, 27.\nCzaplinski, A., Radziwill, A. J., and Steck, A. J. (2003a). \n[Actual aspects of myasthenia gravis treatment], Pol \nMerkuriusz Lek 14, 256-60.\nCzaplinski, A., and Steck, A. J. (2004). Immune me -\ndiated neuropathies--an update on therapeutic \nstrategies, J Neurol 251, 127-37.\nCzaplinski, A., Steck, A. J., Andersen, P . M., and \nWeber, M. (2004). Flail arm syndrome: a clinical \nvariant of amyotrophic lateral sclerosis, Eur J Neurol \n11, 567-8.\nCzaplinski, A., Steck, A. J., and Fuhr, P . (2003b). \nIce pack test for myasthenia gravis. A simple, \nnoninvasive and safe diagnostic method, J Neurol \n250, 883-4.\nCzaplinski, A., Strobel, W., Gobbi, C., Steck, A. J., \nFuhr, P ., and Leppert, D. (2003c). Respiratory \nfailure due to bilateral diaphragm palsy as an early \nmanifestation of ALS, Med Sci Monit 9, CS34-6.D\u2019Orazio, D., Muller, P . Y ., Heinimann, K., Albrecht, \nC., Bendik, I., Herzog, U., Tondelli, P ., Bauerfeind, \nP ., Muller, H., and Dobbie, Z. (2002). Overexpres -\nsion of Wnt target genes in adenomas of familial \nadenomatous polyposis patients, Anticancer Res \n22, 3409-14.\nDaelemans, D., Schols, D., Witvrouw, M., Panne -\ncouque, C., Hatse, S., van Dooren, S., Hamy, F ., \nKlimkait, T., de Clercq, E., and VanDamme, A. M. \n(2000). A second target for the peptoid Tat/trans -\nactivation response element inhibitor CGP64222: \ninhibition of human immunodeficiency virus replica -\ntion by blocking CXC-chemokine receptor 4-medi -\nated virus entry, Mol Pharmacol 57, 116-24.\nDanzer, E., Holzgreve, W., Batukan, C., Miny, P ., \nTercanli, S., and Hoesli, I. (2001). Myomectomy \nduring the first trimester associated with fetal limb \nanomalies and hydrocephalus in a twin pregnancy, \nPrenat Diagn 21, 848-51.\nDanzer, E., Holzgreve, W., Troeger, C., Kostka, U., \nSteimann, S., Bitzer, J., Gratwohl, A., Tichelli, A., \nSeelmann, K., and Surbek, D. V . (2003). Attitudes \nof Swiss mothers toward unrelated umbilical cord \nblood banking 6 months after donation, Transfu -\nsion 43, 604-8.\nDavidson, G., Dono, R., and Zeller, R. (2001). FGF \nsignalling is required for differentiation-induced \ncytoskeletal reorganisation and formation of \nactin-based processes by podocytes, J Cell Sci \n114, 3359-66.\nDe Geyter, C., De Geyter, M., Huber, P . R., Nieschlag, \nE., and Holzgreve, W. (2002). Progesterone serum \nlevels during the follicular phase of the menstrual \ncycle originate from the crosstalk between the \novaries and the adrenal cortex, Hum Reprod 17, \n933-9.\nDe Geyter, C., Schmitter, M., De Geyter, M., Ni -\neschlag, E., Holzgreve, W., and Schneider, H. P . \n(2000). Prospective evaluation of the ultrasound \nappearance of the endometrium in a cohort of 1,186 \ninfertile women, Fertil Steril 73, 106-13.\nDe Libero, G. (2000). Tissue distribution, antigen \nspecificity and effector functions of gamma delta \nT cells in human diseases, Springer Semin Immun -\nopathol 22, 219-38.\nDe Libero, G. (2004). Immunology. The Robin Hood of \nantigen presentation, Science 303, 485-7.\nDe Libero, G., Donda, A., Gober, H. J., Manolova, V ., \nMazorra, Z., Shamshiev, A., and Mori, L. (2002). \nA new aspect in glycolipid biology: glycosphin -\ngolipids as antigens recognized by T lymphocytes, \nNeurochem Res 27, 675-85.\nDe Libero, G., Donda, A., Mori, L., Manolova, V ., and \nShamshiev, A. (2001). Immunity to glycolipid anti -\ngens in microbial infections, J Biol Regul Homeost \nAgents 15, 249-56.\nDe Libero, G., and Mori, L. (2003). Self glycosphin -\ngolipids: new antigens recognized by autoreactive \nT lymphocytes, News Physiol Sci 18, 71-6.\nDegen, L., Matzinger, D., Drewe, J., and Beglinger, \nC. (2001). The effect of cholecystokinin in control -\nling appetite and food intake in humans, Peptides \n22, 1265-9.\nDelafontaine, P ., and Brink, M. (2000). The growth \nhormone and insulin-like growth factor 1 axis in \nheart failure, Ann Endocrinol (Paris) 61, 22-6.\nDelco, F ., Tchambaz, L., Schlienger, R., Drewe, J., \nKrahenbuhl, S. (2004). Dosing in patients with \nliver disease., Drug Safety 2004 (in press).Deller, T., Korte, M., Chabanis, S., Drakew, A., Schwe -\ngler, H., Stefani, G. G., Zuniga, A., Schwarz, K., \nBonhoeffer, T., Zeller, R., Frotscher, M., and Mun -\ndel, P . (2003). Synaptopodin-deficient mice lack \na spine apparatus and show deficits in synaptic \nplasticity, Proc Natl Acad Sci U S A 100, 10494-9. \nEpub 2003 Aug 19.\nDelles, C., Schmidt, B. M., Muller, H. J., Oehmer, \nS., Klingbeil, A. U., and Schmieder, R. E. (2003). \nFunctional relevance of aldosterone for the de -\ntermination of left ventricular mass, Am J Cardiol \n91, 297-301.\nDemarteau, O., Jakob, M., Schafer, D., Heberer, M., \nand Martin, I. (2003a). Development and valida -\ntion of a bioreactor for physical stimulation of engi -\nneered cartilage, Biorheology 40, 331-6.\nDemarteau, O., Wendt, D., Braccini, A., Jakob, M., \nSchafer, D., Heberer, M., and Martin, I. (2003b). \nDynamic compression of cartilage constructs en -\ngineered from expanded human articular chondro -\ncytes, Biochem Biophys Res Commun 310, 580-8.\nDemartines, N., Battegay, E., Liebermann, J., Ober -\nholzer, M., Rufli, T., and Harder, F . (2000). [Tele -\nmedicine: perspectives and multidisciplinary ap -\nproach], Schweiz Med Wochenschr 130, 314-23.\nDevitt, P ., Smith, J. R., and Palmer, E. (2001). Improved \nstudent learning in ophthalmology with computer-\naided instruction, Eye 15, 635-9.\nDhein, S., Giessler, C., Wangemann, T., Silber, R. E., \nZerkowski, H. R., and Brodde, O. E. (2000). Dif -\nferential pattern of endothelin-1-induced inotropic \neffects in right atria and left ventricles of the human \nheart, J Cardiovasc Pharmacol 36, 564-9.\nDiacon, A. H., Wyser, C., Bolliger, C. T., Tamm, M., \nPless, M., Perruchoud, A. P ., and Soler, M. (2000). \nProspective randomized comparison of thora -\ncoscopic talc poudrage under local anesthesia \nversus bleomycin instillation for pleurodesis in \nmalignant pleural effusions, Am J Respir Crit Care \nMed 162, 1445-9.\nDickenmann, M., Schaub, S., Nickeleit, V ., Mihatsch, \nM., Steiger, J., and Brunner, F . (2002). Fibrillary \nglomerulonephritis: early diagnosis associated with \nsteroid responsiveness, Am J Kidney Dis 40, E9.\nDickenmann, M. J., Cathomas, G., Steiger, J., Mihat -\nsch, M. J., Thiel, G., and Tamm, M. (2001). Cy -\ntomegalovirus infection and graft rejection in renal \ntransplantation, Transplantation 71, 764-7.\nDickenmann, M. J., Kabulbayev, K., Steiger, J., \nCathomas, G., Reusser, P ., and Tamm, M. (2004). \nGanciclovir prophylaxis to prevent CMV disease \nin kidney recipients undergoing anti-lymphocyte \nglobulin treatment for acute rejection, Clin Micro -\nbiol Infect 10, 337-9.\nDobbie, Z., Muller, P . Y ., Heinimann, K., Albrecht, C., \nD\u2019Orazio, D., Bendik, I., Muller, H., and Bauerfeind, \nP . (2002). Expression of COX-2 and Wnt pathway \ngenes in adenomas of familial adenomatous poly -\nposis patients treated with meloxicam, Anticancer \nRes 22, 2215-20.\nDomenech, V . S., Nylen, E. S., White, J. C., Snider, \nR. H., Becker, K. L., Landmann, R., and Muller, B. \n(2001). Calcitonin gene-related peptide expression \nin sepsis: postulation of microbial infection-specific \nresponse elements within the calcitonin I gene pro -\nmoter, J Investig Med 49, 514-21.\nDonda, A., Mori, L., Shamshiev, A., Carena, I., Mottet, \nC., Heim, M. H., Beglinger, C., Grunert, F ., Rochlitz, \nC., Terracciano, L., Jantscheff, P ., and De Libero, G. \n(2000). Locally inducible CD66a (CEACAM1) as an \namplifier of the human intestinal T cell response, Eur \nJ Immunol 30, 2593-603.Dono, R., Faulhaber, J., Galli, A., Zuniga, A., Volk, \nT., Texido, G., Zeller, R., and Ehmke, H. (2002). \nFGF2 signaling is required for the development of \nneuronal circuits regulating blood pressure, Circ \nRes 90, E5-E10.\nDory, D., Echchannaoui, H., Letiembre, M., Ferracin, \nF ., Pieters, J., Adachi, Y ., Akashi, S., Zimmerli, W., \nand Landmann, R. (2003). Generation and func -\ntional characterization of a clonal murine periportal \nKupffer cell line from H-2Kb -tsA58 mice, J Leukoc \nBiol 74, 49-59.\nDoucey, M. A., Goffin, L., Naeher, D., Michielin, O., \nBaumgartner, P ., Guillaume, P ., Palmer, E., and Lue -\nscher, I. F . (2003a). CD3 delta establishes a func -\ntional link between the T cell receptor and CD8, J \nBiol Chem 278, 3257-64. Epub 2002 Sep 4.\nDoucey, M. A., Legler, D. F ., Faroudi, M., Boucheron, \nN., Baumgaertner, P ., Naeher, D., Cebecauer, M., \nHudrisier, D., Ruegg, C., Palmer, E., Valitutti, S., \nBron, C., and Luescher, I. F . (2003b). The beta1 and \nbeta3 integrins promote T cell receptor-mediated \ncytotoxic T lymphocyte activation, J Biol Chem 278, \n26983-91. Epub 2003 Apr 10.\nDoyl, V . E., Klimkait, T., Mahmood, N., Slater, M., \nHazen, R. J., and Gilbert, I. H. (2002). Synthesis of \npotential anti-HIV GP120 inhibitors using a lysine \ntemplate, J Enzyme Inhib Med Chem 17, 175-82.\nDrachenberg, C. B., Papadimitriou, J. C., Wali, R., \nNogueira, J., Mendley, S., Hirsch, H. H., Cangro, \nC. B., Klassen, D. K., Weir, M. R., Bartlett, S. T., and \nRamos, E. (2004). Improved outcome of polyoma \nvirus allograft nephropathy with early biopsy, Trans -\nplant Proc 36, 758-9.\nDrewe, J. (2003). [Desired effects and adverse effects \nof cannabis use], Ther Umsch 60, 313-6.\nDrewe, J., Ball, H. A., Beglinger, C., Peng, B., Kemmler, \nA., Schachinger, H., and Haefeli, W. E. (2000a). \nEffect of P-glycoprotein modulation on the clinical \npharmacokinetics and adverse effects of morphine, \nBr J Clin Pharmacol 50, 237-46.\nDrewe, J., Beglinger, C., and Fricker, G. (2001). Effect \nof ischemia on intestinal permeability of lipopoly -\nsaccharides, Eur J Clin Invest 31, 138-44.\nDrewe, J., Delco, F ., Kissel, T., and Beglinger, C. \n(2003). Effect of intravenous infusions of thiamine \non the disposition kinetics of thiamine and its pyro -\nphosphate, J Clin Pharm Ther 28, 47-51.\nDrewe, J., and Krahenbuhl, S. (2000). [Clinical phar -\nmacology: proteins for the transport of drugs], \nSchweiz Med Wochenschr 130, 727-31.\nDrewe, J., Narjes, H., Heinzel, G., Brickl, R. S., Rohr, \nA., and Beglinger, C. (2000b). Absorption of le -\nfradafiban from different sites of the gastrointestinal \ntract, Br J Clin Pharmacol 50, 69-72.\nDriamov, S., Bellahcene, M., Ziegler, A., Barbosa, V ., \nTraub, D., Butz, S., Buser, P . T., and Zaugg, C. E. \n(2004). Antiarrhythmic effect of ischemic precon -\nditioning during low-flow ischemia. The role of \nbradykinin and sarcolemmal versus mitochondrial \nATP-sensitive K(\ue02b) channels, Basic Res Cardiol 99, \n299-308. Epub 2004 Mar 2.\nDubbers, A., Wurthwein, G., Muller, H. J., Schulze-\nWesthoff, P ., Winkelhorst, M., Kurzknabe, E., \nLanvers, C., Pieters, R., Kaspers, G. J., Creutzig, \nU., Ritter, J., and Boos, J. (2000). Asparagine \nsynthetase activity in paediatric acute leukaemias: \nAML-M5 subtype shows lowest activity, Br J Hae -\nmatol 109, 427-9.\nDuber, S., Engel, H., Rolink, A., Kretschmer, K., \nand Weiss, S. (2003). Germline transcripts of \nimmunoglobulin light chain variable regions are \nstructurally diverse and differentially expressed, \nMol Immunol 40, 509-16.132/133Ducreux, S., Zorzato, F ., Muller, C. R., Sewry, C., \nMuntoni, F ., Quinlivan, R., Restagno, G., Girard, T., \nand Treves, S. (2004). Effect of ryanodine receptor \nmutations on IL-6 release and intracellular calcium \nhomeostasis in human myotubes from malignant \nhyperthermia susceptible individuals and patients \naffected by central core disease, J Biol Chem 8, 8.\nDukes, K. A., Sullivan, L. M., Lewis, D., Johnson, K. L., \nBianchi, D. W., Simpson, J. L., Holzgreve, W., Hahn, \nS., Bischoff, F . Z., and Jackson, L. G. (2004). The \neffect of the elapsed time between blood draw and \nprocessing on the recovery of fetal cells from mater -\nnal blood, J Soc Gynecol Investig 11, 154-65.\nDuong, F . H., Filipowicz, M., Tripodi, M., La Monica, \nN., and Heim, M. H. (2004). Hepatitis C virus in -\nhibits interferon signaling through up-regulation \nof protein phosphatase 2A, Gastroenterology \n126, 263-77.\nDuthey, B., Caudron, S., Perroy, J., Bettler, B., Fagni, \nL., Pin, J. P ., and Prezeau, L. (2002). A single subunit \n(GB2) is required for G-protein activation by the \nheterodimeric GABA(B) receptor, J Biol Chem 277, \n3236-41. Epub 2001 Nov 15.\nEberle, A. N., Bodi, J., Orosz, G., Suli-Vargha, H., \nJaggin, V ., and Zumsteg, U. (2001). Antagonist \nand agonist activities of the mouse agouti protein \nfragment (91-131) at the melanocortin-1 receptor, \nJ Recept Signal Transduct Res 21, 25-45.\nEberle, A. N., and Froidevaux, S. (2003). Radiolabeled \nalpha-melanocyte-stimulating hormone analogs for \nreceptor-mediated targeting of melanoma: from tri -\ntium to indium, J Mol Recognit 16, 248-54.\nEchchannaoui, H., Frei, K., Schnell, C., Leib, S. L., \nZimmerli, W., and Landmann, R. (2002). Toll-like \nreceptor 2-deficient mice are highly susceptible to \nStreptococcus pneumoniae meningitis because of \nreduced bacterial clearing and enhanced inflam -\nmation, J Infect Dis 186, 798-806. Epub 2002 \nAug 16.\nEgan, R. A., Pless, M., and Shults, W. T. (2001). Mo -\nnocular blindness as a complication of trigeminal \nradiofrequency rhizotomy, Am J Ophthalmol 131, \n237-40.\nEggenberger, E. R., Desai, N. P ., Kaufman, D. I., and \nPless, M. (2000). Internuclear ophthalmoplegia \nafter coronary artery catheterization and percuta -\nneous transluminal coronary balloon angioplasty, J \nNeuroophthalmol 20, 123-6.\nEgger, D., and Bienz, K. (2002). Recombination of \npoliovirus RNA proceeds in mixed replication \ncomplexes originating from distinct replication \nstart sites, J Virol 76, 10960-71.\nEgger, D., Teterina, N., Ehrenfeld, E., and Bienz, K. \n(2000). Formation of the poliovirus replication \ncomplex requires coupled viral translation, vesicle \nproduction, and viral RNA synthesis, J Virol 74, \n6570-80.\nEgger, D., Wolk, B., Gosert, R., Bianchi, L., Blum, H. \nE., Moradpour, D., and Bienz, K. (2002). Expres -\nsion of hepatitis C virus proteins induces distinct \nmembrane alterations including a candidate viral \nreplication complex, J Virol 76, 5974-84.\nEgger, S. S., Drewe, J., and Schlienger, R. G. (2003). \nPotential drug-drug interactions in the medication \nof medical patients at hospital discharge, Eur J Clin \nPharmacol 58, 773-8.\nEickelberg, O., Pansky, A., Koehler, E., Bihl, M., Tamm, \nM., Hildebrand, P ., Perruchoud, A. P ., Kashgarian, \nM., and Roth, M. (2001). Molecular mechanisms \nof TGF-(beta) antagonism by interferon (gamma) \nand cyclosporine A in lung fibroblasts, Faseb J 15, \n797-806.Eickelberg, O., Roth, M., and Block, L. H. (1997). \nEffects of amlodipine on gene expression and \nextracellular matrix formation in human vascular \nsmooth muscle cells and fibroblasts: implications \nfor vascular protection, Int J Cardiol 62, S31-7.\nEickelberg, O., Roth, M., and Perruchoud, A. P . (1998). \n[Matrix metalloproteases and their inhibitors in the \npleura], Pneumologie 52, 526-30.\nEisterer, W., Bechter, O., Hilbe, W., van Driel, M., \nLokhorst, H. M., Thaler, J., Bloem, A. C., Gunthert, \nU., and Stauder, R. (2001). CD44 isoforms are dif -\nferentially regulated in plasma cell dyscrasias and \nCD44v9 represents a new independent prognos -\ntic parameter in multiple myeloma, Leuk Res 25, \n1051-7.\nEisterer, W., Bechter, O., Soderberg, O., Nilsson, K., \nTerol, M., Greil, R., Thaler, J., Herold, M., Finke, \nL., Gunthert, U., Montserrat, E., and Stauder, R. \n(2004). Elevated levels of soluble CD44 are as -\nsociated with advanced disease and in vitro prolif -\neration of neoplastic lymphocytes in B-cell chronic \nlymphocytic leukaemia, Leuk Res 28, 1043-51.\nElliott, M. A., Becker, C., Boucart, M., and Muller, H. \nJ. (2000a). Enhanced GABA(A) inhibition enhances \nsynchrony coding in human perception, Neurore -\nport 11, 3403-7.\nElliott, M. A., Herrmann, C. S., Mecklinger, A., and \nMuller, H. J. (2000b). The loci of oscillatory visual-\nobject priming: a combined electroencephalo -\ngraphic and reaction-time study, Int J Psychophysiol \n38, 225-41.\nElliott, M. A., and Muller, H. J. (2000). Evidence for 40-\nHz oscillatory short-term visual memory revealed by \nhuman reaction-time measurements, J Exp Psychol \nLearn Mem Cogn 26, 703-18.\nElzi, L., Decker, M., Battegay, M., Rutishauser, J., and \nBlum, J. (2004). Chest pain after travel to the trop -\nics, Lancet 363, 1198.\nEmpl, M., Renaud, S., Erne, B., Fuhr, P ., Straube, A., \nSchaeren-Wiemers, N., and Steck, A. J. (2001). \nTNF-alpha expression in painful and nonpainful \nneuropathies, Neurology 56, 1371-7.\nEngelter, S. T., Lyrer, P . A., Kirsch, E. C., and Steck, A. \nJ. (2000). Long-term follow-up after extracranial \ninternal carotid artery dissection, Eur Neurol 44, \n199-204.\nEngelter, S. T., Rueegg, S., Kirsch, E. C., Fluri, F ., \nProbst, A., Steck, A. J., and Lyrer, P . A. (2002). \nCADASIL mimicking primary angiitis of the central \nnervous system, Arch Neurol 59, 1480-3.\nEngelter, S. T., Wetzel, S. G., Radue, E. W., Rausch, \nM., Steck, A. J., and Lyrer, P . A. (2004). The clinical \nsignificance of diffusion-weighted MR imaging in \ninfratentorial strokes, Neurology 62, 574-80.\nEppenberger-Castori, S., Kueng, W., Benz, C., Caduff, \nR., Varga, Z., Bannwart, F ., Fink, D., Dieterich, H., \nHohl, M., Muller, H., Paris, K., Schoumacher, F ., and \nEppenberger, U. (2001). Prognostic and predictive \nsignificance of ErbB-2 breast tumor levels measured \nby enzyme immunoassay, J Clin Oncol 19, 645-56.\nEppenberger-Castori, S., Moore, D. H., Jr., Thor, A. \nD., Edgerton, S. M., Kueng, W., Eppenberger, U., \nand Benz, C. C. (2002). Age-associated biomarker \nprofiles of human breast cancer, Int J Biochem Cell \nBiol 34, 1318-30.\nErb, M., Steck, A. J., Nave, K. A., and Schaeren-Wie -\nmers, N. (2003). Differential expression of L- and \nS-MAG upon cAMP stimulated differentiation in \noligodendroglial cells, J Neurosci Res 71, 326-37.Erb, P ., Battegay, M., Zimmerli, W., Rickenbach, M., \nand Egger, M. (2000a). Effect of antiretroviral \ntherapy on viral load, CD4 cell count, and progres -\nsion to acquired immunodeficiency syndrome \nin a community human immunodeficiency virus-\ninfected cohort. Swiss HIV Cohort Study, Arch \nIntern Med 160, 1134-40.\nErb, S., Ferracin, F ., Fuhr, P ., Rosler, K. M., Hess, C. \nW., Kuntzer, T., Bogousslavsky, J., Sztajzel, R., and \nSteck, A. J. (2000b). Polyneuropathy attributes: a \ncomparison between patients with anti-MAG and \nanti-sulfatide antibodies, J Neurol 247, 767-72.\nEriksson, U., Duc, G., Froesch, E. R., and Zapf, J. \n(1993). Insulin-like growth factors (IGF) I and II and \nIGF binding proteins (IGFBPs) in human colostrum/\ntransitory milk during the first week postpartum: \ncomparison with neonatal and maternal serum, \nBiochem Biophys Res Commun 196, 267-73.\nEriksson, U., Kurrer, M. O., Bingisser, R., Eugster, H. P ., \nSaremaslani, P ., Follath, F ., Marsch, S., and Widmer, \nU. (2001a). Lethal autoimmune myocarditis in in -\nterferon-gamma receptor-deficient mice: enhanced \ndisease severity by impaired inducible nitric oxide \nsynthase induction, Circulation 103, 18-21.\nEriksson, U., Kurrer, M. O., Schmitz, N., Marsch, S. C., \nFontana, A., Eugster, H. P ., and Kopf, M. (2003a). \nInterleukin-6-deficient mice resist development of \nautoimmune myocarditis associated with impaired \nupregulation of complement C3, Circulation 107, \n320-5.\nEriksson, U., Kurrer, M. O., Sebald, W., Brombacher, \nF ., and Kopf, M. (2001b). Dual role of the IL-12/\nIFN-gamma axis in the development of autoimmune \nmyocarditis: induction by IL-12 and protection by \nIFN-gamma, J Immunol 167, 5464-9.\nEriksson, U., Kurrer, M. O., Sonderegger, I., Iezzi, G., \nTafuri, A., Hunziker, L., Suzuki, S., Bachmaier, K., \nBingisser, R. M., Penninger, J. M., and Kopf, M. \n(2003b). Activation of dendritic cells through the \ninterleukin 1 receptor 1 is critical for the induction of \nautoimmune myocarditis, J Exp Med 197, 323-31.\nEriksson, U., Seifert, B., and Schaffner, A. (2001c). \nComparison of effects of amphotericin B deoxy -\ncholate infused over 4 or 24 hours: randomised \ncontrolled trial, Bmj 322, 579-82.\nErne, B., Sansano, S., Frank, M., and Schaeren-Wiem -\ners, N. (2002). Rafts in adult peripheral nerve my -\nelin contain major structural myelin proteins and \nmyelin and lymphocyte protein (MAL) and CD59 as \nspecific markers, J Neurochem 82, 550-62.\nErne, P ., Jamshidi, P ., Hafner, H.-P ., Thum, P ., Resink, \nT. (2004). Brachytherapy: Potential therapy for \nrefractory coronary Spasm., J Amer Col Cardiol \n(in press).\nEsser, C., Temchura, V ., Majora, M., Hundeiker, C., \nSchwarzler, C., and Gunthert, U. (2004). Signaling \nvia the AHR leads to enhanced usage of CD44v10 \nby murine fetal thymic emigrants: possible role \nfor CD44 in emigration, Int Immunopharmacol \n4, 805-18.\nEsslinger, C., Chapatte, L., Finke, D., Miconnet, I., \nGuillaume, P ., Levy, F ., and MacDonald, H. R. \n(2003). In vivo administration of a lentiviral vac -\ncine targets DCs and induces efficient CD8(\ue02b) T \ncell responses, J Clin Invest 111, 1673-81.\nEstevez, M., Chu, C., and Pless, M. (2002). Small \nB-cell lymphoma presenting as diffuse dural thick -\nening with cranial neuropathies, J Neurooncol 59, \n243-7.\nExer, P ., Staub, J. J., Zulewski, H., Muller, B., Kunz, M., \nand Huber, P . (1992). [Evaluation of TSH suppres -\nsion using a 3d-generation TSH assay: diagnostic \nand therapeutic consequences], Schweiz Med \nWochenschr 122, 1964-7.Fagard, C., Le Braz, M., Gunthard, H., Hirsch, H. H., \nEgger, M., Vernazza, P ., Bernasconi, E., Telenti, A., \nEbnother, C., Oxenius, A., Perneger, T., Perrin, L., \nand Hirschel, B. (2003a). A controlled trial of granu -\nlocyte macrophage-colony stimulating factor during \ninterruption of HAART, Aids 17, 1487-92.\nFagard, C., Oxenius, A., Gunthard, H., Garcia, F ., \nLe Braz, M., Mestre, G., Battegay, M., Furrer, H., \nVernazza, P ., Bernasconi, E., Telenti, A., Weber, \nR., Leduc, D., Yerly, S., Price, D., Dawson, S. J., \nKlimkait, T., Perneger, T. V ., McLean, A., Clotet, \nB., Gatell, J. M., Perrin, L., Plana, M., Phillips, R., \nand Hirschel, B. (2003b). A prospective trial of \nstructured treatment interruptions in human im -\nmunodeficiency virus infection, Arch Intern Med \n163, 1220-6.\nFassas, A., Passweg, J. R., Anagnostopoulos, A., Kazis, \nA., Kozak, T., Havrdova, E., Carreras, E., Graus, F ., \nKashyap, A., Openshaw, H., Schipperus, M., \nDeconinck, E., Mancardi, G., Marmont, A., Hansz, \nJ., Rabusin, M., Zuazu Nagore, F . J., Besalduch, \nJ., Dentamaro, T., Fouillard, L., Hertenstein, B., \nLa Nasa, G., Musso, M., Papineschi, F ., Rowe, J. \nM., Saccardi, R., Steck, A., Kappos, L., Gratwohl, \nA., Tyndall, A., Samijn, J., and Samign, J. (2002). \nHematopoietic stem cell transplantation for multi -\nple sclerosis. A retrospective multicenter study, J \nNeurol 249, 1088-97.\nFassbender, K., Walter, S., Kuhl, S., Landmann, R., \nIshii, K., Bertsch, T., Stalder, A. K., Muehlhauser, \nF ., Liu, Y ., Ulmer, A. J., Rivest, S., Lentschat, A., \nGulbins, E., Jucker, M., Staufenbiel, M., Brechtel, \nK., Walter, J., Multhaup, G., Penke, B., Adachi, \nY ., Hartmann, T., and Beyreuther, K. (2004). The \nLPS receptor (CD14) links innate immunity with \nAlzheimer\ue02bs disease, Faseb J 18, 203-5. Epub \n2003 Nov 3.\nFeinle-Bisset, C., Meier, B., Fried, M., and Beglinger, \nC. (2003). Role of cognitive factors in symptom in -\nduction following high and low fat meals in patients \nwith functional dyspepsia, Gut 52, 1414-8.\nFelger, I., Steiger, S., Hatz, C., Smith, T., and Beck, H. \nP . (2003). Antigenic cross-reactivity between differ -\nent alleles of the Plasmodium falciparum merozoite \nsurface protein 2, Parasite Immunol 25, 531-43.\nFelix, K., Rolink, A., Melchers, F ., and Janz, S. (2003). \nBcl-2 reduces mutant rates in a transgenic lacZ \nreporter gene in mouse pre-B lymphocytes, Mutat \nRes 522, 135-44.\nFellay, J., Boubaker, K., Ledergerber, B., Bernasconi, \nE., Furrer, H., Battegay, M., Hirschel, B., Vernazza, \nP ., Francioli, P ., Greub, G., Flepp, M., and Telenti, \nA. (2001). Prevalence of adverse events associated \nwith potent antiretroviral treatment: Swiss HIV Co -\nhort Study, Lancet 358, 1322-7.\nFelley, C., Morris, M. A., Wonkam, A., Hirschel, \nB., Flepp, M., Wolf, K., Furrer, H., Battegay, M., \nBernasconi, E., Telenti, A., and Frossard, J. L. \n(2004). The role of CFTR and SPINK-1 mutations \nin pancreatic disorders in HIV-positive patients: a \ncase-control study, Aids 18, 1521-1527.\nFeng, J., Tamaskovic, R., Yang, Z., Brazil, D. P ., Merlo, \nA., Hess, D., and Hemmings, B. A. (2004). Sta -\nbilization of Mdm2 via decreased ubiquitination \nis mediated by protein kinase B/Akt-dependent \nphosphorylation, J Biol Chem 28, 28.\nFeuerstein, T. H., Langemann, H., Gratzl, O., and \nMendelowitsch, A. (2000). A four lumen screwing \ndevice for multiparametric brain monitoring, Acta \nNeurochir (Wien) 142, 909-12.Filipovic, M., Jeger, R., Probst, C., Girard, T., Pfisterer, \nM., Gurke, L., Skarvan, K., and Seeberger, M. D. \n(2003). Heart rate variability and cardiac troponin \nI are incremental and independent predictors of \none-year all-cause mortality after major noncardiac \nsurgery in patients at risk of coronary artery disease, \nJ Am Coll Cardiol 42, 1767-76.\nFilipovic, M., Seeberger, M. D., Rohlfs, R., Dergeloo, \nO., Studer, W., Atar, D., Buser, P ., and Skarvan, K. \n(2002). Doppler indices of diastolic transmitral \nflow velocity are invalid indicators of myocardial \nischaemia during high-dose dobutamine infusion \nin anaesthetized patients, Eur J Anaesthesiol 19, \n789-95.\nFinke, D., and Acha-Orbea, H. (2001). Differential \nmigration of in vivo primed B and T lymphocytes \nto lymphoid and non-lymphoid organs, Eur J Im -\nmunol 31, 2603-11.\nFinke, D., Acha-Orbea, H., Mattis, A., Lipp, M., and \nKraehenbuhl, J. (2002). CD4\ue02bCD3- cells induce \nPeyer\u2019s patch development: role of alpha4beta1 in -\ntegrin activation by CXCR5, Immunity 17, 363-73.\nFinke, D., Baribaud, F ., Diggelmann, H., and Acha-Or -\nbea, H. (2001). Extrafollicular plasmablast B cells \nplay a key role in carrying retroviral infection to \nperipheral organs, J Immunol 166, 6266-75.\nFinke, D., and Kraehenbuhl, J. P . (2001). Formation of \nPeyer\ue02bs patches, Curr Opin Genet Dev 11, 561-7.\nFinke, D., Luther, S. A., and Acha-Orbea, H. (2003). \nThe role of neutralizing antibodies for mouse mam -\nmary tumor virus transmission and mammary cancer \ndevelopment, Proc Natl Acad Sci U S A 100, 199-\n204. Epub 2002 Dec 26.\nFinke, D. a. A.-O., H. (2001). Immune response to \nmurine and feline retroviruses, Retroviral Immunol -\nogy, Eds G Pantaleo & B D Walker, Humana Press, \nNew York, NY, 125-157.\nFisher, R. S., Thistle, J., Lembo, A., Novick, J., O\u2019Kane, \nP ., Chey, W. D., Beglinger, C., Rueegg, P ., Shi, V ., \nDogra, A., Luo, D., and Earnest, D. L. (2004). Tegas -\nerod Does not Alter Fasting or Meal-Induced Biliary \nTract Motility, Am J Gastroenterol 99, 1342-9.\nFlammer, J., Pache, M., and Resink, T. (2001). Vasos -\npasm, its role in the pathogenesis of diseases with \nparticular reference to the eye, Prog Retin Eye Res \n20, 319-49.\nFleck, O., and Schar, P . (2004). Translesion DNA \nsynthesis: little fingers teach tolerance, Curr Biol \n14, R389-91.\nFluckiger, U. (2001). [What is the optimal treatment \nduration of group A streptococcal pharyngitis?], \nHno 49, 253-5.\nFluckiger, U., Zimmerli, W., Sax, H., Frei, R., and \nWidmer, A. F . (2000). Clinical impact of an in -\nfectious disease service on the management of \nbloodstream infection, Eur J Clin Microbiol Infect \nDis 19, 493-500.\nFlugel, A., Matsumuro, K., Neumann, H., Klinkert, W. \nE., Birnbacher, R., Lassmann, H., Otten, U., and \nWekerle, H. (2001). Anti-inflammatory activity of \nnerve growth factor in experimental autoimmune \nencephalomyelitis: inhibition of monocyte transen -\ndothelial migration, Eur J Immunol 31, 11-22.\nFluri, F ., Ferracin, F ., Erne, B., and Steck, A. J. (2003). \nMicroheterogeneity of anti-myelin-associated \nglycoprotein antibodies, J Neurol Sci 207, 43-9.\nFolster-Holst, R., Rufli, T., and Christophers, E. (2000). \n[Treatment of scabies with special consideration of \nthe approach in infancy, pregnancy and while nurs -\ning], Hautarzt 51, 7-13.\nFound, A., and Muller, H. J. (2001). Efficient search for \nsize targets on a background texture gradient: is de -\ntection guided by discontinuities in the retinal-size \ngradient of items?, Perception 30, 21-48.Frank, O., Heim, M., Jakob, M., Barbero, A., Schafer, \nD., Bendik, I., Dick, W., Heberer, M., and Martin, \nI. (2002). Real-time quantitative RT-PCR analysis \nof human bone marrow stromal cells during os -\nteogenic differentiation in vitro, J Cell Biochem \n85, 737-46.\nFranz, S. E., Buylaert, M. A., Moll, S., and Schifferli, \nJ. A. (2003). A well-meant present from a friend, \nNephrol Dial Transplant 18, 613-4.\nFreeman, J. A., Thompson, A. J., Fitzpatrick, R., Hutch -\ninson, M., Miltenburger, C., Beckmann, K., Dahlke, \nF ., Kappos, L., Polman, C., and Pozzilli, C. (2001). \nInterferon-beta1b in the treatment of secondary \nprogressive MS: impact on quality of life, Neurol -\nogy 57, 1870-5.\nFreiermuth, O., Todorov, A., Bolli, M., and Heberer, \nM. (2003). [Swiss surgery: quo vadis? Reader \nand market analysis for strategic positioning of a \nspecialty journal], Swiss Surg 9, 43-53.\nFreitag, P ., Kappos, L., Radue, E.W. (2000). [Value \nof MRI in diagnosis and monitoring of disease in \nmultiple sclerosis]. Schw Arch Neurol Psychiat \n151/2: 47-56.\nFremeaux-Bacchi, V ., Noel, L. H., and Schifferli, J. \nA. (2002). No lupus nephritis in the absence of \nantiC1q autoantibodies?, Nephrol Dial Transplant \n17, 2041-3.\nFreudenthaler, S. M., Lucht, I., Schenk, T., Brink, M., \nand Gleiter, C. H. (2000). Dose-dependent effect of \nangiotensin II on human erythropoietin production, \nPflugers Arch 439, 838-44.\nFrigerio, S., Hollander, G. A., and Zumsteg, U. (2002a). \nFunctional IL-18 Is produced by primary pancreatic \nmouse islets and NIT-1 beta cells and participates in \nthe progression towards destructive insulitis, Horm \nRes 57, 94-104.\nFrigerio, S., Junt, T., Lu, B., Gerard, C., Zumsteg, U., \nHollander, G. A., and Piali, L. (2002b). Beta cells are \nresponsible for CXCR3-mediated T-cell infiltration \nin insulitis, Nat Med 8, 1414-20.\nFritsche, G., Nitsch, C., Pietrowsky, R., and Diener, \nH. C. (2000). [Psychological descriptors of exces -\nsive use of analgesic medication], Schmerz 14, \n217-25.\nFritschy, J. M., Sidler, C., Parpan, F ., Gassmann, M., \nKaupmann, K., Bettler, B., and Benke, D. (2004). \nIndependent maturation of the GABA(B) recep -\ntor subunits GABA(B1) and GABA(B2) during \npostnatal development in rodent brain, J Comp \nNeurol 477, 235-52.\nFroestl, W., Bettler, B., Bittiger, H., Heid, J., Kaupmann, \nK., Mickel, S. J., and Strub, D. (2001). Ligands for \nexpression cloning and isolation of GABA(B) recep -\ntors, Farmaco 56, 101-5.\nFroestl, W., Bettler, B., Bittiger, H., Heid, J., Kaupmann, \nK., Mickel, S. J., and Strub, D. (2003). Ligands for \nexpression cloning and isolation of GABA(B) recep -\ntors, Farmaco 58, 173-83.\nFroidevaux, S., Calame-Christe, M., Schuhmacher, J., \nTanner, H., Saffrich, R., Henze, M., and Eberle, A. \nN. (2004). A gallium-labeled DOTA-alpha-melano -\ncyte- stimulating hormone analog for PET imaging \nof melanoma metastases, J Nucl Med 45, 116-23.\nFroidevaux, S., Calame-Christe, M., Sumanovski, \nL., Tanner, H., and Eberle, A. N. (2003). DOTA \nalpha-melanocyte-stimulating hormone analogues \nfor imaging metastatic melanoma lesions, Ann N Y \nAcad Sci 994, 378-83.\nFroidevaux, S., Calame-Christe, M., Tanner, H., \nSumanovski, L., and Eberle, A. N. (2002a). A novel \nDOTA-alpha-melanocyte-stimulating hormone \nanalog for metastatic melanoma diagnosis, J Nucl \nMed 43, 1699-706.134/135Froidevaux, S., and Eberle, A. N. (2002a). Homologous \nregulation of melanocortin-1 receptor (MC1R) ex -\npression in melanoma tumor cells in vivo, J Recept \nSignal Transduct Res 22, 111-21.\nFroidevaux, S., and Eberle, A. N. (2002b). Somato -\nstatin analogs and radiopeptides in cancer therapy, \nBiopolymers 66, 161-83.\nFroidevaux, S., Eberle, A. N., Christe, M., Sumanovski, \nL., Heppeler, A., Schmitt, J. S., Eisenwiener, K., Be -\nglinger, C., and Macke, H. R. (2002b). Neuroen -\ndocrine tumor targeting: study of novel gallium-la -\nbeled somatostatin radiopeptides in a rat pancreatic \ntumor model, Int J Cancer 98, 930-7.\nFroidevaux, S., Heppeler, A., Eberle, A. N., Meier, A. \nM., Hausler, M., Beglinger, C., Behe, M., Powell, \nP ., and Macke, H. R. (2000). Preclinical comparison \nin AR4-2J tumor-bearing mice of four radiolabeled \n1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraace -\ntic acid-somatostatin analogs for tumor diagnosis \nand internal radiotherapy, Endocrinology 141, \n3304-12.\nFuhr, P ., Borggrefe-Chappuis, A., Schindler, C., and \nKappos, L. (2001). Visual and motor evoked po -\ntentials in the course of multiple sclerosis, Brain \n124, 2162-8.\nFuhr, P ., and Kappos, L. (2001). Evoked potentials for \nevaluation of multiple sclerosis, Clin Neurophysiol \n112, 2185-9.\nFuhr, P ., and Leppert, D. (2000). Neuroimages. Cardiac \narrest during partial seizure, Neurology 54, 2026.\nFurrer, H., Battegay, M., Spirig, R., and Flepp, M. \n(2003). [Challenges in HIV long-term care], Dtsch \nMed Wochenschr 128, 1064-9.\nFurtinger, S., Bettler, B., and Sperk, G. (2003). Altered \nexpression of GABAB receptors in the hippocam -\npus after kainic-acid-induced seizures in rats, Brain \nRes Mol Brain Res 113, 107-15.\nGajendran, N., Frey, J. R., Lefkovits, I., Kuhn, L., \nFountoulakis, M., Krapfenbauer, K., and Bren -\nner, H. R. (2002). Proteomic analysis of secreted \nmuscle components: Search for factors involved \nin neuromuscular synapse formation, Proteomics \n2, 1601-15.\nGalbiati, F ., Polastri, L., Gregori, S., Freschi, M., Ca -\nsorati, M., Cavallaro, U., Fiorina, P ., Bertuzzi, F ., \nZerbi, A., Pozza, G., Adorini, L., Folli, F ., Christofori, \nG., and Davalli, A. M. (2002). Antitumorigenic and \nantiinsulinogenic effects of calcitriol on insulinoma \ncells and solid beta-cell tumors, Endocrinology \n143, 4018-30.\nGalbiati, F ., Polastri, L., Thorens, B., Dupraz, P ., Fiorina, \nP ., Cavallaro, U., Christofori, G., and Davalli, A. M. \n(2003). Molecular pathways involved in the anti -\nneoplastic effects of calcitriol on insulinoma cells, \nEndocrinology 144, 1832-41.\nGalli, A., Roure, A., Zeller, R., and Dono, R. (2003). \nGlypican 4 modulates FGF signalling and regulates \ndorsoventral forebrain patterning in Xenopus \nembryos, Development 130, 4919-29. Epub 2003 \nAug 20.\nGalvez, T., Duthey, B., Kniazeff, J., Blahos, J., Rovelli, \nG., Bettler, B., Prezeau, L., and Pin, J. P . (2001). \nAllosteric interactions between GB1 and GB2 \nsubunits are required for optimal GABA(B) recep -\ntor function, Embo J 20, 2152-9.\nGalvez, T., Prezeau, L., Milioti, G., Franek, M., Joly, C., \nFroestl, W., Bettler, B., Bertrand, H. O., Blahos, J., \nand Pin, J. P . (2000a). Mapping the agonist-bind -\ning site of GABAB type 1 subunit sheds light on \nthe activation process of GABAB receptors, J Biol \nChem 275, 41166-74.Galvez, T., Urwyler, S., Prezeau, L., Mosbacher, J., Joly, \nC., Malitschek, B., Heid, J., Brabet, I., Froestl, W., \nBettler, B., Kaupmann, K., and Pin, J. P . (2000b). \nCa(2\ue02b) requirement for high-affinity gamma-ami -\nnobutyric acid (GABA) binding at GABA(B) recep -\ntors: involvement of serine 269 of the GABA(B)R1 \nsubunit, Mol Pharmacol 57, 419-26.\nGannon, G., Mandriota, S. J., Cui, L., Baetens, D., \nPepper, M. S., and Christofori, G. (2002). Overex -\npression of vascular endothelial growth factor-A165 \nenhances tumor angiogenesis but not metastasis \nduring beta-cell carcinogenesis, Cancer Res 62, \n603-8.\nGasser, O., Hess, C., Miot, S., Deon, C., Sanchez, J. \nC., and Schifferli, J. A. (2003). Characterisation \nand properties of ectosomes released by human \npolymorphonuclear neutrophils, Exp Cell Res \n285, 243-57.\nGasser, O. S., and Schifferli, J. A. (2004). Activated \nPolymorphonuclear Neutrophils disseminate \nAnti-inflammatory Microparticles by Ectocytosis, \nBlood 22, 22.\nGassmann, M., Shaban, H., Vigot, R., Sansig, G., \nHaller, C., Barbieri, S., Humeau, Y ., Schuler, V ., \nMuller, M., Kinzel, B., Klebs, K., Schmutz, M., \nFroestl, W., Heid, J., Kelly, P . H., Gentry, C., \nJaton, A. L., Van der Putten, H., Mombereau, C., \nLecourtier, L., Mosbacher, J., Cryan, J. F ., Fritschy, \nJ. M., Luthi, A., Kaupmann, K., and Bettler, B. \n(2004). Redistribution of GABAB(1) protein and \natypical GABAB responses in GABAB(2)-deficient \nmice, J Neurosci 24, 6086-97.\nGatti, E., Velleca, M. A., Biedermann, B. C., Ma, W., \nUnternaehrer, J., Ebersold, M. W., Medzhitov, R., \nPober, J. S., and Mellman, I. (2000). Large-scale \nculture and selective maturation of human Lang -\nerhans cells from granulocyte colony-stimulating \nfactor-mobilized CD34\ue02b progenitors, J Immunol \n164, 3600-7.\nGencay, M., and Roth, M. (2003). Chlamydia pneu -\nmoniae infections in asthma: clinical implications, \nAm J Respir Med 2, 31-8.\nGencay, M., Rudiger, J. J., Tamm, M., Soler, M., Per -\nruchoud, A. P ., and Roth, M. (2001). Increased \nfrequency of Chlamydia pneumoniae antibodies \nin patients with asthma, Am J Respir Crit Care Med \n163, 1097-100.\nGencay, M. M., Tamm, M., Glanville, A., Perruchoud, \nA. P ., and Roth, M. (2003). Chlamydia pneumoniae \nactivates epithelial cell proliferation via NF-kappaB \nand the glucocorticoid receptor, Infect Immun 71, \n5814-22.\nGeorgiadis, D., Berger, A., Kowatschev, E., Lauten -\nschlager, C., Borner, A., Lindner, A., Schulte-Mat -\ntler, W., Zerkowski, H. R., Zierz, S., and Deufel, T. \n(2000). Predictive value of S-100beta and neuron-\nspecific enolase serum levels for adverse neurologic \noutcome after cardiac surgery, J Thorac Cardiovasc \nSurg 119, 138-47.\nGeorgiadis, D., Braun, S., Uhlmann, F ., Bernacca, G. \nM., Schulte-Mattler, W. J., Zierz, S., and Zerkowski, \nH. R. (2001). Doppler microembolic signals in pa -\ntients with two different types of bileaflet valves, J \nThorac Cardiovasc Surg 121, 1101-6.\nGeorgiadis, D., Hempel, A., Baumgartner, R. W., and \nZerkowski, H. R. (2003). Doppler microembolic sig -\nnals during cardiac surgery: comparison between \narterial line and middle cerebral artery, J Thorac \nCardiovasc Surg 126, 1638-9.\nGeorgiadis, D., Stets, R., Schorch, A., Baumgartner, R. \nW., Bernet, F ., and Zerkowski, H. R. (2004). Dop -\npler microembolic signals during cardiopulmonary \nbypass: comparison of two membrane oxygenators, \nNeurol Res 26, 99-102.Gherzi, R., Lee, K. Y ., Briata, P ., Wegmuller, D., \nMoroni, C., Karin, M., and Chen, C. Y . (2004). A \nKH domain RNA binding protein, KSRP, promotes \nARE-directed mRNA turnover by recruiting the \ndegradation machinery, Mol Cell 14, 571-83.\nGhia, P ., Melchers, F ., and Rolink, A. G. (2000). Age-\ndependent changes in B lymphocyte development \nin man and mouse, Exp Gerontol 35, 159-65.\nGhia, P ., Transidico, P ., Veiga, J. P ., Schaniel, C., Sal -\nlusto, F ., Matsushima, K., Sallan, S. E., Rolink, A. \nG., Mantovani, A., Nadler, L. M., and Cardoso, A. \nA. (2001). Chemoattractants MDC and TARC are \nsecreted by malignant B-cell precursors following \nCD40 ligation and support the migration of leuke -\nmia-specific T cells, Blood 98, 533-40.\nGierens, H., Nauck, M., Roth, M., Schinker, R., Schur -\nmann, C., Scharnagl, H., Neuhaus, G., Wieland, H., \nand Marz, W. (2000). Interleukin-6 stimulates LDL \nreceptor gene expression via activation of sterol-\nresponsive and Sp1 binding elements, Arterioscler \nThromb Vasc Biol 20, 1777-83.\nGieselmann, V ., Franken, S., Klein, D., Mansson, J. \nE., Sandhoff, R., Lullmann Rauch, R., Hartmann, \nD., Saravanan, V . P ., De Deyn, P . P ., D\u2019Hooge, R., \nVan Der Linden, A. M., and Schaeren-Wiemers, \nN. (2003). Metachromatic leukodystrophy: conse -\nquences of sulphatide accumulation, Acta Paediatr \nSuppl 92, 74-9; discussion 45.\nGijsens, A., Derycke, A., Missiaen, L., De Vos, D., Hu -\nwyler, J., Eberle, A., and de Witte, P . (2002). Target -\ning of the photocytotoxic compound AlPcS4 to Hela \ncells by transferrin conjugated PEG-liposomes, Int J \nCancer 101, 78-85.\nGill, J., Malin, M., Hollander, G. A., and Boyd, R. \n(2002). Generation of a complete thymic microen -\nvironment by MTS24(\ue02b) thymic epithelial cells, Nat \nImmunol 3, 635-42.\nGilleron, M., Stenger, S., Mazorra, Z., Wittke, F ., Mari -\notti, S., Bohmer, G., Prandi, J., Mori, L., Puzo, G., \nand De Libero, G. (2004). Diacylated Sulfoglycoli -\npids Are Novel Mycobacterial Antigens Stimulating \nCD1-restricted T Cells during Infection with Myco -\nbacterium tuberculosis, J Exp Med 199, 649-659. \nEpub 2004 Feb 23.\nGilli, F ., Bertolotto, A., Sala, A., Hoffmann, F ., Capobi -\nanco, M., Malucchi, S., Glass, T., Kappos, L., Lind -\nberg, R. L., and Leppert, D. (2004). Neutralizing \nantibodies against IFN-beta in multiple sclerosis: \nantagonization of IFN-beta mediated suppression \nof MMPs, Brain 127, 259-68. Epub 2003 Nov 7.\nGinz, H. F ., Girard, T., Censier, K., and Urwyler, A. \n(2004). Similar susceptibility to halothane, caf -\nfeine and ryanodine in vitro reflects pharmacoge -\nnetic variability of malignant hyperthermia, Eur J \nAnaesthesiol 21, 151-7.\nGinz, H. F ., Ummenhofer, W. C., Erb, T., and Urwyler, \nA. (2001). [The hereditary motor-sensory neuropa -\nthy Charcot-Marie-Tooth disease: anesthesiologic \nmanagement--case report with literature review], \nAnaesthesist 50, 767-71.\nGirard, T., Bally, S., Langer, I., and Schurch, M. (2003). \nDiagnosis of malignant hyperthermia susceptibil -\nity during CABG surgery, Acta Anaesthesiol Scand \n47, 233-5.\nGirard, T., Cavagna, D., Padovan, E., Spagnoli, G., \nUrwyler, A., Zorzato, F ., and Treves, S. (2001a). \nB-lymphocytes from malignant hyperthermia-\nsusceptible patients have an increased sensitivity \nto skeletal muscle ryanodine receptor activators, J \nBiol Chem 276, 48077-82.Girard, T., and Filipovic, M. (2004). From the echocar -\ndiography machine to the lecture room: a simple \nmethod for transferring echocardiographic frames \nand loops to a personal computer, Anesth Analg 98, \n703-5, table of contents.\nGirard, T., Treves, S., Censier, K., Mueller, C. R., \nZorzato, F ., and Urwyler, A. (2002). Phenotyping \nmalignant hyperthermia susceptibility by measuring \nhalothane-induced changes in myoplasmic calcium \nconcentration in cultured human skeletal muscle \ncells, Br J Anaesth 89, 571-9.\nGirard, T., Treves, S., Voronkov, E., Siegemund, M., \nand Urwyler, A. (2004). Molecular genetic testing \nfor malignant hyperthermia susceptibility, Anesthe -\nsiology 100, 1076-80.\nGirard, T., Urwyler, A., Censier, K., Mueller, C. R., \nZorzato, F ., and Treves, S. (2001b). Genotype-\nphenotype comparison of the Swiss malignant \nhyperthermia population, Hum Mutat 18, 357-8.\nGiraud, S., Greco, A., Brink, M., Diaz, J. J., and \nDelafontaine, P . (2001). Translation initiation of \nthe insulin-like growth factor I receptor mRNA is \nmediated by an internal ribosome entry site, J Biol \nChem 276, 5668-75.\nGlanville, A. R., Gencay, M., Tamm, M., Chhajed, P ., \nHopkins, P ., Aboyoun, C., Adams, S., Rainer, S., \nRoth, M., Malouf, M. (2004). Chlamydia pneumo -\nniae infection after lung transplantation., J Heart \nLung Transplant 2004 (in press).\nGobbi, C., Buess, M., Probst, A., Ruegg, S., Schraml, \nP ., Herrmann, R., Steck, A. J., and Dirnhofer, S. \n(2003). Enteropathy-associated T-cell lymphoma \nwith initial manifestation in the CNS, Neurology \n60, 1718-9.\nGober, H. J., Kistowska, M., Angman, L., Jeno, P ., \nMori, L., and De Libero, G. (2003). Human T cell \nreceptor gammadelta cells recognize endogenous \nmevalonate metabolites in tumor cells, J Exp Med \n197, 163-8.\nGoedecke, J. H., Barsdorf, M., Beglinger, C., Levitt, \nN. S., and Lambert, E. V . (2003). Effects of a lipase \ninhibitor (Orlistat) on cholecystokinin and appetite \nin response to a high-fat meal, Int J Obes Relat \nMetab Disord 27, 1479-85.\nGoerke, C., Fluckiger, U., Steinhuber, A., Zimmerli, \nW., and Wolz, C. (2001). Impact of the regulatory \nloci agr, sarA and sae of Staphylococcus aureus on \nthe induction of alpha-toxin during device-related \ninfection resolved by direct quantitative transcript \nanalysis, Mol Microbiol 40, 1439-47.\nGolubnitschaja, O., Yeghiazaryan, K., Liu, R., Monke -\nmann, H., Leppert, D., Schild, H., Haefliger, I. O., \nand Flammer, J. (2004). Increased expression of \nmatrix metalloproteinases in mononuclear blood \ncells of normal-tension glaucoma patients, J Glau -\ncoma 13, 66-72.\nGonchar, Y ., Pang, L., Malitschek, B., Bettler, B., and \nBurkhalter, A. (2001). Subcellular localization of \nGABA(B) receptor subunits in rat visual cortex, J \nComp Neurol 431, 182-97.\nGosert, R., Kanjanahaluethai, A., Egger, D., Bienz, K., \nand Baker, S. C. (2001). Comparison of replicase \nlocalization in different types of mouse hepatitis \nvirus (MHV)-infected cells, Adv Exp Med Biol \n494, 275-81.\nGosert, R., Kanjanahaluethai, A., Egger, D., Bienz, K., \nand Baker, S. C. (2002). RNA replication of mouse \nhepatitis virus takes place at double-membrane \nvesicles, J Virol 76, 3697-708.Grapow, M. T., Kern, T., Reineke, D. C., Brett, W., \nBernet, F ., Rueter, F ., Muller-Schweinitzer, E., and \nZerkowski, H. R. (2003a). Improved endothelial \nfunction after a modified harvesting technique of \nthe internal thoracic artery, Eur J Cardiothorac Surg \n23, 956-60; discussion 960-1.\nGrapow, M. T., Matt, P ., Zerkowski, H. R., and Bernet, \nF . (2004). Pseudoaneurysm in a marfan patient 16 \nyears after Bentall operation, Asian Cardiovasc \nThorac Ann 12, 182-3.\nGrapow, M. T., Todorov, A., Bernet, F ., and Zerkowski, \nH. R. (2003b). [Ambulatory long-term management \nof a left ventricular assist device. Current modality \nin terminal heart failure], Swiss Surg 9, 27-30.\nGraumann, U., Reynolds, R., Steck, A. J., and Schaer -\nen-Wiemers, N. (2003). Molecular changes in nor -\nmal appearing white matter in multiple sclerosis \nare characteristic of neuroprotective mechanisms \nagainst hypoxic insult, Brain Pathol 13, 554-73.\nGreiner, E. F ., Kirfel, J., Greschik, H., Huang, D., \nBecker, P ., Kapfhammer, J. P ., and Schule, R. \n(2000). Differential ligand-dependent protein-\nprotein interactions between nuclear receptors \nand a neuronal-specific cofactor, Proc Natl Acad \nSci U S A 97, 7160-5.\nGreub, G., Cozzi-Lepri, A., Ledergerber, B., Stasze -\nwski, S., Perrin, L., Miller, V ., Francioli, P ., Furrer, \nH., Battegay, M., Vernazza, P ., Bernasconi, E., \nGunthard, H. F ., Hirschel, B., Phillips, A. N., and \nTelenti, A. (2002). Intermittent and sustained low-\nlevel HIV viral rebound in patients receiving potent \nantiretroviral therapy, Aids 16, 1967-9.\nGreub, G., Ledergerber, B., Battegay, M., Grob, P ., \nPerrin, L., Furrer, H., Burgisser, P ., Erb, P ., Boggian, \nK., Piffaretti, J. C., Hirschel, B., Janin, P ., Francioli, \nP ., Flepp, M., and Telenti, A. (2000). Clinical pro -\ngression, survival, and immune recovery during \nantiretroviral therapy in patients with HIV-1 and \nhepatitis C virus coinfection: the Swiss HIV Cohort \nStudy, Lancet 356, 1800-5.\nGrobholz, R., Verbeke, C. S., Schleger, C., Kohrmann, \nK. U., Hein, B., Wolf, G., Bleyl, U., Spagnoli, G. C., \nCoplan, K., Kolb, D., Iversen, K., and Jungbluth, \nA. A. (2000). Expression of MAGE antigens and \nanalysis of the inflammatory T-cell infiltrate in hu -\nman seminoma, Urol Res 28, 398-403.\nGroscurth, P ., Eggli, P ., Kapfhammer, J., Rager, G., Hor -\nnung, J. P ., and Fasel, J. D. (2001). Gross anatomy in \nthe surgical curriculum in Switzerland: improved ca -\ndaver preservation, anatomical models, and course \ndevelopment, Anat Rec 265, 254-6.\nGross, T., Martinoli, S., Spagnoli, G., Badia, F ., and \nMalacrida, R. (2001). Attitudes and behavior of \nyoung European adults towards the donation of \norgans--a call for better information, Am J Trans -\nplant 1, 74-81.\nGrossman, R. I., Kappos, L., and Wolinsky, J. S. (2000). \nThe contribution of magnetic resonance imaging \nin the differential diagnosis of the damage of the \ncerebral hemispheres, J Neurol Sci 172, S57-62.\nGschwandtner, U., Aston, J., Borgwardt, S., Drewe, \nM., Feinendegen, C., Lacher, D., Lanzarone, A., \nStieglitz, R. D., and Riecher-Rossler, A. (2003). \nNeuropsychological and neurophysiological \nfindings in individuals suspected to be at risk for \nschizophrenia: preliminary results from the Basel \nearly detection of psychosis study \u2013 Fruherken -\nnung von Psychosen (FEPSY), Acta Psychiatr \nScand 108, 152-5.Guex, A. C., Bucher, H. C., Demartines, N., Fluckiger, \nU., and Battegay, M. (2002). Inflammatory bowel \nperforation during immune restoration after one \nyear of antiretroviral and antituberculous therapy \nin an HIV-1-infected patient: report of a case, Dis \nColon Rectum 45, 977-8.\nGuller, U., Zajac, P ., Schnider, A., Bosch, B., Vorburger, \nS., Zuber, M., Spagnoli, G. C., Oertli, D., Maurer, \nR., Metzger, U., Harder, F ., Heberer, M., and Marti, \nW. R. (2002). Disseminated single tumor cells as \ndetected by real-time quantitative polymerase chain \nreaction represent a prognostic factor in patients \nundergoing surgery for colorectal cancer, Ann Surg \n236, 768-75; discussion 775-6.\nGundlfinger, A., Kapfhammer, J. P ., Kruse, F ., Leitges, \nM., and Metzger, F . (2003). Different regulation of \nPurkinje cell dendritic development in cerebellar \nslice cultures by protein kinase Calpha and -beta, J \nNeurobiol 57, 95-109.\nGuth, U., Moch, H., Herberich, L., and Holzgreve, W. \n(2004a). Noninflammatory breast carcinoma with \nskin involvement, Cancer 100, 470-8.\nGuth, U., Wight, E., Moch, H., and Holzgreve, W. \n(2004b). Detection of minute breast cancers: a \ntherapeutic challenge with a potential danger of \novertreatment, Breast J 10, 373-4.\nGutmann, H., Bruggisser, R., Schaffner, W., Bogman, \nK., Botomino, A., and Drewe, J. (2002). Transport \nof amentoflavone across the blood-brain barrier in \nvitro, Planta Med 68, 804-7.\nGutmann, H., Miller, D. S., Droulle, A., Drewe, J., \nFahr, A., and Fricker, G. (2000). P-glycoprotein- \nand mrp2-mediated octreotide transport in renal \nproximal tubule, Br J Pharmacol 129, 251-6.\nGutzwiller, J. P ., Degen, L., Heuss, L., and Beglinger, \nC. (2004a). Glucagon-like peptide 1 (GLP-1) and \neating, Physiol Behav 82, 17-9.\nGutzwiller, J. P ., Degen, L., Matzinger, D., Prestin, S., \nand Beglinger, C. (2004b). Interaction between \nGLP-1 and CCK33 in inhibiting food intake and \nappetite in men, Am J Physiol Regul Integr Comp \nPhysiol 22, 22.\nGutzwiller, J. P ., Drewe, J., Ketterer, S., Hildebrand, \nP ., Krautheim, A., and Beglinger, C. (2000). Inter -\naction between CCK and a preload on reduction \nof food intake is mediated by CCK-A receptors in \nhumans, Am J Physiol Regul Integr Comp Physiol \n279, R189-95.\nGutzwiller, J. P ., Tschopp, S., Bock, A., Zehnder, C. \nE., Huber, A. R., Kreyenbuehl, M., Gutmann, H., \nDrewe, J., Henzen, C., Goeke, B., and Beglinger, C. \n(2004c). Glucagon-like peptide 1 induces natriure -\nsis in healthy subjects and in insulin-resistant obese \nmen, J Clin Endocrinol Metab 89, 3055-61.\nGybels, Y ., Grapow, M. T., Todorov, A., Wagner, G., \nand Zerkowski, H. R. (2000). Aberrant right pulmo -\nnary artery and double outlet ventricle: one-stage \nrepair, Ann Thorac Surg 69, 630-2.\nGyr, N., Zeller, A., and Battegay, M. (2001). [The Basel \nMedical University Polyclinic on the brink of the \n21st century: retrospective and prospective view], \nSchweiz Rundsch Med Prax 90, 1387-97.\nHaberle, B., Hero, B., Berthold, F ., and von Schweinitz, \nD. (2002). Characteristics and outcome of thoracic \nneuroblastoma, Eur J Pediatr Surg 12, 145-50.\nHabicht, J. M., Matt, P ., Passweg, J. R., Reichenberger, \nF ., Gratwohl, A., Zerkowski, H. R., and Tamm, M. \n(2001). Invasive pulmonary fungal infection in he -\nmatologic patients: is resection effective?, Hematol \nJ 2, 250-6.136/137Habicht, J. M., Passweg, J., Kuhne, T., Leibundgut, \nK., and Zerkowski, H. R. (2000a). Successful lo -\ncal excision and long-term survival for invasive \npulmonary aspergillosis during neutropenia after \nbone marrow transplantation, J Thorac Cardiovasc \nSurg 119, 1286-7.\nHabicht, J. M., Preiss, M., Passweg, J., Dalquen, P ., \nMatt, P ., Adler, H., Frei, R., and Zerkowski, H. R. \n(2002). Invasive pulmonary aspergillosis: effects \nof early resection in a neutropenic rat model, Eur \nJ Cardiothorac Surg 22, 728-32.\nHabicht, J. M., Scherr, P ., Zerkowski, H. R., and \nHoffmann, A. (2000b). Late conduction defects \nfollowing aortic valve replacement, J Heart Valve \nDis 9, 629-32.\nHadziselimovic, F ., Fliegel, C. H., and Miny, P . (2001). \nA novel syndrome involving primary skeletal \ngrowth and retardation in siblings, Clin Dysmor -\nphol 10, 33-6.\nHaecker, F . M., Oertli, D., Gissler, S., Zumsteg, U., Av -\noledo, P ., and Von Schweinitz, D. (2003). Multiple \nendocrine neoplasias type 2A and thyroid medul -\nlary carcinoma: an interdisciplinary challenge, \nPediatr Surg Int 19, 62-4.\nHaecker, F . M., Wehrmann, M., Hacker, H. W., \nStuhldreier, G., and von Schweinitz, D. (2002). \nRenal dysplasia in children with posterior urethral \nvalves: a primary or secondary malformation?, \nPediatr Surg Int 18, 119-22.\nHahn, S., and Holzgreve, W. (2002a). Fetal cells and \ncell-free fetal DNA in maternal blood: new insights \ninto pre-eclampsia, Hum Reprod Update 8, 501-8.\nHahn, S., and Holzgreve, W. (2002b). Prenatal diag -\nnosis using fetal cells and cell-free fetal DNA in \nmaternal blood: what is currently feasible?, Clin \nObstet Gynecol 45, 649-56; discussion 730-2.\nHahn, S., Zhong, X. Y ., Burk, M. R., Troeger, C., Kang, \nA., and Holzgreve, W. (2001). Both maternal and \nfetal cell-free DNA in plasma fluctuate, Ann N Y \nAcad Sci 945, 141-4.\nHahn, S., Zhong, X. Y ., and Holzgreve, W. (2002). Sin -\ngle cell PCR in laser capture microscopy, Methods \nEnzymol 356, 295-301.\nHaller, C., Casanova, E., Mueller, M., Vacher, C.-M., \nVigot, R., Doll, T., Barbieri, S., Gassmann, M., \nBettler, B. (2004). A floxed allele for conditional \ninactivation of the GABA B(1)-gene., Genesis.\nHamy, F ., Brondani, V ., Spoerri, R., Rigo, S., Stamm, C., \nand Klimkait, T. (2003). Specific block of androgen \nreceptor activity by antisense oligonucleotides, \nProstate Cancer Prostatic Dis 6, 27-33.\nHamy, F ., Felder, E., Lipson, K., and Klimkait, T. (2001). \nMerged screening for human immunodeficiency \nvirus Tat and Rev inhibitors, J Biomol Screen 6, \n179-87.\nHamy, F ., Gelus, N., Zeller, M., Lazdins, J. L., Bailly, C., \nand Klimkait, T. (2000). Blocking HIV replication by \ntargeting Tat protein, Chem Biol 7, 669-76.\nHanna, N., Shepherd, F . A., Fossella, F . V ., Pereira, J. R., \nDe Marinis, F ., von Pawel, J., Gatzemeier, U., Tsao, \nT. C., Pless, M., Muller, T., Lim, H. L., Desch, C., \nSzondy, K., Gervais, R., Shaharyar, Manegold, C., \nPaul, S., Paoletti, P ., Einhorn, L., and Bunn, P . A., Jr. \n(2004). Randomized phase III trial of pemetrexed \nversus docetaxel in patients with non-small-cell \nlung cancer previously treated with chemotherapy, \nJ Clin Oncol 22, 1589-97.\nHansel, A., Bucher, H. C., Nuesch, R., and Battegay, \nM. (2001). Reasons for discontinuation of first \nhighly active antiretroviral therapy in a cohort of \nproteinase inhibitor-naive HIV-infected patients, J \nAcquir Immune Defic Syndr 26, 191-3.Hansjee, N., Kaufmann, G., Strub, C., Weber, R., \nBattegay, M., Erb, P . (2004). Persistent apoptosis \nin HIV-1-infected individuals receiving potent \nantiretroviral therapy is associated with poor \nrecovery of CD4 T lymphocytes., J Acq Immune \nDefic Syndr 36: 671-677.\nHardeland, U., Bentele, M., Jiricny, J., and Schar, P . \n(2000). Separating substrate recognition from base \nhydrolysis in human thymine DNA glycosylase by \nmutational analysis, J Biol Chem 275, 33449-56.\nHardeland, U., Bentele, M., Jiricny, J., and Schar, P . \n(2003). The versatile thymine DNA-glycosylase: a \ncomparative characterization of the human, Dro -\nsophila and fission yeast orthologs, Nucleic Acids \nRes 31, 2261-71.\nHardeland, U., Bentele, M., Lettieri, T., Steinacher, \nR., Jiricny, J., and Schar, P . (2001). Thymine DNA \nglycosylase, Prog Nucleic Acid Res Mol Biol 68, \n235-53.\nHardeland, U., Steinacher, R., Jiricny, J., and Schar, P . \n(2002). Modification of the human thymine-DNA \nglycosylase by ubiquitin-like proteins facilitates \nenzymatic turnover, Embo J 21, 1456-64.\nHardmeier, M., Wagenpfeil, S., Freitag, P ., Fisher, E., \nRudick, R. A., Kooijmans-Coutinho, M., Clanet, \nM., Radue, E. W., and Kappos, L. (2003). Atrophy \nis detectable within a 3-month period in untreated \npatients with active relapsing remitting multiple \nsclerosis, Arch Neurol 60, 1736-9.\nHasan, S., El-Andaloussi, N., Hardeland, U., Hassa, \nP . O., Burki, C., Imhof, R., Schar, P ., and Hottiger, \nM. O. (2002). Acetylation regulates the DNA end-\ntrimming activity of DNA polymerase beta, Mol \nCell 10, 1213-22.\nHaselhorst, R., Kappos, L., Bilecen, D., Scheffler, K., \nMori, D., Radu, E. W., and Seelig, J. (2000). Dy -\nnamic susceptibility contrast MR imaging of plaque \ndevelopment in multiple sclerosis: application of an \nextended blood-brain barrier leakage correction, J \nMagn Reson Imaging 11, 495-505.\nHashemolhosseini, S., Moore, C., Landmann, L., \nSander, A., Schwarz, H., Witzemann, V ., Sak -\nmann, B., and Brenner, H. R. (2000). Electrical \nactivity and postsynapse formation in adult muscle: \ngamma-AChRs are not required, Mol Cell Neurosci \n16, 697-707.\nHausermann, P ., Gutersohn, T., Beltraminelli, H., \nSchiller, P ., Buchner, S. A., and Rufli, T. (2002). \n[Oral pemphigus vulgaris. Successful treatment \nwith minocycline and nicotinamide], Hautarzt \n53, 813-5.\nHausermann, P ., Khanna, N., Buess, M., Itin, P . H., \nBattegay, M., Dirnhofer, S., and Buechner, S. A. \n(2004). Cutaneous plasmablastic lymphoma in an \nHIV-positive male: an unrecognized cutaneous \nmanifestation, Dermatology 208, 287-90.\nHausermann, P ., Lutter, S., Meigel, W., Rufli, T. \n(2002a). Das Lewandowsky-Lutz-Syndrom: Die \nErstbeschreibung und drei weitere Basler F\u00e4lle \nder Epidermodysplasia verruciformis., Z Hautkrh \n77: 176-80.\nHausermann, P ., Lutter, S., Meigel, W., Rufli, T. \n(2002b). Zur Person Felix Lewandowsky., Z Hautkrh \n77 77: 182-3.\nHausmann, Kirsch, E., Radu, E., Mindermann, T. H., \nand Gratzl, O. (2001a). Coagulopathy induced \nspinal intradural extramedullary haematoma: \nreport of three cases and review of the literature, \nActa Neurochir (Wien) 143, 135-40.\nHausmann, O. N., Kirsch, E. C., Tolnay, M., and Gratzl, \nO. (2001b). Intramedullary spinal cord tumours: a \nclinical outcome and radiological follow-up study, \nSwiss Med Wkly 131, 582-7.Havlickova, M., Prezeau, L., Duthey, B., Bettler, B., \nPin, J. P ., and Blahos, J. (2002). The intracellular \nloops of the GB2 subunit are crucial for G-protein \ncoupling of the heteromeric gamma-aminobutyrate \nB receptor, Mol Pharmacol 62, 343-50.\nHeese, K., Beck, K. F ., Behrens, M. H., Pluss, K., \nFierlbeck, W., Huwiler, A., Muhl, H., Geiger, H., \nOtten, U., and Pfeilschifter, J. (2003). Effects of high \nglucose on cytokine-induced nerve growth factor \n(NGF) expression in rat renal mesangial cells, Bio -\nchem Pharmacol 65, 293-301.\nHeider, H., and Wintergerst, E. S. (2001). Mimicking \nphosphorylation at Ser-48 strongly reduces surface \nexpression of human macrophage scavenger recep -\ntor class A: implications on cell motility, FEBS Lett \n505, 185-90.\nHeim, M., Frank, O., Kampmann, G., Sochocky, N., \nPennimpede, T., Fuchs, P ., Hunziker, W., Weber, \nP ., Martin, I., and Bendik, I. (2004). The phytoestro -\ngen genistein enhances osteogenesis and represses \nadipogenic differentiation of human primary bone \nmarrow stromal cells, Endocrinology 145, 848-59. \nEpub 2003 Nov 6.\nHeim, M. H. (2000). Intracellular signalling and antivi -\nral effects of interferons, Dig Liver Dis 32, 257-63.\nHeim, M. H. (2003). A new survival trick of hepatitis C \nvirus: blocking the activation of interferon regula -\ntory factor-3, Hepatology 38, 1582-4.\nHeinimann, K., Muller, H., and Dobbie, Z. (2000). \nMicrosatellite instability in colorectal cancer, N \nEngl J Med 342, 1607-8.\nHeinimann, K., Thompson, A., Locher, A., Furlanetto, \nT., Bader, E., Wolf, A., Meier, R., Walter, K., Bauer -\nfeind, P ., Marra, G., Muller, H., Foernzler, D., and \nDobbie, Z. (2001). Nontruncating APC germ-line \nmutations and mismatch repair deficiency play a \nminor role in APC mutation-negative polyposis, \nCancer Res 61, 7616-22.\nHenger, A., Tutt, P ., Riesen, W. F ., Hulter, H. N., and \nKrapf, R. (2000). Acid-base and endocrine effects \nof aldosterone and angiotensin II inhibition in \nmetabolic acidosis in human patients, J Lab Clin \nMed 136, 379-89.\nHengstler, P ., Battegay, E., Cornuz, J., Bucher, H., and \nBattegay, M. (2002). Evidence for prevention and \nscreening: recommendations in adults, Swiss Med \nWkly 132, 363-73.\nHengstler, P ., and Battegay, M. (2001). [Vaccinations in \nadults], Schweiz Rundsch Med Prax 90, 2001-4.\nHeppeler, A., Froidevaux, S., Eberle, A. N., and Mae -\ncke, H. R. (2000). Receptor targeting for tumor \nlocalisation and therapy with radiopeptides, Curr \nMed Chem 7, 971-94.\nHermosilla, E., Lagueny, A., Vital, C., Vital, A., Fer -\nrer, X., Steck, A., and Julien, J. (1996). Peripheral \nneuropathy associated with monoclonal IgG of \nundetermined significance: clinical, electrophysi -\nologic, pathologic and therapeutic study of 14 \ncases, J Peripher Nerv Syst 1, 139-48.\nHerrmann, M., Stern, M., Vollenweider, F ., and Nitsch, \nC. (2004). Effect of inherent epileptic seizures on \nbrain injury after transient cerebral ischemia in \nMongolian gerbils, Exp Brain Res 154, 176-82. \nEpub 2003 Oct 14.\nHerzig, M., and Christofori, G. (2002). Recent advanc -\nes in cancer research: mouse models of tumorigen -\nesis, Biochim Biophys Acta 1602, 97-113.\nHess, C., Altfeld, M., Thomas, S. Y ., Addo, M. M., \nRosenberg, E. S., Allen, T. M., Draenert, R., Eldrige, \nR. L., van Lunzen, J., Stellbrink, H. J., Walker, B. \nD., and Luster, A. D. (2004a). HIV-1 specific CD8\ue02b \nT cells with an effector phenotype and control of \nviral replication, Lancet 363, 863-6.Hess, C., Klimkait, T., Schlapbach, L., Del Zenero, V ., \nSadallah, S., Horakova, E., Balestra, G., Werder, \nV ., Schaefer, C., Battegay, M., and Schifferli, J. A. \n(2002). Association of a pool of HIV-1 with erythro -\ncytes in vivo: a cohort study, Lancet 359, 2230-4.\nHess, C., Means, T. K., Autissier, P ., Woodberry, T., \nAltfeld, M., Addo, M. M., Frahm, N., Brander, C., \nWalker, B. D., and Luster, A. D. (2004b). IL-8 re -\nsponsiveness defines a subset of CD8 T cells poised \nto kill, Blood 3, 3.\nHess, C., Sadallah, S., and Schifferli, J. A. (2000). \nInduction of neutrophil responsiveness to my -\neloperoxidase antibodies by their exposure to su -\npernatant of degranulated autologous neutrophils, \nBlood 96, 2822-7.\nHess, C., and Schifferli, J. A. (2003). Immune adher -\nence revisited: novel players in an old game, News \nPhysiol Sci 18, 104-8.\nHeuss, L. T., and Beglinger, C. (2004). Quality assur -\nance in endoscopy should include data on sedation, \nEndoscopy 36, 569.\nHeuss, L. T., Drewe, J., Schnieper, P ., Tapparelli, C. \nB., Pflimlin, E., and Beglinger, C. (2004). Patient-\ncontrolled versus nurse-administered sedation \nwith propofol during colonoscopy. A prospective \nrandomized trial, Am J Gastroenterol 99, 511-8.\nHeuss, L. T., Schnieper, P ., Drewe, J., Pflimlin, E., and \nBeglinger, C. (2003a). Conscious sedation with pro -\npofol in elderly patients: a prospective evaluation, \nAliment Pharmacol Ther 17, 1493-501.\nHeuss, L. T., Schnieper, P ., Drewe, J., Pflimlin, E., and \nBeglinger, C. (2003b). Risk stratification and safe \nadministration of propofol by registered nurses \nsupervised by the gastroenterologist: a prospec -\ntive observational study of more than 2000 cases, \nGastrointest Endosc 57, 664-71.\nHeuss, L. T., Schnieper, P ., Drewe, J., Pflimlin, E., and \nBeglinger, C. (2003c). Safety of propofol for con -\nscious sedation during endoscopic procedures in \nhigh-risk patients-a prospective, controlled study, \nAm J Gastroenterol 98, 1751-7.\nHildebrandt, B., Heide, I., Thiede, C., Nagel, S., Die -\ning, A., Jonas, S., Neuhaus, P ., Rochlitz, C. F ., Riess, \nH., and Neubauer, A. (2000). Lack of point muta -\ntions in exons 11-23 of the retinoblastoma suscep -\ntibility gene RB-1 in liver metastases of colorectal \ncarcinoma, Oncology 59, 344-6.\nHintermann, E., Erb, C., Talke-Messerer, C., Liu, R., \nTanner, H., Flammer, J., and Eberle, A. N. (2001a). \nExpression of the melanin-concentrating hormone \nreceptor in porcine and human ciliary epithelial \ncells, Invest Ophthalmol Vis Sci 42, 206-9.\nHintermann, E., Tanner, H., Talke-Messerer, C., \nSchlumberger, S., Zumsteg, U., and Eberle, A. N. \n(2001b). Interaction of melanin-concentrating hor -\nmone (MCH), neuropeptide E-I (NEI), neuropeptide \nG-E (NGE), and alpha-MSH with melanocortin and \nMCH receptors on mouse B16 melanoma cells, J \nRecept Signal Transduct Res 21, 93-116.\nHirsch, H. H. (2002). Polyomavirus BK nephropathy: a \n(re-)emerging complication in renal transplantation, \nAm J Transplant 2, 25-30.\nHirsch, H. H. (2003a). BK virus replication and desease \nin solid organ transplantat recipients: an update., \nCurr Opin Organ Transpl 8: 262-8.\nHirsch, H. H. (2003b). [Polyomavirus associated ne -\nphropathy. A new opportunistic complication after \nkidney transplantation], Internist (Berl) 44, 653-5.\nHirsch, H. H. (2003c). [Viral infections after transplan -\ntation], Ther Umsch 60, 641-9.\nHirsch, H. H. (2003d). VP1 messenger RNA levels \nin urine for diagnosing BK virus nephropathy?, \nTransplantation 75, 2160.Hirsch, H. H., and Battegay, M. (2002). Lipodystro -\nphy syndrome by HAART in HIV-infected patients: \nmanifestation, mechanisms and management, In -\nfection 30, 293-8.\nHirsch, H. H., and Battegay, M. (2003). [HIV-infec -\ntion, HAART (highly-active antiretroviral therapy) \nand hyperlipidemia], Dtsch Med Wochenschr \n128, 1051-4.\nHirsch, H. H., Kaufmann, G., Sendi, P ., and Battegay, \nM. (2004). Immune reconstitution in HIV-infected \npatients, Clin Infect Dis 38, 1159-66. Epub 2004 \nApr 5.\nHirsch, H. H., Knowles, W., Dickenmann, M., Pass -\nweg, J., Klimkait, T., Mihatsch, M. J., and Steiger, \nJ. (2002). Prospective study of polyomavirus type \nBK replication and nephropathy in renal-transplant \nrecipients, N Engl J Med 347, 488-96.\nHirsch, H. H., Mohaupt, M., and Klimkait, T. (2001). \nProspective monitoring of BK virus load after dis -\ncontinuing sirolimus treatment in a renal transplant \npatient with BK virus nephropathy, J Infect Dis 184, \n1494-5; author reply 1495-6.\nHirsch, H. H., and Nuesch, R. (2001). [Edema and \nlymphadenopathy. 55-year-old patient with \nedema and lymphadenopathy: significance of fine \nneedle biopsy. Metastatic large cell undifferentiated \ncarcinoma of unknown primary tumor (pancreas, \nstomach, bronchial differential diagnosis)], Schweiz \nRundsch Med Prax 90, 1597-9.\nHirsch, H. H., and Steiger, J. (2003). Polyomavirus BK, \nLancet Infect Dis 3, 611-23.\nHock, C., Heese, K., Muller-Spahn, F ., Huber, P ., \nRiesen, W., Nitsch, R. M., and Otten, U. (2000a). \nIncreased cerebrospinal fluid levels of neurotrophin \n3 (NT-3) in elderly patients with major depression, \nMol Psychiatry 5, 510-3.\nHock, C., Heese, K., Muller-Spahn, F ., Huber, P ., \nRiesen, W., Nitsch, R. M., and Otten, U. (2000b). \nIncreased CSF levels of nerve growth factor in \npatients with Alzheimer\ue02bs disease, Neurology 54, \n2009-11.\nHoesli, I., Danek, M., Lin, D., Li, Y ., Hahn, S., and \nHolzgreve, W. (2002). Circulating erythroblasts \nin maternal blood are not elevated before onset of \npreterm labor, Obstet Gynecol 100, 992-6.\nHoesli, I. M., Strutas, D., Tercanli, S., and Holzgreve, \nW. (2003). Charts for cervical length in singleton \npregnancy, Int J Gynaecol Obstet 82, 161-5.\nHofer, S., Eichhorn, K., Freitag, P ., Reubi, J. C., \nMuller-Brand, J., Maecke, H., and Merlo, A. \n(2001). Successful diffusible brachytherapy (dBT) \nof a progressive low-grade astrocytoma using the \nlocally injected peptidic vector and somatostatin \nanalogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide \n(DOTATOC), Swiss Med Wkly 131, 640-4.\nHoffmann, M., Haller, P ., Bucher, H. C., Gyr, N., and \nBattegay, M. (2001). [Hospitalizations in a cohort \nof 175 severely drug-addicted patients of a medi -\ncally managed opiate withdrawal project], Schweiz \nRundsch Med Prax 90, 2094-101.\nHoffmann, R., Bruno, L., Seidl, T., Rolink, A., and \nMelchers, F . (2003). Rules for gene usage inferred \nfrom a comparison of large-scale gene expression \nprofiles of T and B lymphocyte development, J Im -\nmunol 170, 1339-53.\nHoffmann, R., Seidl, T., Neeb, M., Rolink, A., and \nMelchers, F . (2002). Changes in gene expression \nprofiles in developing B cells of murine bone mar -\nrow, Genome Res 12, 98-111.Hoffmann, T., De Libero, G., Colonna, M., Wodnar-\nFilipowicz, A., Passweg, J., Favre, G., Gratwohl, A., \nand Tichelli, A. (2000). Natural killer-type receptors \nfor HLA class I antigens are clonally expressed in \nlymphoproliferative disorders of natural killer and \nT-cell type, Br J Haematol 110, 525-36.\nHofsaess, U., and Kapfhammer, J. P . (2003). Identifi -\ncation of numerous genes differentially expressed \nin rat brain during postnatal development by sup -\npression subtractive hybridization and expression \nanalysis of the novel rat gene rMMS2, Brain Res Mol \nBrain Res 113, 13-27.\nHohlfeld, R., and Kappos, L. (2004). Workshop Re -\nport: Neuroprotection in Multiple Sclerosis Report \nfrom the MS Forum 16th Modern Management \nWorkshop, March 2004, Cernobbio, Italy*, Int \nMS J 11, 61-3.\nHolzgreve, W., and Hahn, S. (2002). [Non-invasive \nprenatal diagnosis--already a reality?], Gynakol \nGeburtshilfliche Rundsch 42, 84-6.\nHolzgreve, W., Surbek, D. (2004). Aktuelle Entwick -\nlungen der Stammzellforschung: Implikationen f\u00fcr \ndas Banking von Nabelschnurblut-Stammzellen., \nGeburtsh Frauenheilk 2004 64: 357-8.\nHolzgreve, W., Zhong, X. Y ., Burk, M. R., and Hahn, \nS. (2001). Enrichment of fetal cells and free fetal \nDNA from maternal blood: An insight into the Basel \nexperience, Early Pregnancy 5, 43-4.\nHoppe, C., Klitz, W., Cheng, S., Apple, R., Steiner, L., \nRobles, L., Girard, T., Vichinsky, E., and Styles, L. \n(2004). Gene interactions and stroke risk in children \nwith sickle cell anemia, Blood 103, 2391-6. Epub \n2003 Nov 13.\nHorakova, E., Gasser, O., Sadallah, S., Inal, J., Bour -\ngeois, G., Ziekau, I., Klimkait, T., Schifferli, J.A. \n(2004). Complement mediates the binding of HIV \nto erythrocytes., J Immunol 2004 (in press).\nHornstein, P . S., Zaugg, C. E., Zhu, P ., Allegrini, P . R., \nand Buser, P . T. (2001). Combined blockade of en -\ndothelin-1 and thromboxane A(2) receptors against \npostischaemic contractile dysfunction in rat hearts, \nBr J Pharmacol 132, 234-40.\nHosch, M., Muser, J., Hulter, H. N., and Krapf, R. \n(2004). Ureagenesis: evidence for a lack of hepatic \nregulation of acid-base equilibrium in humans, Am \nJ Physiol Renal Physiol 286, F94-9.\nHostettler, K. E., Roth, M., Burgess, J. K., Johnson, \nP . R., Glanville, A. R., Tamm, M., Black, J. L., and \nBorger, P . (2004). Cyclosporine A mediates fibro -\nproliferation through epithelial cells, Transplanta -\ntion 77, 1886-93.\nHristoskova, S., Holzgreve, W., and Hahn, S. (2003). \nFetal nucleated erythrocytes in maternal circulation \ndo not display a classic membrane-associated apop -\ntotic characteristic (phosphatidylserine exposure) \ndespite being positive by terminal dUTP nuclear \nend labeling, Clin Chem 49, 1934-7.\nHruz, P ., Mayr, M., Low, R., Drewe, J., and Huber, G. \n(2002). Fanconi\u2019s syndrome, acute renal failure, and \ntonsil ulcerations after colloidal bismuth subcitrate \nintoxication, Am J Kidney Dis 39, E18.\nHumar, B., D\u2019Orazio, D., Albrecht, C., Bauerfeind, \nP ., Muller, H., Dobbie, Z., and Bendik, I. (2001a). \nExpression of putative anticancer targets in familial \nadenomatous polyposis and its association with the \nAPC mutation status, Int J Oncol 19, 1179-86.\nHumar, B., Giovanoli, O., Wolf, A., Attenhofer, M., \nBendik, I., Meier, R., Muller, H., and Dobbie, Z. \n(2000). Germline alterations in the cyclooxygen -\nase-2 gene are not associated with the develop -\nment of extracolonic manifestations in a large \nswiss familial adenomatous polyposis kindred, Int \nJ Cancer 87, 812-7.138/139Humar, B., Muller, H., and Scott, R. J. (2001b). Cell \ncycle dependent DNA break increase in ataxia tel -\nangiectasia lymphoblasts after radiation exposure, \nMol Pathol 54, 347-50.\nHumar, B., Toro, T., Graziano, F ., Muller, H., Dobbie, \nZ., Kwang-Yang, H., Eng, C., Hampel, H., Gilbert, \nD., Winship, I., Parry, S., Ward, R., Findlay, M., \nChristian, A., Tucker, M., Tucker, K., Merriman, T., \nand Guilford, P . (2002a). Novel germline CDH1 mu -\ntations in hereditary diffuse gastric cancer families, \nHum Mutat 19, 518-25.\nHumar, R., Kiefer, F . N., Berns, H., Resink, T. J., and \nBattegay, E. J. (2002b). Hypoxia enhances vascu -\nlar cell proliferation and angiogenesis in vitro via \nrapamycin (mTOR)-dependent signaling, Faseb J \n16, 771-80.\nHunziker, P . R., Imsand, C., Keller, D., Hess, N., Bar -\nbosa, V ., Nietlispach, F ., Liel-Cohen, N., Weyman, \nA. E., Pfisterer, M., and Buser, P . (2002). Bedside \nquantification of atherosclerosis severity for car -\ndiovascular risk stratification: a prospective cohort \nstudy, J Am Coll Cardiol 39, 702-9.\nHutter, P ., Wijnen, J., Rey-Berthod, C., Thiffault, I., \nVerkuijlen, P ., Farber, D., Hamel, N., Bapat, B., \nThibodeau, S. N., Burn, J., Wu, J., MacNamara, \nE., Heinimann, K., Chong, G., and Foulkes, W. D. \n(2002). An MLH1 haplotype is over-represented on \nchromosomes carrying an HNPCC predisposing \nmutation in MLH1, J Med Genet 39, 323-7.\nHuwyler, J., Cerletti, A., Fricker, G., Eberle, A. N., and \nDrewe, J. (2002). By-passing of P-glycoprotein us -\ning immunoliposomes, J Drug Target 10, 73-9.\nIkeda, N., Krustev, R., and Muller, H. J. (2004). Ther -\nmodynamic consideration on single oil in water \nemulsion film stabilized by cationic surfactant, Adv \nColloid Interface Sci 108-109, 273-86.\nImpagnatiello, M. A., Weitzer, S., Gannon, G., Com -\npagni, A., Cotten, M., and Christofori, G. (2001). \nMammalian sprouty-1 and -2 are membrane-\nanchored phosphoprotein inhibitors of growth \nfactor signaling in endothelial cells, J Cell Biol \n152, 1087-98.\nInal, J. M., Pascual, M., Lesavre, P ., and Schifferli, J. A. \n(2003a). Complement inhibition in renal diseases, \nNephrol Dial Transplant 18, 237-40.\nInal, J. M., and Schifferli, J. A. (2002). Complement C2 \nreceptor inhibitor trispanning and the beta-chain \nof C4 share a binding site for complement C2, J \nImmunol 168, 5213-21.\nInal, J. M., Schneider, B., Armanini, M., and Schifferli, \nJ. A. (2003b). A peptide derived from the parasite \nreceptor, complement C2 receptor inhibitor tris -\npanning, suppresses immune complex-mediated \ninflammation in mice, J Immunol 170, 4310-7.\nInglese, M., van Waesberghe, J. H., Rovaris, M., \nBeckmann, K., Barkhof, F ., Hahn, D., Kappos, L., \nMiller, D. H., Polman, C., Pozzilli, C., Thompson, \nA. J., Yousry, T. A., Wagner, K., Comi, G., and \nFilippi, M. (2003). The effect of interferon beta-1b \non quantities derived from MT MRI in secondary \nprogressive MS, Neurology 60, 853-60.\nIvanov, D., Philippova, M., Antropova, J., Gubaeva, \nF ., Iljinskaya, O., Tararak, E., Bochkov, V ., Erne, P ., \nResink, T., and Tkachuk, V . (2001). Expression of \ncell adhesion molecule T-cadherin in the human \nvasculature, Histochem Cell Biol 115, 231-42.\nIvanov, D., Philippova, M., Tkachuk, V ., Erne, P ., and \nResink, T. (2004). Cell adhesion molecule T-cad -\nherin regulates vascular cell adhesion, phenotype \nand motility, Exp Cell Res 293, 207-18.Iwanaga, Y ., Gu, Y ., Dieterle, T., Presotto, C., Del \nSoldato, P ., Peterson, K. L., Ongini, E., Condorelli, \nG., and Ross, J., Jr. (2004a). A nitric oxide-releas -\ning derivative of enalapril, NCX 899, prevents \nprogressive cardiac dysfunction and remodeling \nin hamsters with heart failure, Faseb J 18, 587-8. \nEpub 2004 Jan 20.\nIwanaga, Y ., Hoshijima, M., Gu, Y ., Iwatate, M., \nDieterle, T., Ikeda, Y ., Date, M. O., Chrast, J., Mat -\nsuzaki, M., Peterson, K. L., Chien, K. R., and Ross, \nJ., Jr. (2004b). Chronic phospholamban inhibition \nprevents progressive cardiac dysfunction and \npathological remodeling after infarction in rats, J \nClin Invest 113, 727-36.\nIwatate, M., Gu, Y ., Dieterle, T., Iwanaga, Y ., Peter -\nson, K. L., Hoshijima, M., Chien, K. R., and Ross, J. \n(2003). In vivo high-efficiency transcoronary gene \ndelivery and Cre-LoxP gene switching in the adult \nmouse heart, Gene Ther 10, 1814-20.\nIzbicki, G., Trachsel, D., Rutishauser, M., Perruchoud, \nA. P ., and Tamm, M. (2000). [Early detection of ex -\nacerbation of lung infections in patients with cystic \nfibrosis by means of daily spirometry], Schweiz Med \nWochenschr 130, 1361-5.\nJacobson, M., Bornstein, S., Palmer, E., and Wallgren, \nP . (2000). Elimination of Sarcoptes scabiei in pig \nherds by single or double administrations of an \navermectin, Acta Vet Scand 41, 227-35.\nJaeger, E. E., Woodford-Richens, K. L., Lockett, M., \nRowan, A. J., Sawyer, E. J., Heinimann, K., Rozen, \nP ., Murday, V . A., Whitelaw, S. C., Ginsberg, A., \nAtkin, W. S., Lynch, H. T., Southey, M. C., Debinski, \nH., Eng, C., Bodmer, W. F ., Talbot, I. C., Hodgson, S. \nV ., Thomas, H. J., and Tomlinson, I. P . (2003). An an -\ncestral Ashkenazi haplotype at the HMPS/CRAC1 \nlocus on 15q13-q14 is associated with hereditary \nmixed polyposis syndrome, Am J Hum Genet 72, \n1261-7. Epub 2003 Apr 14.\nJaggy, C., von Overbeck, J., Ledergerber, B., Schwarz, \nC., Egger, M., Rickenbach, M., Furrer, H. J., Telenti, \nA., Battegay, M., Flepp, M., Vernazza, P ., Bernas -\nconi, E., and Hirschel, B. (2003). Mortality in the \nSwiss HIV Cohort Study (SHCS) and the Swiss \ngeneral population, Lancet 362, 877-8.\nJakob, M., Demarteau, O., Schafer, D., Hintermann, \nB., Dick, W., Heberer, M., and Martin, I. (2001). \nSpecific growth factors during the expansion \nand redifferentiation of adult human articular \nchondrocytes enhance chondrogenesis and car -\ntilaginous tissue formation in vitro, J Cell Biochem \n81, 368-77.\nJakob, M., Demarteau, O., Schafer, D., Stumm, M., \nHeberer, M., and Martin, I. (2003). Enzymatic \ndigestion of adult human articular cartilage yields \na small fraction of the total available cells, Connect \nTissue Res 44, 173-80.\nJakob, M., Demarteau, O., Suetterlin, R., Heberer, M., \nand Martin, I. (2004). Chondrogenesis of expanded \nadult human articular chondrocytes is enhanced by \nspecific prostaglandins, Rheumatology (Oxford) 43, \n852-7. Epub 2004 Apr 27.\nJantscheff, P ., Spagnoli, G., Zajac, P ., and Rochlitz, C. \nF . (2002). Cell fusion: an approach to generating \nconstitutively proliferating human tumor antigen-\npresenting cells, Cancer Immunol Immunother 51, \n367-75. Epub 2002 Jun 25.\nJantscheff, P ., Terracciano, L., Lowy, A., Glatz-Krieger, \nK., Grunert, F ., Micheel, B., Brummer, J., Laffer, U., \nMetzger, U., Herrmann, R., and Rochlitz, C. (2003). \nExpression of CEACAM6 in resectable colorectal \ncancer: a factor of independent prognostic signifi -\ncance, J Clin Oncol 21, 3638-46.Jehle, A. W., Khanna, N., Sigle, J. P ., Glatz-Krieger, \nK., Battegay, M., Steiger, J., Dickenmann, M., \nand Hirsch, H. H. (2004). Acute renal failure on \nimmune reconstitution in an HIV-positive patient \nwith miliary tuberculosis, Clin Infect Dis 38, e32-5. \nEpub 2004 Jan 30.\nJehle, S., Hulter, H. N., and Krapf, R. (2000). On the \nmechanism of growth hormone-induced stimula -\ntion of renal acidification in humans: effect of \ndietary NaCl, Clin Sci (Lond) 99, 47-56.\nJelezarova, E., Schlumberger, M., Sadallah, S., Spath, \nP . J., Schifferli, J. A., and Lutz, H. U. (2001). A C3 \nconvertase assay for nephritic factor functional \nactivity, J Immunol Methods 251, 45-52.\nJensen, A. A., Mosbacher, J., Elg, S., Lingenhoehl, \nK., Lohmann, T., Johansen, T. N., Abrahamsen, \nB., Mattsson, J. P ., Lehmann, A., Bettler, B., and \nBrauner-Osborne, H. (2002). The anticonvulsant \ngabapentin (neurontin) does not act through \ngamma-aminobutyric acid-B receptors, Mol Phar -\nmacol 61, 1377-84.\nJi, J., Wernli, M., Buechner, S., and Erb, P . (2003a). \nFas ligand downregulation with antisense oligonu -\ncleotides in cells and in cultured tissues of normal \nskin epidermis and basal cell carcinoma, J Invest \nDermatol 120, 1094-9.\nJi, J., Wernli, M., Klimkait, T., and Erb, P . (2003b). \nEnhanced gene silencing by the application of \nmultiple specific small interfering RNAs, FEBS Lett \n552, 247-52.\nJimenez Bueno, G., Klimkait, T., Gilbert, I. H., and \nSimons, C. (2003). Solid-phase synthesis of \ndiamine and polyamine amino acid derivatives \nas HIV-1 tat-TAR binding inhibitors, Bioorg Med \nChem 11, 87-94.\nJohnson, D. R., Biedermann, B. C., and Mook-Kan -\namori, B. (2000). Rapid cloning of HLA class I \ncDNAs by locus specific PCR, J Immunol Methods \n233, 119-29.\nJohnson, K. L., Dukes, K. A., Vidaver, J., LeShane, E. \nS., Ramirez, I., Weber, W. D., Bischoff, F . Z., Hahn, \nS., Sharma, A., Dang, D. X., Hire, L. M., Bianchi, \nD. W., Simpson, J. L., Holzgreve, W., Elias, S., and \nKlinger, K. W. (2004a). Interlaboratory comparison \nof fetal male DNA detection from common maternal \nplasma samples by real-time PCR, Clin Chem 50, \n516-21. Epub 2004 Jan 12.\nJohnson, P . R., Burgess, J. K., Underwood, P . A., Au, \nW., Poniris, M. H., Tamm, M., Ge, Q., Roth, M., and \nBlack, J. L. (2004b). Extracellular matrix proteins \nmodulate asthmatic airway smooth muscle cell \nproliferation via an autocrine mechanism, J Allergy \nClin Immunol 113, 690-6.\nJohnson, P . R., Roth, M., Tamm, M., Hughes, M., Ge, \nQ., King, G., Burgess, J. K., and Black, J. L. (2001). \nAirway smooth muscle cell proliferation is increased \nin asthma, Am J Respir Crit Care Med 164, 474-7.\nJones, G., Machado, J., Jr., and Merlo, A. (2001a). Loss \nof focal adhesion kinase (FAK) inhibits epidermal \ngrowth factor receptor-dependent migration and \ninduces aggregation of nh(2)-terminal FAK in the \nnuclei of apoptotic glioblastoma cells, Cancer Res \n61, 4978-81.\nJones, G., Machado, J., Jr., Tolnay, M., and Merlo, A. \n(2001b). PTEN-independent induction of caspase-\nmediated cell death and reduced invasion by the \nfocal adhesion targeting domain (FAT) in human \nastrocytic brain tumors which highly express focal \nadhesion kinase (FAK), Cancer Res 61, 5688-91.\nJoos, L., Carlen Brutsche, I. E., Laule-Kilian, K., Cra -\nwen, M., Tamm, M., and Brutsche, M. H. (2004). \nSystemic Th1- and Th2-gene signals in atopy and \nasthma, Swiss Med Wkly 134, 159-64.Jover, R., Hoffmann, F ., Scheffler-Koch, V ., and \nLindberg, R. L. (2000). Limited heme synthesis in \nporphobilinogen deaminase-deficient mice impairs \ntranscriptional activation of specific cytochrome \nP450 genes by phenobarbital, Eur J Biochem 267, \n7128-37.\nJungbluth, A. A., Busam, K. J., Kolb, D., Iversen, K., \nCoplan, K., Chen, Y . T., Spagnoli, G. C., and Old, L. \nJ. (2000). Expression of MAGE-antigens in normal \ntissues and cancer, Int J Cancer 85, 460-5.\nJuretic, A., Spagnoli, G. C., Schultz-Thater, E., and \nSarcevic, B. (2003). Cancer/testis tumour-associ -\nated antigens: immunohistochemical detection with \nmonoclonal antibodies, Lancet Oncol 4, 104-9.\nKafienah, W., Jakob, M., Demarteau, O., Frazer, A., \nBarker, M. D., Martin, I., and Hollander, A. P . \n(2002). Three-dimensional tissue engineering of \nhyaline cartilage: comparison of adult nasal and \narticular chondrocytes, Tissue Eng 8, 817-26.\nKaiser, C., Kuster, G. M., Erne, P ., Amann, W., Naegeli, \nB., Osswald, S., Buser, P ., Schlapfer, H., Brett, W., \nZerkowski, H. R., Schindler, C., and Pfisterer, M. \n(2004). Risks and benefits of optimised medical \nand revascularisation therapy in elderly patients \nwith angina \u2013 on-treatment analysis of the TIME \ntrial, Eur Heart J 25, 1036-42.\nKalberer, C. P ., Siegler, U., and Wodnar-Filipowicz, A. \n(2003). Human NK cell development in NOD/SCID \nmice receiving grafts of cord blood CD34\ue02b cells, \nBlood 102, 127-35.\nKappos, L. (2002). Interferon beta-1a and beta-1b for \ntreatment of multiple sclerosis, Lancet 360, 1428; \nauthor reply 1428-9.\nKappos, L. (2004). Effect of drugs in secondary disease \nprogression in patients with multiple sclerosis, Mult \nScler 10, S46-54; discussion S54-5.\nKappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., \nConlon, P ., and Steinman, L. (2000). Induction \nof a non-encephalitogenic type 2 T helper-cell \nautoimmune response in multiple sclerosis after \nadministration of an altered peptide ligand in a \nplacebo-controlled, randomized phase II trial. The \nAltered Peptide Ligand in Relapsing MS Study \nGroup, Nat Med 6, 1176-82.\nKappos, L., and Duda, P . (2002). The Janus face of \nCNS-directed autoimmune response: a therapeutic \nchallenge, Brain 125, 2379-80.\nKappos, L., and Kesselring, J. (2003). Interferons in \nrelapsing remitting multiple sclerosis, Lancet 361, \n1821-2; author reply 1823-4.\nKappos, L., Polman, C., Pozzilli, C., Thompson, \nA., Beckmann, K., and Dahlke, F . (2001). Final \nanalysis of the European multicenter trial on IFN -\nbeta-1b in secondary-progressive MS, Neurology \n57, 1969-75.\nKappos, L., Polman, C., Thompson, A. J., Duda, P ., \nClanet, M., Comi, G., Hartung, H. P ., and Mon -\ntalban, X. (2003). Towards a european network \nfor multiple sclerosis trials (ENMST), Mult Scler \n9, 627-9.\nKaufmann, G. R., Khanna, N., Weber, R., Perrin, L., \nFurrer, H., Cavassini, M., Ledergerber, B., Vernazza, \nP ., Bernasconi, E., Rickenbach, M., Hirschel, B., \nand Battegay, M. (2004). Long-term virological \nresponse to multiple sequential regimens of highly \nactive antiretroviral therapy for HIV infection, An -\ntivir Ther 9, 263-74.Kaufmann, G. R., Perrin, L., Pantaleo, G., Opravil, M., \nFurrer, H., Telenti, A., Hirschel, B., Ledergerber, B., \nVernazza, P ., Bernasconi, E., Rickenbach, M., Egger, \nM., and Battegay, M. (2003). CD4 T-lymphocyte \nrecovery in individuals with advanced HIV-1 infec -\ntion receiving potent antiretroviral therapy for 4 \nyears: the Swiss HIV Cohort Study, Arch Intern \nMed 163, 2187-95.\nKaufmann, G. R., Smith, D., Bucher, H. C., Phanu -\nphak, P ., Sendi, P . P ., Mbidde, E. K., Cooper, D. \nA., and Battegay, M. (2002). Potential benefit and \nlimitations of a broad access to potent antiretroviral \ntherapy in developing countries, Expert Opin Inves -\ntig Drugs 11, 1303-13.\nKaupmann, K., Cryan, J. F ., Wellendorph, P ., Momb -\nereau, C., Sansig, G., Klebs, K., Schmutz, M., \nFroestl, W., van der Putten, H., Mosbacher, J., \nBrauner-Osborne, H., Waldmeier, P ., and Bettler, \nB. (2003). Specific gamma-hydroxybutyrate-bind -\ning sites but loss of pharmacological effects of \ngamma-hydroxybutyrate in GABA(B)(1)-deficient \nmice, Eur J Neurosci 18, 2722-30.\nKavalar, R., Sarcevic, B., Spagnoli, G. C., Separovic, \nV ., Samija, M., Terracciano, L., Heberer, M., and \nJuretic, A. (2001). Expression of MAGE tumour-\nassociated antigens is inversely correlated with \ntumour differentiation in invasive ductal breast \ncancers: an immunohistochemical study, Virchows \nArch 439, 127-31.\nKeller, D., Osswald, S., Carrier, L. (Genetik der \nFamili\u00e4ren Hypertrophen Kardiomyopathie.). Kar -\ndiovaskul\u00e4re Medizin 2002, 5: 400-406.\nKeller, D. I., Acharfi, S., Delacretaz, E., Benammar, \nN., Rotter, M., Pfammatter, J. P ., Fressart, V ., \nGuicheney, P ., and Chahine, M. (2003a). A novel \nmutation in SCN5A, delQKP 1507-1509, causing \nlong QT syndrome: role of Q1507 residue in so -\ndium channel inactivation, J Mol Cell Cardiol 35, \n1513-21.\nKeller, D. I., Carrier, L., and Schwartz, K. (2002). Ge -\nnetics of familial cardiomyopathies and arrhythmias, \nSwiss Med Wkly 132, 401-7.\nKeller, D. I., Coirault, C., Rau, T., Cheav, T., Wey -\nand, M., Amann, K., Lecarpentier, Y ., Richard, P ., \nEschenhagen, T., and Carrier, L. (2004). Human \nhomozygous R403W mutant cardiac myosin \npresents disproportionate enhancement of me -\nchanical and enzymatic properties, J Mol Cell \nCardiol 36, 355-62.\nKeller, D. I., Osswald, S., Bremerich, J., Bongartz, G., \nCron, T. A., Hilti, P ., Pfisterer, M. E., and Buser, \nP . T. (2003b). Arrhythmogenic right ventricular \ncardiomyopathy: diagnostic and prognostic value \nof the cardiac MRI in relation to arrhythmia-free \nsurvival, Int J Cardiovasc Imaging 19, 537-43; \ndiscussion 545-7.\nKeller, U., Szinnai, G., Bilz, S., and Berneis, K. (2003c). \nEffects of changes in hydration on protein, glucose \nand lipid metabolism in man: impact on health, Eur \nJ Clin Nutr 57, S69-74.\nKhanna, N., Goldenberger, D., Graber, P ., Battegay, \nM., and Widmer, A. F . (2003). Gastroenteritis out -\nbreak with norovirus in a Swiss university hospital \nwith a newly identified virus strain, J Hosp Infect \n55, 131-6.\nKhanna, N., Klimkait, T., Schiffer, V ., Irigoyen, J., Telen -\nti, A., Hirschel, B., and Battegay, M. (2000). Salvage \ntherapy with abacavir plus a non-nucleoside reverse \ntranscriptase inhibitor and a protease inhibitor in \nheavily pre-treated HIV-1 infected patients. Swiss \nHIV Cohort Study, Aids 14, 791-9.Kiefer, F . N., Misteli, H., Kalak, N., Tschudin, K., \nFingerle, J., Van der Kooij, M., Stumm, M., \nSumanovski, L. T., Sieber, C. C., and Battegay, E. \nJ. (2002a). Inhibition of NO biosynthesis, but not \nelevated blood pressure, reduces angiogenesis \nin rat models of secondary hypertension, Blood \nPress 11, 116-24.\nKiefer, F . N., Neysari, S., Humar, R., Li, W., Munk, V . \nC., and Battegay, E. J. (2003). Hypertension and \nangiogenesis, Curr Pharm Des 9, 1733-44.\nKiefer, G., Battegay, M., Gyr, N., and Hatz, C. (2002b). \n[Mansonella perstans filariasis after stay in Cam -\neroon. A 19-year-old patient born in Cameroon, in \nSwitzerland for the last 10 years], Schweiz Rundsch \nMed Prax 91, 61-6.\nKiewitz, R., Acklin, C., Schafer, B. W., Maco, B., \nUhrik, B., Wuytack, F ., Erne, P ., and Heizmann, C. \nW. (2003). Ca2\ue02b -dependent interaction of S100A1 \nwith the sarcoplasmic reticulum Ca2\ue02b -ATPase2a \nand phospholamban in the human heart, Biochem \nBiophys Res Commun 306, 550-7.\nKindler, C. H., Girard, T., Gong, D., and Urwyler, A. \n(2002). The differential effect of halothane and 1,2-\ndichlorohexafluorocyclobutane on in vitro muscle \ncontractures of patients susceptible to malignant \nhyperthermia, Anesth Analg 94, 1028-33, table \nof contents.\nKlimkait, T. (2000). Restriction PCR \u2013 superior to \nrestriction endonucleases in DNA-cloning ap -\nplications., Journ of Biochem and Mol Biol 22(2): \n162-5.\nKlimkait, T. (2002). A sensitive replicative system to as -\nsess HIV-1 drug resistance, Am Clin Lab 21, 20-4.\nKlingbeil, A. U., Muller, H. J., Delles, C., Fleischmann, \nE., and Schmieder, R. E. (2000). Regression of left \nventricular hypertrophy by AT1 receptor blockade \nin renal transplant recipients, Am J Hypertens 13, \n1295-300.\nKloeter, U. C., Jander, N. G., Buser, P . T., Osswald, \nS., Mueller-Brand, J., and Pfisterer, M. E. (2001). \nLong-term outcome of angioplasty for multivessel \ncoronary disease: importance and price of complete \nrevascularization, Int J Cardiol 79, 197-205.\nKnecht, H., Baumberger, M., Tobon, A., and Steck, \nA. (2004). Sustained remission of CIDP associated \nwith Evans syndrome, Neurology 63, 730-2.\nKocher, T., Schraml, P ., Spagnoli, G. C., Harder, F ., and \nHeberer, M. (2000). Identification of genes differ -\nentially expressed in melanoma sublines derived \nfrom a single surgical specimen characterised by \ndifferent sensitivity to cytotoxic T-lymphocyte activ -\nity, Schweiz Med Wochenschr 130, 617-24.\nKocher, T., Zheng, M., Bolli, M., Simon, R., Forster, \nT., Schultz-Thater, E., Remmel, E., Noppen, C., \nSchmid, U., Ackermann, D., Mihatsch, M. J., Gas -\nser, T., Heberer, M., Sauter, G., and Spagnoli, G. C. \n(2002). Prognostic relevance of MAGE-A4 tumor \nantigen expression in transitional cell carcinoma of \nthe urinary bladder: a tissue microarray study, Int J \nCancer 100, 702-5.\nKoebbe, C. J., Horowitz, M., Jungreis, C., Levy, E., \nand Pless, M. (2003). Alcohol embolization of \ncarotid-cavernous indirect fistulae, Neurosurgery \n52, 1111-5; discussion 1115-6.\nKoehler, M., and Merlo, A. (2001). [Treatment of brain \nmetastases], Ther Umsch 58, 732-7.\nKoleva, M., Schlaf, G., Landmann, R., Gotze, O., \nJungermann, K., and Schieferdecker, H. L. (2002). \nInduction of anaphylatoxin C5a receptors in rat \nhepatocytes by lipopolysaccharide in vivo: media -\ntion by interleukin-6 from Kupffer cells, Gastroen -140/141terology 122, 697-708.\nKon, E., Muraglia, A., Corsi, A., Bianco, P ., Marcacci, \nM., Martin, I., Boyde, A., Ruspantini, I., Chistolini, \nP ., Rocca, M., Giardino, R., Cancedda, R., and \nQuarto, R. (2000). Autologous bone marrow \nstromal cells loaded onto porous hydroxyapatite \nceramic accelerate bone repair in critical-size \ndefects of sheep long bones, J Biomed Mater Res \n49, 328-37.\nKrahenbuhl, L., Lang, C., Ludes, S., Seiler, C., Schafer, \nM., Zimmermann, A., and Krahenbuhl, S. (2003). \nReduced hepatic glycogen stores in patients with \nliver cirrhosis, Liver 23, 101-9.\nKrahenbuhl, S. (2003). [Abuse of benzodiazepines and \nsimilar substances], Ther Umsch 60, 335-40.\nKralovics, R., Buser, A. S., Teo, S. S., Coers, J., Tichelli, \nA., van der Maas, A. P ., and Skoda, R. C. (2003). \nComparison of molecular markers in a cohort of \npatients with chronic myeloproliferative disorders, \nBlood 102, 1869-71.\nKralovics, R., Skoda, R.C. (2004). Molecular patho -\ngenesis of Philadelphia chromosome negative \nmyeloproliferative disorders., Blood Reviews (in \npress).\nKrapf, R. (2002). Development of Cushing\u2019s syndrome \nafter use of a herbal remedy, Lancet 360, 1884.\nKrenger, W., Rossi, S., and Hollander, G. A. (2000a). \nApoptosis of thymocytes during acute graft-versus-\nhost disease is independent of glucocorticoids, \nTransplantation 69, 2190-3.\nKrenger, W., Rossi, S., Piali, L., and Hollander, G. A. \n(2000b). Thymic atrophy in murine acute graft-\nversus-host disease is effected by impaired cell \ncycle progression of host pro-T and pre-T cells, \nBlood 96, 347-54.\nKrenger, W., Schmidlin, H., Cavadini, G., and Hol -\nlander, G. A. (2004). On the relevance of TCR \nrearrangement circles as molecular markers for \nthymic output during experimental graft-versus-\nhost disease, J Immunol 172, 7359-67.\nKristian, S. A., Golda, T., Ferracin, F ., Cramton, S. E., \nNeumeister, B., Peschel, A., Gotz, F ., and Land -\nmann, R. (2004). The ability of biofilm formation \ndoes not influence virulence of Staphylococcus \naureus and host response in a mouse tissue cage \ninfection model, Microb Pathog 36, 237-45.\nKristian, S. A., Lauth, X., Nizet, V ., Goetz, F ., Neu -\nmeister, B., Peschel, A., and Landmann, R. (2003). \nAlanylation of teichoic acids protects Staphylococ -\ncus aureus against Toll-like receptor 2-dependent \nhost defense in a mouse tissue cage infection \nmodel, J Infect Dis 188, 414-23. Epub 2003 Jul 10.\nKrummenacher, J., Muller, H. J., and Heller, D. (2001). \nVisual search for dimensionally redundant pop-out \ntargets: evidence for parallel-coactive processing of \ndimensions, Percept Psychophys 63, 901-17.\nKrummenacher, J., Muller, H. J., and Heller, D. (2002). \nVisual search for dimensionally redundant pop-out \ntargets: parallel-coactive processing of dimensions \nis location specific, J Exp Psychol Hum Percept Per -\nform 28, 1303-22.\nKuban, P ., Reinhardt, M., Muller, B., and Hauser, P . \nC. (2004). On-site simultaneous determination of \nanions and cations in drainage water using a flow \ninjection-capillary electrophoresis system with con -\ntactless conductivity detection, J Environ Monit 6, \n169-74. Epub 2004 Feb 5.\nKudrjashova, E., Bashtrikov, P ., Bochkov, V ., Parfy -\nonova, Y ., Tkachuk, V ., Antropova, J., Iljinskaya, \nO., Tararak, E., Erne, P ., Ivanov, D., Philippova, M., \nand Resink, T. J. (2002). Expression of adhesion \nmolecule T-cadherin is increased during neointima \nformation in experimental restenosis, Histochem Cell Biol 118, 281-90. Epub 2002 Sep 27.\nKuhn, C., Muller-Werdan, U., Schmitt, D. V ., Lange, \nH., Pilz, G., Kreuzer, E., Mohr, F . W., Zerkowski, \nH. R., and Werdan, K. (2000). Improved outcome \nof APACHE II score-defined escalating systemic \ninflammatory response syndrome in patients post \ncardiac surgery in 1996 compared to 1988-1990: \nthe ESSICS-study pilot project, Eur J Cardiothorac \nSurg 17, 30-7.\nKulik, A., Nakadate, K., Nyiri, G., Notomi, T., Mal -\nitschek, B., Bettler, B., and Shigemoto, R. (2002). \nDistinct localization of GABA(B) receptors relative \nto synaptic sites in the rat cerebellum and ventroba -\nsal thalamus, Eur J Neurosci 15, 291-307.\nKuntzer, T., Antoine, J.C., Steck, A.J. (2004). Clinical \nfeatures and pathophysiological bases of sensory \nneuronopathies (ganglionopathies). Muscle Nerve \n2004 (in press).\nKuschel, B., Kochli, O. R., Niederacher, D., Muller, H., \nand Beckmann, M. W. (2000). [Hereditary cancer \nsyndromes in gynecology: what the practitioner \nneeds to know!], Schweiz Med Wochenschr 130, \n362-75.\nKuster, G. M., Buser, P ., Osswald, S., Kaiser, C., Scho -\nnenberger, R., Schindler, C., Amann, W., Ricken -\nbacher, P ., and Pfisterer, M. (2003). Comparison of \npresentation, perception, and six-month outcome \nbetween women and men \ue02b or \ue02b75 years of age with \nangina pectoris, Am J Cardiol 91, 436-9.\nLabuhn, M., Jones, G., Speel, E. J., Maier, D., Zweifel, \nC., Gratzl, O., Van Meir, E. G., Hegi, M. E., and \nMerlo, A. (2001). Quantitative real-time PCR does \nnot show selective targeting of p14(ARF) but \nconcomitant inactivation of both p16(INK4A) and \np14(ARF) in 105 human primary gliomas, Oncogene \n20, 1103-9.\nLacazette, E., Le Calvez, S., Gajendran, N., and Bren -\nner, H. R. (2003). A novel pathway for MuSK to \ninduce key genes in neuromuscular synapse forma -\ntion, J Cell Biol 161, 727-36.\nLaflamme, N., Echchannaoui, H., Landmann, R., and \nRivest, S. (2003). Cooperation between toll-like \nreceptor 2 and 4 in the brain of mice challenged \nwith cell wall components derived from gram-nega -\ntive and gram-positive bacteria, Eur J Immunol 33, \n1127-38.\nLaghi, L., Ranzani, G. N., Bianchi, P ., Mori, A., Heini -\nmann, K., Orbetegli, O., Spaudo, M. R., Luinetti, \nO., Francisconi, S., Roncalli, M., Solcia, E., and \nMalesci, A. (2002). Frameshift mutations of human \ngastrin receptor gene (hGARE) in gastrointestinal \ncancers with microsatellite instability, Lab Invest \n82, 265-71.\nLaifer, G., Widmer, A. F ., Frei, R., Zimmerli, W., and \nFluckiger, U. (2004). Polymerase chain reaction \nfor Mycobacterium tuberculosis: impact on clinical \nmanagement of refugees with pulmonary infiltrates, \nChest 125, 981-6.\nLandmann, L. (2002). Deconvolution improves colo -\ncalization analysis of multiple fluorochromes in 3D \nconfocal data sets more than filtering techniques, J \nMicrosc 208, 134-47.\nLandmann, L., Marbet, P . (2004). Colocalization analy -\nsis yields superior results after image restoration., \nMicr Res Techn 2004 64: 103-112.\nLandmann, R., Muller, B., and Zimmerli, W. (2000). \nCD14, new aspects of ligand and signal diversity, \nMicrobes Infect 2, 295-304.\nLandry, C., Brasseur, F ., Spagnoli, G. C., Marbaix, \nE., Boon, T., Coulie, P ., and Godelaine, D. (2000). \nMonoclonal antibody 57B stains tumor tissues that express gene MAGE-A4, Int J Cancer 86, 835-41.\nLangemann, H., Alessandri, B., Mendelowitsch, A., \nFeuerstein, T., Landolt, H., and Gratzl, O. (2001a). \nExtracellular levels of glucose and lactate measured \nby quantitative microdialysis in the human brain, \nNeurol Res 23, 531-6.\nLangemann, H., Feuerstein, T., Mendelowitsch, A., \nand Gratzl, O. (2001b). Microdialytical monitoring \nof uric and ascorbic acids in the brains of patients \nafter severe brain injury and during neurovascu -\nlar surgery, J Neurol Neurosurg Psychiatry 71, \n169-74.\nLechner-Scott, J., Kappos, L., Hofman, M., Polman, C. \nH., Ronner, H., Montalban, X., Tintore, M., Fronto -\nni, M., Buttinelli, C., Amato, M. P ., Bartolozzi, M. L., \nVersavel, M., Dahlke, F ., Kapp, J. F ., and Gibberd, R. \n(2003). Can the Expanded Disability Status Scale be \nassessed by telephone?, Mult Scler 9, 154-9.\nLee, A. G., Tang, R. A., Feldon, S. E., Pless, M., Schiff -\nman, J. S., Rubin, R. M., and Rao, N. (2001a). \nOrbital presentations of giant cell arteritis, Graefes \nArch Clin Exp Ophthalmol 239, 509-13.\nLee, D. A., and Martin, I. (2004). Bioreactor culture \ntechniques for cartilage-tissue engineering, Meth -\nods Mol Biol 238, 159-70.\nLee, J. H., Johnson, P . R., Roth, M., Hunt, N. H., and \nBlack, J. L. (2001b). ERK activation and mitogenesis \nin human airway smooth muscle cells, Am J Physiol \nLung Cell Mol Physiol 280, L1019-29.\nLee, M. S., and Pless, M. (2003). Apoplectic lym -\nphocytic hypophysitis. Case report, J Neurosurg \n98, 183-5.\nLegendre, U., Battegay, M., Nuttli, I., Dalquen, P ., and \nNuesch, R. (2001). Simultaneous occurrence of 2 \nHIV-related immunereconstitution diseases after \ninitiation of highly active antiretroviral therapy, \nScand J Infect Dis 33, 388-9.\nLehmann, F ., Hildebrand, P ., and Beglinger, C. (2003). \nNew molecular targets for treatment of peptic ulcer \ndisease, Drugs 63, 1785-97.\nLehmann, F . S., and Beglinger, C. (2003). Current role \nof Helicobacter pylori stool tests, Digestion 68, 119-\n23. Epub 2003 Nov 7.\nLehmann, F . S., Drewe, J., Terracciano, L., and Beglin -\nger, C. (2000a). Effect of ornidazole and clarithro -\nmycin resistance on eradication of Helicobacter \npylori in peptic ulcer disease, Aliment Pharmacol \nTher 14, 305-9.\nLehmann, F . S., Renner, E. L., Meyer-Wyss, B., \nWilder-Smith, C. H., Mazzucchelli, L., Ruchti, C., \nDrewe, J., Beglinger, C., and Merki, H. S. (2000b). \nHelicobacter pylori and gastric erosions. Results of \na prevalence study in asymptomatic volunteers, \nDigestion 62, 82-6.\nLehmann, F . S., Terracciano, L., Carena, I., Baeriswyl, \nC., Drewe, J., Tornillo, L., De Libero, G., and Be -\nglinger, C. (2002). In situ correlation of cytokine \nsecretion and apoptosis in Helicobacter pylori-as -\nsociated gastritis, Am J Physiol Gastrointest Liver \nPhysiol 283, G481-8.\nLeib, S. L., Clements, J. M., Lindberg, R. L., Heim -\ngartner, C., Loeffler, J. M., Pfister, L. A., Tauber, \nM. G., and Leppert, D. (2001). Inhibition of matrix \nmetalloproteinases and tumour necrosis factor \nalpha converting enzyme as adjuvant therapy in \npneumococcal meningitis, Brain 124, 1734-42.\nLeib, S. L., Leppert, D., Clements, J., and Tauber, M. \nG. (2000). Matrix metalloproteinases contribute \nto brain damage in experimental pneumococcal meningitis, Infect Immun 68, 615-20.\nLeishman, A. J., Gapin, L., Capone, M., Palmer, E., \nMacDonald, H. R., Kronenberg, M., and Cherou -\ntre, H. (2002). Precursors of functional MHC class \nI- or class II-restricted CD8alphaalpha(\ue02b) T cells are \npositively selected in the thymus by agonist self-\npeptides, Immunity 16, 355-64.\nLeppert, D., Goodin, D. S., and Aminoff, M. J. \n(2003). Stimulus recognition and its relationship \nto the cerebral event-related potential, Neurology \n61, 1533-7.\nLeppert, D., Leib, S. L., Grygar, C., Miller, K. M., \nSchaad, U. B., and Hollander, G. A. (2000). Matrix \nmetalloproteinase (MMP)-8 and MMP-9 in cerebro -\nspinal fluid during bacterial meningitis: association \nwith blood-brain barrier damage and neurological \nsequelae, Clin Infect Dis 31, 80-4.\nLeppert, D., Lindberg, R. L., Kappos, L., and Leib, S. L. \n(2001). Matrix metalloproteinases: multifunctional \neffectors of inflammation in multiple sclerosis and \nbacterial meningitis, Brain Res Brain Res Rev 36, \n249-57.\nLeppert, D., and Radue, E. W. (2001). Medial medul -\nlary syndrome due to vertebral artery dissection, J \nNeurol Neurosurg Psychiatry 70, 130-1.\nLerch, N., Boesch, N., Mueller, H.J., Malik, N.J. (2000). \nPrader-Willi- und Angelman-Syndrom. Molekular -\ngenetische Diagnostik mittels methylierungsspe -\nzifischer Polymerasekettenreaktion., Monatsschr \nKinderheilkd (2000) 148: 691-695.\nLeu, M., Bellmunt, E., Schwander, M., Farinas, I., Bren -\nner, H. R., and Muller, U. (2003). Erbb2 regulates \nneuromuscular synapse formation and is essential \nfor muscle spindle development, Development \n130, 2291-301.\nLeuppi, J. D., Howarth, N., Janssens, J. P ., and Tamm, \nM. (2003a). [Lung embolism in the elderly], Z Ger -\nontol Geriatr 36, 143-8.\nLeuppi, J. D., Salzberg, M., Meyer, L., Bucher, S. E., \nNief, M., Brutsche, M. H., and Tamm, M. (2003b). \nAn individualized, adjustable maintenance regi -\nmen of budesonide/formoterol provides effective \nasthma symptom control at a lower overall dose \nthan fixed dosing, Swiss Med Wkly 133, 302-9.\nLi, Y ., Hahn, D., Zhong, X. Y ., Thomson, P . D., Holz -\ngreve, W., and Hahn, S. (2003a). Detection of \ndonor-specific DNA polymorphisms in the urine of \nrenal transplant recipients, Clin Chem 49, 655-8.\nLi, Y ., Zhong, X. Y ., Kang, A., Troeger, C., Holzgreve, \nW., and Hahn, S. (2003b). Inability to detect cell \nfree fetal DNA in the urine of normal pregnant \nwomen nor in those affected by preeclampsia as -\nsociated HELLP syndrome, J Soc Gynecol Investig \n10, 503-8.\nLi, Y ., Zimmermann, B., Rusterholz, C., Kang, A., Holz -\ngreve, W., and Hahn, S. (2004). Size separation of \ncirculatory DNA in maternal plasma permits ready \ndetection of fetal DNA polymorphisms, Clin Chem \n50, 1002-11. Epub 2004 Apr 8.\nLi, Y ., Zimmermann, B., Zhong, X. Y ., Gupta, A. K., \nHolzgreve, W., and Hahn, S. (2003c). Determina -\ntion of RHD zygosity using real-time quantitative \nPCR, Swiss Med Wkly 133, 442-5.\nLindberg, R. L., De Groot, C. J., Certa, U., Ravid, \nR., Hoffmann, F ., Kappos, L., and Leppert, D. \n(2004). Multiple sclerosis as a generalized CNS \ndisease-comparative microarray analysis of normal \nappearing white matter and lesions in secondary \nprogressive MS, J Neuroimmunol 152, 154-67.\nLindberg, R. L., De Groot, C. J., Montagne, L., Frei -\ntag, P ., van der Valk, P ., Kappos, L., and Leppert, \nD. (2001). The expression profile of matrix metal -\nloproteinases (MMPs) and their inhibitors (TIMPs) \nin lesions and normal appearing white matter of multiple sclerosis, Brain 124, 1743-53.\nLinscheid, P ., Keller, U., Blau, N., Schaer, D. J., and \nMuller, B. (2003a). Diminished production of \nnitric oxide synthase cofactor tetrahydrobiopterin \nby rosiglitazone in adipocytes, Biochem Pharmacol \n65, 593-8.\nLinscheid, P ., Seboek, D., Nylen, E. S., Langer, I., \nSchlatter, M., Becker, K. L., Keller, U., and Muller, \nB. (2003b). In vitro and in vivo calcitonin I gene \nexpression in parenchymal cells: a novel product \nof human adipose tissue, Endocrinology 144, 5578-\n84. Epub 2003 Aug 21.\nLinscheid, P ., Seboek, D., Nylen, E. S., Langer, I., \nSchlatter, M., Keller, U., Becker, K. L., and Muller, \nB. (2003c). In vitro and in vivo calcitonin-I gene \nexpression in parenchymal cells: a novel product \nof human adipose tissue, Endocrinology 21, 21.\nLinscheid, P ., Seboek, D., Schaer, D. J., Zulewski, H., \nKeller, U., and Muller, B. (2004). Expression and \nsecretion of procalcitonin and calcitonin gene-\nrelated peptide by adherent monocytes and by \nmacrophage-activated adipocytes, Crit Care Med \n32, 1715-21.\nLiu, R., Hintermann, E., Erb, C., Tanner, H., Flammer, J., \nEberle, A. N., and Haefliger, I. O. (2001). Modula -\ntion of Na/K-ATPase activity by isoproterenol and \npropranolol in human non-pigmented ciliary epithe -\nlial cells, Klin Monatsbl Augenheilkd 218, 363-5.\nLiu, S., Asparuhova, M., Brondani, V ., Ziekau, I., \nKlimkait, T., and Schumperli, D. (2004). Inhibition \nof HIV-1 multiplication by antisense U7 snRNAs and \nsiRNAs targeting cyclophilin A, Nucleic Acids Res \n32, 3752-9. Print 2004.\nLook, M., van Putten, W., Duffy, M., Harbeck, \nN., Christensen, I. J., Thomssen, C., Kates, R., \nSpyratos, F ., Ferno, M., Eppenberger-Castori, S., \nFred Sweep, C. G., Ulm, K., Peyrat, J. P ., Martin, \nP . M., Magdelenat, H., Brunner, N., Duggan, C., \nLisboa, B. W., Bendahl, P . O., Quillien, V ., Daver, \nA., Ricolleau, G., Meijer-van Gelder, M., Manders, \nP ., Edward Fiets, W., Blankenstein, M., Broet, P ., \nRomain, S., Daxenbichler, G., Windbichler, G., \nCufer, T., Borstnar, S., Kueng, W., Beex, L., Klijn, \nJ., O\u2019Higgins, N., Eppenberger, U., Janicke, F ., \nSchmitt, M., Foekens, J., and Bendah, P . O. (2003). \nPooled analysis of prognostic impact of uPA and \nPAI-1 in breast cancer patients, Thromb Haemost \n90, 538-48.\nLook, M. P ., van Putten, W. L., Duffy, M. J., Harbeck, \nN., Christensen, I. J., Thomssen, C., Kates, R., \nSpyratos, F ., Ferno, M., Eppenberger-Castori, S., \nSweep, C. G., Ulm, K., Peyrat, J. P ., Martin, P . M., \nMagdelenat, H., Brunner, N., Duggan, C., Lisboa, B. \nW., Bendahl, P . O., Quillien, V ., Daver, A., Ricolleau, \nG., Meijer-van Gelder, M. E., Manders, P ., Fiets, W. \nE., Blankenstein, M. A., Broet, P ., Romain, S., Dax -\nenbichler, G., Windbichler, G., Cufer, T., Borstnar, \nS., Kueng, W., Beex, L. V ., Klijn, J. G., O\u2019Higgins, \nN., Eppenberger, U., Janicke, F ., Schmitt, M., and \nFoekens, J. A. (2002). Pooled analysis of prognostic \nimpact of urokinase-type plasminogen activator and \nits inhibitor PAI-1 in 8377 breast cancer patients, J \nNatl Cancer Inst 94, 116-28.\nLorente, P ., Lacampagne, A., Pouzeratte, Y ., Richards, \nS., Malitschek, B., Kuhn, R., Bettler, B., and Vas -\nsort, G. (2000). gamma-aminobutyric acid type B \nreceptors are expressed and functional in mam -\nmalian cardiomyocytes, Proc Natl Acad Sci U S A 97, 8664-9.\nLuft, T., Maraskovsky, E., Schnurr, M., Knebel, K., Kir -\nsch, M., Gorner, M., Skoda, R., Ho, A. D., Nawroth, \nP ., and Bierhaus, A. (2004). Tuning the volume of \nthe immune response: strength and persistence \nof stimulation determine migration and cytokine \nsecretion of dendritic cells, Blood 104, 1066-74. \nEpub 2004 Apr 27.\nLuther-Wyrsch, A., Costello, E., Thali, M., Buetti, E., \nNissen, C., Surbek, D., Holzgreve, W., Gratwohl, \nA., Tichelli, A., and Wodnar-Filipowicz, A. (2001a). \nStable transduction with lentiviral vectors and am -\nplification of immature hematopoietic progenitors \nfrom cord blood of preterm human fetuses, Hum \nGene Ther 12, 377-89.\nLuther-Wyrsch, A., Nissen, C., Surbek, D. V ., Holz -\ngreve, W., Costello, E., Thali, M., Buetti, E., and \nWodnar-Filipowicz, A. (2001b). Fetal hematopoi -\netic stem cells: in vitro expansion and transduction \nusing lentiviral vectors, Ernst Schering Res Found \nWorkshop, 123-44.\nLuther-Wyrsch, A., Nissen, C., and Wodnar-Filipow -\nicz, A. (2001c). Intracellular Fas ligand is elevated \nin T lymphocytes in severe aplastic anaemia, Br J \nHaematol 114, 884-90.\nLuthy, M., Blumenthal, T. D., Langewitz, W., Kiss, A., \nKeller, U., and Schachinger, H. (2003). Prepulse \ninhibition of the human startle eye blink response \nby visual food cues, Appetite 41, 191-5.\nMackensen, A., Herbst, B., Chen, J. L., Kohler, G., \nNoppen, C., Herr, W., Spagnoli, G. C., Cerundolo, \nV ., and Lindemann, A. (2000). Phase I study in \nmelanoma patients of a vaccine with peptide-\npulsed dendritic cells generated in vitro from \nCD34(\ue02b) hematopoietic progenitor cells, Int J \nCancer 86, 385-92.\nMaclachlan, D., Battegay, M., Jacob, A. L., and Tyndall, \nA. (2000). Successful treatment of hepatitis B-as -\nsociated polyarteritis nodosa with a combination of \nlamivudine and conventional immunosuppressive \ntherapy: a case report, Rheumatology (Oxford) \n39, 106-8.\nMader, I., Roser, W., Kappos, L., Hagberg, G., Seelig, \nJ., Radue, E. W., and Steinbrich, W. (2000). Serial \nproton MR spectroscopy of contrast-enhancing \nmultiple sclerosis plaques: absolute metabolic val -\nues over 2 years during a clinical pharmacological \nstudy, AJNR Am J Neuroradiol 21, 1220-7.\nMaetzler, W., Nitsch, C., Bendfeldt, K., Racay, P ., \nVollenweider, F ., and Schwaller, B. (2004). Ec -\ntopic parvalbumin expression in mouse forebrain \nneurons increases excitotoxic injury provoked by \nibotenic acid injection into the striatum, Exp Neurol \n186, 78-88.\nMahboubi, K., Biedermann, B. C., Carroll, J. M., \nand Pober, J. S. (2000). IL-11 activates human \nendothelial cells to resist immune-mediated injury, \nJ Immunol 164, 3837-46.\nMaillet, P ., Chappuis, P . O., Vaudan, G., Dobbie, Z., \nMuller, H., Hutter, P ., and Sappino, A. P . (2000). \nA polymorphism in the ATM gene modulates the \npenetrance of hereditary non-polyposis colorectal \ncancer, Int J Cancer 88, 928-31.\nMak, T. W., Shahinian, A., Yoshinaga, S. K., Wakeham, \nA., Boucher, L. M., Pintilie, M., Duncan, G., Gajew -\nska, B. U., Gronski, M., Eriksson, U., Odermatt, B., \nHo, A., Bouchard, D., Whorisky, J. S., Jordana, M., \nOhashi, P . S., Pawson, T., Bladt, F ., and Tafuri, A. \n(2003). Costimulation through the inducible cos -\ntimulator ligand is essential for both T helper and B \ncell functions in T cell-dependent B cell responses, 142/143Nat Immunol 4, 765-72.\nMallion, J. M., Chamontin, B., Asmar, R., De Leeuw, P . \nW., O\u2019Brien, E., Duprez, D., O\u2019Rourke, M. F ., Rahn, \nK. H., Romero, R., Battegay, E., Hitzenberger, G., \nand Safar, M. E. (2004). Twenty-four-hour am -\nbulatory blood pressure monitoring efficacy of \nperindopril/indapamide first-line combination in \nhypertensive patients: the REASON study, Am J \nHypertens 17, 245-51.\nMaloy, K. J., Burkhart, C., Junt, T. M., Odermatt, \nB., Oxenius, A., Piali, L., Zinkernagel, R. M., and \nHengartner, H. (2000). CD4(\ue02b) T cell subsets dur -\ning virus infection. Protective capacity depends \non effector cytokine secretion and on migratory \ncapability, J Exp Med 191, 2159-70.\nMamot, C., Mild, G., Reuter, J., Laffer, U., Metzger, \nU., Terracciano, L., Boulay, J. L., Herrmann, R., \nand Rochlitz, C. (2003). Infrequent mutation of \nthe tumour-suppressor gene Smad4 in early-stage \ncolorectal cancer, Br J Cancer 88, 420-3.\nMandriota, S. J., Jussila, L., Jeltsch, M., Compagni, \nA., Baetens, D., Prevo, R., Banerji, S., Huarte, J., \nMontesano, R., Jackson, D. G., Orci, L., Alitalo, K., \nChristofori, G., and Pepper, M. S. (2001). Vascular \nendothelial growth factor-C-mediated lymphang -\niogenesis promotes tumour metastasis, Embo J \n20, 672-82.\nManolova, V ., Hirabayashi, Y ., Mori, L., and De Libero, \nG. (2003). CD1a and CD1b surface expression is \nindependent from de novo synthesized glycosphin -\ngolipids, Eur J Immunol 33, 29-37.\nMantamadiotis, T., Lemberger, T., Bleckmann, S. C., \nKern, H., Kretz, O., Martin Villalba, A., Tronche, F ., \nKellendonk, C., Gau, D., Kapfhammer, J., Otto, C., \nSchmid, W., and Schutz, G. (2002). Disruption of \nCREB function in brain leads to neurodegeneration, \nNat Genet 31, 47-54.\nMarchetti, O., Bille, J., Fluckiger, U., Eggimann, P ., \nRuef, C., Garbino, J., Calandra, T., Glauser, M. P ., \nTauber, M. G., and Pittet, D. (2004). Epidemiology \nof candidemia in Swiss tertiary care hospitals: secu -\nlar trends, 1991-2000, Clin Infect Dis 38, 311-20. \nEpub 2004 Jan 14.\nMarki, Y ., Kaufmann, G. R., Battegay, M., and Klimkait, \nT. (2002). Impact of protease polymorphisms and \nviral fitness on human immunodeficiency virus \n(HIV) type 1 viremia in untreated HIV-1 infection, J \nInfect Dis 185, 1844-6.\nMarra, G., D\u2019Atri, S., Corti, C., Bonmassar, L., Cat -\ntaruzza, M. S., Schweizer, P ., Heinimann, K., Bar -\ntosova, Z., Nystrom-Lahti, M., and Jiricny, J. (2001). \nTolerance of human MSH2\ue02b/- lymphoblastoid cells \nto the methylating agent temozolomide, Proc Natl \nAcad Sci U S A 98, 7164-9.\nMartin, I., and Frank, O. (2004). Real-time quantitative \nrt-PCR assays, Methods Mol Biol 238, 231-8.\nMartin, I., Jakob, M., Schafer, D., Dick, W., Spagnoli, \nG., and Heberer, M. (2001a). Quantitative analysis \nof gene expression in human articular cartilage from \nnormal and osteoarthritic joints, Osteoarthritis Car -\ntilage 9, 112-8.\nMartin, I., Mastrogiacomo, M., De Leo, G., Muraglia, \nA., Beltrame, F ., Cancedda, R., and Quarto, R. \n(2002). Fluorescence microscopy imaging of \nbone for automated histomorphometry, Tissue \nEng 8, 847-52.\nMartin, I., Obradovic, B., Treppo, S., Grodzinsky, A. \nJ., Langer, R., Freed, L. E., and Vunjak-Novakovic, \nG. (2000). Modulation of the mechanical proper -\nties of tissue engineered cartilage, Biorheology 37, 141-7.\nMartin, I., Shastri, V . P ., Padera, R. F ., Yang, J., Mackay, \nA. J., Langer, R., Vunjak-Novakovic, G., and Freed, \nL. E. (2001b). Selective differentiation of mamma -\nlian bone marrow stromal cells cultured on three-\ndimensional polymer foams, J Biomed Mater Res \n55, 229-35.\nMartin, I., Suetterlin, R., Baschong, W., Heberer, M., \nVunjak-Novakovic, G., and Freed, L. E. (2001c). \nEnhanced cartilage tissue engineering by sequen -\ntial exposure of chondrocytes to FGF-2 during 2D \nexpansion and BMP-2 during 3D cultivation, J Cell \nBiochem 83, 121-8.\nMartin, I., Wendt, D., and Heberer, M. (2004). The \nrole of bioreactors in tissue engineering, Trends \nBiotechnol 22, 80-6.\nMartin, R., and Leppert, D. (2004). A plea for \u201com -\nics\u201d research in complex diseases such as multiple \nsclerosis--a change of mind is needed, J Neurol \nSci 222, 3-5.\nMartin-Facklam, M., Drewe, J., and Haefeli, W. E. \n(2000). [Drug interactions with the cytochrome P-\n450 system], Dtsch Med Wochenschr 125, 63-7.\nMartina, B., Dieterle, T., Sigle, J. P ., Surber, C., and \nBattegay, E. (2003). Effects of telmisartan and \nlosartan on left ventricular mass in mild-to-moder -\nate hypertension. A randomized, double-blind trial, \nCardiology 99, 169-70.\nMartinez, J. M., Wagner, K. E., Snider, R. H., Nylen, \nE. S., Muller, B., Sarani, B., Becker, K. L., and \nWhite, J. C. (2001). Late immunoneutralization \nof procalcitonin arrests the progression of lethal \nporcine sepsis, Surg Infect (Larchmt) 2, 193-202; \ndiscussion 202-3.\nMarz, P ., Ozbek, S., Fischer, M., Voltz, N., Otten, U., \nand Rose-John, S. (2002). Differential response of \nneuronal cells to a fusion protein of ciliary neuro -\ntrophic factor/soluble CNTF-receptor and leukemia \ninhibitory factor, Eur J Biochem 269, 3023-31.\nMarz, P ., Probst, A., Lang, S., Schwager, M., Rose-\nJohn, S., Otten, U., and Ozbek, S. (2004). Ataxin-\n10, the spinocerebellar ataxia type 10 neurodegen -\nerative disorder protein, is essential for survival of \ncerebellar neurons, J Biol Chem 279, 35542-50. \nEpub 2004 Jun 16.\nMatt, P ., Bernet, F ., Habicht, J., Gambazzi, F ., Passweg, \nJ., Gratwohl, A., Tamm, M., and Zerkowski, H. R. \n(2003). Short- and long-term outcome after lung \nresection for invasive pulmonary aspergillosis, \nThorac Cardiovasc Surg 51, 221-5.\nMatt, P ., Todorov, A., Grapow, M., and Zerkowski, \nH. R. (2004). Ascending aortic thrombus causing \nstroke, Eur J Cardiothorac Surg 25, 286.\nMatzinger, D., Degen, L., Drewe, J., Meuli, J., Due -\nbendorfer, R., Ruckstuhl, N., D\u2019Amato, M., Rovati, \nL., and Beglinger, C. (2000). The role of long chain \nfatty acids in regulating food intake and cholecysto -\nkinin release in humans, Gut 46, 688-693.\nMaurer, M., Riesen, W., Muser, J., Hulter, H. N., and \nKrapf, R. (2003). Neutralization of Western diet \ninhibits bone resorption independently of K intake \nand reduces cortisol secretion in humans, Am J \nPhysiol Renal Physiol 284, F32-40.\nMaymon, R., Tercanli, S., Dreazen, E., Sartorius, G., \nHolzgreve, W., and Herman, A. (2004). Compari -\nson of pregnancy outcome of euploid fetuses with \nincreased nuchal translucency (NT) expressed in \nNT MoM or delta-NT, Ultrasound Obstet Gynecol \n23, 477-81.\nMayr, M., Nickeleit, V ., Hirsch, H. H., Dickenmann, M., \nMihatsch, M. J., and Steiger, J. (2001). Polyomavi -\nrus BK nephropathy in a kidney transplant recipient: \ncritical issues of diagnosis and management, Am J Kidney Dis 38, E13.\nMcKallip, R. J., Fisher, M., Do, Y ., Szakal, A. K., \nGunthert, U., Nagarkatti, P . S., and Nagarkatti, M. \n(2003). Targeted deletion of CD44v7 exon leads \nto decreased endothelial cell injury but not tumor \ncell killing mediated by interleukin-2-activated \ncytolytic lymphocytes, J Biol Chem 278, 43818-30. \nEpub 2003 Aug 6.\nMeienberg, F ., Battegay, E., Bucher, H. C., and Bat -\ntegay, M. (2001). The use of lipid-lowering agents \nin HIV-infected patients, J HIV Ther 6, 40-4.\nMeienberg, F ., Bucher, H. C., Sponagel, L., Zinker -\nnagel, C., Gyr, N., and Battegay, M. (2002). Anxiety \nin health care workers after exposure to potentially \nHIV-contaminated blood or body fluids, Swiss Med \nWkly 132, 321-4.\nMeier, C., Beat, M., Guglielmetti, M., Christ-Crain, \nM., Staub, J. J., and Kraenzlin, M. (2004a). Resto -\nration of euthyroidism accelerates bone turnover \nin patients with subclinical hypothyroidism: a \nrandomized controlled trial, Osteoporos Int 15, \n209-16. Epub 2004 Jan 16.\nMeier, C., Christ-Crain, M., Guglielmetti, M., Huber, \nP ., Staub, J. J., and Muller, B. (2003a). Prolactin \ndysregulation in women with subclinical hypothy -\nroidism: effect of levothyroxine replacement \ntherapy, Thyroid 13, 979-85.\nMeier, C., Christ-Crain, M., Keller, U., and Staub, J. J. \n(2002a). [Mental changes in hypo- and hyperthy -\nroidism], Dtsch Med Wochenschr 127, 1145-50.\nMeier, C., Staub, J. J., Roth, C. B., Guglielmetti, M., \nKunz, M., Miserez, A. R., Drewe, J., Huber, P ., \nHerzog, R., and Muller, B. (2001a). TSH-controlled \nL-thyroxine therapy reduces cholesterol levels and \nclinical symptoms in subclinical hypothyroidism: a \ndouble blind, placebo-controlled trial (Basel Thy -\nroid Study), J Clin Endocrinol Metab 86, 4860-6.\nMeier, C., Trittibach, P ., Guglielmetti, M., Staub, J. J., \nand Muller, B. (2003b). Serum thyroid stimulating \nhormone in assessment of severity of tissue hy -\npothyroidism in patients with overt primary thyroid \nfailure: cross sectional survey, Bmj 326, 311-2.\nMeier, C. R., Krahenbuhl, S., Schlienger, R. G., and \nJick, H. (2002b). Association between body mass \nindex and liver disorders: an epidemiological study, \nJ Hepatol 37, 741-7.\nMeier, G., Waldherr, C., Herrmann, R., Maecke, H., \nMueller-Brand, J., and Pless, M. (2004b). Success -\nful targeted radiotherapy with 90Y-DOTATOC in a \npatient with Merkel cell carcinoma. A Case Report, \nOncology 66, 160-3.\nMeier, R., Wettstein, A., Drewe, J., and Geiser, H. R. \n(2001b). Fish oil (Eicosapen) is less effective than \nmetronidazole, in combination with pantoprazole \nand clarithromycin, for Helicobacter pylori eradica -\ntion, Aliment Pharmacol Ther 15, 851-5.\nMeins, M., Piosik, P ., Schaeren-Wiemers, N., Franzoni, \nS., Troncoso, E., Kiss, J. Z., Brosamle, C., Schwab, \nM. E., Molnar, Z., and Monard, D. (2001). Pro -\ngressive neuronal and motor dysfunction in mice \noverexpressing the serine protease inhibitor pro -\ntease nexin-1 in postmitotic neurons, J Neurosci \n21, 8830-41.\nMelchers, F ., ten Boekel, E., Seidl, T., Kong, X. C., \nYamagami, T., Onishi, K., Shimizu, T., Rolink, A. G., \nand Andersson, J. (2000). Repertoire selection by \npre-B-cell receptors and B-cell receptors, and ge -\nnetic control of B-cell development from immature \nto mature B cells, Immunol Rev 175, 33-46.\nMeli, D. N., Loeffler, J. M., Baumann, P ., Neumann, \nU., Buhl, T., Leppert, D., and Leib, S. L. (2004). In \npneumococcal meningitis a novel water-soluble in -\nhibitor of matrix metalloproteinases and TNF-alpha \nconverting enzyme attenuates seizures and injury of the cerebral cortex, J Neuroimmunol 151, 6-11.\nMendelowitsch, A. (2001). Microdialysis: intraopera -\ntive and posttraumatic applications in neurosurgery, \nMethods 23, 73-81.\nMendelowitsch, A., Ritz, M. F ., Ros, J., Langemann, \nH., and Gratzl, O. (2001). 17beta-Estradiol reduces \ncortical lesion size in the glutamate excitotoxicity \nmodel by enhancing extracellular lactate: a new \nneuroprotective pathway, Brain Res 901, 230-6.\nMendelowitsch, A., Taussky, P ., Rem, J. A., and \nGratzl, O. (2004). Clinical outcome of standard \nextracranial-intracranial bypass surgery in patients \nwith symptomatic atherosclerotic occlusion of the \ninternal carotid artery, Acta Neurochir (Wien) 146, \n95-101. Epub 2004 Jan 30.\nMerlin, T., Woelky-Bruggmann, R., Fearns, C., Freu -\ndenberg, M., and Landmann, R. (2002). Expression \nand role of CD14 in mice sensitized to lipopolysac -\ncharide by Propionibacterium acnes, Eur J Immunol \n32, 761-72.\nMerlo, A. (2003). Genes and pathways driving gliob -\nlastomas in humans and murine disease models, \nNeurosurg Rev 26, 145-58.\nMerlo, A., and Bettler, B. (2004). Glioblastomas on the \nmove, Sci STKE 2004, pe18.\nMerlo, A., Mueller-Brand, J., and Maecke, H. R. \n(2003). Comparing monoclonal antibodies and \nsmall peptidic hormones for local targeting of ma -\nlignant gliomas, Acta Neurochir Suppl 88, 83-91.\nMetzger, F ., and Kapfhammer, J. P . (2000). Protein ki -\nnase C activity modulates dendritic differentiation \nof rat Purkinje cells in cerebellar slice cultures, Eur \nJ Neurosci 12, 1993-2005.\nMetzger, F ., and Kapfhammer, J. P . (2003). Protein \nkinase C: its role in activity-dependent Purkinje \ncell dendritic development and plasticity, Cerebel -\nlum 2, 206-14.\nMetzger, J., Degen, L. P ., Beglinger, C., Siegemund, \nM., Studer, W., Heberer, M., Harder, F ., and von \nFlue, M. O. (2002). Ileocecal valve as substitute \nfor the missing pyloric sphincter after partial distal \ngastrectomy, Ann Surg 236, 28-36.\nMeyer, M., Belke, D. D., Trost, S. U., Swanson, E., \nDieterle, T., Scott, B., Cary, S. P ., Ho, P ., Bluhm, \nW. F ., McDonough, P . M., Silverman, G. J., and \nDillmann, W. H. (2004). A recombinant antibody \nincreases cardiac contractility by mimicking phos -\npholamban phosphorylation, Faseb J 18, 1312-4. \nEpub 2004 Jun 4.\nMeyer, T., Gabriel, H. H., Ratz, M., Muller, H. J., \nand Kindermann, W. (2001). Anaerobic exercise \ninduces moderate acute phase response, Med Sci \nSports Exerc 33, 549-55.\nMichael, S., Thole, M., Dillmann, R., Fahr, A., Drewe, \nJ., and Fricker, G. (2000). Improvement of intestinal \npeptide absorption by a synthetic bile acid deriva -\ntive, cholylsarcosine, Eur J Pharm Sci 10, 133-40.\nMichos, O., Panman, L., Vintersten, K., Beier, K., Zel -\nler, R., and Zuniga, A. (2004). Gremlin-mediated \nBMP antagonism induces the epithelial-mesen -\nchymal feedback signaling controlling metanephric \nkidney and limb organogenesis, Development 131, \n3401-10. Epub 2004 Jun 16.\nMild, G., Bachmann, F ., Boulay, J. L., Glatz, K., Laffer, \nU., Lowy, A., Metzger, U., Reuter, J., Terracciano, \nL., Herrmann, R., and Rochlitz, C. (2002). DCR3 \nlocus is a predictive marker for 5-fluorouracil-based \nadjuvant chemotherapy in colorectal cancer, Int J \nCancer 102, 254-7.\nMiller, D. H., Thompson, A. J., and Kappos, L. (2001). \nMRI and assessment of treatment in multiple scle -rosis, Brain 124, 1052-3.\nMiller, D. S., Nobmann, S. N., Gutmann, H., Toeroek, \nM., Drewe, J., and Fricker, G. (2000). Xenobiotic \ntransport across isolated brain microvessels stud -\nied by confocal microscopy, Mol Pharmacol 58, \n1357-67.\nMilo-Landesman, D., Surana, M., Berkovich, I., Com -\npagni, A., Christofori, G., Fleischer, N., and Efrat, \nS. (2001). Correction of hyperglycemia in diabetic \nmice transplanted with reversibly immortalized pan -\ncreatic beta cells controlled by the tet-on regulatory \nsystem, Cell Transplant 10, 645-50.\nMilting, H., Janssen, P . M., Wangemann, T., Kogler, \nH., Domeier, E., Seidler, T., Hakim, K., Grapow, \nM., Zeitz, O., Prestle, J., and Zerkowski, H. R. \n(2001). FK506 does not affect cardiac contractility \nand adrenergic response in vitro, Eur J Pharmacol \n430, 299-304.\nMing, X. F ., Stoecklin, G., Lu, M., Looser, R., and Mo -\nroni, C. (2001). Parallel and independent regulation \nof interleukin-3 mRNA turnover by phosphatidyli -\nnositol 3-kinase and p38 mitogen-activated protein \nkinase, Mol Cell Biol 21, 5778-89.\nMiny, P ., Heinimann, K., Tercanli, S., and Holzgreve, \nW. (2003). [Genetic testing in pregnancy], Ther \nUmsch 60, 455-61.\nMiny, P ., Tercanli, S., and Holzgreve, W. (2002). De -\nvelopments in laboratory techniques for prenatal \ndiagnosis, Curr Opin Obstet Gynecol 14, 161-8.\nMiot, S., Crespo, S., and Schifferli, J. A. (2002a). Dis -\ntinct forms of DAF in urine and blood, J Immunol \nMethods 260, 43-53.\nMiot, S., Marfurt, J., Lach-Trifilieff, E., Gonzalez-Rubio, \nC., Lopez-Trascasa, M., Sadallah, S., and Schifferli, \nJ. A. (2002b). The Mechanism of Loss of CR1 dur -\ning Maturation of Erythrocytes Is Different between \nFactor I Deficient Patients and Healthy Donors, \nBlood Cells Mol Dis 29, 200-12.\nMiserez, A. R., Clavaguera, F ., Monsch, A. U., Probst, \nA., and Tolnay, M. (2003). Argyrophilic grain dis -\nease: molecular genetic difference to other four-\nrepeat tauopathies, Acta Neuropathol 29, 29.\nMiserez, A. R., Muller, P . Y ., Barella, L., Barella, S., \nStaehelin, H. B., Leitersdorf, E., Kark, J. D., and \nFriedlander, Y . (2002a). Sterol-regulatory ele -\nment-binding protein (SREBP)-2 contributes to \npolygenic hypercholesterolaemia, Atherosclerosis \n164, 15-26.\nMiserez, A. R., Muller, P . Y ., Barella, L., Schwietert, \nM., Erb, P ., Vernazza, P . L., and Battegay, M. \n(2001). A single-nucleotide polymorphism in the \nsterol-regulatory element-binding protein 1c gene \nis predictive of HIV-related hyperlipoproteinaemia, \nAids 15, 2045-9.\nMiserez, A. R., Muller, P . Y ., and Spaniol, V . (2002b). \nIndinavir inhibits sterol-regulatory element-binding \nprotein-1c-dependent lipoprotein lipase and fatty \nacid synthase gene activations, Aids 16, 1587-94.\nMoalem, G., Gdalyahu, A., Shani, Y ., Otten, U., La -\nzarovici, P ., Cohen, I. R., and Schwartz, M. (2000). \nProduction of neurotrophins by activated T cells: \nimplications for neuroprotective autoimmunity, J \nAutoimmun 15, 331-45.\nMoll, S., Miot, S., Sadallah, S., Gudat, F ., Mihatsch, \nM. J., and Schifferli, J. A. (2001). No complement \nreceptor 1 stumps on podocytes in human glomeru -\nlopathies, Kidney Int 59, 160-8.\nMolyneux, P . D., Barker, G. J., Barkhof, F ., Beckmann, \nK., Dahlke, F ., Filippi, M., Ghazi, M., Hahn, D., \nMacManus, D., Polman, C., Pozzilli, C., Kappos, \nL., Thompson, A. J., Wagner, K., Yousry, T., and \nMiller, D. H. (2001). Clinical-MRI correlations in a \nEuropean trial of interferon beta-1b in secondary progressive MS, Neurology 57, 2191-7.\nMolyneux, P . D., Kappos, L., Polman, C., Pozzilli, C., \nBarkhof, F ., Filippi, M., Yousry, T., Hahn, D., Wagn -\ner, K., Ghazi, M., Beckmann, K., Dahlke, F ., Losseff, \nN., Barker, G. J., Thompson, A. J., and Miller, D. H. \n(2000). The effect of interferon beta-1b treatment \non MRI measures of cerebral atrophy in secondary \nprogressive multiple sclerosis. European Study \nGroup on Interferon beta-1b in secondary progres -\nsive multiple sclerosis, Brain 123, 2256-63.\nMoore, C., Leu, M., Muller, U., and Brenner, H. R. \n(2001). Induction of multiple signaling loops by \nMuSK during neuromuscular synapse formation, \nProc Natl Acad Sci U S A 98, 14655-60.\nMoransard, M., Borges, L. S., Willmann, R., Marangi, \nP . A., Brenner, H. R., Ferns, M. J., and Fuhrer, C. \n(2003). Agrin regulates rapsyn interaction with \nsurface acetylcholine receptors, and this underlies \ncytoskeletal anchoring and clustering, J Biol Chem \n278, 7350-9. Epub 2002 Dec 16.\nMorant, R., Bernhard, J., Dietrich, D., Gillessen, S., \nBonomo, M., Borner, M., Bauer, J., Cerny, T., Roch -\nlitz, C., Wernli, M., Gschwend, A., Hanselmann, S., \nHering, F ., and Schmid, H. P . (2004). Capecitabine \nin hormone-resistant metastatic prostatic carcinoma \n\u2013 a phase II trial, Br J Cancer 90, 1312-7.\nMorawietz, H., Goettsch, W., Szibor, M., Barton, M., \nShaw, S., Hakim, K., Zerkowski, H. R., and Holtz, J. \n(2002a). Angiotensin-converting enzyme inhibitor \ntherapy prevents upregulation of endothelin-con -\nverting enzyme-1 in failing human myocardium, \nBiochem Biophys Res Commun 295, 1057-61.\nMorawietz, H., Goettsch, W., Szibor, M., Barton, M., \nShaw, S., Hakim, K., Zerkowski, H. R., and Holtz, J. \n(2002b). Increased expression of endothelin-con -\nverting enzyme-1 in failing human myocardium, \nClin Sci (Lond) 103, 237S-240S.\nMorawietz, H., Szibor, M., Goettsch, W., Bartling, B., \nBarton, M., Shaw, S., Koerfer, R., Zerkowski, H. R., \nand Holtz, J. (2000). Deloading of the left ventricle \nby ventricular assist device normalizes increased \nexpression of endothelin ET(A) receptors but not \nendothelin-converting enzyme-1 in patients with \nend-stage heart failure, Circulation 102, III188-93.\nMordasini, M. R., Krahenbuhl, S., and Schlienger, R. \nG. (2002). Appropriateness of digoxin level moni -\ntoring, Swiss Med Wkly 132, 506-12.\nMorgenthaler, N. G., Struck, J., Chancerelle, Y ., \nWeglohner, W., Agay, D., Bohuon, C., Suarez-Do -\nmenech, V ., Bergmann, A., and Muller, B. (2003). \nProduction of procalcitonin (PCT) in non-thyroidal \ntissue after LPS injection, Horm Metab Res 35, \n290-5.\nMpandi, M., Otten, L. A., Lavanchy, C., Acha-Orbea, \nH., and Finke, D. (2003). Passive immunization with \nneutralizing antibodies interrupts the mouse mam -\nmary tumor virus life cycle, J Virol 77, 9369-77.\nMueller, C., Buerkle, G., Buettner, H. J., Petersen, \nJ., Perruchoud, A. P ., Eriksson, U., Marsch, S., \nand Roskamm, H. (2002). Prevention of contrast \nmedia-associated nephropathy: randomized com -\nparison of 2 hydration regimens in 1620 patients \nundergoing coronary angioplasty, Arch Intern Med \n162, 329-36.\nMueller, C., and Buser, P . (2002). B-type natriuretic \npeptide (BNP): can it improve our management of \npatients with congestive heart failure?, Swiss Med \nWkly 132, 618-22.\nMueller, C., Huber, P ., Laifer, G., Mueller, B., and Per -\nruchoud, A. P . (2004a). Procalcitonin and the early \ndiagnosis of infective endocarditis, Circulation 109, 144/1451707-10. Epub 2004 Apr 5.\nMueller, C., Scholer, A., Laule-Kilian, K., Martina, \nB., Schindler, C., Buser, P ., Pfisterer, M., and Per -\nruchoud, A. P . (2004b). Use of B-type natriuretic \npeptide in the evaluation and management of acute \ndyspnea, N Engl J Med 350, 647-54.\nMueller, H., Flury, N., Eppenberger-Castori, S., Kueng, \nW., David, F ., and Eppenberger, U. (2000). Poten -\ntial prognostic value of mitogen-activated protein \nkinase activity for disease-free survival of primary \nbreast cancer patients, Int J Cancer 89, 384-8.\nMueller, H. J., Dobbie, Z., Heiinimann, K. (2000). \nFamili\u00e4res Kolorektalkarzinom und genetisches \nScreening., Chir Gastroenterol 2000 16:206-212.\nMulle, C., Sailer, A., Swanson, G. T., Brana, C., \nO\u2019Gorman, S., Bettler, B., and Heinemann, S. F . \n(2000). Subunit composition of kainate receptors \nin hippocampal interneurons, Neuron 28, 475-84.\nMuller, B. (2003). [Weight loss cures advertised in \nthe media: only quackery?], Schweiz Rundsch \nMed Prax 92, 279-83.\nMuller, B., and Abelin, T. (1994). [Evaluation of adver -\ntisements of weight-reducing cures in the press], \nSchweiz Med Wochenschr 124, 749-58.\nMuller, B., and Becker, K. L. (2001). Procalcitonin: how \na hormone became a marker and mediator of sepsis, \nSwiss Med Wkly 131, 595-602.\nMuller, B., Becker, K. L., Kranzlin, M., Schachinger, \nH., Huber, P . R., Nylen, E. S., Snider, R. H., White, \nJ. C., Schmidt-Gayk, H., Zimmerli, W., and Ritz, \nR. (2000a). Disordered calcium homeostasis of \nsepsis: association with calcitonin precursors, Eur \nJ Clin Invest 30, 823-31.\nMuller, B., Becker, K. L., Schachinger, H., Ricken -\nbacher, P . R., Huber, P . R., Zimmerli, W., and Ritz, R. \n(2000b). Calcitonin precursors are reliable markers \nof sepsis in a medical intensive care unit, Crit Care \nMed 28, 977-83.\nMuller, B., Christ-Crain, M., Snider, R., Nylen, E., \nBecker, K.L. (2004). Procalcitonin and C-reactive \nProtein \u2013 a dusty way to the holy grail (letter). Clin \nInfect Dis 2004 (in press).\nMuller, B., Kasper, M., Surber, C., and Imanidis, G. \n(2003a). Permeation, metabolism and site of action \nconcentration of nicotinic acid derivatives in human \nskin. Correlation with topical pharmacological ef -\nfect, Eur J Pharm Sci 20, 181-95.\nMuller, B., Peri, G., Doni, A., Perruchoud, A. P ., \nLandmann, R., Pasqualini, F ., and Mantovani, A. \n(2002a). High circulating levels of the IL-1 type \nII decoy receptor in critically ill patients with \nsepsis: association of high decoy receptor levels \nwith glucocorticoid administration, J Leukoc Biol \n72, 643-9.\nMuller, B., Peri, G., Doni, A., Torri, V ., Landmann, R., \nBottazzi, B., and Mantovani, A. (2001a). Circulat -\ning levels of the long pentraxin PTX3 correlate with \nseverity of infection in critically ill patients, Crit Care \nMed 29, 1404-7.\nMuller, B., Suarez Domenech, V ., White, J.C., Wagner, \nK.E., Snider, R.S., Nylen, E.S., Becker, K.L. (2001). \nCalcitonin precursors: prototypes of hormokines., \nJournal An\u00e4stes Intensivbeh 2001 2: 60-2.\nMuller, B., Tsakiris, D. A., Roth, C. B., Guglielmetti, \nM., Staub, J. J., and Marbet, G. A. (2001b). Hae -\nmostatic profile in hypothyroidism as potential risk \nfactor for vascular or thrombotic disease, Eur J Clin \nInvest 31, 131-7.\nMuller, B., White, J. C., Nylen, E. S., Snider, R. H., \nBecker, K. L., and Habener, J. F . (2001c). Ubiquitous \nexpression of the calcitonin-i gene in multiple tis -\nsues in response to sepsis, J Clin Endocrinol Metab 86, 396-404.\nMuller, B., Zulewski, H., Huber, P ., Ratcliffe, J. G., \nand Staub, J. J. (1995). Impaired action of thyroid \nhormone associated with smoking in women with \nhypothyroidism, N Engl J Med 333, 964-9.\nMuller, C., Kuster, G., Buttner, H. J., and Buser, P . \n(2003b). [B-type natriuretic peptide--current use \nin the diagnosis and management of heart failure], \nHerz 28, 374-9.\nMuller, H., Plasilova, M., Russell, A. M., and Heini -\nmann, K. (2003c). Genetic predisposition as a basis \nfor chemoprevention, surgical and other interven -\ntions in colorectal cancer, Recent Results Cancer \nRes 163, 235-47; discussion 264-6.\nMuller, H. H., Heinimann, K., and Dobbie, Z. (2000c). \nGenetics of hereditary colon cancer \u2013 a basis for \nprevention?, Eur J Cancer 36, 1215-23.\nMuller, H. J., Beier, R., da Palma, J. C., Lanvers, C., \nAhlke, E., von Schutz, V ., Gunkel, M., Horn, A., \nSchrappe, M., Henze, G., Kranz, K., and Boos, \nJ. (2002b). PEG-asparaginase (Oncaspar) 2500 \nU/m(2) BSA in reinduction and relapse treatment \nin the ALL/NHL-BFM protocols, Cancer Chemother \nPharmacol 49, 149-54. Epub 2001 Nov 16.\nMuller, H. J., Beier, R., Loning, L., Blutters-Sawatzki, R., \nDorffel, W., Maass, E., Muller-Weihrich, S., Scheel-\nWalter, H. G., Scherer, F ., Stahnke, K., Schrappe, \nM., Horn, A., Lumkemann, K., and Boos, J. (2001d). \nPharmacokinetics of native Escherichia coli aspara -\nginase (Asparaginase medac) and hypersensitivity \nreactions in ALL-BFM 95 reinduction treatment, Br \nJ Haematol 114, 794-9.\nMuller, H. J., Grubert, M., Hilger, R., Richly, H., Port, \nR., Scheulen, M., and Mross, K. (2002c). The influ -\nence of elevated liver function parameters on the \npharmacokinetics of doxorubicin and epirubicin--a \npopulation based pharmacokinetic study of CESAR-\nAPOH. Central European Society for Anticancer \nDrug Research. Working Group for Pharmacology \nin Oncology and Hematology, Int J Clin Pharmacol \nTher 40, 575-7.\nMuller, H. J., Loning, L., Horn, A., Schwabe, D., \nGunkel, M., Schrappe, M., von Schutz, V ., Henze, \nG., Casimiro da Palma, J., Ritter, J., Pinheiro, J. P ., \nWinkelhorst, M., and Boos, J. (2000d). Pegylated \nasparaginase (Oncaspar) in children with ALL: \ndrug monitoring in reinduction according to the \nALL/NHL-BFM 95 protocols, Br J Haematol 110, \n379-84.\nMuller, H. J., and O\u2019Grady, R. B. (2000). Dimension-\nbased visual attention modulates dual-judgment \naccuracy in Duncan\u2019s (1984) one- versus two-ob -\nject report paradigm, J Exp Psychol Hum Percept \nPerform 26, 1332-51.\nMuller, H. J., Port, R. E., Grubert, M., Hilger, R. A., \nScheulen, M., and Mross, K. (2003d). The influ -\nence of liver metastases on the pharmacokinetics of \ndoxorubicin---a population-based pharmacokinetic \nproject of the CESAR-APOH, Int J Clin Pharmacol \nTher 41, 598-9.\nMuller, H. J., Reimann, B., and Krummenacher, J. \n(2003e). Visual search for singleton feature targets \nacross dimensions: Stimulus- and expectancy-driv -\nen effects in dimensional weighting, J Exp Psychol \nHum Percept Perform 29, 1021-35.\nMuller, H. J., and von Muhlenen, A. (2000). Probing \ndistractor inhibition in visual search: inhibition of \nreturn, J Exp Psychol Hum Percept Perform 26, \n1591-605.\nMuller, H. J., Weckesser, M., and Schober, O. (2000e). \nBilateral renal metastasis in follicular thyroid carci -noma, Nuklearmedizin 39, 45-7.\nMuller, P . Y ., Janovjak, H., Miserez, A. R., and Dob -\nbie, Z. (2002d). Processing of gene expression \ndata generated by quantitative real-time RT-PCR, \nBiotechniques 32, 1372-4, 1376, 1378-9.\nMuller, P . Y ., and Miserez, A. R. (2002). Identification \nof mutations in the gene encoding sterol regulatory \nelement binding protein (SREBP)-2 in hypercholes -\nterolaemic subjects, J Med Genet 39, 271-5.\nMuller-Schweinitzer, E., Brett, W., Zerkowski, H. R., \nand Haefeli, W. E. (2000). The mechanism of cry -\noinjury: In vitro studies on human internal mammary \narteries, Br J Pharmacol 130, 636-40.\nMunsch, S., Biedert, E., and Keller, U. (2003). Evalua -\ntion of a lifestyle change programme for the treat -\nment of obesity in general practice, Swiss Med \nWkly 133, 148-54.\nMuruganathan, R., Krustev, R., Muller, H. J., Mohwald, \nH., Kolaric, B., and Klitzing, R. V . (2004). Foam Films \nStabilized by Dodecyl Maltoside. 1. Film Thickness \nand Free Energy of Film Formation, Langmuir 20, \n6352-6358.\nMyhr, K. M., Sadallah, S., Mollnes, T. E., Meri, S., Ny -\nland, H. I., Schifferli, J., and Vedeler, C. A. (2000). \nInterferon-alpha2a effects on complement activa -\ntion and regulation in MS patients, Acta Neurol \nScand 101, 30-5.\nNaeher, D., Luescher, I. F ., and Palmer, E. (2002). A \nrole for the alpha-chain connecting peptide motif \nin mediating TCR-CD8 cooperation, J Immunol \n169, 2964-70.\nNaguib, M., Flood, P ., McArdle, J. J., and Brenner, \nH. R. (2002). Advances in neurobiology of the \nneuromuscular junction: implications for the an -\nesthesiologist, Anesthesiology 96, 202-31.\nNetsch, M., Gutmann, H., Luescher, S., Brill, S., \nSchmidlin, C.B., Kreuter, M.H., Drewe, J. (2004). \nInhibitory activity of a geen tea extract and some \nof its constituents on multidrug resistance-associ -\nated protein 2 functionality., Planta Medica 2004 \n(in press).\nNeuhaus, P ., Oustanina, S., Loch, T., Kruger, M., \nBober, E., Dono, R., Zeller, R., and Braun, T. (2003). \nReduced mobility of fibroblast growth factor (FGF)-\ndeficient myoblasts might contribute to dystrophic \nchanges in the musculature of FGF2/FGF6/mdx \ntriple-mutant mice, Mol Cell Biol 23, 6037-48.\nNeumann, U., Kubota, H., Frei, K., Ganu, V ., and \nLeppert, D. (2004). Characterization of Mca-Lys-\nPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic \nsubstrate with increased specificity constants for \ncollagenases and tumor necrosis factor converting \nenzyme, Anal Biochem 328, 166-73.\nNeven, P ., Quail, D., Levrier, M., Aguas, F ., The, H. \nS., De Geyter, C., Glant, M. D., Beck, H., Bosio-\nLeGoux, B., Schmitt, H., Hottgenroth, A., and \nNickelsen, T. (2004). Uterine effects of estrogen \nplus progestin therapy and raloxifene: adjudicated \nresults from the EURALOX study, Obstet Gynecol \n103, 881-91.\nNickeleit, V ., Hirsch, H. H., Zeiler, M., Gudat, F ., Prince, \nO., Thiel, G., and Mihatsch, M. J. (2000a). BK-virus \nnephropathy in renal transplants-tubular necrosis, \nMHC-class II expression and rejection in a puzzling \ngame, Nephrol Dial Transplant 15, 324-32.\nNickeleit, V ., Klimkait, T., Binet, I. F ., Dalquen, P ., Del \nZenero, V ., Thiel, G., Mihatsch, M. J., and Hirsch, H. \nH. (2000b). Testing for polyomavirus type BK DNA \nin plasma to identify renal-allograft recipients with \nviral nephropathy, N Engl J Med 342, 1309-15.\nNiemann, B., Rochlitz, C., Herrmann, R., and Pless, M. \n(2004). Toxic encephalopathy induced by capecit -abine, Oncology 66, 331-5.\nNiermann, T., Kern, F ., Erne, P ., and Resink, T. (2000). \nThe glycosyl phosphatidylinositol anchor of human \nT-cadherin binds lipoproteins, Biochem Biophys \nRes Commun 276, 1240-7.\nNiermann, T., Schmutz, S., Erne, P ., and Resink, T. \n(2003). Aryl hydrocarbon receptor ligands repress \nT-cadherin expression in vascular smooth muscle \ncells, Biochem Biophys Res Commun 300, 943-9.\nNikolova, Z., Peng, B., Hubert, M., Seiberling, M., \nKeller, U., Ho, Y . Y ., Schran, H., and Capdeville, R. \n(2004a). Bioequivalence, safety, and tolerability of \nimatinib tablets compared with capsules, Cancer \nChemother Pharmacol 23, 23.\nNikolova, Z., Peng, B., Hubert, M., Sieberling, M., \nKeller, U., Ho, Y . Y ., Schran, H., and Capdeville, R. \n(2004b). Bioequivalence, safety, and tolerability of \nimatinib tablets compared with capsules, Cancer \nChemother Pharmacol 53, 433-8.\nNissen, C., Genitsch, A., Sendelov, S., Dalle Carbon -\nare, V ., and Wodnar-Filipowicz, A. (2000). Cell \ncycling stress in the monocyte line as a risk factor \nfor progression of the aplastic anaemia/paroxysmal \nnocturnal haemoglobinuria syndrome to myelodys -\nplastic syndrome, Acta Haematol 103, 33-40.\nNoppen, C., Levy, F ., Burri, L., Zajac, P ., Remmel, \nE., Schaefer, C., Luscher, U., Heberer, M., and \nSpagnoli, G. C. (2000). Naturally processed and \nconcealed HLA-A2.1-restricted epitopes from \ntumor-associated antigen tyrosinase-related pro -\ntein-2, Int J Cancer 87, 241-6.\nNordmann, A., Blattmann, L., Gallino, A., Khetari, R., \nMartina, B., Muller, P ., Plebani, G., Schmid, H., \nand Battegay, E. (2000a). Systematic, immediate \nin-hospital initiation of lipid-lowering drugs during \nacute coronary events improves lipid control, Eur J \nIntern Med 11, 309-316.\nNordmann, A., Frach, B., Walker, T., Martina, B., and \nBattegay, E. (2000b). Comparison of self-reported \nhome blood pressure measurements with automati -\ncally stored values and ambulatory blood pressure, \nBlood Press 9, 200-5.\nNordmann, A., Heilmbauer, I., Walker, T., Martina, \nB., and Battegay, E. (2001). A case-management \nprogram of medium intensity does not improve \ncardiovascular risk factor control in coronary \nartery disease patients: the Heartcare I trial, Am \nJ Med 110, 543-50.\nNoseworthy, J., Kappos, L., and Daumer, M. (2003). \nCompeting interests in multiple sclerosis research, \nLancet 361, 350-1.\nNoue, P ., Bernabe, J., Rampin, O., Vidament, M., \nDumas, T., Palmer, E., and Magistrini, M. (2001). \nSexual behavior of stallions during in-hand natural \nservice and semen collection: an observation in \nFrench studs, Anim Reprod Sci 68, 161-9.\nNuesch, R., Geigy, N., Schaedler, E., and Battegay, \nM. (2002a). Effect of highly active antiretroviral \ntherapy on hospitalization characteristics of HIV-\ninfected patients, Eur J Clin Microbiol Infect Dis \n21, 684-7.\nNuesch, R., Rahm, G., Rudin, W., Steffen, I., Frei, R., \nRufli, T., and Zimmerli, W. (2002b). Clustering of \nbloodstream infections during maggot debridement \ntherapy using contaminated larvae of Protophormia \nterraenovae, Infection 30, 306-9.\nNuesch, R., Schroeder, K., Dieterle, T., Martina, B., \nand Battegay, E. (2001). Relation between insuf -\nficient response to antihypertensive treatment and \npoor compliance with treatment: a prospective \ncase-control study, Bmj 323, 142-6.\nNutt, S. L., Eberhard, D., Horcher, M., Rolink, A. G., \nand Busslinger, M. (2001). Pax5 determines the \nidentity of B cells from the beginning to the end of B-lymphopoiesis, Int Rev Immunol 20, 65-82.\nNylen, E., Muller, B., Becker, K. L., and Snider, R. \n(2003). The future diagnostic role of procalcitonin \nlevels: the need for improved sensitivity, Clin Infect \nDis 36, 823-4; author reply 826-7.\nNylen, E. S., and Muller, B. (2004). Endocrine changes \nin critical illness, J Intensive Care Med 19, 67-82.\nO\u2019Grady, R. B., and Muller, H. J. (2000). Object-based \nselection operates on a grouped array of locations, \nPercept Psychophys 62, 1655-67.\nO\u2019Rourke, D. A., Liu, Z. X., Sellin, L., Spokes, K., \nZeller, R., and Cantley, L. G. (2000). Hepatocyte \ngrowth factor induces MAPK-dependent formin \nIV translocation in renal epithelial cells, J Am Soc \nNephrol 11, 2212-21.\nObradovic, B., Martin, I., Padera, R. F ., Treppo, S., \nFreed, L. E., and Vunjak-Novakovic, G. (2001). \nIntegration of engineered cartilage, J Orthop Res \n19, 1089-97.\nOertli, D., Marti, W. R., Zajac, P ., Noppen, C., Ko -\ncher, T., Padovan, E., Adamina, M., Schumacher, \nR., Harder, F ., Heberer, M., and Spagnoli, G. \nC. (2002). Rapid induction of specific cytotoxic \nT lymphocytes against melanoma-associated \nantigens by a recombinant vaccinia virus vector \nexpressing multiple immunodominant epitopes \nand costimulatory molecules in vivo, Hum Gene \nTher 13, 569-75.\nOkura, Y ., Brink, M., Itabe, H., Scheidegger, K. J., Ka -\nlangos, A., and Delafontaine, P . (2000). Oxidized \nlow-density lipoprotein is associated with apoptosis \nof vascular smooth muscle cells in human athero -\nsclerotic plaques, Circulation 102, 2680-6.\nOkura, Y ., Brink, M., Zahid, A. A., Anwar, A., and \nDelafontaine, P . (2001). Decreased expression of \ninsulin-like growth factor-1 and apoptosis of vas -\ncular smooth muscle cells in human atherosclerotic \nplaque, J Mol Cell Cardiol 33, 1777-89.\nOlivieri, G., Hess, C., Savaskan, E., Ly, C., Meier, F ., \nBaysang, G., Brockhaus, M., and Muller-Spahn, F . \n(2001). Melatonin protects SHSY5Y neuroblastoma \ncells from cobalt-induced oxidative stress, neuro -\ntoxicity and increased beta-amyloid secretion, J \nPineal Res 31, 320-5.\nOpravil, M., Hirschel, B., Lazzarin, A., Furrer, H., \nChave, J. P ., Yerly, S., Bisset, L. R., Fischer, M., \nVernazza, P ., Bernasconi, E., Battegay, M., Leder -\ngerber, B., Gunthard, H., Howe, C., Weber, R., and \nPerrin, L. (2002). A randomized trial of simplified \nmaintenance therapy with abacavir, lamivudine, and \nzidovudine in human immunodeficiency virus infec -\ntion, J Infect Dis 185, 1251-60. Epub 2002 Apr 1.\nOtten, L. A., Finke, D., and Acha-Orbea, H. (2002). \nCan MMTV exploit TLR4?, Trends Microbiol 10, \n303-5; discussion 305-6.\nOtten, U., Marz, P ., Heese, K., Hock, C., Kunz, D., \nand Rose-John, S. (2001). Signals regulating neu -\nrotrophin expression in glial cells, Prog Brain Res \n132, 545-54.\nOudit, G. Y ., Crackower, M. A., Eriksson, U., Sarao, R., \nKozieradzki, I., Sasaki, T., Irie-Sasaki, J., Gidrewicz, \nD., Rybin, V . O., Wada, T., Steinberg, S. F ., Backx, P . \nH., and Penninger, J. M. (2003). Phosphoinositide \n3-kinase gamma-deficient mice are protected from \nisoproterenol-induced heart failure, Circulation \n108, 2147-52. Epub 2003 Sep 8.\nPache, M., Kaiser, H. J., Akhalbedashvili, N., Lienert, \nC., Dubler, B., Kappos, L., and Flammer, J. (2003). \nExtraocular blood flow and endothelin-1 plasma \nlevels in patients with multiple sclerosis, Eur Neu -rol 49, 164-8.\nPadovan, E., Spagnoli, G. C., Ferrantini, M., and \nHeberer, M. (2002a). IFN-alpha2a induces IP-10/\nCXCL10 and MIG/CXCL9 production in monocyte-\nderived dendritic cells and enhances their capacity \nto attract and stimulate CD8\ue02b effector T cells, J Leu -\nkoc Biol 71, 669-76.\nPadovan, E., Terracciano, L., Certa, U., Jacobs, B., \nReschner, A., Bolli, M., Spagnoli, G. C., Borden, E. \nC., and Heberer, M. (2002b). Interferon stimulated \ngene 15 constitutively produced by melanoma cells \ninduces e-cadherin expression on human dendritic \ncells, Cancer Res 62, 3453-8.\nPagano, A., Rovelli, G., Mosbacher, J., Lohmann, \nT., Duthey, B., Stauffer, D., Ristig, D., Schuler, \nV ., Meigel, I., Lampert, C., Stein, T., Prezeau, L., \nBlahos, J., Pin, J., Froestl, W., Kuhn, R., Heid, J., \nKaupmann, K., and Bettler, B. (2001). C-terminal \ninteraction is essential for surface trafficking but not \nfor heteromeric assembly of GABA(b) receptors, J \nNeurosci 21, 1189-202.\nPalmer, E. (2000). Reader interested in increased pacli -\ntaxel reactions, Oncol Nurs Forum 27, 1353.\nPalmer, E. (2002a). Is Swedish pension reform the \nright medicine for aging Europe?, J Aging Soc \nPolicy 14, 35-52.\nPalmer, E. (2002b). Shc: a dominant player after ten \nseasons, Nat Immunol 3, 710-1.\nPalmer, E. (2003). Negative selection--clearing out \nthe bad apples from the T-cell repertoire, Nat Rev \nImmunol 3, 383-91.\nPanman, L., and Zeller, R. (2003). Patterning the limb \nbefore and after SHH signalling, J Anat 202, 3-12.\nPanozzo, L., Battegay, M., Friedl, A., and Vernazza, P . \nL. (2003). High risk behaviour and fertility desires \namong heterosexual HIV-positive patients with a \nserodiscordant partner--two challenging issues, \nSwiss Med Wkly 133, 124-7.\nPansky, A., Hildebrand, P ., Fasler-Kan, E., Baselgia, L., \nKetterer, S., Beglinger, C., and Heim, M. H. (2000). \nDefective Jak-STAT signal transduction pathway in \nmelanoma cells resistant to growth inhibition by \ninterferon-alpha, Int J Cancer 85, 720-5.\nPapakonstantinou, E., Aletras, A. J., Roth, M., Tamm, \nM., and Karakiulakis, G. (2003). Hypoxia modulates \nthe effects of transforming growth factor-beta iso -\nforms on matrix-formation by primary human lung \nfibroblasts, Cytokine 24, 25-35.\nPapakonstantinou, E., Karakiulakis, G., Tamm, M., \nPerruchoud, A. P ., and Roth, M. (2000). Hypoxia \nmodifies the effect of PDGF on glycosaminoglycan \nsynthesis by primary human lung cells, Am J Physiol \nLung Cell Mol Physiol 279, L825-34.\nPapakonstantinou, E., Roth, M., Kokkas, B., Papa -\ndopoulos, C., and Karakiulakis, G. (2001). Losartan \ninhibits the angiotensin II-induced modifications on \nfibrinolysis and matrix deposition by primary hu -\nman vascular smooth muscle cells, J Cardiovasc \nPharmacol 38, 715-28.\nPapakonstantinou, E., Roth, M., Tamm, M., Eickelberg, \nO., Perruchoud, A. P ., and Karakiulakis, G. (2002). \nHypoxia differentially enhances the effects of \ntransforming growth factor-beta isoforms on the \nsynthesis and secretion of glycosaminoglycans \nby human lung fibroblasts, J Pharmacol Exp Ther \n301, 830-7.\nPenner, I. K., Rausch, M., Kappos, L., Opwis, K., \nand Radu, E. W. (2003). Analysis of impairment \nrelated functional architecture in MS patients \nduring performance of different attention tasks, J \nNeurol 250, 461-72.\nPerl, A. K., Hokuto, I., Impagnatiello, M. A., Christo -\nfori, G., and Whitsett, J. A. (2003). Temporal effects \nof Sprouty on lung morphogenesis, Dev Biol 258, 146/147154-68.\nPeters, F ., Ruszat, R., Hirsch, H. H., Bachmann, A., \nand Spicher, T. (2004). [\u201cIt\u2019s moving inside!\u201d Blad -\nder schistosomiasis], Schweiz Rundsch Med Prax \n93, 116-9.\nPetersen, T. R., Gulland, S., Bettelli, E., Kuchroo, V ., \nPalmer, E., and Backstrom, B. T. (2004). A chimeric \nT cell receptor with super-signaling properties, Int \nImmunol 16, 889-94. Epub 2004 May 17.\nPfister, O., Chklovskaia, E., Jansen, W., Meszaros, K., \nNissen, C., Rahner, C., Hurwitz, N., Bogatcheva, N., \nLyman, S. D., and Wodnar-Filipowicz, A. (2000). \nChronic overexpression of membrane-bound flt3 \nligand by T lymphocytes in severe aplastic anaemia, \nBr J Haematol 109, 211-20.\nPfisterer, M., Buser, P ., Osswald, S., Allemann, U., \nAmann, W., Angehrn, W., Eeckhout, E., Erne, P ., \nEstlinbaum, W., Kuster, G., Moccetti, T., Naegeli, \nB., and Rickenbacher, P . (2003). Outcome of elderly \npatients with chronic symptomatic coronary artery \ndisease with an invasive vs optimized medical treat -\nment strategy: one-year results of the randomized \nTIME trial, Jama 289, 1117-23.\nPfrunder, A., Gutmann, H., Beglinger, C., and Drewe, \nJ. (2003a). Gene expression of CYP3A4, ABC-\ntransporters (MDR1 and MRP1-MRP5) and hPXR \nin three different human colon carcinoma cell lines, \nJ Pharm Pharmacol 55, 59-66.\nPfrunder, A., Schiesser, M., Gerber, S., Haschke, \nM., Bitzer, J., and Drewe, J. (2003b). Interaction \nof St John\u2019s wort with low-dose oral contraceptive \ntherapy: a randomized controlled trial, Br J Clin \nPharmacol 56, 683-90.\nPhilippova, M., Ivanov, D., Tkachuk, V ., Erne, P ., and \nResink, T. J. (2003). Polarisation of T-cadherin to the \nleading edge of migrating vascular cells in vitro: a \nfunction in vascular cell motility?, Histochem Cell \nBiol 120, 353-60. Epub 2003 Oct 25.\nPilcher, C. D., Eron, J. J., Jr., Vemazza, P . L., Battegay, \nM., Harr, T., Yerly, S., Vom, S., and Perrin, L. (2001). \nSexual transmission during the incubation period of \nprimary HIV infection, Jama 286, 1713-4.\nPirovino, S., Zehnder-Gerber, B., Christ-Crain, M., Kel -\nler, U., and Muller, B. (2004). [In Process Citation], \nSchweiz Rundsch Med Prax 93, 428-30.\nPlasilova, M., Chattopadhyay, C., Pal, P ., Schaub, N. \nA., Buechner, S. A., Mueller, H., Miny, P ., Ghosh, \nA., and Heinimann, K. (2004a). Homozygous \nmissense mutation in the lamin A/C gene causes \nautosomal recessive Hutchinson-Gilford progeria \nsyndrome, J Med Genet 41, 609-14.\nPlasilova, M., Russell, A. M., Wanner, A., Wolf, A., Do -\nbbie, Z., Muller, H. J., and Heinimann, K. (2004b). \nExclusion of an extracolonic disease modifier locus \non chromosome 1p33-36 in a large Swiss familial \nadenomatous polyposis kindred, Eur J Hum Genet \n12, 365-71.\nPlekhanova, O. S., Parfyonova, Y . V ., Bibilashvily, R., \nStepanova, V . V ., Erne, P ., Bobik, A., and Tkachuk, \nV . A. (2000). Urokinase plasminogen activator en -\nhances neointima growth and reduces lumen size in \ninjured carotid arteries, J Hypertens 18, 1065-9.\nPless, M. (2000). [Value of chemotherapy in cura -\ntive therapy of head and neck therapy], Hno 48, \n873-6.\nPless, M., Belhadj, K., Menssen, H. D., Kern, W., Coif -\nfier, B., Wolf, J., Herrmann, R., Thiel, E., Bootle, \nD., Sklenar, I., Muller, C., Choi, L., Porter, C., \nand Capdeville, R. (2004). Clinical efficacy, toler -\nability, and safety of SAM486A, a novel polyamine \nbiosynthesis inhibitor, in patients with relapsed or \nrefractory non-Hodgkin\u2019s lymphoma: results from \na phase II multicenter study, Clin Cancer Res 10, 1299-305.\nPless, M., Carlsson, M., Sundelin, C., and Persson, K. \n(2001). Pre-school children with developmental \nco-ordination disorder: self-perceived competence \nand group motor skill intervention, Acta Paediatr \n90, 532-8.\nPless, M., Carlsson, M., Sundelin, C., and Persson, K. \n(2002a). Preschool children with developmental \ncoordination disorder: a short-term follow-up of \nmotor status at seven to eight years of age, Acta \nPaediatr 91, 521-8.\nPless, M., and Chang, B. M. (2003). Rosai-Dorfman \ndisease. Extranodal sinus histiocytosis in three \nco-existing sites. A case report, J Neurooncol 61, \n137-41.\nPless, M., Rizzo, J. F ., 3rd, Lamkin, J. C., and Lessell, \nS. (2000). Concordance of bilateral temporal artery \nbiopsy in giant cell arteritis, J Neuroophthalmol 20, \n216-8.\nPless, M., Rizzo, J. F ., 3rd, and Shang, J. (2002b). \nOrbital apex syndrome: a rare presentation of ex -\ntramedullary hematopoiesis: case report and review \nof literature, J Neurooncol 57, 37-40.\nPless, M., and Zivkovic, S. A. (2002). Neurologic \ncomplications of transplantation, Neurologist 8, \n107-20.\nPletz, M. W., Duda, P . W., Kappos, L., and Steck, A. J. \n(2003). Immune-mediated neuropathies: etiology \nand pathogenic relationship to aging processes, J \nNeuroimmunol 137, 1-11.\nPollmann, S., Weidner, R., Muller, H. J., and von \nCramon, D. Y . (2000). A fronto-posterior network \ninvolved in visual dimension changes, J Cogn Neu -\nrosci 12, 480-94.\nPolman, C., Barkhof, F ., Kappos, L., Pozzilli, C., Sand -\nbrink, R., Dahlke, F ., Jakobs, P ., and Lorenz, A. \n(2003a). Oral interferon beta-1a in relapsing-remit -\nting multiple sclerosis: a double-blind randomized \nstudy, Mult Scler 9, 342-8.\nPolman, C., Kappos, L., White, R., Dahlke, F ., Beck -\nmann, K., Pozzilli, C., Thompson, A., Petkau, J., and \nMiller, D. (2003b). Neutralizing antibodies during \ntreatment of secondary progressive MS with inter -\nferon beta-1b, Neurology 60, 37-43.\nPolman, C. H., Kappos, L., Petkau, J., and Thompson, \nA. (2003c). Neutralising antibodies to interferon \nbeta during the treatment of multiple sclerosis, \nJ Neurol Neurosurg Psychiatry 74, 1162; author \nreply 1162-3.\nPolyakov, A., Palmer, E., Devitt, P . G., and Coventry, \nB. J. (2000). Clinicians and computers: friends or \nfoes?, Teach Learn Med 12, 91-5.\nPrang, P ., Del Turco, D., and Kapfhammer, J. P . (2001). \nRegeneration of entorhinal fibers in mouse slice \ncultures is age dependent and can be stimulated \nby NT-4, GDNF, and modulators of G-proteins and \nprotein kinase C, Exp Neurol 169, 135-47.\nPreiss, M., Besler, K., and Zerkowski, H. R. (2003). \nSuicidal crossbow bolt cardiac injury, Surgery \n133, 228-9.\nPreiss, M., Brett, W., and Zerkowski, H. R. (2001a). \nExtreme annuloaortic dilation of the ascending \naorta, Tex Heart Inst J 28, 160.\nPreiss, M., Habicht, J., Bongartz, G., and Zerkowski, \nH. R. (2001b). Aneurysmal and partially throm -\nbosed orifice of a coronary artery fistula into the \nright atrium combined with patent foramen ovale, \nThorac Cardiovasc Surg 49, 120-1.\nPreiss, M., Hosli, I., Holzgreve, W., and Zerkowski, H. \nR. (2001c). [Aortic dissection in pregnancy in Mar -\nfan syndrome--case report and treatment concept], Z Geburtshilfe Neonatol 205, 110-3.\nPRISMS, T., and 2001., P . o. R. a. D. b. I.-B.-a. S. i. M. \nS. S. G. (2001). Long-term efficacy of interfeeron-\nB-1a in relapsing multiple sclerosis., Neurology \n56(12): 1628-1636.\nPuder, J. J., Atar, M., Muller, B., Pavan, M., Keller, U. \n(2004). Using insulin pen needles up to five times \ndoes not increase pain intensity nor affect needle tip \nshape., Diab Res Clin Pract 2004 (in press).\nPuder, J. J., and Keller, U. (2003). Quality of diabetes \ncare: problem of patient or doctor adherence?, \nSwiss Med Wkly 133, 530-4.\nQuinlivan, E. B., Wang, R. X., Stewart, P . W., Kolmoltri, \nC., Regamey, N., Erb, P ., and Vernazza, P . L. (2001). \nLongitudinal sero-reactivity to human herpesvirus \n8 (KSHV) in the Swiss HIV Cohort 4.7 years before \nKS, J Med Virol 64, 157-66.\nQuong, J., Eppenberger-Castori, S., Moore, D., 3rd, \nScott, G. K., Birrer, M. J., Kueng, W., Eppenberger, \nU., and Benz, C. C. (2002). Age-dependent \nchanges in breast cancer hormone receptors and \noxidant stress markers, Breast Cancer Res Treat \n76, 221-36.\nRadojevic, V ., and Kapfhammer, J. P . (2004). Repair of \nthe entorhino-hippocampal projection in vitro, Exp \nNeurol 188, 11-9.\nRadue, E. W., and Kappos, L. (2003). Vancouver \nConsortium of MS Centers\u2019 Magnetic Resonance \nImaging Guidelines, Int MS J 10, 131-3.\nRadziwill, A. J., Kappos, L., Battegay, M., and Steck, \nA. J. (2000). [Neurological complications of HIV in -\nfection. Review: new diagnostic, therapeutic and \nprognostic aspects], Schweiz Med Wochenschr \n130, 457-70.\nRadziwill, A. J., Kuntzer, T., and Steck, A. J. (2002). \n[Immunopathology and treatments of Guillain-\nBarre syndrome and of chronic inflammatory de -\nmyelinating polyneuropathy], Rev Neurol (Paris) \n158, 301-10.\nRadziwill, A. J., Steck, A. J., Renaud, S., and Fuhr, P . \n(2003). Distal motor latency and residual latency \nas sensitive markers of anti-MAG polyneuropathy, \nJ Neurol 250, 962-6.\nRahner, C., Stieger, B., and Landmann, L. (2000). \nApical endocytosis in rat hepatocytes In situ \ninvolves clathrin, traverses a subapical compart -\nment, and leads to lysosomes, Gastroenterology \n119, 1692-707.\nRaineri, I., Wegmueller, D., Gross, B., Certa, U., and \nMoroni, C. (2004). Roles of AUF1 isoforms, HuR \nand BRF1 in ARE-dependent mRNA turnover \nstudied by RNA interference, Nucleic Acids Res \n32, 1279-88. Print 2004.\nRamirez, J. C., Finke, D., Esteban, M., Kraehenbuhl, J. \nP ., and Acha-Orbea, H. (2003). Tissue distribution \nof the Ankara strain of vaccinia virus (MVA) after \nmucosal or systemic administration, Arch Virol \n148, 827-39.\nRamos, E., Drachenberg, C. B., Portocarrero, M., Wali, \nR., Klassen, D. K., Fink, J. C., Farney, A., Hirsch, \nH., Papadimitriou, J. C., Cangro, C. B., Weir, M. \nR., and Bartlett, S. T. (2002). BK virus nephropa -\nthy diagnosis and treatment: experience at the \nUniversity of Maryland Renal Transplant Program, \nClin Transpl, 143-53.\nRamseier, E., Fehr, J., and Hirsch, H. H. (2004). [In \nProcess Citation], Schweiz Rundsch Med Prax \n93, 1055-7.\nRatz, A. E., von Moos, M., and Drewe, J. (2001). [St. \nJohn\u2019s wort: a pharmaceutical with potentially \ndangerous interactions], Schweiz Rundsch Med Prax 90, 843-9.\nRegamey, N., Hess, V ., Passweg, J., Hess, C., Steiger, \nJ., Erb, P ., Cathomas, G., and Tamm, M. (2004). \nInfection with human herpesvirus 8 and trans -\nplant-associated gammopathy, Transplantation \n77, 1551-4.\nRegeniter, A., Siede, W. H., Scholer, A., Huber, P ., \nFrischmuth, N., and Steiger, J. U. (2000a). Erratum \nto \u201cInterpreting complex urinary patterns with MDI \nLABLINK: a statistical evaluation\u201d, Clin Chim Acta \n301, 229-30.\nRegeniter, A., Siede, W. H., Scholer, A., Huber, P ., Fris -\nchmuth, N., and Steiger, J. U. (2000b). Interpreting \ncomplex urinary patterns with MDI LABLINK: a sta -\ntistical evaluation, Clin Chim Acta 297, 261-73.\nRegeniter, A., Steiger, J. U., Scholer, A., Huber, P . R., \nand Siede, W. H. (2003). Windows to the ward: \ngraphically oriented report forms. Presentation \nof complex, interrelated laboratory data for \nelectrophoresis/immunofixation, cerebrospinal \nfluid, and urinary protein profiles, Clin Chem 49, \n41-50.\nReichenberger, F ., Cathomas, G., Weber, R., Sch -\noenenberger, R., and Tamm, M. (2001a). Recurrent \nfever and pulmonary infiltrates in an HIV-positive \npatient, Respiration 68, 548-54.\nReichenberger, F ., Dickenmann, M., Binet, I., Soler, \nM., Bolliger, C., Steiger, J., Brunner, F ., Thiel, G., \nand Tamm, M. (2001b). Diagnostic yield of bron -\nchoalveolar lavage following renal transplantation, \nTranspl Infect Dis 3, 2-7.\nReichenberger, F ., Eickelberg, O., Wyser, C., Per -\nruchoud, A. P ., Roth, M., and Tamm, M. (2001c). \nDistinct endobronchial expression of matrix-metal -\nloproteinases (MMP) and their endogenous inhibi -\ntors in lung cancer, Swiss Med Wkly 131, 273-9.\nReichenberger, F ., and Tamm, M. (2002). [N-ace -\ntylcystein in the therapy of chronic bronchitis], \nPneumologie 56, 793-7.\nReichenberger, F ., Wyser, C., Gonon, M., Cathomas, \nG., and Tamm, M. (2001d). Pulmonary mucosa-as -\nsociated lymphoid tissue lymphoma in a patient \nwith common variable immunodeficiency syn -\ndrome, Respiration 68, 109-12.\nReichlin, S., Dyson, A., Muller, D., Fischer, A., Fischer, \nH. R., and Beglinger, C. (2003). Potential of tele -\nmedicine in primary care, Curr Probl Dermatol \n32, 76-81.\nRemmel, E., Terracciano, L., Noppen, C., Zajac, P ., \nHeberer, M., Spagnoli, G. C., and Padovan, E. \n(2001). Modulation of dendritic cell phenotype \nand mobility by tumor cells in vitro, Hum Immunol \n62, 39-49.\nRenaud, S., Erne, B., Fuhr, P ., Said, G., Lacroix, C., \nSteck, A. J., and Leppert, D. (2003a). Matrix metal -\nloproteinases-9 and -2 in secondary vasculitic neu -\nropathies, Acta Neuropathol (Berl) 105, 37-42.\nRenaud, S., Gregor, M., Fuhr, P ., Lorenz, D., Deuschl, \nG., Gratwohl, A., and Steck, A. J. (2003b). \nRituximab in the treatment of polyneuropathy as -\nsociated with anti-MAG antibodies, Muscle Nerve \n27, 611-5.\nRende, M., Brizi, E., Conner, J., Treves, S., Censier, \nK., Provenzano, C., Taglialatela, G., Sanna, P . P ., \nand Donato, R. (2000). Nerve growth factor (NGF) \ninfluences differentiation and proliferation of \nmyogenic cells in vitro via TrKA, Int J Dev Neurosci \n18, 869-85.\nReschner, A., Moretta, A., Landmann, R., Heberer, M., \nSpagnoli, G. C., and Padovan, E. (2003). The ester-\nbonded palmitoyl side chains of Pam3CysSerLys4 \nlipopeptide account for its powerful adjuvanticity \nto HLA class I-restricted CD8\ue02b T lymphocytes, Eur J Immunol 33, 2044-52.\nResnick, M. B., Sabo, E., Kondratev, S., Kerner, H., \nSpagnoli, G. C., and Yakirevich, E. (2002). Cancer-\ntestis antigen expression in uterine malignancies \nwith an emphasis on carcinosarcomas and papillary \nserous carcinomas, Int J Cancer 101, 190-5.\nRimoldi, D., Rubio-Godoy, V ., Dutoit, V ., Lienard, D., \nSalvi, S., Guillaume, P ., Speiser, D., Stockert, E., \nSpagnoli, G., Servis, C., Cerottini, J. C., Lejeune, \nF ., Romero, P ., and Valmori, D. (2000a). Efficient \nsimultaneous presentation of NY-ESO-1/LAGE-1 \nprimary and nonprimary open reading frame-de -\nrived CTL epitopes in melanoma, J Immunol 165, \n7253-61.\nRimoldi, D., Salvi, S., Schultz-Thater, E., Spagnoli, \nG. C., and Cerottini, J. C. (2000b). Anti-MAGE-3 \nantibody 57B and anti-MAGE-1 antibody 6C1 can \nbe used to study different proteins of the MAGE-A \nfamily, Int J Cancer 86, 749-51.\nRinnova, M., Hradilek, M., Barinka, C., Weber, J., \nSoucek, M., Vondrasek, J., Klimkait, T., and Kon -\nvalinka, J. (2000). A picomolar inhibitor of resistant \nstrains of human immunodeficiency virus protease \nidentified by a combinatorial approach, Arch Bio -\nchem Biophys 382, 22-30.\nRitz, M. F ., Lechner-Scott, J., Scott, R. J., Fuhr, P ., Malik, \nN., Erne, B., Taylor, V ., Suter, U., Schaeren-Wiem -\ners, N., and Steck, A. J. (2000). Characterisation of \nautoantibodies to peripheral myelin protein 22 in \npatients with hereditary and acquired neuropathies, \nJ Neuroimmunol 104, 155-63.\nRobinson, R. L., Anetseder, M. J., Brancadoro, V ., \nvan Broekhoven, C., Carsana, A., Censier, K., \nFortunato, G., Girard, T., Heytens, L., Hopkins, \nP . M., Jurkat-Rott, K., Klinger, W., Kozak-Ribbens, \nG., Krivosic, R., Monnier, N., Nivoche, Y ., Olthoff, \nD., Rueffert, H., Sorrentino, V ., Tegazzin, V ., and \nMueller, C. R. (2003). Recent advances in the di -\nagnosis of malignant hyperthermia susceptibility: \nhow confident can we be of genetic testing?, Eur J \nHum Genet 11, 342-8.\nRochlitz, C., Dreno, B., Jantscheff, P ., Cavalli, F ., \nSquiban, P ., Acres, B., Baudin, M., Escudier, B., \nHeinzerling, L., Morant, R., Herrmann, R., Dietrich, \nP . Y ., and Dummer, R. (2002). Immunotherapy of \nmetastatic melanoma by intratumoral injections \nof Vero cells producing human IL-2: phase II ran -\ndomized study comparing two dose levels, Cancer \nGene Ther 9, 289-95.\nRochlitz, C., Figlin, R., Squiban, P ., Salzberg, M., Pless, \nM., Herrmann, R., Tartour, E., Zhao, Y ., Bizouarne, \nN., Baudin, M., and Acres, B. (2003). Phase I im -\nmunotherapy with a modified vaccinia virus (MVA) \nexpressing human MUC1 as antigen-specific im -\nmunotherapy in patients with MUC1-positive \nadvanced cancer, J Gene Med 5, 690-9.\nRoelcke, U., Eschle, D., Kappos, L., Moschopulos, M., \nLaeng, R. H., and Buettner, U. W. (2002a). Menin -\ngoradiculitis associated with giant cell arteritis, \nNeurology 59, 1811-2.\nRoelcke, U., Hausmann, O., Merlo, A., Missimer, J., \nMaguire, R. P ., Freitag, P ., Radu, E. W., Weinreich, \nR., Gratzl, O., and Leenders, K. L. (2002b). PET im -\naging drug distribution after intratumoral injection: \nthe case for (124)I-iododeoxyuridine in malignant \ngliomas, J Nucl Med 43, 1444-51.\nRolink, A. G. (2004). B-cell development and pre-\nB-1 cell plasticity in vitro, Methods Mol Biol 271, \n271-81.\nRolink, A. G., Andersson, J., and Melchers, F . (2004). \nMolecular mechanisms guiding late stages of B-cell development, Immunol Rev 197, 41-50.\nRolink, A. G., and Melchers, F . (2000). Precursor B \ncells from Pax-5-deficient mice--stem cells for mac -\nrophages, granulocytes, osteoclasts, dendritic cells, \nnatural killer cells, thymocytes and T cells, Curr Top \nMicrobiol Immunol 251, 21-6.\nRolink, A. G., and Melchers, F . (2002). BAFFled B cells \nsurvive and thrive: roles of BAFF in B-cell develop -\nment, Curr Opin Immunol 14, 266-75.\nRolink, A. G., Schaniel, C., Andersson, J., and Melch -\ners, F . (2001). Selection events operating at various \nstages in B cell development, Curr Opin Immunol \n13, 202-7.\nRolink, A. G., Schaniel, C., Bruno, L., and Melchers, F . \n(2002a). In vitro and in vivo plasticity of Pax5-defi -\ncient pre-B I cells, Immunol Lett 82, 35-40.\nRolink, A. G., Schaniel, C., Busslinger, M., Nutt, S. \nL., and Melchers, F . (2000a). Fidelity and infidelity \nin commitment to B-lymphocyte lineage develop -\nment, Immunol Rev 175, 104-11.\nRolink, A. G., Schaniel, C., and Melchers, F . (2002b). \nStability and plasticity of wild-type and Pax5-defi -\ncient precursor B cells, Immunol Rev 187, 87-95.\nRolink, A. G., Tschopp, J., Schneider, P ., and Melchers, \nF . (2002c). BAFF is a survival and maturation factor \nfor mouse B cells, Eur J Immunol 32, 2004-10.\nRolink, A. G., Winkler, T., Melchers, F ., and Anders -\nson, J. (2000b). Precursor B cell receptor-depend -\nent B cell proliferation and differentiation does not \nrequire the bone marrow or fetal liver environment, \nJ Exp Med 191, 23-32.\nRosen, O., Muller, H. J., Gokbuget, N., Langer, W., \nPeter, N., Schwartz, S., Hahling, D., Hartmann, F ., It -\ntel, T. H., Muck, R., Rothmann, F ., Arnold, R., Boos, \nJ., and Hoelzer, D. (2003). Pegylated asparaginase \nin combination with high-dose methotrexate for \nconsolidation in adult acute lymphoblastic leukae -\nmia in first remission: a pilot study, Br J Haematol \n123, 836-41.\nRosette, C., Werlen, G., Daniels, M. A., Holman, P . \nO., Alam, S. M., Travers, P . J., Gascoigne, N. R., \nPalmer, E., and Jameson, S. C. (2001). The impact \nof duration versus extent of TCR occupancy on T \ncell activation: a revision of the kinetic proofreading \nmodel, Immunity 15, 59-70.\nRoskoden, T., Otten, U., and Schwegler, H. (2004). \nEarly postnatal corticosterone administration regu -\nlates neurotrophins and their receptors in septum \nand hippocampus of the rat, Exp Brain Res 154, \n183-91. Epub 2003 Oct 14.\nRossi, S., Blazar, B. R., Farrell, C. L., Danilenko, D. \nM., Lacey, D. L., Weinberg, K. I., Krenger, W., and \nHollander, G. A. (2002). Keratinocyte growth factor \npreserves normal thymopoiesis and thymic micro -\nenvironment during experimental graft-versus-host \ndisease, Blood 100, 682-91.\nRoth, M. (2004). Budesonide/Formoterol: a view -\npoint., Drugs 2004 64(4): 443-4.\nRoth, M., and Block, L. H. (2000). Distinct effects of \nBroncho-Vaxom (OM-85 BV) on gp130 binding \ncytokines, Thorax 55, 678-84.\nRoth, M., Johnson, P . R., Borger, P ., Bihl, M. P ., Rudiger, \nJ. J., King, G. G., Ge, Q., Hostettler, K., Burgess, J. \nK., Black, J. L., and Tamm, M. (2004). Dysfunctional \ninteraction of C/EBPalpha and the glucocorticoid \nreceptor in asthmatic bronchial smooth-muscle \ncells, N Engl J Med 351, 560-74.\nRoth, M., Johnson, P . R., Rudiger, J. J., King, G. G., \nGe, Q., Burgess, J. K., Anderson, G., Tamm, M., \nand Black, J. L. (2002). Interaction between gluco -\ncorticoids and beta2 agonists on bronchial airway \nsmooth muscle cells through synchronised cellular 148/149signalling, Lancet 360, 1293-9.\nRudiger, J. J., Eriksson, U., Schiller, P ., and Leuppi, \nJ. D. (2002a). [Henoch-Schoenlein syndrome in \nan 80-year-old patient], Dtsch Med Wochenschr \n127, 1382-4.\nRudiger, J. J., Roth, M., Bihl, M. P ., Cornelius, B. C., \nJohnson, M., Ziesche, R., and Block, L. H. (2002b). \nInteraction of C/EBPalpha and the glucocorticoid \nreceptor in vivo and in nontransformed human cells, \nFaseb J 16, 177-84.\nRueckschloss, U., Galle, J., Holtz, J., Zerkowski, H. R., \nand Morawietz, H. (2001). Induction of NAD(P)H \noxidase by oxidized low-density lipoprotein in \nhuman endothelial cells: antioxidative potential \nof hydroxymethylglutaryl coenzyme A reductase \ninhibitor therapy, Circulation 104, 1767-72.\nRuegg, S., Engelter, S., Jeanneret, C., Hetzel, A., \nProbst, A., Steck, A. J., and Lyrer, P . (2003). Bilat -\neral vertebral artery occlusion resulting from giant \ncell arteritis: report of 3 cases and review of the \nliterature, Medicine (Baltimore) 82, 1-12.\nRuegg, S., Stahl, M., Buhlmann, M., Dupont, A., \nLyrer, P . A., Humbel, R. L., and Steck, A. J. (2002). \nCerebellar degeneration and polyglandular autoim -\nmune syndrome with anti-glutamic acid decarboxy -\nlase antibodies, J Neurol 249, 348-50.\nRuegg, S. J., Steck, A. J., and Fuhr, P . (2004). Levetira -\ncetam improves paroxysmal symptoms in a patient \nwith stiff-person syndrome, Neurology 62, 338.\nRueter, F ., Hirsch, H. H., Kunz, F ., Buser, P ., Habicht, \nJ. M., Moch, H., Fluckiger, U., and Zerkowski, H. \nR. (2002). Late Aspergillus fumigatus endomyo -\ncarditis with brain abscess as a lethal complication \nafter heart transplantation, J Heart Lung Transplant \n21, 1242-5.\nRuettimann, E., Vacher, C.-M., van der Putten, H., \nKaupmann, K., Gassmann, M., Bettler, B. (2003). \nAltered hippocampal expression of calbindin D-\n28k and calretinin in GABA B(1)-deficient mice., \nBiochem Pharmacol.\nRufli, T. (2000). 82nd annual meeting of the swiss so -\nciety for dermatology and venereology. september \n14-16, 2000, basel, Dermatology 201, 84-100.\nRuiz-Deya, G., Cheng, S., Palmer, E., Thomas, R., \nand Slakey, D. (2001). Open donor, laparoscopic \ndonor and hand assisted laparoscopic donor ne -\nphrectomy: a comparison of outcomes, J Urol 166, \n1270-3; discussion 1273-4.\nRulifson, I. C., Szot, G. L., Palmer, E., and Bluestone, \nJ. A. (2002). Inability to induce tolerance through \ndirect antigen presentation, Am J Transplant 2, \n510-9.\nRumbo, M., Sierro, F ., Debard, N., Kraehenbuhl, J. P ., \nand Finke, D. (2004). Lymphotoxin beta receptor \nsignaling induces the chemokine CCL20 in intesti -\nnal epithelium, Gastroenterology 127, 213-23.\nRuschitzka, F . T., Wenger, R. H., Stallmach, T., \nQuaschning, T., de Wit, C., Wagner, K., Labug -\nger, R., Kelm, M., Noll, G., Rulicke, T., Shaw, S., \nLindberg, R. L., Rodenwaldt, B., Lutz, H., Bauer, \nC., Luscher, T. F ., and Gassmann, M. (2000). \nNitric oxide prevents cardiovascular disease and \ndetermines survival in polyglobulic mice overex -\npressing erythropoietin, Proc Natl Acad Sci U S \nA 97, 11609-13.\nRust, R. C., Landmann, L., Gosert, R., Tang, B. L., \nHong, W., Hauri, H. P ., Egger, D., and Bienz, K. \n(2001). Cellular COPII proteins are involved in \nproduction of the vesicles that form the poliovirus \nreplication complex, J Virol 75, 9808-18.\nSadallah, S., Heim, M., Hess, C., Klimkait, T., Doppler, \nN., Battegay, M., Schifferli, J.A. (2004a). Contrary \nto HIV, Hepatitis C Virus (HCV) is not associated with erythrocytes., J Hepatol 2004 (in press).\nSadallah, S., Heim, M., Hess, C., Klimkait, T., Doppler, \nN., Battegay, M., Schifferli, J.A. (2004b). Differing \nassociation of HCV and HIV-1 with erythrocytes in \nvivo., J of Hepatology (in press).\nSadallah, S., Hess, C., Trendelenburg, M., Vedeler, \nC., Lopez-Trascasa, M., and Schifferli, J. A. (2003). \nAutoantibodies against complement receptor 1 \n(CD35) in SLE, liver cirrhosis and HIV-infected \npatients, Clin Exp Immunol 131, 174-81.\nSaghatelyan, A. K., Snapyan, M., Gorissen, S., \nMeigel, I., Mosbacher, J., Kaupmann, K., Bettler, \nB., Kornilov, A. V ., Nifantiev, N. E., Sakanyan, V ., \nSchachner, M., and Dityatev, A. (2003). Recogni -\ntion molecule associated carbohydrate inhibits \npostsynaptic GABA(B) receptors: a mechanism for \nhomeostatic regulation of GABA release in periso -\nmatic synapses, Mol Cell Neurosci 24, 271-82.\nSander, A., Guth, A., Brenner, H. R., and Witzemann, \nV . (2000). Gene transfer into individual muscle \nfibers and conditional gene expression in living \nanimals, Cell Tissue Res 301, 397-403.\nSandner, S. E., Salama, A. D., Houser, S. L., Palmer, \nE., Turka, L. A., and Sayegh, M. H. (2003). New \nTCR transgenic model for tracking allospecific \nCD4 T-cell activation and tolerance in vivo, Am J \nTransplant 3, 1242-50.\nSaravanan, K., Schaeren-Wiemers, N., Klein, D., Sand -\nhoff, R., Schwarz, A., Yaghootfam, A., Gieselmann, \nV ., and Franken, S. (2004). Specific downregulation \nand mistargeting of the lipid raft-associated protein \nMAL in a glycolipid storage disorder, Neurobiol Dis \n16, 396-406.\nSarcevic, B., Spagnoli, G. C., Terracciano, L., Schultz-\nThater, E., Heberer, M., Gamulin, M., Krajina, Z., \nOresic, T., Separovic, R., and Juretic, A. (2003). \nExpression of cancer/testis tumor associated anti -\ngens in cervical squamous cell carcinoma, Oncology \n64, 443-9.\nSartori, A. A., Schar, P ., Fitz-Gibbon, S., Miller, J. H., \nand Jiricny, J. (2001). Biochemical characterization \nof uracil processing activities in the hyperther -\nmophilic archaeon Pyrobaculum aerophilum, J \nBiol Chem 276, 29979-86. Epub 2001 Jun 8.\nSatie, A. P ., Rajpert-De Meyts, E., Spagnoli, G. C., \nHenno, S., Olivo, L., Jacobsen, G. K., Rioux-\nLeclercq, N., Jegou, B., and Samson, M. (2002). \nThe cancer-testis gene, NY-ESO-1, is expressed in \nnormal fetal and adult testes and in spermatocytic \nseminomas and testicular carcinoma in situ, Lab \nInvest 82, 775-80.\nSayegh, M. H., Wu, Z., Hancock, W. W., Langmuir, P . \nB., Mata, M., Sandner, S., Kishimoto, K., Sho, M., \nPalmer, E., Mitchell, R. N., and Turka, L. A. (2003). \nAllograft rejection in a new allospecific CD4\ue02b TCR \ntransgenic mouse, Am J Transplant 3, 381-9.\nSchachinger, H., Cox, D., Linder, L., Brody, S., and Kel -\nler, U. (2003). Cognitive and psychomotor function \nin hypoglycemia: response error patterns and retest \nreliability, Pharmacol Biochem Behav 75, 915-20.\nSchachinger, H., Dieterle, T., Martina, B., Haberthur, \nC., Huber, P . R., Bock, A., Drewe, J., and Gyr, \nK. (2004a). Increased renovascular response to \nangiotensin II in persons genetically predisposed \nto arterial hypertension disappears after chronic \nangiotensin-converting enzyme inhibition, J Hy -\npertens 22, 175-80.\nSchachinger, H., Muller, B. U., Strobel, W., Drewe, \nJ., and Ritz, R. (2000). Effect of midazolam on \ntransfer function between beat-to-beat arterial \npressure and inter-beat interval length, Br J Anaesth 84, 316-22.\nSchachinger, H., Port, J., Brody, S., Linder, L., Wilhelm, \nF . H., Huber, P . R., Cox, D., and Keller, U. (2004b). \nIncreased high-frequency heart rate variability \nduring insulin-induced hypoglycaemia in healthy \nhumans, Clin Sci (Lond) 106, 583-8.\nSchaefer, D., Martin, I., Jundt, G., Seidel, J., Heberer, \nM., Grodzinsky, A., Bergin, I., Vunjak-Novakovic, \nG., and Freed, L. E. (2002). Tissue-engineered \ncomposites for the repair of large osteochondral \ndefects, Arthritis Rheum 46, 2524-34.\nSchaefer, D., Martin, I., Shastri, P ., Padera, R. F ., \nLanger, R., Freed, L. E., and Vunjak-Novakovic, \nG. (2000). In vitro generation of osteochondral \ncomposites, Biomaterials 21, 2599-606.\nSchaefer, D. B., Wendt, D., Moretti, M., Jakob, M., Jay, \nG. D., Heberer, M., and Martin, I. (2004). Lubricin \nreduces cartilage-cartilage integration, Biorheology \n41, 503-8.\nSchaer, L., Osswald, S., Fuhr, P ., Leppert, D. (2004). \nAV block III recognised by a neurolist., Neurology \n2004 (in press).\nSchaeren-Wiemers, N., Bonnet, A., Erb, M., Erne, B., \nBartsch, U., Kern, F ., Mantei, N., Sherman, D., and \nSuter, U. (2004). The raft-associated protein MAL \nis required for maintenance of proper axon-glia \ninteractions in the central nervous system, J Cell \nBiol 166, 731-42.\nSchafer, D., Rosso, R., Fricker, R., Spagnoli, G., Jundt, \nG., Gerber, H., and Heberer, M. (2000). Functional \noutcome of transplanted knee joints in dogs, Arch \nOrthop Trauma Surg 120, 426-31.\nSchafer, D., Seidel, J., Martin, I., Jundt, G., Heberer, \nM., Grozinsky, A., Vunjak-Novakovic, G., and \nFreed, L. (2004). [Engineering and characteriza -\ntion of functional osteochondral repair tissue], \nOrthopade 33, 721-6.\nSchaller, B., Radziwill, A. J., and Steck, A. J. (2001). \nSuccessful treatment of Guillain-Barre syndrome \nwith combined administration of interferon-beta-\n1a and intravenous immunoglobulin, Eur Neurol \n46, 167-8.\nSchaniel, C., Bruno, L., Melchers, F ., and Rolink, A. \nG. (2002a). Multiple hematopoietic cell lineages \ndevelop in vivo from transplanted Pax5-deficient \npre-B I-cell clones, Blood 99, 472-8.\nSchaniel, C., Gottar, M., Roosnek, E., Melchers, F ., \nand Rolink, A. G. (2002b). Extensive in vivo self-\nrenewal, long-term reconstitution capacity, and \nhematopoietic multipotency of Pax5-deficient \nprecursor B-cell clones, Blood 99, 2760-6.\nSchaniel, C., Melchers, F ., and Rolink, A. G. (2000). \nThe cluster of ABCD chemokines which organizes \nT cell-dependent B cell responses, Curr Top Micro -\nbiol Immunol 251, 181-9.\nSchaniel, C., Rolink, A. G., and Melchers, F . (2001). \nAttractions and migrations of lymphoid cells in the \norganization of humoral immune responses, Adv \nImmunol 78, 111-68.\nSchar, P . (2001). Spontaneous DNA damage, genome \ninstability, and cancer--when DNA replication es -\ncapes control, Cell 104, 329-32.\nSchar, P ., Fasi, M., and Jessberger, R. (2004). SMC1 \ncoordinates DNA double-strand break repair path -\nways, Nucleic Acids Res 32, 3921-9. Print 2004.\nSchatz, O., Monini, P ., Bugarini, R., Neipel, F ., Schulz, \nT. F ., Andreoni, M., Erb, P ., Eggers, M., Haas, J., \nButto, S., Lukwiya, M., Bogner, J. R., Yaguboglu, \nS., Sheldon, J., Sarmati, L., Goebel, F . D., Hinter -\nmaier, R., Enders, G., Regamey, N., Wernli, M., \nSturzl, M., Rezza, G., and Ensoli, B. (2001). Kaposi\u2019s \nsarcoma-associated herpesvirus serology in Europe \nand Uganda: multicentre study with multiple and novel assays, J Med Virol 65, 123-32.\nSchaub, S., Dickenmann, M., Cynke, E., Bircher, A., \nand Steiger, J. (2002). Prednisone-induced neu -\ntropenia after cadaveric kidney transplantation, \nNephrol Dial Transplant 17, 1119-21.\nScheubel, R. J., Bartling, B., Stein, S., Darmer, \nD., Holtz, J., Pregla, R., Hetzer, R., Koerfer, R., \nZerkowski, H. R., and Silber, R. E. (2001). Age-de -\npendent myocardial reinduction of apoptosis inhibi -\ntors under VAD in heart failure, Thorac Cardiovasc \nSurg 49, 268-72.\nSchiedermaier, P ., Harrison, P ., Arthur, M., Grandt, \nD., Sutton, R., Drewe, J., Larsen, F ., and Sieber, \nC. (2002). Effect of the somatostatin analogue \nlanreotide on meal-stimulated portal blood flow in \npatients with liver cirrhosis, Digestion 65, 56-60.\nSchiesser, M., Holzgreve, W., Lapaire, O., Willi, N., \nLuthi, H., Lopez, R., and Tercanli, S. (2003a). Si -\nrenomelia, the mermaid syndrome--detection in the \nfirst trimester, Prenat Diagn 23, 493-5.\nSchiesser, M., Lapaire, O., Holzgreve, W., and Ter -\ncanli, S. (2003b). Umbilical cord edema associated \nwith patent urachus, Ultrasound Obstet Gynecol \n22, 646-7.\nSchiesser, M., Lapaire, O., Tercanli, S., and Holz -\ngreve, W. (2004). Lost intrauterine devices during \npregnancy: maternal and fetal outcome after ultra -\nsound-guided extraction. An analysis of 82 cases, \nUltrasound Obstet Gynecol 23, 486-9.\nSchlienger, R., Kurmann, M., Drewe, J., Muller-Spahn, \nF ., and Seifritz, E. (2000a). Inhibition of phenpro -\ncoumon anticoagulation by carbamazepine, Eur \nNeuropsychopharmacol 10, 219-21.\nSchlienger, R. G., Keller, M. J., and Krahenbuhl, S. \n(2002). Tolterodine-associated acute mixed liver \ninjury, Ann Pharmacother 36, 817-9.\nSchlienger, R. G., Klink, M. H., Eggenberger, C., and \nDrewe, J. (2000b). Seizures associated with thera -\npeutic doses of venlafaxine and trimipramine, Ann \nPharmacother 34, 1402-5.\nSchlumberger, S. E., Jaggin, V ., Tanner, H., and Eberle, \nA. N. (2002a). Endogenous receptor for melanin-\nconcentrating hormone in human neuroblastoma \nKelly cells, Biochem Biophys Res Commun 298, \n54-9.\nSchlumberger, S. E., Saito, Y ., Giller, T., Hintermann, \nE., Tanner, H., Jaggin, V ., Zumsteg, U., Civelli, \nO., and Eberle, A. N. (2003). Different structural \nrequirements for melanin-concentrating hormone \n(MCH) interacting with rat MCH-R1 (SLC-1) and \nmouse B16 cell MCH-R, J Recept Signal Transduct \nRes 23, 69-81.\nSchlumberger, S. E., Talke-Messerer, C., Zumsteg, U., \nand Eberle, A. N. (2002b). Expression of receptors \nfor melanin-concentrating hormone (MCH) in \ndifferent tissues and cell lines, J Recept Signal \nTransduct Res 22, 509-31.\nSchmid, A., and Hirsch, H. H. (2003). [Highly active \nantiretroviral therapy of HIV patients. ART Cohort \nCollaboration], Internist (Berl) 44, 1597-600.\nSchneider, A., Suman, A., Rossi, L., Barmada, M. \nM., Beglinger, C., Parvin, S., Sattar, S., Ali, L., \nKhan, A. K., Gyr, N., and Whitcomb, D. C. (2002). \nSPINK1/PSTI mutations are associated with tropical \npancreatitis and type II diabetes mellitus in Bangla -\ndesh, Gastroenterology 123, 1026-30.\nSchneider, P ., Takatsuka, H., Wilson, A., Mackay, F ., \nTardivel, A., Lens, S., Cachero, T. G., Finke, D., \nBeermann, F ., and Tschopp, J. (2001). Maturation \nof marginal zone and follicular B cells requires B cell \nactivating factor of the tumor necrosis factor family \nand is independent of B cell maturation antigen, J Exp Med 194, 1691-7.\nSchnyder, A., Krahenbuhl, S., Torok, M., Drewe, J., \nand Huwyler, J. (2004). Targeting of skeletal mus -\ncle in vitro using biotinylated immunoliposomes, \nBiochem J 377, 61-7.\nSchomber, T., Kalberer, C. P ., Wodnar-Filipowicz, A., \nand Skoda, R. C. (2004). Gene silencing by lenti -\nvirus-mediated delivery of siRNA in human CD34\ue02b \ncells, Blood 103, 4511-3. Epub 2004 Feb 26.\nSchoumacher, F ., Glaus, A., Mueller, H., Eppenberger, \nU., Bolliger, B., and Senn, H. J. (2001). BRCA1/2 \nmutations in Swiss patients with familial or early-\nonset breast and ovarian cancer, Swiss Med Wkly \n131, 223-6.\nSchrenk, K., Kapfhammer, J. P ., and Metzger, F . \n(2002). Altered dendritic development of cer -\nebellar Purkinje cells in slice cultures from protein \nkinase Cgamma-deficient mice, Neuroscience \n110, 675-89.\nSchrum, A. G., Turka, L. A., and Palmer, E. (2003). \nSurface T-cell antigen receptor expression and \navailability for long-term antigenic signaling, Im -\nmunol Rev 196, 7-24.\nSchubart, D. B., Rolink, A., Schubart, K., and Matthias, \nP . (2000). Cutting edge: lack of peripheral B cells \nand severe agammaglobulinemia in mice simulta -\nneously lacking Bruton\u2019s tyrosine kinase and the \nB cell-specific transcriptional coactivator OBF-1, J \nImmunol 164, 18-22.\nSchubart, K., Massa, S., Schubart, D., Corcoran, L. \nM., Rolink, A. G., and Matthias, P . (2001). B cell \ndevelopment and immunoglobulin gene tran -\nscription in the absence of Oct-2 and OBF-1, Nat \nImmunol 2, 69-74.\nSchuler, M., Herrmann, R., De Greve, J. L., Stewart, A. \nK., Gatzemeier, U., Stewart, D. J., Laufman, L., Gral -\nla, R., Kuball, J., Buhl, R., Heussel, C. P ., Kommoss, \nF ., Perruchoud, A. P ., Shepherd, F . A., Fritz, M. A., \nHorowitz, J. A., Huber, C., and Rochlitz, C. (2001a). \nAdenovirus-mediated wild-type p53 gene transfer \nin patients receiving chemotherapy for advanced \nnon-small-cell lung cancer: results of a multicenter \nphase II study, J Clin Oncol 19, 1750-8.\nSchuler, V ., Luscher, C., Blanchet, C., Klix, N., Sansig, \nG., Klebs, K., Schmutz, M., Heid, J., Gentry, C., Ur -\nban, L., Fox, A., Spooren, W., Jaton, A. L., Vigouret, \nJ., Pozza, M., Kelly, P . H., Mosbacher, J., Froestl, W., \nKaslin, E., Korn, R., Bischoff, S., Kaupmann, K., van \nder Putten, H., and Bettler, B. (2001b). Epilepsy, hy -\nperalgesia, impaired memory, and loss of pre- and \npostsynaptic GABA(B) responses in mice lacking \nGABA(B(1)), Neuron 31, 47-58.\nSchultz-Thater, E., Noppen, C., Gudat, F ., Durmuller, \nU., Zajac, P ., Kocher, T., Heberer, M., and Spag -\nnoli, G. C. (2000). NY-ESO-1 tumour associated \nantigen is a cytoplasmic protein detectable by spe -\ncific monoclonal antibodies in cell lines and clinical \nspecimens, Br J Cancer 83, 204-8.\nSchumacher, R., Adamina, M., Zurbriggen, R., Bolli, \nM., Padovan, E., Zajac, P ., Heberer, M., and Spag -\nnoli, G. C. (2004). Influenza virosomes enhance \nclass I restricted CTL induction through CD4\ue02b T \ncell activation, Vaccine 22, 714-23.\nSchumacher, T., Hofer, S., Eichhorn, K., Wasner, M., \nZimmerer, S., Freitag, P ., Probst, A., Gratzl, O., Re -\nubi, J. C., Maecke, R., Mueller-Brand, J., and Merlo, \nA. (2002). Local injection of the 90Y-labelled pep -\ntidic vector DOTATOC to control gliomas of WHO \ngrades II and III: an extended pilot study, Eur J Nucl \nMed Mol Imaging 29, 486-93.\nSchumann, H., Holtz, J., Zerkowski, H. R., and \nHatzfeld, M. (2000). Expression of secreted friz -\nzled related proteins 3 and 4 in human ventricular \nmyocardium correlates with apoptosis related gene expression, Cardiovasc Res 45, 720-8.\nSchutz, A., Oertli, D., Marti, W. R., Noppen, C., \nPadovan, E., Spagnoli, G. C., Heberer, M., and \nZajac, P . (2001). Immunogenicity of nonreplicat -\ning recombinant vaccinia expressing HLA-A201 \ntargeted or complete MART-1/Melan-A antigen, \nCancer Gene Ther 8, 655-61.\nSchuurmans, M. M., Hoffmann, F ., Lindberg, R. L., \nand Meyer, U. A. (2001). Zinc mesoporphyrin \nrepresses induced hepatic 5-aminolevulinic acid \nsynthase and reduces heme oxygenase activity in \na mouse model of acute hepatic porphyria, Hepatol -\nogy 33, 1217-22.\nSchwab, R. E., Froidevaux, S., Paku, S., Tejeda, M., \nSzende, B., Pap, A., Beglinger, C., Eberle, A. N., \nand Keri, G. (2001). Antiproliferative efficacy of the \nsomatostatin analogue TT-232 in human melanoma \ncells and tumours, Anticancer Res 21, 71-5.\nSchwarzler, C., Oliferenko, S., and Gunthert, U. \n(2001). Variant isoforms of CD44 are required in \nearly thymocyte development, Eur J Immunol 31, \n2997-3005.\nSeboek, D., Linscheid, P ., Zulewski, H., Langer, I., \nChrist-Crain, M., Keller, U., Muller, B. (2004). \nSomatostatin is expressed and secreted by human \nadipose tissue upon infection and inflammation., J \nClin Endocrinol Metab 2004 (in press).\nSeidl, T., Rolink, A., and Melchers, F . (2001). The \nVpreB protein of the surrogate light-chain can pair \nwith some mu heavy-chains in the absence of the \nlambda 5 protein, Eur J Immunol 31, 1999-2006.\nSell, S. M., White, T., Johnson, P ., Johnson, J., Palmer, \nE., Tullis, C., and Lugemwa, P . R. (2002). An \nimproved assay for genotyping the common Alu \ninsertion in the tissue-type plasminogen activation \ngene PLAT, Genet Test 6, 67-8.\nSendi, P ., Al Maiwenn, J., and Battegay, M. (2004a). \nOptimising the performance of an outpatient set -\nting, Swiss Med Wkly 134, 44-9.\nSendi, P ., Hoffmann, M., Bucher, H. C., Erb, P ., Haller, \nP ., Gyr, N., and Battegay, M. (2003). Intravenous \nopiate maintenance in a cohort of injecting drug \naddicts, Drug Alcohol Depend 69, 183-8.\nSendi, P ., Locher, R., Bucheli, B., and Battegay, M. \n(2004b). The decision to get vaccinated against \ninfluenza, Am J Med 116, 856-8.\nSendi, P ., Locher, R., Bucheli, B., and Battegay, M. \n(2004c). Intranasal influenza vaccine in a work -\ning population, Clin Infect Dis 38, 974-80. Epub \n2004 Mar 15.\nSendi, P ., Palmer, A. J., Gafni, A., and Battegay, M. \n(2001). Highly active antiretroviral therapy: phar -\nmacoeconomic issues in the management of HIV \ninfection, Pharmacoeconomics 19, 709-13.\nSendi, P ., Schellenberg, F ., Ungsedhapand, C., \nKaufmann, G. R., Bucher, H. C., Weber, R., and \nBattegay, M. (2004d). Productivity costs and de -\nterminants of productivity in HIV-infected patients, \nClin Ther 26, 791-800.\nShamshiev, A., Donda, A., Prigozy, T. I., Mori, L., Chig -\norno, V ., Benedict, C. A., Kappos, L., Sonnino, S., \nKronenberg, M., and De Libero, G. (2000). The \nalphabeta T cell response to self-glycolipids shows \na novel mechanism of CD1b loading and a require -\nment for complex oligosaccharides, Immunity 13, \n255-64.\nShamshiev, A., Gober, H. J., Donda, A., Mazorra, Z., \nMori, L., and De Libero, G. (2002). Presentation of \nthe same glycolipid by different CD1 molecules, J \nExp Med 195, 1013-21.\nShastri, V . P ., Martin, I., and Langer, R. (2000). Macro -\nporous polymer foams by hydrocarbon templating, 150/151Proc Natl Acad Sci U S A 97, 1970-5.\nSieber, C. C., Beglinger, C., Bart, S., Tschoepl, M., Cur -\nrie, G., Larsen, F ., and Drewe, J. (2004). Lanreotide \neffect on splanchnic blood flow in healthy subjects: \neffect of the rate of infusion, Clin Pharmacol Ther \n75, 70-9.\nSieber, C. C., Sumanovski, L. T., Stumm, M., van der \nKooij, M., and Battegay, E. (2001). In vivo angio -\ngenesis in normal and portal hypertensive rats: role \nof basic fibroblast growth factor and nitric oxide, J \nHepatol 34, 644-50.\nSieber, O. M., Heinimann, K., Gorman, P ., Lamlum, H., \nCrabtree, M., Simpson, C. A., Davies, D., Neale, K., \nHodgson, S. V ., Roylance, R. R., Phillips, R. K., Bod -\nmer, W. F ., and Tomlinson, I. P . (2002a). Analysis of \nchromosomal instability in human colorectal adeno -\nmas with two mutational hits at APC, Proc Natl Acad \nSci U S A 99, 16910-5. Epub 2002 Dec 16.\nSieber, O. M., Heinimann, K., and Tomlinson, I. P . \n(2003a). Genomic instability--the engine of tum -\norigenesis?, Nat Rev Cancer 3, 701-8.\nSieber, O. M., Lamlum, H., Crabtree, M. D., Rowan, \nA. J., Barclay, E., Lipton, L., Hodgson, S., Thomas, \nH. J., Neale, K., Phillips, R. K., Farrington, S. M., \nDunlop, M. G., Mueller, H. J., Bisgaard, M. L., \nBulow, S., Fidalgo, P ., Albuquerque, C., Scarano, \nM. I., Bodmer, W., Tomlinson, I. P ., and Heinimann, \nK. (2002b). Whole-gene APC deletions cause \nclassical familial adenomatous polyposis, but not \nattenuated polyposis or \u201cmultiple\u201d colorectal \nadenomas, Proc Natl Acad Sci U S A 99, 2954-8. \nEpub 2002 Feb 26.\nSieber, O. M., Lipton, L., Crabtree, M., Heinimann, K., \nFidalgo, P ., Phillips, R. K., Bisgaard, M. L., Orntoft, \nT. F ., Aaltonen, L. A., Hodgson, S. V ., Thomas, H. \nJ., and Tomlinson, I. P . (2003b). Multiple colorectal \nadenomas, classic adenomatous polyposis, and \ngerm-line mutations in MYH, N Engl J Med 348, \n791-9.\nSimon-Vermot, I., and Keller, U. (2000). [Conse -\nquences and complications of obesity], Ther \nUmsch 57, 493-7.\nSkeie, G. O., Mygland, A., Treves, S., Gilhus, N. E., \nAarli, J. A., and Zorzato, F . (2003). Ryanodine \nreceptor antibodies in myasthenia gravis: epitope \nmapping and effect on calcium release in vitro, \nMuscle Nerve 27, 81-9.\nSkoda, R. C. (2004). Chronic myeloproliferative \ndisorders: molecular markers and pathogenesis, \nHematol J 5, S122-5.\nSollberger, M., Erne, B., Sansano, S., Steck, A. J., \nand Schaeren-Wiemers, N. (2002). Characteriza -\ntion of human nerve basal lamina for their binding \nproperties of anti-MAG antibodies, J Neurocytol \n31, 5-14.\nSollberger, M., Fluri, F ., Baumann, T., Sonnet, S., \nTamm, M., Steck, A. J., and Brutsche, M. (2004). \nSuccessful treatment of steroid-refractory neurosar -\ncoidosis with infliximab, J Neurol 251, 760-1.\nSormani, M. P ., Bruzzi, P ., Beckmann, K., Wagner, K., \nMiller, D. H., Kappos, L., and Filippi, M. (2003). MRI \nmetrics as surrogate endpoints for EDSS progres -\nsion in SPMS patients treated with IFN beta-1b, \nNeurology 60, 1462-6.\nSpagnoli, G. C., Kloth, J., Terracciano, L., Trutmann, \nM., Chklovskaia, E., Remmel, E., Noppen, C., Zajac, \nP ., Kocher, T., and Heberer, M. (2000). FLT3 ligand \ngene expression and protein production in human \ncolorectal cancer cell lines and clinical tumor speci -mens, Int J Cancer 86, 238-43.\nSpagnoli, G. C., Zajac, P ., Marti, W. R., Oertli, D., Pa -\ndovan, E., Noppen, C., Kocher, T., Adamina, M., \nand Heberer, M. (2002). Cytotoxic T-cell induction \nin metastatic melanoma patients undergoing recom -\nbinant vaccinia virus-based immuno-gene therapy, \nRecent Results Cancer Res 160, 195-201.\nSpan, P . N., Lindberg, R. L., Manders, P ., Tjan-Hei -\njnen, V . C., Heuvel, J. J., Beex, L. V ., and Sweep, \nC. G. (2004). Tissue inhibitors of metalloproteinase \nexpression in human breast cancer: TIMP-3 is as -\nsociated with adjuvant endocrine therapy success, \nJ Pathol 202, 395-402.\nSpan, P . N., Sweep, C. G., Manders, P ., Beex, L. V ., \nLeppert, D., and Lindberg, R. L. (2003). Matrix \nmetalloproteinase inhibitor reversion-inducing \ncysteine-rich protein with Kazal motifs: a prognostic \nmarker for good clinical outcome in human breast \ncarcinoma, Cancer 97, 2710-5.\nSpaniol, M., Bracher, R., Ha, H. R., Follath, F ., and \nKrahenbuhl, S. (2001a). Toxicity of amiodarone \nand amiodarone analogues on isolated rat liver \nmitochondria, J Hepatol 35, 628-36.\nSpaniol, M., Brooks, H., Auer, L., Zimmermann, \nA., Solioz, M., Stieger, B., and Krahenbuhl, S. \n(2001b). Development and characterization of an \nanimal model of carnitine deficiency, Eur J Biochem \n268, 1876-87.\nSpaniol, M., Kaufmann, P ., Beier, K., Wuthrich, J., \nTorok, M., Scharnagl, H., Marz, W., and Krahen -\nbuhl, S. (2003). Mechanisms of liver steatosis in rats \nwith systemic carnitine deficiency due to treatment \nwith trimethylhydraziniumpropionate, J Lipid Res \n44, 144-53.\nSpiegel, I., Salomon, D., Erne, B., Schaeren-Wiemers, \nN., and Peles, E. (2002). Caspr3 and caspr4, two \nnovel members of the caspr family are expressed in \nthe nervous system and interact with PDZ domains, \nMol Cell Neurosci 20, 283-97.\nSpirig, R., Nicca, D., Werder, V ., Voggensperger, J., \nUnger, M., Bischofberger, I., Kesselring, A., Batte -\ngay, M., and De Geest, S. (2002). [Developing and \nestablishing an expanded and more comprehensive \nHIV/AIDS nursing practice], Pflege 15, 293-9.\nSpycher, C., Klonis, N., Spielmann, T., Kump, E., \nSteiger, S., Tilley, L., and Beck, H. P . (2003). \nMAHRP-1, a novel Plasmodium falciparum his -\ntidine-rich protein, binds ferriprotoporphyrin IX \nand localizes to the Maurer\u2019s clefts, J Biol Chem \n278, 35373-83. Epub 2003 Jun 18.\nStaehelin, C., Rickenbach, M., Low, N., Egger, M., \nLedergerber, B., Hirschel, B., D\u2019Acremont, V ., \nBattegay, M., Wagels, T., Bernasconi, E., Kopp, C., \nand Furrer, H. (2003). Migrants from Sub-Saharan \nAfrica in the Swiss HIV Cohort Study: access to \nantiretroviral therapy, disease progression and \nsurvival, Aids 17, 2237-44.\nSteck, A. J. (2000). Auto-antibody tests in peripheral \nneuropathies: pros and cons, J Neurol 247, 423-8.\nSteck, B., Amsler, F ., Kappos, L., and Burgin, D. (2001). \nGender-specific differences in the process of cop -\ning in families with a parent affected by a chronic \nsomatic disease (e.g. multiple sclerosis), Psychopa -\nthology 34, 236-44.\nSteffen, I., Bienz, K., and Klimkait, T. (2003). [Mod -\nern methods of virus diagnosis], Ther Umsch 60, \n589-94.\nSteiger, D., Bubendorf, L., Oberholzer, M., Tamm, \nM., and Leuppi, J. D. (2004). Ciprofloxacin-in -\nduced acute interstitial pneumonitis, Eur Respir \nJ 23, 172-4.\nSteiger, J. (2000). [In Process Citation], Schweiz Med Wochenschr Suppl 120, 11S.\nSteiger, J., Habicht, J., Dalquen, P ., and Tamm, M. \n(2000). Pulmonary nodules following kidney \ntransplantation, Respiration 67, 104-7.\nSteinhauer, S. R., Siegle, G. J., Condray, R., and Pless, \nM. (2004). Sympathetic and parasympathetic in -\nnervation of pupillary dilation during sustained \nprocessing, Int J Psychophysiol 52, 77-86.\nStevens, M. M., Marini, R. P ., Martin, I., Langer, R., \nand Prasad Shastri, V . (2004). FGF-2 enhances \nTGF-beta1-induced periosteal chondrogenesis, J \nOrthop Res 22, 1114-9.\nStockli, R., and Battegay, M. (2001). [Generalized lym -\nphadenopathy in a 43-year-old patient], Schweiz \nRundsch Med Prax 90, 747-9.\nStockli, R., and Keller, U. (2002). [From obesity to \ndiabetes], Ther Umsch 59, 388-92.\nStockli, R., and Keller, U. (2003). [Effectiveness of \ntherapeutic interventions in obesity], Schweiz \nRundsch Med Prax 92, 1999-2006.\nStoeckli, R., Chanda, R., Langer, I., and Keller, U. \n(2004). Changes of body weight and plasma ghre -\nlin levels after gastric banding and gastric bypass, \nObes Res 12, 346-50.\nStoeckli, T. C., Steffen-Klopfstein, I., Erb, P ., Brown, \nT. M., and Kalish, M. L. (2000). Molecular epide -\nmiology of HIV-1 in Switzerland: evidence for a \nsilent mutation in the C2V3 region distinguishing \nintravenous drug users from homosexual men. \nSwiss HIV Cohort Study, J Acquir Immune Defic \nSyndr 23, 58-67.\nStoecklin, G., Colombi, M., Raineri, I., Leuenberger, \nS., Mallaun, M., Schmidlin, M., Gross, B., Lu, M., \nKitamura, T., and Moroni, C. (2002). Functional \ncloning of BRF1, a regulator of ARE-dependent \nmRNA turnover, Embo J 21, 4709-18.\nStoecklin, G., Gross, B., Ming, X. F ., and Moroni, C. \n(2003a). A novel mechanism of tumor suppression \nby destabilizing AU-rich growth factor mRNA, \nOncogene 22, 3554-61.\nStoecklin, G., Lu, M., Rattenbacher, B., and Moroni, \nC. (2003b). A constitutive decay element promotes \ntumor necrosis factor alpha mRNA degradation via \nan AU-rich element-independent pathway, Mol Cell \nBiol 23, 3506-15.\nStoecklin, G., Ming, X. F ., Looser, R., and Moroni, C. \n(2000). Somatic mRNA turnover mutants implicate \ntristetraprolin in the interleukin-3 mRNA degrada -\ntion pathway, Mol Cell Biol 20, 3753-63.\nStoecklin, G., Stoeckle, P ., Lu, M., Muehlemann, O., \nand Moroni, C. (2001). Cellular mutants define a \ncommon mRNA degradation pathway targeting \ncytokine AU-rich elements, Rna 7, 1578-88.\nStoermer, R., Drewe, J., Dursteler-Mac Farland, K. M., \nHock, C., Mueller-Spahn, F ., Ladewig, D., Stohler, \nR., and Mager, R. (2003). Safety of injectable opioid \nmaintenance treatment for heroin dependence, Biol \nPsychiatry 54, 854-61.\nStoffel, F ., Forster, T. H., Steiger, J., Gasser, T. C., and \nSulser, T. (2002). [Manually-assisted laparoscopic \ndonor nephrectomy], Urologe A 41, 258-62.\nStotz, M., Albrecht, R., Zwicker, G., Drewe, J., and \nUmmenhofer, W. (2003). EMS defibrillation-first \npolicy may not improve outcome in out-of-hospital \ncardiac arrest, Resuscitation 58, 277-82.\nStraumann, A., Rossi, L., Simon, H. U., Heer, P ., Spich -\ntin, H. P ., and Beglinger, C. (2003a). Fragility of the \nesophageal mucosa: a pathognomonic endoscopic \nsign of primary eosinophilic esophagitis?, Gastroin -\ntest Endosc 57, 407-12.\nStraumann, A., Spichtin, H. P ., Grize, L., Bucher, K. A., \nBeglinger, C., and Simon, H. U. (2003b). Natural \nhistory of primary eosinophilic esophagitis: a fol -\nlow-up of 30 adult patients for up to 11.5 years, Gastroenterology 125, 1660-9.\nStrebel, A., Bachmann, F ., Wernli, M., and Erb, P . \n(2002). Tumor necrosis factor-related, apopto -\nsis-inducing ligand supports growth of mouse \nmastocytoma tumors by killing tumor-infiltrating \nmacrophages, Int J Cancer 100, 627-34.\nStrebel, A., Harr, T., Bachmann, F ., Wernli, M., and \nErb, P . (2001). Green fluorescent protein as a novel \ntool to measure apoptosis and necrosis, Cytometry \n43, 126-33.\nStrub, M., Fuhr, P ., and Kappos, L. (2000). [Late mani -\nfestation of radiation injury to the plexus brachialis \nand plexus lumbosacralis], Schweiz Med Wochen -\nschr 130, 1407-12.\nStubiger, N., Crane, I. J., Kotter, I., Lamont, G. R., \nZoeller, M., Gunthert, U., Forrester, J. V ., Zierhut, \nM., and Stiemer, R. H. (2003). Interferon alpha 2a \nin IRPB-derived peptide-induced EAU--part I, Adv \nExp Med Biol 528, 537-40.\nStuen, S., Bergstrom, K., and Palmer, E. (2002). Re -\nduced weight gain due to subclinical Anaplasma \nphagocytophilum (formerly Ehrlichia phagocy -\ntophila) infection, Exp Appl Acarol 28, 209-15.\nSturm, J., Keese, M., Zhang, H., Bonninghoff, R., \nMagdeburg, R., Vajkoczy, P ., Dono, R., Zeller, R., \nand Gretz, N. (2004). Liver regeneration in FGF-\n2-deficient mice: VEGF acts as potential functional \nsubstitute for FGF-2, Liver Int 24, 161-8.\nSuarez, J., Belke, D. D., Gloss, B., Dieterle, T., Mc -\nDonough, P . M., Kim, Y . K., Brunton, L. L., and \nDillmann, W. H. (2004). In vivo adenoviral transfer \nof sorcin reverses cardiac contractile abnormalities \nof diabetic cardiomyopathy, Am J Physiol Heart Circ \nPhysiol 286, H68-75. Epub 2003 Sep 4.\nSulser, T., Gurke, L., Langer, I., Dickenmann, M., \nSteiger, J., Gasser, T. C., and Bachmann, A. (2004). \nRetroperitoneoscopic living-donor nephrectomy: \nfirst clinical experiences in 19 operations, J Endou -\nrol 18, 257-62.\nSun, Y ., Marz, P ., Otten, U., Ge, J., and Rose-John, \nS. (2002). The effect of gp130 stimulation on \nglutamate-induced excitotoxicity in primary hip -\npocampal neurons, Biochem Biophys Res Com -\nmun 295, 532-9.\nSune, C., Brennan, L., Stover, D. R., and Klimkait, T. \n(2004). Effect of polymorphisms on the replica -\ntive capacity of protease inhibitor-resistant HIV-1 \nvariants under drug pressure, Clin Microbiol Infect \n10, 119-26.\nSurbek, D., Seelmann, K., Gratwohl, A., Tichelli, A., \nDrack, G., Hohlfeld, P ., Chapuis, B., Schneider, H., \nHolzgreve, W. (2003). Nabelschnurblutspende: un -\nverwandte Spende, famili\u00e4re (gerichtete) Spende \nund autologe Spende (\u201cPrivate Banking\u201d). Gyn\u00e4kol \nGeburtsh Rundsch 2003 43: 118-21.\nSurbek, D. V ., Aufderhaar, U., and Holzgreve, W. \n(2000a). Umbilical cord blood collection for trans -\nplantation: which technique should be preferred?, \nAm J Obstet Gynecol 183, 1587-8.\nSurbek, D. V ., Danzer, E., Steinmann, C., Tichelli, A., \nWodnar-Filipowicz, A., Hahn, S., and Holzgreve, W. \n(2001a). Effect of preeclampsia on umbilical cord \nblood hematopoietic progenitor-stem cells, Am J \nObstet Gynecol 185, 725-9.\nSurbek, D. V ., Glanzmann, R., Senn, H. P ., Hoesli, \nI., and Holzgreve, W. (2000b). Can cord blood \nbe used for autologous transfusion in preterm \nneonates?, Eur J Pediatr 159, 790-1.\nSurbek, D. V ., Hoesli, I. M., and Holzgreve, W. \n(2000c). Morphology assessed by transvaginal ul -\ntrasonography differs in patients in preterm labor \nwith vs. without bacterial vaginosis, Ultrasound Obstet Gynecol 15, 242-5.\nSurbek, D. V ., and Holzgreve, W. (2001a). Fetal cells \nfrom cord blood as stem cell source: current status \nand possible implications in gynaecologic oncology, \nEur J Gynaecol Oncol 22, 6-12.\nSurbek, D. V ., and Holzgreve, W. (2001b). Prenatal \ntransplantation of hematopoietic stem cells: \noverview, Ernst Schering Res Found Workshop, \n115-22.\nSurbek, D. V ., Holzgreve, W., and Nicolaides, K. H. \n(2001b). Haematopoietic stem cell transplantation \nand gene therapy in the fetus: ready for clinical \nuse?, Hum Reprod Update 7, 85-91.\nSurbek, D. V ., Holzgreve, W., Steinmann, C., Hahn, S., \nGratwohl, A., Wodnar-Filipowicz, A., and Tichelli, \nA. (2000d). Preterm birth and the availability of \ncord blood for HPC transplantation, Transfusion \n40, 817-20.\nSurbek, D. V ., Schatt, S., Holzgreve, W. (2001). Stem \nCell Transplantation and gene therapy inuetro., \nInfusion Therapy and Transfusion Medicine 2001 \n28: 150-8.\nSurbek, D. V ., Steinmann, C., Burk, M., Hahn, S., \nTichelli, A., and Holzgreve, W. (2000e). Devel -\nopmental changes in adhesion molecule expres -\nsions in umbilical cord blood CD34 hematopoietic \nprogenitor and stem cells, Am J Obstet Gynecol \n183, 1152-7.\nSurbek, D. V ., Steinmann, C., Tichelli, A., Wodnar-\nFilipowicz, A., and Holzgreve, W. (2000f). De -\ncreased cord blood yield in post-term pregnancy: \na comparative study, Br J Haematol 110, 235-7.\nSurbek, D. V ., Tercanli, S., and Holzgreve, W. (2000g). \nTransabdominal first trimester embryofetoscopy as \na potential approach to early in utero stem cell trans -\nplantation and gene therapy, Ultrasound Obstet \nGynecol 15, 302-7.\nSurbek, D. V ., Visca, E., Steinmann, C., Tichelli, A., \nSchatt, S., Hahn, S., Gratwohl, A., and Holzgreve, \nW. (2000h). Umbilical cord blood collection be -\nfore placental delivery during cesarean delivery \nincreases cord blood volume and nucleated cell \nnumber available for transplantation, Am J Obstet \nGynecol 183, 218-21.\nSurbek, D. V ., Young, A., Danzer, E., Schoeberlein, \nA., Dudler, L., and Holzgreve, W. (2002). Ultra -\nsound-guided stem cell sampling from the early \novine fetus for prenatal ex vivo gene therapy, Am J \nObstet Gynecol 187, 960-3.\nSzinnai, C., Mottet, C., Gutzwiller, J. P ., Drewe, J., \nBeglinger, C., and Sieber, C. C. (2001). Role of \ngender upon basal and postprandial systemic and \nsplanchnic haemodynamics in humans, Scand J \nGastroenterol 36, 540-4.\nSzinnai, G., Meier, C., Komminoth, P ., and Zumsteg, U. \nW. (2003). Review of multiple endocrine neoplasia \ntype 2A in children: therapeutic results of early thy -\nroidectomy and prognostic value of codon analysis, \nPediatrics 111, E132-9.\nTaillard, C., Greub, G., Weber, R., Pfyffer, G. E., Bod -\nmer, T., Zimmerli, S., Frei, R., Bassetti, S., Rohner, \nP ., Piffaretti, J. C., Bernasconi, E., Bille, J., Telenti, \nA., and Prod\u2019hom, G. (2003). Clinical implications \nof Mycobacterium kansasii species heterogene -\nity: Swiss National Survey, J Clin Microbiol 41, \n1240-4.\nTamm, M., Eich, C., Frei, R., Gilgen, S., Breitenbucher, \nA., and Mordasini, C. (2000). [Inhaled colistin in \ncystic fibrosis], Schweiz Med Wochenschr 130, \n1366-72.\nTamm, M., Traenkle, P ., Grilli, B., Soler, M., Bolliger, \nC. T., Dalquen, P ., and Cathomas, G. (2001). Pul -\nmonary cytomegalovirus infection in immunocom -promised patients, Chest 119, 838-43.\nTardivel, A., Tinel, A., Lens, S., Steiner, Q. G., Sauberli, \nE., Wilson, A., Mackay, F ., Rolink, A. G., Beermann, \nF ., Tschopp, J., and Schneider, P . (2004). The anti-\napoptotic factor Bcl-2 can functionally substitute for \nthe B cell survival but not for the marginal zone B \ncell differentiation activity of BAFF, Eur J Immunol \n34, 509-18.\nTartour, E., Mehtali, M., Sastre-Garau, X., Joyeux, I., \nMathiot, C., Pleau, J. M., Squiban, P ., Rochlitz, C., \nCourtney, M., Jantscheff, P ., Herrmann, R., Pouil -\nlart, P ., Fridman, W. H., and Dorval, T. (2000). Phase \nI clinical trial with IL-2-transfected xenogeneic cells \nadministered in subcutaneous metastatic tumours: \nclinical and immunological findings, Br J Cancer 83, \n1454-61.\nTay, A. G., Farhadi, J., Suetterlin, R., Pierer, G., He -\nberer, M., and Martin, I. (2004). Cell yield, prolif -\neration, and postexpansion differentiation capacity \nof human ear, nasal, and rib chondrocytes, Tissue \nEng 10, 762-70.\nte Welscher, P ., Fernandez-Teran, M., Ros, M. A., \nand Zeller, R. (2002a). Mutual genetic antagonism \ninvolving GLI3 and dHAND prepatterns the verte -\nbrate limb bud mesenchyme prior to SHH signaling, \nGenes Dev 16, 421-6.\nte Welscher, P ., Zuniga, A., Kuijper, S., Drenth, T., \nGoedemans, H. J., Meijlink, F ., and Zeller, R. \n(2002b). Progression of vertebrate limb develop -\nment through SHH-mediated counteraction of \nGLI3, Science 298, 827-30. Epub 2002 Sep 5.\nTerada, N., Ohno, N., Yamakawa, H., Baba, T., Fujii, \nY ., Christofori, G., Ohara, O., and Ohno, S. (2003). \nProtein 4.1B in mouse islets of Langerhans and \nbeta-cell tumorigenesis, Histochem Cell Biol 120, \n277-83. Epub 2003 Sep 9.\nTercanli, S., Miny, P ., Siebert, M. S., Hosli, I., Surbek, \nD. V ., and Holzgreve, W. (2001). Fanconi anemia \nassociated with increased nuchal translucency \ndetected by first-trimester ultrasound, Ultrasound \nObstet Gynecol 17, 160-2.\nTerszowski, G., Jankowski, A., Hendriks, W. J., Rolink, \nA. G., and Kisielow, P . (2001). Within the hemo -\npoietic system, LAR phosphatase is a T cell line -\nage-specific adhesion receptor-like protein whose \nphosphatase activity appears dispensable for T cell \ndevelopment, repertoire selection and function, Eur \nJ Immunol 31, 832-40.\nThomas, S. Y ., Hou, R., Boyson, J. E., Means, T. K., \nHess, C., Olson, D. P ., Strominger, J. L., Brenner, \nM. B., Gumperz, J. E., Wilson, S. B., and Luster, \nA. D. (2003). CD1d-restricted NKT cells express \na chemokine receptor profile indicative of Th1-\ntype inflammatory homing cells, J Immunol 171, \n2571-80.\nThurlimann, B., Hess, D., Koberle, D., Senn, I., Balla -\nbeni, P ., Pagani, O., Perey, L., Aebi, S., Rochlitz, C., \nand Goldhirsch, A. (2004). Anastrozole (\u2018Arimidex\u2019) \nversus tamoxifen as first-line therapy in postmeno -\npausal women with advanced breast cancer: results \nof the double-blind cross-over SAKK trial 21/95--a \nsub-study of the TARGET (Tamoxifen or \u2018Arimidex\u2019 \nRandomized Group Efficacy and Tolerability) trial, \nBreast Cancer Res Treat 85, 247-54.\nThut, M. P ., Uehlinger, D., Steiger, J., and Mihatsch, \nM. J. (2002). [Renal biopsy: standard procedure of \nmodern nephrology], Ther Umsch 59, 110-6.\nTietz, A., Heim, M. H., Eriksson, U., Marsch, S., Ter -\nracciano, L., and Krahenbuhl, S. (2003). Fulminant \nliver failure associated with clarithromycin, Ann \nPharmacother 37, 57-60.\nTietz, A., Tamm, M., and Battegay, M. (2000). Myco -\nbacterium kansasii abscess of the chest wall after \ndrainage of bacterial empyema, Eur J Clin Microbiol 152/153Infect Dis 19, 72-3.\nTissot, J. D., Sanchez, J. C., Vuadens, F ., Scherl, A., \nSchifferli, J. A., Hochstrasser, D. F ., Schneider, P ., \nand Duchosal, M. A. (2002). IgM are associated \nto Sp alpha (CD5 antigen-like), Electrophoresis \n23, 1203-6.\nTodesco, L., Torok, M., Krahenbuhl, S., and Wenk, M. \n(2003). Determination of -3858G--\ue02bA and -164C-\n-\ue02bA genetic polymorphisms of CYP1A2 in blood \nand saliva by rapid allelic discrimination: large \ndifference in the prevalence of the -3858G--\ue02bA \nmutation between Caucasians and Asians, Eur J \nClin Pharmacol 59, 343-6.\nTorok, M., Huwyler, J., Gutmann, H., Fricker, G., and \nDrewe, J. (2003). Modulation of transendothe -\nlial permeability and expression of ATP-binding \ncassette transporters in cultured brain capillary \nendothelial cells by astrocytic factors and cell-cul -\nture conditions, Exp Brain Res 153, 356-65. Epub \n2003 Sep 12.\nTowers, S., Princivalle, A., Billinton, A., Edmunds, M., \nBettler, B., Urban, L., Castro-Lopes, J., and Bowery, \nN. G. (2000). GABAB receptor protein and mRNA \ndistribution in rat spinal cord and dorsal root gan -\nglia, Eur J Neurosci 12, 3201-10.\nTrampuz, A., Widmer, A. F ., Fluckiger, U., Haenggi, \nM., Frei, R., and Zimmerli, W. (2004). Changes in \nthe epidemiology of pneumococcal bacteremia in \na Swiss university hospital during a 15-year period, \n1986-2000, Mayo Clin Proc 79, 604-12.\nTrendelenburg, M., Lutz, H. U., Tissot, J. D., Moll, \nS., Hoffmann, T., and Schifferli, J. A. (2003). \nCryoglobulin/albumin complexes in a patient with \nsevere autoimmune syndrome, Scand J Rheumatol \n32, 367-73.\nTrendelenburg, M., and Schifferli, J. A. (2000a). \n[Apoptosis and C1q: possible explanations for the \npathogenesis of systemic lupus erythematosus], Z \nRheumatol 59, 172-5.\nTrendelenburg, M., and Schifferli, J. A. (2000b). [New \nphysiopathological findings in paraproteinemias], \nSchweiz Med Wochenschr 130, 1639-42.\nTrendelenburg, M., and Schifferli, J. A. (2003). Cry -\noglobulins in chronic hepatitis C virus infection, \nClin Exp Immunol 133, 153-5.\nTreves, S., Feriotto, G., Moccagatta, L., Gambari, \nR., and Zorzato, F . (2000). Molecular cloning, \nexpression, functional characterization, chromo -\nsomal localization, and gene structure of junc -\ntate, a novel integral calcium binding protein of \nsarco(endo)plasmic reticulum membrane, J Biol \nChem 275, 39555-68.\nTreves, S., Franzini-Armstrong, C., Moccagatta, L., \nArnoult, C., Grasso, C., Schrum, A., Ducreux, S., \nZhu, M. X., Mikoshiba, K., Girard, T., Smida-Rezgui, \nS., Ronjat, M., and Zorzato, F . (2004). Junctate is a \nkey element in calcium entry induced by activation \nof InsP3 receptors and/or calcium store depletion, \nJ Cell Biol 166, 537-48. Epub 2004 Aug 9.\nTreves, S., Pouliquin, R., Moccagatta, L., and Zorzato, \nF . (2002). Functional properties of EGFP-tagged \nskeletal muscle calcium-release channel (ryanod -\nine receptor) expressed in COS-7 cells: sensitivity \nto caffeine and 4-chloro-m-cresol, Cell Calcium \n31, 1-12.\nTrkola, A., Kuster, H., Leemann, C., Oxenius, A., \nFagard, C., Furrer, H., Battegay, M., Vernazza, P ., \nBernasconi, E., Weber, R., Hirschel, B., Bonhoeffer, \nS., and Guenthard, H. F . (2004). Humoral immunity \nto HIV-1: Kinetics of antibody responses in chronic \ninfection reflect capacity of immune system to improve viral set point, Blood 8, 8.\nTroeger, C., Gugger, M., Holzgreve, W., and Wight, \nE. (2003a). Correlation of perineal ultrasound and \nlateral chain urethrocystography in the anatomical \nevaluation of the bladder neck, Int Urogynecol J Pel -\nvic Floor Dysfunct 14, 380-4. Epub 2003 Nov 20.\nTroeger, C., Schaub, A. F ., Bernasconi, P ., Hosli, I., and \nHolzgreve, W. (2003b). Spectral analysis of fetal \nheart rate variability in fetuses with supraventricular \nextrasystoles, Fetal Diagn Ther 18, 284-8.\nTruninger, K., Malik, N., Ammann, R. W., Muellhaupt, \nB., Seifert, B., Muller, H. J., and Blum, H. E. (2001). \nMutations of the cystic fibrosis gene in patients \nwith chronic pancreatitis, Am J Gastroenterol 96, \n2657-61.\nTsakiris, J. D., Battegay, E., Heilmbauer, I., Walker, T., \nLindberg, R.L.P ., Nordmann, A., Martina, B., Lep -\npert, D. (2004). Inverse regulation of MMP-9 and \nMMP-2 in long-term follow-up after acute coronary \nsyndrome: lack of correlation with platelet and en -\ndothelial cell activation markers., Vasc Dis Preven -\ntion 2004 (in press).\nUlivieri, C., Peter, A., Orsini, E., Palmer, E., and Baldari, \nC. T. (2001). Defective signaling to Fyn by a T cell \nantigen receptor lacking the alpha -chain connect -\ning peptide motif, J Biol Chem 276, 3574-80. Epub \n2000 Oct 31.\nUllmer, E., Mayr, M., Binet, I., Ebnother-Staub, C., \nDalquen, P ., Soler, M., and Tamm, M. (2000). \nGranulomatous Pneumocystis carinii pneumonia \nin Wegener\u2019s granulomatosis, Eur Respir J 15, \n213-6.\nUnterweger, M., De Geyter, C., Frohlich, J. M., \nBongartz, G., and Wiesner, W. (2002). Three-di -\nmensional dynamic MR-hysterosalpingography; a \nnew, low invasive, radiation-free and less painful \nradiological approach to female infertility, Hum \nReprod 17, 3138-41.\nUrwyler, S., Mosbacher, J., Lingenhoehl, K., Heid, J., \nHofstetter, K., Froestl, W., Bettler, B., and Kaup -\nmann, K. (2001). Positive allosteric modulation \nof native and recombinant gamma-aminobutyric \nacid(B) receptors by 2,6-Di-tert-butyl-4-(3-hy -\ndroxy-2,2-dimethyl-propyl)-phenol (CGP7930) \nand its aldehyde analog CGP13501, Mol Pharma -\ncol 60, 963-71.\nVacher, C. M., and Bettler, B. (2003). GABA(B) re -\nceptors as potential therapeutic targets, Curr Drug \nTarget CNS Neurol Disord 2, 248-59.\nValencia, M., Bentele, M., Vaze, M. B., Herrmann, \nG., Kraus, E., Lee, S. E., Schar, P ., and Haber, J. E. \n(2001). NEJ1 controls non-homologous end joining \nin Saccharomyces cerevisiae, Nature 414, 666-9.\nVallat, J. M., Tabaraud, F ., Sindou, P ., Preux, P . M., \nVandenberghe, A., and Steck, A. (2000). Myelin \nwidenings and MGUS-IgA: an immunoelectron \nmicroscopic study, Ann Neurol 47, 808-11.\nValmori, D., Levy, F ., Miconnet, I., Zajac, P ., Spag -\nnoli, G. C., Rimoldi, D., Lienard, D., Cerundolo, V ., \nCerottini, J. C., and Romero, P . (2000). Induction \nof potent antitumor CTL responses by recombinant \nvaccinia encoding a melan-A peptide analogue, J \nImmunol 164, 1125-31.\nVan Driel, M., Gunthert, U., van Kessel, A. C., Joling, \nP ., Stauder, R., Lokhorst, H. M., and Bloem, A. \nC. (2002). CD44 variant isoforms are involved in \nplasma cell adhesion to bone marrow stromal cells, \nLeukemia 16, 135-43.\nVernez, L., Hopfgartner, G., Wenk, M., and Kra -\nhenbuhl, S. (2003). Determination of carnitine \nand acylcarnitines in urine by high-performance \nliquid chromatography-electrospray ionization ion \ntrap tandem mass spectrometry, J Chromatogr A 984, 203-13.\nVernez, L., Wenk, M., and Krahenbuhl, S. (2004). De -\ntermination of carnitine and acylcarnitines in plasma \nby high-performance liquid chromatography/\nelectrospray ionization ion trap tandem mass \nspectrometry, Rapid Commun Mass Spectrom \n18, 1233-8.\nViardot, A., and Muller, B. (2003). [Vertigo and \narterial hypertension in younger patients. Hy -\nperaldosteronism (Conn syndrome) in diastolic \narterial hypertension, chronic hypokalemia, right \nadrenal gland adenoma], Schweiz Rundsch Med \nPrax 92, 821-2.\nVidament, M., Ecot, P ., Noue, P ., Bourgeois, C., Mag -\nistrini, M., and Palmer, E. (2000). Centrifugation \nand addition of glycerol at 22 degres C instead of 4 \ndegrees C improve post-thaw motility and fertility of \nstallion spermatozoa, Theriogenology 54, 907-19.\nVidament, M., Yvon, J. M., Couty, I., Arnaud, G., \nNguekam-Feugang, J., Noue, P ., Cottron, S., Le \nTellier, A., Noel, F ., Palmer, E., and Magistrini, M. \n(2001). Advances in cryopreservation of stallion \nsemen in modified INRA82, Anim Reprod Sci 68, \n201-18.\nVieira Pinheiro, J. P ., Muller, H. J., Schwabe, D., \nGunkel, M., Casimiro da Palma, J., Henze, G., von \nSchutz, V ., Winkelhorst, M., Wurthwein, G., and \nBoos, J. (2001). Drug monitoring of low-dose PEG-\nasparaginase (Oncaspar) in children with relapsed \nacute lymphoblastic leukaemia, Br J Haematol \n113, 115-9.\nVital, A., Lagueny, A., Julien, J., Ferrer, X., Barat, M., \nHermosilla, E., Rouanet-Larriviere, M., Henry, P ., \nBredin, A., Louiset, P ., Herbelleau, T., Boisseau, \nC., Guiraud-Chaumeil, B., Steck, A., and Vital, \nC. (2000). Chronic inflammatory demyelinating \npolyneuropathy associated with dysglobulinemia: \na peripheral nerve biopsy study in 18 cases, Acta \nNeuropathol (Berl) 100, 63-8.\nVoggensperger, J., Nicca, D., Battegay, M., Zellweger, \nJ. P ., and Spirig, R. (2003). [Smoking cessation for \nHIV infected patients], Pflege 16, 283-8.\nVollenweider, F ., Herrmann, M., Otten, U., and Nitsch, \nC. (2003). Interleukin-6 receptor expression and \nlocalization after transient global ischemia in gerbil \nhippocampus, Neurosci Lett 341, 49-52.\nVollmer, M., Wenzel, F ., DeGeyter, C., Zhang, H., \nHolzgreve, W., and Miny, P . (2000). Assessing the \nchromosome copy number in metaphase II oocytes \nby sequential fluorescence in situ hybridization, J \nAssist Reprod Genet 17, 596-602.\nvon Mach, M. A., and Keller, U. (2001). [Comorbidity \nand physical complaints in morbid obesity], Sch -\nweiz Rundsch Med Prax 90, 1569-74.\nvon Meyenburg, C., Hrupka, B. H., Arsenijevic, D., \nSchwartz, G. J., Landmann, R., and Langhans, W. \n(2004). Role for CD14, TLR2, and TLR4 in bacte -\nrial product-induced anorexia, Am J Physiol Regul \nIntegr Comp Physiol 287, R298-305.\nvon Muhlenen, A., and Muller, H. J. (2000). Perceptual \nintegration of motion and form information: evi -\ndence of parallel-continuous processing, Percept \nPsychophys 62, 517-31.\nvon Muhlenen, A., and Muller, H. J. (2001). Visual \nsearch for motion-form conjunctions: is form dis -\ncriminated within the motion system?, J Exp Psychol \nHum Percept Perform 27, 707-18.\nvon Muhlenen, A., Muller, H. J., and Muller, D. (2003). \nSit-and-wait strategies in dynamic visual search, Psychol Sci 14, 309-14.\nVoss, S., Quail, D., Dawson, A., Backstrom, T., Aguas, \nF ., Erenus, M., The, H. S., Bonnar, J., De Geyter, \nC., Hunter, M., and Nickelsen, T. (2002). A ran -\ndomised, double-blind trial comparing raloxifene \nHCl and continuous combined hormone replace -\nment therapy in postmenopausal women: effects on \ncompliance and quality of life, Bjog 109, 874-85.\nVrtic, F ., Haefeli, W. E., Drewe, J., Krahenbuhl, S., \nand Wenk, M. (2003). Interaction of ibuprofen \nand probenecid with drug metabolizing enzyme \nphenotyping procedures using caffeine as the \nprobe drug, Br J Clin Pharmacol 55, 191-8.\nVunjak-Novakovic, G., Obradovic, B., Martin, I., and \nFreed, L. E. (2002). Bioreactor studies of native \nand tissue engineered cartilage, Biorheology 39, \n259-68.\nWacker, A., Stadler, P ., and Pless, M. (2002). [Chordo -\nmas--diagnostic steps and therapeutic consequenc -\nes], Dtsch Med Wochenschr 127, 1389-91.\nWagner, K. E., Martinez, J. M., Vath, S. D., Snider, \nR. H., Nylen, E. S., Becker, K. L., Muller, B., and \nWhite, J. C. (2002). Early immunoneutralization \nof calcitonin precursors attenuates the adverse \nphysiologic response to sepsis in pigs, Crit Care \nMed 30, 2313-21.\nWaldburger, J. M., Rossi, S., Hollander, G. A., Rode -\nwald, H. R., Reith, W., and Acha-Orbea, H. (2003). \nPromoter IV of the class II transactivator gene is es -\nsential for positive selection of CD4\ue02b T cells, Blood \n101, 3550-9. Epub 2002 Dec 27.\nWaldherr, C., Pless, M., Maecke, H. R., Haldemann, \nA., and Mueller-Brand, J. (2001a). The clinical \nvalue of [90Y-DOTA]-D-Phe1-Tyr3-octreotide \n(90Y-DOTATOC) in the treatment of neuroendo -\ncrine tumours: a clinical phase II study, Ann Oncol \n12, 941-5.\nWaldherr, C., Pless, M., Maecke, H. R., Schumacher, \nT., Crazzolara, A., Nitzsche, E. U., Haldemann, A., \nand Mueller-Brand, J. (2002). Tumor response and \nclinical benefit in neuroendocrine tumors after 7.4 \nGBq (90)Y-DOTATOC, J Nucl Med 43, 610-6.\nWaldherr, C., Schumacher, T., Pless, M., Crazzolara, \nA., Maecke, H. R., Nitzsche, E. U., Haldemann, \nA., and Mueller-Brand, J. (2001b). Radiopeptide \ntransmitted internal irradiation of non-iodophil \nthyroid cancer and conventionally untreatable \nmedullary thyroid cancer using, Nucl Med Com -\nmun 22, 673-8.\nWalker, G., Pfeilschifter, J., Otten, U., and Kunz, D. \n(2001). Proteolytic cleavage of inducible nitric ox -\nide synthase (iNOS) by calpain I, Biochim Biophys \nActa 1568, 216-24.\nWalter, M. A., Christ-Crain, M., Eckard, B., Schindler, \nC., Nitzsche, E. U., Muller-Brand, J., and Muller, \nB. (2004). Radioiodine therapy in hyperthyroidism: \ninverse correlation of pretherapeutic iodine uptake \nlevel and post-therapeutic outcome, Eur J Clin In -\nvest 34, 365-70.\nWalter, M. A., Christ-Crain, M., Muller, B., Muller-\nBrand, J. (2004). The Detrimental Effect of Antithy -\nroid Drugs on the Outcome of Radioiodine Therapy \nis not directly due to a Decreased Radioiodine Up -\ntake., Nucl Med Commun 2004 (in press).\nWalter, M. A., Muller, B., and Muller-Brand, J. (2003). \n[Does an individual estimation of halflife improve \nthe results of radioiodine therapy of Graves\u2019 \ndisease?], Nuklearmedizin 42, N29; author reply \nN29.\nWaubant, E., Goodkin, D., Bostrom, A., Bacchetti, P ., \nHietpas, J., Lindberg, R., and Leppert, D. (2003). \nIFNbeta lowers MMP-9/TIMP-1 ratio, which pre -\ndicts new enhancing lesions in patients with SPMS, Neurology 60, 52-7.\nWeber, C., Collet, S., Fried, R., Lambrecht, J.T., Erb, \nP ., Meyer, J. (2001). Low prevalence of hepatitis \nC virus antibody among Swiss dental health care \nworkers., J Hepatol 2004 (in press) 34:963-4.\nWeber, J., Mesters, J. R., Lepsik, M., Prejdova, J., Svec, \nM., Sponarova, J., Mlcochova, P ., Skalicka, K., Stris -\novsky, K., Uhlikova, T., Soucek, M., Machala, L., \nStankova, M., Vondrasek, J., Klimkait, T., Kraeuss -\nlich, H. G., Hilgenfeld, R., and Konvalinka, J. (2002). \nUnusual binding mode of an HIV-1 protease inhibi -\ntor explains its potency against multi-drug-resistant \nvirus strains, J Mol Biol 324, 739-54.\nWeber, J. F ., Kirsch, E., Radu, E. W., Steck, A. J., Kai -\nser, H. J., and Lyrer, P . A. (2003). Angioplasty in a \npatient with ocular ischemia due to occlusion of the \ninternal and stenosis of the external carotid artery, \nCerebrovasc Dis 16, 436-9.\nWehrli, N., Legler, D. F ., Finke, D., Toellner, K. M., \nLoetscher, P ., Baggiolini, M., MacLennan, I. C., and \nAcha-Orbea, H. (2001). Changing responsiveness \nto chemokines allows medullary plasmablasts to \nleave lymph nodes, Eur J Immunol 31, 609-16.\nWeidner, R., Pollmann, S., Muller, H. J., and von \nCramon, D. Y . (2002). Top-down controlled visual \ndimension weighting: an event-related fMRI study, \nCereb Cortex 12, 318-28.\nWelge-Luessen, A., Hauser, R., Schmid, N., Kappos, \nL., and Probst, R. (2003). Endonasal surgery for \ncontact point headaches: a 10-year longitudinal \nstudy, Laryngoscope 113, 2151-6.\nWellinger, R. E., Schar, P ., and Sogo, J. M. (2003). \nRad52-independent accumulation of joint circular \nminichromosomes during S phase in Saccharomy -\nces cerevisiae, Mol Cell Biol 23, 6363-72.\nWendt, D., Marsano, A., Jakob, M., Heberer, M., \nand Martin, I. (2003). Oscillating perfusion of cell \nsuspensions through three-dimensional scaffolds \nenhances cell seeding efficiency and uniformity, \nBiotechnol Bioeng 84, 205-14.\nWenk, M., Todesco, L., and Krahenbuhl, S. (2004). \nEffect of St John\u2019s wort on the activities of CYP1A2, \nCYP3A4, CYP2D6, N-acetyltransferase 2, and xan -\nthine oxidase in healthy males and females, Br J Clin \nPharmacol 57, 495-9.\nWerlen, G., Hausmann, B., Naeher, D., and Palmer, \nE. (2003). Signaling life and death in the thymus: \ntiming is everything, Science 299, 1859-63.\nWerlen, G., Hausmann, B., and Palmer, E. (2000). A \nmotif in the alphabeta T-cell receptor controls posi -\ntive selection by modulating ERK activity, Nature \n406, 422-6.\nWerlen, G., and Palmer, E. (2002). The T-cell receptor \nsignalosome: a dynamic structure with expanding \ncomplexity, Curr Opin Immunol 14, 299-305.\nWhang, K. T., Vath, S. D., Becker, K. L., Snider, R. H., \nNylen, E. S., Muller, B., Li, Q., Tamarkin, L., and \nWhite, J. C. (2000). Procalcitonin and proinflam -\nmatory cytokine interactions in sepsis, Shock 14, \n73-8.\nWicki, A., Malik, N., Gratwohl, A., Tichelli, A., Meyer-\nMonard, S., and Muller, H. (2002). Determination of \nthe donor:host blood cell ratio after haematological \nstem cell transplant by means of semiquantitative \ndetection of short tandem repeat polymorphisms, \nSwiss Med Wkly 132, 288-95.\nWidmer, I., Wernli, M., Bachmann, F ., Gudat, F ., Catho -\nmas, G., and Erb, P . (2002). Differential expression \nof viral Bcl-2 encoded by Kaposi\u2019s sarcoma-associ -\nated herpesvirus and human Bcl-2 in primary effu -\nsion lymphoma cells and Kaposi\u2019s sarcoma lesions, \nJ Virol 76, 2551-6.\nWiederkehr, M., and Krapf, R. (2001). Metabolic and \nendocrine effects of metabolic acidosis in humans, Swiss Med Wkly 131, 127-32.\nWiederkehr, M. R., Kalogiros, J., and Krapf, R. (2004). \nCorrection of metabolic acidosis improves thyroid \nand growth hormone axes in haemodialysis pa -\ntients, Nephrol Dial Transplant 19, 1190-7. Epub \n2004 Feb 19.\nWiederkehr-Adam, M., Ernst, P ., Muller, K., Bieck, \nE., Gombert, F . O., Ottl, J., Graff, P ., Grossmuller, \nF ., and Heim, M. H. (2003). Characterization of \nphosphopeptide motifs specific for the Src homol -\nogy 2 domains of signal transducer and activator \nof transcription 1 (STAT1) and STAT3, J Biol Chem \n278, 16117-28.\nWiederseiner, J. M., Muser, J., Lutz, T., Hulter, H. N., \nand Krapf, R. (2004). Acute metabolic acidosis: \ncharacterization and diagnosis of the disorder and \nthe plasma potassium response, J Am Soc Nephrol \n15, 1589-96.\nWiendl, H., Neuhaus, O., Kappos, L., and Hohlfeld, R. \n(2000). [Multiple sclerosis. Current review of failed \nand discontinued clinical trials of drug treatment], \nNervenarzt 71, 597-610.\nWiesner, W., Ruehm, S. G., Bongartz, G., Kaim, A., \nReese, E., and De Geyter, C. (2001). Three-di -\nmensional dynamic MR hysterosalpingography: a \npreliminary report, Eur Radiol 11, 1439-44.\nWiesner, W., Wetzel, S. G., Kappos, L., Hoshi, M. M., \nWitte, U., Radue, E. W., and Steinbrich, W. (2002). \nSwallowing abnormalities in multiple sclerosis: cor -\nrelation between videofluoroscopy and subjective \nsymptoms, Eur Radiol 12, 789-92.\nWiestner, A., Padosch, S. A., Ghilardi, N., Cesar, J. M., \nOdriozola, J., Shapiro, A., and Skoda, R. C. (2000). \nHereditary thrombocythaemia is a genetically het -\nerogeneous disorder: exclusion of TPO and MPL in \ntwo families with hereditary thrombocythaemia, Br \nJ Haematol 110, 104-9.\nWilliams, P . L., Leib, S. L., Kamberi, P ., Leppert, D., \nSobel, R. A., Bifrare, Y . D., Clemons, K. V ., and \nStevens, D. A. (2002). Levels of matrix metallo -\nproteinase-9 within cerebrospinal fluid in a rabbit \nmodel of coccidioidal meningitis and vasculitis, J \nInfect Dis 186, 1692-5. Epub 2002 Nov 1.\nWillison, H. J., O\u2019Leary, C. P ., Veitch, J., Blumhardt, \nL. D., Busby, M., Donaghy, M., Fuhr, P ., Ford, H., \nHahn, A., Renaud, S., Katifi, H. A., Ponsford, S., \nReuber, M., Steck, A., Sutton, I., Schady, W., Tho -\nmas, P . K., Thompson, A. J., Vallat, J. M., and Winer, \nJ. (2001). The clinical and laboratory features of \nchronic sensory ataxic neuropathy with anti-disia -\nlosyl IgM antibodies, Brain 124, 1968-77.\nWinkler, D. T., Scotti, A. L., and Nitsch, C. (2001). \nIschemia-induced degeneration of CA1 pyramidal \ncells decreases seizure severity in a subgroup \nof epileptic gerbils and affects parvalbumin im -\nmunoreactivity of CA1 interneurons, Exp Neurol \n168, 364-72.\nWitschi, A., Widmer, A. F ., Schnider, B. F ., Wehrle, \nJ., Zerkowski, H. R., and Bernet, F . (2003). Safety \nof heart-lung machines during prolonged standby, \nInfection 31, 350-2.\nWittig, B. M., Johansson, B., Zoller, M., Schwarzler, \nC., and Gunthert, U. (2000). Abrogation of experi -\nmental colitis correlates with increased apoptosis in \nmice deficient for CD44 variant exon 7 (CD44v7), J \nExp Med 191, 2053-64.\nWodnar-Filipowicz, A. (2002). [Plasticity of stem cells: \na change of paradigm?], Ther Umsch 59, 565-70.\nWodnar-Filipowicz, A. (2003). Flt3 ligand: role in con -\ntrol of hematopoietic and immune functions of the 154/155bone marrow, News Physiol Sci 18, 247-51.\nWolf, K., Kirsch, E. C., Sponagel, L., Rufenacht, D. \nA., and Battegay, M. (2002a). Disappearance of \nan intracerebral arteriovenous malformation in \nan HIV-infected patient after initiation of HAART, \nInfection 30, 101-3.\nWolf, K., Tichelli, A., and Battegay, M. (2001). [Ane -\nmia, neutropenia and thrombocytopenia: hemato -\nlogical findings and HIV], Schweiz Rundsch Med \nPrax 90, 1775-9.\nWolf, K., Tsakiris, D. A., Weber, R., Erb, P ., and Bat -\ntegay, M. (2002b). Antiretroviral therapy reduces \nmarkers of endothelial and coagulation activation \nin patients infected with human immunodeficiency \nvirus type 1, J Infect Dis 185, 456-62. Epub 2002 \nJan 18.\nWolinsky, J. S., Toyka, K. V ., Kappos, L., and Gross -\nberg, S. E. (2003). Interferon-beta antibodies: \nimplications for the treatment of MS, Lancet \nNeurol 2, 528.\nWolz, C., Goerke, C., Landmann, R., Zimmerli, W., and \nFluckiger, U. (2002). Transcription of clumping fac -\ntor A in attached and unattached Staphylococcus \naureus in vitro and during device-related infection, \nInfect Immun 70, 2758-62.\nWunderlich, K., Golubnitschaja, O., Pache, M., \nEberle, A. N., and Flammer, J. (2002). Increased \nplasma levels of 20S proteasome alpha-subunit in \nglaucoma patients: an observational pilot study, \nMol Vis 8, 431-5.\nWunderlich, K., Pech, M., Eberle, A. N., Mihatsch, \nM., Flammer, J., and Meyer, P . (2000). Expression \nof connective tissue growth factor (CTGF) mRNA \nin plaques of human anterior subcapsular cataracts \nand membranes of posterior capsule opacification, \nCurr Eye Res 21, 627-36.\nWunderlich, K., Zimmerman, C., Gutmann, H., \nTeuchner, B., Flammer, J., and Drewe, J. (2003). \nVasospastic persons exhibit differential expression \nof ABC-transport proteins, Mol Vis 9, 756-61.\nWyss, A., and Moroni, C. (2000). Calcium-depend -\nent and oncogenic IL-3 mRNA stabilization can be \ndistinguished pharmacologically and by sequence \nrequirements in the 3\u2019UTR, Growth Factors 18, \n109-18.\nYakirevich, E., Sabo, E., Dirnfeld, M., Sova, Y ., Spag -\nnoli, G. C., and Resnick, M. B. (2003a). Morpho -\nmetrical Quantification of Spermatogonial Germ \nCells With the 57B Anti-MAGE-A4 Antibody in the \nEvaluation of Testicular Biopsies for Azoospermia, \nAppl Immunohistochem Mol Morphol 11, 37-44.\nYakirevich, E., Sabo, E., Lavie, O., Mazareb, S., Spag -\nnoli, G. C., and Resnick, M. B. (2003b). Expres -\nsion of the MAGE-A4 and NY-ESO-1 cancer-testis \nantigens in serous ovarian neoplasms, Clin Cancer \nRes 9, 6453-60.\nYao, M., Dieterle, T., Hale, S. L., Dow, J. S., Kedes, \nL. H., Peterson, K. L., and Kloner, R. A. (2003). \nLong-term outcome of fetal cell transplantation on \npostinfarction ventricular remodeling and function, \nJ Mol Cell Cardiol 35, 661-70.\nYerly, S., Vora, S., Rizzardi, P ., Chave, J. P ., Vernazza, \nP . L., Flepp, M., Telenti, A., Battegay, M., Veuthey, \nA. L., Bru, J. P ., Rickenbach, M., Hirschel, B., and \nPerrin, L. (2001). Acute HIV infection: impact on the \nspread of HIV and transmission of drug resistance, \nAids 15, 2287-92.\nYou, Z., Hester, J., Rollins, L., Spagnoli, G. C., van der \nBruggen, P ., and Chen, S. Y . (2001). A retrogen \nstrategy for presentation of an intracellular tumor \nantigen as an exogenous antigen by dendritic \ncells induces potent antitumor T helper and CTL responses, Cancer Res 61, 197-205.\nYoung, A. J., Holzgreve, W., Dudler, L., Schoeberlein, \nA., and Surbek, D. V . (2003). Engraftment of human \ncord blood-derived stem cells in preimmune ovine \nfetuses after ultrasound-guided in utero transplan -\ntation, Am J Obstet Gynecol 189, 698-701.\nYoung, J., De Geest, S., Spirig, R., Flepp, M., Ricken -\nbach, M., Furrer, H., Bernasconi, E., Hirschel, B., \nTelenti, A., Vernazza, P ., Battegay, M., and Bucher, \nH. C. (2004). Stable partnership and progression \nto AIDS or death in HIV infected patients receiv -\ning highly active antiretroviral therapy: Swiss HIV \ncohort study, Bmj 328, 15.\nZajac, P ., Oertli, D., Marti, W., Adamina, M., Bolli, \nM., Guller, U., Noppen, C., Padovan, E., Schultz-\nThater, E., Heberer, M., and Spagnoli, G. (2003). \nPhase I/II clinical trial of a nonreplicative vaccinia \nvirus expressing multiple HLA-A0201-restricted \ntumor-associated epitopes and costimulatory \nmolecules in metastatic melanoma patients, Hum \nGene Ther 14, 1497-510.\nZanetti Dallenbach, R., and De Geyter, C. (2001). \n[What is your diagnosis? Relative hypergonado -\ntrophic ovarian insufficiency after chemotherapy \nfor Hodgkin disease], Schweiz Rundsch Med \nPrax 90, 47-9.\nZaugg, C. E. (2002). [Circadian rhythm of cardiovas -\ncular emergencies], Schweiz Rundsch Med Prax \n91, 1553-5.\nZaugg, C. E. (2003a). [Common biostatistical errors \nin clinical studies], Schweiz Rundsch Med Prax \n92, 218-24.\nZaugg, C. E. (2003b). Standard error as standard?, \nCirculation 107, e89.\nZaugg, C. E., and Buser, P . T. (2001). When calcium \nturns arrhythmogenic: intracellular calcium han -\ndling during the development of hypertrophy and \nheart failure, Croat Med J 42, 24-32.\nZaugg, C. E., Spaniol, M., Kaufmann, P ., Bellahcene, \nM., Barbosa, V ., Tolnay, M., Buser, P . T., and Kra -\nhenbuhl, S. (2003). Myocardial function and energy \nmetabolism in carnitine-deficient rats, Cell Mol Life \nSci 60, 767-75.\nZaugg, C. E., Ziegler, A., Lee, R. J., Barbosa, V ., and \nBuser, P . T. (2002). Postresuscitation stunning: \npostfibrillatory myocardial dysfunction caused by \nreduced myofilament Ca2\ue02b responsiveness after \nventricular fibrillation-induced myocyte Ca2\ue02b over -\nload, J Cardiovasc Electrophysiol 13, 1017-24.\nZelikin, A. N., Lynn, D. M., Farhadi, J., Martin, I., Shas -\ntri, V ., and Langer, R. (2002). Erodible conducting \npolymers for potential biomedical applications, \nAngew Chem Int Ed Engl 41, 141-4.\nZeller, A., Battegay, M., Gyr, N., and Battegay, E. \n(2003a). Evaluation of unstructured medical \nschool examinations: prospective observational \nstudy, Swiss Med Wkly 133, 184-7.\nZeller, A., Handschin, D., Gyr, N., Martina, B., and \nBattegay, E. (2004). Blood pressure and heart rate \nof students undergoing a medical licensing exami -\nnation, Blood Press 13, 20-4.\nZeller, A., Schaub, N., Steffen, I., Battegay, E., Hirsch, \nH. H., and Bircher, A. J. (2003b). Drug hypersen -\nsitivity syndrome to carbamazepine and human \nherpes virus 6 infection: case report and literature \nreview, Infection 31, 254-6.\nZeller, R., and Deschamps, J. (2002). Developmen -\ntal biology: first come, first served, Nature 420, 138-9.\nZerbini, A., Pilli, M., Soliani, P ., Ziegler, S., Pelosi, G., \nOrlandini, A., Cavallo, C., Uggeri, J., Scandroglio, \nR., Crafa, P ., Spagnoli, G. C., Ferrari, C., and Mis -\nsale, G. (2004). Ex vivo characterization of tumor-\nderived melanoma antigen encoding gene-specific \nCD8\ue02bcells in patients with hepatocellular carcinoma, \nJ Hepatol 40, 102-9.\nZerkowski, H. R., Grapow, M. T., Todorov, A., and \nMorawietz, H. (2000). [Reverse remodeling by \nsurgery--fact or fiction?], Z Kardiol 89, 76-84.\nZerkowski, H. R., Grussenmeyer, T., Matt, P ., Grapow, \nM., Engelhardt, S., and Lefkovits, I. (2004). Pro -\nteomics strategies in cardiovascular research, J \nProteome Res 3, 200-8.\nZerkowski, H. R., and Preiss, M. (2001). [Multiple \nheart valve diseases: differential therapeutic con -\nsiderations], Z Kardiol 90, 65-9.\nZhang, H., Holzgreve, W., and De Geyter, C. (2001). \nBcl2-L-10, a novel anti-apoptotic member of the \nBcl-2 family, blocks apoptosis in the mitochondria \ndeath pathway but not in the death receptor path -\nway, Hum Mol Genet 10, 2329-39.\nZhang, H., Vollmer, M., De Geyter, M., Litzistorf, Y ., \nLadewig, A., Durrenberger, M., Guggenheim, R., \nMiny, P ., Holzgreve, W., and De Geyter, C. (2000). \nCharacterization of an immortalized human \ngranulosa cell line (COV434), Mol Hum Reprod \n6, 146-53.\nZhang, J. Q., Biedermann, B., Nitschke, L., and Crock -\ner, P . R. (2004). The murine inhibitory receptor mSi -\nglec-E is expressed broadly on cells of the innate \nimmune system whereas mSiglec-F is restricted to \neosinophils, Eur J Immunol 34, 1175-84.\nZhong, X. Y ., Hahn, D., Troeger, C., Klemm, A., Stein, \nG., Thomson, P ., Holzgreve, W., and Hahn, S. \n(2001a). Cell-free DNA in urine: a marker for kidney \ngraft rejection, but not for prenatal diagnosis?, Ann \nN Y Acad Sci 945, 250-7.\nZhong, X. Y ., Holzgreve, W., and Hahn, S. (2001b). \nCirculatory fetal and maternal DNA in pregnancies \nat risk and those affected by preeclampsia, Ann N \nY Acad Sci 945, 138-40.\nZhong, X. Y ., Holzgreve, W., and Hahn, S. (2002a). \nCell-free fetal DNA in the maternal circulation does \nnot stem from the transplacental passage of fetal \nerythroblasts, Mol Hum Reprod 8, 864-70.\nZhong, X. Y ., Holzgreve, W., and Hahn, S. (2002b). \nThe levels of circulatory cell free fetal DNA in \nmaternal plasma are elevated prior to the onset of \npreeclampsia, Hypertens Pregnancy 21, 77-83.\nZhong, X. Y ., Wang, Y ., Chen, S., Labu, Pubuzhuoma, \nGesangzhuogab, Ouzhuwangmu, Hahn, C., Holz -\ngreve, W., and Hahn, S. (2004). Can Circulatory \nFetal DNA Be Used to Study Placentation at High \nAltitude?, Ann N Y Acad Sci 1022, 124-128.\nZiegler, A., Zaugg, C. E., Buser, P . T., Seelig, J., and \nKunnecke, B. (2002a). Non-invasive measurements \nof myocardial carbon metabolism using in vivo 13C \nNMR spectroscopy, NMR Biomed 15, 222-34.\nZiegler, S., Burki, K., and Skoda, R. C. (2002b). A 2-kb \nc-mpl promoter fragment is sufficient to direct ex -\npression to the megakaryocytic lineage and sites of \nembryonic hematopoiesis in transgenic mice, Blood \n100, 1072-4.\nZimmerli, L., and Leppert, D. (2004). [Polyneuropathy \nseropositive for anti-Hu antibodies], Schweiz Rund -\nsch Med Prax 93, 570-2.\nZimmerman, C., Drewe, J., Flammer, J., and Shaarawy, \nT. (2004). In vitro release of mitomycin C from col -\nlagen implants, Curr Eye Res 28, 1-4.\nZimmermann, B., Holzgreve, W., Wenzel, F ., and \nHahn, S. (2002a). Novel real-time quantitative PCR test for trisomy 21, Clin Chem 48, 362-3.\nZimmermann, B., Holzgreve, W., Zhong, X. Y ., and \nHahn, S. (2002b). Inability to clonally expand fetal \nprogenitors from maternal blood, Fetal Diagn Ther \n17, 97-100.\nZinkernagel, C., Naef, M. R., Bucher, H. C., Ladewig, \nD., Gyr, N., and Battegay, M. (2001a). Onset and \npattern of substance use in intravenous drug users \nof an opiate maintenance program, Drug Alcohol \nDepend 64, 105-9.\nZinkernagel, C., Taffe, P ., Rickenbach, M., Amiet, R., \nLedergerber, B., Volkart, A. C., Rauchfleisch, U., \nKiss, A., Werder, V ., Vernazza, P ., and Battegay, M. \n(2001b). Importance of mental health assessment \nin HIV-infected outpatients, J Acquir Immune Defic \nSyndr 28, 240-9.\nZivkovic, S. A., Heyman, R., and Pless, M. (2003). \nSubacute rhombencephalitis optica responsive \nto intravenous immunoglobulins, Eur J Neurol \n10, 83-6.\nZorzato, F ., Anderson, A. A., Ohlendieck, K., Froem -\nming, G., Guerrini, R., and Treves, S. (2000). Identi -\nfication of a novel 45 kDa protein (JP-45) from rabbit \nsarcoplasmic-reticulum junctional-face membrane, \nBiochem J 351, 537-43.\nZorzato, F ., Yamaguchi, N., Xu, L., Meissner, G., Muller, \nC. R., Pouliquin, P ., Muntoni, F ., Sewry, C., Girard, \nT., and Treves, S. (2003). Clinical and functional ef -\nfects of a deletion in a COOH-terminal lumenal loop \nof the skeletal muscle ryanodine receptor, Hum Mol \nGenet 12, 379-88.\nZuklys, S., Balciunaite, G., Agarwal, A., Fasler-Kan, \nE., Palmer, E., and Hollander, G. A. (2000). Normal \nthymic architecture and negative selection are as -\nsociated with Aire expression, the gene defective \nin the autoimmune-polyendocrinopathy-candidia -\nsis-ectodermal dystrophy (APECED), J Immunol \n165, 1976-83.\nZulewski, H., Abraham, E. J., Gerlach, M. J., Daniel, \nP . B., Moritz, W., Muller, B., Vallejo, M., Thomas, \nM. K., and Habener, J. F . (2001). Multipotential \nnestin-positive stem cells isolated from adult \npancreatic islets differentiate ex vivo into pancre -\natic endocrine, exocrine, and hepatic phenotypes, \nDiabetes 50, 521-33.\nZulewski, H., Muller, B., Exer, P ., Miserez, A. R., and \nStaub, J. J. (1997). Estimation of tissue hypothy -\nroidism by a new clinical score: evaluation of pa -\ntients with various grades of hypothyroidism and \ncontrols, J Clin Endocrinol Metab 82, 771-6.\nZumsteg, U. (2000). [Cystic fibrosis: current therapy. \nDiabetes], Schweiz Med Wochenschr Suppl 122, \n15S-16S.\nZumsteg, U., Frigerio, S., and Hollander, G. A. (2000). \nNitric oxide production and Fas surface expression \nmediate two independent pathways of cytokine-\ninduced murine beta-cell damage, Diabetes 49, \n39-47.\nZuniga, A., Michos, O., Spitz, F ., Haramis, A. P ., Pan -\nman, L., Galli, A., Vintersten, K., Klasen, C., Mans -\nfield, W., Kuc, S., Duboule, D., Dono, R., and Zeller, \nR. (2004). Mouse limb deformity mutations disrupt \na global control region within the large regulatory \nlandscape required for Gremlin expression, Genes \nDev 18, 1553-64. Epub 2004 Jun 15.\nZuniga, A., Quillet, R., Perrin-Schmitt, F ., and Zeller, \nR. (2002). Mouse Twist is required for fibroblast \ngrowth factor-mediated epithelial-mesenchymal \nsignalling and cell survival during limb morpho -\ngenesis, Mech Dev 114, 51-9.156/157158/159\nPersonen Index\nBattegay Eduard, Prof. Dr.  ebattegay@uhbs.ch  76\nBattegay Manuel, Prof. Dr.  mbattegay@uhbs.ch  111\nBeglinger Christoph,Prof. Dr.  beglinger@tmr.ch  58\nBettler Bernhard, Prof. Dr.  bernhard.bettler@unibas.ch  14, 16, 22\nBiedermann Barbara, PD Dr.  barbara.biedermann@unibas.ch  114\nBigliardi-Qi Mei, Dr.  mei.bigliardi-qi@unibas.ch  48\nBrenner Hans-Rudolf, Prof. Dr.  hans-rudolf.brenner@unibas.ch  26\nBrink Marijke, Prof. Dr.  marijke.brink@unibas.ch  14, 38\nB\u00fcchner Stanislaw, Prof. Dr.  sbuechner@uhbs.ch  103\nBuser Peter, Prof. Dr.  pbuser@uhbs.ch  39\nChristofori Gerhard, Prof. Dr.  gerhard.christofori@unibas.ch  6, 14, 78, 82\nDe Geyter Christian, Prof. Dr.  cdegeyter@uhbs.ch  60\nDeLibero Gennaro, Prof. Dr.  gennaro.delibero@unibas.ch  100\nDrewe J\u00fcrgen, Prof. Dr.  drewej@uhbs.ch  44\nEberle Alex-N., Prof. Dr.  alex-n.eberle@unibas.ch  52\nErb Peter, Prof. Dr.  peter.erb@unibas.ch  102\nEriksson Urs, Prof. Dr.  erikssonu@uhbs.ch  14, 98\nErne Paul, Prof. Dr.  paul.erne@ksl.ch  73\nFinke Daniela, Prof. Dr.  daniela.finke@unibas.ch  14, 96\nGirard Thierry, Dr.  thierry.girard@unibas.chGratwohl  125\nGratwohl Alois-A., Prof. Dr.  AGratwohl@uhbs.ch  36, 56\nGratzl Otmar, Prof. Dr.  ogratzl@uhbs.ch  30\nG\u00fcnthert Ursula, PD Dr.  ursula.guenthert@unibas.ch  102\nHahn Sinuhe, PD Dr.  shahn@uhbs.ch  68\nHeberer Michael, Prof. Dr.  mheberer@uhbs.ch  74, 88\nHeim Markus, Prof. Dr.  markus.heim@unibas.ch  62\nHerrmann Richard, Prof. Dr.  herrmann@uhbs.ch  78\nHess Christoph, Dr.  christoph.hess@unibas.ch  106\nHirsch Hans H., Prof. Dr.  hans.hirsch@unibas.ch  14, 122\nHoll\u00e4nder Georges-A., Prof. Dr.  georg-a.hollaender@unibas.ch  6, 92, 116\nHolzgreve Wolfgang, Prof. Dr.  wolfgang.holzgreve@unibas.ch  70\nJobin Jean-Jacques  jean-jacques.jobin@unibas.ch  6\nKapfhammer Josef, Prof. Dr.  josef.kapfhammer@unibas.ch  20\nKappos Ludwig, Prof. Dr.  lkappos@uhbs.ch  34\nKeller Ulrich O., Prof. Dr.  ulrich.keller@unibas.ch  64\nKlimkait Thomas, PD Dr.  thomas.klimkait@unibas.ch  112, 127\nKr\u00e4henb\u00fchl Stephan, Prof. Dr.  kraehenbuehl@uhbs.ch  42\nKrapf Reto, Prof. Dr.  reto.krapf@ksbh.ch  115Landmann Lukas, Prof. Dr.  lukas.landmann@unibas.ch  46\nLandmann Regine, Prof. Dr.  regine.landmann@unibas.ch  110\nLeppert David, Prof. Dr.  david.x.leppert@gsk.com  34\nMartin Ivan, Dr.  imartin@uhbs.ch  74\nMendelowitsch Aminadav, PD Dr.  amendelowitsch@datacom.ch  31\nMerlo Adrian, Prof. Dr.  amerlo@uhbs.ch  23, 24\nMoroni Christoph, Prof. Dr.  christoph.moroni@unibas.ch  5, 6, 86\nM\u00fcller Beat, PD Dr.  happy.mueller@unibas.ch  64\nM\u00fcller Christian, Prof. Dr.  chmueller@uhbs.ch  99\nM\u00fcller Hansjakob, Prof. Dr.  hansjakob.mueller@unibas.ch  84\nNitsch Cordula, Prof. Dr.  cordula.nitsch@unibas.ch  18\nOrend Gertraud, Dr.  gertraud.orend@unibas.ch  83\nOtten Uwe, Prof. Dr.  uwe.otten@unibas.ch  28\nPalmer Ed, Prof. Dr.  ed.palmer@unibas.ch  15, 120\nPerruchoud Andr\u00e9, Prof. Dr.  aperruchoud@uhbs.ch  4, 6\nPless Miklos, Dr.  plessm@uhbs.ch  90\nResink Therese-J., Prof. Dr.  therese-j.resink@unibas.ch  72\nRochlitz Christoph, Prof. Dr.  crochlitz@uhbs.ch  90\nRolink Antonius, Prof. Dr.  antonius.rolink@unibas.ch  15, 92, 94\nRoth Michael, PD Dr.  michaelr@med.usyd.edu.au  66\nRufli Th., Prof. Dr.  trufli@uhbs.ch  49\nSchaeren-Wiemers Nicole, PD Dr.  nicole.schaeren-wiemers@unibas.ch  32\nSch\u00e4r Primo, Prof. Dr.  primo.schaer@unibas.ch  15, 80\nSchifferli J\u00fcrg-A., Prof. Dr.  j.schifferli@unibas.ch  108\nSkoda Radek, Prof. Dr.  radek.skoda@unibas.ch  6, 15, 54\nSpagnoli Giulio C., Prof. Dr.  gspagnoli@uhbs.ch  88\nSteck Andreas J., Prof. Dr.  andreas.steck@unibas.ch  16, 33\nSteiger J\u00fcrg, Prof. Dr.  juerg.steiger@unibas.ch  121\nSurbek Daniel, PD Dr. med.  Daniel.Surbek@unibas.ch  71\nTamm Michael, Prof. Dr.  mtamm@uhbs.ch  66\nTichelli Andr\u00e9, Prof. Dr.  tichellia@uhbs.ch  56\nTreves Susan, Dr.  susan.treves@unibas.ch  124\nWodnar-Filipowicz Aleksandra, Prof. Dr.  aleksandra.wodnar-filipowicz@unibas.ch  54\nWymann Matthias, Prof. Dr.  matthias.wymann@unibas.ch  15\nZeller Rolf, Prof. Dr.  rolf.zeller@unibas.ch  15, 36, 50\nZerkowski Hans-Reinhard, Prof. Dr.  hrzerkowski@uhbs.ch  40\nZumsteg Urs, PD Dr.  urs.zumsteg@unibas.ch  116Wir danken f\u00fcr die freundliche Unterst\u00fctzung \nfolgender Firmen:\nErnst & Young Ltd \nFluka AG\nHuber & Co. AG Labor- und Spitalbedarf \nKendro Laboratory Products AG\nLeica Microsystems (Schweiz) AG\nPharma-Consulting\nConsulting in Biosciences\nThe link between Industry, Academic Research & \nGeneral Public\n\u2022 Technology watch\n\u2022 Database populations\n\u2022 Medical writing and translations \n\u2022 Networking\n\u2022 Teaching\nMOLECULAR BIOLOGY \u2022 PLANT BIOLOGY \u2022\nBIOMEDICAL RESEARCH \u2022 BIOTECHNOLOGIES\nContact:\nADVOLIS Life Science Concepts Ltd.\nOetlingerstrasse 10, 4057 Basel, Switzerland\nTel. +41 (0) 61 683 59 30\nFax.  +41 (0) 61 683 59 31\nwww.advolis.ch\nDr. phil. Alain Denis Meyer\nalain.meyer@advolis.ch\nDr. phil. H\u00e9l\u00e8ne Corbi\u00e8re-Divialle\nhelene.corbiere@advolis.ch\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}